<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns:z="http://www.zotero.org/namespaces/export#"
 xmlns:dcterms="http://purl.org/dc/terms/"
 xmlns:bib="http://purl.org/net/biblio#"
 xmlns:foaf="http://xmlns.com/foaf/0.1/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2033130125&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1471-244X"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lou</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Cui</foaf:surname>
                        <foaf:givenName>Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ou</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhou</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhao</foaf:surname>
                        <foaf:givenName>R.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhu</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zou</foaf:surname>
                        <foaf:givenName>F.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_925"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>factual database</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>treatment response time</dc:subject>
        <dc:subject>young adult</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>Adolescent</dc:subject>
        <dc:subject>Adult</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>Aged</dc:subject>
        <dc:subject>calculation</dc:subject>
        <dc:subject>reporting odds ratio</dc:subject>
        <dc:subject>Antipsychotic Agents</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>epidemiology</dc:subject>
        <dc:subject>FAERS</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>neuroleptic agent</dc:subject>
        <dc:subject>RISK</dc:subject>
        <dc:subject>schizophrenia</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>United States Food and Drug Administration</dc:subject>
        <dc:subject>body weight gain</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>erectile dysfunction</dc:subject>
        <dc:subject>accuracy</dc:subject>
        <dc:subject>bayesian confidence propagation neural network</dc:subject>
        <dc:subject>Bayesian network</dc:subject>
        <dc:subject>ADOLESCENTS</dc:subject>
        <dc:subject>Data Mining</dc:subject>
        <dc:subject>Databases, Factual</dc:subject>
        <dc:subject>paliperidone</dc:subject>
        <dc:subject>nerve cell network</dc:subject>
        <dc:subject>off label drug use</dc:subject>
        <dc:subject>Disproportionality analysis</dc:subject>
        <dc:subject>SCHIZOPHRENIA</dc:subject>
        <dc:subject>sexual dysfunction</dc:subject>
        <dc:subject>Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>drug interaction</dc:subject>
        <dc:subject>Female</dc:subject>
        <dc:subject>clinical monitoring</dc:subject>
        <dc:subject>Pharmacovigilance</dc:subject>
        <dc:subject>statistical analysis</dc:subject>
        <dc:subject>Adverse drug events</dc:subject>
        <dc:subject>proportional reporting ratio</dc:subject>
        <dc:subject>Male</dc:subject>
        <dc:subject>Middle Aged</dc:subject>
        <dc:subject>ANTIPSYCHOTICS</dc:subject>
        <dc:subject>Young Adult</dc:subject>
        <dc:subject>Japan</dc:subject>
        <dc:subject>CARE RESOURCE UTILIZATION</dc:subject>
        <dc:subject>EXTENDED-RELEASE</dc:subject>
        <dc:subject>FORMULATION</dc:subject>
        <dc:subject>galactorrhea</dc:subject>
        <dc:subject>hyperprolactinemia</dc:subject>
        <dc:subject>JADER</dc:subject>
        <dc:subject>Japanese (people)</dc:subject>
        <dc:subject>Japanese Adverse Drug Event Report</dc:subject>
        <dc:subject>multi item poisson shrinkage</dc:subject>
        <dc:subject>multidimensional scaling</dc:subject>
        <dc:subject>OPEN-LABEL</dc:subject>
        <dc:subject>Paliperidone palmitate</dc:subject>
        <dc:subject>Paliperidone Palmitate</dc:subject>
        <dc:subject>prolactin blood level</dc:subject>
        <dc:subject>prolactinoma</dc:subject>
        <dc:subject>psychosexual disorder</dc:subject>
        <dc:subject>Real-world analysis</dc:subject>
        <dc:subject>RELAPSE PREVENTION</dc:subject>
        <dc:subject>SAFETY</dc:subject>
        <dc:subject>self report</dc:subject>
        <dc:subject>sudden death</dc:subject>
        <dc:subject>suicide attempt</dc:subject>
        <dc:title>A multidimensional assessment of adverse events associated with paliperidone palmitate: a real-world pharmacovigilance study using the FAERS and JADER databases</dc:title>
        <dcterms:abstract>Objective: Paliperidone palmitate is a second-generation antipsychotic that has undergone extensive investigation in clinical trials. However, real-world studies assessing its safety in large populations are lacking. As such, this study aimed to comprehensively evaluate real-world adverse drug events (ADEs) linked to paliperidone palmitate by employing data mining techniques on the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database and the Japanese Adverse Drug Event Report (JADER) database. Methods: The study retrieved ADE reports from the FAERS database covering the period from 2009 through the third quarter of 2024, and from the JADER database covering the period from 2013 through the second quarter of 2024. Utilizing disproportionality analyses such as the reporting odds ratios (ROR), proportional reporting ratios (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item Poisson shrinkage (MGPS), significant associations between ADEs and paliperidone palmitate were evaluated. Results: A total of 27,672 ADE reports related to paliperidone palmitate were identified in FAERS, with 285 significantly disproportionate preferred terms (PTs) identified by all four algorithms. Paliperidone palmitate-associated ADEs encompassed 27 System Organ Classes (SOCs). The top three PTs with the highest reported cases were off-label use, drug ineffective, and hospitalization. Common ADEs included increased blood prolactin, galactorrhea, and schizophrenia, which was consistent with drug label. Noteworthy, unexpected signals not listed in the drug label were also identified, such as psychosexual disorders, prolactin-producing pituitary tumors, suicide attempt, and sudden death. The median onset time for all ADEs was 40 days. Furthermore, gender-based difference in risk signals was detected. Females are more likely to experience elevated blood prolactin and weight increase, whereas males are more prone to sexual dysfunction. Among the 1,065 ADE reports from the JADER database, we identified 51 positive signals, 35 of which overlapped with those found in FAERS, including schizophrenia, hyperprolactinemia, and erectile dysfunction. Conclusion: The study findings from two independent databases serve as crucial references for ensuring the safe of paliperidone palmitate. Additionally, the gender-specific monitoring references provided can enhance clinical surveillance efforts and facilitate more effective risk identification.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079721</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2033130125&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1471-244X">
        <prism:volume>25</prism:volume>
        <dc:title>BMC Psychiatry</dc:title>
        <dc:identifier>DOI 10.1186/s12888-025-06493-0</dc:identifier>
        <prism:number>1</prism:number>
        <dcterms:alternative>BMC Psychiatry</dcterms:alternative>
        <dc:identifier>ISSN 1471-244X</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_925">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: F. Zou; Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, 149 Dalian Road, huichuan district, Guizhou, 563003, China; email: 747333233@qq.com; CODEN: BPMSC&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;80&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Excluded&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância | USER-NOTES: {&quot;Silvio&quot;=&gt;[&quot;Não identifiquei alinhamento com DM ou ML aplicada.&quot;]}</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2032853952&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1758-5996"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sridharan</foaf:surname>
                        <foaf:givenName>K.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sivaramakrishnan</foaf:surname>
                        <foaf:givenName>G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_928"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>combination drug therapy</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>*Data Mining</dc:subject>
        <dc:subject>*Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>ADVERSE DRUG-REACTIONS</dc:subject>
        <dc:subject>Algorithms</dc:subject>
        <dc:subject>artificial neural network</dc:subject>
        <dc:subject>classification</dc:subject>
        <dc:subject>Conditional random field</dc:subject>
        <dc:subject>bleeding</dc:subject>
        <dc:subject>bevacizumab</dc:subject>
        <dc:subject>adalimumab</dc:subject>
        <dc:subject>Animals</dc:subject>
        <dc:subject>antineoplastic agent</dc:subject>
        <dc:subject>automated pattern recognition</dc:subject>
        <dc:subject>automation</dc:subject>
        <dc:subject>BIOMEDICAL LITERATURE</dc:subject>
        <dc:subject>CANCER</dc:subject>
        <dc:subject>carfilzomib</dc:subject>
        <dc:subject>adverse drug reactions</dc:subject>
        <dc:subject>alogliptin</dc:subject>
        <dc:subject>CARDIOTOXICITY</dc:subject>
        <dc:subject>data analysis software</dc:subject>
        <dc:subject>Data mining</dc:subject>
        <dc:subject>Data Mining</dc:subject>
        <dc:subject>Data Mining/*methods</dc:subject>
        <dc:subject>dipeptidyl peptidase IV inhibitor</dc:subject>
        <dc:subject>anastrozole</dc:subject>
        <dc:subject>congenital malformation</dc:subject>
        <dc:subject>data extraction</dc:subject>
        <dc:subject>coronavirus disease 2019</dc:subject>
        <dc:subject>dabigatran</dc:subject>
        <dc:subject>disease association</dc:subject>
        <dc:subject>comparative study</dc:subject>
        <dc:subject>Antineoplastic Agents</dc:subject>
        <dc:subject>clinical outcome</dc:subject>
        <dc:subject>artificial intelligence</dc:subject>
        <dc:subject>Artificial Intelligence</dc:subject>
        <dc:subject>Classification (of information)</dc:subject>
        <dc:subject>crizotinib</dc:subject>
        <dc:subject>cetuximab</dc:subject>
        <dc:subject>consumer</dc:subject>
        <dc:subject>cytochrome P450 1A2</dc:subject>
        <dc:subject>cytochrome P450 2C9</dc:subject>
        <dc:subject>cytochrome P450 3A4</dc:subject>
        <dc:subject>angioneurotic edema</dc:subject>
        <dc:subject>data processing</dc:subject>
        <dc:subject>bosutinib</dc:subject>
        <dc:subject>dasatinib</dc:subject>
        <dc:subject>acetylsalicylic acid</dc:subject>
        <dc:subject>clopidogrel</dc:subject>
        <dc:subject>Association rules</dc:subject>
        <dc:subject>comorbidity</dc:subject>
        <dc:subject>*Natural Language Processing</dc:subject>
        <dc:subject>cross validation</dc:subject>
        <dc:subject>CORPUS</dc:subject>
        <dc:subject>Datasets as Topic</dc:subject>
        <dc:subject>ADULTS</dc:subject>
        <dc:subject>diseases</dc:subject>
        <dc:subject>*Algorithms</dc:subject>
        <dc:subject>*Comorbidity</dc:subject>
        <dc:subject>*Drug-Related Side Effects and Adverse Reactions/epidemiology/etiology</dc:subject>
        <dc:subject>*Product Surveillance, Postmarketing</dc:subject>
        <dc:subject>ACTIVATION</dc:subject>
        <dc:subject>active learning (AL)</dc:subject>
        <dc:subject>adverse drug reaction (ADR)</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems/*organization &amp; administration</dc:subject>
        <dc:subject>adverse effects</dc:subject>
        <dc:subject>alemtuzumab</dc:subject>
        <dc:subject>Alogliptin</dc:subject>
        <dc:subject>animal product</dc:subject>
        <dc:subject>Anticancer drug</dc:subject>
        <dc:subject>antineoplastic activity</dc:subject>
        <dc:subject>Antineoplastic Agents/*adverse effects/classification</dc:subject>
        <dc:subject>Association rule mining</dc:subject>
        <dc:subject>bexarotene</dc:subject>
        <dc:subject>Biomedical text mining</dc:subject>
        <dc:subject>Biomedical Text Mining</dc:subject>
        <dc:subject>BONE-RESORPTION</dc:subject>
        <dc:subject>book</dc:subject>
        <dc:subject>bortezomib</dc:subject>
        <dc:subject>brain</dc:subject>
        <dc:subject>Brain</dc:subject>
        <dc:subject>Brain/metabolism</dc:subject>
        <dc:subject>cabozantinib</dc:subject>
        <dc:subject>cancer control</dc:subject>
        <dc:subject>CENTRALITY</dc:subject>
        <dc:subject>chemical analysis</dc:subject>
        <dc:subject>Chromosomes</dc:subject>
        <dc:subject>Co morbidities</dc:subject>
        <dc:subject>commercial rapid assay test</dc:subject>
        <dc:subject>Comorbidity</dc:subject>
        <dc:subject>Comparative analysis</dc:subject>
        <dc:subject>Conditional random fields</dc:subject>
        <dc:subject>controlled vocabulary</dc:subject>
        <dc:subject>Cross validation</dc:subject>
        <dc:subject>dabrafenib</dc:subject>
        <dc:subject>Data Mining/methods</dc:subject>
        <dc:subject>Datasets as Topic/statistics &amp; numerical data</dc:subject>
        <dc:subject>Dermatology</dc:subject>
        <dc:subject>DIFFERENTIATION</dc:subject>
        <dc:subject>Discovery browsing</dc:subject>
        <dc:subject>Disease</dc:subject>
        <dc:subject>Disease comorbidity network</dc:subject>
        <dc:subject>Disease/genetics</dc:subject>
        <dc:title>Interaction between dipeptidyl-peptidase-4 inhibitors and drugs acting on renin angiotensin aldosterone system for the risk of angioedema: a pharmacovigilance assessment using disproportionality and interaction analyses</dc:title>
        <dcterms:abstract>Background: Dipeptidyl peptidase-4 inhibitors (DPP-4is) and drugs interfering with the renin-angiotensin-aldosterone system (RAAS) are frequently co-prescribed in type 2 diabetes management. Both drug classes have been independently associated with angioedema, raising concerns about potential interaction risks. This study aimed to evaluate the safety signals and interaction patterns for angioedema associated with DPP-4is alone and in combination with RAAS-interfering drugs. Methods: We conducted a comprehensive pharmacovigilance analysis using the United States Food and Drug Administration Adverse Event Reporting System (USFDA AERS) database. Disproportionality analyses employing both frequentist (Reporting Odds Ratio, Proportional Reporting Ratio) and Bayesian approaches were performed. Drug-drug interactions were assessed using multiplicative drug-drug interaction model. Additionally, we reviewed published case reports of DPP-4i-associated angioedema. Results: Analysis of 29,163,222 reports identified 588 cases of DPP-4i-associated angioedema. Significant safety signals were detected for DPP-4i monotherapies, while combinations with RAAS-interfering drugs demonstrated stronger signals through both frequentist and Bayesian analyses. Significant interaction signals were observed for sitagliptin/irbesartan, sitagliptin/valsartan, linagliptin/valsartan and alogliptin/lisinopril combinations. Alogliptin/lisinopril and sitagliptin/irbesartan combinations showed the highest risk profiles. Angioedema occurred predominantly in elderly patients (&gt; 65 years) and females. Sixteen case reports corroborated the findings from the database assessment. Clinical outcomes were comparable between monotherapy and combination therapy groups. Conclusion: This pharmacovigilance analysis reveals significant safety signals for angioedema with specific DPP-4i combinations with RAAS-interfering drugs, suggesting potential drug-drug interactions. These findings emphasize the need for careful patient monitoring, particularly in vulnerable populations, when prescribing these combinations. Further prospective studies are warranted to validate these findings and establish definitive causal relationships.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079720</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2032853952&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1758-5996">
        <prism:volume>17</prism:volume>
        <dc:title>Diabetology and Metabolic Syndrome</dc:title>
        <dc:identifier>DOI 10.1186/s13098-024-01570-y</dc:identifier>
        <prism:number>1</prism:number>
        <dcterms:alternative>Diabetol. Metab. Syndr.</dcterms:alternative>
        <dc:identifier>ISSN 1758-5996</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_928">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: J. Yi; Department of Infectious Diseases and Public Health, City University of Hong Kong, SAR, Hong Kong; email: Juanjuyi-c@my.cityu.edu.hk&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: K. Sridharan; Department of Pharmacology &amp; Therapeutics, College of Medicine &amp; Health Sciences, Arabian Gulf University, Manama, Bahrain; email: skannandr@gmail.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 3; Correspondence Address: S. Uddin; School of Project Management, Faculty of Engineering, The University of Sydney, Forest Lodge, 2037, Australia; email: shahadat.uddin@sydney.edu.au&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 4; Correspondence Address: M. Jaberi-Douraki; DATA Consortium, Olathe, United States; email: jaberi@ksu.edu&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 7; Correspondence Address: A. Hasan; Department of Computer Science and Information Systems, Birkbeck, University of London, London, WC1E 7HX, United Kingdom; email: abulhasan@dcs.bbk.ac.uk; CODEN: JBIOB&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 8; Correspondence Address: M. Song; Department of Library and Information Science, Yonsei University, Seoul, 03722, South Korea; email: min.song@yonsei.ac.kr&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 11; Correspondence Address: B. He; Institute of Intelligent System and Bioinformatics, College of Intelligent Systems Science and Engineering, Harbin Engineering University, Harbin, China; email: bohe@hrbeu.edu.cn; W. Feng; Institute of Intelligent System and Bioinformatics, College of Intelligent Systems Science and Engineering, Harbin Engineering University, Harbin, China; email: fengweixing@hrbeu.edu.cn; H. Bi; The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China; email: bohe@hrbeu.edu.cn&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 15; Correspondence Address: H. Kilicoglu; Lister Hill National Center for Biomedical Communications, U.S. National Library of Medicine, Bethesda, 8600 Rockville Pike, United States; email: kilicogluh@mail.nih.gov&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 16; Correspondence Address: A. Coulet; Inria Paris, Paris, France; email: adrien.coulet@inria.fr&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 20; Correspondence Address: R. Xu; Department of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, 2103 Cornell Road, 44106, United States; email: rxx@case.edu; CODEN: BBMIC&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 21; Correspondence Address: W. Zheng; BRITE Institute and Department of Pharmaceutical Sciences, College of Health and Sciences, North Carolina Central University, Durham, 27707, United States; email: wzheng@nccu.edu; CODEN: JBIOB&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 27; Correspondence Address: R. Xu; Center for Clinical Investigation, Case Western Reserve University, Cleveland, 44106, United States; email: rxx@case.edu; CODEN: JBIOB&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;26&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;38&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;4&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;4&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;32&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;5&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;5&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;80&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;7&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;7&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;58&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;10&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;10&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;41&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;14&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;14&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;47&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;22&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;29&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;36&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Included&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://link.springer.com/10.1007/s13300-024-01594-7">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1869-6953,%201869-6961"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xiong</foaf:surname>
                        <foaf:givenName>Si</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gou</foaf:surname>
                        <foaf:givenName>Ruoyu</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liang</foaf:surname>
                        <foaf:givenName>Xudong</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>Hao</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Qin</foaf:surname>
                        <foaf:givenName>Shuitao</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>Bing</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Luo</foaf:surname>
                        <foaf:givenName>Changjun</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>Junan</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_929"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>age</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>data analysis</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>death</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>Adolescent</dc:subject>
        <dc:subject>Adult</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>adverse events</dc:subject>
        <dc:subject>age distribution</dc:subject>
        <dc:subject>Aged</dc:subject>
        <dc:subject>antidepressant agent</dc:subject>
        <dc:subject>antiinfective agent</dc:subject>
        <dc:subject>cerebrovascular accident</dc:subject>
        <dc:subject>chi square test</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>clinical feature</dc:subject>
        <dc:subject>connective tissue disease</dc:subject>
        <dc:subject>cross-sectional study</dc:subject>
        <dc:subject>arthralgia</dc:subject>
        <dc:subject>bleeding</dc:subject>
        <dc:subject>brain hemorrhage</dc:subject>
        <dc:subject>contusion</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>clinical practice</dc:subject>
        <dc:subject>constipation</dc:subject>
        <dc:subject>ataxia</dc:subject>
        <dc:subject>acute coronary syndrome</dc:subject>
        <dc:subject>aflibercept</dc:subject>
        <dc:subject>bevacizumab</dc:subject>
        <dc:subject>brain ischemia</dc:subject>
        <dc:subject>anticoagulant agent</dc:subject>
        <dc:subject>antilipemic agent</dc:subject>
        <dc:subject>antineoplastic agent</dc:subject>
        <dc:subject>arthritis</dc:subject>
        <dc:subject>basal cell carcinoma</dc:subject>
        <dc:subject>CANCER</dc:subject>
        <dc:subject>cataract</dc:subject>
        <dc:subject>Adverse events</dc:subject>
        <dc:subject>alopecia</dc:subject>
        <dc:subject>anemia</dc:subject>
        <dc:subject>Crohn disease</dc:subject>
        <dc:subject>data analysis software</dc:subject>
        <dc:subject>Data Mining</dc:subject>
        <dc:subject>Databases, Factual</dc:subject>
        <dc:subject>dehydration</dc:subject>
        <dc:subject>anxiolytic agent</dc:subject>
        <dc:subject>apixaban</dc:subject>
        <dc:subject>dabigatran</dc:subject>
        <dc:subject>dementia</dc:subject>
        <dc:subject>atrioventricular block</dc:subject>
        <dc:subject>benign neoplasm</dc:subject>
        <dc:subject>breast disease</dc:subject>
        <dc:subject>chronic kidney failure</dc:subject>
        <dc:subject>comparative study</dc:subject>
        <dc:subject>cyst</dc:subject>
        <dc:subject>Adverse drug reaction reporting systems</dc:subject>
        <dc:subject>Antineoplastic Agents</dc:subject>
        <dc:subject>antivirus agent</dc:subject>
        <dc:subject>atorvastatin</dc:subject>
        <dc:subject>clinical outcome</dc:subject>
        <dc:subject>congenital disorder</dc:subject>
        <dc:subject>decreased appetite</dc:subject>
        <dc:subject>Aged, 80 and over</dc:subject>
        <dc:subject>abdominal discomfort</dc:subject>
        <dc:subject>ageusia</dc:subject>
        <dc:subject>Databases, Factual/*statistics &amp; numerical data</dc:subject>
        <dc:subject>acetylsalicylic acid</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems/*statistics &amp; numerical data</dc:subject>
        <dc:subject>Antibodies, Monoclonal</dc:subject>
        <dc:subject>atezolizumab</dc:subject>
        <dc:subject>apraxia</dc:subject>
        <dc:subject>clopidogrel</dc:subject>
        <dc:subject>anticholinergic syndrome</dc:subject>
        <dc:subject>Confounding Factors, Epidemiologic</dc:subject>
        <dc:subject>anticonvulsive agent</dc:subject>
        <dc:subject>application site reaction</dc:subject>
        <dc:subject>cholecystitis</dc:subject>
        <dc:subject>cytokine release syndrome</dc:subject>
        <dc:subject>Antibodies, Monoclonal, Humanized</dc:subject>
        <dc:subject>avelumab</dc:subject>
        <dc:subject>cemiplimab</dc:subject>
        <dc:subject>cabozantinib</dc:subject>
        <dc:subject>ABSORPTION</dc:subject>
        <dc:subject>accidental injury</dc:subject>
        <dc:subject>acute cholecystitis</dc:subject>
        <dc:subject>ACUTE LYMPHOBLASTIC-LEUKEMIA</dc:subject>
        <dc:subject>ADE</dc:subject>
        <dc:subject>agnosia</dc:subject>
        <dc:subject>angiogenesis inhibitor</dc:subject>
        <dc:subject>angiogenesis inhibitors</dc:subject>
        <dc:subject>Angiogenesis Inhibitors</dc:subject>
        <dc:subject>ANTI-IL-23</dc:subject>
        <dc:subject>ANTIANGIOGENIC THERAPY</dc:subject>
        <dc:subject>Antibodies, Bispecific</dc:subject>
        <dc:subject>ANTIBODY</dc:subject>
        <dc:subject>antiulcer agent</dc:subject>
        <dc:subject>axitinib</dc:subject>
        <dc:subject>BASAL-CELL CARCINOMA</dc:subject>
        <dc:subject>bayesian confidence interval progressive neural network</dc:subject>
        <dc:subject>BEVACIZUMAB</dc:subject>
        <dc:subject>bispecific antibody</dc:subject>
        <dc:subject>blinatumomab</dc:subject>
        <dc:subject>Blinatumomab</dc:subject>
        <dc:subject>camrelizumab</dc:subject>
        <dc:subject>catequentinib</dc:subject>
        <dc:subject>cediranib</dc:subject>
        <dc:subject>central nervous system disease</dc:subject>
        <dc:subject>Cheyne Stokes breathing</dc:subject>
        <dc:subject>compartment syndrome</dc:subject>
        <dc:subject>congenital blood vessel malformation</dc:subject>
        <dc:subject>cumulative incidence</dc:subject>
        <dc:subject>cytotoxic T lymphocyte antigen 4</dc:subject>
        <dc:subject>data aggregation</dc:subject>
        <dc:subject>Databases</dc:subject>
        <dc:title>Adverse Events of Oral GLP-1 Receptor Agonist (Semaglutide Tablets): A Real-World Study Based on FAERS from 2019 to 2023</dc:title>
        <dc:date>2024</dc:date>
        <z:language>en</z:language>
        <dc:coverage>rayyan-281079715</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://link.springer.com/10.1007/s13300-024-01594-7</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>0008-01-01</dcterms:dateSubmitted>
        <bib:pages>1717-1733</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1869-6953,%201869-6961">
        <prism:volume>15</prism:volume>
        <dc:title>Diabetes Therapy</dc:title>
        <dc:identifier>DOI 10.1007/s13300-024-01594-7</dc:identifier>
        <prism:number>8</prism:number>
        <dcterms:alternative>Diabetes Ther</dcterms:alternative>
        <dc:identifier>ISSN 1869-6953, 1869-6961</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_929">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: C. Tu; Department of Dermatology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China; email: tuchen2023@126.com; D. Zhang; Department of Dermatology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China; email: zhangdewu0101@163.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: G. Li; Department of Pharmacy, National Cancer Center, National Cnical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical SciencesPeking Union Medical College, Beijing, No. 17, Panjiayuan Nan, Chaoyang District, 100021, China; email: lgh0603@126.com; Y. Wang; Department of Comprehensive Oncology, National Cancer Center, National Cnical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical SciencesPeking Union Medical College, Beijing, No. 17, Panjiayuan Nan, Chaoyang District, 100021, China; email: wangyf@cicams.ac.cn; CODEN: IJIPE&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: R. Wan; State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, No. 17, Panjiayuan Nanli, Chaoyang District, 100021, China; email: wanrui243@163.com; Y. Wang; Department of Comprehensive Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, No. 17, Panjiayuan Nanli, Chaoyang District, 100021, China; email: wangyf@cicams.ac.cn; CODEN: BCMAC&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 2; Correspondence Address: R. Racz; Division of Applied Regulatory Science, US Food and Drug Administration, Silver Spring, United States; email: Rebecca.Racz@fda.hhs.gov; CODEN: EJCPA&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 2; Correspondence Address: X. Wang; State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine/Department of Lymphoma, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Sino-US Center for Lymphoma and Leukemia Research, Tianjin, 300060, China; email: tjzlyy_xianhuow@163.com; H. Zhang; State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine/Department of Lymphoma, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Sino-US Center for Lymphoma and Leukemia Research, Tianjin, 300060, China; email: huilai_zhang@163.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 3; Correspondence Address: I.-W. Kim; Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, 1 Gwanak-ro, Gwanak-gu, 08826, South Korea; email: iwkim2@hanmail.net&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 3; Correspondence Address: Z. Zhang; Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China; email: in-mind@foxmail.com; CODEN: JCPTE&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 9; Correspondence Address: C. Luo; Department of Cardiology, Affiliated Liutie Central Hospital of Guangxi Medical University, Liuzhou, Feie Road Limin District 14, Guangxi, 545007, China; email: luochangjun@gxmu.edu.cn; J. Chen; Department of Endocrinology, Affiliated Liutie Central Hospital of Guangxi Medical University, Liuzhou, Feie Road Limin District 14, Guangxi, 545007, China; email: 261782062@qq.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 10; Correspondence Address: Y. Hou; Department of Urology, The First Hospital of Jilin University, Changchun, China; email: houyc@jlu.edu.cn; H. Guo; Department of Urology, The First Hospital of Jilin University, Changchun, China; email: guohui315@jlu.edu.cn&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 16; Correspondence Address: S. Tang; Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; email: tangshu2008@163.com; X. Zhang; Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; email: Zhxj0524@sina.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 25; Correspondence Address: Q. Zhang; Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; email: qilinzhang88@163.com&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;58&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;69&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;71&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;35&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;8&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;9&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;30&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;11&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;11&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;33&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;27&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;27&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;44&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Included&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Dados reais | USER-NOTES: {&quot;Silvio&quot;=&gt;[&quot;Me parece interessante principalmente pela PLN e Teoria Bayesiana, mas não identifiquei alinhamento explícito comcom Data Mining.&quot;]}</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2033279795&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1432-069X"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Huang</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>P.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_930"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>skin disease</dc:subject>
        <dc:subject>acne</dc:subject>
        <dc:subject>dermatitis</dc:subject>
        <dc:subject>eczema</dc:subject>
        <dc:subject>prurigo</dc:subject>
        <dc:subject>data extraction</dc:subject>
        <dc:subject>anus pruritus</dc:subject>
        <dc:subject>atopic dermatitis</dc:subject>
        <dc:subject>rash</dc:subject>
        <dc:subject>dry skin</dc:subject>
        <dc:subject>erythema</dc:subject>
        <dc:subject>hyperpigmentation</dc:subject>
        <dc:subject>medical information</dc:subject>
        <dc:subject>angioneurotic edema</dc:subject>
        <dc:subject>urticaria</dc:subject>
        <dc:subject>reference database</dc:subject>
        <dc:subject>abnormal hair growth</dc:subject>
        <dc:subject>abnormal skin texture</dc:subject>
        <dc:subject>abrocitinib</dc:subject>
        <dc:subject>acne cystica</dc:subject>
        <dc:subject>lichenoid eruption</dc:subject>
        <dc:subject>maculopapular rash</dc:subject>
        <dc:subject>neurodermatitis</dc:subject>
        <dc:subject>papular rash</dc:subject>
        <dc:subject>pigment disorder</dc:subject>
        <dc:subject>postinflammatory pigmentation change</dc:subject>
        <dc:subject>rosacea</dc:subject>
        <dc:subject>scab</dc:subject>
        <dc:subject>skin bleeding</dc:subject>
        <dc:subject>skin burning sensation</dc:subject>
        <dc:subject>skin defect</dc:subject>
        <dc:subject>skin exfoliation</dc:subject>
        <dc:subject>skin fissure</dc:subject>
        <dc:subject>skin injury</dc:subject>
        <dc:subject>skin irritation</dc:subject>
        <dc:subject>skin manifestation</dc:subject>
        <dc:subject>skin pain</dc:subject>
        <dc:subject>skin swelling</dc:subject>
        <dc:subject>skin weeping</dc:subject>
        <dc:title>A pharmacovigilance analysis of abrocitinib-related skin adverse events based on the FDA Adverse Event Reporting System (FAERS)</dc:title>
        <dcterms:abstract>In January 2022, the U.S. Food and Drug Administration (FDA) approved the marketing of abrocitinib, an oral small molecule selectively inhibiting Janus kinase, for the treatment of patients with recurrent moderate to severe atopic dermatitis. Despite the lack of long-term post-marketing safety studies, this drug was cited with a black box warning by the FDA for potentially increasing the risk of several severe adverse events (AEs). This retrospective pharmacovigilance disproportionality analysis study used data from the FDA Adverse Event Reporting System (FAERS) from the first quarter of 2022 to the first quarter of 2024, aiming to analyze the potential association between abrocitinib and skin AEs. Three disproportionality measurement were performed for data mining, including the reporting odd ratio method, the proportional reporting ratio method and the Medicines and Healthcare products Regulatory Agency method. Out of 3,269,835 AE reports extracted from the database, 699 cases of skin-related AEs were identified, where abrocitinib was implicated as the primary suspect drug. The patient demographic information, outcomes and report sources were analyzed. 34 kinds of positive risk signals were detected, many of which were unexpected safety signals. This study provided a scientific reference to understand the safety of abrocitinib in practical applications.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079723</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2033279795&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1432-069X">
        <prism:volume>317</prism:volume>
        <dc:title>Archives of Dermatological Research</dc:title>
        <dc:identifier>DOI 10.1007/s00403-025-03959-9</dc:identifier>
        <prism:number>1</prism:number>
        <dcterms:alternative>Arch. Dermatol. Res.</dcterms:alternative>
        <dc:identifier>ISSN 1432-069X</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_930">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Excluded&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância | USER-NOTES: {&quot;Silvio&quot;=&gt;[&quot;Não identifiquei alinhamento com DM ou ML aplicada.&quot;]}&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2033214851&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:2314-7253"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sun</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhou</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Luo</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Guo</foaf:surname>
                        <foaf:givenName>Q.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sun</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jia</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Qin</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Guo</foaf:surname>
                        <foaf:givenName>P.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_931"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>age</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data analysis</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>factual database</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>Adolescent</dc:subject>
        <dc:subject>Adult</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>adverse outcome</dc:subject>
        <dc:subject>age distribution</dc:subject>
        <dc:subject>Aged</dc:subject>
        <dc:subject>cardiovascular disease</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>Child</dc:subject>
        <dc:subject>connective tissue disease</dc:subject>
        <dc:subject>descriptive research</dc:subject>
        <dc:subject>disproportionality analysis</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>cardiomyopathy</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>depression</dc:subject>
        <dc:subject>dizziness</dc:subject>
        <dc:subject>epidemiology</dc:subject>
        <dc:subject>FAERS</dc:subject>
        <dc:subject>faintness</dc:subject>
        <dc:subject>abnormal sensation</dc:subject>
        <dc:subject>constipation</dc:subject>
        <dc:subject>fatigue</dc:subject>
        <dc:subject>delirium</dc:subject>
        <dc:subject>atrial fibrillation</dc:subject>
        <dc:subject>eye disease</dc:subject>
        <dc:subject>aripiprazole</dc:subject>
        <dc:subject>bayesian confidence propagation neural network</dc:subject>
        <dc:subject>Bayesian network</dc:subject>
        <dc:subject>bile duct carcinoma</dc:subject>
        <dc:subject>Child, Preschool</dc:subject>
        <dc:subject>adverse drug reactions</dc:subject>
        <dc:subject>Adverse events</dc:subject>
        <dc:subject>allergy</dc:subject>
        <dc:subject>asthenia</dc:subject>
        <dc:subject>CHEMOTHERAPY</dc:subject>
        <dc:subject>data analysis software</dc:subject>
        <dc:subject>Data mining</dc:subject>
        <dc:subject>Databases, Factual</dc:subject>
        <dc:subject>diarrhea</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>analysis</dc:subject>
        <dc:subject>cystitis</dc:subject>
        <dc:subject>diverticulitis</dc:subject>
        <dc:subject>dyspnea</dc:subject>
        <dc:subject>coronavirus disease 2019</dc:subject>
        <dc:subject>demography</dc:subject>
        <dc:subject>Disproportionality analysis</dc:subject>
        <dc:subject>drug database</dc:subject>
        <dc:subject>EFFICACY</dc:subject>
        <dc:subject>clozapine</dc:subject>
        <dc:subject>asthma</dc:subject>
        <dc:subject>breast disease</dc:subject>
        <dc:subject>Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>ear disease</dc:subject>
        <dc:subject>depressed blood pressure</dc:subject>
        <dc:subject>drug efficacy</dc:subject>
        <dc:subject>drug labeling</dc:subject>
        <dc:subject>anaphylactoid reaction</dc:subject>
        <dc:subject>bronchospasm</dc:subject>
        <dc:subject>endocrine disease</dc:subject>
        <dc:subject>benzoxazole derivative</dc:subject>
        <dc:subject>Benzoxazoles</dc:subject>
        <dc:subject>CELL LUNG-CANCER</dc:subject>
        <dc:subject>decreased appetite</dc:subject>
        <dc:subject>aortic regurgitation</dc:subject>
        <dc:subject>afatinib</dc:subject>
        <dc:subject>Aged, 80 and over</dc:subject>
        <dc:subject>allopurinol</dc:subject>
        <dc:subject>amisulpride</dc:subject>
        <dc:subject>antipsychotics</dc:subject>
        <dc:subject>chlorpromazine</dc:subject>
        <dc:subject>droperidol</dc:subject>
        <dc:subject>detection algorithm</dc:subject>
        <dc:subject>data processing</dc:subject>
        <dc:subject>akathisia</dc:subject>
        <dc:subject>extrapyramidal syndrome</dc:subject>
        <dc:subject>acute myeloid leukemia</dc:subject>
        <dc:subject>COMBINATION</dc:subject>
        <dc:subject>erythema multiforme</dc:subject>
        <dc:subject>disease exacerbation</dc:subject>
        <dc:subject>dystonia</dc:subject>
        <dc:subject>cytarabine</dc:subject>
        <dc:subject>ASPIRIN</dc:subject>
        <dc:subject>drug tolerability</dc:subject>
        <dc:subject>daridorexant</dc:subject>
        <dc:subject>drug screening</dc:subject>
        <dc:subject>aciclovir</dc:subject>
        <dc:subject>azacitidine</dc:subject>
        <dc:subject>baloxavir marboxil</dc:subject>
        <dc:subject>bleeding tendency</dc:subject>
        <dc:subject>acrylamide derivative</dc:subject>
        <dc:subject>acute graft versus host disease</dc:subject>
        <dc:subject>ACUTE INFLUENZA</dc:subject>
        <dc:subject>acute respiratory tract disease</dc:subject>
        <dc:subject>ADULTS</dc:subject>
        <dc:subject>Advers drug events</dc:subject>
        <dc:subject>AFATINIB</dc:subject>
        <dc:subject>aniline derivative</dc:subject>
        <dc:subject>antineoplastic metal complex</dc:subject>
        <dc:subject>Baloxavir Marboxil</dc:subject>
        <dc:subject>BGJ398</dc:subject>
        <dc:subject>chlorprothixene</dc:subject>
        <dc:subject>cyanocobalamin</dc:subject>
        <dc:subject>differentiation syndrome</dc:subject>
        <dc:subject>DIFFERENTIATION SYNDROME</dc:subject>
        <dc:subject>diseases</dc:subject>
        <dc:subject>Dizziness</dc:subject>
        <dc:subject>drug research</dc:subject>
        <dc:subject>DRUG-REACTIONS</dc:subject>
        <dc:subject>Drug-related ADRs</dc:subject>
        <dc:subject>eating disorder</dc:subject>
        <dc:subject>enasidenib</dc:subject>
        <dc:subject>Enasidenib</dc:subject>
        <dc:subject>epidermal growth factor receptor</dc:subject>
        <dc:subject>erlotinib</dc:subject>
        <dc:subject>ERLOTINIB</dc:subject>
        <dc:subject>erythrocyte count</dc:subject>
        <dc:subject>essential hypertension</dc:subject>
        <dc:subject>ETANERCEPT</dc:subject>
        <dc:subject>EXPRESSION</dc:subject>
        <dc:title>Safety profiles of IDH inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database</dc:title>
        <dcterms:abstract>Background: With the increased use of isocitrate dehydrogenase (IDH) inhibitors in acute myeloid leukemia (AML) and cholangiocarcinoma, the toxicity of these drugs is a growing concern. This study aimed to evaluate the adverse events (AEs) of IDH inhibitors based on the Food and Drug Administration Adverse Event Reporting System (FAERS) database. Methods: AE reports for IDH inhibitors (enasidenib, ivosidenib, and olutasidenib) were collected and analyzed from the time of launch through the first quarter of 2024. Only IDH inhibitors reported as the target drug and coded as the primary suspect (PS) were included in the analysis. AEs were standardized and classified according to the preferred term (PT) and system organ classification (SOC) in the Medical Dictionary for Regulatory Activities (MedDRA) version 26.0. Disproportionality analyses including the reporting odds ratio and the Bayesian confidence propagation neural network were performed in data mining to assess IDH inhibitor-relatedAEs. Differentiation syndrome was the AE of special interest. Results: The reports number of enasidenib, ivosidenib, and olutasidenib was 11 616 357, 10 067 250, and 2 563 464, respectively. A total of 80 enasidenib-related signals involving 15 SOCs, 78 ivosidenib-related signals involving 17 SOCs, and 7 olutasidenib-related signals involving 4 SOCs were obtained. The most signals reported were “blood and lymphatic system disorders,” “infections and infestations,” and “nervous system disorders” in enasidenib. For signals of ivosidenib, the most frequently reported were “gastrointestinal disorders,” “general disorders and administration site conditions,” and “injury, poisoning and procedural complications.” Ivosidenib was the only IDH inhibitor with signals in “cardiac disorders.” Differentiation syndrome events were reported in 89, 40, and 2 cases for enasidenib, ivosidenib, and olutasidenib, respectively. The median time to onset was 26–31 days for ivosidenib and enasidenib. AML was the most common indication in the differentiation syndrome reports. Conclusions: Our study identifies potential AE signals associated with IDH inhibitors and provides a broader understanding of the safety. The safety profiles highlight the need for long-term safety monitoring of IDH inhibitor recipients. Promptly monitoring and intervention in specific organ systems depending on the type of IDH inhibitor may improve the overall survival or enhance the quality of life. In the future, it will be necessary to validate our findings in prospective large-scale studies and to investigate the underlying mechanisms.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079722</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2033214851&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:2314-7253">
        <prism:volume>11</prism:volume>
        <dc:title>Future Journal of Pharmaceutical Sciences</dc:title>
        <dc:identifier>DOI 10.1186/s43094-025-00769-8</dc:identifier>
        <prism:number>1</prism:number>
        <dcterms:alternative>Future J. Pharm. Sci.</dcterms:alternative>
        <dc:identifier>ISSN 2314-7253</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_931">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: Y. Li; Department of Respiratory Medicine, National Key Clinical Specialty, Xiangya Hospital, Central South University, Hunan, 410078, China; email: liying971@163.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 3; Correspondence Address: W. Peng; Department of Neurology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China; email: pengwei0625@163.com; L. Zhao; Department of Psychiatry, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China; email: zhaoly0703@163.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 4; Correspondence Address: M.A. Barbieri; Department of Clinical and Experimental Medicine, University of Messina, Messina, 98125, Italy; email: mbarbieri@unime.it&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 7; Correspondence Address: Y. Han; Department of Dermatology, The Union Hospital, Fujian Medical University, Fuzhou, Fujian, China; email: dr_hanyue@126.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 9; Correspondence Address: Z. Feng; School of Medicine and Health Management, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; email: zcfeng@hust.edu.cn; D. Feng; School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; email: fengda@hust.edu.cn&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 11; Correspondence Address: Z. An; Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China; email: anzhuoling@163.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 55; Correspondence Address: T.T. Shimabukuro; Immunization Safety Office, Centers for Disease Control and Prevention (CDC), Atlanta, 1600 Clifton Rd, 30329, United States; email: tshimabukuro@cdc.gov; CODEN: PEDIA&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;16&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;33&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;39&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;3&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;3&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;42&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;6&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;6&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;50&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;9&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;10&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;56&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;58&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;61&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;53&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Included&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2039035353&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1932-6203"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wen</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1014"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>death</dc:subject>
        <dc:subject>factual database</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>incidence</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>*Data Mining</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>Bayes Theorem</dc:subject>
        <dc:subject>connective tissue disease</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>health care personnel</dc:subject>
        <dc:subject>outcome assessment</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>United States Food and Drug Administration</dc:subject>
        <dc:subject>bone pain</dc:subject>
        <dc:subject>fatigue</dc:subject>
        <dc:subject>gastrointestinal disease</dc:subject>
        <dc:subject>mental disease</dc:subject>
        <dc:subject>neurologic disease</dc:subject>
        <dc:subject>skin disease</dc:subject>
        <dc:subject>brain infarction</dc:subject>
        <dc:subject>eye disease</dc:subject>
        <dc:subject>very elderly</dc:subject>
        <dc:subject>Bayesian network</dc:subject>
        <dc:subject>data analysis software</dc:subject>
        <dc:subject>Data Mining</dc:subject>
        <dc:subject>Databases, Factual</dc:subject>
        <dc:subject>lymphatic system disease</dc:subject>
        <dc:subject>heart disease</dc:subject>
        <dc:subject>vascular disease</dc:subject>
        <dc:subject>dementia</dc:subject>
        <dc:subject>breast disease</dc:subject>
        <dc:subject>dysphagia</dc:subject>
        <dc:subject>ear disease</dc:subject>
        <dc:subject>hepatobiliary disease</dc:subject>
        <dc:subject>injury</dc:subject>
        <dc:subject>kidney disease</dc:subject>
        <dc:subject>musculoskeletal disease</dc:subject>
        <dc:subject>polyp</dc:subject>
        <dc:subject>procedural site reaction</dc:subject>
        <dc:subject>Antiviral Agents</dc:subject>
        <dc:subject>antivirus agent</dc:subject>
        <dc:subject>drug efficacy</dc:subject>
        <dc:subject>drug approval</dc:subject>
        <dc:subject>hepatitis B</dc:subject>
        <dc:subject>neoplasm</dc:subject>
        <dc:subject>pharmacist</dc:subject>
        <dc:subject>statistical analysis</dc:subject>
        <dc:subject>system organ class</dc:subject>
        <dc:subject>Bayesian confidence propagation neural network</dc:subject>
        <dc:subject>*Adverse Drug Reaction Reporting Systems/statistics &amp; numerical data</dc:subject>
        <dc:subject>proportional reporting ratio</dc:subject>
        <dc:subject>adenine</dc:subject>
        <dc:subject>psychiatric complication</dc:subject>
        <dc:subject>]</dc:subject>
        <dc:subject>*Adenine/analogs &amp; derivatives/adverse effects/therapeutic use</dc:subject>
        <dc:subject>*Antiviral Agents/adverse effects/therapeutic use</dc:subject>
        <dc:subject>*Tenofovir/analogs &amp; derivatives/adverse effects</dc:subject>
        <dc:subject>Adenine</dc:subject>
        <dc:subject>alanine</dc:subject>
        <dc:subject>Alanine</dc:subject>
        <dc:subject>connective tissue</dc:subject>
        <dc:subject>disability assessment</dc:subject>
        <dc:subject>gamma poisson shrinker</dc:subject>
        <dc:subject>Hepatitis B virus</dc:subject>
        <dc:subject>high risk population</dc:subject>
        <dc:subject>immune complex disease</dc:subject>
        <dc:subject>infections associated with other infections or conditions</dc:subject>
        <dc:subject>labyrinthitis</dc:subject>
        <dc:subject>life threat</dc:subject>
        <dc:subject>lipid fingerprinting</dc:subject>
        <dc:subject>organ systems</dc:subject>
        <dc:subject>Poisson distribution</dc:subject>
        <dc:subject>reproductive health</dc:subject>
        <dc:subject>tenofovir</dc:subject>
        <dc:subject>Tenofovir</dc:subject>
        <dc:subject>tenofovir alafenamide</dc:subject>
        <dc:title>A real-world disproportionality analysis of Tenofovir Alafenamide (TAF): Data mining of the FDA adverse event reporting system (FAERS)</dc:title>
        <dcterms:abstract>Objects Tenofovir Alafenamide (TAF) is a novel antiviral drug approved for the treatment of hepatitis B virus (HBV) infection. Our research objective was to evaluate the safety characteristics of TAF in practical settings by analyzing data from the FDA adverse event reporting system (FAERS) database maintained by the Food and Drug Administration (FDA). Method In our investigation, we examined the uneven distribution of adverse events associated with TAF by employing statistical metrics including the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Gamma-Poisson Shrinker (GPS) to determine their significance. Results Out of the 57692002 case reports in the FAERS database, 1911 reported TAF as a major suspected (PS) adverse events (AEs). A disproportionate analysis identified 43 preferred terms (PTs) related to TAF. It is worth noting that we have observed unexpected significant adverse events, such as cerebral infarction, bone pain, swallowing difficulties, drug resistance, dementia, etc., which are not mentioned in the drug instructions. Conclusion These findings unearth novel neurological, metabolic, and resistance - related risks, thereby necessitating a marked increase in clinical vigilance. The identification of signals related to cerebral infarction and dementia implies potential vascular/metabolic interplay, highlighting the importance of lipid monitoring among long - term tenofovir alafenamide (TAF) users. In response, healthcare providers should prioritize strengthening the monitoring of neurological symptoms and lipid profiles, reevaluating bone health assessment and management protocols especially in high - risk populations, and providing support to enhance patient adherence to mitigate resistance risks. This analysis offers crucial post - marketing evidence, which is instrumental in optimizing the risk - benefit balance of TAF in the long - term management of chronic hepatitis B virus (HBV) infection.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079734</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2039035353&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1932-6203">
        <prism:volume>20</prism:volume>
        <dc:title>PLOS ONE</dc:title>
        <dc:identifier>DOI 10.1371/journal.pone.0324675</dc:identifier>
        <prism:number>6</prism:number>
        <dcterms:alternative>Plos One.</dcterms:alternative>
        <dc:identifier>ISSN 1932-6203</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1014">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: Y. Li; Linfen Central Hospital, Linfen, China; email: 17631081@qq.com; CODEN: POLNC&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Included&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L647468986&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:2045-2322"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wan</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhou</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Huang</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1013"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>factual database</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>epidemiology</dc:subject>
        <dc:subject>monoclonal antibody</dc:subject>
        <dc:subject>brodalumab</dc:subject>
        <dc:title>Analysis and mining of brodalumab adverse events based on FAERS database</dc:title>
        <dcterms:abstract>The aim of this study is to evaluate the real-world safety of brodalumab by analyzing adverse events (AEs) associated with the drug. The AE reports related to brodalumab from the FAERS database from 2017 Q1 to 2023 Q4 were collected. Subsequently, we employed four disproportionality analysis methods to identify positive signals among AEs associated with brodalumab, including Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-Item Gamma Poisson Shrinker (MGPS). In 1480 AE reports with brodalumab as the primary suspected drug, 168 preferred terms (PTs) exhibiting positive signals were identified. This study confirmed several known positive AEs, such as injection site vesicles and injection site hemorrhage. In addition, the study identified several positive AEs not listed in the drug product information, including palmoplantar pustulosis and extranodal marginal zone b-cell lymphoma (malt type). This study evaluated the real-world safety profile of brodalumab and identified several unexpected AEs, such as palmoplantar pustulosis and extranodal marginal zone b-cell lymphoma (malt type). These findings provide new safety insights for clinicians and may contribute to the safer and more rational use of brodalumab in clinical practice.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079735</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L647468986&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>18175</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:2045-2322">
        <prism:volume>15</prism:volume>
        <dc:title>Scientific reports</dc:title>
        <dc:identifier>DOI 10.1038/s41598-025-03192-4</dc:identifier>
        <prism:number>1</prism:number>
        <dcterms:alternative>Sci Rep</dcterms:alternative>
        <dc:identifier>ISSN 2045-2322</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1013">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Included&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2039144736&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:2044-6055"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shan</foaf:surname>
                        <foaf:givenName>W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhu</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shen</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1015"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>heart failure</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>age distribution</dc:subject>
        <dc:subject>cardiotoxicity</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>cohort analysis</dc:subject>
        <dc:subject>myocarditis</dc:subject>
        <dc:subject>sex difference</dc:subject>
        <dc:subject>atrial fibrillation</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>clinical outcome</dc:subject>
        <dc:subject>infant</dc:subject>
        <dc:subject>immunopathology</dc:subject>
        <dc:subject>drug monitoring</dc:subject>
        <dc:subject>newborn</dc:subject>
        <dc:subject>pericardial effusion</dc:subject>
        <dc:subject>atezolizumab</dc:subject>
        <dc:subject>ipilimumab</dc:subject>
        <dc:subject>nivolumab</dc:subject>
        <dc:subject>pembrolizumab</dc:subject>
        <dc:subject>immune checkpoint inhibitor</dc:subject>
        <dc:subject>avelumab</dc:subject>
        <dc:subject>cemiplimab</dc:subject>
        <dc:subject>durvalumab</dc:subject>
        <dc:title>Gender and age disparities in cardiac immune-related adverse events associated with immune checkpoint inhibitors: A pharmacovigilance analysis of the FAERS database</dc:title>
        <dcterms:abstract>Objectives The cardiotoxicity of immune checkpoint inhibitors (ICIs) has garnered significant clinical attention due to its high mortality rate. However, limited clinical research and inconsistent results have hindered a comprehensive understanding of this issue. This study seeks to elucidate gender and age differences in cardiac-related adverse reactions, aiming to offer scientific evidence to inform clinical practice. Design A retrospective pharmacovigilance study. Setting Based on the reports of ICIs in the FDA Adverse Event Reporting System database from 2003-2023, we conducted a disproportionality analysis to identify cardiac immune-related adverse events (irAEs) and explored the correlation of age and gender with these adverse events. Main outcome measures The main cardiac irAEs were defined by four preferred terms: myocarditis, atrial fibrillation, cardiac failure and pericardial effusion. Both the proportional reporting ratio (PRR) and reporting odds ratio (ROR) are frequency methods. Data mining was performed using the PRR method, which assesses the relative risk of adverse drug reactions by comparing the frequency of reports associating a specific drug with a particular adverse reaction to the frequency of reports linking any drug to the same reaction. A higher PRR indicates a more robust adverse event signal, suggesting a stronger statistical association between the drug of interest and the target adverse event. In the research process, we primarily used the ROR and PRR from disproportionality analysis to screen for cardiac irAEs, while also elucidating the correlation between these reactions and factors such as age and gender. Results A total of 2033 adverse events were retrieved, and myocarditis was the most common cardiac irAEs. Gender disparities exist in the incidence of various adverse reactions to the same medication. Female patients need to be particularly vigilant for cardiac adverse events when taking atezolizumab, and male patients should be especially cautious for cardiac adverse events when using ipilimumab. Furthermore, ipilimumab produced a positive signal for pericardial effusion in the elderly group but not in the younger group, suggesting that elderly patients may be more susceptible to adverse reactions. Therefore, increased vigilance and careful monitoring are warranted during clinical administration of this medication to elderly patients. Conclusion Our study highlights the gender and age differences in cardiac adverse events with ICIs, providing valuable insights for clinical application.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079733</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2039144736&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:2044-6055">
        <prism:volume>15</prism:volume>
        <dc:title>BMJ Open</dc:title>
        <dc:identifier>DOI 10.1136/bmjopen-2024-090087</dc:identifier>
        <prism:number>6</prism:number>
        <dcterms:alternative>BMJ Open</dcterms:alternative>
        <dc:identifier>ISSN 2044-6055</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1015">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Included&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2034688716&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:2050-6511"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lai</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jin</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhou</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sheng</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xie</foaf:surname>
                        <foaf:givenName>G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Fang</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1017"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>odds ratio</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>melena</dc:subject>
        <dc:subject>rhabdomyolysis</dc:subject>
        <dc:subject>cardiopulmonary insufficiency</dc:subject>
        <dc:subject>cyanosis</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>depression</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>observational study</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>vomiting</dc:subject>
        <dc:subject>altered state of consciousness</dc:subject>
        <dc:subject>brain disease</dc:subject>
        <dc:subject>hallucination</dc:subject>
        <dc:subject>seizure</dc:subject>
        <dc:subject>risk assessment</dc:subject>
        <dc:subject>anticoagulant agent</dc:subject>
        <dc:subject>Bayesian network</dc:subject>
        <dc:subject>anaphylaxis</dc:subject>
        <dc:subject>disseminated intravascular clotting</dc:subject>
        <dc:subject>cystitis</dc:subject>
        <dc:subject>demographics</dc:subject>
        <dc:subject>drug use</dc:subject>
        <dc:subject>drug eruption</dc:subject>
        <dc:subject>lip swelling</dc:subject>
        <dc:subject>bronchitis</dc:subject>
        <dc:subject>enterocolitis</dc:subject>
        <dc:subject>pneumonia</dc:subject>
        <dc:subject>clinical monitoring</dc:subject>
        <dc:subject>lower respiratory tract infection</dc:subject>
        <dc:subject>shock</dc:subject>
        <dc:subject>face edema</dc:subject>
        <dc:subject>facial nerve paralysis</dc:subject>
        <dc:subject>pediatric patient</dc:subject>
        <dc:subject>abnormal dreaming</dc:subject>
        <dc:subject>urticaria</dc:subject>
        <dc:subject>erythema multiforme</dc:subject>
        <dc:subject>abnormal behavior</dc:subject>
        <dc:subject>unconsciousness</dc:subject>
        <dc:subject>baloxavir marboxil</dc:subject>
        <dc:subject>bleeding tendency</dc:subject>
        <dc:subject>confounding variable</dc:subject>
        <dc:subject>eyelid swelling</dc:subject>
        <dc:subject>febrile delirium</dc:subject>
        <dc:subject>human tissue</dc:subject>
        <dc:subject>influenza</dc:subject>
        <dc:subject>ischemic colitis</dc:subject>
        <dc:subject>Japan</dc:subject>
        <dc:subject>liver dysfunction</dc:subject>
        <dc:subject>longitudinal study</dc:subject>
        <dc:subject>paralytic ileus</dc:subject>
        <dc:subject>spatial analysis</dc:subject>
        <dc:title>Safety evaluation of baloxavir marboxil: analysis and discussion utilizing real adverse events from the FAERS database</dc:title>
        <dcterms:abstract>Background: As a novel anti-influenza agent, baloxavir marboxil lacks real-world safety data in large populations. Therefore, this study aimed to investigate adverse drug events (ADEs) associated with baloxavir marboxil by analyzing the Food and Drug Administration Adverse Event Reporting System (FAERS) database. Methods: Adverse event reports involving baloxavir marboxil were extracted from the FAERS database spanning the fourth quarter of 2018 to the third quarter of 2023. Demographic characteristics and reporter profiles were analyzed to characterize the exposed population. A disproportionality analysis was performed using four validated pharmacovigilance algorithms: reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and multi-item gamma Poisson shrinker (MGPS). These complementary approaches were employed to detect, prioritize, and validate potential safety signals. Results: Analysis of 8,824,675 ADE reports from the FAERS database identified 1,654 cases (0.19%) associated with baloxavir marboxil. Pediatric patients (&lt; 18 years) exhibited the highest ADE reporting rate. Geospatial analysis revealed marked clustering, with 98.97% of reports originating from the United States (63.2%) and Japan (35.77%). We detected 47 significant safety signals spanning 27 System Organ Classes (SOCs), including established reactions such as pneumonia (n = 90) and vomiting (n = 77). Novel signals emerging from the analysis comprised hemorrhagic diathesis (n = 3), rhabdomyolysis (n = 25), hepatic dysfunction (n = 13), and cardiorespiratory arrest (n = 7). Notably, bleeding-related events (e.g., ischemic colitis, IC025 = 5.03) and neurological complications (e.g., febrile delirium, IC025 = 9.12) demonstrated statistically significant associations. Conclusion: This pharmacovigilance study identifies previously undercharacterized safety signals associated with baloxavir marboxil, including hemorrhagic complications, liver dysfunction, rhabdomyolysis, and life-threatening cardiorespiratory events. Pediatric populations and patients on anticoagulants may require heightened monitoring. While these findings provide critical pharmacovigilance insights, our study is inherently constrained by the spontaneous reporting system, which introduces potential underreporting, reporting biases, and confounding factors. Future research could employ more rigorous prospective study designs, integrating clinical trials and epidemiological studies, to more accurately assess the safety risks of baloxavir marboxil.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079724</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2034688716&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:2050-6511">
        <prism:volume>26</prism:volume>
        <dc:title>BMC Pharmacology and Toxicology</dc:title>
        <dc:identifier>DOI 10.1186/s40360-025-00940-0</dc:identifier>
        <prism:number>1</prism:number>
        <dcterms:alternative>BMC Pharmacol. Toxicol.</dcterms:alternative>
        <dc:identifier>ISSN 2050-6511</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1017">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Included&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2038433974&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1573-2517"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jiang</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Du</foaf:surname>
                        <foaf:givenName>Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lu</foaf:surname>
                        <foaf:givenName>R.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gao</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhu</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1018"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>clinical feature</dc:subject>
        <dc:subject>connective tissue disease</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>depression</dc:subject>
        <dc:subject>dizziness</dc:subject>
        <dc:subject>clinical practice</dc:subject>
        <dc:subject>automutilation</dc:subject>
        <dc:subject>gastrointestinal disease</dc:subject>
        <dc:subject>mental disease</dc:subject>
        <dc:subject>neurologic disease</dc:subject>
        <dc:subject>skin disease</dc:subject>
        <dc:subject>somnolence</dc:subject>
        <dc:subject>eye disease</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>heart disease</dc:subject>
        <dc:subject>inner ear disease</dc:subject>
        <dc:subject>mediastinum disease</dc:subject>
        <dc:subject>respiratory tract disease</dc:subject>
        <dc:subject>thorax disease</dc:subject>
        <dc:subject>vascular disease</dc:subject>
        <dc:subject>drug use</dc:subject>
        <dc:subject>breast disease</dc:subject>
        <dc:subject>ear disease</dc:subject>
        <dc:subject>infection</dc:subject>
        <dc:subject>infestation</dc:subject>
        <dc:subject>kidney disease</dc:subject>
        <dc:subject>musculoskeletal disease</dc:subject>
        <dc:subject>nutritional disorder</dc:subject>
        <dc:subject>drug approval</dc:subject>
        <dc:subject>extravasation</dc:subject>
        <dc:subject>infusion related reaction</dc:subject>
        <dc:subject>hot flush</dc:subject>
        <dc:subject>medication error</dc:subject>
        <dc:subject>erythema</dc:subject>
        <dc:subject>immunopathology</dc:subject>
        <dc:subject>migraine</dc:subject>
        <dc:subject>urogenital tract disease</dc:subject>
        <dc:subject>drug monitoring</dc:subject>
        <dc:subject>standardization</dc:subject>
        <dc:subject>pregnancy</dc:subject>
        <dc:subject>clinical assessment</dc:subject>
        <dc:subject>brexanolone</dc:subject>
        <dc:subject>conscious sedation</dc:subject>
        <dc:subject>crying</dc:subject>
        <dc:subject>drug mechanism</dc:subject>
        <dc:subject>electroencephalography</dc:subject>
        <dc:subject>FDA adverse event reporting system</dc:subject>
        <dc:subject>hopelessness</dc:subject>
        <dc:subject>incorrect drug monitoring procedure</dc:subject>
        <dc:subject>incorrect product administration duration</dc:subject>
        <dc:subject>infusion site erythema</dc:subject>
        <dc:subject>infusion site extravasation</dc:subject>
        <dc:subject>infusion site pain</dc:subject>
        <dc:subject>intrusive thought</dc:subject>
        <dc:subject>menstruation disorder</dc:subject>
        <dc:subject>panic</dc:subject>
        <dc:subject>perinatal depression</dc:subject>
        <dc:subject>pharmacological procedures</dc:subject>
        <dc:subject>product administration error</dc:subject>
        <dc:subject>product administration interrupted</dc:subject>
        <dc:subject>product vigilance</dc:subject>
        <dc:subject>psychiatric complication</dc:subject>
        <dc:subject>suicidal ideation</dc:subject>
        <dc:subject>zulresso</dc:subject>
        <dc:title>A systematic analysis of safety profile of Brexanolone in real-world use based on FAERS database</dc:title>
        <dcterms:abstract>Objective: This study aims to analyze adverse events (AEs) associated with Brexanolone based on FAERS, to assess its real-world safety characteristics, and to explore potential underlying mechanisms. Methods: Data from the FAERS database since Brexanolone's approval in 2019 were extracted, categorizing and analyzing AEs based on frequency and signal strength. Signal detection was conducted using frequency and Bayesian methods to assess the statistical association between AEs and Brexanolone. Results: A total of 234 Brexanolone-related AE reports were collected. Signal detection results revealed a significant association between Brexanolone and multiple system-organ AEs. Intravenous infusion-related events were notably frequent, including Product Administration Error (35 cases), Incorrect Drug Monitoring Procedure (19 cases), Product Administration Interrupted (14 cases), Incorrect Product Administration Duration (11 cases), and Medication Error (10 cases). These findings indicate a need for more standardized management of Brexanolone administration in clinical practice. Common psychiatric AEs were identified, including Perinatal Depression, Intrusive Thoughts, Electroencephalogram Abnormality, Panic Disorder, Tearfulness, Self-Injurious Ideation, Sedation Complication, and Feelings of Despair. Of these, Tearfulness, Self-Injurious Ideation, Sedation Complication, Feelings of Despair, and Crying are known AEs of Brexanolone. Signal strengths for Perinatal Depression, Intrusive Thoughts, Electroencephalogram Abnormality, and Panic Disorder indicate new potential AEs. Conclusion: The introduction of Brexanolone has brought new hope to postpartum depression treatment, yet the study identifies a range of AEs, particularly associated with intravenous infusion and mental status changes, emphasizing caution in clinical application.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079726</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2038433974&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>186-193</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1573-2517">
        <prism:volume>382</prism:volume>
        <dc:title>Journal of Affective Disorders</dc:title>
        <dc:identifier>DOI 10.1016/j.jad.2025.04.091</dc:identifier>
        <dcterms:alternative>J. Affective Disord.</dcterms:alternative>
        <dc:identifier>ISSN 1573-2517</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1018">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Included&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2035002096&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1129-2377"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Song</foaf:surname>
                        <foaf:givenName>Q.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gao</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tan</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1016"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>postmarketing surveillance</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>connective tissue disease</dc:subject>
        <dc:subject>burning sensation</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>epistaxis</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>abdominal pain</dc:subject>
        <dc:subject>constipation</dc:subject>
        <dc:subject>fatigue</dc:subject>
        <dc:subject>nausea</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>gastrointestinal disease</dc:subject>
        <dc:subject>mental disease</dc:subject>
        <dc:subject>neurologic disease</dc:subject>
        <dc:subject>skin disease</dc:subject>
        <dc:subject>eye disease</dc:subject>
        <dc:subject>prevalence</dc:subject>
        <dc:subject>mediastinum disease</dc:subject>
        <dc:subject>respiratory tract disease</dc:subject>
        <dc:subject>thorax disease</dc:subject>
        <dc:subject>dysgeusia</dc:subject>
        <dc:subject>musculoskeletal disease</dc:subject>
        <dc:subject>eye irritation</dc:subject>
        <dc:subject>eye swelling</dc:subject>
        <dc:subject>rhinorrhea</dc:subject>
        <dc:subject>nose obstruction</dc:subject>
        <dc:subject>oropharynx pain</dc:subject>
        <dc:subject>immunopathology</dc:subject>
        <dc:subject>migraine</dc:subject>
        <dc:subject>ubrogepant</dc:subject>
        <dc:subject>rimegepant</dc:subject>
        <dc:subject>sensitivity analysis</dc:subject>
        <dc:subject>data processing</dc:subject>
        <dc:subject>abdominal discomfort</dc:subject>
        <dc:subject>taste disorder</dc:subject>
        <dc:subject>atogepant</dc:subject>
        <dc:subject>lacrimation</dc:subject>
        <dc:subject>nose disease</dc:subject>
        <dc:subject>physical discomfort</dc:subject>
        <dc:subject>sinus pain</dc:subject>
        <dc:subject>upper airway cough syndrome</dc:subject>
        <dc:subject>zavegepant</dc:subject>
        <dc:title>Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA adverse event reporting system</dc:title>
        <dcterms:abstract>Background: Gepants have demonstrated notable benefits in migraine therapy, yet their safety profiles are not thoroughly investigated. This study comprehensively analyzed the adverse event (AE) risk signals of the currently approved gepants using the U.S. Food and Drug Administration Adverse Event Reporting System database, aiming to gain better understanding of their post-marketing safety features and potential risks. Methods: All data of the gepants (rimegepant, atogepant, ubrogepant, and zavegepant) from January 1st 2020 to December 31st 2024 were retrieved from the database. Descriptive analysis was conducted to characterize the features of gepant-associated AEs. Disproportionality analysis and subsequent sensitivity analysis were employed to evaluate the risk signals of the gepants utilizing the algorithms of reporting odds ratio (ROR), proportional reporting ratio (PRR), and information component (IC). Results: A total of 7766 reports of rimegepant, 3672 reports of atogepant, 1958 reports of ubrogepant, and 463 reports of zavegepant were identified after data processing. Most AEs were occurred within 30 days after gepant administration. The integration of disproportionality analysis and sensitivity analysis indicated that “feeling abnormal” was the most reported AE of rimegepant (n = 185, 6.81%, ROR025 = 6.46, IC025 = 2.59, PRR = 7.24, χ2 = 998.58), while “constipation” was the most common AE of atogepant (n = 288, 16.09%, ROR025 = 19.99, IC025 = 4.10, PRR = 20.72, χ2 = 5418.12). The most prevalent AE of ubrogepant was “fatigue” (n = 60, 7.19%, ROR025 = 1.88, IC025 = 0.84, PRR = 2.38, χ2 = 48.82), whereas “dysgeusia” was the most frequently observed AE of zavegepant (n = 150, 45.18%, ROR025 = 212.07, IC025 = 6.10, PRR = 181.96, χ2 = 26,975.74). Comparative analysis of AEs revealed that two AEs were shared among all gepants and zavegepant had the largest collection of unique AEs (n = 15). Conclusions: The present pharmacovigilance study systematically revealed the significant risk signals of gepants. The common AEs and unique AEs of the four gepants were also identified and explored. Our results would provide valuable reference for the safe use of gepants, guiding personalized drug selection in clinical practice.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079725</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2035002096&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1129-2377">
        <prism:volume>26</prism:volume>
        <dc:title>Journal of Headache and Pain</dc:title>
        <dc:identifier>DOI 10.1186/s10194-025-02091-3</dc:identifier>
        <prism:number>1</prism:number>
        <dcterms:alternative>J. Headache Pain</dcterms:alternative>
        <dc:identifier>ISSN 1129-2377</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1016">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Excluded&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância | USER-NOTES: {&quot;Silvio&quot;=&gt;[&quot;Não identifiquei alinhamento com DM ou ML aplicada.&quot;]}&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2025060420&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1365-2125"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jacob</foaf:surname>
                        <foaf:givenName>A.T.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kumar</foaf:surname>
                        <foaf:givenName>A.H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Halivana</foaf:surname>
                        <foaf:givenName>G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lukose</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Nair</foaf:surname>
                        <foaf:givenName>G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Subeesh</foaf:surname>
                        <foaf:givenName>V.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_979"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data analysis</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>Adolescent</dc:subject>
        <dc:subject>Adult</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>adverse events</dc:subject>
        <dc:subject>Aged</dc:subject>
        <dc:subject>Algorithms</dc:subject>
        <dc:subject>biology</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>Child</dc:subject>
        <dc:subject>chronic obstructive lung disease</dc:subject>
        <dc:subject>citalopram</dc:subject>
        <dc:subject>Computational Biology</dc:subject>
        <dc:subject>connective tissue disease</dc:subject>
        <dc:subject>arthralgia</dc:subject>
        <dc:subject>bleeding</dc:subject>
        <dc:subject>disproportionality analysis</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>dizziness</dc:subject>
        <dc:subject>drug induced disease</dc:subject>
        <dc:subject>abdominal pain</dc:subject>
        <dc:subject>backache</dc:subject>
        <dc:subject>constipation</dc:subject>
        <dc:subject>disease severity</dc:subject>
        <dc:subject>bevacizumab</dc:subject>
        <dc:subject>embolism</dc:subject>
        <dc:subject>automation</dc:subject>
        <dc:subject>capecitabine</dc:subject>
        <dc:subject>carboplatin</dc:subject>
        <dc:subject>Child, Preschool</dc:subject>
        <dc:subject>adverse drug reactions</dc:subject>
        <dc:subject>alopecia</dc:subject>
        <dc:subject>anemia</dc:subject>
        <dc:subject>asthenia</dc:subject>
        <dc:subject>breast cancer</dc:subject>
        <dc:subject>chemically induced</dc:subject>
        <dc:subject>Data Mining</dc:subject>
        <dc:subject>Databases, Factual</dc:subject>
        <dc:subject>dehydration</dc:subject>
        <dc:subject>diarrhea</dc:subject>
        <dc:subject>blepharitis</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>drug utilization</dc:subject>
        <dc:subject>dry eye</dc:subject>
        <dc:subject>computer language</dc:subject>
        <dc:subject>coughing</dc:subject>
        <dc:subject>data extraction</dc:subject>
        <dc:subject>dyspnea</dc:subject>
        <dc:subject>Adverse drug event</dc:subject>
        <dc:subject>drug use</dc:subject>
        <dc:subject>asthma</dc:subject>
        <dc:subject>breast disease</dc:subject>
        <dc:subject>clinical trial (topic)</dc:subject>
        <dc:subject>drug</dc:subject>
        <dc:subject>Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>ear disease</dc:subject>
        <dc:subject>Clinical Trials as Topic</dc:subject>
        <dc:subject>computer model</dc:subject>
        <dc:subject>dexamethasone</dc:subject>
        <dc:subject>cyclophosphamide</dc:subject>
        <dc:subject>atopic dermatitis</dc:subject>
        <dc:subject>dupilumab</dc:subject>
        <dc:subject>data processing</dc:subject>
        <dc:subject>*Emergency Service, Hospital</dc:subject>
        <dc:subject>*Patient Admission</dc:subject>
        <dc:subject>*Registries</dc:subject>
        <dc:subject>accountable care organization</dc:subject>
        <dc:subject>Accountable Care Organizations</dc:subject>
        <dc:subject>adherence</dc:subject>
        <dc:subject>algorithms</dc:subject>
        <dc:subject>allergic disease</dc:subject>
        <dc:subject>Anesthetics, Inhalation</dc:subject>
        <dc:subject>AQP2</dc:subject>
        <dc:subject>Automation</dc:subject>
        <dc:subject>AVPR2</dc:subject>
        <dc:subject>BENEFITS</dc:subject>
        <dc:subject>big data</dc:subject>
        <dc:subject>big data analytics</dc:subject>
        <dc:subject>big data mining</dc:subject>
        <dc:subject>binding affinity</dc:subject>
        <dc:subject>binding site</dc:subject>
        <dc:subject>bioinformatics</dc:subject>
        <dc:subject>bioinformatics software</dc:subject>
        <dc:subject>Biomedical relation extraction</dc:subject>
        <dc:subject>bosutinib</dc:subject>
        <dc:subject>CARE</dc:subject>
        <dc:subject>CD8+ T lymphocyte</dc:subject>
        <dc:subject>CELLS</dc:subject>
        <dc:subject>clinical drug trials</dc:subject>
        <dc:subject>Clinical narratives</dc:subject>
        <dc:subject>Clinical Trials as Topic/methods/*statistics &amp; numerical data</dc:subject>
        <dc:subject>communicable disease</dc:subject>
        <dc:subject>complex drug patterns</dc:subject>
        <dc:subject>conjunctivitis</dc:subject>
        <dc:subject>dasatinib</dc:subject>
        <dc:subject>Data Mining/methods/*statistics &amp; numerical data</dc:subject>
        <dc:subject>DATABASE</dc:subject>
        <dc:subject>Databases, Factual/*statistics &amp; numerical data</dc:subject>
        <dc:subject>Diabetes Insipidus, Nephrogenic</dc:subject>
        <dc:subject>disease classification</dc:subject>
        <dc:subject>docetaxel</dc:subject>
        <dc:subject>DOM tree</dc:subject>
        <dc:subject>drug combination</dc:subject>
        <dc:subject>drug exposition</dc:subject>
        <dc:subject>drug intoxication</dc:subject>
        <dc:subject>drug program</dc:subject>
        <dc:subject>Drug-Related Side Effects and Adverse Reactions/*diagnosis</dc:subject>
        <dc:subject>Drug-Related Side Effects and Adverse Reactions/*epidemiology</dc:subject>
        <dc:subject>dual IL4/13 blockade</dc:subject>
        <dc:subject>DUPILUMAB</dc:subject>
        <dc:subject>EHR</dc:subject>
        <dc:subject>electronic drug alert program</dc:subject>
        <dc:subject>electronic health records</dc:subject>
        <dc:subject>electronic medical record</dc:subject>
        <dc:subject>electronic prescribing</dc:subject>
        <dc:title>Bioinformatics-guided disproportionality analysis of sevoflurane-induced nephrogenic diabetes insipidus using the FDA Adverse Event Reporting System database</dc:title>
        <dcterms:abstract>Aims: Sevoflurane is an ether-based inhalational anaesthetic that induces and maintains general anaesthesia. Our study aimed to detect sevoflurane-induced nephrogenic diabetes insipidus using data mining algorithms (DMAs) and molecular docking. The FAERS database was analysed using OpenVigil 2.1 for disproportionality analysis. Methods: We analysed FAERS data from 2004 to 2022 to determine the incidence of nephrogenic diabetes insipidus associated with sevoflurane. Reporting odds ratios (RORs) and proportional reporting ratios (PRRs) with 95% confidence intervals were calculated. We also used molecular docking with AutoDock Vina to examine sevoflurane's binding affinity to relevant receptors. Results: A total of 554 nephrogenic diabetes insipidus cases were reported in FAERS, of which 2.5% (14 cases) were associated with sevoflurane. Positive signals were observed for sevoflurane with ROR of 76.012 (95% CI: 44.67–129.35) and PRR of 75.72 (χ2: 934.688). Of the 14 cases, 50% required hospitalization, 14% resulted in death, and the remaining cases were categorized as other outcomes. Molecular docking analysis showed that sevoflurane exhibited high binding affinity towards AQP2 (4NEF) and AVPR2 (6U1N) with docking scores of −4.9 and −5.3, respectively. Conclusions: Sevoflurane use is significantly associated with the incidence of nephrogenic diabetes insipidus. Healthcare professionals should be cautious when using this medication and report any adverse events to regulatory agencies. Further research is needed to validate these findings and identify risk factors while performing statistical adjustments to prevent false-positives. Clinical monitoring is crucial to validate potential adverse effects of sevoflurane.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079788</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2025060420&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>1804-1810</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1365-2125">
        <prism:volume>90</prism:volume>
        <dc:title>British Journal of Clinical Pharmacology</dc:title>
        <dc:identifier>DOI 10.1111/bcp.15869</dc:identifier>
        <prism:number>8</prism:number>
        <dcterms:alternative>Br. J. Clin. Pharmacol.</dcterms:alternative>
        <dc:identifier>ISSN 1365-2125</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_979">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 2; Correspondence Address: N.L. Bragazzi; Laboratory for Industrial and Applied Mathematics (LIAM), Department of Mathematics and Statistics, York University, Toronto, Canada; email: robertobragazzi@gmail.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 3; Correspondence Address: D. Ouchi; Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina Gran, Barcelona, Via de les Corts Catalanes 587, àtic, 08007, Spain; email: douchi@idiapjgol.info&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 3; Correspondence Address: V. Subeesh; Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, India; email: subeeshkviswam@gmail.com; G. Nair; Department of Pharmacology, Faculty of Pharmacy, Ramaiah University of Applied Sciences, Bengaluru, India; email: neethugouri@gmail.com; CODEN: BCPHB&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 7; Correspondence Address: R.D. Boyce; University of Pittsburgh, Pittsburgh, Suite 419, 5607 Baum Boulevard, 15206, United States; email: rdb20@pitt.edu&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 8; Correspondence Address: S. Griesbach; Marshfield Clinic, Marshfield, 1000 N. Oak Ave., 54449, United States; email: griesbach.sara@marshfieldclinic.org&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 15; Correspondence Address: U. Baskaran; Department of Computer Science and Engineering, Pondicherry Engineering College, Puducherry, India; email: umamage@gmail.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 23; Correspondence Address: A.C. Tan; Translational Bioinformatics and Cancer Systems Biology Laboratory, Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, 12801 E.17th Avenue, L18-8116, 80045, United States; email: aikchoon.tan@ucdenver.edu; CODEN: ADDTA&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 66; Correspondence Address: Y. Luo; Department of Preventive Medicine, Northwestern University, Chicago, Arthur Rubloff Building, 750 N. Lake Shore, Drive, 60611, United States; email: yuan.luo@northwestern.edu&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;36&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;3&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;3&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;33&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2021354071&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>90</prism:volume>
                <dc:title>British Journal of Clinical Pharmacology</dc:title>
                <dc:identifier>DOI 10.1111/bcp.15673</dc:identifier>
                <prism:number>8</prism:number>
                <dcterms:alternative>Br. J. Clin. Pharmacol.</dcterms:alternative>
                <dc:identifier>ISSN 1365-2125</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Rong</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xie</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jiang</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Qiu</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kong</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_983"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data analysis</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>postmarketing surveillance</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>joint swelling</dc:subject>
        <dc:subject>depression</dc:subject>
        <dc:subject>bone pain</dc:subject>
        <dc:subject>fatigue</dc:subject>
        <dc:subject>insomnia</dc:subject>
        <dc:subject>nausea</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>amnesia</dc:subject>
        <dc:subject>balance disorder</dc:subject>
        <dc:subject>cognitive defect</dc:subject>
        <dc:subject>confusion</dc:subject>
        <dc:subject>very elderly</dc:subject>
        <dc:subject>abdominal distension</dc:subject>
        <dc:subject>anemia</dc:subject>
        <dc:subject>asthenia</dc:subject>
        <dc:subject>diarrhea</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>drug fatality</dc:subject>
        <dc:subject>pleura effusion</dc:subject>
        <dc:subject>memory disorder</dc:subject>
        <dc:subject>peripheral swelling</dc:subject>
        <dc:subject>coronavirus disease 2019</dc:subject>
        <dc:subject>dysgeusia</dc:subject>
        <dc:subject>drug hypersensitivity</dc:subject>
        <dc:subject>dyspepsia</dc:subject>
        <dc:subject>edema</dc:subject>
        <dc:subject>neoplasm</dc:subject>
        <dc:subject>decreased appetite</dc:subject>
        <dc:subject>eye swelling</dc:subject>
        <dc:subject>paresthesia</dc:subject>
        <dc:subject>periorbital edema</dc:subject>
        <dc:subject>thrombocytopenia</dc:subject>
        <dc:subject>dry skin</dc:subject>
        <dc:subject>face edema</dc:subject>
        <dc:subject>infant</dc:subject>
        <dc:subject>muscle weakness</dc:subject>
        <dc:subject>aphasia</dc:subject>
        <dc:subject>abdominal discomfort</dc:subject>
        <dc:subject>newborn</dc:subject>
        <dc:subject>ageusia</dc:subject>
        <dc:subject>avapritinib</dc:subject>
        <dc:subject>disease exacerbation</dc:subject>
        <dc:subject>hemoglobin</dc:subject>
        <dc:subject>photosensitivity</dc:subject>
        <dc:subject>swelling</dc:subject>
        <dc:subject>taste disorder</dc:subject>
        <dc:subject>tryptase</dc:subject>
        <dc:subject>upper abdominal pain</dc:subject>
        <dc:title>A post-marketing pharmacovigilance study of avapritinib: Adverse event data mining and analysis based on the United States Food and Drug Administration Adverse Event Reporting System database</dc:title>
        <dcterms:abstract>Aims: Avapritinib was first approved by the FDA in January 2020 and represents the first precision-targeted drug for gastrointestinal stromal tumours. However, there is a lack of large-scale data relating to adverse events (AEs) related to its use. We aimed to explore the avapritinib-related AEs in real-world practice based on the post-marketing data. Methods: We extracted all avapritinib-related reports submitted to the FDA Adverse Event Reporting System (FAERS) by June 2022. Based on disproportionality analysis and Bayesian analysis, we then calculated the reporting odds ratio (ROR), proportional reporting ratio (PRR), information component (IC) and empirical Bayes geometric mean (EBGM) to evaluate whether there is a significant association between avapritinib and AEs. Gender, age and time to onset were comparable between haemorrhage/non-haemorrhage, serious/non-serious, death/non-death AEs, respectively. Results: In total, 3120 cases related to avapritinib were documented in the FAERS database, and 44% were reported within 30 days of commencing avapritinib. A total of 331 different AE signals were detected, and no significant differences between males and females was identified. Although the number of AEs associated with an abnormal skin texture and executive dysfunction was small, the signal intensity is high, suggesting that these events are strongly correlated with avapritinib. Subgroup analysis showed that elderly male patients were more likely to suffer from serious AEs compared to females (P &lt;.01), but there was no significant difference between the haemorrhage group and the non-haemorrhage group. Analysis of fatalities due to avapritinib-related AEs indicated that sex, age and time-to-onset were all significantly related to death (P &lt;.05). Conclusion: Our study provides a more precise description of the incidence and characteristics of AEs after using avapritinib, clinicians should be particularly careful when prescribing avapritinib to elderly male patients, especially within the 30 days.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079787</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2021354071&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>1816-1826</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_983">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L642610506&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1468-4357"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Heo</foaf:surname>
                        <foaf:givenName>S.-J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jeong</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jung</foaf:surname>
                        <foaf:givenName>D.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jung</foaf:surname>
                        <foaf:givenName>I.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_981"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>age</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data analysis</dc:subject>
        <dc:subject>*Pharmacovigilance</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>Adolescent</dc:subject>
        <dc:subject>Adult</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>Adverse drug reactions</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>adverse events</dc:subject>
        <dc:subject>Aged</dc:subject>
        <dc:subject>area under the curve</dc:subject>
        <dc:subject>Bayes Theorem</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>classifier</dc:subject>
        <dc:subject>clinical feature</dc:subject>
        <dc:subject>cohort analysis</dc:subject>
        <dc:subject>Cohort Studies</dc:subject>
        <dc:subject>cyanosis</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>abdominal pain</dc:subject>
        <dc:subject>backache</dc:subject>
        <dc:subject>agitation</dc:subject>
        <dc:subject>antihypertensive agent</dc:subject>
        <dc:subject>antineoplastic agent</dc:subject>
        <dc:subject>automation</dc:subject>
        <dc:subject>CANCER</dc:subject>
        <dc:subject>cefprozil</dc:subject>
        <dc:subject>ceftriaxone</dc:subject>
        <dc:subject>celecoxib</dc:subject>
        <dc:subject>adverse drug reactions</dc:subject>
        <dc:subject>allergy</dc:subject>
        <dc:subject>anaphylaxis</dc:subject>
        <dc:subject>biguanide</dc:subject>
        <dc:subject>cellulitis</dc:subject>
        <dc:subject>coughing</dc:subject>
        <dc:subject>Antineoplastic Agents</dc:subject>
        <dc:subject>computer simulation</dc:subject>
        <dc:subject>Computer Simulation</dc:subject>
        <dc:subject>bone marrow suppression</dc:subject>
        <dc:subject>Data Collection</dc:subject>
        <dc:subject>canagliflozin</dc:subject>
        <dc:subject>anaphylactoid reaction</dc:subject>
        <dc:subject>CERIVASTATIN</dc:subject>
        <dc:subject>cefalexin</dc:subject>
        <dc:subject>cefazolin</dc:subject>
        <dc:subject>cefdinir</dc:subject>
        <dc:subject>cefotaxime</dc:subject>
        <dc:subject>amphetamine derivative</dc:subject>
        <dc:subject>dapagliflozin</dc:subject>
        <dc:subject>*Adverse Drug Reaction Reporting Systems/statistics &amp; numerical data</dc:subject>
        <dc:subject>CARE</dc:subject>
        <dc:subject>*Antineoplastic Agents/adverse effects</dc:subject>
        <dc:subject>*Data Mining/methods</dc:subject>
        <dc:subject>*Drug-Related Side Effects and Adverse Reactions/epidemiology</dc:subject>
        <dc:subject>acetylsalicylic acid</dc:subject>
        <dc:subject>adderall</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems/*standards</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems/*statistics &amp; numerical data</dc:subject>
        <dc:subject>adverse event reporting</dc:subject>
        <dc:subject>amphetamine plus dexamphetamine</dc:subject>
        <dc:subject>Amphetamines</dc:subject>
        <dc:subject>analytical error</dc:subject>
        <dc:subject>Antihypertensive Agents</dc:subject>
        <dc:subject>attention deficit disorder</dc:subject>
        <dc:subject>attention deficit hyperactivity disorder</dc:subject>
        <dc:subject>autonomic neuropathy</dc:subject>
        <dc:subject>billing and claims</dc:subject>
        <dc:subject>blogging</dc:subject>
        <dc:subject>Blogging</dc:subject>
        <dc:subject>Blogging/statistics &amp; numerical data</dc:subject>
        <dc:subject>Boxed Warning</dc:subject>
        <dc:subject>breast feeding</dc:subject>
        <dc:subject>Breast Feeding</dc:subject>
        <dc:subject>case control study</dc:subject>
        <dc:subject>CASE SERIES</dc:subject>
        <dc:subject>Case-Control Studies</dc:subject>
        <dc:subject>cefaclor</dc:subject>
        <dc:subject>cefadroxil</dc:subject>
        <dc:subject>cefalotin</dc:subject>
        <dc:subject>cefamandole</dc:subject>
        <dc:subject>cefamandole nafate</dc:subject>
        <dc:subject>cefathiamidine</dc:subject>
        <dc:subject>cefazedone</dc:subject>
        <dc:subject>cefepime</dc:subject>
        <dc:subject>cefixime</dc:subject>
        <dc:subject>cefmenoxime</dc:subject>
        <dc:subject>cefodizime</dc:subject>
        <dc:subject>cefonicid</dc:subject>
        <dc:subject>cefoperazone</dc:subject>
        <dc:subject>cefoselis</dc:subject>
        <dc:subject>cefotiam</dc:subject>
        <dc:subject>cefpiramide</dc:subject>
        <dc:subject>cefpodoxime proxetil</dc:subject>
        <dc:subject>cefradine</dc:subject>
        <dc:subject>ceftazidime</dc:subject>
        <dc:subject>ceftezole</dc:subject>
        <dc:subject>ceftizoxime</dc:subject>
        <dc:subject>cefuroxime</dc:subject>
        <dc:subject>cefuroxime axetil</dc:subject>
        <dc:subject>central nervous system agents</dc:subject>
        <dc:subject>cephalosporin</dc:subject>
        <dc:subject>ceralasertib</dc:subject>
        <dc:subject>children</dc:subject>
        <dc:subject>Cholinergic Antagonists</dc:subject>
        <dc:subject>cholinergic receptor blocking agent</dc:subject>
        <dc:subject>Cluster analysis</dc:subject>
        <dc:subject>Cohort study</dc:subject>
        <dc:subject>comprehensive standard method</dc:subject>
        <dc:subject>Computer aided analysis</dc:subject>
        <dc:subject>COST</dc:subject>
        <dc:subject>COX-3</dc:subject>
        <dc:subject>CRITICALLY-ILL PATIENTS</dc:subject>
        <dc:subject>cytarabine</dc:subject>
        <dc:subject>data collection method</dc:subject>
        <dc:title>Signal detection statistics of adverse drug events in hierarchical structure for matched case-control data</dc:title>
        <dcterms:abstract>The tree-based scan statistic is a data mining method used to identify signals of adverse drug reactions in a database of spontaneous reporting systems. It is particularly beneficial when dealing with hierarchical data structures. One may use a retrospective case-control study design from spontaneous reporting systems (SRS) to investigate whether a specific adverse event of interest is associated with certain drugs. However, the existing Bernoulli model of the tree-based scan statistic may not be suitable as it fails to adequately account for dependencies within matched pairs. In this article, we propose signal detection statistics for matched case-control data based on McNemar's test, Wald test for conditional logistic regression, and the likelihood ratio test for a multinomial distribution. Through simulation studies, we demonstrate that our proposed methods outperform the existing approach in terms of the type I error rate, power, sensitivity, and false detection rate. To illustrate our proposed approach, we applied the three methods and the existing method to detect drug signals for dizziness-related adverse events related to antihypertensive drugs using the database of the Korea Adverse Event Reporting System.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079782</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L642610506&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>1112-1121</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1468-4357">
        <prism:volume>25</prism:volume>
        <dc:title>Biostatistics (Oxford, England)</dc:title>
        <dc:identifier>DOI 10.1093/biostatistics/kxad029</dc:identifier>
        <prism:number>4</prism:number>
        <dcterms:alternative>Biostatistics</dcterms:alternative>
        <dc:identifier>ISSN 1468-4357</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_981">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: I. Jung; Division of Biostatistics, Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, 03722, South Korea; email: ijung@yuhs.ac&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: Y. Zeng; Qihuang, National Medical Academy, Jiangxi University of Traditional Chinese Medicine Affiliated Hospital, Nanchang, 330006, China; email: 1006028230@qq.com; M. Zhang; National Medical Academy, Jiangxi University of Traditional Chinese Medicine Affiliated Hospital, Nanchang, 330006, China; email: 1006028230@qq.com; CODEN: CACOF&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 6; Correspondence Address: R. Huang; School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; email: hys19810612@163.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 7; Correspondence Address: T.H. McCoy; Massachusetts General Hospital, Boston, 185 Cambridge Street, 6th Floor, 02114, United States; email: thmccoy@partners.org; CODEN: GHPSD&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 11; Correspondence Address: M.-M. Yan; Clinical Pharmacy Department, Huashan Hospital, Fudan University, Shanghai, China; email: xyqiu@fudan.edu.cn; X.-Y. Qiu; Clinical Pharmacy Department, Huashan Hospital, Fudan University, Shanghai, China; email: xyqiu@fudan.edu.cn&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 13; Correspondence Address: Z.-L. Li; Department of Pharmacy, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China; email: lizhiling22@163.com; B. Zhao; Department of Pharmacy, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China; email: zhaobin@pumch.cn&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 18; Correspondence Address: B.-I. Berg; Department of Cranio-Maxillofacial Surgery, University Hospital of Basel, Basel, Spitalstrasse 21, 4031, Switzerland; email: isabelle.berg@usb.ch&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 23; Correspondence Address: R. Izem; Food and Drug Administration, Center for Drug Evaluation and Research, Office of Biostatistics, Silver Spring, WO Building 21, 20903, United States; email: rima.izem@fda.hhs.gov&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 37; Correspondence Address: S. Comfort; Genentech, A Member of the Roche Group, Roche, South San Francisco, United States; email: comforts@gene.com; CODEN: DRSAE&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 46; Correspondence Address: W. Tong; National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, 72079, United States; email: Weida.Tong@fda.hhs.gov; CODEN: BBMIC&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 101; Correspondence Address: R. Sloane; Wolfson Centre for Personalised Medicine, Institute of Translational Medicine, University of Liverpool, Block A: Waterhouse Building, Liverpool, 1-5 Brownlow Street, L69 3GL, United Kingdom; email: munirp@liverpool.ac.uk; CODEN: BCPHB&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 157; Correspondence Address: A. Sarker; Department of Biomedical Informatics, Arizona State University, Scottsdale, United States; email: abeed.sarker@asu.edu; CODEN: DRSAE&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;30&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;7&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;8&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;74&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;11&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;11&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;34&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;13&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;13&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;38&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;17&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;18&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;60&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;19&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;20&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;34&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;37&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;39&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;42&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Base governamental,Desenvolvimento do método,Naõ utiliza bases oficiais</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2033193651&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1874-1754"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Huang</foaf:surname>
                        <foaf:givenName>A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wei</foaf:surname>
                        <foaf:givenName>Q.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_984"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>postmarketing surveillance</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>cardiovascular disease</dc:subject>
        <dc:subject>apparent life threatening event</dc:subject>
        <dc:subject>arthralgia</dc:subject>
        <dc:subject>disability</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>myalgia</dc:subject>
        <dc:subject>outcome assessment</dc:subject>
        <dc:subject>dizziness</dc:subject>
        <dc:subject>heart arrhythmia</dc:subject>
        <dc:subject>abdominal pain</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>gastrointestinal disease</dc:subject>
        <dc:subject>neurologic disease</dc:subject>
        <dc:subject>hypertensive crisis</dc:subject>
        <dc:subject>Medical Dictionary for Regulatory Activities</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>treatment outcome</dc:subject>
        <dc:subject>hyperlipidemia</dc:subject>
        <dc:subject>drug labeling</dc:subject>
        <dc:subject>paresthesia</dc:subject>
        <dc:subject>muscle weakness</dc:subject>
        <dc:subject>ICD-9</dc:subject>
        <dc:subject>upper abdominal pain</dc:subject>
        <dc:subject>bempedoic acid</dc:subject>
        <dc:subject>mild renal impairment</dc:subject>
        <dc:subject>pharmacogenomics</dc:subject>
        <dc:subject>phenotype</dc:subject>
        <dc:subject>phylogeny</dc:subject>
        <dc:subject>quality control</dc:subject>
        <dc:subject>tendon disease</dc:subject>
        <dc:title>Safety evaluation of bempedoic acid: A pharmacovigilance analysis using FDA adverse event reporting system data</dc:title>
        <dcterms:abstract>Background: Bempedoic acid exhibits promising potential in hyperlipidemia therapy and preventing cardiovascular events. However, investigations into its adverse drug reactions remain scant. This study seeks to utilize data mining techniques with the FDA Adverse Event Reporting System (FAERS) database to assess adverse drug events (ADEs) linked to bempedoic acid. Methods: Based on the drug's market release timeline, we extracted data from the FAERS database covering the fourth quarter of 2020 through the fourth quarter of 2023 for disproportionality analysis. Results: This study gathered a total of 5,797,543 adverse event case reports, of which 735 were linked to bempedoic acid. These reports covered 19 System Organ Classes (SOCs) and 22 Preferred Terms (PTs). Predominantly, the musculoskeletal and nervous systems were implicated in these adverse events. By conducting PT-level screening, various signals for ADEs were detected, including myalgia (ROR 30.33, PRR 28.51, IC 4.83, EBGM 28.47), arthralgia (n = 34, ROR 6.34, PRR 6.09, IC 2.61, EBGM 6.09), tendon disorders (ROR 99.57, PRR 98.75, IC 6.62, EBGM 98.28), and dizziness (ROR 3.18, PRR 3.13, IC 1.65, EBGM 3.13). Particularly noteworthy was the hypertensive crisis (ROR 28.63, PRR 28.51, IC 4.83, EBGM 28.47), which exhibited a robust signal strength, an observation previously unreported in clinical studies and drug labeling. Conclusion: While our results are largely consistent with the drug's specifications, several new adverse reaction signals, such as hypertensive crisis, have not been previously documented. Therefore, further investigations are necessary to assess these unlabeled adverse reactions, offering crucial support for the clinical utilization of bempedoic acid.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079779</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2033193651&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1874-1754">
        <prism:volume>412</prism:volume>
        <dc:title>International Journal of Cardiology</dc:title>
        <dc:identifier>DOI 10.1016/j.ijcard.2024.132305</dc:identifier>
        <dcterms:alternative>Int. J. Cardiol.</dcterms:alternative>
        <dc:identifier>ISSN 1874-1754</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_984">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Excluded&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2033118565&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1873-7714"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jia</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shi</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xue</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shen</foaf:surname>
                        <foaf:givenName>G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wen</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Qiao</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yang</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_980"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>age</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>odds ratio</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>postmarketing surveillance</dc:subject>
        <dc:subject>risk factor</dc:subject>
        <dc:subject>young adult</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>calculation</dc:subject>
        <dc:subject>cerebrovascular accident</dc:subject>
        <dc:subject>dizziness</dc:subject>
        <dc:subject>faintness</dc:subject>
        <dc:subject>disease severity</dc:subject>
        <dc:subject>headache</dc:subject>
        <dc:subject>amnesia</dc:subject>
        <dc:subject>attention disturbance</dc:subject>
        <dc:subject>balance disorder</dc:subject>
        <dc:subject>cognitive defect</dc:subject>
        <dc:subject>coordination disorder</dc:subject>
        <dc:subject>dysarthria</dc:subject>
        <dc:subject>hypersalivation</dc:subject>
        <dc:subject>neurologic disease</dc:subject>
        <dc:subject>seizure</dc:subject>
        <dc:subject>somnolence</dc:subject>
        <dc:subject>speech disorder</dc:subject>
        <dc:subject>transient ischemic attack</dc:subject>
        <dc:subject>risk assessment</dc:subject>
        <dc:subject>memory disorder</dc:subject>
        <dc:subject>consciousness disorder</dc:subject>
        <dc:subject>dementia</dc:subject>
        <dc:subject>quantitative analysis</dc:subject>
        <dc:subject>paresthesia</dc:subject>
        <dc:subject>hypesthesia</dc:subject>
        <dc:subject>migraine</dc:subject>
        <dc:subject>aphasia</dc:subject>
        <dc:subject>akathisia</dc:subject>
        <dc:subject>tardive dyskinesia</dc:subject>
        <dc:subject>bradykinesia</dc:subject>
        <dc:subject>hypokinesia</dc:subject>
        <dc:subject>dystonia</dc:subject>
        <dc:subject>empirical research</dc:subject>
        <dc:subject>hyperactivity</dc:subject>
        <dc:subject>lethargy</dc:subject>
        <dc:subject>Parkinson disease</dc:subject>
        <dc:subject>parkinsonism</dc:subject>
        <dc:subject>rating scale</dc:subject>
        <dc:subject>restless legs syndrome</dc:subject>
        <dc:subject>sex</dc:subject>
        <dc:subject>tremor</dc:subject>
        <dc:subject>valbenazine</dc:subject>
        <dc:title>Mining of neurological adverse events associated with valbenazine: A post-marketing analysis based on FDA adverse event reporting system</dc:title>
        <dcterms:abstract>Purpose: Valbenazine is commonly used to treat tardive dyskinesia, and we conducted a pharmacovigilance analysis using the Food and Drug Administration Adverse Event Reporting System (FAERS) to evaluate neurological safety signals associated with valbenazine. Methods: Data was collected in FAERS from the second quarter of 2017 to the fourth quarter of 2023 for data cleaning. Neurological adverse event (AE) signals of valbenazine were mined by calculating reporting odds ratios (ROR), information component (IC) and empirical Bayesian geometric mean (EBGM). The serious and non-serious cases and signals were prioritized using a rating scale. Results: The number of neurological AE reports where the primary suspect (PS) drug was 8981 for valbenazine. Significant AE signals were identified by the preferred term (PT) analysis for valbenazine, including somnolence (ROR 19.69), tremor (ROR 15.17), and tardive dyskinesia (ROR 236.91), among which 18 AEs were identified as new signals. Patient age (p &lt; 0.009) and sex (p = 0.197) might be associated with an increased risk of neurological AE severity. Notably, the association between valbenazine and neurological disorders remained when stratified by sex, age, and reporter type. AE timing analysis was performed for the drug and four moderate clinical priority signals [i.e., somnolence, balance disorder, parkinsonism, and akathisia (priorities 7)], showing the same early failure type profiles. Conclusions: The increase in neurological safety signals is identified in the post-marketing research of valbenazine. Clinicians need to pay attention to not only common AEs but also be alert to new neurological AE signals when using valbenazine.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079784</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2033118565&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>22-29</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1873-7714">
        <prism:volume>90</prism:volume>
        <dc:title>General Hospital Psychiatry</dc:title>
        <dc:identifier>DOI 10.1016/j.genhosppsych.2024.06.005</dc:identifier>
        <dcterms:alternative>Gen. Hosp. Psychiatry</dcterms:alternative>
        <dc:identifier>ISSN 1873-7714</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_980">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2034781943&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1872-8332"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Huang</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jiang</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ke</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_859"/>
        <dcterms:isReferencedBy rdf:resource="#item_982"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>odds ratio</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>alanine aminotransferase</dc:subject>
        <dc:subject>aspartate aminotransferase</dc:subject>
        <dc:subject>disease severity</dc:subject>
        <dc:subject>nausea</dc:subject>
        <dc:subject>vomiting</dc:subject>
        <dc:subject>brain disease</dc:subject>
        <dc:subject>liver toxicity</dc:subject>
        <dc:subject>mental disease</dc:subject>
        <dc:subject>seizure</dc:subject>
        <dc:subject>pulmonary hypertension</dc:subject>
        <dc:subject>lung embolism</dc:subject>
        <dc:subject>risk assessment</dc:subject>
        <dc:subject>acne</dc:subject>
        <dc:subject>cholangitis</dc:subject>
        <dc:subject>cholestasis</dc:subject>
        <dc:subject>dehydration</dc:subject>
        <dc:subject>diarrhea</dc:subject>
        <dc:subject>pleura effusion</dc:subject>
        <dc:subject>treatment outcome</dc:subject>
        <dc:subject>dermatitis</dc:subject>
        <dc:subject>hypocalcemia</dc:subject>
        <dc:subject>musculoskeletal pain</dc:subject>
        <dc:subject>kidney failure</dc:subject>
        <dc:subject>pancreatitis</dc:subject>
        <dc:subject>drug-induced liver injury</dc:subject>
        <dc:subject>liver function</dc:subject>
        <dc:subject>acute respiratory failure</dc:subject>
        <dc:subject>enterocolitis</dc:subject>
        <dc:subject>decreased appetite</dc:subject>
        <dc:subject>pneumonia</dc:subject>
        <dc:subject>hypokalemia</dc:subject>
        <dc:subject>erythema</dc:subject>
        <dc:subject>lung toxicity</dc:subject>
        <dc:subject>color vision defect</dc:subject>
        <dc:subject>liver failure</dc:subject>
        <dc:subject>liver injury</dc:subject>
        <dc:subject>pericardial effusion</dc:subject>
        <dc:subject>acute respiratory distress syndrome</dc:subject>
        <dc:subject>adagrasib</dc:subject>
        <dc:subject>autoimmune hepatitis</dc:subject>
        <dc:subject>colitis</dc:subject>
        <dc:subject>correlation analysis</dc:subject>
        <dc:subject>disorientation</dc:subject>
        <dc:subject>gastrointestinal toxicity</dc:subject>
        <dc:subject>gene mutation</dc:subject>
        <dc:subject>hemolytic anemia</dc:subject>
        <dc:subject>hypertransaminasemia</dc:subject>
        <dc:subject>jaundice</dc:subject>
        <dc:subject>K ras protein</dc:subject>
        <dc:subject>liver pain</dc:subject>
        <dc:subject>meningitis</dc:subject>
        <dc:subject>non small cell lung cancer</dc:subject>
        <dc:subject>oncogene K ras</dc:subject>
        <dc:subject>QT prolongation</dc:subject>
        <dc:subject>sotorasib</dc:subject>
        <dc:subject>standardization</dc:subject>
        <dc:subject>toxic epidermal necrolysis</dc:subject>
        <dc:subject>xerostomia</dc:subject>
        <dc:title>Safety assessment of KRAS (G12C) inhibitors based on the FDA Adverse Event Reporting System (FAERS) database: A real-world pharmacovigilance study</dc:title>
        <dcterms:abstract>Objectives: KRAS (G12C) inhibitors (sotorasib and adagrasib) have approved treatment in patients with KRAS (G12C)-mutated non-small cell lung cancer (NSCLC). The post-marketing data concerning KRAS (G12C) inhibitors remain limited, and the outcomes of relevant studies are yet to yield conclusive evidence supporting the long-term safety of KRAS (G12C) inhibitors. Materials and methods: This investigation comprehensively assessed adverse events (AEs) attributed to KRAS (G12C) inhibitors by employing advanced data mining techniques, utilizing the FDA Adverse Event Reporting System (FAERS). The dataset encompasses the period from the first quarter of 2021 to the first quarter of 2024. A disproportionality analysis was conducted to quantify the correlation between KRAS (G12C) inhibitors and AEs. The metrics employed for the evaluation of disproportionality comprise the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the information component (IC), and the empirical Bayesian geometric mean (EBGM). Results: A total of 2,253 and 486 reports were identified as related to sotorasib and adagrasib, with the identification of 51 and 26 preferred terms, respectively. The most frequent AEs of sotorasib comprised diarrhoea (ROR 5.27), hepatotoxicity (ROR 38.09), alanine aminotransferase increased (ROR 17.41), aspartate aminotransferase increased (ROR 20.88), and hepatic function abnormal (ROR 19.88). The most common AEs of adagrasib included diarrhoea (ROR 4.21), nausea (ROR 3.84), vomiting (ROR 5.36), decreased appetite (ROR 4.79), and dehydration (ROR 7.00). A relatively reduced risk of hepatotoxicity but a increased risk of serious AEs in adagrasib compared to sotorasib (P &lt; 0.001). Conclusion: Our findings would provide valued evidence for healthcare professionals to recognize AEs associated with KRAS (G12C) inhibitors and differences between sotorasib and adagrasib, and guide their clinical practice.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079781</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2034781943&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1872-8332">
        <prism:volume>196</prism:volume>
        <dc:title>Lung Cancer</dc:title>
        <dc:identifier>DOI 10.1016/j.lungcan.2024.107966</dc:identifier>
        <dcterms:alternative>Lung Cancer</dcterms:alternative>
        <dc:identifier>ISSN 1872-8332</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_859">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Excluded&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Memo rdf:about="#item_982">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Excluded&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L645642347&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1648-9144"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Moon</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ko</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Choi</foaf:surname>
                        <foaf:givenName>Y.-J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shin</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_985"/>
        <dc:subject>acute kidney failure</dc:subject>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>*Data Mining</dc:subject>
        <dc:subject>*Social Media</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>Adult</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>adverse events</dc:subject>
        <dc:subject>adverse outcome</dc:subject>
        <dc:subject>Aged</dc:subject>
        <dc:subject>alanine aminotransferase</dc:subject>
        <dc:subject>alanine aminotransferase blood level</dc:subject>
        <dc:subject>aspartate aminotransferase</dc:subject>
        <dc:subject>aspartate aminotransferase blood level</dc:subject>
        <dc:subject>bilirubin</dc:subject>
        <dc:subject>bilirubin blood level</dc:subject>
        <dc:subject>cohort analysis</dc:subject>
        <dc:subject>arthralgia</dc:subject>
        <dc:subject>Antipsychotic Agents</dc:subject>
        <dc:subject>ATYPICAL ANTIPSYCHOTICS</dc:subject>
        <dc:subject>cardiovascular risk</dc:subject>
        <dc:subject>altered state of consciousness</dc:subject>
        <dc:subject>amnesia</dc:subject>
        <dc:subject>attention disturbance</dc:subject>
        <dc:subject>automutilation</dc:subject>
        <dc:subject>behavior disorder</dc:subject>
        <dc:subject>cognitive defect</dc:subject>
        <dc:subject>bevacizumab</dc:subject>
        <dc:subject>*United States Food and Drug Administration</dc:subject>
        <dc:subject>aggression</dc:subject>
        <dc:subject>agitation</dc:subject>
        <dc:subject>amfebutamone</dc:subject>
        <dc:subject>antihypertensive agent</dc:subject>
        <dc:subject>arthritis</dc:subject>
        <dc:subject>automation</dc:subject>
        <dc:subject>budesonide</dc:subject>
        <dc:subject>bupivacaine</dc:subject>
        <dc:subject>carboplatin</dc:subject>
        <dc:subject>cataract</dc:subject>
        <dc:subject>Adverse events</dc:subject>
        <dc:subject>anemia</dc:subject>
        <dc:subject>breast cancer</dc:subject>
        <dc:subject>cancer chemotherapy</dc:subject>
        <dc:subject>chemically induced</dc:subject>
        <dc:subject>CHEMOTHERAPY</dc:subject>
        <dc:subject>blepharospasm</dc:subject>
        <dc:subject>cancer therapy</dc:subject>
        <dc:subject>*Antipsychotic Agents/adverse effects</dc:subject>
        <dc:subject>adverse drug event</dc:subject>
        <dc:subject>alirocumab</dc:subject>
        <dc:subject>case study</dc:subject>
        <dc:subject>adverse drug events</dc:subject>
        <dc:subject>comparative study</dc:subject>
        <dc:subject>computer model</dc:subject>
        <dc:subject>ANTIBODIES</dc:subject>
        <dc:subject>*Databases, Factual</dc:subject>
        <dc:subject>airway obstruction</dc:subject>
        <dc:subject>anhedonia</dc:subject>
        <dc:subject>anxiety</dc:subject>
        <dc:subject>antipsychotics</dc:subject>
        <dc:subject>abnormal dreaming</dc:subject>
        <dc:subject>aphasia</dc:subject>
        <dc:subject>bruxism</dc:subject>
        <dc:subject>*Adverse Drug Reaction Reporting Systems/statistics &amp; numerical data</dc:subject>
        <dc:subject>anger</dc:subject>
        <dc:subject>apathy</dc:subject>
        <dc:subject>bradyphrenia</dc:subject>
        <dc:subject>COMBINATION</dc:subject>
        <dc:subject>*Data Mining/methods</dc:subject>
        <dc:subject>*Drug-Related Side Effects and Adverse Reactions/epidemiology</dc:subject>
        <dc:subject>Antihypertensive Agents</dc:subject>
        <dc:subject>attention deficit hyperactivity disorder</dc:subject>
        <dc:subject>autoimmune hepatitis</dc:subject>
        <dc:subject>colitis</dc:subject>
        <dc:subject>colorectal cancer</dc:subject>
        <dc:subject>abnormal behavior</dc:subject>
        <dc:subject>abnormal thinking</dc:subject>
        <dc:subject>adrenal insufficiency</dc:subject>
        <dc:subject>advanced cancer</dc:subject>
        <dc:subject>ADVERSE CARDIOVASCULAR EVENTS</dc:subject>
        <dc:subject>alcoholism</dc:subject>
        <dc:subject>ALGORITHMS</dc:subject>
        <dc:subject>analogs and derivatives</dc:subject>
        <dc:subject>analytic method</dc:subject>
        <dc:subject>ANTI-CTLA-4</dc:subject>
        <dc:subject>Antihypertensive Agents/adverse effects</dc:subject>
        <dc:subject>aphonia</dc:subject>
        <dc:subject>appetite disorder</dc:subject>
        <dc:subject>APPROVAL</dc:subject>
        <dc:subject>apraxia</dc:subject>
        <dc:subject>asomatognosia</dc:subject>
        <dc:subject>ASPIRIN</dc:subject>
        <dc:subject>ASSOCIATION</dc:subject>
        <dc:subject>attitude to health</dc:subject>
        <dc:subject>avoidant restrictive food intake disorder</dc:subject>
        <dc:subject>Basal Ganglia Diseases</dc:subject>
        <dc:subject>Basal Ganglia Diseases/chemically induced/epidemiology</dc:subject>
        <dc:subject>bimatoprost</dc:subject>
        <dc:subject>bipolar I disorder</dc:subject>
        <dc:subject>blood cell count</dc:subject>
        <dc:subject>brain injury</dc:subject>
        <dc:subject>cancer survival</dc:subject>
        <dc:subject>CANCER-PATIENTS</dc:subject>
        <dc:subject>CAPTURE</dc:subject>
        <dc:subject>cardiovascular mortality</dc:subject>
        <dc:subject>carvedilol</dc:subject>
        <dc:subject>Charles Bonnet syndrome</dc:subject>
        <dc:subject>CHECKPOINT BLOCKADE</dc:subject>
        <dc:subject>CHECKPOINT INHIBITORS</dc:subject>
        <dc:subject>clinical decision support system</dc:subject>
        <dc:subject>clinical trial</dc:subject>
        <dc:subject>clopidogrel</dc:subject>
        <dc:subject>CLOPIDOGREL</dc:subject>
        <dc:title>Real-World Data Mining for Signal Detection of Antipsychotics-Associated Adverse Events Using the Korea Adverse Event Reporting System (KAERS) Database</dc:title>
        <dcterms:abstract>Background and Objectives: Recent studies suggest that the binary categorization of first-generation antipsychotics (FGAs) as being primarily responsible for extrapyramidal symptoms (EPSs) and second-generation antipsychotics (SGAs) for cardiometabolic abnormalities is an oversimplification. SGAs also demonstrate antagonistic affinity for D2 receptors, indicating their potential to induce EPSs. This study utilized the Korea Adverse Event Reporting System (KAERS) database to explore adverse drug event (ADE) signals related to both FGAs and SGAs. Materials and Methods: Relevant ADE reports from January 2013 to December 2022 were extracted from the KAERS database and analyzed using disproportionality analysis, employing the proportional reporting ratio (PRR), reporting odds ratio (ROR), and information component (IC) with its 95% lower confidence interval (LCI) indices. Results: Of the initial dataset of 2,890,702 ADE reports, those with insufficient data and duplicates were removed, resulting in a final dataset of 5249 reports for analysis. Aripiprazole, an SGA, showed signals for movement disorders, including EPSs (PRR 4.7, ROR 4.8, IC 2.2), tremors (PRR 5.3, ROR 5.4, IC 2.4), and akathisia (PRR 18.6, ROR 19.3, IC 3.5). Notably, for quetiapine, cardiovascular signals were detected, including increased blood pressure (PRR 2.1, ROR 2.3, IC 0.5), and tachyarrhythmia (PRR 13.9, ROR 14.1, IC 1.8), along with peripheral edema (PRR 2.5, ROR 2.5, IC 0.2). Metabolic abnormalities, such as weight gain and increased appetite, were identified for four SGAs: aripiprazole, olanzapine, quetiapine, and risperidone. Safety signals related to movement disorders were not detectable for FGAs, likely due to the limited number of ADE reports available for analysis. Conclusions: Our study findings support that the distribution of ADEs between FGAs and SGAs is not strictly binary. Aripiprazole, despite being an SGA, showed signals for extrapyramidal movement disorders. Four SGAs (aripiprazole, olanzapine, quetiapine, and risperidone) were linked to metabolic side effects, while quetiapine was associated with cardiovascular safety signals.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079778</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L645642347&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1648-9144">
        <prism:volume>60</prism:volume>
        <dc:title>Medicina (Kaunas, Lithuania)</dc:title>
        <dc:identifier>DOI 10.3390/medicina60101714</dc:identifier>
        <prism:number>10</prism:number>
        <dcterms:alternative>Medicina (Kaunas)</dcterms:alternative>
        <dc:identifier>ISSN 1648-9144</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_985">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: H. Contreras-Salinas; Pharmacovigilance Department, Laboratorios Sophia SA de CV, Zapopan, Jalisco, Mexico; email: homero.contreras@sophia.com.mx&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: S. Shin; Department of Biohealth Regulatory Science, Graduate School, Ajou University, Suwon, 16499, South Korea; email: syshin@ajou.ac.kr; Y.-J. Choi; Department of Pharmacy, College of Pharmacy, Kyung Hee University, Seoul, 02447, South Korea; email: yeojin.choi@khu.ac.kr&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 2; Correspondence Address: R. You; Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; email: youruxu2008@163.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 2; Correspondence Address: T.G. Soldatos; Molecular Health GmbH, Heidelberg, 69115, Germany; email: soldatos@molecularhealth.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 8; Correspondence Address: S. Delozier; Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, 2525 West End Ave, 37203, United States; email: sarah.b.delozier@vumc.org; CODEN: JAMAF&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 10; Correspondence Address: W. Dixon; Division of Musculoskeletal and Dermatological Sciences, Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester, Oxford Road, M13 9PL, United Kingdom; email: Will.Dixon@manchester.ac.uk; CODEN: DRSAE&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 12; Correspondence Address: H. Xiao; Institute of Maternal and Child Health, Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University and Technology, Wuhan, 430015, China; email: tjxiaohan@hust.edu.cn; W. Gao; Institute of Maternal and Child Health, Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University and Technology, Wuhan, China; email: gwq1103@ctgu.edu.cn&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 23; Correspondence Address: W. Feng; Institute of Intelligent System and Bioinformatics, College of Automation, Harbin Engineering University, Harbin, China; email: fengweixing@hrbeu.edu.cn; CODEN: SMEDD&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 276; CODEN: POLNC&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;30&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;35&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;47&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;6&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;6&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;15&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;9&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;10&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;34&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;10&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;10&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;39&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;21&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;23&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;42&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;251&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;271&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;47&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Included&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2030695551&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1432-1041"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kumar</foaf:surname>
                        <foaf:givenName>N.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kalaiselvan</foaf:surname>
                        <foaf:givenName>V.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Arora</foaf:surname>
                        <foaf:givenName>M.K.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_986"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>factual database</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>postmarketing surveillance</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>Adult</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>adverse outcome</dc:subject>
        <dc:subject>Aged</dc:subject>
        <dc:subject>cerebrovascular accident</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>clinical feature</dc:subject>
        <dc:subject>cross-sectional study</dc:subject>
        <dc:subject>brain hemorrhage</dc:subject>
        <dc:subject>disability</dc:subject>
        <dc:subject>outcome assessment</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>dizziness</dc:subject>
        <dc:subject>faintness</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>mitigation</dc:subject>
        <dc:subject>headache</dc:subject>
        <dc:subject>observational study</dc:subject>
        <dc:subject>osteoporosis</dc:subject>
        <dc:subject>amnesia</dc:subject>
        <dc:subject>balance disorder</dc:subject>
        <dc:subject>brain disease</dc:subject>
        <dc:subject>cognitive defect</dc:subject>
        <dc:subject>neurologic disease</dc:subject>
        <dc:subject>bevacizumab</dc:subject>
        <dc:subject>brain infarction</dc:subject>
        <dc:subject>Medical Dictionary for Regulatory Activities</dc:subject>
        <dc:subject>fatality</dc:subject>
        <dc:subject>Alzheimer disease</dc:subject>
        <dc:subject>breast cancer</dc:subject>
        <dc:subject>Databases, Factual</dc:subject>
        <dc:subject>congenital malformation</dc:subject>
        <dc:subject>drug fatality</dc:subject>
        <dc:subject>drug indication</dc:subject>
        <dc:subject>groups by age</dc:subject>
        <dc:subject>neurotoxicity</dc:subject>
        <dc:subject>polyneuropathy</dc:subject>
        <dc:subject>posterior reversible encephalopathy syndrome</dc:subject>
        <dc:subject>denosumab</dc:subject>
        <dc:subject>osteoclastoma</dc:subject>
        <dc:subject>data extraction</dc:subject>
        <dc:subject>demographics</dc:subject>
        <dc:subject>memory disorder</dc:subject>
        <dc:subject>dementia</dc:subject>
        <dc:subject>dysgeusia</dc:subject>
        <dc:subject>chronic lymphatic leukemia</dc:subject>
        <dc:subject>drug approval</dc:subject>
        <dc:subject>bone lesion</dc:subject>
        <dc:subject>daratumumab</dc:subject>
        <dc:subject>multiple myeloma</dc:subject>
        <dc:subject>mortality rate</dc:subject>
        <dc:subject>Female</dc:subject>
        <dc:subject>endometrium carcinoma</dc:subject>
        <dc:subject>paresthesia</dc:subject>
        <dc:subject>peripheral neuropathy</dc:subject>
        <dc:subject>hypesthesia</dc:subject>
        <dc:subject>infant</dc:subject>
        <dc:subject>migraine</dc:subject>
        <dc:subject>newborn</dc:subject>
        <dc:subject>monoclonal antibody therapy</dc:subject>
        <dc:subject>lethargy</dc:subject>
        <dc:subject>Parkinson disease</dc:subject>
        <dc:subject>non small cell lung cancer</dc:subject>
        <dc:subject>Antibodies, Monoclonal</dc:subject>
        <dc:subject>atezolizumab</dc:subject>
        <dc:subject>bladder cancer</dc:subject>
        <dc:subject>classical Hodgkin lymphoma</dc:subject>
        <dc:subject>collaborative care team</dc:subject>
        <dc:subject>colorectal cancer</dc:subject>
        <dc:subject>Disproportionality signal analysis</dc:subject>
        <dc:subject>drug induced dementia</dc:subject>
        <dc:subject>esophagus cancer</dc:subject>
        <dc:subject>European Medicines Agency</dc:subject>
        <dc:subject>fallopian tube cancer</dc:subject>
        <dc:subject>FDA Adverse Event Reporting System Database (FAERS)</dc:subject>
        <dc:subject>gastroesophageal junction cancer</dc:subject>
        <dc:subject>geographic distribution</dc:subject>
        <dc:subject>glioblastoma</dc:subject>
        <dc:subject>head and neck squamous cell carcinoma</dc:subject>
        <dc:subject>ipilimumab</dc:subject>
        <dc:subject>liver cell carcinoma</dc:subject>
        <dc:subject>Male</dc:subject>
        <dc:subject>marketing authorization</dc:subject>
        <dc:subject>melanoma</dc:subject>
        <dc:subject>merkel cell carcinoma</dc:subject>
        <dc:subject>microscopic polyangiitis</dc:subject>
        <dc:subject>Middle Aged</dc:subject>
        <dc:subject>Monoclonal antibodies</dc:subject>
        <dc:subject>monoclonal antibody</dc:subject>
        <dc:subject>myasthenia gravis</dc:subject>
        <dc:subject>Nervous System Diseases</dc:subject>
        <dc:subject>neuralgia</dc:subject>
        <dc:subject>Neurological toxicity</dc:subject>
        <dc:subject>neurologist</dc:subject>
        <dc:subject>nivolumab</dc:subject>
        <dc:subject>non-Hodgkin lymphoma</dc:subject>
        <dc:subject>oncologist</dc:subject>
        <dc:subject>osteolytic bone lesion of multiple myeloma</dc:subject>
        <dc:subject>osteolytic bone metastasis of solid tumor</dc:subject>
        <dc:subject>ovary cancer</dc:subject>
        <dc:subject>panitumumab</dc:subject>
        <dc:subject>paraneoplastic hypercalcemia</dc:subject>
        <dc:subject>patient care</dc:subject>
        <dc:subject>pembrolizumab</dc:subject>
        <dc:subject>pemphigus</dc:subject>
        <dc:subject>peritoneum cancer</dc:subject>
        <dc:subject>pleura mesothelioma</dc:subject>
        <dc:title>Neuronal toxicity of monoclonal antibodies (mAbs): an analysis of post-marketing reports from FDA Adverse Event Reporting System (FAERS) safety database</dc:title>
        <dcterms:abstract>Background: Monoclonal antibodies (mAbs) are pivotal in treating various diseases, including cancers and autoimmune disorders. Despite their therapeutic benefits, mAb therapy has been associated with neurological toxicity. Objectives: This study aimed to assess the occurrence of neuronal toxicity associated with mAbs, utilizing data from the FDA Adverse Event Reporting System (FAERS) safety database. The study also sought to delineate the medical characteristics of the reported cases. Methods: A comprehensive analysis of neurological adverse events reported in the FAERS database was conducted, employing computational methodologies such as proportional relative risk (PRR), information component (IC025), and chi-square (χ2). Individual case safety reports (ICSRs) pertaining to neurological disorders linked to mAbs from the date of first global marketing authorization until June 30, 2023, were meticulously examined. Results: The FAERS safety database contains 79,022 ICSRs linking mAbs to nervous system disorders. Rituximab, bevacizumab, denosumab, nivolumab, and trastuzumab were frequently cited. Reported adverse events include headache, peripheral neuropathy, dizziness, and cerebrovascular accident. Most ICSRs (85.81%) were serious, mainly affecting females (57.04%) with a 14.09% fatality rate. Panitumumab, atezolizumab, bevacizumab, and trastuzumab showed strong drug-event associations. Signal disproportionate reporting (SDR) analysis flagged myasthenia gravis, peripheral neuropathy, and neurotoxicity across multiple mAbs, suggesting potential signals. Conclusions: Interdisciplinary collaboration between oncologists and neurologists is crucial for safe mAb use. Our study enhances understanding of mAb neurological safety. Disproportionality signal analysis provides valuable evidence for risk mitigation.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079776</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2030695551&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>1685-1695</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1432-1041">
        <prism:volume>80</prism:volume>
        <dc:title>European Journal of Clinical Pharmacology</dc:title>
        <dc:identifier>DOI 10.1007/s00228-024-03727-0</dc:identifier>
        <prism:number>11</prism:number>
        <dcterms:alternative>Eur. J. Clin. Pharmacol.</dcterms:alternative>
        <dc:identifier>ISSN 1432-1041</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_986">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 2; Correspondence Address: M.K. Arora; School of Pharmaceutical and Population Health Informatics, DIT University, Dehradun, Uttarakhand, 248 009, India; email: mmmarora2@gmail.com; CODEN: EJCPA&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Excluded&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2030274358&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1179-1942"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zaccaria</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Piccolo</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gordillo-Marañón</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Touraille</foaf:surname>
                        <foaf:givenName>G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>de Vries</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_987"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>age</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>combination drug therapy</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>*Data Mining</dc:subject>
        <dc:subject>*Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>*Machine Learning</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>Adolescent</dc:subject>
        <dc:subject>Adult</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>Adverse drug reactions</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>Algorithms</dc:subject>
        <dc:subject>Bayes Theorem</dc:subject>
        <dc:subject>biology</dc:subject>
        <dc:subject>body mass</dc:subject>
        <dc:subject>cardiovascular disease</dc:subject>
        <dc:subject>cerebrovascular accident</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>Child</dc:subject>
        <dc:subject>chronic obstructive lung disease</dc:subject>
        <dc:subject>clinical feature</dc:subject>
        <dc:subject>cohort analysis</dc:subject>
        <dc:subject>Cohort Studies</dc:subject>
        <dc:subject>Computational Biology</dc:subject>
        <dc:subject>arthralgia</dc:subject>
        <dc:subject>bleeding</dc:subject>
        <dc:subject>descriptive research</dc:subject>
        <dc:subject>depression</dc:subject>
        <dc:subject>atrial fibrillation</dc:subject>
        <dc:subject>coronary artery disease</dc:subject>
        <dc:subject>*Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>*Drug Interactions</dc:subject>
        <dc:subject>alendronic acid</dc:subject>
        <dc:subject>Alzheimer disease</dc:subject>
        <dc:subject>amiodarone</dc:subject>
        <dc:subject>amoxicillin</dc:subject>
        <dc:subject>analgesic agent</dc:subject>
        <dc:subject>anticoagulant agent</dc:subject>
        <dc:subject>carboplatin</dc:subject>
        <dc:subject>celecoxib</dc:subject>
        <dc:subject>anaphylaxis</dc:subject>
        <dc:subject>asthenia</dc:subject>
        <dc:subject>Data mining</dc:subject>
        <dc:subject>Data Mining</dc:subject>
        <dc:subject>Data Mining/*methods</dc:subject>
        <dc:subject>Databases, Factual</dc:subject>
        <dc:subject>congenital malformation</dc:subject>
        <dc:subject>data extraction</dc:subject>
        <dc:subject>demographics</dc:subject>
        <dc:subject>adverse drug event</dc:subject>
        <dc:subject>Anticoagulants</dc:subject>
        <dc:subject>apixaban</dc:subject>
        <dc:subject>clinical decision support</dc:subject>
        <dc:subject>consciousness disorder</dc:subject>
        <dc:subject>dabigatran</dc:subject>
        <dc:subject>dementia</dc:subject>
        <dc:subject>Dementia</dc:subject>
        <dc:subject>asthma</dc:subject>
        <dc:subject>chronic kidney failure</dc:subject>
        <dc:subject>comparative study</dc:subject>
        <dc:subject>amitriptyline</dc:subject>
        <dc:subject>atorvastatin</dc:subject>
        <dc:subject>beclometasone</dc:subject>
        <dc:subject>computer model</dc:subject>
        <dc:subject>dexamethasone</dc:subject>
        <dc:subject>Apriori algorithm</dc:subject>
        <dc:subject>bone marrow suppression</dc:subject>
        <dc:subject>Classification (of information)</dc:subject>
        <dc:subject>Computational Biology/*methods</dc:subject>
        <dc:subject>Data Collection</dc:subject>
        <dc:subject>*Databases, Factual</dc:subject>
        <dc:subject>bisoprolol</dc:subject>
        <dc:subject>data processing</dc:subject>
        <dc:subject>clinical article</dc:subject>
        <dc:subject>acetylsalicylic acid</dc:subject>
        <dc:subject>CASE SERIES</dc:subject>
        <dc:subject>clinical decision support system</dc:subject>
        <dc:subject>clopidogrel</dc:subject>
        <dc:subject>*Disease</dc:subject>
        <dc:subject>*Drug-Related Side Effects and Adverse Reactions/diagnosis/epidemiology</dc:subject>
        <dc:subject>abortive agent</dc:subject>
        <dc:subject>ADMISSIONS</dc:subject>
        <dc:subject>amlodipine</dc:subject>
        <dc:subject>anticoagulant-induced bleedings</dc:subject>
        <dc:subject>Association reactions</dc:subject>
        <dc:subject>Association rule</dc:subject>
        <dc:subject>Association rule discovery</dc:subject>
        <dc:subject>Association rules</dc:subject>
        <dc:subject>Atrial Fibrillation</dc:subject>
        <dc:subject>AUSTRALIANS</dc:subject>
        <dc:subject>baby</dc:subject>
        <dc:subject>Bayesian</dc:subject>
        <dc:subject>Bayesian hierarchical model</dc:subject>
        <dc:subject>Bayesian hierarchical modelling</dc:subject>
        <dc:subject>Bayesian networks</dc:subject>
        <dc:subject>Causal relationships</dc:subject>
        <dc:subject>Causality</dc:subject>
        <dc:subject>cervarix</dc:subject>
        <dc:subject>Charlson Comorbidity Index</dc:subject>
        <dc:subject>chronic liver disease</dc:subject>
        <dc:subject>cilostazol</dc:subject>
        <dc:subject>Clinical trial</dc:subject>
        <dc:subject>cocodamol</dc:subject>
        <dc:subject>comorbidity</dc:subject>
        <dc:subject>Condition</dc:subject>
        <dc:subject>contraceptive agent</dc:subject>
        <dc:subject>contraceptive behavior</dc:subject>
        <dc:subject>coping</dc:subject>
        <dc:subject>coping behavior</dc:subject>
        <dc:subject>Coping strategies</dc:subject>
        <dc:subject>current drinker</dc:subject>
        <dc:subject>DABIGATRAN</dc:subject>
        <dc:subject>DESIGN</dc:subject>
        <dc:subject>diabetes mellitus type 2</dc:subject>
        <dc:title>Identification of Pregnancy Adverse Drug Reactions in Pharmacovigilance Reporting Systems: A Novel Algorithm Developed in EudraVigilance</dc:title>
        <dcterms:abstract>Introduction: There is a need to strengthen the evidence base regarding medication use during pregnancy and to facilitate the early detection of safety signals. EudraVigilance (EV) serves as the primary system for managing and analysing information concerning suspected adverse drug reactions (ADRs) within the European Economic Area. Despite its various functionalities, the current format for electronic submissions of safety reports lacks a specific data element indicating medicine exposure during pregnancy. Objective: This paper aims to address the limitations of existing approaches by developing a rule-based algorithm in EV that more reliably identifies cases that are truly representative of an ADR during pregnancy. Methods: The study utilised the standardised MedDRA query (SMQ) 'Pregnancy and neonatal topics' (PNT) as a benchmark for comparison. Recognising that the SMQ PNT also retrieves healthy pregnancy outcomes, contraceptive failure, failed abortifacients as well as ADRs not associated with pregnancy, a novel algorithm was tailored to improve the accuracy of identifying suspected ADRs occurring during pregnancy. Results: Upon testing, the algorithm demonstrated superior performance, correctly predicting 90% of cases reporting an ADR during pregnancy, compared to 54% achieved by the SMQ PNT. The implementation of the algorithm in EV led to the retrieval of 202,426 cases. Conclusion: The development and successful testing of the novel algorithm represents a step forward in pregnancy-specific signal detection in EV. Because signals associated with pregnancy may be diluted in a large database such as EV, this study lays the groundwork for future research to evaluate the effectiveness of disproportionality methods on a more refined subset of pregnancy-related ADR reports.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079775</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2030274358&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>1127-1136</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1179-1942">
        <prism:volume>47</prism:volume>
        <dc:title>Drug Safety</dc:title>
        <dc:identifier>DOI 10.1007/s40264-024-01448-y</dc:identifier>
        <prism:number>11</prism:number>
        <dcterms:alternative>Drug Saf.</dcterms:alternative>
        <dc:identifier>ISSN 1179-1942</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_987">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 2; Correspondence Address: G. Bonaldo; Unit of Pharmacology, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; email: giulia.bonaldo2@unibo.it; CODEN: BCPHB&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 2; Correspondence Address: S. Attelind; Department of Medical Sciences, Clinical Pharmacogenomics, Uppsala University, Uppsala, SE-751 85, Sweden; email: sofia.attelind@medsci.uu.se; CODEN: PDSAE&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 3; Correspondence Address: A.M. Burden; Institute for Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zürich, HCI H 407 Vladimir-Prelog-Weg 4, 8093, Switzerland; email: andrea.burden@pharma.ethz.ch; CODEN: PDSAE&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 3; Correspondence Address: B. Tang; Intelligent Computing Research Center, Harbin Institute of Technology Shenzhen School, China; email: tangbuzhou@gmail.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 4; Correspondence Address: C. Zaccaria; European Medicines Agency, Amsterdam, Domenico Scarlattilaan 6, 1083 HS, Netherlands; email: Cosimo.Zaccaria@ema.europa.eu; CODEN: DRSAE&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 7; Correspondence Address: A. Dirkson; Leiden Institute of Advanced Computer Science, Leiden University, Leiden, Niels Bohrweg 1, 2333 CA, Netherlands; email: a.r.dirkson@liacs.leidenuniv.nl; CODEN: JBIOB&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 7; Correspondence Address: T.R. Shaddox; Department of Biomathematics, David Geffen School of Medicine at UCLA, Los Angeles, 90095, United States; email: tshaddox@ucla.edu&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 21; Correspondence Address: A. Wasylewicz; Department of Healthcare Intelligence, Catharina Hospital, Eindhoven, Netherlands; email: a.t.m.wasylewicz@tue.nl; CODEN: BCPHB&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 46; Correspondence Address: Y.-T. Jia; Department of Pharmacy, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Children’s Hospital of Chongqing Medical University, Chongqing Key Laboratory of Pediatrics, Chongqing, 400014, China; email: jiayuntaomail@hospital.cqmu.edu.cn&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 62; Correspondence Address: R. Cai; Faculty of Computer Science, Guangdong University of Technology, Guangzhou, China; email: cairuichu@gmail.com; CODEN: AIMEE&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;25&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;20&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;7&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;7&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;25&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;19&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;19&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;48&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Excluded&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Base governamental,Desenvolvimento do método</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2028790414&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1542-6270"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhao</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yang</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>K.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_988"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>odds ratio</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>artificial neural network</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>citalopram</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>heart atrium septum defect</dc:subject>
        <dc:subject>heart ventricle septum defect</dc:subject>
        <dc:subject>gastrointestinal discomfort</dc:subject>
        <dc:subject>ataxia</dc:subject>
        <dc:subject>mental disease</dc:subject>
        <dc:subject>neurologic disease</dc:subject>
        <dc:subject>eye disease</dc:subject>
        <dc:subject>Medical Dictionary for Regulatory Activities</dc:subject>
        <dc:subject>agitation</dc:subject>
        <dc:subject>bayesian confidence propagation neural network</dc:subject>
        <dc:subject>escitalopram</dc:subject>
        <dc:subject>fluoxetine</dc:subject>
        <dc:subject>paroxetine</dc:subject>
        <dc:subject>congenital malformation</dc:subject>
        <dc:subject>lymphatic system disease</dc:subject>
        <dc:subject>data extraction</dc:subject>
        <dc:subject>heart disease</dc:subject>
        <dc:subject>inner ear disease</dc:subject>
        <dc:subject>mediastinum disease</dc:subject>
        <dc:subject>benign neoplasm</dc:subject>
        <dc:subject>ear disease</dc:subject>
        <dc:subject>cyst</dc:subject>
        <dc:subject>genital system disease</dc:subject>
        <dc:subject>hematologic disease</dc:subject>
        <dc:subject>hepatobiliary disease</dc:subject>
        <dc:subject>infection</dc:subject>
        <dc:subject>infestation</dc:subject>
        <dc:subject>injury</dc:subject>
        <dc:subject>kidney disease</dc:subject>
        <dc:subject>endocrine disease</dc:subject>
        <dc:subject>familial disease</dc:subject>
        <dc:subject>genetic disorder</dc:subject>
        <dc:subject>anterior eye chamber disease</dc:subject>
        <dc:subject>aortic regurgitation</dc:subject>
        <dc:subject>infant</dc:subject>
        <dc:subject>immunopathology</dc:subject>
        <dc:subject>newborn</dc:subject>
        <dc:subject>drug intoxication</dc:subject>
        <dc:subject>agenesis</dc:subject>
        <dc:subject>androgen insensitivity syndrome</dc:subject>
        <dc:subject>anterior chamber cleavage syndrome</dc:subject>
        <dc:subject>anxiety disorder</dc:subject>
        <dc:subject>aorta anomaly</dc:subject>
        <dc:subject>aortic atresia</dc:subject>
        <dc:subject>aortic coarctation</dc:subject>
        <dc:subject>aortic valve atresia</dc:subject>
        <dc:subject>atresia</dc:subject>
        <dc:subject>bicuspid aortic valve</dc:subject>
        <dc:subject>bladder malformation</dc:subject>
        <dc:subject>bone anteversion</dc:subject>
        <dc:subject>brain malformation</dc:subject>
        <dc:subject>cardiovascular malformation</dc:subject>
        <dc:subject>coloboma</dc:subject>
        <dc:subject>congenital absence of vertebra</dc:subject>
        <dc:subject>congenital aortic valve stenosis</dc:subject>
        <dc:subject>congenital central hypoventilation syndrome</dc:subject>
        <dc:subject>congenital heart disease</dc:subject>
        <dc:subject>congenital long QT syndrome</dc:subject>
        <dc:subject>congenital ureterovesical junction anomaly</dc:subject>
        <dc:subject>congenitally corrected transposition of the great arteries</dc:subject>
        <dc:subject>craniofacial synostosis</dc:subject>
        <dc:subject>de Lange syndrome</dc:subject>
        <dc:subject>diabetic complication</dc:subject>
        <dc:subject>diabetic fetopathy</dc:subject>
        <dc:subject>diaphragm eventration</dc:subject>
        <dc:subject>drug marketing</dc:subject>
        <dc:subject>ductus venosus agenesis</dc:subject>
        <dc:subject>eye malformation</dc:subject>
        <dc:subject>Fallot tetralogy</dc:subject>
        <dc:subject>fetus disease</dc:subject>
        <dc:subject>fluvoxamine maleate</dc:subject>
        <dc:subject>foot malformation</dc:subject>
        <dc:subject>great vessels transposition</dc:subject>
        <dc:subject>heart right ventricle double outlet</dc:subject>
        <dc:subject>hepatomegaly</dc:subject>
        <dc:subject>hereditary lymphedema</dc:subject>
        <dc:subject>hypercoagulability</dc:subject>
        <dc:subject>hypoplastic left heart syndrome</dc:subject>
        <dc:subject>irritability</dc:subject>
        <dc:subject>kinematic imbalances due to suboccipital strain</dc:subject>
        <dc:subject>lipomeningocele</dc:subject>
        <dc:subject>liver fibrosis</dc:subject>
        <dc:subject>marcus gunn syndrome</dc:subject>
        <dc:subject>mitral valve atresia</dc:subject>
        <dc:subject>mitral valve stenosis</dc:subject>
        <dc:subject>multiple malformation syndrome</dc:subject>
        <dc:subject>myoclonus dystonia</dc:subject>
        <dc:subject>neuropathy</dc:subject>
        <dc:subject>nutritional and metabolic disorder</dc:subject>
        <dc:subject>oculomotor apraxia</dc:subject>
        <dc:subject>oscillopsia</dc:subject>
        <dc:title>Safety Profile of Selective Serotonin Reuptake Inhibitors in Real-World Settings: A Pharmacovigilance Study Based on FDA Adverse Event Reporting System</dc:title>
        <dcterms:abstract>Background: Selective serotonin reuptake inhibitors (SSRIs) are the most frequently prescribed agents to treat depression. Considering the growth in antidepressant prescription rates, SSRI-induced adverse events (AEs) need to be comprehensively clarified. Objective: This study was to investigate safety profiles and potential AEs associated with SSRIs using the Food and Drug Administration Adverse Event Reporting System (FAERS). Methods: A retrospective pharmacovigilance analysis was conducted using the FAERS database, with Open Vigil 2.1 used for data extraction. The study included cases from the marketing date of each SSRI (ie, citalopram, escitalopram, fluoxetine, paroxetine, fluvoxamine, and sertraline) to April 30, 2023. We employed the reporting odds ratio and Bayesian confidence propagation neural network as analytical tools to assess the association between SSRIs and AEs. The Medical Dictionary for Regulatory Activities was used to standardize the definition of AEs. AE classification was achieved using system organ classes (SOCs). Results: Overall, 427 655 AE reports were identified for the 6 SSRIs, primarily associated with 25 SOCs, including psychiatric, nervous system, congenital, familial, genetic, cardiac, and reproductive disorders. Notably, sertraline (n = 967) and fluvoxamine (n = 169) exhibited the highest and lowest signal frequencies, respectively. All SSRIs had relatively strong signals related to congenital, psychiatric, and nervous disorders. Conclusions and relevance: Most of our findings are consistent with those reported previously, but some AEs were not previously identified. However, AEs attributed to SSRIs remain ambiguous, warranting further validation. Applying data-mining methods to the FAERS database can provide additional insights that can assist in appropriately utilizing SSRIs.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079774</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2028790414&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>1105-1116</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1542-6270">
        <prism:volume>58</prism:volume>
        <dc:title>Annals of Pharmacotherapy</dc:title>
        <dc:identifier>DOI 10.1177/10600280241231116</dc:identifier>
        <prism:number>11</prism:number>
        <dcterms:alternative>Ann. Pharmacother.</dcterms:alternative>
        <dc:identifier>ISSN 1542-6270</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_988">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Included&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L645845993&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>14</prism:volume>
                <dc:title>Scientific reports</dc:title>
                <dc:identifier>DOI 10.1038/s41598-024-80236-1</dc:identifier>
                <prism:number>1</prism:number>
                <dcterms:alternative>Sci Rep</dcterms:alternative>
                <dc:identifier>ISSN 2045-2322</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Fang</foaf:surname>
                        <foaf:givenName>R.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhou</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Han</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Guan</foaf:surname>
                        <foaf:givenName>N.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_854"/>
        <dcterms:isReferencedBy rdf:resource="#item_989"/>
        <dc:subject>acute kidney failure</dc:subject>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>*Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>*Pharmacovigilance</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>Adolescent</dc:subject>
        <dc:subject>Adult</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>Adverse drug reactions</dc:subject>
        <dc:subject>ADVERSE DRUG-REACTIONS</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>adverse events</dc:subject>
        <dc:subject>adverse outcome</dc:subject>
        <dc:subject>Aged</dc:subject>
        <dc:subject>Algorithms</dc:subject>
        <dc:subject>Anti-Bacterial Agents</dc:subject>
        <dc:subject>antidepressant agent</dc:subject>
        <dc:subject>antiinfective agent</dc:subject>
        <dc:subject>Bayes Theorem</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>Child</dc:subject>
        <dc:subject>classification</dc:subject>
        <dc:subject>classifier</dc:subject>
        <dc:subject>connective tissue disease</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>depression</dc:subject>
        <dc:subject>abdominal pain</dc:subject>
        <dc:subject>brain disease</dc:subject>
        <dc:subject>*Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>*United States Food and Drug Administration</dc:subject>
        <dc:subject>accuracy</dc:subject>
        <dc:subject>analgesic agent</dc:subject>
        <dc:subject>automation</dc:subject>
        <dc:subject>caffeine</dc:subject>
        <dc:subject>carboplatin</dc:subject>
        <dc:subject>Child, Preschool</dc:subject>
        <dc:subject>cholestasis</dc:subject>
        <dc:subject>Adverse event</dc:subject>
        <dc:subject>anemia</dc:subject>
        <dc:subject>Data mining</dc:subject>
        <dc:subject>Data Mining</dc:subject>
        <dc:subject>Data Mining/*methods</dc:subject>
        <dc:subject>Databases, Factual</dc:subject>
        <dc:subject>dehydration</dc:subject>
        <dc:subject>congenital malformation</dc:subject>
        <dc:subject>benzodiazepine</dc:subject>
        <dc:subject>benzodiazepine derivative</dc:subject>
        <dc:subject>Benzodiazepines</dc:subject>
        <dc:subject>consciousness disorder</dc:subject>
        <dc:subject>bacteremia</dc:subject>
        <dc:subject>Antiviral Agents</dc:subject>
        <dc:subject>antivirus agent</dc:subject>
        <dc:subject>candidiasis</dc:subject>
        <dc:subject>artificial intelligence</dc:subject>
        <dc:subject>Artificial Intelligence</dc:subject>
        <dc:subject>Classification (of information)</dc:subject>
        <dc:subject>Data Collection</dc:subject>
        <dc:subject>Aged, 80 and over</dc:subject>
        <dc:subject>DATABASES</dc:subject>
        <dc:subject>angioneurotic edema</dc:subject>
        <dc:subject>Adverse drug events</dc:subject>
        <dc:subject>acute myeloid leukemia</dc:subject>
        <dc:subject>DATABASE</dc:subject>
        <dc:subject>*Data Mining/methods</dc:subject>
        <dc:subject>analytical error</dc:subject>
        <dc:subject>ALGORITHMS</dc:subject>
        <dc:subject>*Antiviral Agents/adverse effects</dc:subject>
        <dc:subject>*Electronic Data Processing</dc:subject>
        <dc:subject>*Electronic Health Records</dc:subject>
        <dc:subject>*Famciclovir</dc:subject>
        <dc:subject>*Language</dc:subject>
        <dc:subject>*Natural Language Processing</dc:subject>
        <dc:subject>ABUSE</dc:subject>
        <dc:subject>ACYCLOVIR</dc:subject>
        <dc:subject>ADE signals</dc:subject>
        <dc:subject>adenine</dc:subject>
        <dc:subject>adenosine</dc:subject>
        <dc:subject>ADMINISTRATIVE DATA</dc:subject>
        <dc:subject>Adverse Drug Reaction</dc:subject>
        <dc:subject>alcohol</dc:subject>
        <dc:subject>Analgesics</dc:subject>
        <dc:subject>Analgesics/*therapeutic use</dc:subject>
        <dc:subject>Anti-Bacterial Agents/therapeutic use</dc:subject>
        <dc:subject>Anti-Inflammatory Agents, Non-Steroidal</dc:subject>
        <dc:subject>Anti-Inflammatory Agents, Non-Steroidal/therapeutic use</dc:subject>
        <dc:subject>Antidepressive Agents</dc:subject>
        <dc:subject>Antidepressive Agents/*therapeutic use</dc:subject>
        <dc:subject>antihistaminic agent</dc:subject>
        <dc:subject>Area Under Curve</dc:subject>
        <dc:subject>Automatic Data Processing</dc:subject>
        <dc:subject>Benchmarking</dc:subject>
        <dc:subject>beta catenin</dc:subject>
        <dc:subject>Bioinformatics</dc:subject>
        <dc:subject>Biomedical corpus</dc:subject>
        <dc:subject>cathinone</dc:subject>
        <dc:subject>cefiderocol</dc:subject>
        <dc:subject>Cefiderocol</dc:subject>
        <dc:subject>cephalosporin derivative</dc:subject>
        <dc:subject>Cephalosporins</dc:subject>
        <dc:subject>CHRONIC RHINOSINUSITIS</dc:subject>
        <dc:subject>cisplatin</dc:subject>
        <dc:subject>classification algorithm</dc:subject>
        <dc:subject>clobazam</dc:subject>
        <dc:subject>cocaine</dc:subject>
        <dc:subject>codeine</dc:subject>
        <dc:subject>COVID-19 pneumonia</dc:subject>
        <dc:subject>Data Mining/*statistics &amp; numerical data</dc:subject>
        <dc:subject>date mining</dc:subject>
        <dc:subject>Depression</dc:subject>
        <dc:title>Pharmacovigilance study of famciclovir in the Food and Drug administration adverse event reporting system database</dc:title>
        <dcterms:abstract>Famciclovir, mainly used to treat herpes zoster, is rapidly transforms into penciclovir when administered orally. Our study evaluated adverse events (AEs) associated with famciclovir by mining data from the publicly available Food and Drug Administration Adverse Event Reporting System (FAERS) database, providing a reference for clinical safety. Disproportionality analysis (including reported odds ratio and proportional reporting ratio) and Bayesian methods (including Bayesian Confidence Propagation Neural Network and Gamma-Poisson Shrinkage) were used to quantify the AE signals associated with famciclovir. A total of 17,652,186 case reports were obtained from the FAERS database, and 432 famiclovir-related AEs were identified. Nausea, headache, altered mental status, vomiting, and dizziness were found to be the most common Aes, corresponding to those reported in the Food and Drug Administration (FDA) drug labelling and clinical trials. Our study found some potential AEs of famciclovir that were not mentioned in the FDA drug labelling, such as toxic encephalopathy, encephalopathy, ataxia, dysarthria, dementia, cerebral infarction, tremor, purpura, skin ulcers, acute pancreatitis, rhabdomyolysis, muscle twitching, increased blood urea, lowered blood pressure, hepatitis, disease recurrence, drug interactions, and pancytopenia. Our study identified potential famciclovir AE signals, providing insights for physicians to reduce possible side effects and promote the safe implementation of the drug in clinical settings.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079773</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L645845993&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>28637</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_854">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: M. Ju; Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China; email: 08301010203@fudan.edu.cn; J. Hu; Department of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, China; email: jind.hu@outlook.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 2; Correspondence Address: J. Li; Dongzhimen Hospital Beijing University of Chinese Medicine, Dermatology, Beijing, Beijing, No.5 Haiyun Cang, Dongcheng District, 100700, China; email: gracelee100@163.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 4; Correspondence Address: L. Li; Columbus, 250 Lincoln Tower, 1800 Cannon Drive, 43210, United States; email: lang.li@osumc.edu&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 13; Correspondence Address: L. Chen; Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China; email: chenl_hxey@scu.edu.cn&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 25; Correspondence Address: R. Vickers-Smith; Department of Epidemiology, University of Kentucky College of Public Health, Lexington, 111 Washington Avenue, 40536, United States; email: rachel.vickers@uky.edu&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 27; Correspondence Address: R. Abagyan; School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego, 92093, United States; email: ruben@ucsd.edu&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 301; Correspondence Address: A. Sarker; Department of Biomedical Informatics, Arizona State University, Scottsdale, 13212 East Shea Blvd., 85259, United States; email: abeed.sarker@asu.edu; CODEN: JBIOB&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;26&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;30&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;28&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;4&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;4&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;74&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;18&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;19&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;36&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;18&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;19&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;87&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Included&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Memo rdf:about="#item_989">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: M. Ju; Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China; email: 08301010203@fudan.edu.cn; J. Hu; Department of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, China; email: jind.hu@outlook.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 2; Correspondence Address: J. Li; Dongzhimen Hospital Beijing University of Chinese Medicine, Dermatology, Beijing, Beijing, No.5 Haiyun Cang, Dongcheng District, 100700, China; email: gracelee100@163.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 4; Correspondence Address: L. Li; Columbus, 250 Lincoln Tower, 1800 Cannon Drive, 43210, United States; email: lang.li@osumc.edu&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 13; Correspondence Address: L. Chen; Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China; email: chenl_hxey@scu.edu.cn&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 25; Correspondence Address: R. Vickers-Smith; Department of Epidemiology, University of Kentucky College of Public Health, Lexington, 111 Washington Avenue, 40536, United States; email: rachel.vickers@uky.edu&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 27; Correspondence Address: R. Abagyan; School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego, 92093, United States; email: ruben@ucsd.edu&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 301; Correspondence Address: A. Sarker; Department of Biomedical Informatics, Arizona State University, Scottsdale, 13212 East Shea Blvd., 85259, United States; email: abeed.sarker@asu.edu; CODEN: JBIOB&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;26&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;30&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;28&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;4&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;4&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;74&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;18&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;19&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;36&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;18&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;19&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;87&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Included&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2038055379&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1438-8871"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ji</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gong</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gong</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>N.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhou</foaf:surname>
                        <foaf:givenName>R.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Deng</foaf:surname>
                        <foaf:givenName>D.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yang</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Song</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jia</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_991"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>citalopram</dc:subject>
        <dc:subject>cardiopulmonary insufficiency</dc:subject>
        <dc:subject>dizziness</dc:subject>
        <dc:subject>faintness</dc:subject>
        <dc:subject>heart arrest</dc:subject>
        <dc:subject>heart arrhythmia</dc:subject>
        <dc:subject>heart palpitation</dc:subject>
        <dc:subject>heart ventricle arrhythmia</dc:subject>
        <dc:subject>heart ventricle extrasystole</dc:subject>
        <dc:subject>heart ventricle fibrillation</dc:subject>
        <dc:subject>heart ventricle tachycardia</dc:subject>
        <dc:subject>long QT syndrome</dc:subject>
        <dc:subject>quetiapine</dc:subject>
        <dc:subject>torsade de pointes</dc:subject>
        <dc:subject>observational study</dc:subject>
        <dc:subject>clinical decision making</dc:subject>
        <dc:subject>atrial fibrillation</dc:subject>
        <dc:subject>very elderly</dc:subject>
        <dc:subject>amiodarone</dc:subject>
        <dc:subject>ciprofloxacin</dc:subject>
        <dc:subject>escitalopram</dc:subject>
        <dc:subject>fluoxetine</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>dronedarone</dc:subject>
        <dc:subject>drug</dc:subject>
        <dc:subject>drug interaction</dc:subject>
        <dc:subject>bisoprolol</dc:subject>
        <dc:subject>infant</dc:subject>
        <dc:subject>chlorpromazine</dc:subject>
        <dc:subject>fluphenazine</dc:subject>
        <dc:subject>haloperidol</dc:subject>
        <dc:subject>moxifloxacin</dc:subject>
        <dc:subject>omeprazole</dc:subject>
        <dc:subject>newborn</dc:subject>
        <dc:subject>drug combination</dc:subject>
        <dc:subject>cimetidine</dc:subject>
        <dc:subject>cisapride</dc:subject>
        <dc:subject>false positive result</dc:subject>
        <dc:subject>fluconazole</dc:subject>
        <dc:subject>furosemide</dc:subject>
        <dc:subject>halofantrine</dc:subject>
        <dc:subject>ibutilide</dc:subject>
        <dc:subject>loperamide</dc:subject>
        <dc:subject>lorazepam</dc:subject>
        <dc:subject>methadone</dc:subject>
        <dc:subject>metoprolol</dc:subject>
        <dc:subject>ondansetron</dc:subject>
        <dc:subject>procainamide</dc:subject>
        <dc:subject>QTc interval</dc:subject>
        <dc:subject>ritonavir</dc:subject>
        <dc:subject>sotalol</dc:subject>
        <dc:subject>unconsciousness</dc:subject>
        <dc:subject>voriconazole</dc:subject>
        <dc:title>Detection of Clinically Significant Drug-Drug Interactions in Fatal Torsades de Pointes: Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System</dc:title>
        <dcterms:abstract>Background: Torsades de pointes (TdP) is a rare yet potentially fatal cardiac arrhythmia that is often drug-induced. Drug-drug interactions (DDIs) are a major risk factor for TdP development, but the specific drug combinations that increase this risk have not been extensively studied. Objective: This study aims to identify clinically significant, high-priority DDIs to provide a foundation to minimize the risk of TdP and effectively manage DDI risks in the future. Methods: We used the following 4 frequency statistical models to detect DDI signals using the Food and Drug Administration Adverse Event Reporting System (FAERS) database: Ω shrinkage measure, combination risk ratio, chi-square statistic, and additive model. The adverse event of interest was TdP, and the drugs targeted were all registered and classified as “suspect,” “interacting,” or “concomitant drugs” in FAERS. The DDI signals were identified and evaluated using the Lexicomp and Drugs.com databases, supplemented with real-world data from the literature. Results: As of September 2023, this study included 4313 TdP cases, with 721 drugs and 4230 drug combinations that were reported for at least 3 cases. The Ω shrinkage measure model demonstrated the most conservative signal detection, whereas the chi-square statistic model exhibited the closest similarity in signal detection tendency to the Ω shrinkage measure model. The κ value was 0.972 (95% CI 0.942-1.002), and the Ppositive and Pnegative values were 0.987 and 0.985, respectively. We detected 2158 combinations using the 4 frequency statistical models, of which 241 combinations were indexed by Drugs.com or Lexicomp and 105 were indexed by both. The most commonly interacting drugs were amiodarone, citalopram, quetiapine, ondansetron, ciprofloxacin, methadone, escitalopram, sotalol, and voriconazole. The most common combinations were citalopram and quetiapine, amiodarone and ciprofloxacin, amiodarone and escitalopram, amiodarone and fluoxetine, ciprofloxacin and sotalol, and amiodarone and citalopram. Although 38 DDIs were indexed by Drugs.com and Lexicomp, they were not detected by any of the 4 models. Conclusions: Clinical evidence on DDIs is limited, and not all combinations of heart rate–corrected QT interval (QTc)–prolonging drugs result in TdP, even when involving high-risk drugs or those with known risk of TdP. This study provides a comprehensive real-world overview of drug-induced TdP, delimiting both clinically significant DDIs and negative DDIs, providing valuable insights into the safety profiles of various drugs, and informing the optimization of clinical practice.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079768</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2038055379&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1438-8871">
        <prism:volume>27</prism:volume>
        <dc:title>Journal of Medical Internet Research</dc:title>
        <dc:identifier>DOI 10.2196/65872</dc:identifier>
        <dcterms:alternative>J. Med. Internet Res.</dcterms:alternative>
        <dc:identifier>ISSN 1438-8871</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_991">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Excluded&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2036561396&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1178-2390"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yin</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sun</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>K.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_992"/>
        <dc:subject>acute kidney failure</dc:subject>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data analysis</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>*Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>Adolescent</dc:subject>
        <dc:subject>Adult</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>Adverse drug reactions</dc:subject>
        <dc:subject>ADVERSE DRUG-REACTIONS</dc:subject>
        <dc:subject>Aged</dc:subject>
        <dc:subject>Algorithms</dc:subject>
        <dc:subject>amoxicillin plus clavulanic acid</dc:subject>
        <dc:subject>antidepressant agent</dc:subject>
        <dc:subject>Artificial intelligence</dc:subject>
        <dc:subject>artificial neural network</dc:subject>
        <dc:subject>Bayes Theorem</dc:subject>
        <dc:subject>cardiovascular disease</dc:subject>
        <dc:subject>cerebrovascular accident</dc:subject>
        <dc:subject>chi square test</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>Child</dc:subject>
        <dc:subject>cohort analysis</dc:subject>
        <dc:subject>connective tissue disease</dc:subject>
        <dc:subject>cytochrome P450</dc:subject>
        <dc:subject>brain hemorrhage</dc:subject>
        <dc:subject>cardiovascular risk</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>clinical practice</dc:subject>
        <dc:subject>clinical decision making</dc:subject>
        <dc:subject>confusion</dc:subject>
        <dc:subject>brain infarction</dc:subject>
        <dc:subject>brain ischemia</dc:subject>
        <dc:subject>adalimumab</dc:subject>
        <dc:subject>amoxicillin</dc:subject>
        <dc:subject>animal</dc:subject>
        <dc:subject>Animals</dc:subject>
        <dc:subject>anticoagulant agent</dc:subject>
        <dc:subject>automated pattern recognition</dc:subject>
        <dc:subject>azithromycin</dc:subject>
        <dc:subject>biological activity</dc:subject>
        <dc:subject>celecoxib</dc:subject>
        <dc:subject>Child, Preschool</dc:subject>
        <dc:subject>ciprofloxacin</dc:subject>
        <dc:subject>clarithromycin</dc:subject>
        <dc:subject>Administration, Oral</dc:subject>
        <dc:subject>antibiotic agent</dc:subject>
        <dc:subject>data analysis software</dc:subject>
        <dc:subject>Data mining</dc:subject>
        <dc:subject>Data Mining</dc:subject>
        <dc:subject>congenital malformation</dc:subject>
        <dc:subject>apixaban</dc:subject>
        <dc:subject>benzodiazepine derivative</dc:subject>
        <dc:subject>bisphosphonic acid derivative</dc:subject>
        <dc:subject>benign neoplasm</dc:subject>
        <dc:subject>breast disease</dc:subject>
        <dc:subject>atorvastatin</dc:subject>
        <dc:subject>artificial intelligence</dc:subject>
        <dc:subject>Artificial Intelligence</dc:subject>
        <dc:subject>allodynia</dc:subject>
        <dc:subject>congenital disorder</dc:subject>
        <dc:subject>allopurinol</dc:subject>
        <dc:subject>cytochrome P450 3A4</dc:subject>
        <dc:subject>alteplase</dc:subject>
        <dc:subject>angioneurotic edema</dc:subject>
        <dc:subject>acetylsalicylic acid</dc:subject>
        <dc:subject>autonomic neuropathy</dc:subject>
        <dc:subject>correlation analysis</dc:subject>
        <dc:subject>atresia</dc:subject>
        <dc:subject>amlodipine</dc:subject>
        <dc:subject>Causal relationships</dc:subject>
        <dc:subject>DABIGATRAN</dc:subject>
        <dc:subject>anticholinergic syndrome</dc:subject>
        <dc:subject>candesartan</dc:subject>
        <dc:subject>*Prescription Drugs</dc:subject>
        <dc:subject>4 aminobutyric acid receptor</dc:subject>
        <dc:subject>adverse reaction</dc:subject>
        <dc:subject>akinetic mutism</dc:subject>
        <dc:subject>allophycocyanin</dc:subject>
        <dc:subject>angioedema</dc:subject>
        <dc:subject>antiasthmatic agent</dc:subject>
        <dc:subject>Anticonvulsants</dc:subject>
        <dc:subject>anticonvulsive agent</dc:subject>
        <dc:subject>APIXABAN</dc:subject>
        <dc:subject>Approximation algorithms</dc:subject>
        <dc:subject>axonal neuropathy</dc:subject>
        <dc:subject>BERT</dc:subject>
        <dc:subject>bioavailability</dc:subject>
        <dc:subject>blood brain barrier</dc:subject>
        <dc:subject>blood clotting factor 10a</dc:subject>
        <dc:subject>blood clotting factor 10a inhibitor</dc:subject>
        <dc:subject>blood clotting factor 11a</dc:subject>
        <dc:subject>blood clotting factor 7a</dc:subject>
        <dc:subject>blood clotting factor 9a</dc:subject>
        <dc:subject>carbasalate calcium</dc:subject>
        <dc:subject>Cardiology</dc:subject>
        <dc:subject>CELL</dc:subject>
        <dc:subject>cellobiose quinone oxidoreductase</dc:subject>
        <dc:subject>Characteristic set</dc:subject>
        <dc:subject>chemical structure</dc:subject>
        <dc:subject>chymotrypsin</dc:subject>
        <dc:subject>computer analysis</dc:subject>
        <dc:subject>computer prediction</dc:subject>
        <dc:subject>conceptual framework</dc:subject>
        <dc:subject>Confounding</dc:subject>
        <dc:subject>consultation</dc:subject>
        <dc:subject>CONVERTING ENZYME-INHIBITOR</dc:subject>
        <dc:subject>Cox regression analysis</dc:subject>
        <dc:subject>dabigratran</dc:subject>
        <dc:subject>data classification</dc:subject>
        <dc:subject>Data mining methods</dc:subject>
        <dc:title>Risk Assessment of Linezolid-Associated Neurological Adverse Drug Reactions Based on the Food and Drug Administration Adverse Event Reporting System Database</dc:title>
        <dcterms:abstract>Objective: To conduct data mining and analysis on neurological adverse drug reactions (ADRs), defined as any unwanted neurological effects caused by the use of linezolid, affecting both the central and peripheral nervous systems. This study also aims to investigate potential drug–drug interactions that may increase the risk of these ADRs when linezolid is used in combination with other medications. The findings aim to provide guidance for the safe clinical use of linezolid. Methods: Data from the US Food and Drug Administration Adverse Event Reporting System between 1 July 2014 and 30 June 2024 were analysed to identify linezolid-related neurological ADRs. The Ω shrinkage measure was used to detect drugs associated with an elevated risk of neurological ADRs. Results: A total of 8521 reports of linezolid-related ADRs were retrieved, of which 20.12% (1720 cases) involved neurological ADRs. Forty-five signals of neurological ADRs were detected, with serotonin syndrome (436 cases, reporting odds ratio [ROR] = 43.66, representing 25.35%) and peripheral neuropathy (413 cases, ROR = 7.88, representing 24.01%) being the most prevalent. Additionally, 23 previously undocumented ADR signals and 21 drugs associated with an increased risk of neurological ADRs (Ω 025 &gt; 0) were identified. Conclusion: This study highlights the need for careful monitoring of neurological ADRs associated with linezolid, vigilance regarding previously undocumented ADRs and the prudent management of concomitant medications. These findings provide essential guidance for the safe clinical use of linezolid.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079765</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2036561396&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>2969-2981</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1178-2390">
        <prism:volume>18</prism:volume>
        <dc:title>Journal of Multidisciplinary Healthcare</dc:title>
        <dc:identifier>DOI 10.2147/JMDH.S507827</dc:identifier>
        <dcterms:alternative>J. Multidiscip.Healthc.</dcterms:alternative>
        <dc:identifier>ISSN 1178-2390</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_992">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: K. Wang; Department of Critical Care Medicine, Tianjin 4th Center Hospital, Tianjin, No. 1, Zhongshan Road, Hebei District, 300142, China; email: wangkun_kun24@126.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 3; Correspondence Address: G. Feng; Department of Pharmacy, Langzhong People's Hospital, Nanchong, Sichuan, 637400, China; email: 95326682@qq.com; CODEN: SEIZE&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 4; Correspondence Address: D.R. Killick; Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Neston, Leahurst Campus, CH64 7TE, United Kingdom; email: david.killick@liverpool.ac.uk; CODEN: JAPRA&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 4; Correspondence Address: M. Fan; First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China; email: fanmaoxia1127@163.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 6; Correspondence Address: W.-Y. Lin; Dept. of Computer Science and Information Engineering, National University of Kaohsiung, Kaohsiung, Taiwan; email: wylin@nuk.edu.tw; CODEN: JBIOB&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 8; Correspondence Address: J.M. Reps; School of Computer Science, Jubilee Campus, University of Nottingham, NG8 1BB, United Kingdom; email: jenna.m.reps@gmail.com; CODEN: CBMDA&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 9; Correspondence Address: B. Liu; Department of Neurology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, 150001, China; email: ican58@163.com; CODEN: SEIZE&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 17; Correspondence Address: A.M. Jones; School of Pharmacy, University of Birmingham, Birmingham, United Kingdom; email: a.m.jones.2@bham.ac.uk&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 72; Correspondence Address: J. van Stekelenborg; Janssen R&amp;D, Horsham, United States; email: JVanstek@its.jnj.com; CODEN: DRSAE&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;4&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;4&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;19&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;4&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;4&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;35&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;7&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;8&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;18&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;8&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;11&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;37&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;16&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;16&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;48&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;56&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;59&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;35&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Maybe&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2036072847&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1879-114X"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tan</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yu</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>He</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zheng</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tan</foaf:surname>
                        <foaf:givenName>Q.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wan</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tan</foaf:surname>
                        <foaf:givenName>R.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_994"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data analysis</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>reporting odds ratio</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>heart arrest</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>brain disease</dc:subject>
        <dc:subject>Medical Dictionary for Regulatory Activities</dc:subject>
        <dc:subject>bayesian confidence propagation neural network</dc:subject>
        <dc:subject>anaphylaxis</dc:subject>
        <dc:subject>hypotension</dc:subject>
        <dc:subject>drug hypersensitivity</dc:subject>
        <dc:subject>anaphylactoid reaction</dc:subject>
        <dc:subject>sneezing</dc:subject>
        <dc:subject>shock</dc:subject>
        <dc:subject>erythema</dc:subject>
        <dc:subject>hyperhidrosis</dc:subject>
        <dc:subject>urticaria</dc:subject>
        <dc:subject>proportional reporting ratio</dc:subject>
        <dc:subject>respiratory arrest</dc:subject>
        <dc:subject>contrast medium extravasation</dc:subject>
        <dc:subject>cross validation</dc:subject>
        <dc:subject>empirical bayes geometric mean</dc:subject>
        <dc:subject>iodixanol</dc:subject>
        <dc:subject>iohexol</dc:subject>
        <dc:subject>iopamidol</dc:subject>
        <dc:subject>iopromide</dc:subject>
        <dc:subject>ioversol</dc:subject>
        <dc:subject>nephrotoxicity</dc:subject>
        <dc:subject>pharyngeal edema</dc:subject>
        <dc:subject>statistical parameters</dc:subject>
        <dc:subject>throat irritation</dc:subject>
        <dc:title>Data Mining and Analysis for Iodinated Contrast Media Adverse Event Signals Based on the Food and Drug Administration Adverse Event Reporting System Database</dc:title>
        <dcterms:abstract>Background: The purpose of this study was to employ the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database to mine and analyze adverse events related to iodinated contrast media (ICM), explore the characteristics of adverse events (AEs) including their occurrence and correlation strength between AEs and drugs, and to provide valuable insights for clinical use. Methods: The FAERS database was queried, data from Q1 of 2004 to Q2 of 2023 were extracted, and AE reports targeting 5 ICMs as the primary suspects were collected. Data mining and analysis were carried out on relevant reports using the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and empirical Bayes geometric mean (EBGM), while the standardized medical dictionary for regulatory activities (MedDRA) queries (SMQ) was used for systematic classification. Results: A total of 11,155,106 AE reports were retrieved from FAERS, with 2,412 for ioversol, 2,001 for iohexol, 987 for iodixanol, 1,154 for iopamidol, and 3,835 for iopromide. ICM-induced AE occurrence targeted 21 system organ classes (SOCs). A total of 329 significant disproportionality Preferred terms (PTs) conforming to the 4 algorithms were simultaneously retained. The results revealed that the medium and strong adverse drug reaction (ADR) signals of the 5 ICMs largely focused on “respiratory, thoracic and mediastinal disorders,” “general disorders and administration site conditions,” “immune system disorders,” and “skin and subcutaneous tissue disorders.” Ioversol (log2ROR = 1.21, Padj = 0.034) and iopromide (log2ROR = 1.32, Padj = 0.004) were both correlated with a higher incidence of a significant ADR signal, namely throat irritation, particularly in females. In addition, ioversol and iopromide also suggested that toxic nephropathy (log2ROR = −2.47, Padj &lt; 0.001) and hyperhidrosis (log2ROR = −1.22, Padj = 0.001) were significant ADR signals, especially in males, respectively. Conclusions: While the AE distribution of the 5 ICMs was consistent, there were variations in specific ADR signal characteristics, warranting further consideration and exploration.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079764</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2036072847&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>82-90</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1879-114X">
        <prism:volume>47</prism:volume>
        <dc:title>Clinical Therapeutics</dc:title>
        <dc:identifier>DOI 10.1016/j.clinthera.2024.11.007</dc:identifier>
        <prism:number>1</prism:number>
        <dcterms:alternative>Clin. Ther.</dcterms:alternative>
        <dc:identifier>ISSN 1879-114X</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_994">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Included&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2036784987&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>19</prism:volume>
                <dc:title>PLoS ONE</dc:title>
                <dc:identifier>DOI 10.1371/journal.pone.0316573</dc:identifier>
                <prism:number>12</prism:number>
                <dcterms:alternative>PLoS ONE</dcterms:alternative>
                <dc:identifier>ISSN 1932-6203</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sun</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Deng</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Huang</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>He</foaf:surname>
                        <foaf:givenName>G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Huang</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_990"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>*Data Mining</dc:subject>
        <dc:subject>*Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>*Pharmacovigilance</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>Adolescent</dc:subject>
        <dc:subject>Adult</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>adverse outcome</dc:subject>
        <dc:subject>Aged</dc:subject>
        <dc:subject>Bayes Theorem</dc:subject>
        <dc:subject>blood</dc:subject>
        <dc:subject>bosentan</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>cohort analysis</dc:subject>
        <dc:subject>bleeding</dc:subject>
        <dc:subject>abdominal pain</dc:subject>
        <dc:subject>amnesia</dc:subject>
        <dc:subject>cerebrovascular disease</dc:subject>
        <dc:subject>*Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>animal</dc:subject>
        <dc:subject>Animals</dc:subject>
        <dc:subject>antihypertensive agent</dc:subject>
        <dc:subject>antilipemic agent</dc:subject>
        <dc:subject>Bayesian network</dc:subject>
        <dc:subject>cerivastatin</dc:subject>
        <dc:subject>cetirizine</dc:subject>
        <dc:subject>COVID-19</dc:subject>
        <dc:subject>coronavirus disease 2019</dc:subject>
        <dc:subject>clozapine</dc:subject>
        <dc:subject>bebtelovimab</dc:subject>
        <dc:subject>comparative study</dc:subject>
        <dc:subject>Antiviral Agents</dc:subject>
        <dc:subject>antivirus agent</dc:subject>
        <dc:subject>atorvastatin</dc:subject>
        <dc:subject>artificial intelligence</dc:subject>
        <dc:subject>bisoprolol</dc:subject>
        <dc:subject>chest tightness</dc:subject>
        <dc:subject>China</dc:subject>
        <dc:subject>convulsion</dc:subject>
        <dc:subject>cold sweat</dc:subject>
        <dc:subject>Antihypertensive Agents</dc:subject>
        <dc:subject>ASSOCIATION</dc:subject>
        <dc:subject>amlodipine</dc:subject>
        <dc:subject>*COVID-19 Drug Treatment</dc:subject>
        <dc:subject>*Histamine H1 Antagonists/adverse effects</dc:subject>
        <dc:subject>*Nervous System Diseases/chemically induced</dc:subject>
        <dc:subject>*Ritonavir/adverse effects/therapeutic use</dc:subject>
        <dc:subject>aceglutamide</dc:subject>
        <dc:subject>Active surveillance</dc:subject>
        <dc:subject>Adult cardiology</dc:subject>
        <dc:subject>Adverse effects</dc:subject>
        <dc:subject>adverse reactions</dc:subject>
        <dc:subject>agranulocytosis</dc:subject>
        <dc:subject>ALLERGIC RHINITIS</dc:subject>
        <dc:subject>altizide plus spironolactone</dc:subject>
        <dc:subject>Angiotensin-Converting Enzyme Inhibitors</dc:subject>
        <dc:subject>Angiotensin-Converting Enzyme Inhibitors/adverse effects</dc:subject>
        <dc:subject>animal experiment</dc:subject>
        <dc:subject>animal model</dc:subject>
        <dc:subject>animal tissue</dc:subject>
        <dc:subject>anticholinergic syndrome</dc:subject>
        <dc:subject>Antihypertensive Agents/*adverse effects/therapeutic use</dc:subject>
        <dc:subject>antihypertensive therapy</dc:subject>
        <dc:subject>Antiviral Agents/adverse effects</dc:subject>
        <dc:subject>atonic seizure</dc:subject>
        <dc:subject>azelnidipine</dc:subject>
        <dc:subject>azilsartan medoxomil</dc:subject>
        <dc:subject>bamlanivimab plus etesevimab</dc:subject>
        <dc:subject>baricitinib</dc:subject>
        <dc:subject>basophil count</dc:subject>
        <dc:subject>bendroflumethiazide</dc:subject>
        <dc:subject>benidipine</dc:subject>
        <dc:subject>beraprost</dc:subject>
        <dc:subject>bezafibrate</dc:subject>
        <dc:subject>BIAS</dc:subject>
        <dc:subject>Calcium Channel Blockers</dc:subject>
        <dc:subject>Calcium Channel Blockers/adverse effects</dc:subject>
        <dc:subject>calcium channel blocking agent</dc:subject>
        <dc:subject>candesartan</dc:subject>
        <dc:subject>cardiac agent</dc:subject>
        <dc:subject>Cardiac Epidemiology</dc:subject>
        <dc:subject>carotid artery injury</dc:subject>
        <dc:subject>Carrier Proteins/genetics</dc:subject>
        <dc:subject>Cell Proliferation/drug effects</dc:subject>
        <dc:subject>Cetirizine</dc:subject>
        <dc:subject>CETIRIZINE</dc:subject>
        <dc:subject>Cetirizine/adverse effects/therapeutic use</dc:subject>
        <dc:subject>cilnidipine</dc:subject>
        <dc:subject>clinical classification</dc:subject>
        <dc:subject>CLINICAL TEXT</dc:subject>
        <dc:subject>clinofibrate</dc:subject>
        <dc:subject>clofibrate</dc:subject>
        <dc:subject>clonic seizure</dc:subject>
        <dc:subject>complication</dc:subject>
        <dc:subject>computational biology</dc:subject>
        <dc:subject>Confounding Factors (Epidemiology)</dc:subject>
        <dc:subject>Confounding Factors, Epidemiologic</dc:subject>
        <dc:subject>correlation matrix</dc:subject>
        <dc:subject>COVID-19 Drug Treatment</dc:subject>
        <dc:subject>COVID-19 pharmacotherapy</dc:subject>
        <dc:subject>COVID-19-related pharmacovigilance</dc:subject>
        <dc:subject>COVID-19/*complications</dc:subject>
        <dc:title>Data mining of adverse drug event signals with Nirmatrelvir/Ritonavir from FAERS</dc:title>
        <dcterms:abstract>Nirmatrelvir/Ritonavir, acting as an effective agent against COVID-19, has achieved considerable results in clinical studies in terms of drug efficacy. However, there is little research about its medication safety. Based on the FDA adverse event reporting system (FAERS) database, this study aims to mine the adverse reaction signals of the latest major recommended drug Nirmatrelvir/Ritonavir for the antiviral treatment of COVID-19, so as to provide a basis for safe and rational drug use. The reporting odds ratio (ROR) was used to explore the adverse event report data of all COVID-19 emergency use authorization (EUA) products in the FAERS database with the deadline of third quarter of 2023. In the analysis, 135427 adverse drug event (ADE) reports were found, and 35250 ADEs were reported with Nirmatrelvir/Ritonavir as the primary suspected drug, which was involved in multiple system. There was a high signal intensity of dysgeusia (ROR = 72.98), diarrhea (ROR = 3.03) and headache (ROR = 1.25), which was compatible with the adverse reactions recorded in the manual for Nirmatrelvir/Ritonavir. In addition, it was suggested that Nirmatrelvir/Ritonavir might cause pale-colored stools (ROR = 45.53), chromaturia (ROR = 3.07), yellow skin (ROR = 3.62), tongue coating (ROR = 35.55) and other new adverse reactions (not included in the instructions manual for Nirmatrelvir/Ritonavir). The ADEs of Nirmatrelvir/Ritonavir that are not in the instructions and are highly relevant in the real world are supplemented, prompting clinical attention to the ADEs of the drug, and providing a theoretical basis for the safe and effective application of the drug.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079772</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2036784987&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Memo rdf:about="#item_990">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: L. Chen; Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, 610041, China; email: chenl_hxey@scu.edu.cn; L. Zhang; Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, 610041, China; email: zhanglingli@scu.edu.cn&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: T. Sakaeda; Department of Pharmacokinetics, Kyoto Pharmaceutical University, Kyoto, 607-8414, Japan; email: sakaedat@mb.kyoto-phu.ac.jp&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 1; Correspondence Address: Y. Uwai; School of Pharmacy, Aichi Gakuin University, Nagoya, 1-100, Kusumoto, Chikusa, 464-8650, Japan; email: yuuwai@dpc.agu.ac.jp&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 2; Correspondence Address: J. Sun; The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha, China; email: inertia848223657@163.com; CODEN: POLNC&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 2; Correspondence Address: Y. Guan; Department of Pharmacy, Shandong University Affiliated Shandong Provincial Third Hospital, Jinan, Shandong, China; email: guanxiaoyao0815@163.com; Q. Zhang; Jinan Adverse Drug Reactions and Medical Device Adverse Event Monitoring Center, Jinan, Shandong, China; email: zhangqiuhong2222@163.com; L. Ji; Shandong Provincial Key Laboratory of Applied Microbiology, Ecology Institute, Qilu University of Technology, Jinan, Shandong, China; email: jilei2022022022@163.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 6; Correspondence Address: M. Jaberi-Douraki; DATA Consortium, www.1DATA.life, United States; email: jaberi@ksu.edu&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 11; Correspondence Address: W.-Q. Wei; Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, 2525 West End Ave., Suite 1500, 37203, United States; email: wei-qi.wei@vumc.org; CODEN: JAMAF&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 36; Correspondence Address: S.V. Wang; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, 1620 Tremont St, 02120, United States; email: Swang1@bwh.harvard.edu; CODEN: EPIDE&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;63&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;22&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;31&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;31&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;12&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;13&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;53&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;33&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;38&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;34&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Included&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2036604952&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1179-1349"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lin</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xu</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Deng</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Cao</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ding</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lin</foaf:surname>
                        <foaf:givenName>T.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_993"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>death</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>hearing impairment</dc:subject>
        <dc:subject>inner ear disease</dc:subject>
        <dc:subject>non small cell lung cancer</dc:subject>
        <dc:subject>capmatinib</dc:subject>
        <dc:subject>disability study</dc:subject>
        <dc:subject>ototoxicity</dc:subject>
        <dc:title>Exploring Ototoxicity Associated with Capmatinib: Insights from a Real-World Data Analysis of the FDA Adverse Event Reporting System (FAERS) Database</dc:title>
        <dcterms:abstract>Background: Capmatinib was approved by the US Food and Drug Administration (FDA) in 2020 for the treatment of non-small cell lung cancer with MET exon 14 mutation (METex14). Real-world studies on the safety of Capmatinib are still lacking. The aim of this study was to explore the significant adverse drug reactions (ADRs) associated with Capmatinib through the FDA Adverse Event Reporting System (FAERS) database. Methods: We employed the reported odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and the Empirical Bayes Geometric Mean (EBGM) as primary algorithms for the disproportionality analysis. Adverse events (AEs) were classified as adverse drug reactions (ADRs) solely upon fulfillment of criteria across all four algorithms. Results: In our study, there were 1767 cases explicitly attributed to Capmatinib. A total of 38 ADRs in preferred terms (PTs) level in 14 system-organ categories (SOCs) were identified after filtering. Notably, unexpected SOC “Ear and labyrinth disorders” and PTs “hypoacusis” and “deafness” were identified, without being specified in the drug label. Conclusion: Our study identified unexpected ADRs associated with Capmatinib, with a focus on ototoxicity-related events, underscoring the need for enhanced clinical monitoring and further investigation into the underlying mechanisms.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079766</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2036604952&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>513-521</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1179-1349">
        <prism:volume>17</prism:volume>
        <dc:title>Clinical Epidemiology</dc:title>
        <dc:identifier>DOI 10.2147/CLEP.S528454</dc:identifier>
        <dcterms:alternative>Clin. Epidemiol.</dcterms:alternative>
        <dc:identifier>ISSN 1179-1349</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_993">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Included&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2034504598&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1663-9812"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Song</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yang</foaf:surname>
                        <foaf:givenName>N.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xing</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhao</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Di</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_999"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>FAERS database</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>incidence</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>thrombosis</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>cerebral thrombosis</dc:subject>
        <dc:subject>deep vein thrombosis</dc:subject>
        <dc:subject>thrombophlebitis</dc:subject>
        <dc:subject>cerebral sinus thrombosis</dc:subject>
        <dc:subject>portal vein thrombosis</dc:subject>
        <dc:subject>adalimumab</dc:subject>
        <dc:subject>Bayesian network</dc:subject>
        <dc:subject>data analysis software</dc:subject>
        <dc:subject>treatment outcome</dc:subject>
        <dc:subject>artery thrombosis</dc:subject>
        <dc:subject>certolizumab pegol</dc:subject>
        <dc:subject>injection site thrombosis</dc:subject>
        <dc:subject>pulmonary thrombosis</dc:subject>
        <dc:subject>brachiocephalic vein thrombosis</dc:subject>
        <dc:subject>carotid artery thrombosis</dc:subject>
        <dc:subject>etanercept</dc:subject>
        <dc:subject>geometry</dc:subject>
        <dc:subject>golimumab</dc:subject>
        <dc:subject>hepatic vascular thrombosis</dc:subject>
        <dc:subject>infliximab</dc:subject>
        <dc:subject>intracardiac thrombus</dc:subject>
        <dc:subject>lateral sinus thrombosis</dc:subject>
        <dc:subject>pelvic venous thrombosis</dc:subject>
        <dc:subject>peripheral artery thrombosis</dc:subject>
        <dc:subject>postoperative thrombosis</dc:subject>
        <dc:subject>pulmonary artery thrombosis</dc:subject>
        <dc:subject>R 4.4.1</dc:subject>
        <dc:subject>superficial thrombophlebitis</dc:subject>
        <dc:subject>thrombotic adverse event</dc:subject>
        <dc:subject>thrombus</dc:subject>
        <dc:subject>tumor necrosis factor inhibitor</dc:subject>
        <dc:subject>upper extremity deep vein thrombosis</dc:subject>
        <dc:subject>vein thrombosis</dc:subject>
        <dc:title>Thrombotic adverse events associated with TNF-alpha blockers: a real-world pharmacovigilance analysis of the FAERS database</dc:title>
        <dcterms:abstract>Objective: This research is designed to explore the connection between tumor necrosis factor-α (TNF-α) blocker drugs and thrombotic adverse events. Methods: The study included data from the FDA Adverse Event Reporting System (FAERS) spanning from the first quarter of 2004 to the first quarter of 2024. We employed the disproportional analysis approach to analyze the signals of thrombosis-related adverse events associated with TNF-α blockers. Moreover, subgroup analyses were conducted to investigate the circumstances of different age and gender groups. Additionally, the induction time and Weibull distribution were utilized for the further interpretation of the data. Results: During the study period, among 1,382,627 patients in the FAERS database who had adverse events linked to TNF-α inhibitors, 9,714 could be attributed to thrombosis-related adverse events. In the remaining patients, different types of infection events accounted for a large proportion of the proportion. (N = 165,765) Thrombosis-related adverse event signals were detected in all five types of TNF-α inhibitor drugs. Among them, in the analysis of adalimumab, the adverse event signal of postpartum thrombosis was the strongest, and the positive signal of axillary vein thrombosis was the weakest. The analysis based on gender subgroups discovered some positive signals of adverse events that were not observed in the overall population. The Weibull distribution analysis indicated that all five drugs exhibited an premature aging type characteristic, and their induction decreased gradually over time. Conclusion: This study suggests that TNF - α blockers are associated with various adverse events of thrombosis, with different risks in different patient groups and treatment stages. Clinical doctors should assess individual thrombosis risk and closely monitor coagulation related indicators when using TNF - α inhibitors. This study offers valuable insights for optimizing treatment and improving safety.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079761</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2034504598&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1663-9812">
        <prism:volume>16</prism:volume>
        <dc:title>Frontiers in Pharmacology</dc:title>
        <dc:identifier>DOI 10.3389/fphar.2025.1512806</dc:identifier>
        <dcterms:alternative>Front. Pharmacol.</dcterms:alternative>
        <dc:identifier>ISSN 1663-9812</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_999">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Included&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2034416003&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>16</prism:volume>
                <dc:title>Frontiers in Pharmacology</dc:title>
                <dc:identifier>DOI 10.3389/fphar.2025.1561020</dc:identifier>
                <dcterms:alternative>Front. Pharmacol.</dcterms:alternative>
                <dc:identifier>ISSN 1663-9812</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hu</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhao</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mao</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>He</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ye</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yang</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_998"/>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>FAERS database</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>incidence</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>head injury</dc:subject>
        <dc:subject>outcome assessment</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>dizziness</dc:subject>
        <dc:subject>fatigue</dc:subject>
        <dc:subject>headache</dc:subject>
        <dc:subject>nausea</dc:subject>
        <dc:subject>pain</dc:subject>
        <dc:subject>vomiting</dc:subject>
        <dc:subject>cognitive defect</dc:subject>
        <dc:subject>gastrointestinal disease</dc:subject>
        <dc:subject>neurologic disease</dc:subject>
        <dc:subject>somnolence</dc:subject>
        <dc:subject>atrial fibrillation</dc:subject>
        <dc:subject>risk assessment</dc:subject>
        <dc:subject>Alzheimer disease</dc:subject>
        <dc:subject>data analysis software</dc:subject>
        <dc:subject>diarrhea</dc:subject>
        <dc:subject>edema</dc:subject>
        <dc:subject>quantitative analysis</dc:subject>
        <dc:subject>urinary tract disease</dc:subject>
        <dc:subject>drug efficacy</dc:subject>
        <dc:subject>fever</dc:subject>
        <dc:subject>follow up</dc:subject>
        <dc:subject>tremor</dc:subject>
        <dc:subject>quality control</dc:subject>
        <dc:subject>pruritus</dc:subject>
        <dc:subject>aducanumab</dc:subject>
        <dc:subject>donanemab</dc:subject>
        <dc:subject>lecanemab</dc:subject>
        <dc:subject>R version 4.4</dc:subject>
        <dc:subject>WHO VigiAccess database</dc:subject>
        <dc:title>A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases</dc:title>
        <dcterms:abstract>Background: Lecanemab and Aducanumab are two novel anti-amyloid beta (Aβ) therapies for Alzheimer’s disease (AD) that have shown promise in slowing cognitive decline. However, their safety profiles remain unclear due to limited real-world evidence. This study aims to analyze and compare adverse drug reactions (ADRs) of these drugs using data from the WHO-VigiAccess and FAERS databases. Methods: A retrospective analysis was conducted using ADR data from the VigiAccess and FAERS databases, focusing on System Organ Class (SOC) and Preferred Term (PT) classifications. Descriptive statistics and reporting odds ratio (ROR) analysis were employed to evaluate and compare ADR profiles. Results: Lecanemab and Aducanumab exhibited distinct ADRs. Results from both the VigiAccess and FAERS databases indicated that the most SOC associated with both drugs was nervous system disorders (34.7% in VigiAccess, 36.8% in FAERS). Further multivariable logistic regression analysis revealed that Aducanumab was associated with a higher risk of nervous system disorders (OR = 4.72, 95% CI: 3.53–6.39, P &lt; 0.001). Among the reported AEs, headache was the most frequently reported for Lecanemab (9.4% in VigiAccess, 8.96% in FAERS), while Aducanumab was primarily associated with amyloid-related imaging abnormalities (ARIA) (19.1% in VigiAccess, 23.58% in FAERS). In the blood and lymphatic systems, Anemia was observed in both drugs. However, thrombocyto-penia was more prevalent in Lecanemab, while platelet dysfunction and myelosuppression were more frequently observed in Aducanumab. Additionally, hospitalization and mortality rates were higher for Aducanumab compared to Lecanemab. Conclusion: This study compared the ADRs of Lecanemab and Aducanumab, revealing that ARIA was the most common AE for both drugs. However, Lecanemab showed a lower risk of ARIA, cerebral hemorrhage, and severe events. These findings emphasize the need for further clinical research to clarify the long-term safety and efficacy of both drugs.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079759</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2034416003&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Memo rdf:about="#item_998">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Included&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2035213050&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:2052-3211"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zheng</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liang</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ma</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Su</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_995"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>age</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>torsade de pointes</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>clinical decision making</dc:subject>
        <dc:subject>geriatric patient</dc:subject>
        <dc:subject>hallucination</dc:subject>
        <dc:subject>azithromycin</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>groups by age</dc:subject>
        <dc:subject>nerve cell network</dc:subject>
        <dc:subject>off label drug use</dc:subject>
        <dc:subject>coronavirus disease 2019</dc:subject>
        <dc:subject>drug hypersensitivity</dc:subject>
        <dc:subject>drug therapy</dc:subject>
        <dc:subject>rash</dc:subject>
        <dc:subject>QT prolongation</dc:subject>
        <dc:subject>macrolide</dc:subject>
        <dc:subject>Mycoplasma pneumonia</dc:subject>
        <dc:subject>pregnancy</dc:subject>
        <dc:subject>premature labor</dc:subject>
        <dc:subject>pruritus</dc:subject>
        <dc:subject>special situation for pharmacovigilance</dc:subject>
        <dc:subject>Stevens Johnson syndrome</dc:subject>
        <dc:title>Age-stratified pharmacovigilance of azithromycin: a multimethod signal detection analysis in the FAERS database</dc:title>
        <dcterms:abstract>Background: Azithromycin, a widely prescribed macrolide antibiotic, faces emerging safety concerns due to inappropriate use and age-specific adverse drug reactions (ADRs). This study characterises age-stratified safety profiles of azithromycin using pharmacovigilance data. Methods: Adverse event (AE) reports for azithromycin prescribed in Mycoplasma pneumoniae pneumonia treatment (2004–2024) were extracted from the FDA Adverse Event Reporting System (FAERS). Disproportionality analyses (Reporting Odds Ratio, Proportional Reporting Ratio, Bayesian Confidence Propagation Neural Network, Multi-item Gamma Poisson Shrinker) identified safety signals across four age groups: 0–17, 18–44, 45–64, and ≥65 years. Results: Among 7,496 AE reports, age-specific risks varied significantly. Paediatric populations (0–17 years) exhibited predominant cutaneous/hypersensitivity reactions (rash, pruritus, Stevens-Johnson syndrome) and unlabelled psychiatric signals (hallucinations). Adults (18–44 years) showed pregnancy-related risks (preterm delivery). Geriatric patients (≥65 years) had heightened cardiac risks (QT prolongation, torsades de pointes), often exacerbated by off-label COVID-19 use. The 45–64-year cohort displayed the highest signal frequency, primarily involving drug hypersensitivity. Off-label prescribing accounted for 65% of geriatric AEs. Conclusion: Azithromycin safety profiles differ markedly across age groups. Children face dermatologic and neuropsychiatric risks, while elderly patients are vulnerable to cardiac complications. Strict adherence to labelled indications, age-specific monitoring, and avoidance of off-label use–particularly during public health crises–are critical to mitigating ADRs. These findings underscore the need for stratified clinical decision-making and targeted pharmacovigilance.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079763</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2035213050&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:2052-3211">
        <prism:volume>18</prism:volume>
        <dc:title>Journal of Pharmaceutical Policy and Practice</dc:title>
        <dc:identifier>DOI 10.1080/20523211.2025.2525356</dc:identifier>
        <prism:number>1</prism:number>
        <dcterms:alternative>J. pharm. policy pract.</dcterms:alternative>
        <dc:identifier>ISSN 2052-3211</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_995">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Excluded&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2034730956&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>16</prism:volume>
                <dc:title>Frontiers in Pharmacology</dc:title>
                <dc:identifier>DOI 10.3389/fphar.2025.1569602</dc:identifier>
                <dcterms:alternative>Front. Pharmacol.</dcterms:alternative>
                <dc:identifier>ISSN 1663-9812</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhao</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hu</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mao</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>He</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yang</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_996"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>disability</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>health care personnel</dc:subject>
        <dc:subject>hypoxic ischemic encephalopathy</dc:subject>
        <dc:subject>muscle spasm</dc:subject>
        <dc:subject>coma</dc:subject>
        <dc:subject>bayesian confidence propagation neural network</dc:subject>
        <dc:subject>data analysis software</dc:subject>
        <dc:subject>sciatica</dc:subject>
        <dc:subject>demographics</dc:subject>
        <dc:subject>patient safety</dc:subject>
        <dc:subject>proportional reporting ratio</dc:subject>
        <dc:subject>alcoholism</dc:subject>
        <dc:subject>arachnoiditis</dc:subject>
        <dc:subject>areflexia</dc:subject>
        <dc:subject>autonomic dysreflexia</dc:subject>
        <dc:subject>baclofen</dc:subject>
        <dc:subject>brain toxicity</dc:subject>
        <dc:subject>drug tolerability</dc:subject>
        <dc:subject>hyporeflexia</dc:subject>
        <dc:subject>intracranial hypotension</dc:subject>
        <dc:subject>liquorrhea</dc:subject>
        <dc:subject>metabolic encephalopathy</dc:subject>
        <dc:subject>multi item gamma poisson shrinkage</dc:subject>
        <dc:subject>muscle hypotonia</dc:subject>
        <dc:subject>muscle relaxant agent</dc:subject>
        <dc:subject>opisthotonus</dc:subject>
        <dc:subject>radicular pain</dc:subject>
        <dc:subject>sciatic nerve palsy</dc:subject>
        <dc:subject>sciatic neuropathy</dc:subject>
        <dc:title>Neurological adverse events associated with baclofen: a pharmacovigilance study based on FDA adverse event reporting system</dc:title>
        <dcterms:abstract>Background: Baclofen, a centrally acting muscle relaxant, is widely utilized for the management of muscle spasms and alcohol use disorders associated with conditions. However, its neurological safety and tolerability in a large population remain limited. This study aimed to assess the neurological safety and potential risks of baclofen in the real world. Methods: Data covering the period from the first quarter of 2004 to the third quarter of 2024 were collected from the Food and Drug Administration Adverse Event Reporting System (FAERS). Four disproportionality analysis methods were employed: the Reporting Odds Ratio, the Proportional Reporting Ratio, Bayesian Confidence Propagation Neural Network, and the Multi-item Gamma Poisson Shrinkage (MGPS). These methods were used to detect and evaluate adverse events Adverse drug events associated with baclofen. Additionally, the time to onset analysis was conducted. Results: A total of 432 neurological-related preferred terms (PTs) were identified. The number of PT that were positive for all four algorithms was 40, and the top 5 PT were Hypotonia, Encephalopathy, Coma, Unresponsive to stimuli, and Cerebrospinal fluid leakage. The top 5 PTs for ROR values are Intracranial hypotension [ROR 66.24 (55.45–79.13)], Cerebrospinal fluid leakage [ROR 51.34 (45.84–57.51)], Autonomic dysreflexia [ROR 47.4 (32.27–69.63)], Basal ganglion degeneration [ROR 33.03 (18.54–58.84)], Sciatic nerve palsy [ROR 21.6 (11.14–41.87)]. The median onset time for baclofen -related ADEs was 27 days. Most cases (n = 241, 55.5%) occurred within the first month of baclofen administration. In an analysis of severe vs. non-severe ADEs, the study found that the incidence of severe cases was higher than that of non-severe cases, with no gender-related differences observed. Conclusion: This study identified clinically significant PTs using four different algorithms and performed gender subgroup analysis. The TTO analysis indicated that the onset of most ADEs occurred within 27 days. Furthermore, the frequency of severe ADEs was higher than that of non-severe ones. Clinicians should closely monitor for neurological adverse effects caused by baclofen, particularly severe ADEs, and consider individualized dosing strategies. Further research based on real-world data is needed to validate these findings.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079762</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2034730956&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Memo rdf:about="#item_996">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Included&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2034430391&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>16</prism:volume>
                <dc:title>Frontiers in Pharmacology</dc:title>
                <dc:identifier>DOI 10.3389/fphar.2025.1510992</dc:identifier>
                <dcterms:alternative>Front. Pharmacol.</dcterms:alternative>
                <dc:identifier>ISSN 1663-9812</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yang</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wei</foaf:surname>
                        <foaf:givenName>W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_997"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>Adolescent</dc:subject>
        <dc:subject>Adult</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>adverse event reporting system</dc:subject>
        <dc:subject>adverse events</dc:subject>
        <dc:subject>Aged</dc:subject>
        <dc:subject>alanine aminotransferase</dc:subject>
        <dc:subject>artificial neural network</dc:subject>
        <dc:subject>aspartate aminotransferase</dc:subject>
        <dc:subject>Bayes Theorem</dc:subject>
        <dc:subject>bilirubin</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>Child</dc:subject>
        <dc:subject>citalopram</dc:subject>
        <dc:subject>cohort analysis</dc:subject>
        <dc:subject>abdominal pain</dc:subject>
        <dc:subject>abnormal sensation</dc:subject>
        <dc:subject>backache</dc:subject>
        <dc:subject>automutilation</dc:subject>
        <dc:subject>balance disorder</dc:subject>
        <dc:subject>atrial fibrillation</dc:subject>
        <dc:subject>congestive heart failure</dc:subject>
        <dc:subject>bayesian confidence propagation neural network</dc:subject>
        <dc:subject>Bayesian network</dc:subject>
        <dc:subject>CANCER</dc:subject>
        <dc:subject>Child, Preschool</dc:subject>
        <dc:subject>Adverse event</dc:subject>
        <dc:subject>alopecia</dc:subject>
        <dc:subject>anemia</dc:subject>
        <dc:subject>asthenia</dc:subject>
        <dc:subject>blurred vision</dc:subject>
        <dc:subject>cellulitis</dc:subject>
        <dc:subject>clonazepam</dc:subject>
        <dc:subject>ascites</dc:subject>
        <dc:subject>benzodiazepine</dc:subject>
        <dc:subject>bacteremia</dc:subject>
        <dc:subject>breast disease</dc:subject>
        <dc:subject>chronic lymphatic leukemia</dc:subject>
        <dc:subject>agoraphobia</dc:subject>
        <dc:subject>bronchitis</dc:subject>
        <dc:subject>clinical outcome</dc:subject>
        <dc:subject>bone marrow suppression</dc:subject>
        <dc:subject>bone marrow depression</dc:subject>
        <dc:subject>bronchopulmonary aspergillosis</dc:subject>
        <dc:subject>congenital disorder</dc:subject>
        <dc:subject>CELL LUNG-CANCER</dc:subject>
        <dc:subject>Aged, 80 and over</dc:subject>
        <dc:subject>auditory hallucination</dc:subject>
        <dc:subject>blister</dc:subject>
        <dc:subject>carbamazepine</dc:subject>
        <dc:subject>aspergillosis</dc:subject>
        <dc:subject>autoimmune hemolytic anemia</dc:subject>
        <dc:subject>bacterial infection</dc:subject>
        <dc:subject>clinical monitoring</dc:subject>
        <dc:subject>conjunctival hyperemia</dc:subject>
        <dc:subject>aspiration pneumonia</dc:subject>
        <dc:subject>blunted affect</dc:subject>
        <dc:subject>acute myeloid leukemia</dc:subject>
        <dc:subject>anger</dc:subject>
        <dc:subject>CELLS</dc:subject>
        <dc:subject>acetylsalicylic acid</dc:subject>
        <dc:subject>adagrasib</dc:subject>
        <dc:subject>bipolar I disorder</dc:subject>
        <dc:subject>anxiety disorder</dc:subject>
        <dc:subject>amlodipine</dc:subject>
        <dc:subject>clobazam</dc:subject>
        <dc:subject>agranulocytosis</dc:subject>
        <dc:subject>anticonvulsive agent</dc:subject>
        <dc:subject>ACUTE MYELOID-LEUKEMIA</dc:subject>
        <dc:subject>ADEs signaling</dc:subject>
        <dc:subject>alcohol intoxication</dc:subject>
        <dc:subject>allergic blepharitis</dc:subject>
        <dc:subject>allergic contact dermatitis</dc:subject>
        <dc:subject>alpha fetoprotein</dc:subject>
        <dc:subject>amide</dc:subject>
        <dc:subject>amyotrophic lateral sclerosis</dc:subject>
        <dc:subject>antibody-drug conjugate</dc:subject>
        <dc:subject>ANTIBODY-DRUG CONJUGATE</dc:subject>
        <dc:subject>anticonvulsant therapy</dc:subject>
        <dc:subject>antiepileptic drug</dc:subject>
        <dc:subject>ANTIPSYCHOTICS</dc:subject>
        <dc:subject>aortic dissection</dc:subject>
        <dc:subject>APOPTOSIS</dc:subject>
        <dc:subject>application site erythema</dc:subject>
        <dc:subject>application site pain</dc:subject>
        <dc:subject>artery dissection</dc:subject>
        <dc:subject>ATTITUDES</dc:subject>
        <dc:subject>autoscopy</dc:subject>
        <dc:subject>AZACITIDINE</dc:subject>
        <dc:subject>B cell lymphoma</dc:subject>
        <dc:subject>B-CELL LYMPHOMA</dc:subject>
        <dc:subject>barbituric acid derivative</dc:subject>
        <dc:subject>BCL-2 INHIBITOR</dc:subject>
        <dc:subject>BCPNN</dc:subject>
        <dc:subject>bendamustine</dc:subject>
        <dc:subject>Benzoates</dc:subject>
        <dc:subject>benzoic acid</dc:subject>
        <dc:subject>beta alanine</dc:subject>
        <dc:subject>beta-Alanine</dc:subject>
        <dc:subject>bilateral diffuse uveal melanocytic proliferation</dc:subject>
        <dc:subject>BINDING</dc:subject>
        <dc:subject>BIOMARKER</dc:subject>
        <dc:subject>bladder spasm</dc:subject>
        <dc:subject>BRAF</dc:subject>
        <dc:subject>bulbar paralysis</dc:subject>
        <dc:subject>BUPROPION</dc:subject>
        <dc:subject>cancer growth</dc:subject>
        <dc:subject>Carcinoma, Non-Small-Cell Lung</dc:subject>
        <dc:subject>Carcinoma, Ovarian Epithelial</dc:subject>
        <dc:subject>CHRONIC LYMPHOCYTIC-LEUKEMIA</dc:subject>
        <dc:subject>CITRATE</dc:subject>
        <dc:subject>clinical assessment</dc:subject>
        <dc:subject>clinical research</dc:subject>
        <dc:subject>Clostridium difficile infection</dc:subject>
        <dc:subject>combination therapy</dc:subject>
        <dc:subject>conjunctival hemorrhage</dc:subject>
        <dc:title>A real-world pharmacovigilance study of efgartigimod alfa in the FDA adverse event reporting system database</dc:title>
        <dcterms:abstract>Objective: Efgartigimod alfa, approved for treating generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive, has uncertain long-term safety in large populations This study analyzed adverse events (AEs) linked to efgartigimod alfa using data from the FDA Adverse Event Reporting System (FAERS). Methods: We collected and analyzed efgartigimod alfa-related reports from the FAERS database from the first quarter of 2022 through the second quarter of 2024. Disproportionality analysis was used in data mining to quantify efgartigimod alfa-related AE signals. Results: A total of 3,040 reports with efgartigimod alfa as the primary suspect and 12,487 AEs were retrieved from FAERS. The most frequently reported serious outcome was hospitalization (53.22%), and death occurred in 270 cases (8.88%). Disproportionality analysis detected 137 AE signals, with the most common in nervous system disorders (22.69%), general disorders and administration site conditions (16.90%), and infections and infestations (14.05%). Notably, in addition to infection-related AEs identified during clinical trials, this study detected unexpected signals, including inappropriate schedule of product administration (ROR 2.60, PRR 2.53, IC 1.34, EBGM 2.53) and nephrolithiasis (ROR 8.13, PRR 7.99, IC 2.99, EBGM 7.95). The median onset time of AEs was 81.0 days. Conclusion: Our study provides a comprehensive assessment of the post-marketing safety of efgartigimod alfa and highlights the need for continued vigilance regarding infection-related adverse events. Additionally, the detection of inappropriate schedules of product administration underscores the importance of enhanced training and pharmacist involvement in medication management. Further research is warranted to explore the potential association between efgartigimod alfa and nephrolithiasis.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079760</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2034430391&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Memo rdf:about="#item_997">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: T. Huang; Department of Pharmacy, Eye &amp; ENT Hospital, Fudan University, Shanghai, No.83 Fenyang Rd, 200031, China; email: taominhuang@126.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: W. Wei; Department of Pharmacy, People’s Hospital of Zhongjiang County, Deyang, Sichuan, China; email: weiweieric0405@163.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: Y. Guo; Jinan Hospital of Guang an men Hospital, China Academy of Chinese Medical Sciences, Jinan, Shandong Province, 250012, China; email: guoyankui126@126.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: Y. Lian; Department of Gastroenterology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China; email: yifanlink@xmu.edu.cn; X. Jiang; Department of Orthopedics, Xiang’an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China; email: jxhrmyy@126.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 2; Correspondence Address: T. Qin; Department of Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China; email: qint6@mail.sysu.edu.cn; J. Yu; Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China; email: josse_yu@foxmail.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 2; Correspondence Address: Y. Chen; Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, 510000, China; email: puple2000@163.com; CODEN: MEDIA&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 4; Correspondence Address: B. Wu; Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China; email: binw83@hotmail.com; CODEN: EODSA&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 4; Correspondence Address: L. Zhang; Department of Pharmacy, The First Affiliated Hospital of Army Medical University, Third Military Medical University), Chongqing, China; email: 1126621684@qq.com; J. Hu; Department of Pharmacy, The First Affiliated Hospital of Army Medical University, Third Military Medical University), Chongqing, China; email: 18219797@qq.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 4; Correspondence Address: X. Xi; Department of Pharmacy, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China; email: 650101@hospital.cqmu.edu.cn&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 5; Correspondence Address: C. Shen; Department of Pharmacology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China; email: scw810@126.com; C. Lu; Department of Pharmacology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China; email: cece2021@163.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 16; Correspondence Address: F. Li; Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China; email: lifeie@tjh.tjmu.edu.cn; J. Li; Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China; email: lijuan@tjh.tjmu.edu.cn; CODEN: POLNC&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 33; Correspondence Address: H. Yang; Department of Gynecological Oncology, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, China; email: haiyanzheda@163.com; Z. Wan; Department of Minimally Invasive and Interventional Therapy for Cancer, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China; email: wanzheng0626@xmu.edu.cn&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 54; Correspondence Address: F. Li; Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, No. 1095 Jiefang Avenue, 430030, China; email: lifeie@tjh.tjmu.edu.cn; J. Li; Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, No. 1095 Jiefang Avenue, 430030, China; email: lijuan@tjh.tjmu.edu.cn&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 54; Correspondence Address: J. Li; Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, No. 1095 Jiefang Avenue, 430030, China; email: lijuan@tjh.tjmu.edu.cn; F. Li; Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, No. 1095 Jiefang Avenue, 430030, China; email: lifeie@tjh.tjmu.edu.cn&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;40&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;40&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;47&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;64&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;35&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;3&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;3&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;48&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;4&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;4&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;39&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;4&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;4&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;62&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;5&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;5&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;57&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;16&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;16&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;47&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;33&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;33&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;41&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;51&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;53&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;51&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;54&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;55&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;37&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Excluded&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2034400902&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1529-8019"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yu</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Qi</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yan</foaf:surname>
                        <foaf:givenName>W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jiang</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1002"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>odds ratio</dc:subject>
        <dc:subject>young adult</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>alanine aminotransferase</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>depression</dc:subject>
        <dc:subject>abdominal pain</dc:subject>
        <dc:subject>headache</dc:subject>
        <dc:subject>hypercalcemia</dc:subject>
        <dc:subject>insomnia</dc:subject>
        <dc:subject>nausea</dc:subject>
        <dc:subject>parathyroid disease</dc:subject>
        <dc:subject>parathyroid hormone</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>sleep disorder</dc:subject>
        <dc:subject>gastrointestinal disease</dc:subject>
        <dc:subject>mental disease</dc:subject>
        <dc:subject>reporting and data system</dc:subject>
        <dc:subject>deep vein thrombosis</dc:subject>
        <dc:subject>basal cell carcinoma</dc:subject>
        <dc:subject>cholesterol blood level</dc:subject>
        <dc:subject>allergy</dc:subject>
        <dc:subject>diarrhea</dc:subject>
        <dc:subject>groups by age</dc:subject>
        <dc:subject>nerve cell network</dc:subject>
        <dc:subject>hypercholesterolemia</dc:subject>
        <dc:subject>body weight loss</dc:subject>
        <dc:subject>ear disease</dc:subject>
        <dc:subject>cyst</dc:subject>
        <dc:subject>infestation</dc:subject>
        <dc:subject>polyp</dc:subject>
        <dc:subject>drug labeling</dc:subject>
        <dc:subject>neoplasm</dc:subject>
        <dc:subject>back propagation neural network</dc:subject>
        <dc:subject>laryngitis</dc:subject>
        <dc:subject>Bowen disease</dc:subject>
        <dc:subject>migraine</dc:subject>
        <dc:subject>postoperative complication</dc:subject>
        <dc:subject>abdominal discomfort</dc:subject>
        <dc:subject>liver injury</dc:subject>
        <dc:subject>pericarditis</dc:subject>
        <dc:subject>myasthenia gravis</dc:subject>
        <dc:subject>postoperative thrombosis</dc:subject>
        <dc:subject>alertness</dc:subject>
        <dc:subject>apremilast</dc:subject>
        <dc:subject>calcium blood level</dc:subject>
        <dc:subject>central nervous system</dc:subject>
        <dc:subject>cholesterol level</dc:subject>
        <dc:subject>defecation urgency</dc:subject>
        <dc:subject>dry lip</dc:subject>
        <dc:subject>dynamic Bayesian network</dc:subject>
        <dc:subject>ear</dc:subject>
        <dc:subject>ear infection</dc:subject>
        <dc:subject>enteropathy</dc:subject>
        <dc:subject>folliculitis</dc:subject>
        <dc:subject>frequent bowel movement</dc:subject>
        <dc:subject>Helicobacter infection</dc:subject>
        <dc:subject>information</dc:subject>
        <dc:subject>intestine polyp</dc:subject>
        <dc:subject>irritable colon</dc:subject>
        <dc:subject>lip</dc:subject>
        <dc:subject>lip disease</dc:subject>
        <dc:subject>middle ear efusion</dc:subject>
        <dc:subject>mood</dc:subject>
        <dc:subject>mucosa</dc:subject>
        <dc:subject>opportunistic infection</dc:subject>
        <dc:subject>parathyroid gland</dc:subject>
        <dc:subject>peripheral vein</dc:subject>
        <dc:subject>physiological stress</dc:subject>
        <dc:subject>pseudolymphoma</dc:subject>
        <dc:subject>psoriasis</dc:subject>
        <dc:subject>sinus headache</dc:subject>
        <dc:subject>skin papilloma</dc:subject>
        <dc:subject>soft stool</dc:subject>
        <dc:subject>stomach disease</dc:subject>
        <dc:subject>synovial bursa</dc:subject>
        <dc:subject>tension headache</dc:subject>
        <dc:subject>thyroxine</dc:subject>
        <dc:subject>upper respiratory tract infection</dc:subject>
        <dc:subject>vein disease</dc:subject>
        <dc:subject>wound infection</dc:subject>
        <dc:title>Is Safety Profile of Apremilast in Elderly Patients Same With That in Young and Middle-Aged Patients? A Real-World Disproportionality Analysis of the FDA Adverse Event Reporting System</dc:title>
        <dcterms:abstract>Background and Objective: Elderly individuals face heightened risks of infections, thrombosis, cardiovascular issues, and neoplasms, necessitating increased vigilance regarding adverse drug events (ADEs). The safety of apremilast in elderly patients has not been adequately explored in clinical trials. This study was to evaluate the safety profile of apremilast in young and middle-aged patients and elderly patients separately, through data mining of the US Food and Drug Administration Adverse Event Reporting System (FAERS). Methods: Reports in the FAERS from the third quarter of 2014 to the second quarter of 2023 were collected and analyzed. Disproportionality analyses (the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi-item gamma Poisson shrinker (MGPS) algorithms) were employed to quantify the ADE signals of apremilast in the age groups of 18–65 years and over 65 years. Results: After data cleaning, a total of 54,926 and 14,156 ADE reports were retrieved, with 66 and 61 ADE signals identified in young and middle-aged patients and in elderly patients, respectively. Several unexpected ADE signals not listed in the drug labeling information were detected, including pericarditis, increased cholesterol levels, liver injury, postoperative thrombosis, serum calcium, and parathyroid abnormalities. Furthermore, weight loss, psychiatric abnormalities, and infections in particular sites (ear, bursa mucosa, and central nervous system) were more significant in elderly patients. Conclusions: The study indicated several unexpected ADEs through disproportionality analysis and highlighted unique safety features in the elderly group. These findings may assist clinicians in managing psoriasis with apremilast.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079758</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2034400902&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1529-8019">
        <prism:volume>2025</prism:volume>
        <dc:title>Dermatologic Therapy</dc:title>
        <dc:identifier>DOI 10.1155/dth/8851158</dc:identifier>
        <prism:number>1</prism:number>
        <dcterms:alternative>Dermatol. Ther.</dcterms:alternative>
        <dc:identifier>ISSN 1529-8019</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1002">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Maybe&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2033093325&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>16</prism:volume>
                <dc:title>Frontiers in Pharmacology</dc:title>
                <dc:identifier>DOI 10.3389/fphar.2025.1462510</dc:identifier>
                <dcterms:alternative>Front. Pharmacol.</dcterms:alternative>
                <dc:identifier>ISSN 1663-9812</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tian</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jin</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ning</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1000"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data analysis</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>neurologic disease</dc:subject>
        <dc:subject>eye disease</dc:subject>
        <dc:subject>unclassified drug</dc:subject>
        <dc:subject>lymphatic system disease</dc:subject>
        <dc:subject>adverse drug events</dc:subject>
        <dc:subject>hematologic disease</dc:subject>
        <dc:subject>hepatobiliary disease</dc:subject>
        <dc:subject>antifungal agent</dc:subject>
        <dc:subject>data processing</dc:subject>
        <dc:subject>photosensitivity</dc:subject>
        <dc:subject>voriconazole</dc:subject>
        <dc:subject>data source</dc:subject>
        <dc:subject>frequency analysis</dc:subject>
        <dc:subject>isavuconazole</dc:subject>
        <dc:subject>OPENFDA</dc:subject>
        <dc:subject>posaconazole</dc:subject>
        <dc:subject>rational drug use</dc:subject>
        <dc:subject>signal mining</dc:subject>
        <dc:subject>triazole antifungal</dc:subject>
        <dc:subject>VORICONAZOLE</dc:subject>
        <dc:title>A post-marketing pharmacovigilance study of triazole antifungals: adverse event data mining and analysis based on the FDA adverse event reporting system database</dc:title>
        <dcterms:abstract>Background: To explore and analyze post-marketing adverse drug event (ADE) signals for voriconazole, posaconazole, and isavuconazole, and to compare the safety differences among the three drugs, aiming to provide insights for rational clinical use. Methods: Using the Open Vigil 2.1 online tool, extract adverse drug event (ADE) report data for voriconazole, posaconazole, and isavuconazole from the U.S. Food and Drug Administration’s Adverse Event Reporting System (FAERS) database from the time the drugs were marketed up to the third quarter of 2023. Employ the Reporting Odds Ratio (ROR) and Proportional Reporting Ratio (PRR) methods for data mining. Filter out ADE signals detected by both the ROR and PRR methods, and categorize these ADE signals by System Organ Class (SOC) according to the Medical Dictionary for Regulatory Activities (MedDRA 26.0). Results: A total of 8,898 ADE reports with voriconazole as the primary suspect drug were retrieved, 1,948 for posaconazole, and 944 for isavuconazole. From the basic analysis of the adverse event reports, male patients (50.31%) outnumber female patients (32.11%). In terms of age, the majority of patients are over 45 years old (52.72%). The reports primarily come from the United States, Japan, France, China, and other countries. A total of 607 ADE signals were identified, with 402 for voriconazole, 159 for posaconazole, and 46 for isavuconazole. Voriconazole ADEs primarily involved the following SOCs: Investigations (9.45%), Eye Disorders (8.46%), and Nervous System Disorders (7.21%); Posaconazole ADEs primarily involved the following SOCs: Investigations (13.84%), General Disorders and Administration Site Conditions (11.95%), and Nervous System Disorders (6.29%); Isavuconazole ADEs primarily involved the following SOCs: General Disorders and Administration Site Conditions (15.22%), Hepatobiliary Disorders (10.87%), and Blood and Lymphatic System Disorders (10.87%). Conclusion: Voriconazole, posaconazole, and isavuconazole all potentially pose safety risks related to hepatobiliary disorders and cardiac disorders. Additionally, voriconazole carries a higher safety risk for eye disorders and nervous system disorders. Newly discovered ADE signals not mentioned in the drug package inserts include voriconazole-induced rhabdomyolysis, posaconazole-induced peripheral neuropathy, and isavuconazole-induced visual impairment and mental confusion. These findings are significant for guiding rational clinical use of these medications.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079756</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2033093325&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Memo rdf:about="#item_1000">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: H. Ning; Department of Pharmacy, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China; email: ningh67@163.com&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;22&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Maybe&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2032825487&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1744-764X"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Qi</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jiang</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zheng</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1004"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>connective tissue disease</dc:subject>
        <dc:subject>brain hemorrhage</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>subdural hematoma</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>headache</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>amnesia</dc:subject>
        <dc:subject>cognitive defect</dc:subject>
        <dc:subject>confusion</dc:subject>
        <dc:subject>gastrointestinal disease</dc:subject>
        <dc:subject>mental disease</dc:subject>
        <dc:subject>neurologic disease</dc:subject>
        <dc:subject>reporting and data system</dc:subject>
        <dc:subject>seizure</dc:subject>
        <dc:subject>sex difference</dc:subject>
        <dc:subject>skin disease</dc:subject>
        <dc:subject>atrial fibrillation</dc:subject>
        <dc:subject>brain infarction</dc:subject>
        <dc:subject>deep vein thrombosis</dc:subject>
        <dc:subject>eye disease</dc:subject>
        <dc:subject>ischemic stroke</dc:subject>
        <dc:subject>subarachnoid hemorrhage</dc:subject>
        <dc:subject>transient ischemic attack</dc:subject>
        <dc:subject>Alzheimer disease</dc:subject>
        <dc:subject>body weight</dc:subject>
        <dc:subject>groups by age</dc:subject>
        <dc:subject>lymphatic system disease</dc:subject>
        <dc:subject>malignant neoplasm</dc:subject>
        <dc:subject>heart disease</dc:subject>
        <dc:subject>inner ear disease</dc:subject>
        <dc:subject>mediastinum disease</dc:subject>
        <dc:subject>memory disorder</dc:subject>
        <dc:subject>respiratory tract disease</dc:subject>
        <dc:subject>thorax disease</dc:subject>
        <dc:subject>vascular disease</dc:subject>
        <dc:subject>dementia</dc:subject>
        <dc:subject>benign neoplasm</dc:subject>
        <dc:subject>brain edema</dc:subject>
        <dc:subject>breast disease</dc:subject>
        <dc:subject>ear disease</dc:subject>
        <dc:subject>cyst</dc:subject>
        <dc:subject>genital system disease</dc:subject>
        <dc:subject>hematologic disease</dc:subject>
        <dc:subject>hepatobiliary disease</dc:subject>
        <dc:subject>infection</dc:subject>
        <dc:subject>infestation</dc:subject>
        <dc:subject>injury</dc:subject>
        <dc:subject>intoxication</dc:subject>
        <dc:subject>kidney disease</dc:subject>
        <dc:subject>metabolic disorder</dc:subject>
        <dc:subject>musculoskeletal disease</dc:subject>
        <dc:subject>nutritional disorder</dc:subject>
        <dc:subject>polyp</dc:subject>
        <dc:subject>urinary tract disease</dc:subject>
        <dc:subject>gait disorder</dc:subject>
        <dc:subject>immunopathology</dc:subject>
        <dc:subject>aphasia</dc:subject>
        <dc:subject>lethargy</dc:subject>
        <dc:subject>disorientation</dc:subject>
        <dc:subject>aducanumab</dc:subject>
        <dc:subject>amyloid</dc:subject>
        <dc:subject>drug dose increase</dc:subject>
        <dc:subject>falling</dc:subject>
        <dc:subject>hemosiderin</dc:subject>
        <dc:subject>mental instability</dc:subject>
        <dc:subject>microbleeding</dc:subject>
        <dc:subject>recommended drug dose</dc:subject>
        <dc:subject>siderosis</dc:subject>
        <dc:subject>urine incontinence</dc:subject>
        <dc:title>Mining and analysis of adverse events associated with aducanumab: a real-world study using FDA Adverse Event Reporting System database</dc:title>
        <dcterms:abstract>Background: Aducanumab, a monoclonal antibody, received approval for the treatment of Alzheimer’s disease in 2021. However, it remains controversial over the security of this drug. In this study, aducanumab-related adverse events (AEs) were evaluated through data mining based on the FDA Adverse Event Reporting System (FAERS) database. Research design and methods: The AE reports induced by aducanumab as the primary suspected drug were extracted from the FAERS database. The clinical characteristics of aducanumab-associated reports were analyzed. The potential new AE signals of aducanumab were explored using four disproportionality analysis methods. Furthermore, the difference in aducanumab-associated AE signals was investigated concerning sex, age, weight, dose, onset time, and continent. Results: In total, 328 reports and 793 AEs associated with aducanumab were identified. Six new AEs were identified. No significant sex and weight difference in aducanumab-related signals was found. Notably, nervous system disorders, especially ‘amyloid related imaging abnormality-edema/effusion’ and ‘amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits,’ were more frequently to be reported within 121–240 days, particularly in Europe. Conclusions: This study contributes real-world evidence regarding the safety of aducanumab.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079754</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2032825487&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>469-478</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1744-764X">
        <prism:volume>24</prism:volume>
        <dc:title>Expert Opinion on Drug Safety</dc:title>
        <dc:identifier>DOI 10.1080/14740338.2024.2448205</dc:identifier>
        <prism:number>4</prism:number>
        <dcterms:alternative>Expert Opin. Drug Saf.</dcterms:alternative>
        <dc:identifier>ISSN 1744-764X</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1004">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Included&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2033101391&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>16</prism:volume>
                <dc:title>Frontiers in Pharmacology</dc:title>
                <dc:identifier>DOI 10.3389/fphar.2025.1524702</dc:identifier>
                <dcterms:alternative>Front. Pharmacol.</dcterms:alternative>
                <dc:identifier>ISSN 1663-9812</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jiang</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Pan</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kong</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1003"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data analysis</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>disease course</dc:subject>
        <dc:subject>*Data Mining</dc:subject>
        <dc:subject>*Pharmacovigilance</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>Adolescent</dc:subject>
        <dc:subject>Adult</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>ADVERSE DRUG-REACTIONS</dc:subject>
        <dc:subject>Aged</dc:subject>
        <dc:subject>Anti-Bacterial Agents</dc:subject>
        <dc:subject>antiinfective agent</dc:subject>
        <dc:subject>artificial neural network</dc:subject>
        <dc:subject>cardiovascular disease</dc:subject>
        <dc:subject>chi square test</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>Child</dc:subject>
        <dc:subject>classification</dc:subject>
        <dc:subject>classifier</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>clinical practice</dc:subject>
        <dc:subject>clinical decision making</dc:subject>
        <dc:subject>atrial fibrillation</dc:subject>
        <dc:subject>avatrombopag</dc:subject>
        <dc:subject>*Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>*United States Food and Drug Administration</dc:subject>
        <dc:subject>accuracy</dc:subject>
        <dc:subject>cefprozil</dc:subject>
        <dc:subject>ceftriaxone</dc:subject>
        <dc:subject>Adverse event</dc:subject>
        <dc:subject>asthenia</dc:subject>
        <dc:subject>cancer chemotherapy</dc:subject>
        <dc:subject>chemically induced</dc:subject>
        <dc:subject>data analysis software</dc:subject>
        <dc:subject>Data Mining</dc:subject>
        <dc:subject>Databases, Factual</dc:subject>
        <dc:subject>diarrhea</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>drug fatality</dc:subject>
        <dc:subject>Canada</dc:subject>
        <dc:subject>drug database</dc:subject>
        <dc:subject>drug information</dc:subject>
        <dc:subject>electronic health record</dc:subject>
        <dc:subject>Electronic Health Records</dc:subject>
        <dc:subject>adverse drug events</dc:subject>
        <dc:subject>cytomegalovirus infection</dc:subject>
        <dc:subject>DISEASE</dc:subject>
        <dc:subject>Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>antifungal agent</dc:subject>
        <dc:subject>Antiviral Agents</dc:subject>
        <dc:subject>antivirus agent</dc:subject>
        <dc:subject>DRUG</dc:subject>
        <dc:subject>drug drug interaction</dc:subject>
        <dc:subject>drug interaction</dc:subject>
        <dc:subject>Drug Interactions</dc:subject>
        <dc:subject>aging</dc:subject>
        <dc:subject>Aged, 80 and over</dc:subject>
        <dc:subject>cefalexin</dc:subject>
        <dc:subject>cefazolin</dc:subject>
        <dc:subject>cefdinir</dc:subject>
        <dc:subject>cefotaxime</dc:subject>
        <dc:subject>drug monitoring</dc:subject>
        <dc:subject>bioinformatics</dc:subject>
        <dc:subject>cefaclor</dc:subject>
        <dc:subject>cefadroxil</dc:subject>
        <dc:subject>cefepime</dc:subject>
        <dc:subject>cefixime</dc:subject>
        <dc:subject>cefradine</dc:subject>
        <dc:subject>ceftazidime</dc:subject>
        <dc:subject>cefuroxime</dc:subject>
        <dc:subject>children</dc:subject>
        <dc:subject>drug marketing</dc:subject>
        <dc:subject>ACYCLOVIR</dc:subject>
        <dc:subject>cephalosporin derivative</dc:subject>
        <dc:subject>2016 REVISION</dc:subject>
        <dc:subject>acalabrutinib</dc:subject>
        <dc:subject>ACALABRUTINIB</dc:subject>
        <dc:subject>ADULT PATIENTS</dc:subject>
        <dc:subject>adults</dc:subject>
        <dc:subject>AMERICA</dc:subject>
        <dc:subject>Avatrombopag</dc:subject>
        <dc:subject>B cell malignancies</dc:subject>
        <dc:subject>biosurveillance</dc:subject>
        <dc:subject>BLOOD</dc:subject>
        <dc:subject>broad spectrum antifungal agent</dc:subject>
        <dc:subject>Bruton tyrosine kinase inhibitor</dc:subject>
        <dc:subject>BTK inhibitors</dc:subject>
        <dc:subject>cefditoren</dc:subject>
        <dc:subject>cefoxitin</dc:subject>
        <dc:subject>cefpodoxime</dc:subject>
        <dc:subject>Ceftriaxone</dc:subject>
        <dc:subject>Ceftriaxone/adverse effects/*pharmacology</dc:subject>
        <dc:subject>Cefuroxime</dc:subject>
        <dc:subject>Cefuroxime/adverse effects/*pharmacology</dc:subject>
        <dc:subject>CELL TRANSPLANTATION</dc:subject>
        <dc:subject>chi squared automatic interaction detection algorithm</dc:subject>
        <dc:subject>consumer health information</dc:subject>
        <dc:subject>CORPUS</dc:subject>
        <dc:subject>CYTOMEGALOVIRUS-INFECTION</dc:subject>
        <dc:subject>daridorexant</dc:subject>
        <dc:subject>data science</dc:subject>
        <dc:subject>Database</dc:subject>
        <dc:subject>decision tree</dc:subject>
        <dc:subject>decision tree analysis</dc:subject>
        <dc:subject>Decision Trees</dc:subject>
        <dc:subject>diagnostic accuracy</dc:subject>
        <dc:subject>disease severity assessment</dc:subject>
        <dc:subject>Drug discovery</dc:subject>
        <dc:subject>DRUG DISCOVERY</dc:subject>
        <dc:subject>Drug Monitoring</dc:subject>
        <dc:subject>drug screening</dc:subject>
        <dc:subject>drug-drug interaction</dc:subject>
        <dc:subject>dual orexin receptor antagonists (DORAs)</dc:subject>
        <dc:subject>electrocardiogram</dc:subject>
        <dc:subject>Electrophysiologic Techniques, Cardiac</dc:subject>
        <dc:subject>ELTROMBOPAG</dc:subject>
        <dc:title>Data mining and safety analysis of voriconazole in patients with a hematological malignant tumor based on the FAERS database: differences between children and adults</dc:title>
        <dcterms:abstract>Objective: Voriconazole is a broad-spectrum antifungal agent. It is used widely for the prevention and treatment of invasive fungal infections in patients with a hematological malignancy, but studies on its safety in this population are scarce. We assessed the adverse drug events (ADEs) of voriconazole in this population based on the US Food and Drug Administration Adverse Event Reporting System (FAERS) database to improve understanding of the safety of voriconazole. Research design and methods: ADE reports for patients with a hematological malignant tumor using voriconazole between the first quarter of 2004 to the first quarter of 2024 were retrieved. Then, they were classified using the preferred terminology (PT) and system organ category (SOC) in the Medical Dictionary for Regulatory Activities. Data mining was done using reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS). Results: A total of 605 ADEs were included: 116 (19.17%) in children and 489 (80.83%) in adults. The types of SOC involved in children and adults were 22 and 24, respectively. The only positive SOC signal that satisfied all four algorithms simultaneously in children was “psychiatric disorders”, whereas in adults they were “endocrine disorders” and “hepatobiliary disorders”. At the PT level, the types involved in children and adults were 28 and 74, respectively. The highest ROR signal intensities were found for “hallucinations, mixed” in children and “toxic optic neuropathy” in adults. The median time of onset of the ADE in children and adults was 11 and 8.5 days, respectively. Conclusion: We used four algorithms (ROR, PRR, BCPNN, MGPS) to mine the signals of voriconazole in patients with a hematological malignant tumor, and compared the differences between children and adults. This study is important for targeting the monitoring, and could help to improve the safety of voriconazole.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079757</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2033101391&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Memo rdf:about="#item_1003">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: L. Kong; Department of Pharmacy, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China; email: konglingti@163.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 3; Correspondence Address: M. Wu; Department of Oral and Maxillofacial Surgery, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huaian, 1 Huanghe West Road, Jiangsu, 223300, China; email: hayywm@njmu.edu.cn&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 8; Correspondence Address: J. Zhou; Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing, China; email: zhoujinming@imb.pumc.edu.cn&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 9; Correspondence Address: K. Iseki; Department of Pharmacy, Hokkaido University Hospital, Sapporo, Japan; email: ken-i@pharm.hokudai.ac.jp; CODEN: JCPTE&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 17; Correspondence Address: J. Hu; Department of Pharmacy, The First Affiliated Hospital of Nanchang University, Nanchang, China; email: hujinfang333@126.com; H. Peng; Department of Pharmacy, The First Affiliated Hospital of Nanchang University, Nanchang, China; email: wavypeng1985@126.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 26; Correspondence Address: K. Iseki; Department of Pharmacy, Hokkaido University Hospital; Kita 14-jo, Sapporo, Nishi 5-chome, Kita-ku, 060-8648, Japan; email: ken-i@pharm.hokudai.ac.jp; CODEN: JECPF&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 65; Correspondence Address: A. Sarker; Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, 423 Guardian Drive 421A, 19104, United States; email: abeed@pennmedicine.upenn.edu; CODEN: JAMAF&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 69; Correspondence Address: N.P. Tatonetti; Department of Biomedical Informatics, Columbia University, New York, 622 West 168th St., PH20, 10032, United States; email: nick.tatonetti@columbia.edu; CODEN: JACCD&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;43&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;29&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;5&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;5&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;53&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;6&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;6&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;30&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;9&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;9&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;30&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;15&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;15&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;34&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;26&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;26&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;29&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;53&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;56&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;55&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Included&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2032898571&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:2042-0994"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jiang</foaf:surname>
                        <foaf:givenName>T.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>N.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gan</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Su</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xiang</foaf:surname>
                        <foaf:givenName>G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1001"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>*Data Mining</dc:subject>
        <dc:subject>*Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>*Semantics</dc:subject>
        <dc:subject>acute heart infarction</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>Adolescent</dc:subject>
        <dc:subject>Adult</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>adverse outcome</dc:subject>
        <dc:subject>Aged</dc:subject>
        <dc:subject>alanine aminotransferase</dc:subject>
        <dc:subject>Algorithms</dc:subject>
        <dc:subject>artificial neural network</dc:subject>
        <dc:subject>aspartate aminotransferase</dc:subject>
        <dc:subject>bilirubin</dc:subject>
        <dc:subject>arthralgia</dc:subject>
        <dc:subject>brain hemorrhage</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>abnormal sensation</dc:subject>
        <dc:subject>body weight gain</dc:subject>
        <dc:subject>clinical practice</dc:subject>
        <dc:subject>deep vein thrombosis</dc:subject>
        <dc:subject>*Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>*United States Food and Drug Administration</dc:subject>
        <dc:subject>analgesic agent</dc:subject>
        <dc:subject>animal</dc:subject>
        <dc:subject>Animals</dc:subject>
        <dc:subject>anticoagulant agent</dc:subject>
        <dc:subject>aripiprazole</dc:subject>
        <dc:subject>arthritis</dc:subject>
        <dc:subject>azithromycin</dc:subject>
        <dc:subject>bile duct cancer</dc:subject>
        <dc:subject>anemia</dc:subject>
        <dc:subject>breast cancer</dc:subject>
        <dc:subject>cancer chemotherapy</dc:subject>
        <dc:subject>CHEMOTHERAPY</dc:subject>
        <dc:subject>CLASSIFICATION</dc:subject>
        <dc:subject>creatinine</dc:subject>
        <dc:subject>Data mining</dc:subject>
        <dc:subject>Data Mining</dc:subject>
        <dc:subject>Data Mining/*methods</dc:subject>
        <dc:subject>Databases, Factual</dc:subject>
        <dc:subject>diarrhea</dc:subject>
        <dc:subject>ascites</dc:subject>
        <dc:subject>demographics</dc:subject>
        <dc:subject>acute pancreatitis</dc:subject>
        <dc:subject>bisphosphonic acid derivative</dc:subject>
        <dc:subject>bromazepam</dc:subject>
        <dc:subject>clinical decision support</dc:subject>
        <dc:subject>atypical antipsychotic agent</dc:subject>
        <dc:subject>bacteremia</dc:subject>
        <dc:subject>antivirus agent</dc:subject>
        <dc:subject>candidiasis</dc:subject>
        <dc:subject>*Artificial Intelligence</dc:subject>
        <dc:subject>amphotericin B</dc:subject>
        <dc:subject>artificial intelligence</dc:subject>
        <dc:subject>change point analysis</dc:subject>
        <dc:subject>cyclophosphamide</dc:subject>
        <dc:subject>aplasia</dc:subject>
        <dc:subject>bone marrow depression</dc:subject>
        <dc:subject>bronchopulmonary aspergillosis</dc:subject>
        <dc:subject>*Databases, Factual</dc:subject>
        <dc:subject>ADVERSE EVENTS</dc:subject>
        <dc:subject>Aged, 80 and over</dc:subject>
        <dc:subject>computer program</dc:subject>
        <dc:subject>DATABASES</dc:subject>
        <dc:subject>chlorpromazine</dc:subject>
        <dc:subject>diagnostic test accuracy study</dc:subject>
        <dc:subject>acute myeloid leukemia</dc:subject>
        <dc:subject>cytarabine</dc:subject>
        <dc:subject>ALGORITHMS</dc:subject>
        <dc:subject>*Electronic Health Records</dc:subject>
        <dc:subject>animal model</dc:subject>
        <dc:subject>antiasthmatic agent</dc:subject>
        <dc:subject>cross validation</dc:subject>
        <dc:subject>ACUTE MYELOID-LEUKEMIA</dc:subject>
        <dc:subject>amyotrophic lateral sclerosis</dc:subject>
        <dc:subject>CORPUS</dc:subject>
        <dc:subject>diagnostic accuracy</dc:subject>
        <dc:subject>*Intensive Care Units</dc:subject>
        <dc:subject>*Patient Discharge</dc:subject>
        <dc:subject>aciclovir</dc:subject>
        <dc:subject>acute febrile neutrophilic dermatosis</dc:subject>
        <dc:subject>ACUTE KIDNEY INJURY</dc:subject>
        <dc:subject>ACUTE MYELOGENOUS LEUKEMIA</dc:subject>
        <dc:subject>ADVERSE</dc:subject>
        <dc:subject>aminoglycoside antibiotic agent</dc:subject>
        <dc:subject>AML</dc:subject>
        <dc:subject>analysis of variance</dc:subject>
        <dc:subject>Analysis of Variance</dc:subject>
        <dc:subject>antiobesity agent</dc:subject>
        <dc:subject>antiparkinson agent</dc:subject>
        <dc:subject>azacitidine</dc:subject>
        <dc:subject>Bias</dc:subject>
        <dc:subject>cachexia</dc:subject>
        <dc:subject>CANCER QLQ-C30</dc:subject>
        <dc:subject>case-based reasoning</dc:subject>
        <dc:subject>causal inference</dc:subject>
        <dc:subject>CAUSALITY ASSESSMENT</dc:subject>
        <dc:subject>CD135 antigen</dc:subject>
        <dc:subject>central stimulant agent</dc:subject>
        <dc:subject>cesium ion</dc:subject>
        <dc:subject>Clinical Decision-Making</dc:subject>
        <dc:subject>Commerce</dc:subject>
        <dc:subject>commercial phenomena</dc:subject>
        <dc:subject>COMPETITION BIAS</dc:subject>
        <dc:subject>computerized</dc:subject>
        <dc:subject>cost effectiveness analysis</dc:subject>
        <dc:subject>CREATININE CLEARANCE</dc:subject>
        <dc:subject>critical care</dc:subject>
        <dc:subject>Datasets as Topic</dc:subject>
        <dc:subject>daunorubicin</dc:subject>
        <dc:subject>dextromethorphan</dc:subject>
        <dc:title>Unveiling unexpected adverse events: post-marketing safety surveillance of gilteritinib and midostaurin from the FDA Adverse Event Reporting database</dc:title>
        <dcterms:abstract>Background: Gilteritinib and midostaurin are FLT3 inhibitors that have made significant progress in the treatment of acute myeloid leukemia. However, their real-world safety profile in a large sample population is incomplete. Objectives: We aimed to provide a pharmacovigilance study of the adverse events (AEs) associated with gilteritinib and midostaurin through the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database. Design: A retrospective analysis of the FAERS database was conducted by disproportionality analyses. Methods: We conducted disproportionality analyses to identify drug-AE associations, including the reporting odds ratio and the Bayesian confidence propagation neural network. A signal was detected if both methods achieved statistical significance. Results: There were 1887 and 2091 case reports for gilteritinib and midostaurin, respectively. We have separately retained significant disproportionality AEs across two algorithms, with a total of 53 AEs for gilteritinib and 46 for midostaurin. The common AEs observed with gilteritinib included febrile neutropenia, pyrexia, anemia, and thrombocytopenia. Similarly, the prevalent AEs associated with midostaurin were nausea, vomiting, diarrhea, pyrexia, and febrile neutropenia. The common AEs of both drugs are consistent with previous clinical trials. Notably, we also revealed unexpected significant AEs for both drugs. For gilteritinib, 29 positive signals for AEs not mentioned in its instructions were identified, such as cerebral hemorrhage, tumor lysis syndrome, and interstitial lung disease. Midostaurin exhibited 24 positive signals for AEs not listed in its instructions, including neutropenic colitis, neutropenic sepsis, and septic shock. Conclusion: This study highlights the need for continued monitoring and evaluation of these drugs in clinical practice, as it first reveals their AEs in a large real-world sample population. Some AEs are generally consistent with the instructions and previous studies, but some unexpected AEs are detected for each drug. Due to the limitations of the spontaneous report database, such as including potential underreporting, overreporting, lack of causal relationship, unable to calculate incidence, and other confounding factors, more pharmacoepidemiology studies are needed to validate our findings.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079755</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2032898571&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:2042-0994">
        <prism:volume>16</prism:volume>
        <dc:title>Therapeutic Advances in Drug Safety</dc:title>
        <dc:identifier>DOI 10.1177/20420986241308089</dc:identifier>
        <dcterms:alternative>Ther. Adv. Drug Saf.</dcterms:alternative>
        <dc:identifier>ISSN 2042-0994</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1001">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: Y. Liu; Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing, No. 10 Changjiang Branch Road, Yuzhong District, 400042, China; email: liuyao@tmmu.edu.cn&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 4; Correspondence Address: E. Aramaki; Department of Information Science, Nara Institute of Science and Technology, Ikoma, 8916-5, Takayama-cho, 630-0192, Japan; email: aramaki@is.naist.jp&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 12; Correspondence Address: H. Yokoi; Clinical Research Support Center, Kagawa University Hospital, Kagawa, Japan; email: yokoi.hideto.md@kagawa-u.ac.jp&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 20; Correspondence Address: K. Klein; Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, Netherlands; email: k.klein1@uu.nl; CODEN: CLPTA&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 32; Correspondence Address: S. Imai; Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan; email: s.imai@pharm.hokudai.ac.jp; CODEN: POLNC&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 56; Correspondence Address: P.M. Coloma; Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands; email: p.coloma@erasmusmc.nl; CODEN: DRSAE&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 115; Correspondence Address: H.J. Duggirala; Rockville, 7519 Standish Place, HFV-200, United States; email: Hesha.Duggirala@fda.hhs.gov; CODEN: JAMAF&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;64&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;39&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;3&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;4&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;50&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;10&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;10&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;37&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;21&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;22&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;28&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;32&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;32&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;45&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;101&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;111&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;53&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Included&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2031952041&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:2168-4804"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chakraborty</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tiwari</foaf:surname>
                        <foaf:givenName>R.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_767"/>
        <dcterms:isReferencedBy rdf:resource="#item_1005"/>
        <dc:subject>acute kidney failure</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>postmarketing surveillance</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>depression</dc:subject>
        <dc:subject>dizziness</dc:subject>
        <dc:subject>fatigue</dc:subject>
        <dc:subject>headache</dc:subject>
        <dc:subject>nausea</dc:subject>
        <dc:subject>pain</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>vomiting</dc:subject>
        <dc:subject>seizure</dc:subject>
        <dc:subject>somnolence</dc:subject>
        <dc:subject>amoxicillin</dc:subject>
        <dc:subject>ceftriaxone</dc:subject>
        <dc:subject>diarrhea</dc:subject>
        <dc:subject>clonazepam</dc:subject>
        <dc:subject>dyspnea</dc:subject>
        <dc:subject>drug database</dc:subject>
        <dc:subject>chronic kidney failure</dc:subject>
        <dc:subject>drug hypersensitivity</dc:subject>
        <dc:subject>kidney disease</dc:subject>
        <dc:subject>kidney failure</dc:subject>
        <dc:subject>fever</dc:subject>
        <dc:subject>decreased appetite</dc:subject>
        <dc:subject>rash</dc:subject>
        <dc:subject>pseudomembranous colitis</dc:subject>
        <dc:subject>cefalexin</dc:subject>
        <dc:subject>detection algorithm</dc:subject>
        <dc:subject>tremor</dc:subject>
        <dc:subject>cefuroxime</dc:subject>
        <dc:subject>anxiety disorder</dc:subject>
        <dc:subject>lorazepam</dc:subject>
        <dc:subject>anticonvulsive agent</dc:subject>
        <dc:subject>computer analysis</dc:subject>
        <dc:subject>falling</dc:subject>
        <dc:subject>beta lactam antibiotic</dc:subject>
        <dc:subject>brivaracetam</dc:subject>
        <dc:subject>cluster analysis</dc:subject>
        <dc:subject>clustering algorithm</dc:subject>
        <dc:subject>drug classification</dc:subject>
        <dc:subject>drug fever</dc:subject>
        <dc:subject>drug overdose</dc:subject>
        <dc:subject>fenfluramine</dc:subject>
        <dc:subject>lamotrigine</dc:subject>
        <dc:subject>liver disease</dc:subject>
        <dc:subject>meropenem</dc:subject>
        <dc:subject>outlier detection</dc:subject>
        <dc:subject>primidone</dc:subject>
        <dc:subject>simulation</dc:subject>
        <dc:title>A Clustering Ensemble Method for Drug Safety Signal Detection in Post-Marketing Surveillance</dc:title>
        <dcterms:abstract>Post-marketing surveillance refers to the process of monitoring the safety of drugs once they reach the market, after the successful completion of clinical trials. In this work, we investigate a computational approach using data mining tools to detect safety signals from post-market safety databases, or in other words, to identify adverse events (AEs) with disproportionately high reporting rates compared to other AEs, associated with a particular drug or a drug class. Essentially, we view this as a problem of cluster analysis-based anomaly detection on post-market safety data, where the goal is to ‘unsupervisedly’ detect the anomalous or the signal AEs. Our findings demonstrate the potential of using a clustering ensemble method to detect drug safety signals. It employs multiple clustering or anomaly detection algorithms, followed by a performance comparison of the candidate algorithms based on a collection of appropriate measures of goodness of clustering results. The method is general enough to include any number of clustering or anomaly detection algorithms and goodness measures, and performs better than any of the candidate algorithms in identifying the signal AEs. Extensive simulation studies illustrate that the ensemble method detects the AE signals from synthetic post-market safety datasets pretty accurately across the different scenarios explored. Based on the cases reported to the FDA Adverse Event Reporting System (FAERS) between 2013 and 2022, we further demonstrate that the ensemble method successfully identifies and confirms most of the adverse events that are known to occur most frequently in reaction to antiepileptic drugs and β-lactam antibiotics.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079752</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2031952041&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>89-101</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:2168-4804">
        <prism:volume>59</prism:volume>
        <dc:title>Therapeutic Innovation and Regulatory Science</dc:title>
        <dc:identifier>DOI 10.1007/s43441-024-00705-7</dc:identifier>
        <prism:number>1</prism:number>
        <dcterms:alternative>Ther. Innov. Regul. Sci.</dcterms:alternative>
        <dc:identifier>ISSN 2168-4804</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_767">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Maybe&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Desenvolvimento do método,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Memo rdf:about="#item_1005">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Maybe&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Desenvolvimento do método,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L646182998&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>15</prism:volume>
                <dc:title>Scientific reports</dc:title>
                <dc:identifier>DOI 10.1038/s41598-024-75421-1</dc:identifier>
                <prism:number>1</prism:number>
                <dcterms:alternative>Sci Rep</dcterms:alternative>
                <dc:identifier>ISSN 2045-2322</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xu</foaf:surname>
                        <foaf:givenName>Q.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tang</foaf:surname>
                        <foaf:givenName>W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhou</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yuan</foaf:surname>
                        <foaf:givenName>P.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1007"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>factual database</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>young adult</dc:subject>
        <dc:subject>*Data Mining</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>Adolescent</dc:subject>
        <dc:subject>Adult</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>Aged</dc:subject>
        <dc:subject>Bayes Theorem</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>Child</dc:subject>
        <dc:subject>epidemiology</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>*Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>Adverse events</dc:subject>
        <dc:subject>Data Mining</dc:subject>
        <dc:subject>Databases, Factual</dc:subject>
        <dc:subject>Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>Female</dc:subject>
        <dc:subject>*Databases, Factual</dc:subject>
        <dc:subject>Male</dc:subject>
        <dc:subject>Middle Aged</dc:subject>
        <dc:subject>monoclonal antibody</dc:subject>
        <dc:subject>*Antibodies, Monoclonal, Humanized/adverse effects/therapeutic use</dc:subject>
        <dc:subject>Antibodies, Monoclonal, Humanized</dc:subject>
        <dc:subject>Drug safety</dc:subject>
        <dc:subject>Drug-Related Side Effects and Adverse Reactions/epidemiology</dc:subject>
        <dc:subject>FAERS Database</dc:subject>
        <dc:subject>gastrointestinal agent</dc:subject>
        <dc:subject>Gastrointestinal Agents</dc:subject>
        <dc:subject>Gastrointestinal Agents/adverse effects/therapeutic use</dc:subject>
        <dc:subject>Inflammatory bowel disease</dc:subject>
        <dc:subject>vedolizumab</dc:subject>
        <dc:subject>Vedolizumab</dc:subject>
        <dc:subject>Young Adult</dc:subject>
        <dc:title>Data mining and analysis of adverse events of Vedolizumab based on the FAERS database</dc:title>
        <dcterms:abstract>This study aims to mine and analyze adverse events (AEs) of Vedolizumab based on the FAERS database to better understand its safety and potential risks in the real world. Data from the second quarter of 2014 to the third quarter of 2023 were collected, employing various signal mining methods such as Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Empirical Bayesian Geometric Mean (EBGM). The study gathered 14,753,012 reports of AEs, of which 46,726 were related to Vedolizumab. Signal mining identified 401 Preferred Terms (PTs) involving 27 System Organ Classes (SOCs). There was an increasing trend in the number of reports, with a slightly higher proportion of reports from women compared to men, and the primary reporting group was adults, especially those aged between 18 and 65 years. New potential AE signals were identified, such as a higher incidence of Pregnancy, Haematochezia, and Clostridium difficile infection. Although less frequent, strong signals were noted for Incisional hernia, Intestinal fistula infection, Anastomotic complication, Drug metabolising enzyme increased, Gingival graft, Intestinal anastomosis complication, Anorectal infection, Perineal rash, and Abdominal hernia obstructive. Despite the positive prospects of Vedolizumab in the treatment of inflammatory bowel diseases, the AEs related to its use identified in this study, particularly the newly identified potential risks, suggest that even targeted therapies can have systemic effects beyond expectations.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079750</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L646182998&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>278</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1007">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: X. Zhang; Nanjing University of Chinese Medicine Wuxi Affiliated Hospital: Wuxi Hospital of Traditional Chinese Medicine, Wuxi, 214071, China; email: xinjiangzq@126.com; P. Yuan; Nanjing University of Chinese Medicine Wuxi Affiliated Hospital: Wuxi Hospital of Traditional Chinese Medicine, Wuxi, 214071, China; email: gastroyp11@aliyun.com&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Included&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2031959733&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>24</prism:volume>
                <dc:title>Expert Opinion on Drug Safety</dc:title>
                <dc:identifier>DOI 10.1080/14740338.2024.2419995</dc:identifier>
                <prism:number>3</prism:number>
                <dcterms:alternative>Expert Opin. Drug Saf.</dcterms:alternative>
                <dc:identifier>ISSN 1744-764X</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhao</foaf:surname>
                        <foaf:givenName>Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ji</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ren</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ding</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1009"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data analysis</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>odds ratio</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>connective tissue disease</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>impaired fracture healing</dc:subject>
        <dc:subject>osteoporosis</dc:subject>
        <dc:subject>rheumatoid arthritis</dc:subject>
        <dc:subject>senile osteoporosis</dc:subject>
        <dc:subject>gastrointestinal disease</dc:subject>
        <dc:subject>mental disease</dc:subject>
        <dc:subject>neurologic disease</dc:subject>
        <dc:subject>skin disease</dc:subject>
        <dc:subject>eye disease</dc:subject>
        <dc:subject>alendronic acid</dc:subject>
        <dc:subject>drug indication</dc:subject>
        <dc:subject>lymphatic system disease</dc:subject>
        <dc:subject>malignant neoplasm</dc:subject>
        <dc:subject>femur fracture</dc:subject>
        <dc:subject>periodontitis</dc:subject>
        <dc:subject>heart disease</dc:subject>
        <dc:subject>inner ear disease</dc:subject>
        <dc:subject>mediastinum disease</dc:subject>
        <dc:subject>respiratory tract disease</dc:subject>
        <dc:subject>thorax disease</dc:subject>
        <dc:subject>vascular disease</dc:subject>
        <dc:subject>Bayesian Confidence Propagation Neural Network</dc:subject>
        <dc:subject>breast disease</dc:subject>
        <dc:subject>ear disease</dc:subject>
        <dc:subject>cyst</dc:subject>
        <dc:subject>genital system disease</dc:subject>
        <dc:subject>hematologic disease</dc:subject>
        <dc:subject>hepatobiliary disease</dc:subject>
        <dc:subject>infection</dc:subject>
        <dc:subject>infestation</dc:subject>
        <dc:subject>kidney disease</dc:subject>
        <dc:subject>metabolic disorder</dc:subject>
        <dc:subject>musculoskeletal disease</dc:subject>
        <dc:subject>nutritional disorder</dc:subject>
        <dc:subject>polyp</dc:subject>
        <dc:subject>quantitative analysis</dc:subject>
        <dc:subject>urinary tract disease</dc:subject>
        <dc:subject>congenital disorder</dc:subject>
        <dc:subject>endocrine disease</dc:subject>
        <dc:subject>familial disease</dc:subject>
        <dc:subject>genetic disorder</dc:subject>
        <dc:subject>neoplasm</dc:subject>
        <dc:subject>mouth disease</dc:subject>
        <dc:subject>immunopathology</dc:subject>
        <dc:subject>statistical analysis</dc:subject>
        <dc:subject>proportional reporting ratio</dc:subject>
        <dc:subject>vulvovaginitis</dc:subject>
        <dc:subject>application site reaction</dc:subject>
        <dc:subject>atrophy</dc:subject>
        <dc:subject>calcification</dc:subject>
        <dc:subject>calcium deficiency</dc:subject>
        <dc:subject>carotid artery bruit</dc:subject>
        <dc:subject>Empirical Bayes Geometric Mean</dc:subject>
        <dc:subject>epidural fibrosis</dc:subject>
        <dc:subject>erythroplasia</dc:subject>
        <dc:subject>estrogen deficiency</dc:subject>
        <dc:subject>fibrocystic breast disease</dc:subject>
        <dc:subject>fibroma</dc:subject>
        <dc:subject>hallux varus</dc:subject>
        <dc:subject>hypercementosis</dc:subject>
        <dc:subject>iliotibial band friction syndrome</dc:subject>
        <dc:subject>impaction fracture</dc:subject>
        <dc:subject>metabolic bone disease</dc:subject>
        <dc:subject>necrosis</dc:subject>
        <dc:subject>obstruction</dc:subject>
        <dc:subject>occlusion</dc:subject>
        <dc:subject>osteoma</dc:subject>
        <dc:subject>osteopenia</dc:subject>
        <dc:subject>ovary disease</dc:subject>
        <dc:subject>patellofemoral pain syndrome</dc:subject>
        <dc:subject>pregnancy disorder</dc:subject>
        <dc:subject>prophylaxis</dc:subject>
        <dc:subject>spondylolisthesis</dc:subject>
        <dc:subject>stress fracture</dc:subject>
        <dc:subject>turnover rate</dc:subject>
        <dc:subject>ulcer</dc:subject>
        <dc:subject>urethra disease</dc:subject>
        <dc:subject>uterus disease</dc:subject>
        <dc:subject>uterus myoma</dc:subject>
        <dc:title>Mining and analysis of adverse event signals for alendronate based on the real-world data of FDA adverse event reporting system database</dc:title>
        <dcterms:abstract>Objective: Our study aims to assess alendronate-related adverse events (AEs) from the US FDA adverse event reporting system database. Methods: The AE data associated with alendronate between the first quarter of 2004 and the first quarter of 2024 were selected. Various signal quantification methods, including the ROR, PRR, BCPNN, and EBGM, were applied for analysis. Results: In 34,943 reports where alendronate was the primary suspected drug for the AE, 24 affected system organ classes and 1046 significant preferred terms were identified in this study. Several significant AEs beyond drug instructions with strong signals were determined, including low turnover osteopathy, fracture delayed union, fracture nonunion, loss of anatomical alignment after fracture reduction, fracture malunion, periprosthetic fracture, carotid bruit, oral fibroma, traumatic occlusion, and phlebolith. The median time to onset of alendronate-related AEs was 306 days (interquartile range [IQR] 12–1,461 days), and the majority of cases occurred 2 years later (18.80%) and within 30 days (14.49%). Conclusions: The current study detected multiple potential new AE signals for alendronate, and more clinical research is required to further validate our results and clarify their associations.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079753</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2031959733&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>297-304</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1009">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Included&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2029695537&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>24</prism:volume>
                <dc:title>Expert Opinion on Drug Safety</dc:title>
                <dc:identifier>DOI 10.1080/14740338.2024.2348572</dc:identifier>
                <prism:number>1</prism:number>
                <dcterms:alternative>Expert Opin. Drug Saf.</dcterms:alternative>
                <dc:identifier>ISSN 1744-764X</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xu</foaf:surname>
                        <foaf:givenName>Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Huang</foaf:surname>
                        <foaf:givenName>D.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>Q.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shen</foaf:surname>
                        <foaf:givenName>Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1006"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>death</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>alanine aminotransferase</dc:subject>
        <dc:subject>alanine aminotransferase blood level</dc:subject>
        <dc:subject>aspartate aminotransferase</dc:subject>
        <dc:subject>aspartate aminotransferase blood level</dc:subject>
        <dc:subject>gastrointestinal hemorrhage</dc:subject>
        <dc:subject>intestine perforation</dc:subject>
        <dc:subject>sepsis</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>alkaline phosphatase</dc:subject>
        <dc:subject>alkaline phosphatase blood level</dc:subject>
        <dc:subject>clinical practice</dc:subject>
        <dc:subject>hypercalcemia</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>liver toxicity</dc:subject>
        <dc:subject>thrombophlebitis</dc:subject>
        <dc:subject>anemia</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>disseminated intravascular clotting</dc:subject>
        <dc:subject>hemorrhagic cystitis</dc:subject>
        <dc:subject>polyneuropathy</dc:subject>
        <dc:subject>femoral neck fracture</dc:subject>
        <dc:subject>bacteremia</dc:subject>
        <dc:subject>cytomegalovirus infection</dc:subject>
        <dc:subject>drug eruption</dc:subject>
        <dc:subject>infection</dc:subject>
        <dc:subject>Coronavirus infection</dc:subject>
        <dc:subject>bone marrow suppression</dc:subject>
        <dc:subject>leukopenia</dc:subject>
        <dc:subject>blood toxicity</dc:subject>
        <dc:subject>cytopenia</dc:subject>
        <dc:subject>enterocolitis</dc:subject>
        <dc:subject>extravasation</dc:subject>
        <dc:subject>febrile neutropenia</dc:subject>
        <dc:subject>fever</dc:subject>
        <dc:subject>hepatitis B</dc:subject>
        <dc:subject>ileus</dc:subject>
        <dc:subject>immunoglobulin deficiency</dc:subject>
        <dc:subject>infusion related reaction</dc:subject>
        <dc:subject>leukocyte count</dc:subject>
        <dc:subject>lymphocytopenia</dc:subject>
        <dc:subject>decreased appetite</dc:subject>
        <dc:subject>pneumonia</dc:subject>
        <dc:subject>digestive system perforation</dc:subject>
        <dc:subject>fungemia</dc:subject>
        <dc:subject>hypokalemia</dc:subject>
        <dc:subject>myelodysplastic syndrome</dc:subject>
        <dc:subject>neutropenia</dc:subject>
        <dc:subject>peripheral neuropathy</dc:subject>
        <dc:subject>thrombocytopenia</dc:subject>
        <dc:subject>tumor lysis syndrome</dc:subject>
        <dc:subject>treatment response</dc:subject>
        <dc:subject>interstitial lung disease</dc:subject>
        <dc:subject>C reactive protein</dc:subject>
        <dc:subject>gamma glutamyl transferase blood level</dc:subject>
        <dc:subject>gamma glutamyltransferase</dc:subject>
        <dc:subject>erythema multiforme</dc:subject>
        <dc:subject>lactate dehydrogenase</dc:subject>
        <dc:subject>lactate dehydrogenase blood level</dc:subject>
        <dc:subject>diffuse large B cell lymphoma</dc:subject>
        <dc:subject>COVID-19 pneumonia</dc:subject>
        <dc:subject>agranulocytosis</dc:subject>
        <dc:subject>B cell lymphoma</dc:subject>
        <dc:subject>Clostridium difficile infection</dc:subject>
        <dc:subject>opportunistic infection</dc:subject>
        <dc:subject>amylase</dc:subject>
        <dc:subject>amylase blood level</dc:subject>
        <dc:subject>central nervous system metastasis</dc:subject>
        <dc:subject>cholecystitis</dc:subject>
        <dc:subject>cytokine release syndrome</dc:subject>
        <dc:subject>device infection</dc:subject>
        <dc:subject>esophagus candidiasis</dc:subject>
        <dc:subject>follicular lymphoma</dc:subject>
        <dc:subject>hemophagocytic syndrome</dc:subject>
        <dc:subject>hydronephrosis</dc:subject>
        <dc:subject>hyperbilirubinemia</dc:subject>
        <dc:subject>lower gastrointestinal bleeding</dc:subject>
        <dc:subject>lymphadenopathy</dc:subject>
        <dc:subject>lymphocyte count</dc:subject>
        <dc:subject>mucosa inflammation</dc:subject>
        <dc:subject>organizing pneumonia</dc:subject>
        <dc:subject>pancytopenia</dc:subject>
        <dc:subject>polatuzumab vedotin</dc:subject>
        <dc:subject>progressive multifocal leukoencephalopathy</dc:subject>
        <dc:subject>Rhinovirus infection</dc:subject>
        <dc:subject>sensory neuropathy</dc:subject>
        <dc:subject>septic shock</dc:subject>
        <dc:subject>staphylococcal bacteremia</dc:subject>
        <dc:subject>staphylococcal pneumonia</dc:subject>
        <dc:subject>thrush</dc:subject>
        <dc:subject>upper gastrointestinal bleeding</dc:subject>
        <dc:subject>uremia</dc:subject>
        <dc:title>A real-world pharmacovigilance analysis of the FDA adverse event reporting system events for polatuzumab vedotin</dc:title>
        <dcterms:abstract>Background: Polatuzumab vedotin is the first antibody-drug conjugate approved by the US Food and Drug Administration (FDA) for patients with diffuse large B-cell lymphoma. This study evaluated adverse events (AEs) associated with polatuzumab vedotin by data mining of the FDA Adverse Event Reporting System (FAERS). Methods: This study included AEs registered in FAERS between 2019 Q2 and 2023 Q2. Four algorithms were used to quantify the signals of polatuzumab vedotin-associated AEs, including reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker. Results: A total of 7,609,450 reports were collected from the FAERS database, and 1,388 reports of polatuzumab vedotin were identified as primary suspected AEs. Polatuzumab vedotin-associated AEs involved 26 organ systems. According to the four algorithms, 108 significant disproportionality AEs were retained simultaneously. Unexpected significant AEs included gastrointestinal hemorrhage, ileus, gastrointestinal perforation, cholecystitis, hypogammaglobulinemia, hepatitis B reactivation, hypercalcemia, hydronephrosis, cystitis hemorrhagic, interstitial lung disease, and thrombophlebitis. The median time to onset of polatuzumab vedotin-associated AEs was 20 (interquartile range 4–56) days. Conclusions: Our study identified significant new AE signals for polatuzumab vedotin through real-world disproportionality analysis data and may provide additional evidence for risk identification of polatuzumab vedotin.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079751</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2029695537&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>49-57</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1006">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Excluded&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2031981965&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1346-8138"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tan</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ou</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yang</foaf:surname>
                        <foaf:givenName>T.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yan</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1008"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>treatment response time</dc:subject>
        <dc:subject>unclassified drug</dc:subject>
        <dc:subject>data analysis software</dc:subject>
        <dc:subject>clinical outcome</dc:subject>
        <dc:subject>rash</dc:subject>
        <dc:subject>toxic epidermal necrolysis</dc:subject>
        <dc:subject>atezolizumab</dc:subject>
        <dc:subject>ipilimumab</dc:subject>
        <dc:subject>nivolumab</dc:subject>
        <dc:subject>pembrolizumab</dc:subject>
        <dc:subject>Stevens Johnson syndrome</dc:subject>
        <dc:subject>immune checkpoint inhibitor</dc:subject>
        <dc:subject>monotherapy</dc:subject>
        <dc:subject>avelumab</dc:subject>
        <dc:subject>bullous pemphigoid</dc:subject>
        <dc:subject>cemiplimab</dc:subject>
        <dc:subject>cytotoxic T lymphocyte associated antigen 4 inhibitor</dc:subject>
        <dc:subject>dostarlimab</dc:subject>
        <dc:subject>durvalumab</dc:subject>
        <dc:subject>eosinophilia</dc:subject>
        <dc:subject>lung cancer</dc:subject>
        <dc:subject>physical disease</dc:subject>
        <dc:subject>programmed cell death 1 inhibitor</dc:subject>
        <dc:subject>programmed cell death ligand 1 inhibitor</dc:subject>
        <dc:subject>R software v 4.3.1</dc:subject>
        <dc:subject>skin cancer</dc:subject>
        <dc:subject>subcutaneous tissue disorder</dc:subject>
        <dc:subject>ticilimumab</dc:subject>
        <dc:subject>toripalimab</dc:subject>
        <dc:title>Immune checkpoint inhibitor-associated bullous pemphigoid: A retrospective and real-world study based on the United States Food and Drug Administration adverse event reporting system</dc:title>
        <dcterms:abstract>This study aimed to describe bullous pemphigoid (BP) associated with immune checkpoint inhibitors (ICIs) reported in the United States Food and Drug Administration adverse event reporting system (FAERS). We obtained reports of ICI-associated BP from the first quarter of 2011 to the first quarter of 2024 in the FAERS database. The reporting odds ratio (ROR) method of the disproportionality analysis was performed to assess the potential risk for ICI-associated BP. We also described the clinical characteristics of ICI-associated BP and evaluated the time to onset (TTO) of BP developed after treatment with ICIs. Eight hundred and six cases of ICI-associated BP were gathered, in which 56.58% of the patients were aged 65 years or older. The majority of patients were male, accounting for 68.49% of all cases. The prevalent potential cancer type was skin cancer (31.64%). The results of the disproportionality analysis showed that males (ROR = 2.10 [1.78–2.49]), patients aged 65 or older (ROR = 2.13 [1.79–2.55]), and patients with skin cancer (ROR = 2.08 [1.80–2.43]) were more likely to develop ICI-associated BP. In comparison to cytotoxic T-lymphocyte-associated antigen 4 inhibitor and programmed cell death ligand 1 inhibitor, programmed cell death 1 inhibitor-associated BP has a higher risk of development (ROR = 24.45 [22.52–26.56]). ICI-associated BP had a median TTO of 204 days (interquartile range 57–426 days). ICI-associated BP is a rare but important immune-related adverse event. Our study provided helpful information to help medical professionals further understand ICI-associated BP.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079749</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2031981965&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>309-316</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1346-8138">
        <prism:volume>52</prism:volume>
        <dc:title>Journal of Dermatology</dc:title>
        <dc:identifier>DOI 10.1111/1346-8138.17517</dc:identifier>
        <prism:number>2</prism:number>
        <dcterms:alternative>J. Dermatol.</dcterms:alternative>
        <dc:identifier>ISSN 1346-8138</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1008">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Excluded&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2036339139&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1934-2403"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Huang</foaf:surname>
                        <foaf:givenName>R.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>P.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hu</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1011"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>incidence</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>cardiotoxicity</dc:subject>
        <dc:subject>dizziness</dc:subject>
        <dc:subject>fatigue</dc:subject>
        <dc:subject>nausea</dc:subject>
        <dc:subject>vomiting</dc:subject>
        <dc:subject>amnesia</dc:subject>
        <dc:subject>Bayesian network</dc:subject>
        <dc:subject>chill</dc:subject>
        <dc:subject>diarrhea</dc:subject>
        <dc:subject>confidence interval</dc:subject>
        <dc:subject>follow up</dc:subject>
        <dc:subject>sensitivity analysis</dc:subject>
        <dc:subject>adrenal insufficiency</dc:subject>
        <dc:subject>electrocardiogram</dc:subject>
        <dc:subject>adrenal cortex cancer</dc:subject>
        <dc:subject>appetite</dc:subject>
        <dc:subject>loss of appetite</dc:subject>
        <dc:subject>mitotane</dc:subject>
        <dc:subject>QT interval</dc:subject>
        <dc:subject>risk management</dc:subject>
        <dc:subject>training</dc:subject>
        <dc:title>Comprehensive Analysis of Mitotane-Related Adverse Events Using the Food and Drug Administration Adverse Event Reporting System</dc:title>
        <dcterms:abstract>Objective: Mitotane is currently the only product approved by the Food and Drug Administration for the treatment of adrenocortical cancer. However, there is a lack of comprehensive studies on the adverse events of mitotane. Methods: Adverse event reports for mitotane in the Food and Drug Administration Adverse Event Reporting System database since 2004 were collected and analyzed to identify mitotane as the primary suspect drug. Reporting ratios, multi-item γ Poisson constrictors, proportional reporting ratios, and Bayesian confidence propagation neural networks were used to analyze the disproportionality of mitotane-related adverse events. Results: A total of 21 433 114 adverse event reports were retrieved from the Food and Drug Administration Adverse Event Reporting System database, with 772 cases identified where mitotane was the primary suspected drug. Positive signals were observed for adverse reactions listed on the drug label, such as nausea, diarrhea, vomiting, dizziness, loss of appetite, and adrenal insufficiency. Additionally, potential adverse reactions not specified on the label were detected, including fatigue, malignant tumor progression, ovarian cysts, chills, amnesia, and Q-T interval prolongation on the electrocardiogram. These findings highlight the critical need for vigilant monitoring of adverse events, particularly during the first few months of treatment. Conclusion: This study provides preliminary safety data on the practical application of mitotane, confirming some known adverse reactions and revealing other potential risks. These findings provide critical safety information for clinicians prescribing mitotane for the treatment of adrenocortical cancer.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079745</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2036339139&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>278-285</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1934-2403">
        <prism:volume>31</prism:volume>
        <dc:title>Endocrine Practice</dc:title>
        <dc:identifier>DOI 10.1016/j.eprac.2024.11.007</dc:identifier>
        <prism:number>3</prism:number>
        <dcterms:alternative>Endocr. Pract.</dcterms:alternative>
        <dc:identifier>ISSN 1934-2403</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1011">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2034706756&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:2077-0383"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Popa Ilie</foaf:surname>
                        <foaf:givenName>I.R.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Butuca</foaf:surname>
                        <foaf:givenName>A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Homorodean</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Dobrea</foaf:surname>
                        <foaf:givenName>C.M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Morgovan</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Frum</foaf:surname>
                        <foaf:givenName>A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ghibu</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1012"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>death</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>hypertension</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>odds ratio</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>blood</dc:subject>
        <dc:subject>connective tissue disease</dc:subject>
        <dc:subject>arthralgia</dc:subject>
        <dc:subject>descriptive research</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>myalgia</dc:subject>
        <dc:subject>sepsis</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>dizziness</dc:subject>
        <dc:subject>heart ventricle extrasystole</dc:subject>
        <dc:subject>backache</dc:subject>
        <dc:subject>body weight gain</dc:subject>
        <dc:subject>fatigue</dc:subject>
        <dc:subject>headache</dc:subject>
        <dc:subject>insomnia</dc:subject>
        <dc:subject>limb pain</dc:subject>
        <dc:subject>nausea</dc:subject>
        <dc:subject>pain</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>vomiting</dc:subject>
        <dc:subject>gastrointestinal disease</dc:subject>
        <dc:subject>mental disease</dc:subject>
        <dc:subject>neurologic disease</dc:subject>
        <dc:subject>skin disease</dc:subject>
        <dc:subject>eye disease</dc:subject>
        <dc:subject>asthenia</dc:subject>
        <dc:subject>diarrhea</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>sex ratio</dc:subject>
        <dc:subject>rib fracture</dc:subject>
        <dc:subject>spine fracture</dc:subject>
        <dc:subject>heart disease</dc:subject>
        <dc:subject>hypotension</dc:subject>
        <dc:subject>peripheral swelling</dc:subject>
        <dc:subject>vascular disease</dc:subject>
        <dc:subject>coronavirus disease 2019</dc:subject>
        <dc:subject>drug use</dc:subject>
        <dc:subject>cyst</dc:subject>
        <dc:subject>infection</dc:subject>
        <dc:subject>infestation</dc:subject>
        <dc:subject>kidney disease</dc:subject>
        <dc:subject>metabolic disorder</dc:subject>
        <dc:subject>musculoskeletal disease</dc:subject>
        <dc:subject>polyp</dc:subject>
        <dc:subject>procedural site reaction</dc:subject>
        <dc:subject>heart atrium flutter</dc:subject>
        <dc:subject>neoplasm</dc:subject>
        <dc:subject>decreased appetite</dc:subject>
        <dc:subject>rash</dc:subject>
        <dc:subject>mycosis</dc:subject>
        <dc:subject>muscle weakness</dc:subject>
        <dc:subject>urogenital tract disease</dc:subject>
        <dc:subject>subcutaneous tissue</dc:subject>
        <dc:subject>elevated blood pressure</dc:subject>
        <dc:subject>drug intoxication</dc:subject>
        <dc:subject>adrenal insufficiency</dc:subject>
        <dc:subject>adrenal cancer</dc:subject>
        <dc:subject>adrenal cortex hyperfunction</dc:subject>
        <dc:subject>hydrocortisone</dc:subject>
        <dc:subject>nutritional deficiency</dc:subject>
        <dc:subject>osilodrostat</dc:subject>
        <dc:subject>tissue injury</dc:subject>
        <dc:title>Osilodrostat Safety Profile: Findings from Real-World Data in the FAERS Database</dc:title>
        <dcterms:abstract>Background/Objectives: Cushing’s syndrome (CS), including Cushing’s disease (CD)—the most common type—has a substantial negative impact on morbidity, mortality, and patients’ quality of life. Medical management of CS is essential for controlling hypercortisolism as part of preoperative preparation for definitive surgical treatment and for managing residual or relapsed hypercortisolism post-surgery. Osilodrostat, a dual inhibitor of glucocorticoid and mineralocorticoid biosynthetic pathways, has been approved for the medical treatment of CS since early 2020. However, real-world data on its adverse effects remain limited. We mined the FAERS database and analyzed the reports associated with osilodrostat up to 1 October 2024. Methods: Descriptive and disproportionality methods based on Relative Odds Ratio (ROR), Chi-square (χ2), and Proportional Reporting Ratio (PRR), were used to discern potential safety signals and assess the significance of osilodrostat-associated adverse events. Results: This study identified 782 reports in which osilodrostat was the primary suspected drug, containing 593 preferred terms (PTs) and 2481 occurrences. The most frequently registered events belonged to the following SOCs: “General disorders and administration site conditions” (n = 457, 18.4%), “Injury, poisoning and procedural complications” (n = 311, 12.5%), “Gastrointestinal disorders” (n = 278, 11.2%), “Investigations” (n = 260, 10.5%), and “Nervous system disorders” (n = 184, 7.4%). Among PTs, off-label use was the most commonly reported, aligning with the fact that the vast majority of cases originated from the U.S. (84%), where osilodrostat is officially approved only for the treatment of CD. Disproportionality analysis confirmed previously known and new potential adverse drug reactions associated with osilodrostat treatment, including reports of cardiac flutter (n: 4; PRR: 19.42; χ2: 49.57), ventricular extrasystoles (n: 4; PRR: 11.85; χ2: 29.62), muscular weakness (n: 8; PRR: 2.25; χ2: 4.38), rib fracture (n: 4; PRR: 6.66; χ2: 13.99), spinal fracture (n: 3; PRR: 4.66; χ2: 5.35), sepsis (n: 9; PRR: 2.63; χ2: 7.56), fungal infections (n: 4; PRR: 3.67; χ2: 5.33), and COVID-19 (n: 32; PRR: 5.07; χ2: 101.16). Conclusions: This study highlights new risks and offers valuable insights into osilodrostat use; however, further research and validation are necessary, particularly for adverse reactions not yet explicitly documented in the summary of product characteristics.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079739</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2034706756&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:2077-0383">
        <prism:volume>14</prism:volume>
        <dc:title>Journal of Clinical Medicine</dc:title>
        <dc:identifier>DOI 10.3390/jcm14103518</dc:identifier>
        <prism:number>10</prism:number>
        <dcterms:alternative>J. Clin. Med.</dcterms:alternative>
        <dc:identifier>ISSN 2077-0383</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1012">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Included&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2030074760&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:2047-2927"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tan</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Luo</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lan</foaf:surname>
                        <foaf:givenName>W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Huang</foaf:surname>
                        <foaf:givenName>G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yang</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xi</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1010"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>Medical Dictionary for Regulatory Activities</dc:subject>
        <dc:subject>antineoplastic agent</dc:subject>
        <dc:subject>dutasteride</dc:subject>
        <dc:subject>dutasteride plus tamsulosin</dc:subject>
        <dc:subject>finasteride</dc:subject>
        <dc:subject>tamsulosin</dc:subject>
        <dc:subject>testosterone</dc:subject>
        <dc:subject>cyclosporine</dc:subject>
        <dc:subject>allopurinol</dc:subject>
        <dc:subject>carbamazepine</dc:subject>
        <dc:subject>big data</dc:subject>
        <dc:subject>nivolumab</dc:subject>
        <dc:subject>anticonvulsive agent</dc:subject>
        <dc:subject>central stimulant agent</dc:subject>
        <dc:subject>cryopreservation</dc:subject>
        <dc:subject>fertility preservation</dc:subject>
        <dc:subject>immune checkpoint inhibitor</dc:subject>
        <dc:subject>levetiracetam</dc:subject>
        <dc:subject>monotherapy</dc:subject>
        <dc:subject>prescription insert</dc:subject>
        <dc:subject>semen analysis</dc:subject>
        <dc:subject>semen cryopreservation</dc:subject>
        <dc:subject>semen parameters</dc:subject>
        <dc:subject>sperm count</dc:subject>
        <dc:subject>sperm quality</dc:subject>
        <dc:subject>spermatogenesis</dc:subject>
        <dc:subject>spermatogonium</dc:subject>
        <dc:subject>spermatozoon density</dc:subject>
        <dc:subject>testis tissue</dc:subject>
        <dc:subject>valproic acid</dc:subject>
        <dc:title>A pharmacovigilance study of drug-reduced male semen quality based on the Food and Drug Administration adverse event reporting system database</dc:title>
        <dcterms:abstract>Background: Real-world big data studies on drug-reduced male semen quality are few and far between, with most studies based on animal trials, small scale retrospective studies, or a limited number of pre-market clinical trials. Methods: This study aimed to identify culprit drugs that reduced male semen quality based on the United States Food and Drug Administration adverse event reporting system. The Medical Dictionary for Regulatory Activities preferred terms and standardized Medical Dictionary for Regulatory Activities queries were used to define reduced male semen quality. Adverse events related to drug-reduced male semen quality were then analyzed by disproportionality analysis using the United States Food and Drug Administration adverse event reporting system data between 2004 and 2023. Results: At the preferred term level, 59 drugs with risk signals were detected to be associated with drug-reduced male semen quality, with the three most frequently reported second-level Anatomical Therapeutic Chemical groups being antineoplastic agents (n = 16, 27.12%), psychoanaleptics (n = 9, 15.25%), and psycholeptics (n = 6, 10.17%). At the standardized Medical Dictionary for Regulatory Activities queries level, the five drugs with the greatest number of cases were finasteride (845 cases, IC025 = 7.72), dutasteride (163 cases, IC025 = 7.22), tamsulosin (148 cases, IC025= 5.99), testosterone (101 cases, IC025= 4.08), and valproic acid (54 cases, IC025= 2.44). Additionally, clinical information about drug-reduced male semen quality is absent from the Summary of Product Characteristics of 41 drugs in our study. Conclusions: Using the United States Food and Drug Administration adverse event reporting system database, we offer a list of drugs with risk signals for reducing male semen quality. In the future, there is still a need for more studies on drugs whose effects on male semen quality are not fully understood.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079748</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2030074760&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>217-225</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:2047-2927">
        <prism:volume>13</prism:volume>
        <dc:title>Andrology</dc:title>
        <dc:identifier>DOI 10.1111/andr.13668</dc:identifier>
        <prism:number>2</prism:number>
        <dcterms:alternative>Andrology</dcterms:alternative>
        <dc:identifier>ISSN 2047-2927</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1010">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L644301132&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>14</prism:volume>
                <dc:title>Scientific reports</dc:title>
                <dc:identifier>DOI 10.1038/s41598-024-62238-1</dc:identifier>
                <prism:number>1</prism:number>
                <dcterms:alternative>Sci Rep</dcterms:alternative>
                <dc:identifier>ISSN 2045-2322</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yin</foaf:surname>
                        <foaf:givenName>G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Song</foaf:surname>
                        <foaf:givenName>G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xue</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>F.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_975"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data analysis</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>death</dc:subject>
        <dc:subject>*Data Mining</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>Adolescent</dc:subject>
        <dc:subject>Adult</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>adverse events</dc:subject>
        <dc:subject>adverse outcome</dc:subject>
        <dc:subject>Aged</dc:subject>
        <dc:subject>artificial neural network</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>Child</dc:subject>
        <dc:subject>clinical feature</dc:subject>
        <dc:subject>arthralgia</dc:subject>
        <dc:subject>disability</dc:subject>
        <dc:subject>disproportionality analysis</dc:subject>
        <dc:subject>bipolar disorder</dc:subject>
        <dc:subject>bradycardia</dc:subject>
        <dc:subject>depression</dc:subject>
        <dc:subject>dizziness</dc:subject>
        <dc:subject>abdominal pain</dc:subject>
        <dc:subject>bone pain</dc:subject>
        <dc:subject>clinical practice</dc:subject>
        <dc:subject>constipation</dc:subject>
        <dc:subject>automutilation</dc:subject>
        <dc:subject>delirium</dc:subject>
        <dc:subject>delusion</dc:subject>
        <dc:subject>congestive heart failure</dc:subject>
        <dc:subject>deep vein thrombosis</dc:subject>
        <dc:subject>*United States Food and Drug Administration</dc:subject>
        <dc:subject>aggression</dc:subject>
        <dc:subject>amfebutamone</dc:subject>
        <dc:subject>antineoplastic agent</dc:subject>
        <dc:subject>arthritis</dc:subject>
        <dc:subject>bile duct carcinoma</dc:subject>
        <dc:subject>body weight</dc:subject>
        <dc:subject>adverse drug reactions</dc:subject>
        <dc:subject>Adverse events</dc:subject>
        <dc:subject>albumin-bound paclitaxel</dc:subject>
        <dc:subject>alogliptin</dc:subject>
        <dc:subject>alopecia</dc:subject>
        <dc:subject>anaphylaxis</dc:subject>
        <dc:subject>anemia</dc:subject>
        <dc:subject>asthenia</dc:subject>
        <dc:subject>atelectasis</dc:subject>
        <dc:subject>breast cancer</dc:subject>
        <dc:subject>Breast Neoplasms</dc:subject>
        <dc:subject>breast tumor</dc:subject>
        <dc:subject>CHEMOTHERAPY</dc:subject>
        <dc:subject>chill</dc:subject>
        <dc:subject>data analysis software</dc:subject>
        <dc:subject>Data mining</dc:subject>
        <dc:subject>Data Mining</dc:subject>
        <dc:subject>Databases, Factual</dc:subject>
        <dc:subject>dehydration</dc:subject>
        <dc:subject>diarrhea</dc:subject>
        <dc:subject>dipeptidyl peptidase IV inhibitor</dc:subject>
        <dc:subject>clonazepam</dc:subject>
        <dc:subject>disseminated intravascular clotting</dc:subject>
        <dc:subject>coughing</dc:subject>
        <dc:subject>data extraction</dc:subject>
        <dc:subject>acute pancreatitis</dc:subject>
        <dc:subject>DISPROPORTIONALITY</dc:subject>
        <dc:subject>adverse drug events</dc:subject>
        <dc:subject>chronic kidney failure</dc:subject>
        <dc:subject>comparative study</dc:subject>
        <dc:subject>Antineoplastic Agents</dc:subject>
        <dc:subject>abemaciclib</dc:subject>
        <dc:subject>cyclin dependent kinase 4</dc:subject>
        <dc:subject>cyclin dependent kinase 6</dc:subject>
        <dc:subject>amyloidosis</dc:subject>
        <dc:subject>CELL LUNG-CANCER</dc:subject>
        <dc:subject>crizotinib</dc:subject>
        <dc:subject>back propagation neural network</dc:subject>
        <dc:subject>BREAST-CANCER</dc:subject>
        <dc:subject>*Databases, Factual</dc:subject>
        <dc:subject>Aged, 80 and over</dc:subject>
        <dc:subject>cytochrome P450 3A4</dc:subject>
        <dc:subject>digestive system perforation</dc:subject>
        <dc:subject>anxiety</dc:subject>
        <dc:subject>antipsychotics</dc:subject>
        <dc:subject>angioneurotic edema</dc:subject>
        <dc:subject>Bayesian confidence propagation neural network</dc:subject>
        <dc:subject>bruxism</dc:subject>
        <dc:subject>abdominal discomfort</dc:subject>
        <dc:subject>*Adverse Drug Reaction Reporting Systems/statistics &amp; numerical data</dc:subject>
        <dc:subject>*Fulvestrant/adverse effects</dc:subject>
        <dc:subject>absolute neutrophil count</dc:subject>
        <dc:subject>adverse event profile</dc:subject>
        <dc:subject>Adverse event reporting system</dc:subject>
        <dc:subject>ALK inhibitor</dc:subject>
        <dc:subject>anger</dc:subject>
        <dc:subject>Antineoplastic Agents, Hormonal</dc:subject>
        <dc:subject>Antineoplastic Agents, Hormonal/adverse effects</dc:subject>
        <dc:subject>antineoplastic hormone agonists and antagonists</dc:subject>
        <dc:subject>apathy</dc:subject>
        <dc:subject>bipolar II disorder</dc:subject>
        <dc:subject>bradykinesia</dc:subject>
        <dc:subject>bradyphrenia</dc:subject>
        <dc:subject>Breast Neoplasms/drug therapy</dc:subject>
        <dc:subject>C reactive protein abnormal</dc:subject>
        <dc:subject>catatonia</dc:subject>
        <dc:subject>CDK4/6 inhibitor</dc:subject>
        <dc:subject>CDK6</dc:subject>
        <dc:subject>chronic insomnia</dc:subject>
        <dc:subject>COMBINATION</dc:subject>
        <dc:subject>Crizotinib</dc:subject>
        <dc:subject>dalpiciclib</dc:subject>
        <dc:subject>diagnostic procedure</dc:subject>
        <dc:subject>Dipeptidyl Peptidase-4 inhibitors</dc:subject>
        <dc:subject>DISORDER</dc:subject>
        <dc:subject>drug abuse</dc:subject>
        <dc:title>Adverse event signal mining and serious adverse event influencing factor analysis of fulvestrant based on FAERS database</dc:title>
        <dcterms:abstract>Fulvestrant, as the first selective estrogen receptor degrader, is widely used in the endocrine treatment of breast cancer. However, in the real world, there is a lack of relevant reports on adverse reaction data mining for fulvestrant. To perform data mining on adverse events (AEs) associated with fulvestrant and explore the risk factors contributing to severe AEs, providing a reference for the rational use of fulvestrant in clinical practice. Retrieved adverse event report information associated with fulvestrant from the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database, covering the period from market introduction to September 30, 2023. Suspicious AEs were screened using the reporting odds ratio (ROR) and proportional reporting ratio methods based on disproportionality analysis. Univariate and multivariate logistic regression analyses were conducted on severe AEs to explore the risk factors associated with fulvestrant-induced severe AEs. A total of 6947 reports related to AEs associated with fulvestrant were obtained, including 5924 reports of severe AEs and 1023 reports of non-severe AEs. Using the disproportionality analysis method, a total of 210 valid AEs were identified for fulvestrant, with 45 AEs (21.43%) not listed in the product labeling, involving 11 systems and organs. The AEs associated with fulvestrant were sorted by frequency of occurrence, with neutropenia (325 cases) having the highest number of reports. By signal strength, injection site pruritus showed the strongest signal (ROR = 658.43). The results of the logistic regression analysis showed that concurrent use of medications with extremely high protein binding (≥ 98%) is an independent risk factor for severe AEs associated with fulvestrant. Age served as a protective factor for fulvestrant-related AEs. The co-administration of fulvestrant with CYP3A4 enzyme inhibitors did not show statistically significant correlation with the occurrence of severe AEs. Co-administration of drugs with extremely high protein binding (≥ 98%) may increase the risk of severe adverse reactions of fulvestrant. Meanwhile, age (60-74 years) may reduce the risk of severe AEs of fulvestrant. However, further clinical research is still needed to explore and verify whether there is interaction between fulvestrant and drugs with high protein binding through more clinical studies.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079794</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L644301132&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>11367</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_975">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: J. Guo; Department of Clinical Pharmacy, PLA 960th Hospital, Jinan, China; email: gjm90h@126.com; CODEN: EODSA&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: X. Li; The Affiliated Kangning Hospital of Wenzhou Medical University, Zhejiang Provincial Clinical Research Center for Mental Health, Wenzhou, Zhejiang, China; email: xili_ihb@126.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 1; Correspondence Address: B. Long; Radiation Oncology Center, Chongqing University Cancer Hospital, Chongqing, 181 Hanyu Road, Shapingba District, 400030, China; email: Iongbin.112@163.com; J. Sui; Radiation Oncology Center, Chongqing University Cancer Hospital, Chongqing, 181 Hanyu Road, Shapingba District, 400030, China; email: Jiangdong.sui@cqu.edu.cn; Y. Wang; Radiation Oncology Center, Chongqing University Cancer Hospital, Chongqing, 181 Hanyu Road, Shapingba District, 400030, China; email: wangy123@cqu.edu.cn&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 1; Correspondence Address: J. Yu; Department of Clinical Pharmacy, The First Hospital of Hebei Medical University, Shijiazhuang, China; email: yujing@hebmu.edu.cn&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 1; Correspondence Address: R. Yin; Department of Obstetrics and Gynecology, West China Second University Hospital of Sichuan University, Chengdu, Sichuan, China; email: yinrutie@scu.edu.cn; L. Liu; Department of Obstetrics and Gynecology, Women and Children’s Hospital of Chongqing Medical University, Chongqing, China; email: liulubin1975@126.com; Q. Dai; Institute of Rheumatology and Immunology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China; email: daiqian@nsmc.edu.cn&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 2; Correspondence Address: J. Xu; Nursing Department, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, #3 East Qingchun Road, Zhejiang, 310016, China; email: jianmeixu2023@126.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 3; Correspondence Address: Y. Li; Department of Pharmacy, Nanjing First Hospital, Nanjing Medical University, Nanjing, China; email: yangli2008pharma@163.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 4; Correspondence Address: F. Liu; Department of Pharmacy, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, Hunan, 410011, China; email: liufen@hnca.org.cn&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;28&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;31&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;49&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;37&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;32&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;35&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;4&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;5&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;29&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;33&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;35&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;52&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2032886342&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:2589-5370"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shen</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hu</foaf:surname>
                        <foaf:givenName>R.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lin</foaf:surname>
                        <foaf:givenName>A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jiang</foaf:surname>
                        <foaf:givenName>A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tang</foaf:surname>
                        <foaf:givenName>B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Cheng</foaf:surname>
                        <foaf:givenName>Q.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Miao</foaf:surname>
                        <foaf:givenName>K.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Luo</foaf:surname>
                        <foaf:givenName>P.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_976"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>incidence</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>treatment response time</dc:subject>
        <dc:subject>young adult</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>cohort analysis</dc:subject>
        <dc:subject>health care personnel</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>basal cell carcinoma</dc:subject>
        <dc:subject>cancer risk</dc:subject>
        <dc:subject>data analysis software</dc:subject>
        <dc:subject>malignant neoplasm</dc:subject>
        <dc:subject>axicabtagene ciloleucel</dc:subject>
        <dc:subject>brexucabtagene autoleucel</dc:subject>
        <dc:subject>CD19 antigen</dc:subject>
        <dc:subject>chimeric antigen receptor T-cell immunotherapy</dc:subject>
        <dc:subject>myelodysplastic syndrome</dc:subject>
        <dc:subject>infant</dc:subject>
        <dc:subject>acute myeloid leukemia</dc:subject>
        <dc:subject>alkylating agent</dc:subject>
        <dc:subject>anthracycline</dc:subject>
        <dc:subject>antimetabolite</dc:subject>
        <dc:subject>DNA topoisomerase inhibitor</dc:subject>
        <dc:subject>gastrointestinal carcinoma</dc:subject>
        <dc:subject>ICD-10</dc:subject>
        <dc:subject>ICD-9</dc:subject>
        <dc:subject>idecabtagene vicleucel</dc:subject>
        <dc:subject>kymriah</dc:subject>
        <dc:subject>large granular lymphocyte leukemia</dc:subject>
        <dc:subject>lisocabtagene maraleucel</dc:subject>
        <dc:subject>long term care</dc:subject>
        <dc:subject>newborn</dc:subject>
        <dc:subject>R version 4.2.0</dc:subject>
        <dc:subject>second cancer</dc:subject>
        <dc:subject>squamous cell carcinoma</dc:subject>
        <dc:subject>T cell lymphoma</dc:subject>
        <dc:subject>tisagenlecleucel T</dc:subject>
        <dc:subject>Vinca alkaloid</dc:subject>
        <dc:title>Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase</dc:title>
        <dcterms:abstract>Background: The FDA's alerts regarding the T-cell lymphoma risk post CAR-T therapy has garnered global attention, yet a comprehensive profile of second primary malignancies (SPMs) following CAR-T treatment is lacking. Methods: We extracted adverse event reports of hematological malignancies (HMs) patients with clearly definable SPMs from the FAERS and VigiBase databases (2017–2023). Disproportionality analysis using reporting odds ratio (ROR) and adjusted ROR was performed to assess associations between SPMs and CAR-T therapy. Time-to-onset analysis explored factors affecting SPM manifestation. Findings: SPMs post CAR T-cell therapy include HMs and solid tumors. T-cell lymphoma and myelodysplastic syndromes were consistently identified as positive signals across the overall and subgroup analyses. Hematological SPMs showed earlier onset with increasing annual incidence post CAR-T therapy, whereas solid tumors exhibit delayed manifestation. SPMs in CAR-T recipients had significantly earlier onset than non-recipients. Furthermore, age-specific characteristics reveal earlier SPM manifestations in pediatric, adolescent, and young adult populations compared to older populations post CAR-T therapy. Interpretation: The current SPM profile highlights the necessity of long-term safety monitoring for all CAR-T recipients given the observed yearly increase of SPMs. Customizing long-term SPM screening across different age groups may enhance early detection and intervention strategies, ultimately improving patient outcomes in the follow-up of CAR-T recipients. Funding: This work was supported by grants from the Natural Science Foundation of Guangdong Province (2018A030313846 and 2021A1515012593), the Science and Technology Planning Project of Guangdong Province (2019A030317020), the National Natural Science Foundation of China (81802257, 81871859, 81772457, 82172750, 82172811, and 82260546), the Guangdong Basic and Applied Basic Research Foundation (Guangdong–Guangzhou Joint Funds) (2022A1515111212), and the Science and Technology Program of Guangzhou (2023A04J1257).</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079792</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2032886342&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:2589-5370">
        <prism:volume>73</prism:volume>
        <dc:title>eClinicalMedicine</dc:title>
        <dc:identifier>DOI 10.1016/j.eclinm.2024.102684</dc:identifier>
        <dcterms:alternative>eClinicalMedicine</dcterms:alternative>
        <dc:identifier>ISSN 2589-5370</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_976">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2028614301&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1552-4604"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yao</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Peng</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Huang</foaf:surname>
                        <foaf:givenName>Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gan</foaf:surname>
                        <foaf:givenName>G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_977"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>age</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>death</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>disability</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>melena</dc:subject>
        <dc:subject>prothrombin time</dc:subject>
        <dc:subject>reporting odds ratio</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>abdominal pain</dc:subject>
        <dc:subject>constipation</dc:subject>
        <dc:subject>disease severity</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>vomiting</dc:subject>
        <dc:subject>delirium</dc:subject>
        <dc:subject>reporting and data system</dc:subject>
        <dc:subject>Medical Dictionary for Regulatory Activities</dc:subject>
        <dc:subject>fatality</dc:subject>
        <dc:subject>bayesian confidence propagation neural network</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>congenital malformation</dc:subject>
        <dc:subject>food and drug administration adverse event reporting system</dc:subject>
        <dc:subject>demographics</dc:subject>
        <dc:subject>consciousness disorder</dc:subject>
        <dc:subject>dysgeusia</dc:subject>
        <dc:subject>brain edema</dc:subject>
        <dc:subject>infection</dc:subject>
        <dc:subject>mortality rate</dc:subject>
        <dc:subject>gender</dc:subject>
        <dc:subject>pneumonia</dc:subject>
        <dc:subject>China</dc:subject>
        <dc:subject>clinical monitoring</dc:subject>
        <dc:subject>hypokalemia</dc:subject>
        <dc:subject>Pseudomonas infection</dc:subject>
        <dc:subject>injection site phlebitis</dc:subject>
        <dc:subject>angioneurotic edema</dc:subject>
        <dc:subject>data processing</dc:subject>
        <dc:subject>pharmacist</dc:subject>
        <dc:subject>physician</dc:subject>
        <dc:subject>urticaria</dc:subject>
        <dc:subject>avibactam plus ceftazidime</dc:subject>
        <dc:subject>clinical article</dc:subject>
        <dc:subject>erythema multiforme</dc:subject>
        <dc:subject>France</dc:subject>
        <dc:subject>Great Britain</dc:subject>
        <dc:subject>hemorrhagic shock</dc:subject>
        <dc:subject>hypernatremia</dc:subject>
        <dc:subject>Klebsiella infection</dc:subject>
        <dc:subject>lactate dehydrogenase</dc:subject>
        <dc:subject>lactate dehydrogenase blood level</dc:subject>
        <dc:subject>lymphocytosis</dc:subject>
        <dc:subject>multi item gamma poisson shrinker algorithm</dc:subject>
        <dc:subject>nephrolithiasis</dc:subject>
        <dc:subject>petechia</dc:subject>
        <dc:subject>proportional reporting ratio</dc:subject>
        <dc:subject>treatment indication</dc:subject>
        <dc:subject>vulvovaginitis</dc:subject>
        <dc:title>A Real-World Pharmacovigilance Study of Ceftazidime/Avibactam: Data Mining of the Food and Drug Administration Adverse Event Reporting System Database</dc:title>
        <dcterms:abstract>Ceftazidime/avibactam (CAZ/AVI) is a combination of a well-known third-generation, broad-spectrum cephalosporin with a new beta-lactamase inhibitor that has been approved for the treatment of various infectious diseases (especially multidrug-resistant Gram-negative bacterial infections) by the Food and Drug Administration (FDA). The current study extensively assessed CAZ/AVI-related adverse events (AEs) in the real world through data mining of the FDA Adverse Event Reporting System (FAERS) database to better understand toxicities. The signals of CAZ/AVI-related AEs were quantified using disproportionality analyses, including the reporting odds ratio, the proportional reporting ratio, the Bayesian confidence propagation neural network, and the multi-item gamma Poisson shrinker algorithms. Out of 10,114,815 records retrieved from the FAERS database, 628 cases were identified, where CAZ/AVI was implicated as the primary suspect drug. A total of 61 preferred terms with significant disproportionality that simultaneously met the criteria of all four algorithms were retained. Several unexpected safety signals may also occur, including melena, hypernatremia, depressed level of consciousness, brain edema, petechiae, delirium, and shock hemorrhagic. The median onset time for AEs associated with CAZ/AVI was 4 days, with most cases occurring within 3 days after CAZ/AVI initiation.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079790</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2028614301&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>820-827</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1552-4604">
        <prism:volume>64</prism:volume>
        <dc:title>Journal of Clinical Pharmacology</dc:title>
        <dc:identifier>DOI 10.1002/jcph.2420</dc:identifier>
        <prism:number>7</prism:number>
        <dcterms:alternative>J. Clin. Pharmacol.</dcterms:alternative>
        <dc:identifier>ISSN 1552-4604</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_977">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2028061934&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1432-1912"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ke</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Huang</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lin</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Huang</foaf:surname>
                        <foaf:givenName>P.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1019"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>heart failure</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>acute heart infarction</dc:subject>
        <dc:subject>age distribution</dc:subject>
        <dc:subject>cardiotoxicity</dc:subject>
        <dc:subject>cardiovascular disease</dc:subject>
        <dc:subject>bradycardia</dc:subject>
        <dc:subject>cardiogenic shock</dc:subject>
        <dc:subject>cardiomyopathy</dc:subject>
        <dc:subject>cardiovascular risk</dc:subject>
        <dc:subject>drug induced disease</dc:subject>
        <dc:subject>heart arrest</dc:subject>
        <dc:subject>heart arrhythmia</dc:subject>
        <dc:subject>heart palpitation</dc:subject>
        <dc:subject>heart ventricle tachycardia</dc:subject>
        <dc:subject>sinus tachycardia</dc:subject>
        <dc:subject>supraventricular premature beat</dc:subject>
        <dc:subject>supraventricular tachycardia</dc:subject>
        <dc:subject>tachycardia</dc:subject>
        <dc:subject>risk reduction</dc:subject>
        <dc:subject>acute coronary syndrome</dc:subject>
        <dc:subject>angina pectoris</dc:subject>
        <dc:subject>atrial fibrillation</dc:subject>
        <dc:subject>coronary artery disease</dc:subject>
        <dc:subject>heart infarction</dc:subject>
        <dc:subject>heart muscle ischemia</dc:subject>
        <dc:subject>brentuximab vedotin</dc:subject>
        <dc:subject>drug indication</dc:subject>
        <dc:subject>clinical outcome</dc:subject>
        <dc:subject>cyclophosphamide</dc:subject>
        <dc:subject>cancer immunotherapy</dc:subject>
        <dc:subject>anaplastic large cell lymphoma</dc:subject>
        <dc:subject>cancer combination chemotherapy</dc:subject>
        <dc:subject>dacarbazine</dc:subject>
        <dc:subject>diffuse large B cell lymphoma</dc:subject>
        <dc:subject>doxorubicin</dc:subject>
        <dc:subject>etoposide</dc:subject>
        <dc:subject>Hodgkin disease</dc:subject>
        <dc:subject>hypokinesia</dc:subject>
        <dc:subject>lung insufficiency</dc:subject>
        <dc:subject>mitral valve regurgitation</dc:subject>
        <dc:subject>monoclonal antibody therapy</dc:subject>
        <dc:subject>pericardial effusion</dc:subject>
        <dc:subject>pericarditis</dc:subject>
        <dc:subject>peripheral T cell lymphoma</dc:subject>
        <dc:subject>prednisone</dc:subject>
        <dc:subject>respiratory arrest</dc:subject>
        <dc:subject>ventricular hypokinesia</dc:subject>
        <dc:subject>vinblastine</dc:subject>
        <dc:title>Cardiac toxicity of brentuximab vedotin: a real-word disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database</dc:title>
        <dcterms:abstract>Brentuximab vedotin (BV) has obtained approval for the therapeutic management of classical Hodgkin lymphoma as well as systemic anaplastic large cell lymphoma. Given the inherent constraints of conventional clinical trials, the correlation between BV and cardiac adverse events (AEs) remains enigmatic. The objective of this investigation is to comprehensively assess cardiac AEs attributed to BV by employing advanced data mining techniques, utilizing the FDA Adverse Event Reporting System (FAERS). The indices for the assessment of disproportionality encompass the reporting odds ratio (ROR), the proportional reporting ratio, the information component, and the empirical Bayesian geometric mean. Employing these sophisticated metrics, we gauged the extent of disproportionate occurrences. The dataset was sourced from the FAERS from the first quarter of 2012 to first quarter of 2023, facilitating a comprehensive analysis of the potential correlation between BV and cardiac AEs. This scrutiny encompassed a comparative analysis of both cardiac and non-cardiac AEs. A total of 495 cases of BV’s cardiac AEs were discerned, with the identification of 31 preferred terms (PTs). Among these, 8 PTs emerged as conspicuous signals of cardiac AEs, notably encompassing ventricular hypokinesia (ROR 7.59), tachyarrhythmia (ROR 7.06), sinus tachycardia (ROR 6.18), cardiopulmonary failure (ROR 4.44), pericardial effusion (ROR 4.32), acute coronary syndrome (ROR 4.02), cardiomyopathy (ROR 3.30), and tachycardia (ROR 2.76). The manifestation of severe outcomes demonstrates a discernible correlation with the cardiac AEs (P &lt; 0.001). Our investigation furnishes invaluable insights for healthcare practitioners to proactively mitigate the incidence of BV-associated cardiac AEs.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079789</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2028061934&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>5253-5264</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1432-1912">
        <prism:volume>397</prism:volume>
        <dc:title>Naunyn-Schmiedeberg's Archives of Pharmacology</dc:title>
        <dc:identifier>DOI 10.1007/s00210-024-02955-6</dc:identifier>
        <prism:number>7</prism:number>
        <dcterms:alternative>Naunyn-Schmiedeberg's Arch. Pharmacol.</dcterms:alternative>
        <dc:identifier>ISSN 1432-1912</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1019">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2030658173&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>15</prism:volume>
                <dc:title>Frontiers in Pharmacology</dc:title>
                <dc:identifier>DOI 10.3389/fphar.2024.1423075</dc:identifier>
                <dcterms:alternative>Front. Pharmacol.</dcterms:alternative>
                <dc:identifier>ISSN 1663-9812</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Cheng</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhao</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mou</foaf:surname>
                        <foaf:givenName>F.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Qian</foaf:surname>
                        <foaf:givenName>R.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Huang</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xu</foaf:surname>
                        <foaf:givenName>Q.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yu</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_815"/>
        <dcterms:isReferencedBy rdf:resource="#item_1246"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>area under the curve</dc:subject>
        <dc:subject>disproportionality analysis</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>health care personnel</dc:subject>
        <dc:subject>DRUGS</dc:subject>
        <dc:subject>quetiapine</dc:subject>
        <dc:subject>clinical practice</dc:subject>
        <dc:subject>erectile dysfunction</dc:subject>
        <dc:subject>aripiprazole</dc:subject>
        <dc:subject>asenapine</dc:subject>
        <dc:subject>data analysis software</dc:subject>
        <dc:subject>paliperidone</dc:subject>
        <dc:subject>risperidone</dc:subject>
        <dc:subject>ARIPIPRAZOLE</dc:subject>
        <dc:subject>atypical antipsychotic agent</dc:subject>
        <dc:subject>atypical antipsychotics</dc:subject>
        <dc:subject>brexpiprazole</dc:subject>
        <dc:subject>clozapine</dc:subject>
        <dc:subject>dopamine receptor</dc:subject>
        <dc:subject>ejaculation disorder</dc:subject>
        <dc:subject>FREQUENCY</dc:subject>
        <dc:subject>GraphPad Prism 9</dc:subject>
        <dc:subject>hypersexuality</dc:subject>
        <dc:subject>HYPERSEXUALITY</dc:subject>
        <dc:subject>hypoactive sexual desire disorder</dc:subject>
        <dc:subject>iloperidone</dc:subject>
        <dc:subject>impulse control disorder</dc:subject>
        <dc:subject>linear regression analysis</dc:subject>
        <dc:subject>loxapine</dc:subject>
        <dc:subject>Microsoft Excel 20</dc:subject>
        <dc:subject>muscarinic receptor</dc:subject>
        <dc:subject>olanzapine</dc:subject>
        <dc:subject>PALIPERIDONE</dc:subject>
        <dc:subject>psychotropic agent</dc:subject>
        <dc:subject>R version 4.3.0</dc:subject>
        <dc:subject>real-world data</dc:subject>
        <dc:subject>receptor occupancy</dc:subject>
        <dc:subject>safety signal</dc:subject>
        <dc:subject>SCHIZOPHRENIA</dc:subject>
        <dc:subject>sexual addiction</dc:subject>
        <dc:subject>sexual behavior</dc:subject>
        <dc:subject>sexual dysfunction</dc:subject>
        <dc:subject>SIGNAL</dc:subject>
        <dc:subject>social hierarchy</dc:subject>
        <dc:subject>SPSS 23.0</dc:subject>
        <dc:subject>ziprasidone</dc:subject>
        <dc:title>The atypical antipsychotics and sexual dysfunction: a pharmacovigilance-pharmacodynamic study</dc:title>
        <dcterms:abstract>Background: Atypical antipsychotics (AAPs)-induced sexual dysfunction (SD) is a frequent issue in clinical practice, often underestimated by clinicians and not extensively researched. The current study aimed to quantify the strength of association between the use of different AAPs and SD using real-world data from the FDA Adverse Event Reporting System (FAERS), as well as investigate the receptor mechanisms that are involved. Methods: Data from the FAERS database from the first quarter of 2004 to the third quarter of 2023 were queried through OpenVigil 2.1. Disproportionality analysis was estimated using the reporting odds ratio (ROR) and information component (IC) methods, and linear regression was used to investigate the relationship between ROR and receptor occupancy which was estimated using in vitro receptor binding profiles. Results: Our analysis yielded 4839 reports that co-mentioned AAP and SD events, and the findings revealed statistical associations between 12 AAPs and SD. The highest signal value was identified for iloperidone reporting retrograde ejaculation with iloperidone (ROR = 832.09, ROR025 = 552.77; IC = 9.58, IC025 = 6.36), followed by compulsive sexual behavior with aripiprazole (ROR = 533.02, ROR025 = 435.90; IC = 7.30, IC025 = 5.97), and psychosexual disorder for aripiprazole (ROR = 145.80, ROR025 = 109.57; IC025 = 6.47, IC025 = 4.86). Different characteristics of the SD side effects in each AAPs were discovered after further data mining. Regression analysis revealed potential effects for receptor occupancy of D2, D3, and 5-HT1A receptors on ROR. However, no significant correlation persisted following sensitivity analyses. Conclusion: This is the first study to investigate the AAP-SD associations by using FAERS. In this study, we report for the first time a significant association between aripiprazole and SD based on real-world data. The study suggests that different AAPs have varying levels of association with SD, and the D2, D3, and 5-HT1A receptor occupancy may contribute to potential mechanisms. The findings of this study warrant further validation of more studies and clinical causality assessment.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079825</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2030658173&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Memo rdf:about="#item_815">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 2; Correspondence Address: Q. Xu; Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China; email: hualixqq@163.com; S. Yu; Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China; email: yushunying@smhc.org.cn&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;3&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;3&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;51&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Memo rdf:about="#item_1246">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 2; Correspondence Address: Q. Xu; Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China; email: hualixqq@163.com; S. Yu; Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China; email: yushunying@smhc.org.cn&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;3&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;3&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;51&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2025060458&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>23</prism:volume>
                <dc:title>Expert Opinion on Drug Safety</dc:title>
                <dc:identifier>DOI 10.1080/14740338.2023.2251390</dc:identifier>
                <prism:number>3</prism:number>
                <dcterms:alternative>Expert Opin. Drug Saf.</dcterms:alternative>
                <dc:identifier>ISSN 1744-764X</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Cao</foaf:surname>
                        <foaf:givenName>B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gu</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shen</foaf:surname>
                        <foaf:givenName>Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shen</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_826"/>
        <dcterms:isReferencedBy rdf:resource="#item_1264"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>connective tissue disease</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>dizziness</dc:subject>
        <dc:subject>heart palpitation</dc:subject>
        <dc:subject>abnormal sensation</dc:subject>
        <dc:subject>headache</dc:subject>
        <dc:subject>nausea</dc:subject>
        <dc:subject>neck pain</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>tinnitus</dc:subject>
        <dc:subject>vertigo</dc:subject>
        <dc:subject>gastrointestinal disease</dc:subject>
        <dc:subject>mental disease</dc:subject>
        <dc:subject>neurologic disease</dc:subject>
        <dc:subject>skin disease</dc:subject>
        <dc:subject>somnolence</dc:subject>
        <dc:subject>eye disease</dc:subject>
        <dc:subject>hemiparesis</dc:subject>
        <dc:subject>lymphatic system disease</dc:subject>
        <dc:subject>malignant neoplasm</dc:subject>
        <dc:subject>oral paresthesia</dc:subject>
        <dc:subject>heart disease</dc:subject>
        <dc:subject>inner ear disease</dc:subject>
        <dc:subject>mediastinum disease</dc:subject>
        <dc:subject>respiratory tract disease</dc:subject>
        <dc:subject>thorax disease</dc:subject>
        <dc:subject>vascular disease</dc:subject>
        <dc:subject>breast disease</dc:subject>
        <dc:subject>ear disease</dc:subject>
        <dc:subject>cyst</dc:subject>
        <dc:subject>genital system disease</dc:subject>
        <dc:subject>hematologic disease</dc:subject>
        <dc:subject>hepatobiliary disease</dc:subject>
        <dc:subject>infection</dc:subject>
        <dc:subject>infestation</dc:subject>
        <dc:subject>injury</dc:subject>
        <dc:subject>kidney disease</dc:subject>
        <dc:subject>metabolic disorder</dc:subject>
        <dc:subject>musculoskeletal disease</dc:subject>
        <dc:subject>nutritional disorder</dc:subject>
        <dc:subject>polyp</dc:subject>
        <dc:subject>endocrine disease</dc:subject>
        <dc:subject>neoplasm</dc:subject>
        <dc:subject>cold sweat</dc:subject>
        <dc:subject>abnormal dreaming</dc:subject>
        <dc:subject>aura</dc:subject>
        <dc:subject>connective tissue diseases affecting the skin</dc:subject>
        <dc:subject>drug induced headache</dc:subject>
        <dc:subject>euphoria</dc:subject>
        <dc:subject>immunopathology</dc:subject>
        <dc:subject>migraine</dc:subject>
        <dc:subject>migraine with aura</dc:subject>
        <dc:subject>sedation</dc:subject>
        <dc:subject>thorax pain</dc:subject>
        <dc:subject>throat tightness</dc:subject>
        <dc:subject>treatment response</dc:subject>
        <dc:subject>ubrelvy</dc:subject>
        <dc:subject>ubrogepant</dc:subject>
        <dc:subject>urogenital tract disease</dc:subject>
        <dc:title>Evaluating Ubrogepant-related adverse events using the FDA adverse event reporting system</dc:title>
        <dcterms:abstract>Background: Migraine has a high prevalence in the population and accounts for 12% of primary headaches. Ubrogepant is used for the treatment of acute migraine, and although some clinical trials have demonstrated the safety of Ubrogepant, its long-term safety in a large sample of the population remains to be investigated. Methods: We collected data from the US Food and Drug Administration Adverse Event Reporting System (FAERS) database. We used reporting odds ratio (ROR), the proportional reporting ratio (PRR), the information component (IC) and the empirical Bayes geometric mean (EBGM) to evaluate Ubrogepant-induced adverse events (AEs). Results: We screened out 2,067 reports of Ubrogepant as primary suspected (PS) and 6,190 reports of Ubrogepant-induced AEs as PS. Our results showed that Ubrogepant-induced AEs targeted 4 system organ classes (SOCs), detected 32 Preferred terms (PTs) signals in 9 SOCs, including common Ubrogepant label consistent with Migraine, Nausea, Somnolence, Paraesthesia oral and Dizziness, It also includes the AEs of Hemiparesis, Mental impairment, Dysstasia, Tinnitus, Chest pain, Cold sweat, Neck pain, etc. that have not been demonstrated in previous studies. Conclusions: Our study identified new AEs that have not been reported, which provides a new guidance to deepen the comprehension of the safety of Ubrogepant.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079806</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2025060458&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>297-303</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_826">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Memo rdf:about="#item_1264">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2026330363&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>23</prism:volume>
                <dc:title>Expert Opinion on Drug Safety</dc:title>
                <dc:identifier>DOI 10.1080/14740338.2023.2274946</dc:identifier>
                <prism:number>3</prism:number>
                <dcterms:alternative>Expert Opin. Drug Saf.</dcterms:alternative>
                <dc:identifier>ISSN 1744-764X</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Cai</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jia</foaf:surname>
                        <foaf:givenName>B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Fu</foaf:surname>
                        <foaf:givenName>Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhao</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_835"/>
        <dcterms:isReferencedBy rdf:resource="#item_1260"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>combination drug therapy</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>death</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>hypertension</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>treatment response time</dc:subject>
        <dc:subject>alanine aminotransferase</dc:subject>
        <dc:subject>alanine aminotransferase blood level</dc:subject>
        <dc:subject>aspartate aminotransferase</dc:subject>
        <dc:subject>aspartate aminotransferase blood level</dc:subject>
        <dc:subject>arthralgia</dc:subject>
        <dc:subject>bleeding</dc:subject>
        <dc:subject>disability</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>outcome assessment</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>heart arrhythmia</dc:subject>
        <dc:subject>nausea</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>geriatric patient</dc:subject>
        <dc:subject>information processing</dc:subject>
        <dc:subject>atrial fibrillation</dc:subject>
        <dc:subject>heart muscle ischemia</dc:subject>
        <dc:subject>ischemic heart disease</dc:subject>
        <dc:subject>Medical Dictionary for Regulatory Activities</dc:subject>
        <dc:subject>risk assessment</dc:subject>
        <dc:subject>anticoagulant agent</dc:subject>
        <dc:subject>antidiabetic agent</dc:subject>
        <dc:subject>antilipemic agent</dc:subject>
        <dc:subject>diarrhea</dc:subject>
        <dc:subject>groups by age</dc:subject>
        <dc:subject>musculoskeletal pain</dc:subject>
        <dc:subject>diabetes mellitus</dc:subject>
        <dc:subject>dysgeusia</dc:subject>
        <dc:subject>peripheral edema</dc:subject>
        <dc:subject>drug approval</dc:subject>
        <dc:subject>hyperglycemia</dc:subject>
        <dc:subject>hypersensitivity</dc:subject>
        <dc:subject>consumer</dc:subject>
        <dc:subject>airway obstruction</dc:subject>
        <dc:subject>liver enzyme</dc:subject>
        <dc:subject>health practitioner</dc:subject>
        <dc:subject>abdominal discomfort</dc:subject>
        <dc:subject>taste disorder</dc:subject>
        <dc:subject>comorbidity</dc:subject>
        <dc:subject>drug tolerability</dc:subject>
        <dc:subject>data source</dc:subject>
        <dc:subject>liver disease</dc:subject>
        <dc:subject>clinical evaluation</dc:subject>
        <dc:subject>contingency table</dc:subject>
        <dc:subject>coronary atherosclerosis</dc:subject>
        <dc:subject>digestive system function disorder</dc:subject>
        <dc:subject>dyslipidemia</dc:subject>
        <dc:subject>eructation</dc:subject>
        <dc:subject>ezetimibe</dc:subject>
        <dc:subject>fatty liver</dc:subject>
        <dc:subject>FDA Adverse Event Reporting System</dc:subject>
        <dc:subject>fenofibrate</dc:subject>
        <dc:subject>hydroxymethylglutaryl coenzyme A reductase inhibitor</dc:subject>
        <dc:subject>hypertriglyceridemia</dc:subject>
        <dc:subject>icosapentaenoic acid ethyl ester</dc:subject>
        <dc:subject>intersectionality</dc:subject>
        <dc:subject>PCSK9 inhibitor</dc:subject>
        <dc:subject>smelling disorder</dc:subject>
        <dc:subject>triacylglycerol</dc:subject>
        <dc:subject>triacylglycerol blood level</dc:subject>
        <dc:title>Real-world safety of icosapent ethyl: analysis based on spontaneous reports in FAERS database</dc:title>
        <dcterms:abstract>Background: The triglyceride-lowering drug, icosapent ethyl (IPE), was granted a new indication for the reduction of atherosclerotic cardiovascular disease risk in 2019. This study aimed to investigate the safety profile of IPE by mining the FDA Adverse Event Reporting System (FAERS) database. Methods: The reporting odds ratio was used to analyze IPE’s adverse events (AEs) based on the FAERS data from July 2012 to December 2022. We described the characteristics of AE reports and evaluated the clinical prioritization of AEs. Then we defined and analyzed nine interested adverse drug reactions (ADRs) in both overall and subgroups, and investigated the times to onset. Results: The findings of our study strengthen the evidence for an increased risk of atrial fibrillation using IPE. IPE alone may not increase the risk of bleeding unless combined with antithrombotic drugs. Similar to statins, IPE alone can increase the risk of musculoskeletal pain, drug-related hepatic disorders, and hyperglycemia, but the risk could not double when IPE was combined with statins. Most ADRs occur in the early stage of treatment. Conclusions: This study provides a comprehensive real-world safety profile of IPE, which indicates that IPE is well-tolerated.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079811</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2026330363&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>373-383</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_835">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Memo rdf:about="#item_1260">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2031728794&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:2980-2156"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Aksoyalp</foaf:surname>
                        <foaf:givenName>Z.Ş.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Temel</foaf:surname>
                        <foaf:givenName>A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_841"/>
        <dcterms:isReferencedBy rdf:resource="#item_1269"/>
        <dc:subject>acute kidney failure</dc:subject>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>odds ratio</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>prescription</dc:subject>
        <dc:subject>disproportionality analysis</dc:subject>
        <dc:subject>nausea</dc:subject>
        <dc:subject>diarrhea</dc:subject>
        <dc:subject>confidence interval</dc:subject>
        <dc:subject>infection</dc:subject>
        <dc:subject>canagliflozin</dc:subject>
        <dc:subject>THERAPY</dc:subject>
        <dc:subject>disease risk assessment</dc:subject>
        <dc:subject>mycosis</dc:subject>
        <dc:subject>Adverse drug events</dc:subject>
        <dc:subject>antidiabetic drugs</dc:subject>
        <dc:subject>antimicrobial activity</dc:subject>
        <dc:subject>canagliflozin plus metformin</dc:subject>
        <dc:subject>COTRANSPORTER 2 INHIBITORS</dc:subject>
        <dc:subject>dapagliflozin</dc:subject>
        <dc:subject>dapagliflozin plus metformin</dc:subject>
        <dc:subject>DIABETES-MELLITUS</dc:subject>
        <dc:subject>diagnostic test accuracy study</dc:subject>
        <dc:subject>empagliflozin</dc:subject>
        <dc:subject>empagliflozin plus metformin</dc:subject>
        <dc:subject>ertugliflozin</dc:subject>
        <dc:subject>ertugliflozin plus metformin</dc:subject>
        <dc:subject>FOCUS</dc:subject>
        <dc:subject>hypoglycemia</dc:subject>
        <dc:subject>lactic acidosis</dc:subject>
        <dc:subject>metformin</dc:subject>
        <dc:subject>multivariate analysis</dc:subject>
        <dc:subject>sodium glucose cotransporter 2 inhibitor</dc:subject>
        <dc:subject>TYPE-2</dc:subject>
        <dc:subject>urinary tract infection</dc:subject>
        <dc:title>Urinary Tract Infections and Fungal Infections Associated with Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors and Metformin Combination: A Real-World Study from 2013 to 2023 Based on the FDA Adverse Event Reporting System (FAERS) Database</dc:title>
        <dcterms:abstract>Objective: This study aimed to compare the rates of urinary tract infections (UTIs) and fungal infections associated with metformin, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, and their combination. Materials and Methods: We collected data on UTIs and fungal infections related to metformin, SGLT-2 inhibitors, and their combinations from the FDA Adverse Event Reporting System (FAERS) database. We calculated the reporting odds ratio (ROR) and 95% confidence intervals (CI) to assess the risk associated with these adverse events when using these medications. We evaluated differences in categorical variables using the Chi-squared test. Results: SGLT-2 inhibitors present a higher risk of UTIs and fungal infections compared to metformin. Empagliflozin showed the lowest risk of UTIs (ROR 0.928, 95% CI 0.858–1.005), while dapagliflozin exhibited the lowest risk of fungal infections (ROR 0.874, 95% CI 0.815–0.938). Additionally, patients using SGLT-2 inhibitors alone reported more cases of UTIs and fungal infections than those treated with a combination of SGLT-2 inhibitors and metformin (ROR&gt;1). Conclusion: SGLT-2 inhibitors are associated with an increased risk of UTIs and fungal infections compared to combination therapy with an SGLT-2 inhibitor and metformin. The reduced infection reports with combined SGLT-2 inhibitors and metformin therapy may be due to the potential antimicrobial activity of metformin.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079796</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2031728794&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>282-289</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:2980-2156">
        <prism:volume>46</prism:volume>
        <dc:title>Journal of Clinical Practice and Research</dc:title>
        <dc:identifier>DOI 10.14744/cpr.2024.60933</dc:identifier>
        <prism:number>3</prism:number>
        <dcterms:alternative>J. Clin. Pract. Res.</dcterms:alternative>
        <dc:identifier>ISSN 2980-2156</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_841">
        <rdf:value>&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;39&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Memo rdf:about="#item_1269">
        <rdf:value>&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;39&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2020196359&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>89</prism:volume>
                <dc:title>British Journal of Clinical Pharmacology</dc:title>
                <dc:identifier>DOI 10.1111/bcp.15587</dc:identifier>
                <prism:number>4</prism:number>
                <dcterms:alternative>Br. J. Clin. Pharmacol.</dcterms:alternative>
                <dc:identifier>ISSN 1365-2125</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shao</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shi</foaf:surname>
                        <foaf:givenName>D.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Dai</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1232"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>age</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>*Data Mining</dc:subject>
        <dc:subject>*Drug Labeling</dc:subject>
        <dc:subject>*Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>*Machine Learning</dc:subject>
        <dc:subject>*Models, Theoretical</dc:subject>
        <dc:subject>*Pharmacovigilance</dc:subject>
        <dc:subject>*Semantics</dc:subject>
        <dc:subject>*Social Media</dc:subject>
        <dc:subject>*Software</dc:subject>
        <dc:subject>Acidosis, Lactic</dc:subject>
        <dc:subject>acute heart failure</dc:subject>
        <dc:subject>acute heart infarction</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>Adolescent</dc:subject>
        <dc:subject>Adult</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse drug reaction</dc:subject>
        <dc:subject>Adverse drug reaction (ADRs)</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>Adverse drug reactions</dc:subject>
        <dc:subject>ADVERSE DRUG-REACTIONS</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>adverse event reporting system</dc:subject>
        <dc:subject>adverse events</dc:subject>
        <dc:subject>adverse hepatobiliary reaction</dc:subject>
        <dc:subject>adverse outcome</dc:subject>
        <dc:subject>AGE</dc:subject>
        <dc:subject>age distribution</dc:subject>
        <dc:subject>Age Factors</dc:subject>
        <dc:subject>Aged</dc:subject>
        <dc:subject>alanine aminotransferase</dc:subject>
        <dc:subject>alanine aminotransferase blood level</dc:subject>
        <dc:subject>Alanine Transaminase</dc:subject>
        <dc:subject>Algorithms</dc:subject>
        <dc:subject>ambrisentan</dc:subject>
        <dc:subject>AMBRISENTAN</dc:subject>
        <dc:subject>amikacin</dc:subject>
        <dc:subject>aminosalicylic acid</dc:subject>
        <dc:subject>amoxicillin plus clavulanic acid</dc:subject>
        <dc:subject>androgen deficiency</dc:subject>
        <dc:subject>androgen therapy</dc:subject>
        <dc:subject>ANNOTATED CORPUS</dc:subject>
        <dc:subject>Anti-Bacterial Agents</dc:subject>
        <dc:subject>antidepressant agent</dc:subject>
        <dc:subject>antiinfective agent</dc:subject>
        <dc:subject>Antitubercular Agents</dc:subject>
        <dc:subject>ANTITUBERCULOSIS DRUGS</dc:subject>
        <dc:subject>area under the curve</dc:subject>
        <dc:subject>arsenic trioxide</dc:subject>
        <dc:subject>Artificial intelligence</dc:subject>
        <dc:subject>artificial neural network</dc:subject>
        <dc:subject>aspartate aminotransferase</dc:subject>
        <dc:subject>aspartate aminotransferase blood level</dc:subject>
        <dc:subject>Aspartate Aminotransferases</dc:subject>
        <dc:subject>Bacteria</dc:subject>
        <dc:subject>Bacteria biotopes</dc:subject>
        <dc:subject>Bacteria/metabolism</dc:subject>
        <dc:subject>bacterium</dc:subject>
        <dc:subject>Bayes Theorem</dc:subject>
        <dc:subject>bedaquiline</dc:subject>
        <dc:subject>Bell's palsy</dc:subject>
        <dc:subject>bilirubin</dc:subject>
        <dc:subject>Bilirubin</dc:subject>
        <dc:subject>bilirubin blood level</dc:subject>
        <dc:subject>Biological modeling</dc:subject>
        <dc:subject>Biological Modeling</dc:subject>
        <dc:subject>biology</dc:subject>
        <dc:subject>Biomedical Research</dc:subject>
        <dc:subject>blood</dc:subject>
        <dc:subject>body mass</dc:subject>
        <dc:subject>bosentan</dc:subject>
        <dc:subject>Bosentan</dc:subject>
        <dc:subject>BOSENTAN</dc:subject>
        <dc:subject>calculation</dc:subject>
        <dc:subject>capreomycin</dc:subject>
        <dc:subject>cardiotoxicity</dc:subject>
        <dc:subject>cardiovascular disease</dc:subject>
        <dc:subject>cerebrovascular accident</dc:subject>
        <dc:subject>Character recognition</dc:subject>
        <dc:subject>chemical and drug induced liver injury</dc:subject>
        <dc:subject>Chemical and Drug Induced Liver Injury</dc:subject>
        <dc:subject>chi square test</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>Child</dc:subject>
        <dc:subject>chronic obstructive lung disease</dc:subject>
        <dc:subject>cilastatin</dc:subject>
        <dc:subject>cilastatin plus imipenem</dc:subject>
        <dc:subject>citalopram</dc:subject>
        <dc:subject>Citalopram</dc:subject>
        <dc:subject>classification</dc:subject>
        <dc:subject>classifier</dc:subject>
        <dc:subject>clinical effects</dc:subject>
        <dc:subject>clinical feature</dc:subject>
        <dc:subject>clofazimine</dc:subject>
        <dc:subject>cohort analysis</dc:subject>
        <dc:subject>Cohort Studies</dc:subject>
        <dc:subject>combination regimens</dc:subject>
        <dc:subject>Computational Biology</dc:subject>
        <dc:subject>computer graphics</dc:subject>
        <dc:subject>Computer Graphics</dc:subject>
        <dc:subject>computer interface</dc:subject>
        <dc:subject>Conditional random field</dc:subject>
        <dc:subject>connective tissue disease</dc:subject>
        <dc:subject>Convolutional neural network</dc:subject>
        <dc:subject>Cross-Sectional Studies</dc:subject>
        <dc:subject>cross-sectional study</dc:subject>
        <dc:subject>cycloserine</dc:subject>
        <dc:subject>Cytochrome P-450 Enzyme System</dc:subject>
        <dc:subject>cytochrome P450</dc:subject>
        <dc:title>Linezolid and the risk of QT interval prolongation: A pharmacovigilance study of the Food and Drug Administration Adverse Event Reporting System</dc:title>
        <dcterms:abstract>Aims: Few studies have investigated linezolid (LZD)-associated cardiotoxicity. This study explored the potential association between LZD and QT interval prolongation. Methods: Adverse event reports of QT interval prolongation associated with LZD from the Food and Drug Administration Adverse Event Reporting System from January 2013 to December 2021 were analysed and the reporting odds ratio (ROR) with 95% confidence intervals were calculated. Results: A total of 6738 adverse event reports of LZD as the primary and secondary suspected drug were obtained from the database, including 192 reports with electrocardiogram QT prolonged (QTp), and the ROR value was 26.1 (95% CI = 22.6–30.2). There were 8 reports of long QT syndrome, ROR 14.2 (95% CI = 7.1–28.5); 5 reports of torsade de pointes, ROR 3.2 (95% CI = 1.3–7.6); and 5 reports of ventricular tachycardia, ROR 1.9 (95% CI = 0.8–4.5). Subgroup analysis revealed that patients with tuberculosis treated with LZD had a higher reporting rate among all QTp reports, exhibiting an odds ratio of 330.0 (95% CI = 223.1–488.1). The odds ratios of QTp associated with LZD treatments in patients with and without tuberculosis were 4.2 (95% CI = 3.4–5.3) and 1.2 (95% CI = 0.8–1.6), respectively. Conclusion: The study showed an association between LZD and QT interval prolongation. In the report on patients with tuberculosis, the incidence of QTp was higher when treated with LZD.</dcterms:abstract>
        <dc:date>2023</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079842</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2020196359&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>1386-1392</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1232">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: D.A. Perwitasari; Faculty of Pharmacy, Universitas Ahmad Dahlan, Yogyakarta, Indonesia; email: dyah.perwitasari@pharm.uad.ac.id; CODEN: POLNC&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 4; Correspondence Address: X.M. Hart; Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg, Mannheim, University J5, 68159, Germany; email: xenia.hart@zi-mannheim.de; CODEN: PHRME&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 5; Correspondence Address: D. Shi; Department of Pharmacy, First Affiliated Hospital of Wenzhou Medical University, Wenzhou City, Zhejiang Province, 325000, China; email: shidawei800@126.com; Y. Dai; Department of Pharmacy, First Affiliated Hospital of Wenzhou Medical University, Wenzhou City, China; email: daiying02@163.com; CODEN: BCPHB&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 7; Correspondence Address: C. Sun; Department of Pharmacy, Children’s Hospital of Nanjing Medical University, Nanjing, No. 72, Guangzhou road, Gulou District, Jiangsu, 210000, China; email: ydsunchuan@163.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 10; Correspondence Address: M.-M. Yan; Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China; email: xyqiu@fudan.edu.cn; X.-Y. Qiu; Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China; email: xyqiu@fudan.edu.cn&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 14; Correspondence Address: C. Zhang; Department of Pharmacy, First Affiliated Hospital of Wenzhou Medical University, Wenzhou City, China; email: zch760217@163.com; D. Shi; Department of Pharmacy, First Affiliated Hospital of Wenzhou Medical University, Wenzhou City, China; email: shidawei800@126.com; CODEN: JCPTE&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 17; Correspondence Address: L. Li; Indiana University, School of Medicine, Indianapolis, 46202, United States; email: lali@iu.edu&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 18; Correspondence Address: J. Hur; Department of Biomedical Sciences, University of North Dakota School of Medicine and Health Sciences, Grand Forks, 1301 North Columbia Rd, 58202, United States; email: junguk.hur@med.und.edu; CODEN: BBMIC&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 22; Correspondence Address: R. Singh; San Francisco State University, Department of Computer Science, San Francisco, 94132, United States; email: rahul@sfsu.edu; CODEN: BBMIC&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 25; Correspondence Address: R. Li; Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, United States; email: vwo3@cdc.gov; CODEN: PDSAE&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 33; Correspondence Address: A. Özgür; Department of Computer Engineering, Boǧaziçi University, Istanbul, 34342, Turkey; email: arzucan.ozgur@boun.edu.tr; CODEN: BBMIC&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 34; Correspondence Address: M. Krallinger; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, 08010, Spain; email: mkrallinger@cnio.es; CODEN: NARHA&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;23&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;4&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;4&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;22&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;6&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;6&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;43&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;11&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;11&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;50&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;11&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;13&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;36&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;15&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;16&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;51&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;19&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;21&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;42&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;19&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;25&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;47&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;21&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;23&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;18&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2021877930&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:2210-7711"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wei</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tian</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Guo</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zheng</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xu</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ye</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1228"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data analysis</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>acute heart infarction</dc:subject>
        <dc:subject>activated partial thromboplastin time</dc:subject>
        <dc:subject>Adverse Event Reporting System database</dc:subject>
        <dc:subject>ankle sprain</dc:subject>
        <dc:subject>apparent life threatening event</dc:subject>
        <dc:subject>arterial haemorrhage</dc:subject>
        <dc:subject>arthralgia</dc:subject>
        <dc:subject>bile duct stone</dc:subject>
        <dc:subject>bleeding</dc:subject>
        <dc:subject>blood clotting factor 8</dc:subject>
        <dc:subject>brain hemorrhage</dc:subject>
        <dc:subject>broadly neutralizing antibody</dc:subject>
        <dc:subject>burning sensation</dc:subject>
        <dc:subject>contusion</dc:subject>
        <dc:subject>descriptive research</dc:subject>
        <dc:subject>device related thrombosis</dc:subject>
        <dc:subject>disability</dc:subject>
        <dc:subject>disproportionality analysis</dc:subject>
        <dc:subject>Dressler syndrome</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>emicizumab</dc:subject>
        <dc:subject>epidural hematoma</dc:subject>
        <dc:subject>epistaxis</dc:subject>
        <dc:subject>eyelid bleeding</dc:subject>
        <dc:subject>face injury</dc:subject>
        <dc:subject>fracture</dc:subject>
        <dc:subject>gastrointestinal hemorrhage</dc:subject>
        <dc:subject>gingiva bleeding</dc:subject>
        <dc:subject>head injury</dc:subject>
        <dc:subject>health care personnel</dc:subject>
        <dc:subject>hemarthrosis</dc:subject>
        <dc:subject>hematoma</dc:subject>
        <dc:subject>hematothorax</dc:subject>
        <dc:subject>hemophilia A</dc:subject>
        <dc:subject>hemophilic arthropathy</dc:subject>
        <dc:subject>hemospermia</dc:subject>
        <dc:subject>hypoxic ischemic encephalopathy</dc:subject>
        <dc:subject>immunoglobulin G4</dc:subject>
        <dc:subject>information component</dc:subject>
        <dc:subject>injection site erythema</dc:subject>
        <dc:subject>injection site pain</dc:subject>
        <dc:subject>injection site pruritus</dc:subject>
        <dc:subject>injection site rash</dc:subject>
        <dc:subject>injection site reaction</dc:subject>
        <dc:subject>injection site swelling</dc:subject>
        <dc:subject>internal bleeding</dc:subject>
        <dc:subject>intestine perforation</dc:subject>
        <dc:subject>intraabdominal haemorrhage</dc:subject>
        <dc:subject>joint effusion</dc:subject>
        <dc:subject>joint injury</dc:subject>
        <dc:subject>joint swelling</dc:subject>
        <dc:subject>kidney hemorrhage</dc:subject>
        <dc:subject>Klebsiella pneumoniae</dc:subject>
        <dc:subject>limb fracture</dc:subject>
        <dc:subject>limb injury</dc:subject>
        <dc:subject>lip hemorrhage</dc:subject>
        <dc:subject>liver cirrhosis</dc:subject>
        <dc:subject>logarithm</dc:subject>
        <dc:subject>lung hemorrhage</dc:subject>
        <dc:subject>lupus erythematosus nephritis</dc:subject>
        <dc:subject>lymphoma</dc:subject>
        <dc:subject>melena</dc:subject>
        <dc:subject>mesenteric artery thrombosis</dc:subject>
        <dc:subject>mesenteric haematoma</dc:subject>
        <dc:subject>metabolic acidosis</dc:subject>
        <dc:subject>muscle bleeding</dc:subject>
        <dc:subject>myalgia</dc:subject>
        <dc:subject>nephritis</dc:subject>
        <dc:subject>neutropenic sepsis</dc:subject>
        <dc:subject>oesophageal varices haemorrhage</dc:subject>
        <dc:subject>oral bleeding</dc:subject>
        <dc:subject>outcome assessment</dc:subject>
        <dc:subject>peritonitis</dc:subject>
        <dc:subject>Preferred Term in the Medical Dictionary for Regulatory Activities</dc:subject>
        <dc:subject>probability</dc:subject>
        <dc:subject>prothrombin time</dc:subject>
        <dc:subject>psychomotor hyperactivity</dc:subject>
        <dc:subject>range of motion</dc:subject>
        <dc:subject>reporting odds ratio</dc:subject>
        <dc:subject>research</dc:subject>
        <dc:subject>rhabdomyolysis</dc:subject>
        <dc:subject>rheumatic polymyalgia</dc:subject>
        <dc:subject>sepsis</dc:subject>
        <dc:subject>shock haemorrhage</dc:subject>
        <dc:subject>skin laceration</dc:subject>
        <dc:subject>soft tissue haemorrhage</dc:subject>
        <dc:subject>statistical shrinkage transformation</dc:subject>
        <dc:subject>subdural hematoma</dc:subject>
        <dc:subject>superior cava vein syndrome</dc:subject>
        <dc:subject>testicular haemorrhage</dc:subject>
        <dc:subject>thrombosis</dc:subject>
        <dc:subject>thrombotic microangiopathy</dc:subject>
        <dc:subject>traumatic haemorrhage</dc:subject>
        <dc:subject>vein injury</dc:subject>
        <dc:title>Data mining and analysis for emicizumab adverse event signals based on the Food and Drug Administration Adverse Event Reporting System database</dc:title>
        <dcterms:abstract>Background: Emicizumab is the latest treatment for patients with hemophilia A. Its safety in real-world data is limited, and regulatory agencies and clinical researchers have raised concerns about the risk of adverse events. Aim: This study aimed to detect potential adverse event signals of emicizumab using the FDA Adverse Event Reporting System (FAERS) database. Method: Data in FAERS from the fourth quarter of 2017 to the second quarter of 2021 were searched. Cases of adverse events were extracted using the Preferred Term in the Medical Dictionary for Regulatory Activities (version 24.0). Disproportionality analysis was performed using the reporting odds ratio (ROR) and information component (IC) methods based on statistical shrinkage transformation. Results: A total of 5,598,717 patients were included, of which 1,244 took emicizumab. A total of 703 emicizumab-related adverse event signals were mined, and 101 positive signals were detected. Haemarthrosis (ROR/ROR975/ROR025 = 155.62/184.34/131.38, IC/IC975/IC025 = 7.28/7.48/7.01), haemorrhage (ROR/ROR975/ROR025 = 71.01/81.18/62.12, IC/IC975/IC025 = 6.15/6.31/5.94), muscle haemorrhage (ROR/ROR975/ROR025 = 53.38/75.83/37.58, IC/IC975/IC025 = 5.74/6.16/5.15), traumatic haemorrhage (ROR/ROR975/ROR025 = 27.78/46.29/16.67, IC/IC975/IC025 = 4.80/5.40/3.92), haematoma (ROR/ROR975/ROR025 = 18.15/26.35/12.51, IC/IC975/IC025 = 4.18/4.63/3.55), device-related thrombosis (ROR/ROR975/ROR025 = 21.27/37.57/12.04, IC/IC975/IC025 = 4.41/5.08/3.43), and activated partial thromboplastin time prolonged (ROR/ROR975/ROR025 = 20.68/36.51/11.71, IC/IC975/IC025 = 4.37/5.04/3.39) had the strongest signal intensities. Haemorrhage, haemarthrosis, arthralgia, fall, and injection site pain were reported more frequently. Conclusion: This study found that mild arthralgia and injection site reaction were associated with emicizumab. Attention should also be paid to other serious adverse events related to emicizumab, such as acute myocardial infarction and sepsis, to ensure patient safety.</dcterms:abstract>
        <dc:date>2023</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079840</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2021877930&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>622-629</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:2210-7711">
        <prism:volume>45</prism:volume>
        <dc:title>International Journal of Clinical Pharmacy</dc:title>
        <dc:identifier>DOI 10.1007/s11096-022-01514-4</dc:identifier>
        <prism:number>3</prism:number>
        <dcterms:alternative>Int. J. Clin. Pharm.</dcterms:alternative>
        <dc:identifier>ISSN 2210-7711</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1228">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2025080358&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1525-5069"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>P.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xu</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhou</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Fei</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1229"/>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>adverse outcome</dc:subject>
        <dc:subject>age distribution</dc:subject>
        <dc:subject>descriptive research</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>depression</dc:subject>
        <dc:subject>dizziness</dc:subject>
        <dc:subject>vertigo</dc:subject>
        <dc:subject>acute psychosis</dc:subject>
        <dc:subject>altered state of consciousness</dc:subject>
        <dc:subject>amnesia</dc:subject>
        <dc:subject>apnea</dc:subject>
        <dc:subject>ataxia</dc:subject>
        <dc:subject>attention disturbance</dc:subject>
        <dc:subject>automutilation</dc:subject>
        <dc:subject>balance disorder</dc:subject>
        <dc:subject>behavior disorder</dc:subject>
        <dc:subject>brain disease</dc:subject>
        <dc:subject>clinical decision making</dc:subject>
        <dc:subject>cognitive defect</dc:subject>
        <dc:subject>coma</dc:subject>
        <dc:subject>confusion</dc:subject>
        <dc:subject>coordination disorder</dc:subject>
        <dc:subject>delirium</dc:subject>
        <dc:subject>delusion</dc:subject>
        <dc:subject>diplopia</dc:subject>
        <dc:subject>dose response</dc:subject>
        <dc:subject>dysarthria</dc:subject>
        <dc:subject>dysphoria</dc:subject>
        <dc:subject>epilepsy</dc:subject>
        <dc:subject>erectile dysfunction</dc:subject>
        <dc:subject>evidence based medicine</dc:subject>
        <dc:subject>gastrointestinal disease</dc:subject>
        <dc:subject>geriatric patient</dc:subject>
        <dc:subject>hallucination</dc:subject>
        <dc:subject>hyperammonemia</dc:subject>
        <dc:subject>hypersalivation</dc:subject>
        <dc:subject>hyponatremia</dc:subject>
        <dc:subject>information processing</dc:subject>
        <dc:subject>liver toxicity</dc:subject>
        <dc:subject>mental disease</dc:subject>
        <dc:subject>mental health</dc:subject>
        <dc:subject>mood disorder</dc:subject>
        <dc:subject>motor dysfunction</dc:subject>
        <dc:subject>NCT00699582</dc:subject>
        <dc:subject>NCT00699972</dc:subject>
        <dc:subject>NCT00700310</dc:subject>
        <dc:subject>neurologic disease</dc:subject>
        <dc:subject>paranoia</dc:subject>
        <dc:subject>perampanel</dc:subject>
        <dc:subject>persecutory delusion</dc:subject>
        <dc:subject>personality disorder</dc:subject>
        <dc:subject>psychosis</dc:subject>
        <dc:subject>reporting and data system</dc:subject>
        <dc:subject>respiration depression</dc:subject>
        <dc:subject>restlessness</dc:subject>
        <dc:subject>seizure</dc:subject>
        <dc:subject>sex difference</dc:subject>
        <dc:subject>skin disease</dc:subject>
        <dc:subject>somnolence</dc:subject>
        <dc:subject>speech disorder</dc:subject>
        <dc:subject>suicide</dc:subject>
        <dc:subject>urine retention</dc:subject>
        <dc:title>Mining and analysis of adverse drug reactions associated with perampanel based on FAERS database</dc:title>
        <dcterms:abstract>Introduction: Perampanel (PER) is a non-competitive AMPA glutamate receptor antagonist used as an anti-seizure medication. Large post-marketing databases are still lacking for safety analysis of the new generation of anti-seizure medications. Based on the FDA's adverse event reporting system (FAERS) database, this study aimed to investigate, assess, and offer evidence for the safety of PER to support clinical decision-making. Methods: Perampanel-related adverse reaction signals were mined using the reporting odds ratio (ROR), medicines and healthcare products regulatory agency (MHRA), and Bayesian confidence propagation neural network (BCPNN). The rate and occurrence of reported adverse responses were examined. Results: With the three methodologies used in combination, 83 signals mostly related to psychosis and different nervous system disorders were detected. Among them, suicide behavior, respiratory depression, hepatotoxicity, cognitive impairment, and other possible novel signals warranted consideration. Further examination of the age and gender differences in the detected signals revealed that elderly patients should be closely monitored for any change in consciousness and the occurrence of movement disorders; male patients should be observed for negative mental reactions like a personal attack and homicidal ideation; and female patients should be watched for the occurrence of negative reactions in memory, weight, vision, liver function, and other specific areas. Conclusions: This study found that PER had the risk of causing suicide behavior, respiratory depression, hepatotoxicity, and cognitive impairment among other adverse effects. When used clinically, PER should be closely monitored for the occurrence of adverse effects on mental health and behavior. However, these results should be interpreted with caution.</dcterms:abstract>
        <dc:date>2023</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079839</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2025080358&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1525-5069">
        <prism:volume>145</prism:volume>
        <dc:title>Epilepsy and Behavior</dc:title>
        <dc:identifier>DOI 10.1016/j.yebeh.2023.109283</dc:identifier>
        <dcterms:alternative>Epilepsy Behav.</dcterms:alternative>
        <dc:identifier>ISSN 1525-5069</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1229">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2023338030&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>63</prism:volume>
                <dc:title>Journal of Clinical Pharmacology</dc:title>
                <dc:identifier>DOI 10.1002/jcph.2244</dc:identifier>
                <prism:number>8</prism:number>
                <dcterms:alternative>J. Clin. Pharmacol.</dcterms:alternative>
                <dc:identifier>ISSN 1552-4604</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zeng</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Guo</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xiao</foaf:surname>
                        <foaf:givenName>F.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1233"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>heart failure</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>hypertension</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>acute heart failure</dc:subject>
        <dc:subject>acute heart infarction</dc:subject>
        <dc:subject>cardiovascular disease</dc:subject>
        <dc:subject>cerebrovascular accident</dc:subject>
        <dc:subject>cross-sectional study</dc:subject>
        <dc:subject>brain hemorrhage</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>subdural hematoma</dc:subject>
        <dc:subject>thrombosis</dc:subject>
        <dc:subject>thrombotic microangiopathy</dc:subject>
        <dc:subject>cardiomyopathy</dc:subject>
        <dc:subject>heart arrhythmia</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>visual acuity</dc:subject>
        <dc:subject>acute coronary syndrome</dc:subject>
        <dc:subject>aflibercept</dc:subject>
        <dc:subject>age related macular degeneration</dc:subject>
        <dc:subject>angina pectoris</dc:subject>
        <dc:subject>arterial thromboembolism</dc:subject>
        <dc:subject>artery occlusion</dc:subject>
        <dc:subject>atrial fibrillation</dc:subject>
        <dc:subject>bevacizumab</dc:subject>
        <dc:subject>blindness</dc:subject>
        <dc:subject>brain embolism</dc:subject>
        <dc:subject>brain hematoma</dc:subject>
        <dc:subject>brain infarction</dc:subject>
        <dc:subject>brain ischemia</dc:subject>
        <dc:subject>cardioembolic stroke</dc:subject>
        <dc:subject>carotid stenosis</dc:subject>
        <dc:subject>cerebellum hemorrhage</dc:subject>
        <dc:subject>cerebellum infarction</dc:subject>
        <dc:subject>cerebral thrombosis</dc:subject>
        <dc:subject>cerebrovascular disease</dc:subject>
        <dc:subject>congestive heart failure</dc:subject>
        <dc:subject>coronary artery disease</dc:subject>
        <dc:subject>deep vein thrombosis</dc:subject>
        <dc:subject>diabetic retinopathy</dc:subject>
        <dc:subject>embolism</dc:subject>
        <dc:subject>eye disease</dc:subject>
        <dc:subject>heart infarction</dc:subject>
        <dc:subject>heart muscle ischemia</dc:subject>
        <dc:subject>hemiparesis</dc:subject>
        <dc:subject>hemiplegia</dc:subject>
        <dc:subject>hypertensive crisis</dc:subject>
        <dc:subject>intracranial aneurysm</dc:subject>
        <dc:subject>ischemic heart disease</dc:subject>
        <dc:subject>ischemic stroke</dc:subject>
        <dc:subject>lung edema</dc:subject>
        <dc:subject>macular edema</dc:subject>
        <dc:subject>malignant hypertension</dc:subject>
        <dc:subject>Medical Dictionary for Regulatory Activities</dc:subject>
        <dc:subject>monoplegia</dc:subject>
        <dc:subject>polypoidal choroidal vasculopathy</dc:subject>
        <dc:subject>pulmonary hypertension</dc:subject>
        <dc:subject>ranibizumab</dc:subject>
        <dc:subject>retina vein occlusion</dc:subject>
        <dc:subject>retinal artery occlusion</dc:subject>
        <dc:subject>retinal vascular disease</dc:subject>
        <dc:subject>retrolental fibroplasia</dc:subject>
        <dc:subject>subarachnoid hemorrhage</dc:subject>
        <dc:subject>subretinal neovascularization</dc:subject>
        <dc:subject>systolic hypertension</dc:subject>
        <dc:subject>thrombophlebitis</dc:subject>
        <dc:subject>transient ischemic attack</dc:subject>
        <dc:subject>transitional blindness</dc:subject>
        <dc:subject>unclassified drug</dc:subject>
        <dc:subject>unstable angina pectoris</dc:subject>
        <dc:subject>venous thromboembolism</dc:subject>
        <dc:title>Cardiovascular and Cerebrovascular Safety of Ranibizumab, Bevacizumab, and Aflibercept in Ocular Diseases: An Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) Database</dc:title>
        <dcterms:abstract>The cardiovascular and cerebrovascular safety of ranibizumab, bevacizumab, and aflibercept for ocular diseases is unclear. This study aimed to evaluate and compare the cardiovascular and cerebrovascular safety in patients receiving ranibizumab, bevacizumab, and aflibercept for ocular disease. A cross-sectional study was conducted from 2017 (Q1) to 2021 (Q4) in the US Food and Drug Administration Adverse Event Reporting System (FAERS) database. The outcomes of interest were central nervous system vascular disorders, ischemic heart disease, hypertension, pulmonary hypertension, torsade de pointes/QT prolongation, embolic and thrombotic events, cardiac arrhythmias, cardiac failure, and cardiomyopathy. Data mining was performed by a disproportional method with a compression, using compressed reporting odds ratios (sRORs) with 95% confidence intervals (CIs) to measure signals. The results showed 1462 cardiovascular and cerebrovascular events associated with aflibercept, 834 with ranibizumab, and 150 with bevacizumab. Ranibizumab, bevacizumab, and aflibercept were linked to central nervous system vascular disorders (sROR, 5.57[95%CI, 4.95-6.26] vs sROR, 2.23 [95%CI, 1.75-2.85] vs sROR, 2.73[95%CI, 2.43–3.06]), ischemic heart disease (sROR, 3.31[95%CI, 2.65–4.13] vs sROR, 1.98 [95%CI, 1.24-3.16] vs sROR, 3.00 [95%CI, 2.46-3.65]), embolic and thrombotic (sROR, 3.36 [95%CI, 3.04-3.72] vs sROR, 2.16 [95%CI, 1.70-2.74] vs sROR, 5.25 [95%CI, 4.82-5.72]). Both ranibizumab and bevacizumab produced hypertension (sROR, 1.73 [95%CI, 1.41-2.12] vs sROR, 1.46 [95%CI, 1.03-2.06]) and arrhythmias (sROR, 2.82 [95%CI, 1.99-3.99] vs sROR, 2.13 [95%CI, 1.08-4.22]) signals. The signals of heart failure were detected in ranibizumab (sROR, 5.64 [95%CI, 4.08-7.79]) and aflibercept (sROR, 2.80 [95%CI, 2.03-3.86]). Ranibizumab, bevacizumab, and aflibercept for ocular disease have different safety profiles in cardiovascular and cerebrovascular. The overall cardiovascular and cerebrovascular risk of the patient should be thoroughly assessed in order to select the safest drug for treatment.</dcterms:abstract>
        <dc:date>2023</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079838</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2023338030&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>909-917</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1233">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2022465036&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1755-5949"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shu</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ding</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>Q.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1234"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data analysis</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>odds ratio</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>cardiovascular disease</dc:subject>
        <dc:subject>disproportionality analysis</dc:subject>
        <dc:subject>health care personnel</dc:subject>
        <dc:subject>2ND-GENERATION ANTIPSYCHOTICS</dc:subject>
        <dc:subject>ANTIDEPRESSANTS</dc:subject>
        <dc:subject>Antipsychotic Agents</dc:subject>
        <dc:subject>ATYPICAL ANTIPSYCHOTICS</dc:subject>
        <dc:subject>bipolar disorder</dc:subject>
        <dc:subject>Bipolar Disorder</dc:subject>
        <dc:subject>bradycardia</dc:subject>
        <dc:subject>Brugada syndrome</dc:subject>
        <dc:subject>cardiac adverse events</dc:subject>
        <dc:subject>cardiogenic shock</dc:subject>
        <dc:subject>cardiomyopathy</dc:subject>
        <dc:subject>cardiopulmonary insufficiency</dc:subject>
        <dc:subject>cardiovascular risk</dc:subject>
        <dc:subject>CHILDREN</dc:subject>
        <dc:subject>cyanosis</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>depression</dc:subject>
        <dc:subject>dilated cardiomyopathy</dc:subject>
        <dc:subject>dizziness</dc:subject>
        <dc:subject>drug induced disease</dc:subject>
        <dc:subject>DRUGS</dc:subject>
        <dc:subject>epidemiology</dc:subject>
        <dc:subject>FAERS</dc:subject>
        <dc:subject>faintness</dc:subject>
        <dc:subject>heart arrest</dc:subject>
        <dc:subject>heart arrhythmia</dc:subject>
        <dc:subject>heart atrium septum defect</dc:subject>
        <dc:subject>heart palpitation</dc:subject>
        <dc:subject>heart right bundle branch block</dc:subject>
        <dc:subject>heart ventricle arrhythmia</dc:subject>
        <dc:subject>heart ventricle extrasystole</dc:subject>
        <dc:subject>heart ventricle fibrillation</dc:subject>
        <dc:subject>heart ventricle septum defect</dc:subject>
        <dc:subject>heart ventricle tachycardia</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>long QT syndrome</dc:subject>
        <dc:subject>mitigation</dc:subject>
        <dc:subject>myocarditis</dc:subject>
        <dc:subject>neuroleptic agent</dc:subject>
        <dc:subject>patent ductus arteriosus</dc:subject>
        <dc:subject>positional dizziness</dc:subject>
        <dc:subject>QTC INTERVAL PROLONGATION</dc:subject>
        <dc:subject>quetiapine</dc:subject>
        <dc:subject>Quetiapine Fumarate</dc:subject>
        <dc:subject>RISK</dc:subject>
        <dc:subject>schizophrenia</dc:subject>
        <dc:subject>side effect assessment</dc:subject>
        <dc:subject>sinus tachycardia</dc:subject>
        <dc:subject>supraventricular premature beat</dc:subject>
        <dc:subject>supraventricular tachycardia</dc:subject>
        <dc:subject>tachycardia</dc:subject>
        <dc:subject>TORSADE</dc:subject>
        <dc:subject>torsade de pointes</dc:subject>
        <dc:subject>tricuspid valve disease</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>United States Food and Drug Administration</dc:subject>
        <dc:title>Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system</dc:title>
        <dcterms:abstract>Objective: Quetiapine, an atypical second-generation antipsychotic drug, is approved for treatment of schizophrenia, bipolar disorder, and depression. Due to the limitations of clinical trials, the association between quetiapine and rare cardiac adverse events (AEs) is still unclear. This study is to evaluate quetiapine-associated cardiac AEs through data mining of FDA Adverse Event Reporting System (FAERS). Methods: Reporting odds ratio (ROR) was used to quantify the signals of quetiapine-related cardiac AEs from the first quarter (Q1) of 2018–2022 Q1. Serious and nonserious cases were compared, and signals were prioritized using a rating scale. Results: A total of 1004 cases of quetiapine-associated cardiac AEs were identified, with 31 signals being detected, among which 13 AEs were identified as new and unexpected signals. Besides, nine and 22 cardiac AEs were identified as moderate and weak clinical priority. The median TTO for moderate and weak clinical priority signals were 0 and 4 days, respectively. All of the cardiac AEs had early failure type characteristics, suggesting that most of the patients developed cardiac AEs in a few days after quetiapine treatment, and that the risk of cardiac AEs occurrence would be gradually decreased over time. Conclusion: Our study provided valuable evidence for health-care professionals to mitigate the risk of quetiapine-associated cardiac AEs based on an extensive analysis of a real-world, large-sample FAERS database, and prioritize cardiac AE signals.</dcterms:abstract>
        <dc:date>2023</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079837</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2022465036&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>2705-2716</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1755-5949">
        <prism:volume>29</prism:volume>
        <dc:title>CNS Neuroscience and Therapeutics</dc:title>
        <dc:identifier>DOI 10.1111/cns.14215</dc:identifier>
        <prism:number>9</prism:number>
        <dcterms:alternative>CNS Neurosci. Ther.</dcterms:alternative>
        <dc:identifier>ISSN 1755-5949</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1234">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 19; Correspondence Address: L. Liu; School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, No. 92 Weijin Road Nankai District, 300072, China; email: 15002691112@163.com; Q. Zhang; Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, No.1277 Jiefang Avenue, 430022, China; email: qilinzhang88@163.com&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;18&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;19&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;43&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2024957374&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1433-2965"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shi</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Cheng</foaf:surname>
                        <foaf:givenName>Q.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhao</foaf:surname>
                        <foaf:givenName>Y.-Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zou</foaf:surname>
                        <foaf:givenName>S.-P.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sun</foaf:surname>
                        <foaf:givenName>M.-H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1235"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>factual database</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>postmarketing surveillance</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>age distribution</dc:subject>
        <dc:subject>arthralgia</dc:subject>
        <dc:subject>contusion</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>injection site erythema</dc:subject>
        <dc:subject>injection site pain</dc:subject>
        <dc:subject>injection site pruritus</dc:subject>
        <dc:subject>injection site rash</dc:subject>
        <dc:subject>injection site reaction</dc:subject>
        <dc:subject>myalgia</dc:subject>
        <dc:subject>dizziness</dc:subject>
        <dc:subject>heart arrhythmia</dc:subject>
        <dc:subject>heart palpitation</dc:subject>
        <dc:subject>abaloparatide</dc:subject>
        <dc:subject>abdominal pain</dc:subject>
        <dc:subject>abnormal sensation</dc:subject>
        <dc:subject>alkaline phosphatase</dc:subject>
        <dc:subject>alkaline phosphatase blood level</dc:subject>
        <dc:subject>arthropathy</dc:subject>
        <dc:subject>backache</dc:subject>
        <dc:subject>body weight gain</dc:subject>
        <dc:subject>bone pain</dc:subject>
        <dc:subject>clinical practice</dc:subject>
        <dc:subject>constipation</dc:subject>
        <dc:subject>disease severity</dc:subject>
        <dc:subject>fatigue</dc:subject>
        <dc:subject>fragility fracture</dc:subject>
        <dc:subject>gastrointestinal discomfort</dc:subject>
        <dc:subject>gingiva disease</dc:subject>
        <dc:subject>gingiva erythema</dc:subject>
        <dc:subject>hair disease</dc:subject>
        <dc:subject>headache</dc:subject>
        <dc:subject>heart rate</dc:subject>
        <dc:subject>hypercalcemia</dc:subject>
        <dc:subject>hyperphosphatemia</dc:subject>
        <dc:subject>impaired fracture healing</dc:subject>
        <dc:subject>injection site bleeding</dc:subject>
        <dc:subject>injection site contusion</dc:subject>
        <dc:subject>injection site discoloration</dc:subject>
        <dc:subject>injection site discomfort</dc:subject>
        <dc:subject>injection site hypersensitivity</dc:subject>
        <dc:subject>injection site irritation</dc:subject>
        <dc:subject>injection site urticaria</dc:subject>
        <dc:subject>insomnia</dc:subject>
        <dc:subject>jaw pain</dc:subject>
        <dc:subject>limb pain</dc:subject>
        <dc:subject>muscle spasm</dc:subject>
        <dc:subject>muscle tightness</dc:subject>
        <dc:subject>nail disease</dc:subject>
        <dc:subject>nausea</dc:subject>
        <dc:subject>neck pain</dc:subject>
        <dc:subject>nervousness</dc:subject>
        <dc:subject>observational study</dc:subject>
        <dc:subject>orthostatic hypertension</dc:subject>
        <dc:subject>orthostatic hypotension</dc:subject>
        <dc:subject>osteoporosis</dc:subject>
        <dc:subject>Paget bone disease</dc:subject>
        <dc:subject>pain</dc:subject>
        <dc:subject>paranasal sinus disease</dc:subject>
        <dc:subject>parathyroid disease</dc:subject>
        <dc:subject>parathyroid hormone</dc:subject>
        <dc:subject>pollakisuria</dc:subject>
        <dc:subject>postmenopause osteoporosis</dc:subject>
        <dc:subject>rheumatoid arthritis</dc:subject>
        <dc:subject>risk benefit analysis</dc:subject>
        <dc:subject>risk reduction</dc:subject>
        <dc:subject>senile osteoporosis</dc:subject>
        <dc:subject>sensory dysfunction</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>skin tumor</dc:subject>
        <dc:subject>sleep disorder</dc:subject>
        <dc:subject>soft tissue tumor</dc:subject>
        <dc:subject>spinal pain</dc:subject>
        <dc:subject>stomach distension</dc:subject>
        <dc:subject>tinnitus</dc:subject>
        <dc:subject>tooth pain</dc:subject>
        <dc:subject>trichorrhexis</dc:subject>
        <dc:subject>vertigo</dc:subject>
        <dc:subject>visual acuity</dc:subject>
        <dc:subject>visual impairment</dc:subject>
        <dc:subject>vomiting</dc:subject>
        <dc:subject>waist circumference</dc:subject>
        <dc:title>A real-world pharmacovigilance study of abaloparatide based on the FDA Adverse Event Reporting System (FAERS)</dc:title>
        <dcterms:abstract>Summary: Abaloparatide (ABL) is a US Food and Drug Administration-approved parathyroid hormone-related peptide analog for treatment of osteoporosis in postmenopausal women at high risk of fracture. However, real-world data regarding its long-term safety and tolerability in large sample population are incomplete. We evaluated abaloparatide-associated safety signals by data mining of the FDA pharmacovigilance database. Introduction: We investigated 33,480(0.14%) ABL-related adverse events (AEs) through data mining of Food and Drug Administration Adverse Event Reporting System (FAERS) retrospectively. Methods: Reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi-item gamma Poisson shrinker (MGPS) were employed to quantify the signals of ABL-related AEs from 2017Quarter2 to 2022.Serious and non-serious cases were compared by Mann-Whitney U test or Chi-squared (χ 2) test. Results: We collected 8,470,497 reports from the FAERS database, including 11,487 reports defined ABL as the primary suspected (PS) drug. Additionally, 36.16% of the reports were submitted by healthcare professionals (n=4154), compared to 62.26% reported by consumers (n=7140). A total 99 signals simultaneously conforming to four algorithms were detected, among which, 35 signals were identified as unexpected signals. Such as growing pains (n=13), waist circumference increased (n=21), sensory disturbance (n=103), tinnitus (n=65), visual acuity reduced (n=54), blood alkaline phosphatase increased (n=61), and hair growth abnormal (n=13). Patient age (p &lt; 0.001) might be associated with an increased risk of AEs severity. The most common timeframe for AE occurrence was 0–7 days. Conclusion: Our study provided a deeper and broader understanding of abaloparatide’s safety profiles, which would help healthcare professionals to mitigate the risk of AEs in clinical practice, a low number of unexpected AEs supporting ongoing additional pharmacovigilance.</dcterms:abstract>
        <dc:date>2023</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079835</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2024957374&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>2047-2058</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1433-2965">
        <prism:volume>34</prism:volume>
        <dc:title>Osteoporosis International</dc:title>
        <dc:identifier>DOI 10.1007/s00198-023-06877-6</dc:identifier>
        <prism:number>12</prism:number>
        <dcterms:alternative>Osteoporosis Int.</dcterms:alternative>
        <dc:identifier>ISSN 1433-2965</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1235">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2032800452&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>15</prism:volume>
                <dc:title>Frontiers in Pharmacology</dc:title>
                <dc:identifier>DOI 10.3389/fphar.2024.1486422</dc:identifier>
                <dcterms:alternative>Front. Pharmacol.</dcterms:alternative>
                <dc:identifier>ISSN 1663-9812</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lu</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xu</foaf:surname>
                        <foaf:givenName>Q.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhu</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1236"/>
        <dc:subject>acute kidney failure</dc:subject>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>*Pharmacovigilance</dc:subject>
        <dc:subject>acute heart failure</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>Adolescent</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>adverse event reporting system</dc:subject>
        <dc:subject>adverse events</dc:subject>
        <dc:subject>age distribution</dc:subject>
        <dc:subject>Aged</dc:subject>
        <dc:subject>Algorithms</dc:subject>
        <dc:subject>ambrisentan</dc:subject>
        <dc:subject>antidepressant agent</dc:subject>
        <dc:subject>antiinfective agent</dc:subject>
        <dc:subject>artificial neural network</dc:subject>
        <dc:subject>Bayes Theorem</dc:subject>
        <dc:subject>biology</dc:subject>
        <dc:subject>cerebrovascular accident</dc:subject>
        <dc:subject>Chemical and Drug Induced Liver Injury</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>Child</dc:subject>
        <dc:subject>citalopram</dc:subject>
        <dc:subject>arthralgia</dc:subject>
        <dc:subject>CHILDREN</dc:subject>
        <dc:subject>abdominal pain</dc:subject>
        <dc:subject>backache</dc:subject>
        <dc:subject>bevacizumab</dc:subject>
        <dc:subject>*Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>*Child, Hospitalized</dc:subject>
        <dc:subject>*Drug Interactions</dc:subject>
        <dc:subject>*Neural Networks, Computer</dc:subject>
        <dc:subject>*Pattern Recognition, Automated</dc:subject>
        <dc:subject>*Support Vector Machine</dc:subject>
        <dc:subject>*United States Food and Drug Administration</dc:subject>
        <dc:subject>accuracy</dc:subject>
        <dc:subject>acetylcholinesterase</dc:subject>
        <dc:subject>ACETYLCHOLINESTERASE</dc:subject>
        <dc:subject>acetylcysteine</dc:subject>
        <dc:subject>acne</dc:subject>
        <dc:subject>actemra</dc:subject>
        <dc:subject>ACUTE LIVER-FAILURE</dc:subject>
        <dc:subject>adalimumab</dc:subject>
        <dc:subject>adverse drug reaction analysis</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems/*trends</dc:subject>
        <dc:subject>aggression</dc:subject>
        <dc:subject>agitation</dc:subject>
        <dc:subject>alendronic acid</dc:subject>
        <dc:subject>Alzheimer disease</dc:subject>
        <dc:subject>Alzheimer Disease</dc:subject>
        <dc:subject>Alzheimer's disease</dc:subject>
        <dc:subject>Alzheimer&amp;apos</dc:subject>
        <dc:subject>amfebutamone</dc:subject>
        <dc:subject>amiodarone</dc:subject>
        <dc:subject>amoxicillin</dc:subject>
        <dc:subject>AMOXICILLIN</dc:subject>
        <dc:subject>analgesic agent</dc:subject>
        <dc:subject>angiotensin 2 receptor antagonist</dc:subject>
        <dc:subject>animal</dc:subject>
        <dc:subject>Animals</dc:subject>
        <dc:subject>anticholinesterase drugs</dc:subject>
        <dc:subject>anticoagulant agent</dc:subject>
        <dc:subject>antidiabetic agent</dc:subject>
        <dc:subject>antihypertensive agent</dc:subject>
        <dc:subject>antilipemic agent</dc:subject>
        <dc:subject>antineoplastic agent</dc:subject>
        <dc:subject>antirheumatic agent</dc:subject>
        <dc:subject>aripiprazole</dc:subject>
        <dc:subject>arthritis</dc:subject>
        <dc:subject>asenapine</dc:subject>
        <dc:subject>ASTHMA</dc:subject>
        <dc:subject>automated pattern recognition</dc:subject>
        <dc:subject>automation</dc:subject>
        <dc:subject>azithromycin</dc:subject>
        <dc:subject>basal cell carcinoma</dc:subject>
        <dc:subject>bayesian confidence propagation neural network</dc:subject>
        <dc:subject>Bayesian network</dc:subject>
        <dc:subject>benzatropine</dc:subject>
        <dc:subject>bicarbonate</dc:subject>
        <dc:subject>bile duct cancer</dc:subject>
        <dc:subject>bile duct carcinoma</dc:subject>
        <dc:subject>biological activity</dc:subject>
        <dc:subject>biological model</dc:subject>
        <dc:subject>BIOMEDICAL LITERATURE</dc:subject>
        <dc:subject>biomedical text mining</dc:subject>
        <dc:subject>blood clotting disorder</dc:subject>
        <dc:subject>body weight</dc:subject>
        <dc:subject>budesonide</dc:subject>
        <dc:subject>bupivacaine</dc:subject>
        <dc:subject>burn</dc:subject>
        <dc:subject>busulfan</dc:subject>
        <dc:subject>BUTYRYLCHOLINESTERASE</dc:subject>
        <dc:subject>caffeine</dc:subject>
        <dc:subject>CANCER</dc:subject>
        <dc:subject>cancer risk</dc:subject>
        <dc:subject>capecitabine</dc:subject>
        <dc:subject>carbidopa</dc:subject>
        <dc:subject>carboplatin</dc:subject>
        <dc:subject>cardiovascular agent</dc:subject>
        <dc:subject>cardiovascular system</dc:subject>
        <dc:subject>carfilzomib</dc:subject>
        <dc:subject>cataract</dc:subject>
        <dc:subject>causality</dc:subject>
        <dc:subject>cefprozil</dc:subject>
        <dc:subject>ceftriaxone</dc:subject>
        <dc:subject>celecoxib</dc:subject>
        <dc:subject>cerivastatin</dc:subject>
        <dc:subject>cetirizine</dc:subject>
        <dc:subject>cetylpyridinium salt</dc:subject>
        <dc:subject>Child, Hospitalized</dc:subject>
        <dc:subject>Child, Preschool</dc:subject>
        <dc:subject>chimeric antigen receptor</dc:subject>
        <dc:subject>chlorhexidine</dc:subject>
        <dc:subject>cholangitis</dc:subject>
        <dc:subject>cholestasis</dc:subject>
        <dc:subject>cholesterol blood level</dc:subject>
        <dc:subject>cholinesterase</dc:subject>
        <dc:subject>cholinesterase inhibitor</dc:subject>
        <dc:subject>ciprofloxacin</dc:subject>
        <dc:subject>clarithromycin</dc:subject>
        <dc:title>Drug-induced coagulopathies: a real-world pharmacovigilance study using the FDA adverse event reporting system</dc:title>
        <dcterms:abstract>Background: This study aims to investigate adverse drug reaction signals associated with coagulopathies through data mining using the Adverse Event Reporting System (FAERS) of the US Food and Drug Administration. Prompt identification of high-risk drugs provides a valuable basis for enhancing clinical drug safety. Methods: The adverse event reports related to coagulopathies from Q1 2004 to Q2 2024 were extracted from the ASCII data packages in FAERS. The reporting odds ratio (ROR), proportional reporting ratio (PRR), and Bayesian confidence propagation neural network (BCPNN) were used to identify adverse drug reaction signals associated with coagulopathies. Results: During the reporting period, 40,545 reports were retrieved, with a slightly higher proportion of females than males. Among the top 30 drugs associated with the occurrence of coagulopathies, 24 drugs exhibited positive signals in risk analysis. Based on the individual drug reporting odds ratio (95% confidence interval) as a measure of risk signal strength, the top five drugs are as follows: gemcitabine [ROR (95% CI):16.87 (15.83–17.98)], busulfan [ROR (95% CI):15.51 (13.69–17.58)], anti-thymocyte globulin [ROR (95% CI):15.49 (13.49–17.78)], tacrolimus [ROR (95% CI):12.7 (11.57–13.95)], etonogestrel and ethinylestradiol vaginal ring [ROR (95% CI):11.88 (10.95–12.89)]. After categorizing the drugs, the strongest risk signal is sex hormones and modulators of the genital system [ROR (95% CI):11.88 (10.95–12.89)], followed by analgesics [ROR (95%CI): 6.73 (6.38–7.1)], immunosuppressants [ROR (95% CI):3.91 (3.76–4.05)], antineoplastic agents [ROR (95% CI):3.33 (3.22–3.45)], corticosteroids for systemic use [ROR (95% CI): 2.94 (2.73–3.18)], antiepileptics [ROR (95% CI):1.93 (1.71–2.18)], drugs used in diabetes [ROR (95% CI):1.5 (1.34–1.67)], antibacterials for systemic use [ROR (95% CI):1.46 (1.28–1.68)]. Conclusion: Our findings indicate that multiple drugs are associated with an increased risk of coagulopathies. From the pharmacovigilance perspective, proactive analysis of these drugs aids in clinical monitoring and enhances risk identification of coagulopathies.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079834</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2032800452&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Memo rdf:about="#item_1236">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: H. Gao; Shengli Clinical College of Fujian Medical University, Department of Pharmacy, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China; email: 13763806058@163.com; M. Chen; Shengli Clinical College of Fujian Medical University, Department of Pharmacy, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China; email: 9201951091@fjmu.edu.cn&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: S. Wang; Department of Pharmacy, Children’s Hospital of Nanjing Medical University, Nanjing, No. 72, Guangzhou Road, Gulou District, Jiangsu, China; email: 13770548609@163.com; CODEN: EODSA&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: Y. Lu; Pharmacy Department, Xiamen Fifth Hospital, Xiamen, Fujian, China; email: 13792830916@163.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 1; Correspondence Address: C. Sun; Department of Gastroenterology, Ningbo Hospital of Traditional Chinese Medicine, Affiliated to Zhejiang Chinese Medical University, Ningbo, China; email: changbosun2008@163.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 2; Correspondence Address: G.-R. Fan; Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China; email: fanguorong@sjtu.edu.cn; CODEN: JCPTE&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 4; Correspondence Address: M. Russom; Eritrean Pharmacovigilance Centre, National Medicines and Food Administration, Ministry of Health, Asmara, Eritrea; email: satiswt@gmail.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 4; Correspondence Address: R.M. Rishoej; Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark; email: rmrishoj@health.sdu.dk; CODEN: BCPTB&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 5; Correspondence Address: Q. Yang; Department of Pharmacy, Shanghai Children’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200062, China; email: yangql@shchildren.com.cn; Z. Li; Department of Pharmacy, Shanghai Children’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200062, China; email: lizhiling22@163.com; CODEN: BIDMB&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 6; Correspondence Address: A. Tropsha; Laboratory for Molecular Modeling, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, 27599, United States; email: alex_tropsha@unc.edu; CODEN: MIONB&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 11; Correspondence Address: Y. Liu; Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing, No. 10 Changjiang Branch Road, Yuzhong District, 400042, China; email: swhliuyao@163.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 13; Correspondence Address: P. Liu; Department of Cardiology, Yantai Yuhuangding Hospital Affiliated to Qingdao University, Yantai, China; email: 7730909@qq.com; C. Guo; Department of Pharmacy, Yantai Yuhuangding Hospital Affiliated to Qingdao University, Yantai, China; email: shgcy@vip.qq.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 20; Correspondence Address: J.-P. Jourdan; Department of Pharmacy, Caen University Hospital, Caen, F-14000, France; email: jean-pierre.jourdan@unicaen.fr; CODEN: BCPHB&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 28; Correspondence Address: S. Proestel; Division of Epidemiology, Office of Biostatistics and Epidemiology, FDA Center for Biologics Evaluation and Research, Silver Spring, White Oak Building 71, 1260, 10903 New Hampshire Avenue, 20993, United States; email: Scott.Proestel@fda.hhs.gov; CODEN: JAMAF&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 36; Correspondence Address: F. Wang; Division of Health Informatics, Department of Healthcare Policy and Research, Weill Cornell Medicine at Cornell University, New York, 425 East 61st Street, DV-308, 10065, United States; email: few2001@med.cornell.edu&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 81; Correspondence Address: J. Kang; Department of Computer Science and Engineering, Korea University, Seoul, South Korea; email: kangj@korea.ac.kr; CODEN: POLNC&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 142; Correspondence Address: Y. Zhang; College of Computer Science and Technology, Dalian University of Technology, Dalian, 116023, China; email: zhyj@dlut.edu.cn; CODEN: BOINF&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;40&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;40&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;92&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;31&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;33&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;58&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;4&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;4&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;44&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;12&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;12&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;42&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;12&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;12&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;57&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;14&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;14&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;46&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;18&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;18&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;58&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;24&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;27&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;28&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;29&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;31&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;117&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2032628347&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>15</prism:volume>
                <dc:title>Frontiers in Pharmacology</dc:title>
                <dc:identifier>DOI 10.3389/fphar.2024.1439781</dc:identifier>
                <dcterms:alternative>Front. Pharmacol.</dcterms:alternative>
                <dc:identifier>ISSN 1663-9812</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tang</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1237"/>
        <dc:subject>acute kidney failure</dc:subject>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>Adolescent</dc:subject>
        <dc:subject>Adult</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>Adverse drug reactions</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>adverse events</dc:subject>
        <dc:subject>Aged</dc:subject>
        <dc:subject>alanine aminotransferase</dc:subject>
        <dc:subject>Anti-Bacterial Agents</dc:subject>
        <dc:subject>antiinfective agent</dc:subject>
        <dc:subject>aspartate aminotransferase</dc:subject>
        <dc:subject>Bayes Theorem</dc:subject>
        <dc:subject>bilirubin</dc:subject>
        <dc:subject>bilirubin blood level</dc:subject>
        <dc:subject>cardiotoxicity</dc:subject>
        <dc:subject>cardiovascular disease</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>Child</dc:subject>
        <dc:subject>cohort analysis</dc:subject>
        <dc:subject>Cohort Studies</dc:subject>
        <dc:subject>arthralgia</dc:subject>
        <dc:subject>cardiomyopathy</dc:subject>
        <dc:subject>cardiovascular risk</dc:subject>
        <dc:subject>abdominal pain</dc:subject>
        <dc:subject>alkaline phosphatase</dc:subject>
        <dc:subject>backache</dc:subject>
        <dc:subject>body weight gain</dc:subject>
        <dc:subject>bone pain</dc:subject>
        <dc:subject>clinical practice</dc:subject>
        <dc:subject>constipation</dc:subject>
        <dc:subject>congestive heart failure</dc:subject>
        <dc:subject>amoxicillin</dc:subject>
        <dc:subject>antidiabetic agent</dc:subject>
        <dc:subject>azithromycin</dc:subject>
        <dc:subject>2,4 thiazolidinedione derivative</dc:subject>
        <dc:subject>4CMenB vaccine</dc:subject>
        <dc:subject>abdominal distension</dc:subject>
        <dc:subject>acquired immune deficiency syndrome</dc:subject>
        <dc:subject>acute disseminated encephalomyelitis</dc:subject>
        <dc:subject>acute sinusitis</dc:subject>
        <dc:subject>Administration, Oral</dc:subject>
        <dc:subject>ADOLESCENTS</dc:subject>
        <dc:subject>adverse drug reactions</dc:subject>
        <dc:subject>adverse drug reactions (ADRs)</dc:subject>
        <dc:subject>Adverse event</dc:subject>
        <dc:subject>Adverse Event</dc:subject>
        <dc:subject>Adverse events</dc:subject>
        <dc:subject>ADVISORY-COMMITTEE</dc:subject>
        <dc:subject>albumin</dc:subject>
        <dc:subject>albumin-bound paclitaxel</dc:subject>
        <dc:subject>Albumin-Bound Paclitaxel</dc:subject>
        <dc:subject>Albumins</dc:subject>
        <dc:subject>ALERT</dc:subject>
        <dc:subject>allergic reaction</dc:subject>
        <dc:subject>allergy</dc:subject>
        <dc:subject>alogliptin</dc:subject>
        <dc:subject>alopecia</dc:subject>
        <dc:subject>alpha glucosidase inhibitor</dc:subject>
        <dc:subject>Amoxicillin</dc:subject>
        <dc:subject>anaphylaxis</dc:subject>
        <dc:subject>anemia</dc:subject>
        <dc:subject>antibiotic agent</dc:subject>
        <dc:subject>ANTIBIOTIC USE</dc:subject>
        <dc:subject>ANTIMICROBIAL RESISTANCE</dc:subject>
        <dc:subject>antiretroviral therapy</dc:subject>
        <dc:subject>antiviral resistance</dc:subject>
        <dc:subject>Aspect</dc:subject>
        <dc:subject>asthenia</dc:subject>
        <dc:subject>atelectasis</dc:subject>
        <dc:subject>autopsy</dc:subject>
        <dc:subject>bexsero</dc:subject>
        <dc:subject>Big Data</dc:subject>
        <dc:subject>biguanide</dc:subject>
        <dc:subject>blurred vision</dc:subject>
        <dc:subject>body fat distribution</dc:subject>
        <dc:subject>bone disease</dc:subject>
        <dc:subject>breast cancer</dc:subject>
        <dc:subject>Breast Neoplasms</dc:subject>
        <dc:subject>breast tumor</dc:subject>
        <dc:subject>bursitis</dc:subject>
        <dc:subject>cancer chemotherapy</dc:subject>
        <dc:subject>cancer patient</dc:subject>
        <dc:subject>cancer staging</dc:subject>
        <dc:subject>CARBAPENEMS</dc:subject>
        <dc:subject>CARDIOTOXICITY</dc:subject>
        <dc:subject>Cardiovascular disease</dc:subject>
        <dc:subject>Cardiovascular Diseases</dc:subject>
        <dc:subject>CASE-DEFINITION</dc:subject>
        <dc:subject>CD4 lymphocyte count</dc:subject>
        <dc:subject>cellulitis</dc:subject>
        <dc:subject>chemically induced</dc:subject>
        <dc:subject>chemotherapy</dc:subject>
        <dc:subject>CHEMOTHERAPY</dc:subject>
        <dc:subject>chill</dc:subject>
        <dc:subject>cholesterol</dc:subject>
        <dc:subject>CLASSIFICATION</dc:subject>
        <dc:subject>cobicistat plus elvitegravir plus emtricitabine plus tenofovir alafenamide</dc:subject>
        <dc:subject>COLLECTION</dc:subject>
        <dc:subject>COMPLICATED INTRAABDOMINAL INFECTIONS</dc:subject>
        <dc:subject>CONSUMPTION</dc:subject>
        <dc:subject>conversion disorder</dc:subject>
        <dc:subject>COVID-19</dc:subject>
        <dc:subject>creatinine</dc:subject>
        <dc:subject>Crohn disease</dc:subject>
        <dc:subject>Cushing syndrome</dc:subject>
        <dc:subject>data analysis software</dc:subject>
        <dc:subject>Data mining</dc:subject>
        <dc:subject>Data Mining</dc:subject>
        <dc:subject>DATA MINING METHODS</dc:subject>
        <dc:subject>Data Mining/*methods</dc:subject>
        <dc:subject>Databases, Factual</dc:subject>
        <dc:subject>decision making</dc:subject>
        <dc:subject>Decision Making</dc:subject>
        <dc:subject>dehydration</dc:subject>
        <dc:subject>diarrhea</dc:subject>
        <dc:subject>digestive tube</dc:subject>
        <dc:subject>dipeptidyl peptidase IV inhibitor</dc:subject>
        <dc:title>Signal detection and analysis of adverse events associated with Genvoya® based the FAERS database</dc:title>
        <dcterms:abstract>Objective: This study aims to evaluate and understand the safety profile of Genvoya® by mining and analyzing adverse drug event (ADE, adverse drug event) reports from the FDA Adverse Event Reporting System (FAERS, FDA Adverse Event Reporting System) database, thus providing valuable reference information for individuals infected with HIV. Methods: Data were obtained from the FAERS database, covering the period from the first quarter of 2015 to the fourth quarter of 2023, focusing on reports where Genvoya® was the primary suspected drug. Data import and extraction were conducted using MySQL 8.0, with adverse events standardized according to the Medical Dictionary for Regulatory Activities (MedDRA, Medical Dictionary for Regulatory Activities) 27.0 terminology. Potential adverse event signals were identified through disproportionality analysis, including the reporting odds ratio (ROR, reporting odds ratio) method and the comprehensive standard by the Medicines and Healthcare products Regulatory Agency (MHRA, Medicines and Healthcare products Regulatory Agency) method. Statistical analyses and graphical representations were performed. Results: A total of 2, 376 adverse drug event reports related to Genvoya® were analyzed. Reports from male patients accounted for 74.33%, while those from female patients accounted for 22.39%. Common adverse events included weight gain, drug interactions, and increased viral load. Additionally, new potential adverse reactions, such as fat redistribution, HIV-associated neurocognitive disorders, and meningoencephalitis, were identified. These reactions were not adequately described in the existing literature and drug labels. Conclusion: Multiple adverse reactions were observed with the use of Genvoya®. Clinicians should closely monitor these reactions and implement necessary preventive and intervention measures based on patient-specific conditions and treatment guidelines. Although this study has limitations, the analysis of FAERS database data has revealed various potential risks associated with Genvoya®, providing important safety references for HIV treatment.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079833</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2032628347&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Memo rdf:about="#item_1237">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: L. Chen; Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China; email: chenl_hxey@scu.edu.cn&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 2; Correspondence Address: Y.-F. Kuo; Galveston, 700 Harborside Drive, Ewing Hall, 1.134, 77555-1148, United States; email: yokuo@utmb.edu; CODEN: OCOLF&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 3; Correspondence Address: X. Liu; Department of Gastrointestinal Surgery, The Fifth People's Hospital of Chongqing, Chongqing, 400062, China; email: 20052607@qq.com; CODEN: INJPD&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 4; Correspondence Address: H. Osama; Department of Clinical Pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni Suef, Egypt; email: hasnaa_osama2010@yahoo.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 6; Correspondence Address: S. Perez-Vilar; U.S. Food and Drug Administration, Silver Spring, 10903 New Hampshire Ave., Bldg. 22, Room 2481, 20993-0002, United States; email: silvia.perezvilar@fda.hhs.gov; CODEN: VACCD&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 8; Correspondence Address: J. Duffy; Immunization Safety Office (MS V18-4), Centers for Disease Control and Prevention, Atlanta, 1600 Clifton Road, 30329, United States; email: jduffy@cdc.gov&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 12; Correspondence Address: J.-Y. Shin; School of Pharmacy, Sungkyunkwan University, Suwon, 2066 Seobu-ro, Jangan-gu, 16419, South Korea; email: shin.jy@skku.edu; CODEN: YOMJA&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 13; Correspondence Address: B.-J. Park; Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, 103 Daehak-ro, Jongno-gu, 03080, South Korea; email: bjpark@snu.ac.kr; CODEN: YOMJA&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 14; Correspondence Address: C. Sharma; Rheumatology, Fiona Stanley Hospital, Perth, Australia; email: chanakya_s@hotmail.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 15; Correspondence Address: B.-J. Park; Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, 103 Daehak-ro, Jongno-gu, 03080, South Korea; email: bjpark@snu.ac.kr; CODEN: JKMSE&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 43; Correspondence Address: A.H. Sweidan; Faculty of Computers and Information, Fayoum University, Faiyum, Egypt; email: aha07@fayoum.edu.eg&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;26&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;3&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;3&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;26&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;3&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;4&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;17&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;4&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;5&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;40&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;7&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;7&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;41&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;9&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;11&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;27&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;14&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;14&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;32&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;15&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;15&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;36&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;26&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;27&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;51&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2031873437&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>23</prism:volume>
                <dc:title>Expert Opinion on Drug Safety</dc:title>
                <dc:identifier>DOI 10.1080/14740338.2024.2416540</dc:identifier>
                <prism:number>12</prism:number>
                <dcterms:alternative>Expert Opin. Drug Saf.</dcterms:alternative>
                <dc:identifier>ISSN 1744-764X</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xu</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Huang</foaf:surname>
                        <foaf:givenName>W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xie</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ouyang</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1241"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>incidence</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>risk factor</dc:subject>
        <dc:subject>acute coronary syndrome</dc:subject>
        <dc:subject>arterial thromboembolism</dc:subject>
        <dc:subject>brain infarction</dc:subject>
        <dc:subject>deep vein thrombosis</dc:subject>
        <dc:subject>heart infarction</dc:subject>
        <dc:subject>venous thromboembolism</dc:subject>
        <dc:subject>agonist</dc:subject>
        <dc:subject>avatrombopag</dc:subject>
        <dc:subject>cerebral sinus thrombosis</dc:subject>
        <dc:subject>coronary artery thrombosis</dc:subject>
        <dc:subject>coronary occlusion</dc:subject>
        <dc:subject>corticosteroid</dc:subject>
        <dc:subject>eltrombopag</dc:subject>
        <dc:subject>fatality</dc:subject>
        <dc:subject>immunoglobulin</dc:subject>
        <dc:subject>kidney vein thrombosis</dc:subject>
        <dc:subject>lung embolism</dc:subject>
        <dc:subject>portal vein thrombosis</dc:subject>
        <dc:subject>risk assessment</dc:subject>
        <dc:subject>rituximab</dc:subject>
        <dc:subject>romiplostim</dc:subject>
        <dc:subject>thromboembolism</dc:subject>
        <dc:subject>thrombopoietin receptor</dc:subject>
        <dc:subject>very elderly</dc:subject>
        <dc:title>Thromboembolism adverse event profiles of thrombopoietin receptor agonists: a real-world, pharmacovigilance study</dc:title>
        <dcterms:abstract>Background: Thrombopoietin receptor agonists (TPO-RAs) are currently approved for the treatment of thrombocytopenia in different conditions. The relationship between TPO-RAs and thromboembolic events (TEEs) remains controversial. Research design and methods: We extracted TPO-RAs adverse reaction reports after their marketing until now, using the FDA adverse event reporting system (FAERS). Positive signals were detected by reporting odds ratios (RORs). And the Weibull shape parameter test was utilized to analyze the time-to-onset profiles. Result: Thromboembolic events accounted for 8.97% among TPO-RAs reports. Increased reporting of TEEs was related to TPO-RAs treatment compared with the entire FAERS database [ROR = 2.65 (2.56, 2.73)]. In addition, venous thrombotic events [ROR = 4.13 (3.92, 4.35)] were reported more frequently than arterial events ROR = 1.81 (1.7, 1.93)]. Age over 60 years [odds ratio (OR) = 1.10 (1.01, 1.20), p = 0.029] and weight over 80 kg [OR = 1.36 (1.17, 1.58), p &lt; 0.001] of patients might have higher risk of TEEs during TPO-RAs therapy. Conclusion: Evidence from the real world suggested that TPO-RAs were associated with higher incidence of TEEs, particularly venous thrombosis. The risk of TPO-RAs-associated TEEs mostly happened in the early stages of treatment and decreased over time.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079832</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2031873437&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>1531-1543</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1241">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2031719308&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>23</prism:volume>
                <dc:title>Expert Opinion on Drug Safety</dc:title>
                <dc:identifier>DOI 10.1080/14740338.2024.2410436</dc:identifier>
                <prism:number>11</prism:number>
                <dcterms:alternative>Expert Opin. Drug Saf.</dcterms:alternative>
                <dc:identifier>ISSN 1744-764X</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhong</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zheng</foaf:surname>
                        <foaf:givenName>Q.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhao</foaf:surname>
                        <foaf:givenName>B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ren</foaf:surname>
                        <foaf:givenName>T.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1238"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>incidence</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>age distribution</dc:subject>
        <dc:subject>apparent life threatening event</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>sex difference</dc:subject>
        <dc:subject>breast cancer</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>acidosis</dc:subject>
        <dc:subject>ascites</dc:subject>
        <dc:subject>cancer therapy</dc:subject>
        <dc:subject>computer language</dc:subject>
        <dc:subject>congenital malformation</dc:subject>
        <dc:subject>disseminated intravascular clotting</dc:subject>
        <dc:subject>drug fatality</dc:subject>
        <dc:subject>drug indication</dc:subject>
        <dc:subject>groups by age</dc:subject>
        <dc:subject>hemorrhagic cystitis</dc:subject>
        <dc:subject>inappropriate vasopressin secretion</dc:subject>
        <dc:subject>lymphatic system disease</dc:subject>
        <dc:subject>malignant neoplasm</dc:subject>
        <dc:subject>microtubule</dc:subject>
        <dc:subject>multiple organ failure</dc:subject>
        <dc:subject>nerve cell network</dc:subject>
        <dc:subject>neurotoxicity</dc:subject>
        <dc:subject>pleura effusion</dc:subject>
        <dc:subject>polyneuropathy</dc:subject>
        <dc:subject>posterior reversible encephalopathy syndrome</dc:subject>
        <dc:subject>practice guideline</dc:subject>
        <dc:subject>prevalence</dc:subject>
        <dc:subject>sex ratio</dc:subject>
        <dc:subject>treatment duration</dc:subject>
        <dc:subject>treatment outcome</dc:subject>
        <dc:subject>vasopressin release</dc:subject>
        <dc:subject>vincristine</dc:subject>
        <dc:subject>vinorelbine tartrate</dc:subject>
        <dc:title>A real-world pharmacovigilance study using disproportionality analysis of United States Food and Drug Administration Adverse Event Reporting System events for vinca alkaloids: comparing vinorelbine and Vincristine</dc:title>
        <dcterms:abstract>Background: Vinca alkaloids are widely used in cancer treatment for their ability to target microtubule dynamics. While their efficacy in treating certain cancers is well-established, the full spectrum of their adverse event profiles remains an area of ongoing research. Methods: We analyzed AEs related to vinorelbine and vincristine using a retrospective case/non-case approach with data from the FDA Adverse Event Reporting System (FAERS). We applied various algorithms to detect AE signals: the reporting odds ratio (ROR) and proportional reporting ratio (PRR) measured disproportionality and association strength; the Bayesian confidence propagation neural network (BCPNN) calculated the Information Component (IC) for associations against background rates; and the multi-item gamma Poisson shrinker (MGPS) yielded empirical Bayes geometric mean (EBGM) values, accounting for reporting variability. Results: Both medications significantly involve the blood and lymphatic systems, with vinorelbine reporting 401 cases in this System Organ Class (SOC), exhibiting a ROR of 17.4, PRR of 12.4, IC of 3.63, and EBGM of 12.38. An intersection analysis of Preferred Terms (PTs) has uncovered previously unreported AEs shared by both drugs, including posterior reversible encephalopathy syndrome and inappropriate antidiuretic hormone secretion. Conclusions: This analysis highlights the need for ongoing research of the risks associated with vinorelbine and vincristine.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079830</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2031719308&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>1427-1437</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1238">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2031539141&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>15</prism:volume>
                <dc:title>Frontiers in Pharmacology</dc:title>
                <dc:identifier>DOI 10.3389/fphar.2024.1339721</dc:identifier>
                <dcterms:alternative>Front. Pharmacol.</dcterms:alternative>
                <dc:identifier>ISSN 1663-9812</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>He</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>R.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shen</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1239"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>death</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>incidence</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>young adult</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>adverse events</dc:subject>
        <dc:subject>arthralgia</dc:subject>
        <dc:subject>disability</dc:subject>
        <dc:subject>disproportionality analysis</dc:subject>
        <dc:subject>gingiva bleeding</dc:subject>
        <dc:subject>limb fracture</dc:subject>
        <dc:subject>myalgia</dc:subject>
        <dc:subject>FAERS</dc:subject>
        <dc:subject>arthropathy</dc:subject>
        <dc:subject>backache</dc:subject>
        <dc:subject>fragility fracture</dc:subject>
        <dc:subject>gingiva disease</dc:subject>
        <dc:subject>hypercalcemia</dc:subject>
        <dc:subject>jaw pain</dc:subject>
        <dc:subject>neck pain</dc:subject>
        <dc:subject>sleep disorder</dc:subject>
        <dc:subject>spinal pain</dc:subject>
        <dc:subject>bursitis</dc:subject>
        <dc:subject>cellulitis</dc:subject>
        <dc:subject>data analysis software</dc:subject>
        <dc:subject>congenital malformation</dc:subject>
        <dc:subject>malignant neoplasm</dc:subject>
        <dc:subject>abscess</dc:subject>
        <dc:subject>analysis</dc:subject>
        <dc:subject>ankle fracture</dc:subject>
        <dc:subject>azapropazone</dc:subject>
        <dc:subject>bone metastasis</dc:subject>
        <dc:subject>bone necrosis</dc:subject>
        <dc:subject>compression fracture</dc:subject>
        <dc:subject>cystitis</dc:subject>
        <dc:subject>denosumab</dc:subject>
        <dc:subject>dental caries</dc:subject>
        <dc:subject>dermatitis</dc:subject>
        <dc:subject>diverticulitis</dc:subject>
        <dc:subject>eczema</dc:subject>
        <dc:subject>exostosis</dc:subject>
        <dc:subject>face pain</dc:subject>
        <dc:subject>femoral neck fracture</dc:subject>
        <dc:subject>femur fracture</dc:subject>
        <dc:subject>food and drug administration adverse event reporting system</dc:subject>
        <dc:subject>gingiva pain</dc:subject>
        <dc:subject>gingivitis</dc:subject>
        <dc:subject>hip fracture</dc:subject>
        <dc:subject>humerus fracture</dc:subject>
        <dc:subject>hypercholesterolemia</dc:subject>
        <dc:subject>hyperesthesia</dc:subject>
        <dc:subject>hyperlipidemia</dc:subject>
        <dc:subject>hyperparathyroidism</dc:subject>
        <dc:subject>hypocalcemia</dc:subject>
        <dc:subject>hypophosphatemia</dc:subject>
        <dc:subject>inguinal pain</dc:subject>
        <dc:subject>jaw osteonecrosis</dc:subject>
        <dc:subject>kyprolia</dc:subject>
        <dc:subject>liver metastasis</dc:subject>
        <dc:subject>lumbar spine fracture</dc:subject>
        <dc:subject>lung metastasis</dc:subject>
        <dc:subject>metastatic breast cancer</dc:subject>
        <dc:subject>mouth infection</dc:subject>
        <dc:subject>mouth pain</dc:subject>
        <dc:subject>musculoskeletal pain</dc:subject>
        <dc:subject>nerve compression</dc:subject>
        <dc:subject>occupational exposure</dc:subject>
        <dc:subject>off label drug use</dc:subject>
        <dc:subject>oral paresthesia</dc:subject>
        <dc:subject>osteitis</dc:subject>
        <dc:subject>osteoarthritis</dc:subject>
        <dc:subject>osteoclastoma</dc:subject>
        <dc:subject>osteomyelitis</dc:subject>
        <dc:subject>osteonecrosis of the jaw</dc:subject>
        <dc:subject>otalgia</dc:subject>
        <dc:subject>pelvis fracture</dc:subject>
        <dc:subject>periodontal disease</dc:subject>
        <dc:subject>periodontitis</dc:subject>
        <dc:subject>pralia</dc:subject>
        <dc:subject>prolix</dc:subject>
        <dc:subject>prurigo</dc:subject>
        <dc:subject>R software</dc:subject>
        <dc:subject>radius fracture</dc:subject>
        <dc:subject>RANKL (receptor activator for nuclear factor k B ligand)</dc:subject>
        <dc:subject>ranmark</dc:subject>
        <dc:subject>rib fracture</dc:subject>
        <dc:subject>sciatica</dc:subject>
        <dc:subject>scoliosis</dc:subject>
        <dc:subject>skin infection</dc:subject>
        <dc:subject>spine fracture</dc:subject>
        <dc:subject>spine malformation</dc:subject>
        <dc:subject>temporomandibular joint disorder</dc:subject>
        <dc:subject>tetany</dc:subject>
        <dc:subject>thoracic spine fracture</dc:subject>
        <dc:subject>tibia fracture</dc:subject>
        <dc:subject>tooth disease</dc:subject>
        <dc:subject>tooth infection</dc:subject>
        <dc:subject>trismus</dc:subject>
        <dc:subject>vertebral canal stenosis</dc:subject>
        <dc:subject>vitamin D deficiency</dc:subject>
        <dc:subject>wrist fracture</dc:subject>
        <dc:subject>xgeva</dc:subject>
        <dc:title>A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for denosumab</dc:title>
        <dcterms:abstract>Background: Denosumab is authorized to treat several diseases, including cancer and bone disorders. Nevertheless, its use in clinical practice has been affected by safety concerns. The work retrospectively investigated adverse events (AEs) of denosumab to better understand toxicities. Methods: The FAERS data base data from Q1 of 2010 to Q3 of 2023 was chosen. The definition of Medical Dictionary for Regulatory Activities (MedDRA) was dependent on preferred terms (PTs) and system organ class (SOCs). Following the removal of duplicate reports, a disproportionality analysis was conducted to identify safety signals through the calculation of reporting odds ratios (ROR). Results: During the reporting period, 130611 denosumab-related cases were identified; 670 pTs with a substantial disproportionality were retained. The connective and musculoskeletal tissue disorders, poisoning, injury, and procedural complications, as well as medical and surgical procedures, were among the important SOCs that satisfied the criteria. Reports at PT levels including off-label use, death, osteonecrosis of the jaw, arthralgia, and pain in extremities were determined. Severe consequences in terms of life-threatening injuries and death accounted for 841 and 19704 cases, respectively of the reported cases. Conclusion: These findings underscore the critical importance of pharmacovigilance and are consistent with established clinical observations. Notably, osteonecrosis of the jaw, arthralgia, pain in extremities, back pain, myalgia, and bone pain were identified as the most prevalent risk signals associated with denosumab.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079829</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2031539141&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Memo rdf:about="#item_1239">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 2; Correspondence Address: Y. Liu; Southwest University Hospital, Chongqing, China; email: yingqiliu@email.swu.edu.cn&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2031210955&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>15</prism:volume>
                <dc:title>Frontiers in Pharmacology</dc:title>
                <dc:identifier>DOI 10.3389/fphar.2024.1425617</dc:identifier>
                <dcterms:alternative>Front. Pharmacol.</dcterms:alternative>
                <dc:identifier>ISSN 1663-9812</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mao</foaf:surname>
                        <foaf:givenName>K.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>P.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sun</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhong</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zheng</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xu</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1240"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>hypertension</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>FAERS</dc:subject>
        <dc:subject>visual acuity</dc:subject>
        <dc:subject>eye disease</dc:subject>
        <dc:subject>Medical Dictionary for Regulatory Activities</dc:subject>
        <dc:subject>CANCER</dc:subject>
        <dc:subject>data analysis software</dc:subject>
        <dc:subject>antibody drug conjugate</dc:subject>
        <dc:subject>antibody-drug conjugates (ADCs)</dc:subject>
        <dc:subject>astigmatism</dc:subject>
        <dc:subject>belantamab mafodotin</dc:subject>
        <dc:subject>blepharitis</dc:subject>
        <dc:subject>blepharospasm</dc:subject>
        <dc:subject>brentuximab vedotin</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>drug utilization</dc:subject>
        <dc:subject>dry eye</dc:subject>
        <dc:subject>electronic spreadsheet</dc:subject>
        <dc:subject>enfortumab vedotin</dc:subject>
        <dc:subject>eye toxicity</dc:subject>
        <dc:subject>foreign body</dc:subject>
        <dc:subject>glaucoma</dc:subject>
        <dc:subject>inotuzumab ozogamicin</dc:subject>
        <dc:subject>keratopathy</dc:subject>
        <dc:subject>Microsoft Excel 2019</dc:subject>
        <dc:subject>mirvetuximab soravtansine</dc:subject>
        <dc:subject>night blindness</dc:subject>
        <dc:subject>ocular toxicity</dc:subject>
        <dc:subject>oncology</dc:subject>
        <dc:subject>polymerization</dc:subject>
        <dc:subject>punctate keratitis</dc:subject>
        <dc:subject>R software version 4.1.2</dc:subject>
        <dc:subject>sacituzumab govitecan</dc:subject>
        <dc:subject>TOXICITY</dc:subject>
        <dc:subject>trastuzumab</dc:subject>
        <dc:subject>trastuzumab emtansine</dc:subject>
        <dc:title>Ocular adverse events associated with antibody-drug conjugates in oncology: a pharmacovigilance study based on FDA adverse event reporting system (FAERS)</dc:title>
        <dcterms:abstract>Background: Antibody-drug conjugates (ADCs) have emerged as the focus and hotspots in the cancer field, yet the accompanying ocular toxicity has often been underestimated. We aimed to comprehensively and comparatively analyze the risk of ocular toxicity associated with various ADCs using the FDA Adverse Event Reporting System (FAERS) database. Methods: Data were extracted from the FAERS database from Q3 2011 to Q3 2023. We analyzed the clinical characteristics of ADCs-related ocular adverse events (AEs). These data were further mined by proportional analysis and Bayesian approach to detect signals of ADCs-induced ocular AEs. Moreover, the time to onset of ocular toxicity was also evaluated. Results: A total of 1,246 cases of ocular AEs were attributed to ADCs. Ocular toxicity signals were observed in patients treated with belantamab mafodotin, brentuximab vedotin, enfortumab vedotin, mirvetuximab soravtansine, sacituzumab govitecan, trastuzumab deruxtecan, and trastuzumab emtansine. Of these, belantamab mafodotin, trastuzumab emtansine, and mirvetuximab soravtansine, whose payloads are microtubule polymerization inhibitors, were more susceptible to ocular toxicity. The ten most common ADCs-related ocular AEs signals are keratopathy [ROR = 1,273.52, 95% CI (1,129.26–1,436.21)], visual acuity reduced [ROR = 22.83, 95% CI (21.2–24.58)], dry eye [ROR = 9.69, 95% CI (8.81–10.66)], night blindness [ROR = 259.87, 95% CI (228.23–295.89)], vision blurred [ROR = 1.78, 95% CI (1.57–2.02)], photophobia [ROR = 10.45, 95% CI (9.07–12.05)], foreign body sensation in eyes [ROR = 23.35, 95% CI (19.88–27.42)], ocular toxicity [ROR = 144.62, 95% CI (117.3–178.32)], punctate keratitis [ROR = 126.21, 95% CI (101.66–156.69)], eye disorder [ROR = 2.71, 95% CI (2.21–3.32)]. In terms of onset time, sacituzumab govitecan displayed an earlier onset of 21 days, while trastuzumab deruxtecan exhibited the latest onset of 223 days. Conclusion: ADCs may increase the risk of ocular toxicity in cancer patients, leading to serious mortality. With the widespread application of newly launched ADCs, combining the FAERS data with other data sources is crucial for monitoring the ocular toxicity of ADCs. In addition, novel ocular toxicity signals not documented in product labeling were detected. Further research will be necessary to validate our findings in the future.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079828</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2031210955&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Memo rdf:about="#item_1240">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 6; Correspondence Address: H. Zheng; Department of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People’s Hospital, Quzhou, Zhejiang, China; email: 1486561833@qq.com; L. Xu; Department of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People’s Hospital, Quzhou, Zhejiang, China; email: 15968762338@163.com&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;5&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;5&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;36&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2031719320&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>23</prism:volume>
                <dc:title>Expert Opinion on Drug Safety</dc:title>
                <dc:identifier>DOI 10.1080/14740338.2024.2411370</dc:identifier>
                <prism:number>12</prism:number>
                <dcterms:alternative>Expert Opin. Drug Saf.</dcterms:alternative>
                <dc:identifier>ISSN 1744-764X</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ji</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Qiu</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1242"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>screening</dc:subject>
        <dc:subject>citalopram</dc:subject>
        <dc:subject>drug induced disease</dc:subject>
        <dc:subject>amfebutamone</dc:subject>
        <dc:subject>amfebutamone plus dextromethorphan</dc:subject>
        <dc:subject>anastrozole</dc:subject>
        <dc:subject>atomoxetine</dc:subject>
        <dc:subject>bicalutamide</dc:subject>
        <dc:subject>buprenorphine plus naloxone</dc:subject>
        <dc:subject>chlortalidone</dc:subject>
        <dc:subject>clomipramine</dc:subject>
        <dc:subject>clonazepam</dc:subject>
        <dc:subject>degarelix</dc:subject>
        <dc:subject>doxazosin</dc:subject>
        <dc:subject>drospirenone</dc:subject>
        <dc:subject>drospirenone plus ethinylestradiol</dc:subject>
        <dc:subject>drospirenone plus ethinylestradiol plus mefolate calcium</dc:subject>
        <dc:subject>duloxetine</dc:subject>
        <dc:subject>dutasteride</dc:subject>
        <dc:subject>dutasteride plus tamsulosin</dc:subject>
        <dc:subject>elagolix</dc:subject>
        <dc:subject>escitalopram</dc:subject>
        <dc:subject>estradiol plus norethisterone acetate plus relugolix</dc:subject>
        <dc:subject>ethinylestradiol plus norethisterone acetate</dc:subject>
        <dc:subject>ethinylestradiol plus norgestimate</dc:subject>
        <dc:subject>ethinylestradiol plus norgestrel</dc:subject>
        <dc:subject>etonogestrel</dc:subject>
        <dc:subject>finasteride</dc:subject>
        <dc:subject>flibanserin</dc:subject>
        <dc:subject>fluoxetine</dc:subject>
        <dc:subject>fluvoxamine</dc:subject>
        <dc:subject>gemfibrozil</dc:subject>
        <dc:subject>goserelin</dc:subject>
        <dc:subject>isotretinoin</dc:subject>
        <dc:subject>ketoconazole</dc:subject>
        <dc:subject>leuprorelin</dc:subject>
        <dc:subject>levonorgestrel</dc:subject>
        <dc:subject>levothyroxine sodium</dc:subject>
        <dc:subject>libido disorder</dc:subject>
        <dc:subject>lurasidone</dc:subject>
        <dc:subject>medroxyprogesterone</dc:subject>
        <dc:subject>milnacipran</dc:subject>
        <dc:subject>minoxidil</dc:subject>
        <dc:subject>naltrexone</dc:subject>
        <dc:subject>norethisterone</dc:subject>
        <dc:subject>paliperidone</dc:subject>
        <dc:subject>pamidronic acid</dc:subject>
        <dc:subject>paroxetine</dc:subject>
        <dc:subject>pegvisomant</dc:subject>
        <dc:subject>ramelteon</dc:subject>
        <dc:subject>relugolix</dc:subject>
        <dc:subject>risperidone</dc:subject>
        <dc:subject>rotigotine</dc:subject>
        <dc:subject>sertraline</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>silodosin</dc:subject>
        <dc:subject>tadalafil</dc:subject>
        <dc:subject>tamsulosin</dc:subject>
        <dc:subject>testosterone</dc:subject>
        <dc:subject>venlafaxine</dc:subject>
        <dc:subject>vilazodone</dc:subject>
        <dc:subject>vortioxetine</dc:subject>
        <dc:title>Adverse event profiles of drug-induced decreased libido: an assessment of the US food and drug administration Adverse Event Reporting System</dc:title>
        <dcterms:abstract>Background: Drug-induced decreased libido significantly affects the quality of life and relationships of patients. However, no comprehensive study has examined the relationship between drugs and libido. This study assessed drug-induced decreased libido by mining data from the US Food and Drug Administration Adverse Event Reporting System (FAERS). Research Design and Methods: Adverse drug event (ADE) reports from the first quarter of 2004 to the fourth quarter of 2023 in FAERS were collected and screened for reports of decreased libido and were subjected to medication signal mining by using the disproportionality analysis. Results: Overall 10,773 ADE reports were obtained. Thirty-three of the top 50 drugs with the highest frequency of ADE reports did not mention the risk of reduced libido in their instructions. Fifty-eight drugs showed potential decreased libido risk based on the disproportionality analysis, with 40 of the drugs not mentioning the risk of reduced libido in their instructions. Of these 40 drugs, drugs used in genito urinary and sex hormones and nervous system were the drug class with the greatest number of ADE reports. Conclusion: A data mining exercise using FAERS for drugs that cause decreased libido has identified 40 drugs with new signals of adverse effects that should be closely monitored in medical practice.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079831</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2031719320&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>1523-1529</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1242">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2031084896&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>15</prism:volume>
                <dc:title>Frontiers in Pharmacology</dc:title>
                <dc:identifier>DOI 10.3389/fphar.2024.1392263</dc:identifier>
                <dcterms:alternative>Front. Pharmacol.</dcterms:alternative>
                <dc:identifier>ISSN 1663-9812</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1243"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data analysis</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>FAERS database</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>artificial neural network</dc:subject>
        <dc:subject>dizziness</dc:subject>
        <dc:subject>very elderly</dc:subject>
        <dc:subject>bayesian confidence propagation neural network</dc:subject>
        <dc:subject>cardiovascular system</dc:subject>
        <dc:subject>data analysis software</dc:subject>
        <dc:subject>coughing</dc:subject>
        <dc:subject>data extraction</dc:subject>
        <dc:subject>demographics</dc:subject>
        <dc:subject>diabetes mellitus</dc:subject>
        <dc:subject>dyspnea</dc:subject>
        <dc:subject>empirical bayesian geometric mean</dc:subject>
        <dc:subject>ENALAPRIL</dc:subject>
        <dc:subject>hearing impairment</dc:subject>
        <dc:subject>heart disease</dc:subject>
        <dc:subject>HEART-FAILURE</dc:subject>
        <dc:subject>hypotension</dc:subject>
        <dc:subject>inner ear</dc:subject>
        <dc:subject>inner ear disease</dc:subject>
        <dc:subject>mediastinum disease</dc:subject>
        <dc:subject>memory disorder</dc:subject>
        <dc:subject>NEPRILYSIN INHIBITION</dc:subject>
        <dc:subject>peripheral swelling</dc:subject>
        <dc:subject>potassium blood level</dc:subject>
        <dc:subject>R version 4.2.1</dc:subject>
        <dc:subject>respiratory tract disease</dc:subject>
        <dc:subject>sacubitril plus valsartan</dc:subject>
        <dc:subject>sacubitril/valsartan</dc:subject>
        <dc:subject>thorax disease</dc:subject>
        <dc:subject>vascular disease</dc:subject>
        <dc:title>A real-world disproportionality analysis of sacubitril/valsartan: data mining of the FDA adverse event reporting system</dc:title>
        <dcterms:abstract>Purpose: Sacubitril/valsartan is extensively used in heart failure; however, there are few long-term safety studies of it in a wide range of populations. The aim of this study was to evaluate sacubitril/valsartan-induced adverse events (AEs) through data mining of the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Methods: Reports in the FAERS from the third quarter of 2015 (FDA approval of sacubitril/valsartan) to the fourth quarter of 2023 were collected and analyzed. Disproportionality analyses, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and empirical Bayesian geometric mean (EBGM) algorithms were adopted in data mining to quantify signals of sacubitril/valsartan-associated AEs. Results: A total of 12,001,275 reports of sacubitril/valsartan as the “primary suspected (PS)” and 99,651 AEs induced by sacubitril/valsartan were identified. More males than females reported AEs (59.95% vs. 33.31%), with the highest number of reports in the 60–70 years age group (8.11%), and most AEs occurred &lt; 7 days (14.13%) and ≥ 60 days (10.69%) after dosing. Sacubitril/valsartan-induced AE occurrence targeted 24 system organ classes (SOCs) and 294 preferred terms (PTs). Of these, 4 SOCs were strongly positive for all four algorithms, including cardiac disorders, vascular disorders, ear and labyrinth disorders, and respiratory, thoracic and mediastinal disorders. Among all PTs, consistent with the specification, hypotension (n = 10,078) had the highest number of reports, and dizziness, cough, peripheral swelling, blood potassium increased, and renal impairment were also reported in high numbers. Notably, this study also discovered a high frequency of side effects such as death, dyspnea, weight change, feeling abnormal, hearing loss, memory impairment, throat clearing, and diabetes mellitus. Conclusion: This study identified potential new AE signals and gained a more general understanding of the safety of sacubitril/valsartan, promoting its rational adoption in the cardiovascular system.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079827</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2031084896&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Memo rdf:about="#item_1243">
        <rdf:value>&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;3&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;3&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;26&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2030975398&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>15</prism:volume>
                <dc:title>Frontiers in Pharmacology</dc:title>
                <dc:identifier>DOI 10.3389/fphar.2024.1353848</dc:identifier>
                <dcterms:alternative>Front. Pharmacol.</dcterms:alternative>
                <dc:identifier>ISSN 1663-9812</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1245"/>
        <dc:subject>acute kidney failure</dc:subject>
        <dc:subject>acute kidney injury</dc:subject>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data analysis</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>*Data Mining</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>Adolescent</dc:subject>
        <dc:subject>Adult</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>ADVERSE DRUG-REACTIONS</dc:subject>
        <dc:subject>Aged</dc:subject>
        <dc:subject>Algorithms</dc:subject>
        <dc:subject>antiinfective agent</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>Child</dc:subject>
        <dc:subject>disproportionality analysis</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>Antipsychotic Agents</dc:subject>
        <dc:subject>CHILDREN</dc:subject>
        <dc:subject>depression</dc:subject>
        <dc:subject>abdominal pain</dc:subject>
        <dc:subject>constipation</dc:subject>
        <dc:subject>brain infarction</dc:subject>
        <dc:subject>anticoagulant agent</dc:subject>
        <dc:subject>Child, Preschool</dc:subject>
        <dc:subject>ciprofloxacin</dc:subject>
        <dc:subject>abdominal distension</dc:subject>
        <dc:subject>adverse drug reactions</dc:subject>
        <dc:subject>Adverse event</dc:subject>
        <dc:subject>anemia</dc:subject>
        <dc:subject>chemically induced</dc:subject>
        <dc:subject>creatinine</dc:subject>
        <dc:subject>data analysis software</dc:subject>
        <dc:subject>Data mining</dc:subject>
        <dc:subject>Data Mining</dc:subject>
        <dc:subject>Databases, Factual</dc:subject>
        <dc:subject>dehydration</dc:subject>
        <dc:subject>diarrhea</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>ascites</dc:subject>
        <dc:subject>data extraction</dc:subject>
        <dc:subject>diabetes mellitus</dc:subject>
        <dc:subject>*Antipsychotic Agents/adverse effects</dc:subject>
        <dc:subject>aAlirocumab</dc:subject>
        <dc:subject>acute pancreatitis</dc:subject>
        <dc:subject>adverse drug event</dc:subject>
        <dc:subject>Adverse drug event</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems/statistics &amp; numerical data</dc:subject>
        <dc:subject>albiglutide</dc:subject>
        <dc:subject>alirocumab</dc:subject>
        <dc:subject>alprazolam</dc:subject>
        <dc:subject>anorexia</dc:subject>
        <dc:subject>Anti-Anxiety Agents</dc:subject>
        <dc:subject>Anti-Anxiety Agents/*adverse effects</dc:subject>
        <dc:subject>Anticoagulants</dc:subject>
        <dc:subject>antidiuretic agent</dc:subject>
        <dc:subject>Antipsychotic drugs</dc:subject>
        <dc:subject>anus pruritus</dc:subject>
        <dc:subject>anxiolytic agent</dc:subject>
        <dc:subject>apixaban</dc:subject>
        <dc:subject>aplastic anemia</dc:subject>
        <dc:subject>association</dc:subject>
        <dc:subject>benzodiazepine</dc:subject>
        <dc:subject>benzodiazepine derivative</dc:subject>
        <dc:subject>Benzodiazepines</dc:subject>
        <dc:subject>Benzodiazepines/*adverse effects</dc:subject>
        <dc:subject>bezoar</dc:subject>
        <dc:subject>bisphosphonic acid derivative</dc:subject>
        <dc:subject>bone density</dc:subject>
        <dc:subject>bromazepam</dc:subject>
        <dc:subject>Canada</dc:subject>
        <dc:subject>Canada Vigilance Adverse Reaction Online Database</dc:subject>
        <dc:subject>CARDIOVASCULAR OUTCOMES</dc:subject>
        <dc:subject>case study</dc:subject>
        <dc:subject>chlordiazepoxide</dc:subject>
        <dc:subject>cholelithiasis</dc:subject>
        <dc:subject>cholestatic hepatitis</dc:subject>
        <dc:subject>Ciprofloxacin</dc:subject>
        <dc:subject>clinical care</dc:subject>
        <dc:subject>Clinical care</dc:subject>
        <dc:subject>clinical decision support</dc:subject>
        <dc:subject>Clinical decision support</dc:subject>
        <dc:subject>clinical informatics</dc:subject>
        <dc:subject>Clinical informatics</dc:subject>
        <dc:subject>clorazepate</dc:subject>
        <dc:subject>clotiazepam</dc:subject>
        <dc:subject>cloxazolam</dc:subject>
        <dc:subject>confidence interval</dc:subject>
        <dc:subject>Confidence Intervals</dc:subject>
        <dc:subject>consciousness disorder</dc:subject>
        <dc:subject>coronavirus disease 2019</dc:subject>
        <dc:subject>creatinine blood level</dc:subject>
        <dc:subject>dabigatran</dc:subject>
        <dc:subject>Data processing</dc:subject>
        <dc:subject>dementia</dc:subject>
        <dc:subject>Dementia</dc:subject>
        <dc:subject>Dementia/*chemically induced</dc:subject>
        <dc:subject>demography</dc:subject>
        <dc:subject>Demography</dc:subject>
        <dc:subject>diazepam</dc:subject>
        <dc:subject>direct oral anticoagulant</dc:subject>
        <dc:subject>Direct oral anticoagulant</dc:subject>
        <dc:subject>disease association</dc:subject>
        <dc:subject>DISPROPORTIONALITY</dc:subject>
        <dc:subject>Disproportionality analysis</dc:subject>
        <dc:subject>drug database</dc:subject>
        <dc:subject>drug information</dc:subject>
        <dc:subject>Drug Prescriptions</dc:subject>
        <dc:subject>Drug Prescriptions/statistics &amp; numerical data</dc:subject>
        <dc:subject>drug use</dc:subject>
        <dc:subject>dulaglutide</dc:subject>
        <dc:subject>dysgeusia</dc:subject>
        <dc:subject>edoxaban</dc:subject>
        <dc:subject>EFFICACY</dc:subject>
        <dc:subject>electronic health record</dc:subject>
        <dc:subject>Electronic Health Records</dc:subject>
        <dc:title>Association between PCSK9 inhibitors and acute kidney injury: a pharmacovigilance study</dc:title>
        <dcterms:abstract>Background: PCSK9 inhibitors are a novel class of lipid-lowering medications, and numerous clinical studies have confirmed their significant role in improving the progression of chronic kidney disease. However, recent case reports have indicated new evidence regarding their association with acute kidney injury (AKI), with some patients experiencing acute tubular injury after PCSK9 inhibitors use. Objectives: To clarify the relationship between PCSK9 inhibitors and AKI, we conducted a pharmacovigilance study. Methods: Using the Food and Drug Administration Adverse Event Reporting System (FAERS) database from the third quarter of 2015 to the fourth quarter of 2022, a disproportionality analysis was employed to identify adverse events suggestive of AKI after PCSK9 inhibitors use. The drugs of interest included evolocumab and alirocumab. Results: A total of 144,341 adverse event reports related to PCSK9 inhibitors were analyzed, among which 444 cases were suspected of AKI for evolocumab, and 172 cases for alirocumab. Evolocumab had a greater impact on AKI in males (ROR 1.4, 95% CI 1.54–1.69). The ROR and 95% CI for evolocumab and Alirocumab were 0.13 (0.12–0.14) and 0.26 (0.23–0.30) respectively. Further analysis of AKI associated with the concomitant use of PCSK9 inhibitors with cephalosporins, furosemide, torsemide, pantoprazole, omeprazole, and esomeprazole revealed ROR and 95% CI of 0.38 (0.23–0.62), 0.38 (0.31–0.48), 0.18 (0.08–0.38), 0.23 (0.17–0.29), 0.20 (0.16–0.26), and 0.14 (0.10–0.20) respectively. Conclusion: Through the FAERS database, we analyzed the clinical characteristics of AKI associated with PCSK9 inhibitors, exploring its risks. Our findings suggest that PCSK9 inhibitors might have a potential protective effect against AKI and exhibit similar effects when co-administered with other nephrotoxic drugs.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079826</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2030975398&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Memo rdf:about="#item_1245">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 3; Correspondence Address: H. Liu; Hunan Provincial People’s Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China; email: kxyj2023@163.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 3; Correspondence Address: R. Eriksson; Disease Systems Biology Program, Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Copenhagen N, Blegdamsvej 3B, DK-2200, Denmark; email: robert.eriksson@cpr.ku.dk&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 4; Correspondence Address: Z. Wang; Department of Pharmacy, Shanxi Cardiovascular Disease Hospital, Taiyuan, Shanxi, China; email: zew74340@gmail.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 19; Correspondence Address: P. Yildirim; Okan Universitesi, Bilgisayar Muhendisligi Bolumu Akfirat, Tuzla, 34959, Turkey; email: pinar.yildirim@okan.edu.tr&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 25; Correspondence Address: S. Yokoyama; Division of Clinical Drug Informatics, School of Pharmacy, Kindai University, Higashi-osaka, 3-4-1 Kowakae, Osaka, 577-8502, Japan; email: yokoyama@phar.kindai.ac.jp&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 55; Correspondence Address: M. Takada; Division of Clinical Drug Informatics, School of Pharmacy, Kindai University, Higashi-osaka, 3-4-1, Kowakae, 577-8502, Japan; email: takada@phar.kindaiacjp&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 105; Correspondence Address: L. Chen; Department of Pharmacy and Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, China; email: chenl_hxey@scu.edu.cn&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;3&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;3&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;18&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;3&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;3&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;80&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;6&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;6&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;20&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;18&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;19&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;43&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;20&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;20&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;40&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;101&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;103&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;34&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2030652800&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:2630-6344"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jiang</foaf:surname>
                        <foaf:givenName>W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Guo</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhou</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1244"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>death</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>adverse outcome</dc:subject>
        <dc:subject>cardiotoxicity</dc:subject>
        <dc:subject>cardiovascular disease</dc:subject>
        <dc:subject>cerebrovascular accident</dc:subject>
        <dc:subject>connective tissue disease</dc:subject>
        <dc:subject>cross-sectional study</dc:subject>
        <dc:subject>arthralgia</dc:subject>
        <dc:subject>disability</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>bradycardia</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>dizziness</dc:subject>
        <dc:subject>drug induced disease</dc:subject>
        <dc:subject>abnormal sensation</dc:subject>
        <dc:subject>backache</dc:subject>
        <dc:subject>bone pain</dc:subject>
        <dc:subject>constipation</dc:subject>
        <dc:subject>atrial fibrillation</dc:subject>
        <dc:subject>cerebrovascular disease</dc:subject>
        <dc:subject>congestive heart failure</dc:subject>
        <dc:subject>embolism</dc:subject>
        <dc:subject>amiodarone</dc:subject>
        <dc:subject>antineoplastic agent</dc:subject>
        <dc:subject>azithromycin</dc:subject>
        <dc:subject>cholesterol blood level</dc:subject>
        <dc:subject>alopecia</dc:subject>
        <dc:subject>antibiotic agent</dc:subject>
        <dc:subject>asthenia</dc:subject>
        <dc:subject>bone disease</dc:subject>
        <dc:subject>cholesterol</dc:subject>
        <dc:subject>COVID-19</dc:subject>
        <dc:subject>creatinine</dc:subject>
        <dc:subject>data analysis software</dc:subject>
        <dc:subject>Data Mining</dc:subject>
        <dc:subject>Databases, Factual</dc:subject>
        <dc:subject>diarrhea</dc:subject>
        <dc:subject>clonazepam</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>cancer therapy</dc:subject>
        <dc:subject>drug indication</dc:subject>
        <dc:subject>bone necrosis</dc:subject>
        <dc:subject>denosumab</dc:subject>
        <dc:subject>dyspnea</dc:subject>
        <dc:subject>adverse drug event</dc:subject>
        <dc:subject>coronavirus disease 2019</dc:subject>
        <dc:subject>creatinine blood level</dc:subject>
        <dc:subject>dysgeusia</dc:subject>
        <dc:subject>acute generalized exanthematous pustulosis</dc:subject>
        <dc:subject>ADRM</dc:subject>
        <dc:subject>adverse drug events</dc:subject>
        <dc:subject>adverse drug reaction monitoring</dc:subject>
        <dc:subject>antiarrhythmic agent</dc:subject>
        <dc:subject>artery thrombosis</dc:subject>
        <dc:subject>asthma</dc:subject>
        <dc:subject>ATRIAL-FIBRILLATION</dc:subject>
        <dc:subject>atrioventricular block</dc:subject>
        <dc:subject>azd 1222</dc:subject>
        <dc:subject>bacteremia</dc:subject>
        <dc:subject>bamlanivimab</dc:subject>
        <dc:subject>Bayesian Confidence Propagation Neural Network</dc:subject>
        <dc:subject>bebtelovimab</dc:subject>
        <dc:subject>Beers crite ria</dc:subject>
        <dc:subject>Beers criteria</dc:subject>
        <dc:subject>benign neoplasm</dc:subject>
        <dc:subject>BENZODIAZEPINES</dc:subject>
        <dc:subject>biochemical marker</dc:subject>
        <dc:subject>body temperature</dc:subject>
        <dc:subject>body weight loss</dc:subject>
        <dc:subject>BONE</dc:subject>
        <dc:subject>bone and joint infections</dc:subject>
        <dc:subject>bone cyst</dc:subject>
        <dc:subject>bone metabolism</dc:subject>
        <dc:subject>bone metabolism disorder</dc:subject>
        <dc:subject>bone sarcoma</dc:subject>
        <dc:subject>bone tumor</dc:subject>
        <dc:subject>brain edema</dc:subject>
        <dc:subject>breast disease</dc:subject>
        <dc:subject>calcium metabolism disorders</dc:subject>
        <dc:subject>cardiomegaly</dc:subject>
        <dc:subject>cardioversion</dc:subject>
        <dc:subject>cartilage tumor</dc:subject>
        <dc:subject>casirivimab</dc:subject>
        <dc:subject>casirivimab plus imdevimab</dc:subject>
        <dc:subject>CHA2DS2-VASc score</dc:subject>
        <dc:subject>chloroquine</dc:subject>
        <dc:subject>chronic kidney failure</dc:subject>
        <dc:subject>chronic leukemia</dc:subject>
        <dc:subject>chronic lymphatic leukemia</dc:subject>
        <dc:subject>clinical trial (topic)</dc:subject>
        <dc:subject>Colombia</dc:subject>
        <dc:subject>comparative study</dc:subject>
        <dc:subject>connective tissue tumor</dc:subject>
        <dc:subject>crowdsourcing</dc:subject>
        <dc:subject>cx 024414</dc:subject>
        <dc:subject>cytomegalovirus infection</dc:subject>
        <dc:subject>Denosumab</dc:subject>
        <dc:subject>DISEASE</dc:subject>
        <dc:subject>disease model</dc:subject>
        <dc:subject>dislocation</dc:subject>
        <dc:subject>disorders of mineral, electrolyte and metal metabolism</dc:subject>
        <dc:subject>dronedarone</dc:subject>
        <dc:subject>drug</dc:subject>
        <dc:subject>drug effect</dc:subject>
        <dc:subject>drug eruption</dc:subject>
        <dc:subject>drug hypersensitivity</dc:subject>
        <dc:subject>drug industry</dc:subject>
        <dc:subject>drug metabolite</dc:subject>
        <dc:subject>drug side effects</dc:subject>
        <dc:subject>drug therapy</dc:subject>
        <dc:subject>Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>dysphagia</dc:subject>
        <dc:subject>ear disease</dc:subject>
        <dc:subject>eculizumab</dc:subject>
        <dc:subject>elasomeran</dc:subject>
        <dc:subject>elderly</dc:subject>
        <dc:subject>electrocardiography</dc:subject>
        <dc:subject>electromyography</dc:subject>
        <dc:subject>EMERGENCY</dc:subject>
        <dc:title>Adverse drug events of denosumab: Data-mining based on the United States Food and Drug Administration Adverse Event Reporting System database</dc:title>
        <dcterms:abstract>Objective: This study seeks to analyze data from the United States (U.S.) Food and Drug Administration Adverse Event Reporting System (FAERS) to identify potential adverse drug event (ADE) signals associated with denosumab and provide valuable insights into the clinical safety of denosumab usage. Methods: Data on denosumab-related ADEs reported from the FAERS between the second quarter of 2010 to the first quarter of 2022 were extracted using OpenVigil 2.1. The Reporting Odds Ratio (ROR) and Proportional Reporting Ratio (PRR) were calculated as measures to detect potential ADE signals. Results: The analysis of FAERS data uncovers potential ADE signals associated with the use of denosumab. These signals encompass a spectrum of adverse effects, including well-established risks such as musculoskeletal pain, hypocalcemia, and osteonecrosis of the jaw. Moreover, novel potential adverse events emerge, including oral diseases, fractures occurring in various locations, and signals indicating tumors beyond the drug's approved indications. Conclusions: This study highlights the significance of closely monitoring patients for potential adverse events during denosumab treatment. Healthcare professionals should exercise heightened vigilance for the development of oral diseases, fractures, and tumors in individuals receiving denosumab therapy. The identification of these additional ADE signals should inform clinical decision-making, patient risk assessments, and ongoing efforts in pharmacovigilance, thereby ensuring the safe and effective utilization of denosumab.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079824</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2030652800&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>1220-1230</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:2630-6344">
        <prism:volume>28</prism:volume>
        <dc:title>Journal of Research in Pharmacy</dc:title>
        <dc:identifier>DOI 10.29228/jrp.803</dc:identifier>
        <prism:number>4</prism:number>
        <dcterms:alternative>J. Res. Pham.</dcterms:alternative>
        <dc:identifier>ISSN 2630-6344</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1244">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: C. Guzmán; Department of Pharmacy, Faculty of Health Sciences, Universidad de Córdoba, Monteria, Colombia; email: cantonioguzman@correo.unicordoba.edu.co&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: Z. Liu; Department of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China; email: liuzhelong@163.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 1&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 1; Correspondence Address: Y. Meng; Department of Nephrology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China; email: mbao124@qq.com; S.-F. Wang; The First Department of Specialty Medicine, Inner Mongolia Corps Hospital of The Chinese People’s Armed Police Force, Hohhot, China; email: wshfxyz@163.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 1; Correspondence Address: Y. Xu; Department of Cardiology, Intervention Cardiology Center, Wuhan No. 1 Hospital, Wuhan, China; email: xy15501113099@126.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 2; Correspondence Address: L. Ghamkhar; National Center for Health Insurance Research, Tehran, Iran; email: lghamkhar@yahoo.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 7; Correspondence Address: Y. Yuan; Department of Pharmacy, Jincheng People’s Hospital, Jincheng, China; email: yuanyinxia@126.com&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;31&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;31&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;33&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;35&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;32&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;7&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;7&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;26&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;43&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;45&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;56&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2030629634&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>23</prism:volume>
                <dc:title>Expert Opinion on Drug Safety</dc:title>
                <dc:identifier>DOI 10.1080/14740338.2024.2382226</dc:identifier>
                <prism:number>10</prism:number>
                <dcterms:alternative>Expert Opin. Drug Saf.</dcterms:alternative>
                <dc:identifier>ISSN 1744-764X</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Rao</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Cheng</foaf:surname>
                        <foaf:givenName>P.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1247"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data analysis</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>heart failure</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>artificial neural network</dc:subject>
        <dc:subject>cardiovascular disease</dc:subject>
        <dc:subject>connective tissue disease</dc:subject>
        <dc:subject>gastrointestinal hemorrhage</dc:subject>
        <dc:subject>cardiomyopathy</dc:subject>
        <dc:subject>dizziness</dc:subject>
        <dc:subject>faintness</dc:subject>
        <dc:subject>heart ventricle fibrillation</dc:subject>
        <dc:subject>heart ventricle tachycardia</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>gastrointestinal disease</dc:subject>
        <dc:subject>mental disease</dc:subject>
        <dc:subject>neurologic disease</dc:subject>
        <dc:subject>skin disease</dc:subject>
        <dc:subject>angina pectoris</dc:subject>
        <dc:subject>atrial fibrillation</dc:subject>
        <dc:subject>brain infarction</dc:subject>
        <dc:subject>eye disease</dc:subject>
        <dc:subject>lung edema</dc:subject>
        <dc:subject>anemia</dc:subject>
        <dc:subject>creatinine</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>lymphatic system disease</dc:subject>
        <dc:subject>malignant neoplasm</dc:subject>
        <dc:subject>heart disease</dc:subject>
        <dc:subject>hypotension</dc:subject>
        <dc:subject>inner ear disease</dc:subject>
        <dc:subject>mediastinum disease</dc:subject>
        <dc:subject>respiratory tract disease</dc:subject>
        <dc:subject>thorax disease</dc:subject>
        <dc:subject>vascular disease</dc:subject>
        <dc:subject>creatinine blood level</dc:subject>
        <dc:subject>benign neoplasm</dc:subject>
        <dc:subject>breast disease</dc:subject>
        <dc:subject>drug hypersensitivity</dc:subject>
        <dc:subject>ear disease</dc:subject>
        <dc:subject>amino terminal pro brain natriuretic peptide</dc:subject>
        <dc:subject>brain natriuretic peptide</dc:subject>
        <dc:subject>cardiorenal syndrome</dc:subject>
        <dc:subject>cyst</dc:subject>
        <dc:subject>depressed blood pressure</dc:subject>
        <dc:subject>dyspepsia</dc:subject>
        <dc:subject>edema</dc:subject>
        <dc:subject>gastroesophageal reflux</dc:subject>
        <dc:subject>genital system disease</dc:subject>
        <dc:subject>glomerulus filtration rate</dc:subject>
        <dc:subject>heart ejection fraction</dc:subject>
        <dc:subject>hematologic disease</dc:subject>
        <dc:subject>hepatobiliary disease</dc:subject>
        <dc:subject>hypervolemia</dc:subject>
        <dc:subject>infection</dc:subject>
        <dc:subject>infestation</dc:subject>
        <dc:subject>injury</dc:subject>
        <dc:subject>international normalized ratio</dc:subject>
        <dc:subject>intoxication</dc:subject>
        <dc:subject>kidney disease</dc:subject>
        <dc:subject>lip swelling</dc:subject>
        <dc:subject>malaise</dc:subject>
        <dc:subject>metabolic disorder</dc:subject>
        <dc:subject>musculoskeletal disease</dc:subject>
        <dc:subject>nutritional disorder</dc:subject>
        <dc:subject>peripheral edema</dc:subject>
        <dc:subject>polyp</dc:subject>
        <dc:subject>presyncope</dc:subject>
        <dc:subject>procedural site reaction</dc:subject>
        <dc:subject>quantitative analysis</dc:subject>
        <dc:subject>systolic blood pressure</dc:subject>
        <dc:subject>tongue swelling</dc:subject>
        <dc:subject>urinary tract disease</dc:subject>
        <dc:subject>vericiguat</dc:subject>
        <dc:title>Assessment of adverse events of the novel cardiovascular drug vericiguat: a real-world pharmacovigilance study based on FAERS</dc:title>
        <dcterms:abstract>Background: This study aims to analyze the adverse event reports (AERs) to vericiguat using data from the Food and Drug Administration Adverse Event Reporting System (FAERS) and provide evidence for the clinical use. Methods: AERs due to vericiguat from 2021Q1 to 2024Q1 identified as the primary suspect were screened, with duplicate reports subsequently eliminated. Various quantitative signal detection methods, including reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network, and multi-item gamma poisson shrinker, were then employed for data mining and analysis. Signal strength is represented by the 95% confidence interval, information component (IC), and empirical Bayesian geometric mean (EBGM). Results: A total of 617 vericiguat-related AERs were identified. Strong signals were observed in 21 system organ classes. Furthermore, the most frequently reported preferred terms (PT) was hypotension (n = 86, ROR 25.92, PRR 24.11, IC 4.59, EBGM 24.07), followed by dizziness (n = 52, ROR 6.44, PRR 6.20, IC 2.63, EBGM 6.20), malaise (n = 25, ROR 3.59, PRR 3.54, IC 1.82, EBGM 3.54), blood pressure decreased (n = 23, ROR 20.00, PRR 19.64, IC 4.29, EBGM 19.61), and anemia (n = 21, ROR 6.67, PRR 6.57, IC 2.72, EBGM 6.57). Conclusions: This study extended the adverse reactions documented in the FDA instruction and provided supplementary evidence regarding the clinical safety of vericiguat.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079823</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2030629634&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>1317-1325</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1247">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2030597402&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>15</prism:volume>
                <dc:title>Frontiers in Pharmacology</dc:title>
                <dc:identifier>DOI 10.3389/fphar.2024.1365706</dc:identifier>
                <dcterms:alternative>Front. Pharmacol.</dcterms:alternative>
                <dc:identifier>ISSN 1663-9812</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>F.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zheng</foaf:surname>
                        <foaf:givenName>J.-X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>X.-D.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1248"/>
        <dc:subject>acute kidney failure</dc:subject>
        <dc:subject>adult</dc:subject>
        <dc:subject>age</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data analysis</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>*Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>adverse events</dc:subject>
        <dc:subject>Aged</dc:subject>
        <dc:subject>Algorithms</dc:subject>
        <dc:subject>Artificial intelligence</dc:subject>
        <dc:subject>Bayes Theorem</dc:subject>
        <dc:subject>biology</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>classification</dc:subject>
        <dc:subject>classifier</dc:subject>
        <dc:subject>Computational Biology</dc:subject>
        <dc:subject>computer interface</dc:subject>
        <dc:subject>CHILDREN</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>clinical practice</dc:subject>
        <dc:subject>accuracy</dc:subject>
        <dc:subject>animal</dc:subject>
        <dc:subject>Animals</dc:subject>
        <dc:subject>antineoplastic agent</dc:subject>
        <dc:subject>automation</dc:subject>
        <dc:subject>azithromycin</dc:subject>
        <dc:subject>BIOMEDICAL LITERATURE</dc:subject>
        <dc:subject>chimeric antigen receptor</dc:subject>
        <dc:subject>clarithromycin</dc:subject>
        <dc:subject>Adverse events</dc:subject>
        <dc:subject>anemia</dc:subject>
        <dc:subject>antiretroviral therapy</dc:subject>
        <dc:subject>Data mining</dc:subject>
        <dc:subject>Data Mining</dc:subject>
        <dc:subject>Data Mining/*methods</dc:subject>
        <dc:subject>Databases, Factual</dc:subject>
        <dc:subject>Bayesian Confidence Propagation Neural Network</dc:subject>
        <dc:subject>brain edema</dc:subject>
        <dc:subject>clinical trial (topic)</dc:subject>
        <dc:subject>comparative study</dc:subject>
        <dc:subject>crowdsourcing</dc:subject>
        <dc:subject>Antineoplastic Agents</dc:subject>
        <dc:subject>clinical outcome</dc:subject>
        <dc:subject>Clinical Trials as Topic</dc:subject>
        <dc:subject>*Artificial Intelligence</dc:subject>
        <dc:subject>*Chemically-Induced Disorders/genetics/metabolism</dc:subject>
        <dc:subject>*Crowdsourcing/methods/standards</dc:subject>
        <dc:subject>*Drug Repositioning</dc:subject>
        <dc:subject>*Knowledge Bases</dc:subject>
        <dc:subject>*MEDLINE</dc:subject>
        <dc:subject>*Periodicals as Topic</dc:subject>
        <dc:subject>*Pharmaceutical Preparations</dc:subject>
        <dc:subject>abacavir</dc:subject>
        <dc:subject>Abstracting</dc:subject>
        <dc:subject>acute motor axonal neuropathy</dc:subject>
        <dc:subject>Adaptor Proteins, Signal Transducing</dc:subject>
        <dc:subject>adoptive immunotherapy</dc:subject>
        <dc:subject>ADVERSE DRUG EVENTS</dc:subject>
        <dc:subject>Adverse Event Reporting System</dc:subject>
        <dc:subject>AGENT</dc:subject>
        <dc:subject>AGITATION</dc:subject>
        <dc:subject>amphotericin B</dc:subject>
        <dc:subject>anti-HIV drug</dc:subject>
        <dc:subject>Antibodies</dc:subject>
        <dc:subject>antibody</dc:subject>
        <dc:subject>Antigens, CD19</dc:subject>
        <dc:subject>Antineoplastic Agents/*therapeutic use</dc:subject>
        <dc:subject>Apriori algorithm</dc:subject>
        <dc:subject>artificial intelligence</dc:subject>
        <dc:subject>Artificial Intelligence</dc:subject>
        <dc:subject>atazanavir</dc:subject>
        <dc:subject>atovaquone</dc:subject>
        <dc:subject>axicabtagene ciloleucel</dc:subject>
        <dc:subject>Bayesian change point analysis</dc:subject>
        <dc:subject>BAYESIAN-ANALYSIS</dc:subject>
        <dc:subject>Biological Ontologies</dc:subject>
        <dc:subject>biological ontology</dc:subject>
        <dc:subject>biological therapy</dc:subject>
        <dc:subject>Biomedical literature</dc:subject>
        <dc:subject>bone marrow suppression</dc:subject>
        <dc:subject>brexucabtagene autoleucel</dc:subject>
        <dc:subject>Cancer drug</dc:subject>
        <dc:subject>Cancer drug side effect</dc:subject>
        <dc:subject>CAR-T therapy</dc:subject>
        <dc:subject>CD19 antigen</dc:subject>
        <dc:subject>CD28 antigen</dc:subject>
        <dc:subject>CD28 Antigens</dc:subject>
        <dc:subject>Cell- and Tissue-Based Therapy</dc:subject>
        <dc:subject>change point analysis</dc:subject>
        <dc:subject>Change point analysis</dc:subject>
        <dc:subject>Chemical analysis</dc:subject>
        <dc:subject>chemically induced disorder</dc:subject>
        <dc:subject>Chemically-Induced Disorders</dc:subject>
        <dc:subject>chimeric antigen receptor T-cell immunotherapy</dc:subject>
        <dc:subject>chorioretinitis</dc:subject>
        <dc:subject>Classification (of information)</dc:subject>
        <dc:subject>cobicistat</dc:subject>
        <dc:subject>Computational Biology/*methods</dc:subject>
        <dc:subject>cotrimoxazole</dc:subject>
        <dc:subject>Crowdsourcing</dc:subject>
        <dc:subject>cyclophosphamide</dc:subject>
        <dc:subject>CYTOKINE RELEASE SYNDROME</dc:subject>
        <dc:subject>darunavir</dc:subject>
        <dc:subject>Data Collection</dc:subject>
        <dc:subject>Data Mining/methods/standards</dc:subject>
        <dc:title>Clinical adverse events to dexmedetomidine: a real-world drug safety study based on the FAERS database</dc:title>
        <dcterms:abstract>Objective: Adverse events associated with dexmedetomidine were analyzed using data from the FDA’s FAERS database, spanning from 2004 to the third quarter of 2023. This analysis serves as a foundation for monitoring dexmedetomidine’s safety in clinical applications. Methods: Data on adverse events associated with dexmedetomidine were standardized and analyzed to identify clinical adverse events closely linked to its use. This analysis employed various signal quantification analysis algorithms, including Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-Item Gamma Poisson Shrinker (MGPS). Results: In the FAERS database, dexmedetomidine was identified as the primary suspect in 1,910 adverse events. Our analysis encompassed 26 organ system levels, from which we selected 346 relevant Preferred Terms (PTs) for further examination. Notably, adverse drug reactions such as diabetes insipidus, abnormal transcranial electrical motor evoked potential monitoring, acute motor axonal neuropathy, and trigeminal cardiac reflex were identified. These reactions are not explicitly mentioned in the drug’s specification, indicating the emergence of new signals for adverse drug reactions. Conclusion: Data mining in the FAERS database has elucidated the characteristics of dexmedetomidine-related adverse drug reactions. This analysis enhances our understanding of dexmedetomidine’s drug safety, aids in the clinical management of pharmacovigilance studies, and offers valuable insights for refining drug-use protocols.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079822</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2030597402&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Memo rdf:about="#item_1248">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 2; Correspondence Address: X.-D. Wu; Department of Anesthesiology, Shengli Clinical Medical College, Fujian Provincial Hospital, Fujian Medical University, Fuzhou, China; email: wxiaodan@sina.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 3; Correspondence Address: G. Li; Department of Pharmacy, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, No. 17, Panjiayuan Nanli, Chaoyang District, 100021, China; email: lgh0603@126.com; Y. Wang; Department of Comprehensive Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, No. 17, Panjiayuan Nanli, Chaoyang District, 100021, China; email: wangyf@cicams.ac.cn; CODEN: BCMAC&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 6; Correspondence Address: T. Ledieu; INSERM, UMR 1099, Rennes, France; email: thibault.ledieu@gmail.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 10&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 13; Correspondence Address: R. Xu; Medical Informatics Program, Center for Clinical Investigation, Case Western Reserve University, Cleveland, 44106, United States; email: rxx@case.edu; CODEN: JBIOB&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 13; Correspondence Address: S.-Y. Jung; College of Pharmacy, Chung-Ang University, Seoul, 06974, South Korea; email: jsyoung@cau.ac.kr; S.-Y. Jung; Department of Global Innovative Drugs, Graduate School of Chung-Ang University, Seoul, 06974, South Korea; email: jsyoung@cau.ac.kr&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 16; CODEN: BBMIC&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;23&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;67&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;3&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;3&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;40&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;6&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;6&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;23&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;8&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;11&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;24&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;11&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;12&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;35&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;13&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;15&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;36&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2029791098&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:2212-3911"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Raghuvanshi</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Rahman</foaf:surname>
                        <foaf:givenName>M.A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Posa</foaf:surname>
                        <foaf:givenName>M.K.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kumar</foaf:surname>
                        <foaf:givenName>A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1252"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>postmarketing surveillance</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>sex difference</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>groups by age</dc:subject>
        <dc:subject>osteomyelitis</dc:subject>
        <dc:subject>canagliflozin</dc:subject>
        <dc:subject>dolutegravir</dc:subject>
        <dc:subject>drug approval</dc:subject>
        <dc:subject>gout</dc:subject>
        <dc:subject>hematochezia</dc:subject>
        <dc:subject>hemoptysis</dc:subject>
        <dc:subject>hyperglycemia</dc:subject>
        <dc:subject>ibrutinib</dc:subject>
        <dc:subject>kidney failure</dc:subject>
        <dc:subject>leukopenia</dc:subject>
        <dc:subject>macitentan</dc:subject>
        <dc:subject>pancreatitis</dc:subject>
        <dc:subject>pomalidomide</dc:subject>
        <dc:title>Identification of Novel Signals Associated with US-FDA Approved Drugs (2013) Using Disproportionality Analysis</dc:title>
        <dcterms:abstract>Background: Drugs are related with various adverse drug reactions (ADRs), however, many unexpected ADRs of drugs are reported through post-marketing surveillance. Aim: The current study's goal is to uncover potential signals connected with FDA-approved medications in the United States (2013). Methods: Open Vigil 2.1-MedDRA-v24 (data 20004Q1-2021Q3) was used as a tool to query the FAERS data. To find possible signals, disproportionality measures such as Proportional Reporting Ratio (PRR 2) with associated Chi-square value, Reporting Odds Ratio (ROR 2) with 95% confidence interval, and case count (3) were calculated. Results: A total of eight potential signals were identified with five drugs. Positive signals were found with pomalidomide, canagliflozin, dolutegravir sodium, macitentan and ibrutinib. Conclusion: However, further causality assessment is required to confirm the association of these drugs with identified potential signals.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079820</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2029791098&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>395-401</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:2212-3911">
        <prism:volume>19</prism:volume>
        <dc:title>Current Drug Safety</dc:title>
        <dc:identifier>DOI 10.2174/0115748863276447231108092936</dc:identifier>
        <prism:number>3</prism:number>
        <dcterms:alternative>Curr. Drug Saf.</dcterms:alternative>
        <dc:identifier>ISSN 2212-3911</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1252">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Included&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2029490186&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>19</prism:volume>
                <dc:title>PLoS ONE</dc:title>
                <dc:identifier>DOI 10.1371/journal.pone.0296450</dc:identifier>
                <prism:number>1</prism:number>
                <dcterms:alternative>PLoS ONE</dcterms:alternative>
                <dc:identifier>ISSN 1932-6203</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Uneda</foaf:surname>
                        <foaf:givenName>K.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kawai</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kaneko</foaf:surname>
                        <foaf:givenName>A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kayo</foaf:surname>
                        <foaf:givenName>T.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Akiba</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ishigami</foaf:surname>
                        <foaf:givenName>T.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yoshida-Komiya</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Suzuki</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mitsuma</foaf:surname>
                        <foaf:givenName>T.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1249"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>age</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>combination drug therapy</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>disease course</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>heart failure</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>hypertension</dc:subject>
        <dc:subject>*Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>*Pharmacovigilance</dc:subject>
        <dc:subject>*Social Media</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse drug reaction</dc:subject>
        <dc:subject>Adverse drug reaction (ADRs)</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>Adverse drug reactions</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>Aged</dc:subject>
        <dc:subject>cardiotoxicity</dc:subject>
        <dc:subject>clinical feature</dc:subject>
        <dc:subject>bleeding</dc:subject>
        <dc:subject>disability</dc:subject>
        <dc:subject>disproportionality analysis</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>bradycardia</dc:subject>
        <dc:subject>cardiomyopathy</dc:subject>
        <dc:subject>epidemiology</dc:subject>
        <dc:subject>FAERS</dc:subject>
        <dc:subject>heart arrhythmia</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>abdominal pain</dc:subject>
        <dc:subject>constipation</dc:subject>
        <dc:subject>gastrointestinal disease</dc:subject>
        <dc:subject>coronary artery disease</dc:subject>
        <dc:subject>corticosteroid</dc:subject>
        <dc:subject>fatality</dc:subject>
        <dc:subject>ASTHMA</dc:subject>
        <dc:subject>body weight</dc:subject>
        <dc:subject>Adverse event</dc:subject>
        <dc:subject>anaphylaxis</dc:subject>
        <dc:subject>data analysis software</dc:subject>
        <dc:subject>Data mining</dc:subject>
        <dc:subject>Data Mining</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>dementia</dc:subject>
        <dc:subject>disease association</dc:subject>
        <dc:subject>DISPROPORTIONALITY</dc:subject>
        <dc:subject>drug use</dc:subject>
        <dc:subject>EFFICACY</dc:subject>
        <dc:subject>adverse drug events</dc:subject>
        <dc:subject>asthma</dc:subject>
        <dc:subject>chronic kidney failure</dc:subject>
        <dc:subject>clinical trial (topic)</dc:subject>
        <dc:subject>drug</dc:subject>
        <dc:subject>drug effect</dc:subject>
        <dc:subject>Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>bronchitis</dc:subject>
        <dc:subject>clinical outcome</dc:subject>
        <dc:subject>10-fold cross-validation</dc:subject>
        <dc:subject>ACID</dc:subject>
        <dc:subject>aging</dc:subject>
        <dc:subject>alectinib</dc:subject>
        <dc:subject>ALK INHIBITORS</dc:subject>
        <dc:subject>allergic rhinitis</dc:subject>
        <dc:subject>ALLERGY</dc:subject>
        <dc:subject>Amyloid cardiomyopathy</dc:subject>
        <dc:subject>Amyloid Neuropathies, Familial</dc:subject>
        <dc:subject>AMYLOIDOSIS</dc:subject>
        <dc:subject>Amyloidosis, Hereditary, Transthyretin-Related</dc:subject>
        <dc:subject>anaplastic lymphoma kinase inhibitor</dc:subject>
        <dc:subject>anaplastic lymphoma kinase tyrosine kinase inhibitors</dc:subject>
        <dc:subject>ANTIBODIES</dc:subject>
        <dc:subject>atopic dermatitis</dc:subject>
        <dc:subject>benralizumab</dc:subject>
        <dc:subject>benzoxazole derivative</dc:subject>
        <dc:subject>Benzoxazoles</dc:subject>
        <dc:subject>brigatinib</dc:subject>
        <dc:subject>CARDIAC-TAMPONADE</dc:subject>
        <dc:subject>cardiopulmonary arrest</dc:subject>
        <dc:subject>CELL LUNG-CANCER</dc:subject>
        <dc:subject>ceritinib</dc:subject>
        <dc:subject>Chinese drug</dc:subject>
        <dc:subject>Chinese medicine</dc:subject>
        <dc:subject>chronic urticaria</dc:subject>
        <dc:subject>CNKI database</dc:subject>
        <dc:subject>crizotinib</dc:subject>
        <dc:subject>CRIZOTINIB TREATMENT</dc:subject>
        <dc:subject>danazol</dc:subject>
        <dc:subject>Danazol</dc:subject>
        <dc:subject>diuretic agent</dc:subject>
        <dc:subject>DOUBLE-BLIND</dc:subject>
        <dc:subject>drug bioavailability</dc:subject>
        <dc:subject>drug megadose</dc:subject>
        <dc:subject>dupilumab</dc:subject>
        <dc:subject>ELDERLY-PATIENT</dc:subject>
        <dc:subject>Evaluation results</dc:subject>
        <dc:subject>EVENTS</dc:subject>
        <dc:subject>familial amyloid polyneuropathy</dc:subject>
        <dc:subject>fasenra pen</dc:subject>
        <dc:subject>Female</dc:subject>
        <dc:subject>follow up</dc:subject>
        <dc:subject>food allergy</dc:subject>
        <dc:subject>gastric inhibitory polypeptide</dc:subject>
        <dc:subject>gender</dc:subject>
        <dc:subject>gestrinone</dc:subject>
        <dc:subject>GIP</dc:subject>
        <dc:subject>glucagon like peptide 1 receptor agonist</dc:subject>
        <dc:subject>Glycyrrhiza</dc:subject>
        <dc:subject>Glycyrrhiza extract</dc:subject>
        <dc:subject>gong liu xiao jiao nang</dc:subject>
        <dc:subject>gynecological examination</dc:subject>
        <dc:subject>Health</dc:subject>
        <dc:subject>heart left ventricle failure</dc:subject>
        <dc:subject>heart tamponade</dc:subject>
        <dc:subject>hot flush</dc:subject>
        <dc:subject>hyperaldosteronism</dc:subject>
        <dc:subject>hypersensitivity</dc:subject>
        <dc:subject>Hypertension</dc:subject>
        <dc:subject>HYPERTENSION</dc:subject>
        <dc:subject>Identification method</dc:subject>
        <dc:title>Analysis of clinical factors associated with Kampo formula-induced pseudoaldosteronism based on self-reported information from the Japanese Adverse Drug Event Report database</dc:title>
        <dcterms:abstract>Drug-induced pseudoaldosteronism is a typical adverse effect of Kampo formulas. Previous research described the potential risks of Kampo formula-linked pseudoaldosteronism. However, few studies assessed the risk factors using a real-world database and a data-mining approach. Using the Japanese Adverse Drug Event Report database, we extracted pseudoaldosteronism reports for 148 Kampo formulas covered by Japanese national health insurance. Adverse events were decided according to the preferred terminology of the Medical Dictionary for Regulatory Activities/Japanese version 25.1. We calculated reporting odds ratio (RORs) and identified Kampo formulas as suspected causes of pseudoaldosteronism. Moreover, we evaluated clinical factors associated with Kampo formula-induced pseudoaldosteronism via logistic regression. From April 2004 to November 2022, 6334 adverse events related to the Kampo formulas were reported. We selected 2471 reports containing complete clinical data, including 210 reports on pseudoaldosteronism. In the pseudoaldosteronism group, 69.0% of patients were female, and 85.2% were ≥70 years old. The formulas most commonly associated with pseudoaldosteronism were Shakuyakukanzoto, Yokukansan, and Ryokeijutsukanto (ROR [95% confidence interval {CI}] = 18.3 [13.0–25.9], 8.1 [5.4–12.0], and 5.5 [1.4–21.9], respectively). Logistic analysis identified female sex (odds ratio [OR] [95% CI] = 1.7 [1.2–2.6]; P = 0.006), older age (≥70, 5.0 [3.2–7.8]; P &lt; 0.001), low body weight (&lt;50 kg, 2.2 [1.5–3.2]; P &lt; 0.001), diuretics usage (2.1 [1.3–4.8]; P = 0.004), hypertension (1.6 [1.1–2.4]; P = 0.014), and dementia (7.0 [4.2–11.6]; P &lt; 0.001) as pseudoaldosteronism-related factors. Additionally, the daily Glycyrrhiza dose (OR = 2.1 [1.9–2.3]; P &lt; 0.001) and duration of administration (&gt;14 days, OR = 2.8 [1.7–4.5]; P &lt; 0.001) were associated with adverse events. We did not observe an interaction between aging and hypertension. Careful follow-up is warranted during long-term Glycyrrhiza-containing Kampo formula use in patients with multiple clinical factors for pseudoaldosteronism.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079819</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2029490186&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Memo rdf:about="#item_1249">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 1; Correspondence Address: F. Wu; Department of Pharmacy, Fuwai Yunnan Hospital, Chinese Academy of Medical Sciences, Kunming, China; email: wufan@kmmu.edu.cn&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 1; Correspondence Address: F. Zou; Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, China; email: 747333233@qq.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 6; Correspondence Address: K. Uneda; Department of Kampo Medicine, Aizu Medical Center, Fukushima Medical University, Fukushima, Aizuwakamatsu, Japan; email: uneda@fmu.ac.jp; CODEN: POLNC&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 14; Correspondence Address: Y. Zheng; Department of Gynaecology, Maternal and Child Health Hospital of Foshan, Foshan City, No. 11 Renmin West Road, Chancheng District, 528000, China; email: zhengyh2013916@163.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 21; Correspondence Address: S. Matsuda; Chugai Pharmaceutical Co Ltd, Drug Safety Data Management Department, Chuo-ku Tokyo, 2-1-1 Nihonbashi-Muromachi, 1038324, Japan; email: matsudasni@chugai-pharm.co.jp&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 26; Correspondence Address: L. Chen; Department of Pharmacy, West China Second Hospital, Sichuan University, Chengdu, China; email: chenl_hxey@scu.edu.cn&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 39; Correspondence Address: K. Guan; Department of Allergy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment on Allergic Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China; email: dr_guankai@126.com; B. Zhao; Department of Pharmacy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing, China; email: zhaobin@pumch.cn&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 144; Correspondence Address: I. Korkontzelos; National Centre for Text Mining, School of Computer Science, University of Manchester, Manchester Institute of Biotechnology, M1 7DN Manchester, 131 Princess Street, United Kingdom; email: Ioannis.Korkontzelos@manchester.ac.uk; CODEN: JBIOB&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;34&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;23&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;6&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;6&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;34&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;7&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;8&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;14&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;26&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;26&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;51&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;32&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;35&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;26&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;87&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;89&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;45&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Excluded&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2029448025&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>15</prism:volume>
                <dc:title>Frontiers in Pharmacology</dc:title>
                <dc:identifier>DOI 10.3389/fphar.2024.1378090</dc:identifier>
                <dcterms:alternative>Front. Pharmacol.</dcterms:alternative>
                <dc:identifier>ISSN 1663-9812</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>She</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Guo</foaf:surname>
                        <foaf:givenName>Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhai</foaf:surname>
                        <foaf:givenName>Q.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Du</foaf:surname>
                        <foaf:givenName>Q.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1250"/>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>alanine aminotransferase</dc:subject>
        <dc:subject>aspartate aminotransferase</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>FAERS</dc:subject>
        <dc:subject>observational study</dc:subject>
        <dc:subject>Medical Dictionary for Regulatory Activities</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>data extraction</dc:subject>
        <dc:subject>abemaciclib</dc:subject>
        <dc:subject>apoptosis</dc:subject>
        <dc:subject>astrocyte</dc:subject>
        <dc:subject>carbon metabolism</dc:subject>
        <dc:subject>carcinogenesis</dc:subject>
        <dc:subject>cell proliferation</dc:subject>
        <dc:subject>cyclin dependent kinase 4</dc:subject>
        <dc:subject>cyclin dependent kinase 6</dc:subject>
        <dc:subject>cyclin-dependent kinase 4/6 inhibitors</dc:subject>
        <dc:subject>disproportionality analyses</dc:subject>
        <dc:subject>drug-induced liver injuries</dc:subject>
        <dc:subject>drug-induced liver injury</dc:subject>
        <dc:subject>E1A associated p300 protein</dc:subject>
        <dc:subject>gene expression</dc:subject>
        <dc:subject>gene interaction</dc:subject>
        <dc:subject>gene network analysis</dc:subject>
        <dc:subject>gene ontology</dc:subject>
        <dc:subject>insulin resistance</dc:subject>
        <dc:subject>liver function</dc:subject>
        <dc:subject>microarray analysis</dc:subject>
        <dc:subject>microRNA</dc:subject>
        <dc:subject>OpenVigil</dc:subject>
        <dc:subject>overall survival</dc:subject>
        <dc:subject>palbociclib</dc:subject>
        <dc:subject>pathway enrichment analysis</dc:subject>
        <dc:subject>protein analysis</dc:subject>
        <dc:subject>protein p53</dc:subject>
        <dc:subject>protein phosphorylation</dc:subject>
        <dc:subject>protein protein interaction</dc:subject>
        <dc:subject>protein-protein interaction</dc:subject>
        <dc:subject>ribociclib</dc:subject>
        <dc:subject>signal transduction</dc:subject>
        <dc:subject>STAT3 protein</dc:subject>
        <dc:subject>ubiquitination</dc:subject>
        <dc:subject>Wnt signaling</dc:subject>
        <dc:title>CDK4/6 inhibitors in drug-induced liver injury: a pharmacovigilance study of the FAERS database and analysis of the drug–gene interaction network</dc:title>
        <dcterms:abstract>Objective: The aim of this study was to investigate the potential risk of drug-induced liver injury (DILI) caused by the CDK4/6 inhibitors (CDK4/6is abemaciclib, ribociclib, and palbociclib by comprehensively analyzing the FDA Adverse Event Reporting System (FAERS) database. Moreover, potential toxicological mechanisms of CDK4/6is-related liver injury were explored via drug–gene network analysis. Methods: In this retrospective observational study, we collected reports of DILI associated with CDK4/6i use from the FAERS dated January 2014 to March 2023. We conducted disproportionality analyses using the reporting odds ratio (ROR) with a 95% confidence interval (CI). Pathway enrichment analysis and drug-gene network analyses were subsequently performed to determine the potential mechanisms underlying CDK4/6i-induced liver injury. Results: We found positive signals for DILI with ribociclib (ROR = 2.60) and abemaciclib (ROR = 2.37). DILIs associated with liver-related investigations, signs, and symptoms were confirmed in all three reports of CDK4/6is. Moreover, ascites was identified as an unlisted hepatic adverse effect of palbociclib. We isolated 189 interactive target genes linking CDK4/6 inhibitors to hepatic injury. Several key genes, such as STAT3, HSP90AA1, and EP300, were revealed via protein-protein analysis, emphasizing their central roles within the network. KEGG pathway enrichment of these genes highlighted multiple pathways. Conclusion: Our study revealed variations in hepatobiliary toxicity among the different CDK4/6 inhibitors, with ribociclib showing the highest risk of liver injury, followed by abemaciclib, while palbociclib appeared relatively safe. Our findings emphasize the need for cautious use of CDK4/6 inhibitors, and regular liver function monitoring is recommended for long-term CDK4/6 inhibitor use.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079818</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2029448025&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Memo rdf:about="#item_1250">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 6; Correspondence Address: Q. Du; Department of Pharmacy, Fudan University Shanghai Cancer Center, Shanghai, China; email: dujoan-88@163.com; Z. Zhang; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China; email: spencezhang@hotmail.com&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Excluded&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2030100876&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1178-2005"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lan</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hu</foaf:surname>
                        <foaf:givenName>D.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Huang</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ma</foaf:surname>
                        <foaf:givenName>Q.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xu</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>He</foaf:surname>
                        <foaf:givenName>Q.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1251"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>factual database</dc:subject>
        <dc:subject>*Data Mining</dc:subject>
        <dc:subject>Adult</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>Adverse drug reactions</dc:subject>
        <dc:subject>adverse events</dc:subject>
        <dc:subject>Aged</dc:subject>
        <dc:subject>Algorithms</dc:subject>
        <dc:subject>antiinfective agent</dc:subject>
        <dc:subject>calculation</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>depression</dc:subject>
        <dc:subject>epidemiology</dc:subject>
        <dc:subject>FAERS</dc:subject>
        <dc:subject>clinical practice</dc:subject>
        <dc:subject>dysphoria</dc:subject>
        <dc:subject>corticosteroid</dc:subject>
        <dc:subject>*Drug Interactions</dc:subject>
        <dc:subject>amoxicillin</dc:subject>
        <dc:subject>antineoplastic agent</dc:subject>
        <dc:subject>azithromycin</dc:subject>
        <dc:subject>budesonide</dc:subject>
        <dc:subject>carboplatin</dc:subject>
        <dc:subject>ceftriaxone</dc:subject>
        <dc:subject>celecoxib</dc:subject>
        <dc:subject>cholangitis</dc:subject>
        <dc:subject>clarithromycin</dc:subject>
        <dc:subject>Data mining</dc:subject>
        <dc:subject>Data Mining</dc:subject>
        <dc:subject>Databases, Factual</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>drug utilization</dc:subject>
        <dc:subject>cystitis</dc:subject>
        <dc:subject>demographics</dc:subject>
        <dc:subject>coronavirus disease 2019</dc:subject>
        <dc:subject>disease association</dc:subject>
        <dc:subject>Disproportionality analysis</dc:subject>
        <dc:subject>adverse drug events</dc:subject>
        <dc:subject>clinical trial (topic)</dc:subject>
        <dc:subject>comparative study</dc:subject>
        <dc:subject>drug</dc:subject>
        <dc:subject>drug effect</dc:subject>
        <dc:subject>Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>ACARBOSE</dc:subject>
        <dc:subject>accidental death</dc:subject>
        <dc:subject>ACUTE-RENAL-FAILURE</dc:subject>
        <dc:subject>Administration, Inhalation</dc:subject>
        <dc:subject>Administration, Intranasal</dc:subject>
        <dc:subject>Adrenal Cortex Hormones</dc:subject>
        <dc:subject>Adverse drug reaction reporting systems</dc:subject>
        <dc:subject>agoraphobia</dc:subject>
        <dc:subject>allergic conjunctivitis</dc:subject>
        <dc:subject>amiloride</dc:subject>
        <dc:subject>amitriptyline</dc:subject>
        <dc:subject>amoxapine</dc:subject>
        <dc:subject>amphetamine</dc:subject>
        <dc:subject>ANTIDEPRESSANT</dc:subject>
        <dc:subject>antifungal agent</dc:subject>
        <dc:subject>Antineoplastic Agents</dc:subject>
        <dc:subject>Antiviral Agents</dc:subject>
        <dc:subject>antivirus agent</dc:subject>
        <dc:subject>ATOPIC-DERMATITIS</dc:subject>
        <dc:subject>atorvastatin</dc:subject>
        <dc:subject>beclometasone</dc:subject>
        <dc:subject>Betacoronavirus</dc:subject>
        <dc:subject>bile duct cyst</dc:subject>
        <dc:subject>bronchitis</dc:subject>
        <dc:subject>candidiasis</dc:subject>
        <dc:subject>captopril</dc:subject>
        <dc:subject>certolizumab pegol</dc:subject>
        <dc:subject>ciclesonide</dc:subject>
        <dc:subject>clinical outcome</dc:subject>
        <dc:subject>Clinical Trials as Topic</dc:subject>
        <dc:subject>CMap</dc:subject>
        <dc:subject>colecalciferol</dc:subject>
        <dc:subject>comprehensive</dc:subject>
        <dc:subject>Computational methods</dc:subject>
        <dc:subject>Computational pharmacology</dc:subject>
        <dc:subject>Computational predictions</dc:subject>
        <dc:subject>computer</dc:subject>
        <dc:subject>computer model</dc:subject>
        <dc:subject>computer simulation</dc:subject>
        <dc:subject>Computer Simulation</dc:subject>
        <dc:subject>contrast medium</dc:subject>
        <dc:subject>COPD</dc:subject>
        <dc:subject>Coronavirus infection</dc:subject>
        <dc:subject>Coronavirus Infections</dc:subject>
        <dc:subject>COVID-19 drug</dc:subject>
        <dc:subject>devices</dc:subject>
        <dc:subject>dexamethasone</dc:subject>
        <dc:subject>diagnosis</dc:subject>
        <dc:subject>diclofenac</dc:subject>
        <dc:subject>Disproportionality  analysis</dc:subject>
        <dc:subject>disproportionate reporting rate</dc:subject>
        <dc:subject>Disproportionate reporting rate</dc:subject>
        <dc:subject>dissociation</dc:subject>
        <dc:subject>dissociative disorder</dc:subject>
        <dc:subject>doxepin</dc:subject>
        <dc:subject>doxycycline</dc:subject>
        <dc:subject>DRUG</dc:subject>
        <dc:subject>drug drug interaction</dc:subject>
        <dc:subject>drug efficacy</dc:subject>
        <dc:subject>drug interaction</dc:subject>
        <dc:subject>Drug interactions</dc:subject>
        <dc:subject>Drug Interactions</dc:subject>
        <dc:subject>drug labeling</dc:subject>
        <dc:subject>drug safety surveillance</dc:subject>
        <dc:subject>Drug safety surveillance</dc:subject>
        <dc:subject>Drug-drug interaction</dc:subject>
        <dc:subject>Drug-drug interactions</dc:subject>
        <dc:subject>drug-induced pruritus</dc:subject>
        <dc:subject>Electronic medical record</dc:subject>
        <dc:subject>emphysema</dc:subject>
        <dc:subject>enalapril</dc:subject>
        <dc:subject>enoxaparin</dc:subject>
        <dc:subject>esketamine</dc:subject>
        <dc:subject>esophagitis</dc:subject>
        <dc:subject>estradiol</dc:subject>
        <dc:subject>eye infection</dc:subject>
        <dc:subject>eye irritation</dc:subject>
        <dc:title>Comparison of Infection Risks Between Various Inhaled and Intranasal Corticosteroids: A Pharmacovigilance Analysis Based on the FAERS Database</dc:title>
        <dcterms:abstract>Purpose: This study conducted a pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) database to compare the infection risk of inhaled or nasal Beclomethasone, Fluticasone, Budesonide, Ciclesonide, Mometasone, and Triamcinolone Acetonide. Methods: We used proportional imbalance analysis to evaluate the correlation between ICS/INCs and infection events. The data was extracted from the FAERS database from April 2015 to September 2023. Further analysis was conducted on the clinical characteristics, site of infection, and pathogenic bacteria of ICS and INCs infection adverse events (AEs). We used bubble charts to display their top 5 infection adverse events. Results: We analyzed 21,837 reports of infection AEs related to ICS and INCs, with an average age of 62.12 years. Among them, 61.14% of infection reports were related to females. One-third of infections reported to occur in the lower respiratory tract with Fluticasone, Budesonide, Ciclesonidec, and Mometasone; over 40% of infections reported by Triamcinolone Acetonide were eye infections; the rate of oral infections caused by Beclomethasone were 7.39%. The reported rates of fungal and viral infections caused by beclomethasone were 21.15% and 19.2%, respectively. The mycobacterial infections caused by Budesonide and Ciclesonidec account for 3.29% and 2.03%, respectively. Bubble plots showed that the ICS group had more fungal infections, oral infections, pneumonia, tracheitis, etc. The INCs group had more eye symptoms, rhinitis, sinusitis, nasopharyngitis, etc. Conclusion: Women who use ICS and INCs are more prone to infection events. Compared to Budesonide, Fluticasone seemed to have a higher risk of pneumonia and oral candidiasis. Mometasone might lead to more upper respiratory tract infections. The risk of oral infection was higher with Beclomethasone. Beclomethasone causes more fungal and viral infections, while Ciclesonide and Budesonide are more susceptible to mycobacterial infections.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079821</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2030100876&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>1457-1469</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1178-2005">
        <prism:volume>19</prism:volume>
        <dc:title>International Journal of COPD</dc:title>
        <dc:identifier>DOI 10.2147/COPD.S466588</dc:identifier>
        <dcterms:alternative>Int. J. COPD</dcterms:alternative>
        <dc:identifier>ISSN 1178-2005</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1251">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: Y. Lan; Department of Pharmacy, Affiliated Hospital of Southwest Jiaotong University, The Third People’s Hospital of Chengdu, Chengdu, Sichuan, 610031, China; email: lanying0212@126.com; L. Chen; Department of Pharmacology, Faculty of Medicine, University of the Basque Country, UPV/EHU, Leioa, Spain; email: chenl_hxey@scu.edu.cn&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 4; Correspondence Address: D. Chen; The Department of Anesthesiology, Ningbo Medical Center Lihuili Hospital, Ningbo, China; email: chen_dd163@163.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 5; Correspondence Address: Y. Uesawa; Department of Medical Molecular Informatics, Meiji Pharmaceutical University, Kiyose, 2-522-1 Noshio, Tokyo, 204-8588, Japan; email: uesawa@my-pharm.ac.jp&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 6; Correspondence Address: J. Huang; Departmant of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States; email: jing14@upenn.edu&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 12; Correspondence Address: J. Fang; Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, No. 12 Jichang Road, 510000, China; email: fangjs@gzucm.edu.cn; C. Cai; Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China; email: chuipu@gzucm.edu.cn; CODEN: FCTOD&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 29; Correspondence Address: K.E. Hultgren; College of Pharmacy, Purdue University, West Lafayette, 575 W Stadium Ave, United States; email: khultgre@purdue.edu&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 46; Correspondence Address: I. Jung; Division of Biostatistics, Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, 50-1 Yonsei-ro, Seodaemun-gu, 03722, South Korea; email: ijung@yuhs.ac&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 146; Correspondence Address: R. Safdari; Department of Health Information Management, School of Allied-Health Sciences, Tehran University of Medical Sciences, Tehran, Iran; email: rsafdari@tums.ac.ir; CODEN: JBIOB&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;26&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;4&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;4&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;41&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;5&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;5&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;60&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;6&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;7&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;21&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;13&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;13&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;55&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;41&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;43&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;26&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Maybe&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2029132112&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>15</prism:volume>
                <dc:title>Frontiers in Pharmacology</dc:title>
                <dc:identifier>DOI 10.3389/fphar.2024.1333662</dc:identifier>
                <dcterms:alternative>Front. Pharmacol.</dcterms:alternative>
                <dc:identifier>ISSN 1663-9812</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhao</foaf:surname>
                        <foaf:givenName>B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Fu</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Cui</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Luo</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1256"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>postmarketing surveillance</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>disproportionality analysis</dc:subject>
        <dc:subject>FAERS</dc:subject>
        <dc:subject>fatigue</dc:subject>
        <dc:subject>nausea</dc:subject>
        <dc:subject>Medical Dictionary for Regulatory Activities</dc:subject>
        <dc:subject>anemia</dc:subject>
        <dc:subject>data analysis software</dc:subject>
        <dc:subject>diarrhea</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>analysis</dc:subject>
        <dc:subject>hyperlipidemia</dc:subject>
        <dc:subject>liver metastasis</dc:subject>
        <dc:subject>mouth pain</dc:subject>
        <dc:subject>EFFICACY</dc:subject>
        <dc:subject>breast disease</dc:subject>
        <dc:subject>carcinogenesis</dc:subject>
        <dc:subject>angiomyolipoma</dc:subject>
        <dc:subject>arterial stenosis</dc:subject>
        <dc:subject>back propagation neural network</dc:subject>
        <dc:subject>biliary ischemia</dc:subject>
        <dc:subject>BREAST-CANCER</dc:subject>
        <dc:subject>cardiac graft rejection</dc:subject>
        <dc:subject>decreased appetite</dc:subject>
        <dc:subject>endometrium carcinoma</dc:subject>
        <dc:subject>everolimus</dc:subject>
        <dc:subject>Everolimus</dc:subject>
        <dc:subject>hemangiofibroma</dc:subject>
        <dc:subject>hepatic artery stenosis</dc:subject>
        <dc:subject>human experiment</dc:subject>
        <dc:subject>human herpesvirus 7 infection</dc:subject>
        <dc:subject>INDUCED PNEUMONITIS</dc:subject>
        <dc:subject>INHIBITOR</dc:subject>
        <dc:subject>insulin</dc:subject>
        <dc:subject>insulin release</dc:subject>
        <dc:subject>ischemia</dc:subject>
        <dc:subject>kidney metastasis</dc:subject>
        <dc:subject>lymphangioleiomyomatosis</dc:subject>
        <dc:subject>lymphocele</dc:subject>
        <dc:subject>MANAGEMENT</dc:subject>
        <dc:subject>medication error</dc:subject>
        <dc:subject>mesoblastic nephroma</dc:subject>
        <dc:subject>metastatic renal cell carcinoma</dc:subject>
        <dc:subject>pancreas islet cell tumor</dc:subject>
        <dc:subject>pleura metastasis</dc:subject>
        <dc:subject>pneumonia</dc:subject>
        <dc:subject>pulmonary carcinoid</dc:subject>
        <dc:subject>R software version 4.0.2</dc:subject>
        <dc:subject>rash</dc:subject>
        <dc:subject>renal cell carcinoma</dc:subject>
        <dc:subject>rhabdomyoma</dc:subject>
        <dc:subject>sirolimus</dc:subject>
        <dc:subject>stomatitis</dc:subject>
        <dc:subject>SUNITINIB</dc:subject>
        <dc:subject>THERAPY</dc:subject>
        <dc:subject>thorax drainage</dc:subject>
        <dc:subject>tuberous sclerosis</dc:subject>
        <dc:subject>urinary tract fistula</dc:subject>
        <dc:title>A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system</dc:title>
        <dcterms:abstract>Background: Everolimus is an inhibitor of the mammalian target of rapamycin and is used to treat various tumors. The presented study aimed to evaluate the Everolimus-associated adverse events (AEs) through data mining of the US Food and Drug Administration Adverse Event Reporting System (FAERS). Methods: The AE records were selected by searching the FDA Adverse Event Reporting System database from the first quarter of 2009 to the first quarter of 2022. Potential adverse event signals were mined using the disproportionality analysis, including reporting odds ratio the proportional reporting ratio the Bayesian confidence propagation neural network and the empirical Bayes geometric mean and MedDRA was used to systematically classify the results. Results: A total of 24,575 AE reports of Everolimus were obtained using data from the FAERS database, and Everolimus-induced AEs occurrence targeted 24 system organ classes after conforming to the four algorithms simultaneously. The common significant SOCs were identified, included benign, malignant and unspecified neoplasms, reproductive system and breast disorders, etc. The significant AEs were then mapped to preferred terms such as stomatitis, pneumonitis and impaired insulin secretion, which have emerged in the study usually reported in patients with Everolimus. Of note, unexpected significant AEs, including biliary ischaemia, angiofibroma, and tuberous sclerosis complex were uncovered in the label. Conclusion: This study provided novel insights into the monitoring, surveillance, and management of adverse drug reaction associated with Everolimus. The outcome of serious adverse events and the corresponding detection signals, as well as the unexpected significant adverse events signals are worthy of attention in order to improving clinical medication safety during treatment of Everolimus.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079815</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2029132112&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Memo rdf:about="#item_1256">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 24; Correspondence Address: L. Luo; Department of Breast Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, China; email: Lanluo@whu.edu.cn&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;22&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;22&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;32&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Included&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2028810209&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>23</prism:volume>
                <dc:title>Expert Opinion on Drug Safety</dc:title>
                <dc:identifier>DOI 10.1080/14740338.2024.2322712</dc:identifier>
                <prism:number>11</prism:number>
                <dcterms:alternative>Expert Opin. Drug Saf.</dcterms:alternative>
                <dc:identifier>ISSN 1744-764X</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xiong</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Huang</foaf:surname>
                        <foaf:givenName>T.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1255"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>hypertension</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>postmarketing surveillance</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>cardiovascular disease</dc:subject>
        <dc:subject>cerebrovascular accident</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>limb fracture</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>nervousness</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>visual impairment</dc:subject>
        <dc:subject>diplopia</dc:subject>
        <dc:subject>artery occlusion</dc:subject>
        <dc:subject>blindness</dc:subject>
        <dc:subject>brain infarction</dc:subject>
        <dc:subject>retinal artery occlusion</dc:subject>
        <dc:subject>cataract</dc:subject>
        <dc:subject>blurred vision</dc:subject>
        <dc:subject>dry eye</dc:subject>
        <dc:subject>glaucoma</dc:subject>
        <dc:subject>coughing</dc:subject>
        <dc:subject>diabetes mellitus</dc:subject>
        <dc:subject>hearing impairment</dc:subject>
        <dc:subject>memory disorder</dc:subject>
        <dc:subject>eye irritation</dc:subject>
        <dc:subject>choroidal effusion</dc:subject>
        <dc:subject>adrenal tumor</dc:subject>
        <dc:subject>anterior eye chamber</dc:subject>
        <dc:subject>anterior eye chamber disease</dc:subject>
        <dc:subject>aortic aneurysm</dc:subject>
        <dc:subject>aortic regurgitation</dc:subject>
        <dc:subject>bone erosion</dc:subject>
        <dc:subject>brolucizumab</dc:subject>
        <dc:subject>cornea edema</dc:subject>
        <dc:subject>cornea opacity</dc:subject>
        <dc:subject>corneal deposit</dc:subject>
        <dc:subject>dry throat</dc:subject>
        <dc:subject>epiphora</dc:subject>
        <dc:subject>eye discomfort</dc:subject>
        <dc:subject>eye edema</dc:subject>
        <dc:subject>eye inflammation</dc:subject>
        <dc:subject>eye pain</dc:subject>
        <dc:subject>eye swelling</dc:subject>
        <dc:subject>eye synechia</dc:subject>
        <dc:subject>eyelid edema</dc:subject>
        <dc:subject>hyperreflexia</dc:subject>
        <dc:subject>intraocular hemorrhage</dc:subject>
        <dc:subject>intraocular hypertension</dc:subject>
        <dc:subject>intraocular hypotension</dc:subject>
        <dc:subject>iridocyclitis</dc:subject>
        <dc:subject>iritis</dc:subject>
        <dc:subject>laryngitis</dc:subject>
        <dc:subject>metamorphopsia</dc:subject>
        <dc:subject>microscopic colitis</dc:subject>
        <dc:subject>ocular fibrosis</dc:subject>
        <dc:subject>ocular hyperemia</dc:subject>
        <dc:subject>optic nerve atrophy</dc:subject>
        <dc:subject>optic neuritis</dc:subject>
        <dc:subject>osteolysis</dc:subject>
        <dc:subject>papilledema</dc:subject>
        <dc:subject>paresthesia</dc:subject>
        <dc:subject>periorbital edema</dc:subject>
        <dc:subject>photophobia</dc:subject>
        <dc:subject>photopsia</dc:subject>
        <dc:subject>retina blood vessel occlusion</dc:subject>
        <dc:subject>retina disease</dc:subject>
        <dc:subject>retina edema</dc:subject>
        <dc:subject>retina exudate</dc:subject>
        <dc:subject>retina hemorrhage</dc:subject>
        <dc:subject>retina ischemia</dc:subject>
        <dc:subject>retina macula hole</dc:subject>
        <dc:subject>retina vasculitis</dc:subject>
        <dc:subject>retinal perivascular sheathing</dc:subject>
        <dc:subject>retinal thickness</dc:subject>
        <dc:subject>rhinorrhea</dc:subject>
        <dc:subject>scar</dc:subject>
        <dc:subject>sneezing</dc:subject>
        <dc:subject>subretinal fluid</dc:subject>
        <dc:subject>systemic disease</dc:subject>
        <dc:subject>tooth abscess</dc:subject>
        <dc:subject>upper limb</dc:subject>
        <dc:subject>visual disorder</dc:subject>
        <dc:subject>visual field defect</dc:subject>
        <dc:subject>vitreous floaters</dc:subject>
        <dc:subject>vitreous opacity</dc:subject>
        <dc:title>Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS)</dc:title>
        <dcterms:abstract>Background: The safety information of brolucizumab primarily comes from clinical trials experience. This study aimed to explore the ocular and systemic adverse events (AEs) associated with brolucizumab among real-world patients through data mining the FDA Adverse Event Reporting System (FAERS) database. Methods: AE reports submitted to the FAERS database between October 2019 and March 2023 were extracted. The reporting odds ratio was used to evaluate AE signals associated with brolucizumab. Results: There were 4,380,839 AE reports extracted from the FAERS database, and 3,313 of which were with brolucizumab as primary suspected. A total of 150 ocular AE signals were identified. Ninety-nine were known ocular AEs listed in brolucizumab’ label, primarily including vision-related AEs, intraocular infections, and retinal disorders. Fifty-one were unexpected ocular AE signals, including keratic precipitates, retinal perivascular sheathing, dry eye, glaucoma, etc. Meanwhile, several serious systemic AE signals, including arterial thromboembolic events and rhinorrhea, were also identified. Conclusions: Several unexpected ocular and systemic AE signals associated with brolucizumab were identified through data mining of the FAERS database.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079814</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2028810209&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>1447-1452</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1255">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Excluded&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2028600544&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>15</prism:volume>
                <dc:title>Frontiers in Pharmacology</dc:title>
                <dc:identifier>DOI 10.3389/fphar.2024.1349543</dc:identifier>
                <dcterms:alternative>Front. Pharmacol.</dcterms:alternative>
                <dc:identifier>ISSN 1663-9812</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Romão</foaf:surname>
                        <foaf:givenName>B.M.S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Duval</foaf:surname>
                        <foaf:givenName>F.V.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lima</foaf:surname>
                        <foaf:givenName>E.C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Silva</foaf:surname>
                        <foaf:givenName>F.A.B.D.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Matos</foaf:surname>
                        <foaf:givenName>G.C.D.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1257"/>
        <dc:subject>acute kidney failure</dc:subject>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data analysis</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>death</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>Adult</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>adverse events</dc:subject>
        <dc:subject>Aged</dc:subject>
        <dc:subject>Algorithms</dc:subject>
        <dc:subject>artificial neural network</dc:subject>
        <dc:subject>calculation</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>cohort analysis</dc:subject>
        <dc:subject>Cytochrome P-450 Enzyme System</dc:subject>
        <dc:subject>cytochrome P450</dc:subject>
        <dc:subject>cyanosis</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>dizziness</dc:subject>
        <dc:subject>abdominal pain</dc:subject>
        <dc:subject>delirium</dc:subject>
        <dc:subject>blindness</dc:subject>
        <dc:subject>*Drug Interactions</dc:subject>
        <dc:subject>*Neural Networks, Computer</dc:subject>
        <dc:subject>accuracy</dc:subject>
        <dc:subject>acetylcysteine</dc:subject>
        <dc:subject>acne</dc:subject>
        <dc:subject>actemra</dc:subject>
        <dc:subject>Bayesian network</dc:subject>
        <dc:subject>biological activity</dc:subject>
        <dc:subject>ciprofloxacin</dc:subject>
        <dc:subject>clarithromycin</dc:subject>
        <dc:subject>abdominal distension</dc:subject>
        <dc:subject>adverse drug reactions</dc:subject>
        <dc:subject>alopecia</dc:subject>
        <dc:subject>anaphylaxis</dc:subject>
        <dc:subject>chemically induced</dc:subject>
        <dc:subject>chill</dc:subject>
        <dc:subject>COVID-19</dc:subject>
        <dc:subject>creatinine</dc:subject>
        <dc:subject>Data mining</dc:subject>
        <dc:subject>Data Mining</dc:subject>
        <dc:subject>Data Mining/*methods</dc:subject>
        <dc:subject>Databases, Factual</dc:subject>
        <dc:subject>diarrhea</dc:subject>
        <dc:subject>congenital malformation</dc:subject>
        <dc:subject>dermatitis</dc:subject>
        <dc:subject>Adverse drug event</dc:subject>
        <dc:subject>bromazepam</dc:subject>
        <dc:subject>coronavirus disease 2019</dc:subject>
        <dc:subject>creatinine blood level</dc:subject>
        <dc:subject>DISPROPORTIONALITY</dc:subject>
        <dc:subject>adverse drug events</dc:subject>
        <dc:subject>comparative study</dc:subject>
        <dc:subject>drug effect</dc:subject>
        <dc:subject>ACUTE-RENAL-FAILURE</dc:subject>
        <dc:subject>captopril</dc:subject>
        <dc:subject>clinical outcome</dc:subject>
        <dc:subject>DRUG</dc:subject>
        <dc:subject>drug drug interaction</dc:subject>
        <dc:subject>amphotericin B</dc:subject>
        <dc:subject>atazanavir</dc:subject>
        <dc:subject>cyclophosphamide</dc:subject>
        <dc:subject>cell proliferation</dc:subject>
        <dc:subject>CELL LUNG-CANCER</dc:subject>
        <dc:subject>drug bioavailability</dc:subject>
        <dc:subject>*Databases, Factual</dc:subject>
        <dc:subject>*Food-Drug Interactions</dc:subject>
        <dc:subject>acenocoumarol</dc:subject>
        <dc:subject>Acute Kidney Injury</dc:subject>
        <dc:subject>adverse drug effects</dc:subject>
        <dc:subject>adverse drug reaction reporting systems/standards</dc:subject>
        <dc:subject>Adverse drug reaction reporting systems/standards</dc:subject>
        <dc:subject>ADVERSE EVENTS</dc:subject>
        <dc:subject>ADVERSE-EVENT REPORTS</dc:subject>
        <dc:subject>afatinib</dc:subject>
        <dc:subject>Aged, 80 and over</dc:subject>
        <dc:subject>allopurinol</dc:subject>
        <dc:subject>amifostine</dc:subject>
        <dc:subject>ANTIBIOTICS</dc:subject>
        <dc:subject>atenolol</dc:subject>
        <dc:subject>auditory hallucination</dc:subject>
        <dc:subject>BASE-LINE CREATININE</dc:subject>
        <dc:subject>belinostat</dc:subject>
        <dc:subject>bisoprolol</dc:subject>
        <dc:subject>blister</dc:subject>
        <dc:subject>brain damage</dc:subject>
        <dc:subject>carbamazepine</dc:subject>
        <dc:subject>carbonate dehydratase II</dc:subject>
        <dc:subject>carrier protein</dc:subject>
        <dc:subject>Carrier Proteins</dc:subject>
        <dc:subject>Cell Proliferation</dc:subject>
        <dc:subject>cell survival</dc:subject>
        <dc:subject>CERIVASTATIN</dc:subject>
        <dc:subject>cetuximab</dc:subject>
        <dc:subject>chest tightness</dc:subject>
        <dc:subject>China</dc:subject>
        <dc:subject>clemastine</dc:subject>
        <dc:subject>COMBINATIONS</dc:subject>
        <dc:subject>Computational Biology/methods</dc:subject>
        <dc:subject>computer program</dc:subject>
        <dc:subject>CONSENSUS</dc:subject>
        <dc:subject>consumer</dc:subject>
        <dc:subject>convulsion</dc:subject>
        <dc:subject>cornea disease</dc:subject>
        <dc:subject>corneal detachment</dc:subject>
        <dc:subject>CRITERIA</dc:subject>
        <dc:subject>cutaneous toxicity</dc:subject>
        <dc:subject>cyclooxygenase 1</dc:subject>
        <dc:subject>cyclooxygenase 2</dc:subject>
        <dc:subject>cytochrome P450 1A2</dc:subject>
        <dc:subject>cytochrome P450 2B6</dc:subject>
        <dc:subject>cytochrome P450 2C11</dc:subject>
        <dc:subject>cytochrome P450 2C8</dc:subject>
        <dc:subject>cytochrome P450 2C9</dc:subject>
        <dc:subject>cytochrome P450 2D6</dc:subject>
        <dc:subject>cytochrome P450 2E1</dc:subject>
        <dc:subject>cytochrome P450 3A4</dc:subject>
        <dc:subject>dacomitinib</dc:subject>
        <dc:subject>DATABASES</dc:subject>
        <dc:subject>deep learning</dc:subject>
        <dc:subject>Deep learning</dc:subject>
        <dc:subject>deep neural network</dc:subject>
        <dc:subject>DeepDDI</dc:subject>
        <dc:subject>diflunisal</dc:subject>
        <dc:subject>dipyrone</dc:subject>
        <dc:subject>drug absorption</dc:subject>
        <dc:subject>drug blood level</dc:subject>
        <dc:title>Detection of potential safety signals related to the use of remdesivir and tocilizumab in the COVID era during pregnancy, resorting to open data from the FDA adverse event reporting system (FAERS)</dc:title>
        <dcterms:abstract>Background: The in-hospital treatment for COVID-19 may include medicines from various therapeutic classes, such as antiviral remdesivir and immunosuppressant tocilizumab. Safety data for these medicines are based on controlled clinical trials and case reports, limiting the knowledge about less frequent, rare or unique population adverse events excluded from clinical trials. Objective: This study aims at analyzing the reports of Adverse Drug Events (ADEs) related to these two medicines, focusing on events in pregnant women and foetuses. Methods: Data from the open-access FDA Adverse Event Reporting System (FAERS) from 2020 to 2022 were used to create a dashboard on the Grafana platform to ease querying and analyzing report events. Potential safety signals were generated using the ROR disproportionality measure. Results: Remdesivir was notified as the primary suspect in 7,147 reports and tocilizumab in 19,602. Three hundred and three potential safety signals were identified for remdesivir, of which six were related to pregnant women and foetuses (including abortion and foetal deaths). Tocilizumab accumulated 578 potential safety signals, and three of them were associated with this population (including neonatal death). Discussion: None of the possible signals generated for this population were found in the product labels. According to the NIH and the WHO protocols, both medicines are recommended for pregnant women hospitalized with COVID-19. Conclusion: Despite the known limitations of working with open data from spontaneous reporting systems (e.g., absence of certain clinical data, underreporting, a tendency to report severe events and recent medicines) and disproportionality analysis, the findings suggest concerning associations that need to be confirmed or rejected in subsequent clinical studies.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079813</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2028600544&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Memo rdf:about="#item_1257">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: D. Killick; Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, United Kingdom; email: drk@liverpool.ac.uk&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 1; Correspondence Address: D. Zong; Medical Information Analysis Laboratory, College of Medical Devices, Shenyang Pharmaceutical University, Shenyang, China; email: 15040274832@163.com; Z. Li; Medical Information Analysis Laboratory, College of Medical Devices, Shenyang Pharmaceutical University, Shenyang, China; email: zuojing1006@hotmail.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 4; Correspondence Address: G.C.D. Matos; Observatory of Medicines Surveillance and Use, Pharmacy School, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil; email: guaciracmatos@gmail.com; F.A.B.D. Silva; Scientific Computing Program, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil; email: fabricio.silva@fiocruz.br&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 6; Correspondence Address: G. Jiang; Department of Health Sciences Research, Mayo Clinic, Rochester, 200 First St SW, 55905, United States; email: jiang.guoqian@mayo.edu&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 7; Correspondence Address: O. Pattanaprateep; Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, 270 Rama VI Rd, Ratchathewi, 10400, Thailand; email: oraluck.pat@mahidol.edu; C. Dejthevaporn; Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, 270 Rama VI Rd, Ratchathewi, 10400, Thailand; email: charungthai.dej@mahidol.ac.th&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 13; CODEN: DRSAE&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 17; Correspondence Address: K.K. Burkhart; Medical Informatics Team, Office of Clinical Pharmacology, Office of Translational Science, Division of Applied Regulatory Science, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Bldg 64, Rm 2012, 10903 New Hampshire Ave, 20993, United States; email: keith.burkhart@fda.hhs.gov&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 22; Correspondence Address: T. Miao; Department of Pharmacy, Shandong Provincial Third Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China; email: renjibo8539@163.com; X. Liu; Department of Pharmacy, Shandong Provincial Third Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China; email: 781943907@qq.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 437; Correspondence Address: S.Y. Lee; Metabolic and Biomolecular Engineering National Research Laboratory, Department of Chemical and Biomolecular Engineering (BK21 Plus Program), Institute for the BioCentury, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, 34141, South Korea; email: leesy@kaist.ac.kr; CODEN: PNASA&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;42&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;44&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;5&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;5&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;33&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;5&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;5&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;40&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;7&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;7&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;44&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;10&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;14&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;66&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;12&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;15&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;16&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;12&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;15&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;28&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;104&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;114&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;152&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Maybe&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2029381650&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>23</prism:volume>
                <dc:title>Expert Opinion on Drug Safety</dc:title>
                <dc:identifier>DOI 10.1080/14740338.2024.2328321</dc:identifier>
                <prism:number>5</prism:number>
                <dcterms:alternative>Expert Opin. Drug Saf.</dcterms:alternative>
                <dc:identifier>ISSN 1744-764X</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yun</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhou</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>D.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>Q.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1253"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>heart failure</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>artificial neural network</dc:subject>
        <dc:subject>connective tissue disease</dc:subject>
        <dc:subject>descriptive research</dc:subject>
        <dc:subject>hypercalcemia</dc:subject>
        <dc:subject>gastrointestinal disease</dc:subject>
        <dc:subject>mental disease</dc:subject>
        <dc:subject>acute coronary syndrome</dc:subject>
        <dc:subject>atrial fibrillation</dc:subject>
        <dc:subject>eye disease</dc:subject>
        <dc:subject>lung edema</dc:subject>
        <dc:subject>Medical Dictionary for Regulatory Activities</dc:subject>
        <dc:subject>immunoglobulin</dc:subject>
        <dc:subject>bayesian confidence propagation neural network</dc:subject>
        <dc:subject>anaphylaxis</dc:subject>
        <dc:subject>anemia</dc:subject>
        <dc:subject>chill</dc:subject>
        <dc:subject>disseminated intravascular clotting</dc:subject>
        <dc:subject>lymphatic system disease</dc:subject>
        <dc:subject>malignant neoplasm</dc:subject>
        <dc:subject>food and drug administration adverse event reporting system</dc:subject>
        <dc:subject>coughing</dc:subject>
        <dc:subject>dyspnea</dc:subject>
        <dc:subject>heart disease</dc:subject>
        <dc:subject>inner ear disease</dc:subject>
        <dc:subject>mediastinum disease</dc:subject>
        <dc:subject>coronavirus disease 2019</dc:subject>
        <dc:subject>bacteremia</dc:subject>
        <dc:subject>breast disease</dc:subject>
        <dc:subject>cytomegalovirus infection</dc:subject>
        <dc:subject>genital system disease</dc:subject>
        <dc:subject>hematologic disease</dc:subject>
        <dc:subject>hepatobiliary disease</dc:subject>
        <dc:subject>infection</dc:subject>
        <dc:subject>infestation</dc:subject>
        <dc:subject>intoxication</dc:subject>
        <dc:subject>kidney disease</dc:subject>
        <dc:subject>metabolic disorder</dc:subject>
        <dc:subject>musculoskeletal disease</dc:subject>
        <dc:subject>bone marrow suppression</dc:subject>
        <dc:subject>chorioretinitis</dc:subject>
        <dc:subject>leukopenia</dc:subject>
        <dc:subject>acute myopia</dc:subject>
        <dc:subject>acute respiratory failure</dc:subject>
        <dc:subject>AL amyloidosis</dc:subject>
        <dc:subject>allodynia</dc:subject>
        <dc:subject>amyloidosis</dc:subject>
        <dc:subject>anaphylactoid reaction</dc:subject>
        <dc:subject>aplasia</dc:subject>
        <dc:subject>aseptic meningitis</dc:subject>
        <dc:subject>bacterial endocarditis</dc:subject>
        <dc:subject>blood toxicity</dc:subject>
        <dc:subject>body dysmorphic disorder</dc:subject>
        <dc:subject>bone lesion</dc:subject>
        <dc:subject>bone marrow depression</dc:subject>
        <dc:subject>bronchopulmonary aspergillosis</dc:subject>
        <dc:subject>bronchospasm</dc:subject>
        <dc:subject>chickenpox</dc:subject>
        <dc:subject>choroidal effusion</dc:subject>
        <dc:subject>closed angle glaucoma</dc:subject>
        <dc:subject>congenital disorder</dc:subject>
        <dc:subject>Coombs test</dc:subject>
        <dc:subject>cryptococcal meningitis</dc:subject>
        <dc:subject>cryptococcosis</dc:subject>
        <dc:subject>Cytomegalovirus</dc:subject>
        <dc:subject>cytomegalovirus enterocolitis</dc:subject>
        <dc:subject>cytopenia</dc:subject>
        <dc:subject>daratumumab</dc:subject>
        <dc:subject>disseminated cryptococcosis</dc:subject>
        <dc:subject>disseminated varicella zoster virus infection</dc:subject>
        <dc:subject>diverticular perforation</dc:subject>
        <dc:subject>endocrine disease</dc:subject>
        <dc:subject>enterocolitis</dc:subject>
        <dc:subject>erysipelas</dc:subject>
        <dc:subject>erythrocyte antibody</dc:subject>
        <dc:subject>extravasation</dc:subject>
        <dc:subject>familial disease</dc:subject>
        <dc:subject>febrile neutropenia</dc:subject>
        <dc:subject>fever</dc:subject>
        <dc:subject>genetic disorder</dc:subject>
        <dc:subject>Guillain Barre syndrome</dc:subject>
        <dc:subject>heart amyloidosis</dc:subject>
        <dc:subject>heart atrium flutter</dc:subject>
        <dc:subject>hemolysis</dc:subject>
        <dc:subject>hepatitis B</dc:subject>
        <dc:subject>hepatitis E</dc:subject>
        <dc:subject>hyperpyrexia</dc:subject>
        <dc:subject>hyperviscosity syndrome</dc:subject>
        <dc:subject>hypoxia</dc:subject>
        <dc:subject>ileus</dc:subject>
        <dc:subject>immunoglobulin deficiency</dc:subject>
        <dc:subject>immunoglobulin G</dc:subject>
        <dc:subject>immunoglobulin M</dc:subject>
        <dc:subject>infusion related reaction</dc:subject>
        <dc:subject>injection site extravasation</dc:subject>
        <dc:subject>JC virus</dc:subject>
        <dc:subject>larynx edema</dc:subject>
        <dc:subject>leishmaniasis</dc:subject>
        <dc:subject>leukemia</dc:subject>
        <dc:subject>leukocyte count</dc:subject>
        <dc:subject>leukoencephalopathy</dc:subject>
        <dc:subject>Listeria meningitis</dc:subject>
        <dc:subject>listeriosis</dc:subject>
        <dc:subject>lymphocytopenia</dc:subject>
        <dc:subject>multi item gamma poisson shrinker</dc:subject>
        <dc:subject>multiple myeloma</dc:subject>
        <dc:subject>myopia</dc:subject>
        <dc:subject>natural killer cell count</dc:subject>
        <dc:subject>neoplasm</dc:subject>
        <dc:title>A real‑world pharmacovigilance study of FDA adverse event reporting system events for daratumumab</dc:title>
        <dcterms:abstract>Background: Daratumumab, a first-in-class humanized IgG1κ monoclonal antibody that targets the CD38 epitope, has been approved for treatment of multiple myeloma by FDA. The current study was to evaluate daratumumab-related adverse events (AEs) through data mining of the US Food and Drug Administration Adverse Event Reporting System (FAERS). Research design and methods: Disproportionality analyses, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN) and the multi-item gamma Poisson shrinker (MGPS) algorithms were employed to quantify the signals of daratumumab-associated AEs. Results: Out of 10,378,816 reports collected from the FAERS database, 8727 reports of daratumumab-associated AEs were identified. A total of 183 significant disproportionality preferred terms (PTs) were retained. Unexpected significant AEs such as meningitis aseptic, leukoencephalopathy, tumor lysis syndrome, disseminated intravascular coagulation, hyperviscosity syndrome, sudden hearing loss, ileus and diverticular perforation were also detected. The median onset time of daratumumab-related AEs was 11 days (interquartile range [IQR] 0–76 days), and most of the cases occurred within 30 days. Conclusion: Our study found potential new and unexpected AEs signals for daratumumab, suggesting prospective clinical studies are needed to confirm these results and illustrate their relationship.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079817</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2029381650&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>581-591</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1253">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Excluded&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2029156826&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>23</prism:volume>
                <dc:title>Expert Opinion on Drug Safety</dc:title>
                <dc:identifier>DOI 10.1080/14740338.2024.2327503</dc:identifier>
                <prism:number>4</prism:number>
                <dcterms:alternative>Expert Opin. Drug Saf.</dcterms:alternative>
                <dc:identifier>ISSN 1744-764X</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>J.-J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhao</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yang</foaf:surname>
                        <foaf:givenName>X.-Q.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hu</foaf:surname>
                        <foaf:givenName>F.-B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1254"/>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>coronavirus disease 2019</dc:subject>
        <dc:subject>cytomegalovirus infection</dc:subject>
        <dc:subject>cyclophosphamide</dc:subject>
        <dc:subject>azathioprine</dc:subject>
        <dc:subject>cyclosporine</dc:subject>
        <dc:subject>graft rejection</dc:subject>
        <dc:subject>hepatosplenic T cell lymphoma</dc:subject>
        <dc:subject>hypofibrinogenemia</dc:subject>
        <dc:subject>immunosuppressive agent</dc:subject>
        <dc:subject>methotrexate</dc:subject>
        <dc:subject>mortality rate</dc:subject>
        <dc:subject>mycophenolate mofetil</dc:subject>
        <dc:subject>tacrolimus</dc:subject>
        <dc:title>Data mining and safety analysis of traditional immunosuppressive drugs: a pharmacovigilance investigation based on the FAERS database</dc:title>
        <dcterms:abstract>Objective: The purpose of this study aimed to explore the new and serious adverse events(AEs) of Tacrolimus(FK506), cyclosporine(CsA), azathioprine(AZA), mycophenolate mofetil(MMF), cyclophosphamide(CTX) and methotrexate(MTX), which have not been concerned. Methods: The FAERS data from January 2016 and December 2022 were selected for disproportionality analysis to discover the potential risks of traditional immunosuppressive drugs. Results: Compared with CsA, FK506 has more frequent transplant rejection, and is more related to renal impairment, COVID-19, cytomegalovirus infection and aspergillus infection. However, CsA has a high infection-related fatality rate. In addition, we also found some serious and rare AE in other drugs which were rarely reported in previous studies. For example, AZA is closely related to hepatosplenic T-cell lymphoma with high fatality rate and MTX is strongly related to hypofibrinogenemia. Conclusion: The AEs report on this study confirmed that the results were basically consistent with the previous studies, but there were also some important safety signals that were inconsistent with or not mentioned in previous published studies. Expert opinion: The opinion section discusses some of the limitations and shortcomings, proposing the areas where more effort should be invested in order to improve the safety of immunosuppressive drugs.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079816</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2029156826&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>513-525</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1254">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Included&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2027607868&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>23</prism:volume>
                <dc:title>Expert Opinion on Drug Safety</dc:title>
                <dc:identifier>DOI 10.1080/14740338.2023.2296966</dc:identifier>
                <prism:number>7</prism:number>
                <dcterms:alternative>Expert Opin. Drug Saf.</dcterms:alternative>
                <dc:identifier>ISSN 1744-764X</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liang</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Huang</foaf:surname>
                        <foaf:givenName>G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yang</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Noguchi</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shen</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1259"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>heart failure</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>acute heart infarction</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>artificial neural network</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>oral bleeding</dc:subject>
        <dc:subject>sepsis</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>brain disease</dc:subject>
        <dc:subject>acute coronary syndrome</dc:subject>
        <dc:subject>deep vein thrombosis</dc:subject>
        <dc:subject>malignant hypertension</dc:subject>
        <dc:subject>anemia</dc:subject>
        <dc:subject>cellulitis</dc:subject>
        <dc:subject>chill</dc:subject>
        <dc:subject>drug indication</dc:subject>
        <dc:subject>polyneuropathy</dc:subject>
        <dc:subject>compression fracture</dc:subject>
        <dc:subject>dyspnea</dc:subject>
        <dc:subject>aplastic anemia</dc:subject>
        <dc:subject>bacteremia</dc:subject>
        <dc:subject>calcium metabolism disorders</dc:subject>
        <dc:subject>cytomegalovirus infection</dc:subject>
        <dc:subject>hematologic disease</dc:subject>
        <dc:subject>hypervolemia</dc:subject>
        <dc:subject>chorioretinitis</dc:subject>
        <dc:subject>AL amyloidosis</dc:subject>
        <dc:subject>amyloidosis</dc:subject>
        <dc:subject>aseptic meningitis</dc:subject>
        <dc:subject>bacterial endocarditis</dc:subject>
        <dc:subject>bone marrow depression</dc:subject>
        <dc:subject>bronchospasm</dc:subject>
        <dc:subject>cryptococcal meningitis</dc:subject>
        <dc:subject>cryptococcosis</dc:subject>
        <dc:subject>daratumumab</dc:subject>
        <dc:subject>enterocolitis</dc:subject>
        <dc:subject>fever</dc:subject>
        <dc:subject>Guillain Barre syndrome</dc:subject>
        <dc:subject>hepatitis E</dc:subject>
        <dc:subject>ileus</dc:subject>
        <dc:subject>infusion related reaction</dc:subject>
        <dc:subject>JC virus</dc:subject>
        <dc:subject>larynx edema</dc:subject>
        <dc:subject>leishmaniasis</dc:subject>
        <dc:subject>listeriosis</dc:subject>
        <dc:subject>multiple myeloma</dc:subject>
        <dc:subject>food allergy</dc:subject>
        <dc:subject>heart left ventricle failure</dc:subject>
        <dc:subject>accommodation disorder</dc:subject>
        <dc:subject>airway obstruction</dc:subject>
        <dc:subject>aspergillosis</dc:subject>
        <dc:subject>autoimmune hemolytic anemia</dc:subject>
        <dc:subject>bacterial infection</dc:subject>
        <dc:subject>Bowen disease</dc:subject>
        <dc:subject>cardiovascular infection</dc:subject>
        <dc:subject>central nervous system infection</dc:subject>
        <dc:subject>cerebral toxoplasmosis</dc:subject>
        <dc:subject>clinical monitoring</dc:subject>
        <dc:subject>demyelinating disease</dc:subject>
        <dc:subject>digestive system perforation</dc:subject>
        <dc:subject>digestive system ulcer</dc:subject>
        <dc:subject>disease risk assessment</dc:subject>
        <dc:subject>diskitis</dc:subject>
        <dc:subject>electrolyte disturbance</dc:subject>
        <dc:subject>encephalitis</dc:subject>
        <dc:subject>endocarditis</dc:subject>
        <dc:subject>epididymitis</dc:subject>
        <dc:subject>Escherichia coli infection</dc:subject>
        <dc:subject>fungemia</dc:subject>
        <dc:subject>gastroenteritis</dc:subject>
        <dc:subject>gastrointestinal infection</dc:subject>
        <dc:subject>heart supraventricular arrhythmia</dc:subject>
        <dc:subject>hypokalemia</dc:subject>
        <dc:subject>immune deficiency</dc:subject>
        <dc:subject>inflammation</dc:subject>
        <dc:subject>larynx spasm</dc:subject>
        <dc:subject>larynx stenosis</dc:subject>
        <dc:subject>liver enzyme</dc:subject>
        <dc:subject>lower respiratory tract infection</dc:subject>
        <dc:subject>muscle disease</dc:subject>
        <dc:subject>mycosis</dc:subject>
        <dc:subject>myelodysplastic syndrome</dc:subject>
        <dc:subject>neutropenia</dc:subject>
        <dc:subject>nose obstruction</dc:subject>
        <dc:subject>oral pruritus</dc:subject>
        <dc:subject>orchitis</dc:subject>
        <dc:subject>oropharynx pain</dc:subject>
        <dc:subject>otitis media</dc:subject>
        <dc:subject>Parainfluenza virus infection</dc:subject>
        <dc:subject>peripheral neuropathy</dc:subject>
        <dc:subject>plasmacytoma</dc:subject>
        <dc:subject>platelet count</dc:subject>
        <dc:subject>polyomavirus infection</dc:subject>
        <dc:subject>pseudomembranous colitis</dc:subject>
        <dc:subject>Pseudomonas infection</dc:subject>
        <dc:subject>radiculopathy</dc:subject>
        <dc:subject>refraction error</dc:subject>
        <dc:subject>refractory cancer</dc:subject>
        <dc:subject>respiratory acidosis</dc:subject>
        <dc:subject>respiratory syncytial virus infection</dc:subject>
        <dc:subject>respiratory tract inflammation</dc:subject>
        <dc:subject>shock</dc:subject>
        <dc:subject>sinus node disease</dc:subject>
        <dc:subject>spinal cord disease</dc:subject>
        <dc:subject>spinal cord infection</dc:subject>
        <dc:subject>sudden deafness</dc:subject>
        <dc:subject>superinfection</dc:subject>
        <dc:subject>systemic mycosis</dc:subject>
        <dc:subject>thrombocytopenia</dc:subject>
        <dc:subject>tumor lysis syndrome</dc:subject>
        <dc:title>Safety of daratumumab in the real-world: a pharmacovigilance study based on FAERS database</dc:title>
        <dcterms:abstract>Background: Daratumumab is widely used in multiple myeloma (MM) and light chain amyloidosis (AL amyloidosis). The purpose of this study was to identify adverse event (AE) signals for daratumumab through the FDA Adverse Event Reporting System (FAERS) database to assess its safety in a large sample of people. Methods: Based on data from the FAERS database, three disproportionality analysis methods were used to mine AE signals for daratumumab, including reporting odd ratio (ROR), proportional reporting ratio (PRR), and bayesian configuration promotion neural network (BCPNN). Results: A total of 9220 AE reports with daratumumab as the primary suspect drug were collected, containing 23,946 AEs. Within these reports, 252 preferred terms (PT) levels, 73 high level term (HLT) levels and 11 system organ class (SOC) levels of AE signals were detected, along with some new AEs. Most AEs occurred within the first month after drug administration. Conclusion: Our findings were consistent with the results of established studies that daratumumab has a good safety profile. The newly identified AEs are of concern and prospective clinical studies are needed to confirm whether they are causally related to daratumumab. This study provided an early warning for the safe use of daratumumab and also provided guidance for further safety studies.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079812</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2027607868&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>905-916</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1259">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Silvio&quot;=&gt;&quot;Excluded&quot;, &quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2026259294&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>23</prism:volume>
                <dc:title>Expert Opinion on Drug Safety</dc:title>
                <dc:identifier>DOI 10.1080/14740338.2023.2271834</dc:identifier>
                <prism:number>3</prism:number>
                <dcterms:alternative>Expert Opin. Drug Saf.</dcterms:alternative>
                <dc:identifier>ISSN 1744-764X</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhao</foaf:surname>
                        <foaf:givenName>Q.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1258"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>age</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data analysis</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>burning sensation</dc:subject>
        <dc:subject>injection site reaction</dc:subject>
        <dc:subject>cardiopulmonary insufficiency</dc:subject>
        <dc:subject>cyanosis</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>dizziness</dc:subject>
        <dc:subject>drug induced disease</dc:subject>
        <dc:subject>heart arrest</dc:subject>
        <dc:subject>abnormal sensation</dc:subject>
        <dc:subject>arthropathy</dc:subject>
        <dc:subject>bone pain</dc:subject>
        <dc:subject>headache</dc:subject>
        <dc:subject>muscle spasm</dc:subject>
        <dc:subject>muscle tightness</dc:subject>
        <dc:subject>nausea</dc:subject>
        <dc:subject>apnea</dc:subject>
        <dc:subject>brain disease</dc:subject>
        <dc:subject>cognitive defect</dc:subject>
        <dc:subject>hypersalivation</dc:subject>
        <dc:subject>motor dysfunction</dc:subject>
        <dc:subject>eye disease</dc:subject>
        <dc:subject>lung edema</dc:subject>
        <dc:subject>allergy</dc:subject>
        <dc:subject>anaphylaxis</dc:subject>
        <dc:subject>coughing</dc:subject>
        <dc:subject>dyspnea</dc:subject>
        <dc:subject>consciousness disorder</dc:subject>
        <dc:subject>dysgeusia</dc:subject>
        <dc:subject>dysphagia</dc:subject>
        <dc:subject>depressed blood pressure</dc:subject>
        <dc:subject>injury</dc:subject>
        <dc:subject>lip swelling</dc:subject>
        <dc:subject>drug labeling</dc:subject>
        <dc:subject>chorioretinitis</dc:subject>
        <dc:subject>anaphylactoid reaction</dc:subject>
        <dc:subject>bronchospasm</dc:subject>
        <dc:subject>extravasation</dc:subject>
        <dc:subject>injection site extravasation</dc:subject>
        <dc:subject>larynx edema</dc:subject>
        <dc:subject>hot flush</dc:subject>
        <dc:subject>hypersensitivity</dc:subject>
        <dc:subject>eye swelling</dc:subject>
        <dc:subject>eyelid edema</dc:subject>
        <dc:subject>airway obstruction</dc:subject>
        <dc:subject>larynx spasm</dc:subject>
        <dc:subject>abnormal eye sensation</dc:subject>
        <dc:subject>amputation</dc:subject>
        <dc:subject>anhedonia</dc:subject>
        <dc:subject>anxiety</dc:subject>
        <dc:subject>bacterial arthritis</dc:subject>
        <dc:subject>body temperature disorder</dc:subject>
        <dc:subject>bone biopsy</dc:subject>
        <dc:subject>brain biopsy</dc:subject>
        <dc:subject>breathing rate</dc:subject>
        <dc:subject>cold</dc:subject>
        <dc:subject>cold sensation</dc:subject>
        <dc:subject>cold sweat</dc:subject>
        <dc:subject>conjunctival hyperemia</dc:subject>
        <dc:subject>contracture</dc:subject>
        <dc:subject>contrast medium deposition</dc:subject>
        <dc:subject>contrast medium reaction</dc:subject>
        <dc:subject>contrast medium toxicity</dc:subject>
        <dc:subject>cytokine</dc:subject>
        <dc:subject>deformity</dc:subject>
        <dc:subject>drug urine level</dc:subject>
        <dc:subject>dry skin</dc:subject>
        <dc:subject>dysphonia</dc:subject>
        <dc:subject>ear edema</dc:subject>
        <dc:subject>ear pruritus</dc:subject>
        <dc:subject>emotional stress</dc:subject>
        <dc:subject>encephalalgia</dc:subject>
        <dc:subject>erythema</dc:subject>
        <dc:subject>exfoliative rash</dc:subject>
        <dc:subject>extremity contracture</dc:subject>
        <dc:subject>eye jaundice</dc:subject>
        <dc:subject>eye movement disorder</dc:subject>
        <dc:subject>face edema</dc:subject>
        <dc:subject>facial nerve paralysis</dc:subject>
        <dc:subject>fear of death</dc:subject>
        <dc:subject>fibrosis</dc:subject>
        <dc:subject>flushing</dc:subject>
        <dc:subject>foreign body sensation</dc:subject>
        <dc:subject>formication</dc:subject>
        <dc:subject>gadobenic acid</dc:subject>
        <dc:subject>gadobutrol</dc:subject>
        <dc:subject>gadolinium deposition disease</dc:subject>
        <dc:subject>gadolinium pentetate meglumine</dc:subject>
        <dc:subject>gadoteridol</dc:subject>
        <dc:subject>gait disorder</dc:subject>
        <dc:subject>general condition deterioration</dc:subject>
        <dc:subject>hyperhidrosis</dc:subject>
        <dc:subject>hyperkeratosis</dc:subject>
        <dc:subject>hyperpigmentation</dc:subject>
        <dc:subject>hyperventilation</dc:subject>
        <dc:subject>hypesthesia</dc:subject>
        <dc:subject>immobility</dc:subject>
        <dc:subject>infant</dc:subject>
        <dc:subject>injection site inflammation</dc:subject>
        <dc:subject>injection site phlebitis</dc:subject>
        <dc:subject>injection site thrombosis</dc:subject>
        <dc:subject>joint contracture</dc:subject>
        <dc:subject>joint lock</dc:subject>
        <dc:subject>joint mobility</dc:subject>
        <dc:subject>joint stiffness</dc:subject>
        <dc:subject>kidney pain</dc:subject>
        <dc:subject>lacrimation disorder</dc:subject>
        <dc:subject>macular rash</dc:subject>
        <dc:subject>metal poisoning</dc:subject>
        <dc:subject>mitochondrial toxicity</dc:subject>
        <dc:subject>mortality</dc:subject>
        <dc:subject>motor performance</dc:subject>
        <dc:subject>mouth discomfort</dc:subject>
        <dc:subject>mouth disease</dc:subject>
        <dc:subject>mouth edema</dc:subject>
        <dc:subject>mucosal paresthesia</dc:subject>
        <dc:subject>muscle atrophy</dc:subject>
        <dc:subject>muscle contracture</dc:subject>
        <dc:subject>muscle twitch</dc:subject>
        <dc:subject>muscle weakness</dc:subject>
        <dc:subject>musculoskeletal chest pain</dc:subject>
        <dc:subject>musculoskeletal stiffness</dc:subject>
        <dc:subject>myofibrosis</dc:subject>
        <dc:subject>myosclerosis</dc:subject>
        <dc:subject>nasal discomfort</dc:subject>
        <dc:subject>nephrogenic systemic fibrosis</dc:subject>
        <dc:subject>neuroimaging</dc:subject>
        <dc:title>Data mining and analysis of the adverse events derived signals of 4 gadolinium-based contrast agents based on the US Food and drug administration adverse event reporting system</dc:title>
        <dcterms:abstract>Background: To detect and analyze risk signals of the drug-related adverse events (AEs) of 4 gadolinium-based contrast agents (GBCAs) (gadopentetate dimeglumine (Gd-DTPA), gadobenate dimeglumine (Gd-BOPTA), gadoteridol (Gd-HP-DO3A), and gadobutrol (Gd-BT-DO3A)) according to the US Food and Drug Administration Adverse Event Reporting System (FAERS) database and ensure the clinical safety. Research design and methods: The AEs that are associated with the 4 GBCAs were collected from the FAERS database from 2004Q1 to 2022Q3. The risk signals were mined using reporting odds ratio (ROR) and proportional reporting ratio (PRR). Results: 424 risk signals were excavated, in which 151 risk signals were associated with Gd-DTPA, 93 risk signals were related to Gd-BOPTA, 79 risk signals were relevant to Gd-HP-DO3A, and 101 risk signals were associated with Gd-BT-DO3A. The AE signals involved 20 system organ classes (SOCs). Two of the top four SOCs were identical, namely ‘skin and subcutaneous tissue disorders’ and ‘general disorders and administration site conditions.’ Conclusions: The safety signals of 4 GBCAs were detected, and the SOCs associated with the AEs of the 4 GBCAs were different. Besides, some AEs obtained in this study were not mentioned in the package inserts, which need more attention and research to ensure the clinical safety.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079810</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2026259294&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>339-352</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1258">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2025244740&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>23</prism:volume>
                <dc:title>Expert Opinion on Drug Safety</dc:title>
                <dc:identifier>DOI 10.1080/14740338.2023.2251881</dc:identifier>
                <prism:number>6</prism:number>
                <dcterms:alternative>Expert Opin. Drug Saf.</dcterms:alternative>
                <dc:identifier>ISSN 1744-764X</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yan</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yuan</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xu</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1261"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>factual database</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>odds ratio</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>disproportionality analysis</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>neuroleptic agent</dc:subject>
        <dc:subject>quetiapine</dc:subject>
        <dc:subject>deep vein thrombosis</dc:subject>
        <dc:subject>venous thromboembolism</dc:subject>
        <dc:subject>lung embolism</dc:subject>
        <dc:subject>aripiprazole</dc:subject>
        <dc:subject>asenapine</dc:subject>
        <dc:subject>lurasidone</dc:subject>
        <dc:subject>paliperidone</dc:subject>
        <dc:subject>risperidone</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>analysis</dc:subject>
        <dc:subject>food and drug administration adverse event reporting system</dc:subject>
        <dc:subject>data extraction</dc:subject>
        <dc:subject>disease association</dc:subject>
        <dc:subject>brexpiprazole</dc:subject>
        <dc:subject>clozapine</dc:subject>
        <dc:subject>iloperidone</dc:subject>
        <dc:subject>loxapine</dc:subject>
        <dc:subject>olanzapine</dc:subject>
        <dc:subject>ziprasidone</dc:subject>
        <dc:subject>amisulpride</dc:subject>
        <dc:subject>antipsychotics</dc:subject>
        <dc:subject>cariprazine</dc:subject>
        <dc:subject>chlorpromazine</dc:subject>
        <dc:subject>deep venous thrombosis</dc:subject>
        <dc:subject>droperidol</dc:subject>
        <dc:subject>fluphenazine</dc:subject>
        <dc:subject>haloperidol</dc:subject>
        <dc:subject>lithium</dc:subject>
        <dc:subject>Pharmacovigilance</dc:subject>
        <dc:subject>pimavanserin</dc:subject>
        <dc:subject>pimozide</dc:subject>
        <dc:subject>pipamperone</dc:subject>
        <dc:subject>prochlorperazine</dc:subject>
        <dc:subject>pulmonary thromboembolism</dc:subject>
        <dc:subject>PULMONARY-EMBOLISM</dc:subject>
        <dc:subject>RISK-FACTOR</dc:subject>
        <dc:subject>thioridazine</dc:subject>
        <dc:subject>THROMBOSIS</dc:subject>
        <dc:title>A pharmacovigilance study of the association between antipsychotic drugs and venous thromboembolism based on Food and Drug Administration Adverse Event Reporting System data</dc:title>
        <dcterms:abstract>Background: This study aimed to measure and present a comprehensive overview of the association of antipsychotic drugs and venous thromboembolism (VTE) in the Food and Drug Administration Adverse Event Reporting System (FAERS). Method: All VTE cases treated with antipsychotic drugs as primary suspected medicines were extracted from the FAERS database from 2004 to 2021. Disproportionality analyses were conducted by estimating the reporting odds ratio (ROR) and the information component (IC). Results: In the FAERS system, 4,455 VTE cases associated with antipsychotics were identified. The VTE signal was detected with olanzapine, haloperidol, paliperidone, and quetiapine. The RORs and 95% confidence intervals (95% CI) of olanzapine, haloperidol, paliperidone, and quetiapine were (ROR = 2.53 95% Cl 2.38–2.69 IC = 1.31 95% Cl 1.11–1.52), (ROR = 2.17 95% Cl 1.91–2.46 IC = 1.1 95% Cl 0.66–1.52), (ROR = 1.6 95% Cl 1.4–1.83 IC = 0.67 95% Cl 0.22–1.11), and (ROR = 1.37 95% Cl 1.28–1.47 IC = 0.45 95% Cl 0.23–0.67). Pulmonary embolism occurred in more than 50% of VTE events (2760 cases, 52.84%). Conclusion: The data mining of FAERS suggested an association between VTE and antipsychotic drugs, which reminds medical workers to pay attention to the serious adverse drug effects of antipsychotic drugs leading to venous thromboembolism.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079809</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2025244740&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>771-776</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1261">
        <rdf:value>&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;29&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2025169826&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>23</prism:volume>
                <dc:title>Expert Opinion on Drug Safety</dc:title>
                <dc:identifier>DOI 10.1080/14740338.2023.2251398</dc:identifier>
                <prism:number>3</prism:number>
                <dcterms:alternative>Expert Opin. Drug Saf.</dcterms:alternative>
                <dc:identifier>ISSN 1744-764X</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lai</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wan</foaf:surname>
                        <foaf:givenName>Q.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jiao</foaf:surname>
                        <foaf:givenName>S.-F.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sun</foaf:surname>
                        <foaf:givenName>X.-C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hu</foaf:surname>
                        <foaf:givenName>J.-F.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Peng</foaf:surname>
                        <foaf:givenName>H.-W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1262"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>heart failure</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>hypertension</dc:subject>
        <dc:subject>incidence</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>acute heart infarction</dc:subject>
        <dc:subject>cardiotoxicity</dc:subject>
        <dc:subject>bleeding</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>cardiomyopathy</dc:subject>
        <dc:subject>heart arrhythmia</dc:subject>
        <dc:subject>myocarditis</dc:subject>
        <dc:subject>sinus tachycardia</dc:subject>
        <dc:subject>supraventricular tachycardia</dc:subject>
        <dc:subject>orthostatic hypertension</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>acute coronary syndrome</dc:subject>
        <dc:subject>atrial fibrillation</dc:subject>
        <dc:subject>deep vein thrombosis</dc:subject>
        <dc:subject>embolism</dc:subject>
        <dc:subject>heart infarction</dc:subject>
        <dc:subject>heart muscle ischemia</dc:subject>
        <dc:subject>hypertensive crisis</dc:subject>
        <dc:subject>Medical Dictionary for Regulatory Activities</dc:subject>
        <dc:subject>systolic hypertension</dc:subject>
        <dc:subject>cancer patient</dc:subject>
        <dc:subject>drug industry</dc:subject>
        <dc:subject>cardiorenal syndrome</dc:subject>
        <dc:subject>drug approval</dc:subject>
        <dc:subject>heart left ventricle failure</dc:subject>
        <dc:subject>THERAPY</dc:subject>
        <dc:subject>clinical monitoring</dc:subject>
        <dc:subject>shock</dc:subject>
        <dc:subject>flushing</dc:subject>
        <dc:subject>drug monitoring</dc:subject>
        <dc:subject>pericardial effusion</dc:subject>
        <dc:subject>ventricular hypokinesia</dc:subject>
        <dc:subject>liver cell carcinoma</dc:subject>
        <dc:subject>peripheral artery thrombosis</dc:subject>
        <dc:subject>superficial thrombophlebitis</dc:subject>
        <dc:subject>aortic dissection</dc:subject>
        <dc:subject>cabozantinib</dc:subject>
        <dc:subject>AORTIC DISSECTION</dc:subject>
        <dc:subject>aortic thrombosis</dc:subject>
        <dc:subject>arterial hemorrhage</dc:subject>
        <dc:subject>blood pressure fluctuation</dc:subject>
        <dc:subject>cabometys</dc:subject>
        <dc:subject>CARCINOMA</dc:subject>
        <dc:subject>Cardiac adverse events</dc:subject>
        <dc:subject>cardiac discomfort</dc:subject>
        <dc:subject>dry gangrene</dc:subject>
        <dc:subject>FDA Adverse Events Reporting System</dc:subject>
        <dc:subject>heart aneurysm</dc:subject>
        <dc:subject>hepatocellular cancer</dc:subject>
        <dc:subject>hyperemia</dc:subject>
        <dc:subject>hypovolemic shock</dc:subject>
        <dc:subject>internal hemorrhage</dc:subject>
        <dc:subject>lenvatinib</dc:subject>
        <dc:subject>LENVATINIB</dc:subject>
        <dc:subject>lenvima</dc:subject>
        <dc:subject>lymphedema</dc:subject>
        <dc:subject>medical personnel</dc:subject>
        <dc:subject>medication therapy management</dc:subject>
        <dc:subject>nexavar</dc:subject>
        <dc:subject>non-proportional analysis</dc:subject>
        <dc:subject>phlebitis</dc:subject>
        <dc:subject>regorafenib</dc:subject>
        <dc:subject>REGORAFENIB</dc:subject>
        <dc:subject>right ventricular hypertrophy</dc:subject>
        <dc:subject>sorafenib</dc:subject>
        <dc:subject>SORAFENIB</dc:subject>
        <dc:subject>stivarga</dc:subject>
        <dc:subject>Takotsubo cardiomyopathy</dc:subject>
        <dc:subject>thrombophlebitis migrans</dc:subject>
        <dc:subject>tyrosine kinases inhibitors</dc:subject>
        <dc:subject>vasodilatory shock</dc:subject>
        <dc:subject>worker</dc:subject>
        <dc:title>Cardiovascular toxicities following the use of tyrosine kinase inhibitors in hepatocellular cancer patients: a retrospective, pharmacovigilance study</dc:title>
        <dcterms:abstract>Background: Cardiac adverse events (AEs) are common in tyrosine kinase inhibitors(TKIs). This study explored the cardiac AEs of TKIs through the Food and Drug Administration’s Adverse Event Reporting System (FAERS). Methods: Disproportionality analysis and Bayesian analysis were utilized for data mining of the suspected cardiac AEs of TKIs, based on FAERS data from January 2004 to December 2021. Results: A total of 4708 cardiac AEs reports of sorafenib, regorafenib, lenvatinib, and cabozantinib were identified. Hypertension accounts for the most reported cardiac AE. Lenvatinib appears to induce cardiac failure with the highest signals strength [ROR = 7.7 (3.46,17.17)]. Acute myocardial infarction was detected in lenvatinib [ROR = 7.91 (5.64,11.09)] and sorafenib [ROR = 2.22 (1.74, 2.84)]. Acute coronary syndrome was detected in lenvatinib [ROR = 11.57 (6.84, 19.58)] and sorafenib [ROR = 2.81 (1.87,4.24)]. Atrial fibrillation was detected in sorafenib [ROR = 1.82 (1.55,2.14)] and regorafenib [ROR = 1.36 (1.03,1.81)]. Meanwhile, aortic dissections were detected in sorafenib [ROR = 5.08 (3.31,7.8)] and regorafenib [ROR = 3.39 (1.52,7.56)]. Most patients developed hypertension and cardiac failure within 30 days of initiating TKI treatments. Patients taking lenvatinib had an increased incidence of developing acute coronary syndrome after 180 days of treatment. Conclusion: Analysis of FAERS data provides a precise profile on the characteristics of cardiac AEs associated with different TKI regimens. Distinct monitoring and appropriate management are needed in the care of TKI recipients.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079808</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2025169826&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>287-296</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1262">
        <rdf:value>&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;8&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;8&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;44&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2024991769&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>23</prism:volume>
                <dc:title>Expert Opinion on Drug Safety</dc:title>
                <dc:identifier>DOI 10.1080/14740338.2023.2248877</dc:identifier>
                <prism:number>2</prism:number>
                <dcterms:alternative>Expert Opin. Drug Saf.</dcterms:alternative>
                <dc:identifier>ISSN 1744-764X</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Singh</foaf:surname>
                        <foaf:givenName>R.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kumar</foaf:surname>
                        <foaf:givenName>A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lather</foaf:surname>
                        <foaf:givenName>V.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sharma</foaf:surname>
                        <foaf:givenName>R.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Pandita</foaf:surname>
                        <foaf:givenName>D.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1265"/>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>electronic health record</dc:subject>
        <dc:subject>calcitonin gene related peptide</dc:subject>
        <dc:subject>calcitonin gene related peptide receptor antagonist</dc:subject>
        <dc:subject>erenumab</dc:subject>
        <dc:subject>fremanezumab</dc:subject>
        <dc:subject>galcanezumab</dc:subject>
        <dc:subject>molecular docking</dc:subject>
        <dc:subject>polypharmacology</dc:subject>
        <dc:subject>Raynaud phenomenon</dc:subject>
        <dc:subject>rimegepant</dc:subject>
        <dc:subject>sensitivity analysis</dc:subject>
        <dc:subject>somatomedin C receptor</dc:subject>
        <dc:subject>systems biology</dc:subject>
        <dc:subject>systems pharmacology</dc:subject>
        <dc:title>Identification of novel signal of Raynaud’s phenomenon with Calcitonin Gene-Related Peptide(CGRP) antagonists using data mining algorithms and network pharmacological approaches</dc:title>
        <dcterms:abstract>Background: Calcitonin gene-related peptide (CGRP) antagonists are recently approved for the treatment of migraine. Aim: The main aim of the current study was to find out the association of CGRP antagonists with RP using data mining algorithms integrated with network pharmacological approaches. Research design and methods: The individual case safety reports were extracted using OpenVigil2.1-MedDRA-V17 (2004Q1-2022Q3), the United States Adverse Event Reporting System (US FAERS). The data mining algorithms i.e. reporting odds ratio (ROR) with 95% confidence and proportionality reporting ratio (PRR) with associated chi-square value were calculated along with a minimum of three ICSRs to identify the signal. Further, the network was constructed using Cytoscape 3.7.2. Finally, molecular docking was performed using Glide, Schrodinger Inc. Results: The PRR ≥2 with a linked chi-square value ≥4, add up of co-occurrence ≥3, and a lower limit of 95% confidence interval of ROR exceeding 2 indicates a positive signal of RP. Further, the network pharmacological and molecular docking results have shown the involvement of insulin-like growth factor 1-receptor (IGF1R) pathways. Conclusion: The RP is recognized as a novel signal with all CGRP antagonists.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079805</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2024991769&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>231-238</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1265">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2024776708&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>23</prism:volume>
                <dc:title>Expert Opinion on Drug Safety</dc:title>
                <dc:identifier>DOI 10.1080/14740338.2023.2243220</dc:identifier>
                <prism:number>6</prism:number>
                <dcterms:alternative>Expert Opin. Drug Saf.</dcterms:alternative>
                <dc:identifier>ISSN 1744-764X</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zou</foaf:surname>
                        <foaf:givenName>W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yuan</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhong</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Fu</foaf:surname>
                        <foaf:givenName>Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1263"/>
        <dc:subject>article</dc:subject>
        <dc:subject>data analysis</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>heart ventricle extrasystole</dc:subject>
        <dc:subject>muscle spasm</dc:subject>
        <dc:subject>nail disease</dc:subject>
        <dc:subject>sex difference</dc:subject>
        <dc:subject>skin disease</dc:subject>
        <dc:subject>congestive heart failure</dc:subject>
        <dc:subject>diarrhea</dc:subject>
        <dc:subject>data extraction</dc:subject>
        <dc:subject>dyspnea</dc:subject>
        <dc:subject>clinical outcome</dc:subject>
        <dc:subject>rash</dc:subject>
        <dc:subject>stomatitis</dc:subject>
        <dc:subject>dry skin</dc:subject>
        <dc:subject>aspiration pneumonia</dc:subject>
        <dc:subject>interstitial lung disease</dc:subject>
        <dc:subject>lung infection</dc:subject>
        <dc:subject>lung toxicity</dc:subject>
        <dc:subject>onycholysis</dc:subject>
        <dc:subject>osimertinib</dc:subject>
        <dc:subject>pulmonary thrombosis</dc:subject>
        <dc:title>Gender differences in adverse events related to Osimertinib: a real-world pharmacovigilance analysis of FDA adverse event reporting system</dc:title>
        <dcterms:abstract>Objective: We analyze and identify the signals of gender differences in adverse events (ADEs) related to Osimertinib and provide reference for clinical implementation of individualized drug use. Methods: ADE reports of Osimertinib received from FAERS database from the first quarter of 2016 to the fourth quarter of 2022 were extracted. Reporting odds ratio (ROR) data analysis strategy was used for mining of signal strength that represents gender differences in ADEs related to Osimertinib. Results: The number of Osimertinib ADE reports included in the analysis was 7968 in females and 7570 in males, respectively. According to ROR, men were more likely to develop pneumonia aspiration, lung infection, interstitial lung disease, pulmonary toxicity, dyspnea, ventricular extrasystoles, and pulmonary thrombosis, while women were more likely to develop cardiac failure congestive, stomatitis, diarrhea, muscle spasms, nail disorder, onycholysis, skin disorder, dry skin, and rash. Conclusion: Gender differences existed in ADE signals related to Osimertinib. The higher risk of ADEs in male patients was lung diseases that seem more serious than those nail toxicities or skin problems that occurred in female patients. In order to ensure the safety of medication, we should be alert to the differences between different genders and take corresponding preventive measures to reduce the occurrence of serious ADEs.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079803</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2024776708&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>763-770</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1263">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2024960182&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>23</prism:volume>
                <dc:title>Expert Opinion on Drug Safety</dc:title>
                <dc:identifier>DOI 10.1080/14740338.2023.2245745</dc:identifier>
                <prism:number>2</prism:number>
                <dcterms:alternative>Expert Opin. Drug Saf.</dcterms:alternative>
                <dc:identifier>ISSN 1744-764X</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shi</foaf:surname>
                        <foaf:givenName>F.-E.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yu</foaf:surname>
                        <foaf:givenName>Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sun</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gao</foaf:surname>
                        <foaf:givenName>P.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhu</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1266"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>death</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>postmarketing surveillance</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>acute heart infarction</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>cerebrovascular accident</dc:subject>
        <dc:subject>chi square test</dc:subject>
        <dc:subject>bleeding</dc:subject>
        <dc:subject>brain hemorrhage</dc:subject>
        <dc:subject>disability</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>hematoma</dc:subject>
        <dc:subject>lung hemorrhage</dc:subject>
        <dc:subject>cardiogenic shock</dc:subject>
        <dc:subject>heart arrest</dc:subject>
        <dc:subject>heart arrhythmia</dc:subject>
        <dc:subject>heart ventricle fibrillation</dc:subject>
        <dc:subject>heart ventricle tachycardia</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>neurologic disease</dc:subject>
        <dc:subject>seizure</dc:subject>
        <dc:subject>brain hematoma</dc:subject>
        <dc:subject>brain infarction</dc:subject>
        <dc:subject>eye disease</dc:subject>
        <dc:subject>heart infarction</dc:subject>
        <dc:subject>ischemic stroke</dc:subject>
        <dc:subject>lung edema</dc:subject>
        <dc:subject>Medical Dictionary for Regulatory Activities</dc:subject>
        <dc:subject>subarachnoid hemorrhage</dc:subject>
        <dc:subject>lung embolism</dc:subject>
        <dc:subject>risk assessment</dc:subject>
        <dc:subject>congenital malformation</dc:subject>
        <dc:subject>drug indication</dc:subject>
        <dc:subject>groups by age</dc:subject>
        <dc:subject>lymphatic system disease</dc:subject>
        <dc:subject>treatment outcome</dc:subject>
        <dc:subject>data extraction</dc:subject>
        <dc:subject>heart disease</dc:subject>
        <dc:subject>hypotension</dc:subject>
        <dc:subject>mediastinum disease</dc:subject>
        <dc:subject>respiratory tract disease</dc:subject>
        <dc:subject>thorax disease</dc:subject>
        <dc:subject>vascular disease</dc:subject>
        <dc:subject>drug information</dc:subject>
        <dc:subject>hematologic disease</dc:subject>
        <dc:subject>hepatobiliary disease</dc:subject>
        <dc:subject>infection</dc:subject>
        <dc:subject>infestation</dc:subject>
        <dc:subject>injury</dc:subject>
        <dc:subject>intoxication</dc:subject>
        <dc:subject>drug efficacy</dc:subject>
        <dc:subject>congenital disorder</dc:subject>
        <dc:subject>familial disease</dc:subject>
        <dc:subject>genetic disorder</dc:subject>
        <dc:subject>larynx edema</dc:subject>
        <dc:subject>hypersensitivity</dc:subject>
        <dc:subject>retina macula hole</dc:subject>
        <dc:subject>consumer</dc:subject>
        <dc:subject>clinical monitoring</dc:subject>
        <dc:subject>eye movement disorder</dc:subject>
        <dc:subject>immunopathology</dc:subject>
        <dc:subject>aspiration pneumonia</dc:subject>
        <dc:subject>actilyse</dc:subject>
        <dc:subject>acute ischemic stroke</dc:subject>
        <dc:subject>alteplase</dc:subject>
        <dc:subject>angioneurotic edema</dc:subject>
        <dc:subject>aphasia</dc:subject>
        <dc:subject>cathflo activase</dc:subject>
        <dc:subject>cerebral blindness</dc:subject>
        <dc:subject>data processing</dc:subject>
        <dc:subject>drug identification</dc:subject>
        <dc:subject>ECG abnormality</dc:subject>
        <dc:subject>fibrinolytic therapy</dc:subject>
        <dc:subject>health practitioner</dc:subject>
        <dc:subject>hemianopia</dc:subject>
        <dc:subject>high level group term</dc:subject>
        <dc:subject>lip edema</dc:subject>
        <dc:subject>lowest level term</dc:subject>
        <dc:subject>medical procedures</dc:subject>
        <dc:subject>metalyse</dc:subject>
        <dc:subject>patient safety</dc:subject>
        <dc:subject>pharmacist</dc:subject>
        <dc:subject>physician</dc:subject>
        <dc:subject>postoperative complication</dc:subject>
        <dc:subject>preferred term</dc:subject>
        <dc:subject>pupil disease</dc:subject>
        <dc:subject>quadrantanopia</dc:subject>
        <dc:subject>retina detachment</dc:subject>
        <dc:subject>retina tear</dc:subject>
        <dc:subject>ST segment elevation</dc:subject>
        <dc:subject>statistical analysis</dc:subject>
        <dc:subject>surgery</dc:subject>
        <dc:subject>system organ class</dc:subject>
        <dc:subject>tenecteplase</dc:subject>
        <dc:subject>TNKase</dc:subject>
        <dc:subject>tongue edema</dc:subject>
        <dc:subject>urticaria</dc:subject>
        <dc:title>Comparing adverse events of tenecteplase and alteplase: a real-world analysis of the FDA adverse event reporting system (FAERS)</dc:title>
        <dcterms:abstract>Objectives: The aim of this study is to monitor, identify, and compare the adverse events (AEs) related to tenecteplase and alteplase, with the objective of exploring the potential safety of tenecteplase for acute ischemic stroke (AIS) and guiding its use to enhance patient safety. Methods: In order to evaluate the disproportionality of AEs associated with tenecteplase and alteplase in real-world data, four algorithms (ROR, PRR, BCPNN, EBGM) were utilized as measures to detect signals of AEs related to both drugs. Subsequently, Breslow-Day statistical analysis was applied to compare the RORs of the main system organ classes (SOCs) and key preferred terms (PTs) between tenecteplase and alteplase. Results: A statistical analysis was performed utilizing data gleaned from the Food and Drug Administration Adverse Event Reporting System (FAERS) database, encompassing 19,514,140 case reports from 2004Q1 to 2023Q1. There were 1,004 cases where tenecteplase was reported as the primary suspected (PS) and 2,363 tenecteplase-related adverse drug reactions (ADRs) at the PTs level were identified, the two data of alteplase were 10,945 and 25,266, respectively. The occurrence of drug-induced ADRs was analyzed across 27 organ systems, The analysis revealed several expected ADRs, such as Haemorrhage, Hypersensitivity which were consistent with the two drug-labels. It is of note that the signal strengths of ‘death,’ ‘ventricular fibrillation,’ ‘cardiogenic shock’ and ‘pneumonia aspiration’ at the PT level were markedly higher for tenecteplase than for alteplase, whereas the signal strength of ‘angioedema’ at the PT level was significantly higher for alteplase in comparison to tenecteplase. Additionally, unexpected significant ADRs associated with ocular adverse reactions and pneumonia aspiration at the PT level were identified, indicating potential AEs not currently mentioned in the drug instructions. Conclusion: This study identified and compared signals of ADRs associated with tenecteplase and alteplase, although tenecteplase is as effective as alteplase and has advantages such as ease of use and affordability, it cannot replace alteplase in the treatment of AIS until its safety profile is fully recognized. Additionally, previously unreported ocular ADRs and pneumonia were identified, providing valuable insights into the relationship between ADRs and the use of these thrombolytic drugs. These findings underscore the importance of continuous monitoring and effective detection of AEs to ultimately enhance the safety of AIS patients undergoing thrombolytic therapy.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079804</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2024960182&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>221-229</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1266">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2026584554&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1440-1746"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sun</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zuo</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhu</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1267"/>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>age distribution</dc:subject>
        <dc:subject>cross-sectional study</dc:subject>
        <dc:subject>rhabdomyolysis</dc:subject>
        <dc:subject>sex difference</dc:subject>
        <dc:subject>demographics</dc:subject>
        <dc:subject>clinical outcome</dc:subject>
        <dc:subject>mortality rate</dc:subject>
        <dc:subject>drug monitoring</dc:subject>
        <dc:subject>esomeprazole</dc:subject>
        <dc:subject>lansoprazole</dc:subject>
        <dc:subject>omeprazole</dc:subject>
        <dc:subject>pantoprazole</dc:subject>
        <dc:subject>patient selection</dc:subject>
        <dc:subject>rabeprazole</dc:subject>
        <dc:subject>reference database</dc:subject>
        <dc:title>A pharmacovigilance study of association between proton-pump inhibitors and rhabdomyolysis event based on FAERS database</dc:title>
        <dcterms:abstract>Background and Aim: The association between proton-pump inhibitors (PPIs) and rhabdomyolysis were unclear. The aim of this study was to explore and systematically analyze the potential link between five PPIs and the rhabdomyolysis events using the FDA Adverse Event Reporting System (FAERS) database. Methods: Suspected rhabdomyolysis events associated with PPIs were identified by data mining with the reporting odds ratio (ROR), proportional reporting ratio (PRR), the information component (IC), and Empirical Bayes Geometric Mean (EBGM). Demographic information, drug administration, and outcomes of PPI-induced rhabdomyolysis events were also analyzed. Results: There were 3311 reports associated with PPI-induced rhabdomyolysis that were identified. After removing duplicates, 1899 cases were determined to contain complete patient demographic data. The average age was 65 ± 18 year and 57% were male. Omeprazole and pantoprazole had the same largest percentage of reports. Lansoprazole had the highest ROR index of 12.67, followed by esomeprazole (11.18), omeprazole (10.27), rabeprazole (10.06), and pantoprazole (9.24). PRR, IC, and EBGM showed similar patterns. This suggested that lansoprazole exhibited the strongest correlation with rhabdomyolysis. In rhabdomyolysis events, PPIs were mainly “concomitant” (&gt;60%), and only a few cases were “primary suspects” (&lt;15%). Rabeprazole showed the lowest death rate while lansoprazole showed the highest. Conclusions: The study suggested that significant rhabdomyolysis signals were associated with PPIs. Further research should be performed in drug safety evaluation for a more comprehensive association.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079801</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2026584554&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>289-296</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1440-1746">
        <prism:volume>39</prism:volume>
        <dc:title>Journal of Gastroenterology and Hepatology (Australia)</dc:title>
        <dc:identifier>DOI 10.1111/jgh.16411</dc:identifier>
        <prism:number>2</prism:number>
        <dcterms:alternative>J. Gastroenterol. Hepatol.</dcterms:alternative>
        <dc:identifier>ISSN 1440-1746</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1267">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2028564991&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>347</prism:volume>
                <dc:title>Journal of Affective Disorders</dc:title>
                <dc:identifier>DOI 10.1016/j.jad.2023.11.076</dc:identifier>
                <dcterms:alternative>J. Affective Disord.</dcterms:alternative>
                <dc:identifier>ISSN 1573-2517</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhu</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Qu</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Du</foaf:surname>
                        <foaf:givenName>Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhou</foaf:surname>
                        <foaf:givenName>Q.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shen</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jiang</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhou</foaf:surname>
                        <foaf:givenName>Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhou</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1271"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data analysis</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>clinical feature</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>muscle spasm</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>gastrointestinal disease</dc:subject>
        <dc:subject>hypersalivation</dc:subject>
        <dc:subject>mental disease</dc:subject>
        <dc:subject>psychosis</dc:subject>
        <dc:subject>skin disease</dc:subject>
        <dc:subject>eye disease</dc:subject>
        <dc:subject>Medical Dictionary for Regulatory Activities</dc:subject>
        <dc:subject>Bayesian network</dc:subject>
        <dc:subject>cataract</dc:subject>
        <dc:subject>libido disorder</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>lymphatic system disease</dc:subject>
        <dc:subject>heart disease</dc:subject>
        <dc:subject>mediastinum disease</dc:subject>
        <dc:subject>respiratory tract disease</dc:subject>
        <dc:subject>thorax disease</dc:subject>
        <dc:subject>vascular disease</dc:subject>
        <dc:subject>hypersexuality</dc:subject>
        <dc:subject>breast disease</dc:subject>
        <dc:subject>hematologic disease</dc:subject>
        <dc:subject>hepatobiliary disease</dc:subject>
        <dc:subject>infection</dc:subject>
        <dc:subject>infestation</dc:subject>
        <dc:subject>kidney disease</dc:subject>
        <dc:subject>metabolic disorder</dc:subject>
        <dc:subject>nutritional disorder</dc:subject>
        <dc:subject>urinary tract disease</dc:subject>
        <dc:subject>congenital disorder</dc:subject>
        <dc:subject>endocrine disease</dc:subject>
        <dc:subject>familial disease</dc:subject>
        <dc:subject>genetic disorder</dc:subject>
        <dc:subject>multi item gamma poisson shrinker</dc:subject>
        <dc:subject>accommodation disorder</dc:subject>
        <dc:subject>cariprazine</dc:subject>
        <dc:subject>immunopathology</dc:subject>
        <dc:subject>akathisia</dc:subject>
        <dc:subject>amphetamine derivative</dc:subject>
        <dc:subject>Bayesian confidence propagation neural network</dc:subject>
        <dc:subject>blunted affect</dc:subject>
        <dc:subject>bruxism</dc:subject>
        <dc:subject>color vision defect</dc:subject>
        <dc:subject>extrapyramidal syndrome</dc:subject>
        <dc:subject>facial expression</dc:subject>
        <dc:subject>gunshot injury</dc:subject>
        <dc:subject>hypomania</dc:subject>
        <dc:subject>lens cortex</dc:subject>
        <dc:subject>mania</dc:subject>
        <dc:subject>oculogyric crisis</dc:subject>
        <dc:subject>oromandibular dystonia</dc:subject>
        <dc:subject>subcutaneous tissue</dc:subject>
        <dc:subject>tachypnea</dc:subject>
        <dc:subject>tardive dyskinesia</dc:subject>
        <dc:subject>tongue disease</dc:subject>
        <dc:subject>tongue movement disturbance</dc:subject>
        <dc:subject>tongue protrusion</dc:subject>
        <dc:title>Mining and analysis of adverse event signals of Cariprazine based on the real-world data of FAERS database</dc:title>
        <dcterms:abstract>Objective: This study aims to analyze the adverse events (AEs) of Cariprazine based on the FAERS database, providing evidence for its safety surveillance. Methods: For signal quantification of Cariprazine-related AEs, we used disproportionality analysis including the Ratio of Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-Item Gamma Poisson Shrinker (MGPS) algorithms. Results: We selected Cariprazine-related AE reports from the FAERS database from the fourth quarter of 2015 to the first quarter of 2023, and performed a detailed data analysis. Out of a total of 12,278,580 case reports, 3659 were found to be directly related to Cariprazine. We identified 140 Preferred Terms (PT) to describe these AEs, finding that they involved 27 organ systems. Specifically, AEs related to eye disorders such as Cataract cortical, Cataract nuclear, Accommodation disorder, Lenticular opacities, Oculogyric crisis, Dyschromatopsia were not explicitly mentioned in the drug's leaflet, indicating the presence of new ADR signals. Conclusion: Analysis of the FAERS database identified AEs associated with Cariprazine, notably in eye disorders not previously documented in the drug's official leaflet. These findings emphasize the need for continuous post-market surveillance and awareness among healthcare professionals regarding potential new ADR signals.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079800</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2028564991&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>45-50</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1271">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2027984629&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>46</prism:volume>
                <dc:title>International Journal of Clinical Pharmacy</dc:title>
                <dc:identifier>DOI 10.1007/s11096-023-01676-9</dc:identifier>
                <prism:number>2</prism:number>
                <dcterms:alternative>Int. J. Clin. Pharm.</dcterms:alternative>
                <dc:identifier>ISSN 2210-7711</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Qi</foaf:surname>
                        <foaf:givenName>Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tong</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhu</foaf:surname>
                        <foaf:givenName>D.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1272"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>age</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data analysis</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>factual database</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>hypertension</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>connective tissue disease</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>epistaxis</dc:subject>
        <dc:subject>outcome assessment</dc:subject>
        <dc:subject>bradycardia</dc:subject>
        <dc:subject>dizziness</dc:subject>
        <dc:subject>heart palpitation</dc:subject>
        <dc:subject>fatigue</dc:subject>
        <dc:subject>gastrointestinal discomfort</dc:subject>
        <dc:subject>gingiva disease</dc:subject>
        <dc:subject>headache</dc:subject>
        <dc:subject>muscle spasm</dc:subject>
        <dc:subject>nail disease</dc:subject>
        <dc:subject>nausea</dc:subject>
        <dc:subject>risk benefit analysis</dc:subject>
        <dc:subject>tinnitus</dc:subject>
        <dc:subject>alopecia</dc:subject>
        <dc:subject>asthenia</dc:subject>
        <dc:subject>diarrhea</dc:subject>
        <dc:subject>diverticulitis</dc:subject>
        <dc:subject>diabetes mellitus</dc:subject>
        <dc:subject>hearing impairment</dc:subject>
        <dc:subject>inner ear disease</dc:subject>
        <dc:subject>consciousness disorder</dc:subject>
        <dc:subject>dysgeusia</dc:subject>
        <dc:subject>body weight loss</dc:subject>
        <dc:subject>ear disease</dc:subject>
        <dc:subject>metabolic disorder</dc:subject>
        <dc:subject>musculoskeletal disease</dc:subject>
        <dc:subject>nutritional disorder</dc:subject>
        <dc:subject>drug efficacy</dc:subject>
        <dc:subject>hematochezia</dc:subject>
        <dc:subject>hyperglycemia</dc:subject>
        <dc:subject>infusion related reaction</dc:subject>
        <dc:subject>decreased appetite</dc:subject>
        <dc:subject>dry skin</dc:subject>
        <dc:subject>patient safety</dc:subject>
        <dc:subject>abdominal discomfort</dc:subject>
        <dc:subject>amenorrhea</dc:subject>
        <dc:subject>autophony</dc:subject>
        <dc:subject>bilateral hearing loss</dc:subject>
        <dc:subject>elevated blood pressure</dc:subject>
        <dc:subject>endocrine ophthalmopathy</dc:subject>
        <dc:subject>Food and Drug Administration Adverse Event Reporting System database</dc:subject>
        <dc:subject>hearing disorder</dc:subject>
        <dc:subject>hyperacusis</dc:subject>
        <dc:subject>onychoclasis</dc:subject>
        <dc:subject>perception deafness</dc:subject>
        <dc:subject>signal processing</dc:subject>
        <dc:subject>teprotumumab</dc:subject>
        <dc:title>Data mining and analysis of adverse event signals associated with teprotumumab using the Food and Drug Administration adverse event reporting system database</dc:title>
        <dcterms:abstract>Background: Teprotumumab was approved by the US Food and Drug Administration (FDA) for the treatment of thyroid eye disease in 2020. However, its adverse events (AEs) have not been investigated in real-world settings. Aim: This study aimed to detect and evaluate AEs associated with teprotumumab in the real-world setting by conducting a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. Method: Reporting odds ratio (ROR) was used to detect risk signals from the data from January 2020 to March 2023 in the FAERS database. Results: A total of 3,707,269 cases were retrieved, of which 1542 were related to teprotumumab. The FAERS analysis identified 99 teprotumumab-related AE signals in 14 System Organ Classes (SOCs). The most frequent AEs were muscle spasms (n = 287), fatigue (n = 174), blood glucose increase (n = 121), alopecia (n = 120), nausea (n = 118), hyperacusis (n = 117), and headache (n = 117). The AEs with strongest signal strengths were autophony (ROR = 14,475.49), deafness permanent (ROR = 1853.35), gingival recession (ROR = 190.74), deafness neurosensory (ROR = 129.89), nail growth abnormal (ROR = 103.67), onychoclasis (ROR = 73.58), ear discomfort (ROR = 72.88), and deafness bilateral (ROR = 62.46). Eleven positive AE signals were found at the standardized MedDRA queries (SMQs) level, of which the top five SMQs were hyperglycemia/new-onset diabetes mellitus, hearing impairment, gastrointestinal nonspecific symptoms and therapeutic procedures, noninfectious diarrhea, and hypertension. Age significantly increased the risk of hearing impairment. Conclusion: This study identified potential new and unexpected AE signals of teprotumumab. Our findings emphasize the importance of pharmacovigilance analysis in the real world to identify and manage AEs effectively, ultimately improving patient safety during teprotumumab treatment.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079797</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2027984629&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>471-479</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1272">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2027658739&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1179-2019"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Du</foaf:surname>
                        <foaf:givenName>R.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1268"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>hypertension</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>alanine aminotransferase</dc:subject>
        <dc:subject>alanine aminotransferase blood level</dc:subject>
        <dc:subject>aspartate aminotransferase</dc:subject>
        <dc:subject>aspartate aminotransferase blood level</dc:subject>
        <dc:subject>tachycardia</dc:subject>
        <dc:subject>abdominal pain</dc:subject>
        <dc:subject>pain</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>Medical Dictionary for Regulatory Activities</dc:subject>
        <dc:subject>dyspnea</dc:subject>
        <dc:subject>hypotension</dc:subject>
        <dc:subject>bronchospasm</dc:subject>
        <dc:subject>fever</dc:subject>
        <dc:subject>hypoxia</dc:subject>
        <dc:subject>rash</dc:subject>
        <dc:subject>platelet count</dc:subject>
        <dc:subject>urticaria</dc:subject>
        <dc:subject>C reactive protein</dc:subject>
        <dc:subject>cancer immunotherapy</dc:subject>
        <dc:subject>capillary leak syndrome</dc:subject>
        <dc:subject>dinutuximab</dc:subject>
        <dc:subject>Ewing sarcoma</dc:subject>
        <dc:subject>hypoalbuminemia</dc:subject>
        <dc:subject>hypoxemia</dc:subject>
        <dc:subject>naxitamab</dc:subject>
        <dc:subject>neuroblastoma</dc:subject>
        <dc:subject>osteosarcoma</dc:subject>
        <dc:subject>oxygen saturation</dc:subject>
        <dc:subject>small cell lung cancer</dc:subject>
        <dc:title>Toxicity Spectrum of Anti-GD2 Immunotherapy: A Real-World Study Leveraging the US Food and Drug Administration Adverse Event Reporting System</dc:title>
        <dcterms:abstract>Background: Anti-disialoganglioside (anti-GD2) monoclonal antibodies are effective immunotherapeutic drugs for treating neuroblastoma, yet their toxicity spectrum is unclear. Objective: This study aimed to assess the toxicity profiles of three anti-GD2 monoclonal antibodies (dinutuximab, dinutuximab β, and naxitamab) in clinical applications by mining and evaluating the adverse drug reaction (ADR) signals from the US Food and Drug Administration Adverse Event Reporting System. Methods: Data in the US Food and Drug Administration Adverse Event Reporting System from the time anti-GD2 monoclonal antibodies became available in the market to the first quarter of 2023 were searched. The signals of anti-GD2 monoclonal antibody-associated ADRs were quantified using four types of algorithms, including the reporting odds ratio, the proportional reporting ratio, the combination of the proportional reporting ratio and χ2 statistic method used by the UK Medicines and Healthcare Products Regulatory Agency, and the Bayesian confidence propagation neural network. The ADRs were categorized by System Organ Class based on the Medical Dictionary for Regulatory Activities, and were sorted according to the frequency and signal strength of ADRs. Results: A total of 370 adverse drug event reports with anti-GD2 monoclonal antibodies listed as the ‘primary suspected drugs’ were identified, with 116 ADR signals detected, of which 22 were not in the drug labels. Among the adverse drug event reports, 276 reports concerned dinutuximab/dinutuximab β as primary suspected drugs with 90 ADR signals, involving 19 System Organ Classes, of which 21 signals were not in the label; 94 adverse drug event reports concerned naxitamab as the primary suspected drug with 26 ADR signals, involving 11 System Organ Classes, of which one was not in the label. For dinutuximab/dinutuximab β-related ADRs, the top five most frequent were “fever”, “abdominal pain”, “elevated aspartate aminotransferase (AST)”, “elevated alanine aminotransferase (ALT)” and “hypotension”; the top five most intensive signals were “hypoalbuminemia”, “elevated AST”, “capillary leakage syndrome”, “hypoxia” and “elevated ALT”. For naxitamab-related ADRs, the top five most frequent were “hypotension”, “pain”, “urticarial”, “hypertension” and “rash”; the top five most intensive signals were “hypotension”, “urticaria”, “hypoxemia”, “bronchospasm” and “hypertension”. Involved System Organ Classes included “investigations” and “respiratory, thoracic and mediastinal disorders” containing the most types of ADR signals in dinutuximab/dintuximab β-related ADRs and naxitamab-related ADRs, respectively. Conclusions: Our study comprehensively analyzed the toxicity profiles of anti-GD2 monoclonal antibodies and provides an important reference for clinical monitoring and ADR identification of these drugs.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079799</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2027658739&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>175-185</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1179-2019">
        <prism:volume>26</prism:volume>
        <dc:title>Pediatric Drugs</dc:title>
        <dc:identifier>DOI 10.1007/s40272-023-00613-7</dc:identifier>
        <prism:number>2</prism:number>
        <dcterms:alternative>Pediatr. Drugs</dcterms:alternative>
        <dc:identifier>ISSN 1179-2019</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1268">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2029802849&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1873-5010"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shi</foaf:surname>
                        <foaf:givenName>A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Nguyen</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kuo</foaf:surname>
                        <foaf:givenName>C.B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Beringer</foaf:surname>
                        <foaf:givenName>P.M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1270"/>
        <dc:subject>acute kidney failure</dc:subject>
        <dc:subject>adult</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>alanine aminotransferase</dc:subject>
        <dc:subject>alanine aminotransferase blood level</dc:subject>
        <dc:subject>aspartate aminotransferase</dc:subject>
        <dc:subject>aspartate aminotransferase blood level</dc:subject>
        <dc:subject>abdominal pain</dc:subject>
        <dc:subject>dry eye</dc:subject>
        <dc:subject>demographics</dc:subject>
        <dc:subject>respiratory tract disease</dc:subject>
        <dc:subject>fever</dc:subject>
        <dc:subject>abdominal discomfort</dc:subject>
        <dc:subject>elexacaftor plus ivacaftor plus tezacaftor</dc:subject>
        <dc:subject>gamma glutamyl transferase blood level</dc:subject>
        <dc:subject>gamma glutamyltransferase</dc:subject>
        <dc:subject>hepatic encephalopathy</dc:subject>
        <dc:subject>hospital patient</dc:subject>
        <dc:subject>liver failure</dc:subject>
        <dc:subject>liver function test</dc:subject>
        <dc:subject>liver injury</dc:subject>
        <dc:subject>liver necrosis</dc:subject>
        <dc:subject>patient monitoring</dc:subject>
        <dc:subject>placebo</dc:subject>
        <dc:title>Drug-induced liver injury associated with elexacaftor/tezacaftor/ivacaftor: A pharmacovigilance analysis of the FDA adverse event reporting system (FAERS)</dc:title>
        <dcterms:abstract>Introduction: The efficacy and safety of elexacaftor/tezacaftor/ivacaftor (ETI) have been established in prospective clinical trials. Liver function test elevations were observed in a greater proportion of patients receiving ETI compared with placebo; however, the relatively small number of patients and short duration of study preclude detection of rare but clinically significant associations with drug-induced liver injury (DILI). To address this gap, we assessed the real-world risk of DILI associated with ETI through data mining of the FDA adverse event reporting system (FAERS). Methods: Disproportionality analyses were conducted on FAERS data from the fourth quarter of 2019 through the third quarter of 2022. Comparative patient demographics, onset time and outcomes for ETI-DILI were also obtained. Results: 452 reports of DILI associated with ETI were found, representing 2.1 % of all adverse event reports for ETI. All disproportionality measures were significant for ETI-DILI at p &lt; 0.05; the reporting odds ratio (ROR) (2.82) was comparable to that of drugs classified by FDA as “Most-DILI concern”. The most notable demographic finding was a male majority (5:4 male to female ratio) for ETI-DILI compared to a female majority (4:5 male to female ratio) for non ETI-DILI. Median ETI-DILI onset time was 50.5 days, and hospitalization was the second most common complication. Conclusion: Using FAERS data, ETI was found to be disproportionately associated with DILI. Future research is needed to investigate the hepatotoxic mechanisms and assess potential mitigation strategies for ETI-induced hepatotoxicity.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079795</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2029802849&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>566-572</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1873-5010">
        <prism:volume>23</prism:volume>
        <dc:title>Journal of Cystic Fibrosis</dc:title>
        <dc:identifier>DOI 10.1016/j.jcf.2024.01.001</dc:identifier>
        <prism:number>3</prism:number>
        <dcterms:alternative>J. Cyst. Fibrosis</dcterms:alternative>
        <dc:identifier>ISSN 1873-5010</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1270">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-84923042149&amp;doi=10.7150%2fijms.10656&amp;partnerID=40&amp;md5=9763a9a0269bcca2d4b4526472c9af7f">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:14491907%20(ISSN)"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Fujimoto</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Higuchi</foaf:surname>
                        <foaf:givenName>T.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hosomi</foaf:surname>
                        <foaf:givenName>K.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Takada</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1278"/>
        <dc:subject>Article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>factual database</dc:subject>
        <dc:subject>FAERS database</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>risk factor</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>United States Food and Drug Administration</dc:subject>
        <dc:subject>risk assessment</dc:subject>
        <dc:subject>cancer risk</dc:subject>
        <dc:subject>breast cancer</dc:subject>
        <dc:subject>chemically induced</dc:subject>
        <dc:subject>Data Mining</dc:subject>
        <dc:subject>Databases, Factual</dc:subject>
        <dc:subject>disease association</dc:subject>
        <dc:subject>drug use</dc:subject>
        <dc:subject>Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>atorvastatin</dc:subject>
        <dc:subject>reference database</dc:subject>
        <dc:subject>colorectal cancer</dc:subject>
        <dc:subject>esophagus cancer</dc:subject>
        <dc:subject>melanoma</dc:subject>
        <dc:subject>lung cancer</dc:subject>
        <dc:subject>hydroxymethylglutaryl coenzyme A reductase inhibitor</dc:subject>
        <dc:subject>stomach cancer</dc:subject>
        <dc:subject>mevinolin</dc:subject>
        <dc:subject>pitavastatin</dc:subject>
        <dc:subject>pravastatin</dc:subject>
        <dc:subject>rosuvastatin</dc:subject>
        <dc:subject>simvastatin</dc:subject>
        <dc:subject>Risk Factors</dc:subject>
        <dc:subject>food and drug administration</dc:subject>
        <dc:subject>prostate cancer</dc:subject>
        <dc:subject>Cancer risk</dc:subject>
        <dc:subject>Colorectal Neoplasms</dc:subject>
        <dc:subject>fluindostatin</dc:subject>
        <dc:subject>hematologic malignancy</dc:subject>
        <dc:subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors</dc:subject>
        <dc:subject>pancreas cancer</dc:subject>
        <dc:subject>Pancreatic Neoplasms</dc:subject>
        <dc:subject>Statin use</dc:subject>
        <dc:title>Association between statin use and cancer: Data mining of a spontaneous reporting database and a claims database</dc:title>
        <dcterms:abstract>Purpose: In recent years, the potential risk of cancer associated with statin use has been a focus of much interest. However, it remains uncertain whether statin therapy is associated with cancer risk. To examine the association between statin use and the risk of cancer, we conducted data mining using the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) and a large organized database of claims constructed by a database vendor (The Japan Medical Data Center Co., Ltd, Tokyo, Japan [JMDC]). Methods: Relevant reports in the FAERS, which included data from the first quarter of 2004 through the end of 2012, were identified and analyzed. The reporting odds ratio (ROR) was used to detect spontaneous report signals and was calculated using the case/non-case method. Additionally, signals were detected via the information component (IC) using the IC025 metric. Furthermore, event sequence symmetry analysis (ESSA) was applied to identify the risk of cancer following treatment with statins over the period January 2005 to July 2013. Results: In the FAERS database analyses, significant signals for colorectal cancer and pancreatic cancer were found for statins as a class. In the ESSA, significant associations between statin use and colorectal cancer and pancreatic cancer were found, with adjusted sequence ratios (95% confidence intervals) of 1.20 (1.08-1.34) and 1.31 (1.13-1.53), respectively, at an interval of 48 months. Conclusions: Multi-methodological approaches using different algorithms and databases suggest that statin use is associated with an increased risk for colorectal cancer and pancreatic cancer. © 2015 Ivyspring International Publisher.</dcterms:abstract>
        <dc:date>2015</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281102132</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-84923042149&amp;doi=10.7150%2fijms.10656&amp;partnerID=40&amp;md5=9763a9a0269bcca2d4b4526472c9af7f</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>223-233</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:14491907%20(ISSN)">
        <prism:volume>12</prism:volume>
        <dc:title>International Journal of Medical Sciences</dc:title>
        <dc:identifier>DOI 10.7150/ijms.10656</dc:identifier>
        <prism:number>3</prism:number>
        <dcterms:alternative>Int. J. Med. Sci.</dcterms:alternative>
        <dc:identifier>ISSN 14491907 (ISSN)</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1278">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 49; Correspondence Address: M. Takada; Division of Clinical Drug Informatics, School of Pharmacy, Kinki University, Higashi-osaka, 3-4-1, Kowakae, 577-8502, Japan; email: takada@phar.kindai.ac.jp&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="#item_1064">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>16</prism:volume>
                <dc:title>FRONTIERS IN PHARMACOLOGY</dc:title>
                <dc:identifier>DOI 10.3389/fphar.2025.1469597</dc:identifier>
                <dc:identifier>ISSN 1663-9812</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Feng</foaf:surname>
                        <foaf:givenName>YK</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Fa</foaf:surname>
                        <foaf:givenName>X</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>YF</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>T</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sun</foaf:surname>
                        <foaf:givenName>X</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>FP</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_878"/>
        <dcterms:isReferencedBy rdf:resource="#item_1307"/>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>adverse events</dc:subject>
        <dc:subject>FAERS</dc:subject>
        <dc:subject>HYPERTENSION</dc:subject>
        <dc:subject>SUNITINIB</dc:subject>
        <dc:subject>gastrointestinal stromal tumor</dc:subject>
        <dc:subject>IMATINIB</dc:subject>
        <dc:subject>KINASE INHIBITOR</dc:subject>
        <dc:subject>KIT</dc:subject>
        <dc:subject>RATIOS</dc:subject>
        <dc:subject>RECEPTOR</dc:subject>
        <dc:subject>RENAL-CELL CARCINOMA</dc:subject>
        <dc:subject>ripretinib</dc:subject>
        <dc:subject>SURVIVAL</dc:subject>
        <dc:subject>TYROSINE KINASE</dc:subject>
        <dc:title>A real-world disproportionality analysis of ripretinib data mining of the public version of FDA adverse event reporting system</dc:title>
        <dcterms:abstract>Background Tyrosine kinase inhibitors (TKIs) are the preferred targeted therapy for advanced gastrointestinal stromal tumors (GIST). Ripretinib, the first tyrosine kinase switch control inhibitor, has not yet been extensively studied for long-term safety in large populations. This study evaluates Ripretinib-related adverse events (AEs) in real-world applications by analyzing data from the FDA's Adverse Event Reporting System (FAERS).Methods To quantify signals of AEs, we employed several disproportionality analyses: the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS).Results In the FAERS database, out of 7,064,646 reports, 3,161 were identified as related to Ripretinib AEs, with 438 significant disproportionality in preferred terms. The most common adverse reactions were tiredness, hair loss, nausea, constipation, diarrhea, loss of appetite, palmar-plantar erythrodysesthesia syndrome, and vomiting. These reactions align with the medication instructions and reports from corresponding clinical trials. Notably, the label includes unexpected and significant AEs such as &quot;hepatic neoplasm&quot;, &quot;hair texture abnormal&quot;, &quot;metastases to liver&quot; and &quot;red blood cell count decreased&quot;. The median onset time for Ripretinib-related AEs was 99 days, with an interquartile range of 27-245 days. Most cases (26.74%, n = 165) occurred within the first month of Ripretinib administration.Conclusion Our findings align with clinical observations. We identified novel and unexpected AEs signatures of Ripretinib, indicating that prospective clinical studies are necessary to confirm these findings and clarify their implications. These results could provide valuable evidence to guide further safety studies on Ripretinib.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281088806</dc:coverage>
        <dcterms:dateSubmitted>0003-01-01</dcterms:dateSubmitted>
    </bib:Article>
    <bib:Memo rdf:about="#item_878">
        <rdf:value>&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;42&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Memo rdf:about="#item_1307">
        <rdf:value>&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;42&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2002771239&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1878-1705"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Fan</foaf:surname>
                        <foaf:givenName>Q.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hu</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yang</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhao</foaf:surname>
                        <foaf:givenName>B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_913"/>
        <dcterms:isReferencedBy rdf:resource="#item_1192"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>postmarketing surveillance</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>myocarditis</dc:subject>
        <dc:subject>fatality</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>mortality rate</dc:subject>
        <dc:subject>atezolizumab</dc:subject>
        <dc:subject>ipilimumab</dc:subject>
        <dc:subject>nivolumab</dc:subject>
        <dc:subject>pembrolizumab</dc:subject>
        <dc:subject>monotherapy</dc:subject>
        <dc:subject>avelumab</dc:subject>
        <dc:subject>durvalumab</dc:subject>
        <dc:subject>lung cancer</dc:subject>
        <dc:subject>priority journal</dc:subject>
        <dc:title>Myocarditis following the use of different immune checkpoint inhibitor regimens: A real-world analysis of post-marketing surveillance data</dc:title>
        <dcterms:abstract>Backgrounds: Although myocarditis has been reported in patients treated with immune checkpoint inhibitors (ICIs), there are few real-world studies to compare the occurrences and characteristics of myocarditis after different ICI regimens. Methods: Disproportionality analysis and Bayesian analysis were utilized for data mining of the suspected adverse events of myocarditis after ICIs use based on the Food and Drug Administration's Adverse Event Reporting System (FAERS) from January 2004 to June 2018. The times to onset and fatality rates of myocarditis following different ICI regimens were also compared. Results: A total of 315 reports of myocarditis adverse events were identified with ICIs. Among 6 ICI monotherapies, avelumab had the highest association with myocarditis based on the highest reporting odds ratio (ROR = 42.65, 95% two-sided CI = 15.86–114.72), proportional reporting ratio (PRR = 42.61, χ2 = 159.63) and empirical Bayes geometric mean (EBGM = 41.87, 95% one-sided CI = 15.57). The combination therapies of ipilimumab plus pembrolizumab or nivolumab had higher RORs, PRRs and EBGMs than did pembrolizumab or nivolumab monotherapy. Myocarditis associated with the ipilimumab plus nivolumab treatment appeared to have earlier onset (16.5 [IQR 14–29.75] days vs 32 [IQR 16–77] days, p&lt;0.01) and higher fatality rate (65.75% vs 50.40%, p&lt;0.05) than that associated with nivolumab monotherapy. Conclusions: Analysis of FAERS data provides more precise profile on the occurrences and characteristics of myocarditis after different ICI regimens. The findings support continued surveillance, risk factor identification, and comparative studies.</dcterms:abstract>
        <dc:date>2019</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079915</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2002771239&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1878-1705">
        <prism:volume>76</prism:volume>
        <dc:title>International Immunopharmacology</dc:title>
        <dc:identifier>DOI 10.1016/j.intimp.2019.105866</dc:identifier>
        <dcterms:alternative>Int. Immunopharmacol.</dcterms:alternative>
        <dc:identifier>ISSN 1878-1705</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_913">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Memo rdf:about="#item_1192">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85182234286&amp;doi=10.1038%2fs41598-023-50013-7&amp;partnerID=40&amp;md5=c63a39aa3c848bf8da0bd0b267f7faf4">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:20452322%20(ISSN)"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Eshwar</foaf:surname>
                        <foaf:givenName>V.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kamath</foaf:surname>
                        <foaf:givenName>A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1273"/>
        <dcterms:isReferencedBy rdf:resource="#item_1301"/>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>United States Food and Drug Administration</dc:subject>
        <dc:subject>Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>monoclonal antibody</dc:subject>
        <dc:subject>psoriasis</dc:subject>
        <dc:subject>Antibodies, Monoclonal, Humanized</dc:subject>
        <dc:subject>Psoriasis</dc:subject>
        <dc:subject>secukinumab</dc:subject>
        <dc:title>Assessment of safety profile of secukinumab in real-world scenario using United States food and drug administration adverse event reporting system database</dc:title>
        <dcterms:abstract>Secukinumab is an anti-IL-17 monoclonal antibody approved for treating psoriasis and various arthritides. A comprehensive evaluation of its safety, especially in a real-world setting, is necessary. This study aimed to describe the adverse events (AE) associated with secukinumab use using the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database. FAERS data files containing AE reports from 2015 to 2021 were downloaded for data mining. Primary or secondary suspect medications indicated for psoriasis were identified and analyzed. Medical dictionary for regulatory activities (MedDRA version 24.1) was used to analyze the AE terms. To detect potential safety signals of AE from secukinumab use, disproportionality analysis was used. A total of 365,590 adverse event reports were identified; of these, 44,761 reports involved the use of secukinumab. Safety signals were identified for ocular infections and gastrointestinal adverse events at the standardised MedDRA query level. Safety signals for oral candidiasis, oral herpes, conjunctivitis, eye infections, and ulcerative colitis were identified at the preferred term level. The findings of our study are consistent with those of earlier studies, such as the increased risk of infections and inflammatory bowel disease. However, our study also identified additional safety signals that need to be further evaluated. © 2024, The Author(s).</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281101988</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85182234286&amp;doi=10.1038%2fs41598-023-50013-7&amp;partnerID=40&amp;md5=c63a39aa3c848bf8da0bd0b267f7faf4</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:20452322%20(ISSN)">
        <prism:volume>14</prism:volume>
        <dc:title>Scientific Reports</dc:title>
        <dc:identifier>DOI 10.1038/s41598-023-50013-7</dc:identifier>
        <prism:number>1</prism:number>
        <dcterms:alternative>Sci. Rep.</dcterms:alternative>
        <dc:identifier>ISSN 20452322 (ISSN)</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1273">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 12; Correspondence Address: A. Kamath; Department of Pharmacology, Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, India; email: ashwin.kamath@manipal.edu&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Memo rdf:about="#item_1301">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 12; Correspondence Address: A. Kamath; Department of Pharmacology, Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, India; email: ashwin.kamath@manipal.edu&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85145084049&amp;doi=10.3389%2ffendo.2022.1032199&amp;partnerID=40&amp;md5=bd2ecb82984cb0c0b5e8ea7f4454caeb">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:16642392%20(ISSN)"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Dong</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sun</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_900"/>
        <dcterms:isReferencedBy rdf:resource="#item_1332"/>
        <dc:subject>acute kidney failure</dc:subject>
        <dc:subject>acute kidney injury</dc:subject>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>postmarketing surveillance</dc:subject>
        <dc:subject>prognosis</dc:subject>
        <dc:subject>risk factor</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>adverse event reporting system</dc:subject>
        <dc:subject>health care personnel</dc:subject>
        <dc:subject>CARDIOVASCULAR OUTCOMES</dc:subject>
        <dc:subject>dulaglutide</dc:subject>
        <dc:subject>glucagon like peptide 1 receptor agonist</dc:subject>
        <dc:subject>mortality</dc:subject>
        <dc:subject>semaglutide</dc:subject>
        <dc:subject>glucagon-like peptide-1 receptor agonist</dc:subject>
        <dc:subject>LIRAGLUTIDE</dc:subject>
        <dc:subject>lixisenatide</dc:subject>
        <dc:subject>onset time</dc:subject>
        <dc:subject>outcome</dc:subject>
        <dc:title>Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data</dc:title>
        <dcterms:abstract>Clinical studies after marketing have shown that the use of glucagon-like peptide-1 receptor agonist(GLP-1RA) may lead to acute kidney injury(AKI). However, few epidemiological studies have investigated the risk, clinical features, and outcomes of AKI caused by different GLP-1RA. In this study, Adverse Event Reporting System (FAERS) data were used to compare the association between different GLP-1RA and AKI in the real world. Methods: FAERS data from January 2004 to December 2021 were mined using disproportionality analysis and Bayesian analysis to determine the correlation between different GLP-1RA and AKI, and the onset time, mortality, and hospitalization rate of different GLP-1RA were analyzed. Results: We identified 2670 cases of AKI events associated with GLP-1RA, of which liraglutide was the most commonly reported (34.98%). The patients with AKI were mainly males (47.94%), and the age group was mainly 45-84 years old (73.15%). obese patients with weight more than 99kg (24.42%) were more likely to have AKI. According to different signal mining methods, reporting odds ratio (ROR) (1.50, 95% confidence interval =1.41-1.60) and Bayesian confidence Propagation neural network (0.57, 95% confidence interval =0.54), liraglutide was more strongly associated with AKI than other GLP-1RA. The median time to onset of AKI was 63 days [quartile range (IQR): 15-458.5 days]. In addition, the hospitalization rate and fatality rate of patients with GLP-1RA-related AKI were 45.28% and 4.23% respectively. Conclusions: Based on the data in the FAERS database, we analyzed the risk, onset time, and adverse reaction outcomes of GLP-1RA-induced AKI in detail. The results showed that liraglutide had the highest risk of AKI. From the early stage of treatment, we need to monitor patients’ renal function regularly, especially for patients with high kidney risks such as obesity and age. Copyright © 2022 Dong and Sun.</dcterms:abstract>
        <dc:date>2022</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281088748</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85145084049&amp;doi=10.3389%2ffendo.2022.1032199&amp;partnerID=40&amp;md5=bd2ecb82984cb0c0b5e8ea7f4454caeb</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:16642392%20(ISSN)">
        <prism:volume>13</prism:volume>
        <dc:title>Frontiers in Endocrinology</dc:title>
        <dc:identifier>DOI 10.3389/fendo.2022.1032199</dc:identifier>
        <dcterms:alternative>Front. Endocrinol.</dcterms:alternative>
        <dc:identifier>ISSN 16642392 (ISSN)</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_900">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 21; Correspondence Address: C. Sun; Department of Pharmacy, Children’s Hospital of Nanjing Medical University, Nanjing, China; email: ydsunchuan@163.com&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;14&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;14&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;44&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Memo rdf:about="#item_1332">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 21; Correspondence Address: C. Sun; Department of Pharmacy, Children’s Hospital of Nanjing Medical University, Nanjing, China; email: ydsunchuan@163.com&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;14&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;14&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;44&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="#item_1069">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1942-597X%201559-4076"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ding</foaf:surname>
                        <foaf:givenName>Tiffany</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>Elizabeth S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_892"/>
        <dcterms:isReferencedBy rdf:resource="#item_1338"/>
        <dc:subject>*Data Mining</dc:subject>
        <dc:subject>*Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>Adolescent</dc:subject>
        <dc:subject>Adult</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>Aged</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>United States Food and Drug Administration</dc:subject>
        <dc:subject>Female</dc:subject>
        <dc:subject>Pharmacovigilance</dc:subject>
        <dc:subject>Male</dc:subject>
        <dc:subject>Middle Aged</dc:subject>
        <dc:subject>Datasets as Topic</dc:subject>
        <dc:subject>Young Adult</dc:subject>
        <dc:subject>Risk Factors</dc:subject>
        <dc:subject>Suicidal Ideation</dc:subject>
        <dc:subject>Suicide, Attempted/statistics &amp; numerical data</dc:subject>
        <dc:subject>Suicide/*statistics &amp; numerical data</dc:subject>
        <dc:title>Mining Drugs and Indications for Suicide-Related Adverse Events.</dc:title>
        <dcterms:abstract>There has been a significant increase in suicide rates in the United States (U.S.) over the past two decades. Studies have highlighted the need for further  exploration of suicide risk factors, particularly combinations of factors. In  this study, a pharmacovigilance analysis was conducted to better understand drugs  and indications as risk factors for suicide using data from the U.S. Food and  Drug Administration (FDA) Adverse Event Reporting System (FAERS) and Adverse  Event Open Learning through Universal Standardization (AEOLUS), a standardized  version of FAERS. Association rule mining techniques were applied to 85,071 cases  involving suicide-related adverse reactions and demographic subsets of these  cases. Preliminary results reveal combinations of drugs and indications that may  increase the likelihood of suicide, with certain combinations potentially  affecting some demographic groups more than others. Further work is needed to  validate the initial findings, explore subpopulations, and determine the broader  implications for suicide prevention.</dcterms:abstract>
        <dc:date>2019</dc:date>
        <z:language>eng</z:language>
        <dc:coverage>rayyan-281080037</dc:coverage>
        <bib:pages>1011-1020</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1942-597X%201559-4076">
        <prism:volume>2019</prism:volume>
        <dc:title>AMIA ... Annual Symposium proceedings. AMIA Symposium</dc:title>
        <dcterms:alternative>AMIA Annu Symp Proc</dcterms:alternative>
        <dc:identifier>ISSN 1942-597X 1559-4076</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_892">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Memo rdf:about="#item_1338">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="#item_1070">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>14</prism:volume>
                <dc:title>FRONTIERS IN PHARMACOLOGY</dc:title>
                <dc:identifier>DOI 10.3389/fphar.2023.1259908</dc:identifier>
                <dc:identifier>ISSN 1663-9812</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Cui</foaf:surname>
                        <foaf:givenName>ZW</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Cheng</foaf:surname>
                        <foaf:givenName>FY</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>LH</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zou</foaf:surname>
                        <foaf:givenName>F</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Pan</foaf:surname>
                        <foaf:givenName>RM</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tian</foaf:surname>
                        <foaf:givenName>YH</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>XY</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>She</foaf:surname>
                        <foaf:givenName>J</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>YD</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yang</foaf:surname>
                        <foaf:givenName>XY</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_884"/>
        <dcterms:isReferencedBy rdf:resource="#item_1324"/>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>FAERS</dc:subject>
        <dc:subject>adverse drug event</dc:subject>
        <dc:subject>etoposide</dc:subject>
        <dc:subject>DRUG-REACTIONS</dc:subject>
        <dc:subject>DISPROPORTIONALITY ANALYSIS</dc:subject>
        <dc:subject>CELL-LUNG-CANCER</dc:subject>
        <dc:subject>COLONY-STIMULATING FACTORS</dc:subject>
        <dc:subject>FEBRILE NEUTROPENIA</dc:subject>
        <dc:subject>PHASE-II TRIAL</dc:subject>
        <dc:subject>PRIMARY PROPHYLAXIS</dc:subject>
        <dc:subject>PUBLIC VERSION</dc:subject>
        <dc:subject>real-word analysis</dc:subject>
        <dc:subject>TOPOISOMERASE-II</dc:subject>
        <dc:subject>TUMOR LYSIS SYNDROME</dc:subject>
        <dc:title>A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?</dc:title>
        <dcterms:abstract>Introduction: Etoposide is a broad-spectrum antitumor drug that has been extensively studied in clinical trials. However, limited information is available regarding its real-world adverse reactions. Therefore, this study aimed to assess and evaluate etoposide-related adverse events in a real-world setting by using data mining method on the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database.Methods: Through the analysis of 16,134,686 reports in the FAERS database, a total of 9,892 reports of etoposide-related adverse drug events (ADEs) were identified. To determine the significance of these ADEs, various disproportionality analysis algorithms were applied, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi-item gamma Poisson shrinker (MGPS) algorithms.Results: As a result, 478 significant disproportionality preferred terms (PTs) that were identified by all four algorithms were retained. These PTs included commonly reported adverse events such as thrombocytopenia, leukopenia, anemia, stomatitis, and pneumonitis, which align with those documented in the drug's instructions and previous clinical trials. However, our analysis also uncovered unexpected and significant ADEs, including thrombotic microangiopathy, ototoxicity, second primary malignancy, nephropathy toxic, and ovarian failure. Furthermore, we examined the time-to-onset (TTO) of these ADEs using the Weibull distribution test and found that the median TTO for etoposide-associated ADEs was 10 days (interquartile range [IQR] 2-32 days). The majority of cases occurred within the first month (73.8%) after etoposide administration. Additionally, our analysis revealed specific high-risk signals for males, such as pneumonia and cardiac infarction, while females showed signals for drug resistance and ototoxicity.Discussion: These findings provide valuable insight into the occurrence of ADEs following etoposide initiation, which can potentially support clinical monitoring and risk identification efforts.</dcterms:abstract>
        <dc:date>2023</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281088771</dc:coverage>
        <dcterms:dateSubmitted>0010-01-01</dcterms:dateSubmitted>
    </bib:Article>
    <bib:Memo rdf:about="#item_884">
        <rdf:value>&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;20&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;20&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;99&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Memo rdf:about="#item_1324">
        <rdf:value>&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;20&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;20&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;99&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85200197416&amp;doi=10.1590%2f1414-431X2024e13392&amp;partnerID=40&amp;md5=04512f299519b55077eb267dd1363d80">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:0100879X%20(ISSN)"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Cui</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhao</foaf:surname>
                        <foaf:givenName>B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhong</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_897"/>
        <dcterms:isReferencedBy rdf:resource="#item_1329"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>factual database</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>incidence</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>postmarketing surveillance</dc:subject>
        <dc:subject>young adult</dc:subject>
        <dc:subject>Adult</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>Algorithms</dc:subject>
        <dc:subject>Bayes Theorem</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>FAERS</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>United States Food and Drug Administration</dc:subject>
        <dc:subject>Medical Dictionary for Regulatory Activities</dc:subject>
        <dc:subject>very elderly</dc:subject>
        <dc:subject>Data mining</dc:subject>
        <dc:subject>Databases, Factual</dc:subject>
        <dc:subject>cyclosporine</dc:subject>
        <dc:subject>immunosuppressive agent</dc:subject>
        <dc:subject>Female</dc:subject>
        <dc:subject>Pharmacovigilance</dc:subject>
        <dc:subject>patient safety</dc:subject>
        <dc:subject>Male</dc:subject>
        <dc:subject>Middle Aged</dc:subject>
        <dc:subject>adverse food reaction</dc:subject>
        <dc:subject>anastomosis</dc:subject>
        <dc:subject>Cyclosporine</dc:subject>
        <dc:subject>DICTIONARY</dc:subject>
        <dc:subject>immune system</dc:subject>
        <dc:subject>Immunosuppressant agent</dc:subject>
        <dc:subject>Immunosuppressive Agents</dc:subject>
        <dc:subject>pregnancy outcome</dc:subject>
        <dc:subject>Serious adverse events</dc:subject>
        <dc:subject>SIGNAL GENERATION</dc:subject>
        <dc:subject>spermatozoon</dc:subject>
        <dc:title>A real-world disproportionality analysis of cyclosporine from the FDA Adverse Event Reporting System (FAERS) database</dc:title>
        <dcterms:abstract>Cyclosporine is an immunosuppressant used to prevent organ rejection in kidney, liver, and heart allogeneic transplants. This study aimed to assess the safety of cyclosporine through the analysis of adverse events (AEs) related to cyclosporine in the US Food and Drug Administration Adverse Event Reporting System (FAERS). To detect AEs associated with cyclosporine, a pharmacovigilance analysis was conducted using four algorithms on the FAERS database: reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and empirical Bayes geometric mean (EBGM). A statistical analysis was performed on data extracted from the FAERS database, covering 19,582 case reports spanning from 2013 to 2022. Among these cases, 3,911 AEs were identified, with 476 linked to cyclosporine as the primary suspected drug. Cyclosporin-induced AEs targeted 27 System Organ Classes (SOCs). Notably, the highest case at the SOC level included eye disorders, injury, poisoning, and procedural complications, as well as immune system disorders, all of which are listed on the cyclosporine label. Furthermore, we discovered novel potential AEs associated with hepatobiliary disorders, among others. Moreover, unexpected adverse drug reactions (ADRs), such as biliary anastomosis complication and spermatozoa progressive motility decrease, were identified. Importantly, these newly identified ADRs were not mentioned on the cyclosporine label, which were involved in injury, poisoning, and procedural complications, and investigations at the SOC level. The study used pharmacovigilance analysis of FAERS database to identify new and unexpected potential ADRs relating to cyclosporine, which can provide safety tips for the safe use of cyclosporine. © 2024, Associacao Brasileira de Divulgacao Cientifica. All rights reserved.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281088751</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85200197416&amp;doi=10.1590%2f1414-431X2024e13392&amp;partnerID=40&amp;md5=04512f299519b55077eb267dd1363d80</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:0100879X%20(ISSN)">
        <prism:volume>57</prism:volume>
        <dc:title>Brazilian Journal of Medical and Biological Research</dc:title>
        <dc:identifier>DOI 10.1590/1414-431X2024e13392</dc:identifier>
        <dcterms:alternative>Braz. J. Med. Biol. Res.</dcterms:alternative>
        <dc:identifier>ISSN 0100879X (ISSN)</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_897">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 1; Correspondence Address: X. Zhong; NHC Key Laboratory of Male Reproduction and Genetics, Guangdong Provincial Reproductive Science Institute (Guangdong Provincial Fertility Hospital), Guangzhou, China; email: xingmingzh@126.com; CODEN: RBPMB&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;32&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Memo rdf:about="#item_1329">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 1; Correspondence Address: X. Zhong; NHC Key Laboratory of Male Reproduction and Genetics, Guangdong Provincial Reproductive Science Institute (Guangdong Provincial Fertility Hospital), Guangzhou, China; email: xingmingzh@126.com; CODEN: RBPMB&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;32&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85094219697&amp;doi=10.1097%2fMD.0000000000022669&amp;partnerID=40&amp;md5=12842ddc7a18e619da289f623d0c8921">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:00257974%20(ISSN)"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Choi</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yoon</foaf:surname>
                        <foaf:givenName>D.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Park</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Joung</foaf:surname>
                        <foaf:givenName>K.-I.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shin</foaf:surname>
                        <foaf:givenName>J.-Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Osemene.</foaf:surname>
                        <foaf:givenName>I.N.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1281"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>young adult</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>Adolescent</dc:subject>
        <dc:subject>Adult</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>Child</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>Child, Preschool</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>Female</dc:subject>
        <dc:subject>infant</dc:subject>
        <dc:subject>Male</dc:subject>
        <dc:subject>Middle Aged</dc:subject>
        <dc:subject>Anticonvulsants</dc:subject>
        <dc:subject>anticonvulsive agent</dc:subject>
        <dc:subject>Young Adult</dc:subject>
        <dc:subject>topiramate</dc:subject>
        <dc:subject>preschool child</dc:subject>
        <dc:subject>Infant</dc:subject>
        <dc:subject>Korea Institute of Drug Safety &amp; Risk Management Korea Adverse Event Reporting System database (K...</dc:subject>
        <dc:subject>Topiramate</dc:subject>
        <dc:title>Topiramate-related adverse events: Pattern and signals in the Korea Adverse Event Reporting System, 2010-2017</dc:title>
        <dcterms:abstract>Despite safety concerns associated with topiramate use, the pattern of adverse events and signal analysis of antiepileptic drugs remain elusive.We aimed to determine patient demographics and characteristics of reported AEs of topiramate and to detect the associated signals by comparing those of other antiepileptics.We used the Korea Institute of Drug Safety &amp; Risk Management-Korea Adverse Event Reporting System Database (KIDS-KD) from 2010 to 2017 to determine patient demographics and characteristics of reported AEs for topiramate and other antiepileptics. The proportional reporting ratio, reporting odds ratio, and information component were used in signal detection. Signals were compared against drug labels in Korea, the UK, the EU, and the US.A total of 1300 adverse events cases of topiramate were reported, and the number of topiramate-adverse event pairs was 1861. For topiramate, the proportion of women of childbearing age (20-39 years) with adverse events was more than double that for other antiepileptics. A majority of the 36 detected signals were of neuropsychiatric disorders such as cognitive disorders, concentration impaired, amnesia, hypoaesthesia. Patients with topiramate-induced adverse events were likely to be young and female. Also, adverse events related to carbonic anhydrase isoenzyme showed specifically great disproportionalities.Rigorous clinical management is needed to ensure proper and safe use of topiramate. Special precautions should be taken when prescribing in women of childbearing age. © 2020 Lippincott Williams and Wilkins. All rights reserved.</dcterms:abstract>
        <dc:date>2020</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281102069</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85094219697&amp;doi=10.1097%2fMD.0000000000022669&amp;partnerID=40&amp;md5=12842ddc7a18e619da289f623d0c8921</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:00257974%20(ISSN)">
        <prism:volume>99</prism:volume>
        <dc:title>Medicine (United States)</dc:title>
        <dc:identifier>DOI 10.1097/MD.0000000000022669</dc:identifier>
        <prism:number>42</prism:number>
        <dcterms:alternative>Medicine</dcterms:alternative>
        <dc:identifier>ISSN 00257974 (ISSN)</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1281">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 7; Correspondence Address: J.-Y. Shin; School of Pharmacy, Sungkyunkwan University, Suwon, 2066 Seobu-ro, Jangan-gu, Gyeong gi-do, South Korea; email: shin.jy@skku.edu; CODEN: MEDIA&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2002329485&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1532-0464"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhou</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>T.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhao</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ye</foaf:surname>
                        <foaf:givenName>K.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liao</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_910"/>
        <dcterms:isReferencedBy rdf:resource="#item_1189"/>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>Adverse drug reactions</dc:subject>
        <dc:subject>Algorithms</dc:subject>
        <dc:subject>biology</dc:subject>
        <dc:subject>Character recognition</dc:subject>
        <dc:subject>Computational Biology</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>information processing</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>data extraction</dc:subject>
        <dc:subject>electronic health record</dc:subject>
        <dc:subject>Electronic Health Records</dc:subject>
        <dc:subject>Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>devices</dc:subject>
        <dc:subject>Data Collection</dc:subject>
        <dc:subject>China</dc:subject>
        <dc:subject>Pharmacovigilance</dc:subject>
        <dc:subject>data processing</dc:subject>
        <dc:subject>Brain</dc:subject>
        <dc:subject>priority journal</dc:subject>
        <dc:subject>Bidirectional Long Short Term Memory Conditional Random Field</dc:subject>
        <dc:subject>Chinese</dc:subject>
        <dc:subject>Chinese natural language processing</dc:subject>
        <dc:subject>Conditional Random Field</dc:subject>
        <dc:subject>hospital</dc:subject>
        <dc:subject>Hospitals</dc:subject>
        <dc:subject>Iterative methods</dc:subject>
        <dc:subject>language</dc:subject>
        <dc:subject>Language</dc:subject>
        <dc:subject>Learning algorithms</dc:subject>
        <dc:subject>Lexical Feature based Bidirectional Long Short Term Memory Conditional Random Field</dc:subject>
        <dc:subject>Lexical feature based bidirectional long short-term memory</dc:subject>
        <dc:subject>Lexical features</dc:subject>
        <dc:subject>Long short-term memory</dc:subject>
        <dc:subject>Machine learning</dc:subject>
        <dc:subject>Named entity recognition</dc:subject>
        <dc:subject>Named Entity Recognition</dc:subject>
        <dc:subject>natural language processing</dc:subject>
        <dc:subject>Natural Language Processing</dc:subject>
        <dc:subject>Natural language processing systems</dc:subject>
        <dc:subject>Neural Networks, Computer</dc:subject>
        <dc:subject>Pharmacodynamics</dc:subject>
        <dc:subject>Random processes</dc:subject>
        <dc:subject>reproducibility</dc:subject>
        <dc:subject>Reproducibility of Results</dc:subject>
        <dc:subject>Supervised learning</dc:subject>
        <dc:subject>supervised machine learning</dc:subject>
        <dc:subject>Supervised Machine Learning</dc:subject>
        <dc:subject>Tri-training</dc:subject>
        <dc:title>Named entity recognition from Chinese adverse drug event reports with lexical feature based BiLSTM-CRF and tri-training</dc:title>
        <dcterms:abstract>Background: The Adverse Drug Event Reports (ADERs) from the spontaneous reporting system are important data sources for studying Adverse Drug Reactions (ADRs) as well as post-marketing pharmacovigilance. Apart from the conventional ADR information contained in the structured section of ADERs, more detailed information such as pre- and post- ADR symptoms, multi-drug usages and ADR-relief treatments are described in the free-text section, which can be mined through Natural Language Processing (NLP) tools. Objective: The goal of this study was to extract ADR-related entities from free-text section of Chinese ADERs, which can act as supplements for the information contained in structured section, so as to further assist in ADR evaluation. Methods: Three models of Conditional Random Field (CRF), Bidirectional Long Short-Term Memory-CRF (BiLSTM-CRF) and Lexical Feature based BiLSTM-CRF (LF-BiLSTM-CRF) were constructed to conduct Named Entity Recognition (NER) tasks in free-text section of Chinese ADERs. A semi-supervised learning method of tri-training was applied on the basis of the three established models to give un-annotated raw data with reliable tags. Results: Among the three basic models, the LF-BiLSTM-CRF achieved the highest average F1 score of 94.35%. After the process of tri-training, almost half of the un-annotated cases were tagged with labels, and the performances of all the three models improved after iterative training. Conclusions: The LF-BiLSTM-CRF model that we constructed could achieve a comparatively high F1 score, and the fusion of CRF, while BiLSTM-CRF and LF-BiLSTM-CRF in tri-training might further strengthen the reliability of predicted tags. The results suggested the usefulness of our methods in developing the specialized NER tools for identifying ADR-related information from Chinese ADERs.</dcterms:abstract>
        <dc:date>2019</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079922</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2002329485&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1532-0464">
        <prism:volume>96</prism:volume>
        <dc:title>Journal of Biomedical Informatics</dc:title>
        <dc:identifier>DOI 10.1016/j.jbi.2019.103252</dc:identifier>
        <dcterms:alternative>J. Biomed. Informatics</dcterms:alternative>
        <dc:identifier>ISSN 1532-0464</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_910">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 69; Correspondence Address: J. Liao; School of Science, China Pharmaceutical University, Nanjing, #639 Longmian Avenue, Jiangning District, 211198, China; email: liaojun@cpu.edu.cn; CODEN: JBIOB&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Base governamental,Desenvolvimento do método</rdf:value>
    </bib:Memo>
    <bib:Memo rdf:about="#item_1189">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 69; Correspondence Address: J. Liao; School of Science, China Pharmaceutical University, Nanjing, #639 Longmian Avenue, Jiangning District, 211198, China; email: liaojun@cpu.edu.cn; CODEN: JBIOB&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Base governamental,Desenvolvimento do método</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2019386213&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>44</prism:volume>
                <dc:title>International Journal of Clinical Pharmacy</dc:title>
                <dc:identifier>DOI 10.1007/s11096-022-01472-x</dc:identifier>
                <prism:number>6</prism:number>
                <dcterms:alternative>Int. J. Clin. Pharm.</dcterms:alternative>
                <dc:identifier>ISSN 2210-7711</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>J.-J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Huo</foaf:surname>
                        <foaf:givenName>X.-C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>S.-X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>F.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhao</foaf:surname>
                        <foaf:givenName>Q.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_811"/>
        <dcterms:isReferencedBy rdf:resource="#item_1218"/>
        <dc:subject>acute kidney failure</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>hyperkalemia</dc:subject>
        <dc:subject>odds ratio</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>postmarketing surveillance</dc:subject>
        <dc:subject>prescription</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>rhabdomyolysis</dc:subject>
        <dc:subject>sepsis</dc:subject>
        <dc:subject>heart ventricle tachycardia</dc:subject>
        <dc:subject>myocarditis</dc:subject>
        <dc:subject>supraventricular tachycardia</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>brain disease</dc:subject>
        <dc:subject>seizure</dc:subject>
        <dc:subject>skin disease</dc:subject>
        <dc:subject>embolism</dc:subject>
        <dc:subject>thrombophlebitis</dc:subject>
        <dc:subject>cholestasis</dc:subject>
        <dc:subject>chill</dc:subject>
        <dc:subject>creatinine</dc:subject>
        <dc:subject>multiple organ failure</dc:subject>
        <dc:subject>mediastinum disease</dc:subject>
        <dc:subject>respiratory tract disease</dc:subject>
        <dc:subject>thorax disease</dc:subject>
        <dc:subject>bacteremia</dc:subject>
        <dc:subject>drug eruption</dc:subject>
        <dc:subject>infection</dc:subject>
        <dc:subject>infestation</dc:subject>
        <dc:subject>kidney disease</dc:subject>
        <dc:subject>candidiasis</dc:subject>
        <dc:subject>drug labeling</dc:subject>
        <dc:subject>drug-induced liver injury</dc:subject>
        <dc:subject>bacterial endocarditis</dc:subject>
        <dc:subject>fever</dc:subject>
        <dc:subject>rash</dc:subject>
        <dc:subject>aortic regurgitation</dc:subject>
        <dc:subject>diskitis</dc:subject>
        <dc:subject>endocarditis</dc:subject>
        <dc:subject>Escherichia coli infection</dc:subject>
        <dc:subject>fungemia</dc:subject>
        <dc:subject>Pseudomonas infection</dc:subject>
        <dc:subject>thrombocytopenia</dc:subject>
        <dc:subject>bacterial arthritis</dc:subject>
        <dc:subject>lactic acidosis</dc:subject>
        <dc:subject>patient monitoring</dc:subject>
        <dc:subject>acute myeloid leukemia</dc:subject>
        <dc:subject>hemophagocytic syndrome</dc:subject>
        <dc:subject>septic shock</dc:subject>
        <dc:subject>staphylococcal bacteremia</dc:subject>
        <dc:subject>eosinophilia</dc:subject>
        <dc:subject>compartment syndrome</dc:subject>
        <dc:subject>myositis</dc:subject>
        <dc:subject>liver cell damage</dc:subject>
        <dc:subject>Clostridium infection</dc:subject>
        <dc:subject>DRESS syndrome</dc:subject>
        <dc:subject>interstitial nephritis</dc:subject>
        <dc:subject>acute lung injury</dc:subject>
        <dc:subject>allergic pneumonitis</dc:subject>
        <dc:subject>antibiotic resistance</dc:subject>
        <dc:subject>antibiotic sensitivity</dc:subject>
        <dc:subject>aortic valve disease</dc:subject>
        <dc:subject>creatine kinase</dc:subject>
        <dc:subject>creatine kinase blood level</dc:subject>
        <dc:subject>cubicin</dc:subject>
        <dc:subject>daptomycin</dc:subject>
        <dc:subject>enterococcal infection</dc:subject>
        <dc:subject>epidural abscess</dc:subject>
        <dc:subject>geotrichosis</dc:subject>
        <dc:subject>heart valve abscess</dc:subject>
        <dc:subject>hyperoxaluria</dc:subject>
        <dc:subject>infectious arthritis</dc:subject>
        <dc:subject>kidney tubule necrosis</dc:subject>
        <dc:subject>Loeffler pneumonia</dc:subject>
        <dc:subject>lung infiltrate</dc:subject>
        <dc:subject>lung mycosis</dc:subject>
        <dc:subject>mental deficiency</dc:subject>
        <dc:subject>myopathy</dc:subject>
        <dc:subject>necrotizing fasciitis</dc:subject>
        <dc:subject>oliguria</dc:subject>
        <dc:subject>papule</dc:subject>
        <dc:subject>respiratory failure</dc:subject>
        <dc:subject>Staphylococcus infection</dc:subject>
        <dc:subject>toxic myopathy</dc:subject>
        <dc:subject>valvular heart disease</dc:subject>
        <dc:title>Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system</dc:title>
        <dcterms:abstract>Background: Previous reports on daptomycin’s adverse drug reactions (ADRs) have been insufficient, often because of limited data. Pharmacovigilance risk signal detection is innovative and has been applied to the safety monitoring and reevaluation of drugs post-marketing. Aim: The study aimed to promote safe daptomycin prescribing by mining and evaluating the daptomycin ADR signals from the US Food and Drug Administration Adverse Event Reporting System (FAERS). Method: A disproportionality analysis (reporting odds ratio ROR and proportional reporting ratio PRR) was utilized for FAERS data mining from the first quarter of 2004 to the second quarter of 2021 (the most recent quarterly data at the time of the study). Preferred Terms of ADR reports were categorized by System Organ Class (SOC) based on the Medical Dictionary for Regulatory Activities. Results: This study retrieved 12,221 cases within the reporting period. A total of 140 repetitive signals were obtained by ROR and PRR, of which 53 new ADR signals were not recorded in the drug labels/datasheets. The top three ADR reports were “blood creatine phosphokinase elevation” (ROR, 56.66, 95% confidence interval (CI) 51.07–62.87, PRR 51.94), “eosinophilic pneumonia” (ROR 696.71, 95%CI 603.21–804.70, PRR 657.57), and “rhabdomyolysis” (ROR 22.85, 95%CI 19.94–26.18, PRR 21.83). The highest ROR of “antimicrobial susceptibility test resistant” was found at 9808.14. Reports of rare adverse events, such as “necrotizing fasciitis and compartment syndrome,” have emerged. The significant SOCs were “Infections and Infestations” and “Investigations.” Conclusion: New daptomycin ADR signals were detected. Clinicians should monitor these potential ADRs in patients receiving daptomycin.</dcterms:abstract>
        <dc:date>2022</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079858</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2019386213&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>1351-1360</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_811">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Memo rdf:about="#item_1218">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85088589908&amp;doi=10.1002%2fcam4.3198&amp;partnerID=40&amp;md5=d6e9ada30ab8c9924a24594621ed59c5">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:20457634%20(ISSN)"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Qin</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Fan</foaf:surname>
                        <foaf:givenName>Q.-Q.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhao</foaf:surname>
                        <foaf:givenName>B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mei</foaf:surname>
                        <foaf:givenName>D.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>X.-M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1285"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>age</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>factual database</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>postmarketing surveillance</dc:subject>
        <dc:subject>prognosis</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>risk factor</dc:subject>
        <dc:subject>young adult</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>Adolescent</dc:subject>
        <dc:subject>Adult</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>Age Factors</dc:subject>
        <dc:subject>Aged</dc:subject>
        <dc:subject>Bayes Theorem</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>United States Food and Drug Administration</dc:subject>
        <dc:subject>unclassified drug</dc:subject>
        <dc:subject>risk assessment</dc:subject>
        <dc:subject>antineoplastic agent</dc:subject>
        <dc:subject>Databases, Factual</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>drug fatality</dc:subject>
        <dc:subject>kidney disease</dc:subject>
        <dc:subject>Adverse Event Reporting System</dc:subject>
        <dc:subject>mortality rate</dc:subject>
        <dc:subject>Female</dc:subject>
        <dc:subject>mortality</dc:subject>
        <dc:subject>cancer immunotherapy</dc:subject>
        <dc:subject>cancer combination chemotherapy</dc:subject>
        <dc:subject>atezolizumab</dc:subject>
        <dc:subject>ipilimumab</dc:subject>
        <dc:subject>Male</dc:subject>
        <dc:subject>Middle Aged</dc:subject>
        <dc:subject>nivolumab</dc:subject>
        <dc:subject>pembrolizumab</dc:subject>
        <dc:subject>nephrotoxicity</dc:subject>
        <dc:subject>Young Adult</dc:subject>
        <dc:subject>immune checkpoint inhibitor</dc:subject>
        <dc:subject>monotherapy</dc:subject>
        <dc:subject>avelumab</dc:subject>
        <dc:subject>durvalumab</dc:subject>
        <dc:subject>Risk Factors</dc:subject>
        <dc:subject>pharmacoepidemiology</dc:subject>
        <dc:subject>priority journal</dc:subject>
        <dc:subject>Risk Assessment</dc:subject>
        <dc:subject>Retrospective Studies</dc:subject>
        <dc:subject>Pharmacoepidemiology</dc:subject>
        <dc:subject>Antineoplastic Combined Chemotherapy Protocols</dc:subject>
        <dc:subject>Hospitalization</dc:subject>
        <dc:subject>Immune Checkpoint Inhibitors</dc:subject>
        <dc:subject>Kidney Diseases</dc:subject>
        <dc:subject>Prognosis</dc:subject>
        <dc:subject>renal adverse effects</dc:subject>
        <dc:subject>time factor</dc:subject>
        <dc:subject>Time Factors</dc:subject>
        <dc:title>Renal adverse effects following the use of different immune checkpoint inhibitor regimens: A real-world pharmacoepidemiology study of post-marketing surveillance data</dc:title>
        <dcterms:abstract>Backgrounds: Although kidney impairments have been reported following immune checkpoint inhibitors (ICIs) in clinical studies, there are few pharmacoepidemiology studies to compare the occurrences, clinical features, and prognosis of renal adverse effects. Methods: Disproportionality and Bayesian analysis were used in data mining to screen the suspected renal adverse effects after the administration of different ICIs, based on FDA's Adverse Event Reporting System (FAERS) from January 2004 to September 2019. The time to onset, fatality and hospitalization rates of renal adverse effects were also investigated. Results: We identified 1444 reports of renal adverse effects. Affected patients tended to be older than 65 years (52.7%). Renal effects were most commonly reported in nivolumab monotherapy (33.24%). Atezolizumab appeared the strongest association among six ICI monotherapies, based on the highest reporting odds ratio (ROR = 144.38, two-sided 95% CI = 123.08 −169.37), proportional reporting ratio (PRR = 139.13, χ2 = 21 425.38), and empirical Bayes geometric mean (EBGM = 131.75, one-sided 95% CI = 115.28). The combination treatments showed higher RORs, PRRs, and EBGMs, compared with either nivolumab or pembrolizumab monotherapy. The median onset time of renal adverse effects was 48 (interquartile range [IQR] 18.75-121.25) days after the monotherapies of ICI regimens. Patients treated with the combination of nivolumab plus ipilimumab were younger than receivers in nivolumab monotherapy (63.81 ± 12.03 vs 66.39 ± 11.53, P =.004); The fatality rate of renal adverse effects appeared lower in the combination group, compared to nivolumab monotherapy (18.53% vs 27.50%, P =.004). The top hospitalization rates due to renal effects occurred in patients with combination therapies. Conclusion: Based on the FAERS database, we profiled renal adverse effects after various ICIs with real-world data in occurrences, clinical characteristics, and prognosis. Renal effects should be tightly monitored, especially within the first several months after ICIs administration. Particular concern should be paid for patients with a tendency for kidney impairments, such as old age. © 2020 The Authors. Cancer Medicine published by John Wiley &amp; Sons Ltd.</dcterms:abstract>
        <dc:date>2020</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281102053</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85088589908&amp;doi=10.1002%2fcam4.3198&amp;partnerID=40&amp;md5=d6e9ada30ab8c9924a24594621ed59c5</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>6576-6585</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:20457634%20(ISSN)">
        <prism:volume>9</prism:volume>
        <dc:title>Cancer Medicine</dc:title>
        <dc:identifier>DOI 10.1002/cam4.3198</dc:identifier>
        <prism:number>18</prism:number>
        <dcterms:alternative>Cancer Med.</dcterms:alternative>
        <dc:identifier>ISSN 20457634 (ISSN)</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1285">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 27; Correspondence Address: B. Zhao; Pharmacy Department, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China; email: zhaobin@pumch.cn&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2018500776&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1879-4068"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xu</foaf:surname>
                        <foaf:givenName>T.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_809"/>
        <dcterms:isReferencedBy rdf:resource="#item_1214"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>age</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>odds ratio</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>risk factor</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>cardiovascular disease</dc:subject>
        <dc:subject>gastrointestinal disease</dc:subject>
        <dc:subject>neurologic disease</dc:subject>
        <dc:subject>skin disease</dc:subject>
        <dc:subject>eye disease</dc:subject>
        <dc:subject>confidence interval</dc:subject>
        <dc:subject>hematologic disease</dc:subject>
        <dc:subject>kidney disease</dc:subject>
        <dc:subject>musculoskeletal disease</dc:subject>
        <dc:subject>endocrine disease</dc:subject>
        <dc:subject>sensitivity analysis</dc:subject>
        <dc:subject>sex</dc:subject>
        <dc:subject>atezolizumab</dc:subject>
        <dc:subject>ipilimumab</dc:subject>
        <dc:subject>nivolumab</dc:subject>
        <dc:subject>pembrolizumab</dc:subject>
        <dc:subject>liver disease</dc:subject>
        <dc:subject>immune checkpoint inhibitor</dc:subject>
        <dc:subject>monotherapy</dc:subject>
        <dc:subject>avelumab</dc:subject>
        <dc:subject>cemiplimab</dc:subject>
        <dc:subject>durvalumab</dc:subject>
        <dc:subject>drug dose regimen</dc:subject>
        <dc:subject>immune related adverse event</dc:subject>
        <dc:subject>immune response</dc:subject>
        <dc:subject>lung disease</dc:subject>
        <dc:subject>patient-reported outcome</dc:subject>
        <dc:title>Immune-related adverse events in older adults: Data mining of the FDA Adverse Event Reporting System</dc:title>
        <dcterms:abstract>Introduction: Recent studies reveal that there is no difference in the efficacy of immune checkpoint inhibitors (ICIs) between younger adults and older adults. However, it remains unclear whether age is a risk factor for immune-related adverse events (irAEs). Materials and methods: To analyze the association between irAEs and age based on data from the Food and Drug Administration Adverse Event Reporting System (FAERS) database between January 2004 and December 2020, we performed a case/noncase study on ICI-related adverse events. Cases were defined as adverse event cases with ICI therapy and irAEs, and noncases were defined as adverse event cases with ICI therapy and without irAEs. One case was matched to a noncase using the sex, reporter, report year, and type of ICI regimen. The reporting odds ratios (RORs) were used to assess the disproportionality of irAEs between older adults (≥65 years) and younger adults (&lt;65 years). Results: The study shows that compared with younger adults, the ROR of older adults was 1.12 (95% confidence interval [CI]: 1.08–1.16) and 1.18 (95% CI: 1.14–1.23) before and after matching, respectively. The signal of age-related irAEs was detected in patients treated with ICI monotherapy but not in patients treated with combination therapy. Further analysis revealed a spectrum of age-related toxicities including cardiovascular toxicities, lung toxicities, musculoskeletal toxicities, nervous system toxicities, renal toxicities, and skin toxicities. Conclusion: In this analysis performed based on the FAERS, irAE cases were more likely to be reported in older adults. Our pharmacovigilance study complements the safety data of clinical trials. Further studies are expected to explore the underlying reasons for irAEs in older adults.</dcterms:abstract>
        <dc:date>2022</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079864</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2018500776&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>1017-1022</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1879-4068">
        <prism:volume>13</prism:volume>
        <dc:title>Journal of Geriatric Oncology</dc:title>
        <dc:identifier>DOI 10.1016/j.jgo.2022.05.009</dc:identifier>
        <prism:number>7</prism:number>
        <dcterms:alternative>J. Geriatr. Oncol.</dcterms:alternative>
        <dc:identifier>ISSN 1879-4068</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_809">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Memo rdf:about="#item_1214">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2016961238&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1573-2584"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Cui</foaf:surname>
                        <foaf:givenName>Q.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhou</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhao</foaf:surname>
                        <foaf:givenName>B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mei</foaf:surname>
                        <foaf:givenName>D.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                   <foaf:Person><foaf:surname>Xuemei</foaf:surname></foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_805"/>
        <dcterms:isReferencedBy rdf:resource="#item_1216"/>
        <dc:subject>acute kidney failure</dc:subject>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>creatinine</dc:subject>
        <dc:subject>treatment outcome</dc:subject>
        <dc:subject>diabetes mellitus</dc:subject>
        <dc:subject>creatinine blood level</dc:subject>
        <dc:subject>canagliflozin</dc:subject>
        <dc:subject>mortality rate</dc:subject>
        <dc:subject>canagliflozin plus metformin</dc:subject>
        <dc:subject>dapagliflozin</dc:subject>
        <dc:subject>dapagliflozin plus metformin</dc:subject>
        <dc:subject>empagliflozin</dc:subject>
        <dc:subject>ertugliflozin plus metformin</dc:subject>
        <dc:subject>sodium glucose cotransporter 2 inhibitor</dc:subject>
        <dc:subject>ICD-10</dc:subject>
        <dc:subject>phylogeny</dc:subject>
        <dc:subject>non insulin dependent diabetes mellitus</dc:subject>
        <dc:subject>sitagliptin</dc:subject>
        <dc:subject>dapagliflozin plus saxagliptin</dc:subject>
        <dc:subject>diabetic nephropathy</dc:subject>
        <dc:subject>diabetic patient</dc:subject>
        <dc:subject>empagliflozin plus linagliptin</dc:subject>
        <dc:subject>estimated glomerular filtration rate</dc:subject>
        <dc:subject>interstitial nephritis</dc:subject>
        <dc:subject>kidney injury</dc:subject>
        <dc:subject>peritoneal dialysis</dc:subject>
        <dc:subject>renin angiotensin aldosterone system</dc:subject>
        <dc:subject>saxagliptin</dc:subject>
        <dc:subject>sodium glucose cotransporter 2</dc:subject>
        <dc:title>Acute kidney injury following SGLT2 inhibitors among diabetic patients: a pharmacovigilance study</dc:title>
        <dcterms:abstract>Purpose: The sodium–glucose cotransporter-2 (SGLT2) inhibitors have changed the treatment of type 2 diabetes mellitus. Several studies evaluated SGLT2 inhibitor-related acute kidney injury (AKI), but pharmacoepidemiology studies are needed to compare the adverse events in different SGLT2 inhibitors (SGLT2i). Methods: We used disproportionality analysis and Bayesian analysis in data mining to screen the AKI cases after initiating different SGLT2i among diabetic patients, based on the FDA’s Adverse Event Reporting System (FAERS) updated to December 2020. We also investigated the onset time and fatality rates of SGLT2i-associated AKI, which was based on preferred terms (PTs) coded for the renal adverse events in the structure of the FARES database. Results: We identified 2483 cases of AKI following SGLT2i regimens among diabetic patients. Most of them were 45–64 years old (58.46%) and &gt; 65 years old (28.67%). Canagliflozin generated the largest number of AKI reports (n = 1650, 66.45%) in our study. Canagliflozin showed the strongest association among SGLT2i, evidenced by the highest reporting odds ratio (ROR = 3.70, two-sided 95% CI 3.51–3.91), proportional reporting ratio (PRR = 3.39, χ2 = 2635.06), and empirical Bayes geometric mean (EBGM = 3.18, one-sided 95% CI 3.04). The median onset time to AKI was 72.0 (interquartile range [IQR] 21.0–266.0) days after SGLT2i initiation. The general hospitalization rate of SGLT2i-associated AKI was 63.50%, and the fatality rate was 1.59%. The deceased patients (62.94 ± 10.69 years) were significantly older than the survived ones (57.82 ± 11.84 years) (P = 0.011). Conclusion: We compared AKI events in the real-world practice of various SGLT2i among diabetic cases from the FAERS database. It is essential to monitor kidney function during the early administration of SGLT2i. Concern should be paid for AKI in patients older than 65 taking SGLT2i.</dcterms:abstract>
        <dc:date>2022</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079861</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2016961238&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>2949-2957</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1573-2584">
        <prism:volume>54</prism:volume>
        <dc:title>International Urology and Nephrology</dc:title>
        <dc:identifier>DOI 10.1007/s11255-022-03211-7</dc:identifier>
        <prism:number>11</prism:number>
        <dcterms:alternative>Int. Urol. Nephrol.</dcterms:alternative>
        <dc:identifier>ISSN 1573-2584</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_805">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Memo rdf:about="#item_1216">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2018972227&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>22</prism:volume>
                <dc:title>Expert Opinion on Drug Safety</dc:title>
                <dc:identifier>DOI 10.1080/14740338.2022.2120609</dc:identifier>
                <prism:number>3</prism:number>
                <dcterms:alternative>Expert Opin. Drug Saf.</dcterms:alternative>
                <dc:identifier>ISSN 1744-764X</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xu</foaf:surname>
                        <foaf:givenName>T.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1230"/>
        <dcterms:isReferencedBy rdf:resource="#item_1274"/>
        <dc:subject>acute kidney failure</dc:subject>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>angiotensin receptor antagonist</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>combination drug therapy</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>prognosis</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>risk assessment</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>drug fatality</dc:subject>
        <dc:subject>drug indication</dc:subject>
        <dc:subject>sacubitril plus valsartan</dc:subject>
        <dc:subject>chronic kidney failure</dc:subject>
        <dc:subject>canagliflozin</dc:subject>
        <dc:subject>empagliflozin</dc:subject>
        <dc:subject>sodium glucose cotransporter 2 inhibitor</dc:subject>
        <dc:subject>monotherapy</dc:subject>
        <dc:subject>kidney injury</dc:subject>
        <dc:subject>enkephalinase inhibitor</dc:subject>
        <dc:title>Angiotensin receptor-neprilysin inhibitor and sodium-dependent glucose cotransporter-2 inhibitor-associated renal injury: a pharmacovigilance study</dc:title>
        <dcterms:abstract>Background: Angiotensin receptor-neprilysin inhibitor (ARNI) and sodium-dependent glucose cotransporter-2 inhibitors (SGLT-2Is) had a certain risk of renal injury. However, overlapping nephrotoxicity of combination therapy was unclear. Research design and methods: We performed a disproportionality analysis based on the Food and Drug Administration Adverse Event Reporting System from 1 January 2004 to 31 December 2020. Renal injury cases were defined as acute kidney injury (AKI) and chronic kidney disease (CKD) cases. Results: We detected a significant association between ARNI, SGLT-2Is, the combination therapy and AKI as well as CKD, in which the combination therapy generated the highest strength association with both AKI (ROR: 8.06, 95% CI 5.41–12.01) and CKD (ROR: 2.69, 95% CI 1.27–5.71). Compared with ARNI or SGLT-2I alone, the combination therapy generated AKI signals. There were no differences in the onset time of renal injury cases between the combination therapy and monotherapy. Compared to cases without renal injury, the combination therapy did not increase the proportion of fatality and hospitalizations in cases with AKI or CKD. Conclusion: The combination of ARNI and SGLT-2Is was associated with a significantly increased reporting proportion of AKI. However, due to the limitations of the FAERS database, our results required further studies to assess our findings.</dcterms:abstract>
        <dc:date>2023</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079844</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2018972227&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>259-266</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1230">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Memo rdf:about="#item_1274">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2004481561&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>19</prism:volume>
                <dc:title>Expert Opinion on Drug Safety</dc:title>
                <dc:identifier>DOI 10.1080/14740338.2020.1734559</dc:identifier>
                <prism:number>5</prism:number>
                <dcterms:alternative>Expert Opin. Drug Saf.</dcterms:alternative>
                <dc:identifier>ISSN 1744-764X</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chan</foaf:surname>
                        <foaf:givenName>C.L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Soh</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tan</foaf:surname>
                        <foaf:givenName>S.H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ang</foaf:surname>
                        <foaf:givenName>P.S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Rudrappa</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>S.C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Evans</foaf:surname>
                        <foaf:givenName>S.J.W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_915"/>
        <dcterms:isReferencedBy rdf:resource="#item_1196"/>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>Medical Dictionary for Regulatory Activities</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>comparative study</dc:subject>
        <dc:subject>quantitative analysis</dc:subject>
        <dc:subject>jaundice</dc:subject>
        <dc:subject>European Medicines Agency</dc:subject>
        <dc:subject>Singapore</dc:subject>
        <dc:subject>hepatitis</dc:subject>
        <dc:subject>aminotransferase</dc:subject>
        <dc:subject>emergency health service</dc:subject>
        <dc:subject>qualitative analysis</dc:subject>
        <dc:subject>World Health Organization</dc:subject>
        <dc:title>Quantitative data mining in signal detection: the Singapore experience</dc:title>
        <dcterms:abstract>Background: In Singapore, the Health Sciences Authority (HSA) reviews an average of 20,000 spontaneous adverse event (AE) reports yearly. Potential safety signals are identified manually and discussed on a weekly basis. In this study, we compared the use of four quantitative data mining (QDM) methods with weekly manual review to determine if signals of disproportionate reporting (SDRs) can improve the efficiency of manual reviews and thereby enhance drug safety signal detection. Methods: We formulated a QDM triage strategy to reduce the number of SDRs for weekly review and compared the results against those derived from manual reviews alone for the same 6-month period. We then incorporated QDM triage into the manual review workflow for the subsequent two 6-month periods and made further comparisons against QDM triage alone. Results: The incorporation of QDM triage into routine manual reviews resulted in a reduction of 20% to 30% in the number of drug–AE pairs identified for further evaluation. Sequential Probability Ratio Test (SPRT) detected more signals that mirror human manual signal detection than the other three methods. Conclusions: The adoption of QDM triage into our manual reviews is a more efficient way forward in signal detection, avoiding missing important drug safety signals.</dcterms:abstract>
        <dc:date>2020</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079904</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2004481561&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>633-639</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_915">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Desenvolvimento do método,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Memo rdf:about="#item_1196">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Desenvolvimento do método,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118739676&amp;doi=10.3389%2ffphar.2021.767999&amp;partnerID=40&amp;md5=735b5bf6cc4f68656ec935a59f565787">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:16639812%20(ISSN)"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bian</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>P.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Cui</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xu</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Guan</foaf:surname>
                        <foaf:givenName>K.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhao</foaf:surname>
                        <foaf:givenName>B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1293"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>prognosis</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>age distribution</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>sex difference</dc:subject>
        <dc:subject>anaphylaxis</dc:subject>
        <dc:subject>drug fatality</dc:subject>
        <dc:subject>asthma</dc:subject>
        <dc:subject>bronchospasm</dc:subject>
        <dc:subject>mortality rate</dc:subject>
        <dc:subject>allergic rhinitis</dc:subject>
        <dc:subject>atopic dermatitis</dc:subject>
        <dc:subject>dupilumab</dc:subject>
        <dc:subject>food allergy</dc:subject>
        <dc:subject>hypersensitivity</dc:subject>
        <dc:subject>infant</dc:subject>
        <dc:subject>immunopathology</dc:subject>
        <dc:subject>allergen specific immunotherapy</dc:subject>
        <dc:subject>chronic spontaneous urticaria</dc:subject>
        <dc:subject>FDA adverse event reporting system (FAERS)</dc:subject>
        <dc:subject>immunotherapy</dc:subject>
        <dc:subject>mast cell activation syndrome</dc:subject>
        <dc:subject>nose polyp</dc:subject>
        <dc:subject>obstructive airway disease</dc:subject>
        <dc:subject>omalizumab</dc:subject>
        <dc:subject>omalizumab (xolair)</dc:subject>
        <dc:subject>sinusitis</dc:subject>
        <dc:subject>skin test</dc:subject>
        <dc:title>Anaphylaxis Associated With Allergen Specific Immunotherapy, Omalizumab, and Dupilumab: A Real World Study Based on the US Food and Drug Administration Adverse Event Reporting System</dc:title>
        <dcterms:abstract>Background: Real-world studies on the allergen specific immunotherapy (AIT), omalizumab, and dupilumab associated anaphylactic events are limited. We aimed to analyze the characteristics of drug associated anaphylaxis, and to compare the differences among different drugs. Methods: A disproportionality analysis and Bayesian analysis were used in data mining to identify suspected anaphylaxis associated with AIT, omalizumab, and dupilumab based on the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) from January 2004 to March 2021. Demographic information, time interval to onset, and death rates of AIT, omalizumab, and dupilumab associated anaphylaxis were also analyzed. Results: Totally 9,969 anaphylactic events were identified. Reports of AIT, omalizumab, and dupilumab associated anaphylactic events were 64, 7,784, and 2,121, respectively. AIT had a high reporting odds ratio (ROR) of 5.03 [95%confidental interval (CI) 3.69–6.85], followed by omalizumab (ROR 2.24, 95% CI 2.18–2.29), and dupilumab had a negative signal for anaphylaxis. In children, most anaphylactic reactions (68%) were reported in the 12–17-year-old group. More reports of anaphylaxis related to AIT were in boys (73%), while more reports of anaphylaxis related to omalizumab (63%) and dupilumab (58%) were in girls. Most symptoms occurred on the day of drug initiation. The death rate of AIT related anaphylaxis was the lowest (0%), the death rate of omalizumab was 0.87%, while the death rate of dupilumab was 4.76%. No significant differences were observed among these drugs. Conclusion: AIT and omalizumab had a positive signal for anaphylaxis, while dupilumab had a negative signal for anaphylaxis. Patients should be strictly monitored after administration of AIT and also biologics. It also gives us a suggestion for choosing a combined biologics with AIT when the risk of anaphylaxis was considered. © Copyright © 2021 Bian, Zhang, Li, Wang, Cui, Xu, Guan, Zhao and Chen.</dcterms:abstract>
        <dc:date>2021</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281102021</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118739676&amp;doi=10.3389%2ffphar.2021.767999&amp;partnerID=40&amp;md5=735b5bf6cc4f68656ec935a59f565787</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:16639812%20(ISSN)">
        <prism:volume>12</prism:volume>
        <dc:title>Frontiers in Pharmacology</dc:title>
        <dc:identifier>DOI 10.3389/fphar.2021.767999</dc:identifier>
        <dcterms:alternative>Front. Pharmacol.</dcterms:alternative>
        <dc:identifier>ISSN 16639812 (ISSN)</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1293">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 16; Correspondence Address: K. Guan; Department of Allergy, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China; email: dr_guankai@126.com; Z. Chen; Department of Pediatrics, Hospital of Sun Yat‐Sen University, Guangzhou, China; email: chenzhuanggui@126.com; B. Zhao; Department of Pharmacy, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China; email: zhaobin@pumch.cn&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-84976583609&amp;doi=10.1371%2fjournal.pone.0157753&amp;partnerID=40&amp;md5=85daa0da2878facd5af08364b4240a12">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:19326203%20(ISSN)"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Böhm</foaf:surname>
                        <foaf:givenName>R.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Von Hehn</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Herdegen</foaf:surname>
                        <foaf:givenName>T.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Klein</foaf:surname>
                        <foaf:givenName>H.-J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bruhn</foaf:surname>
                        <foaf:givenName>O.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Petri</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Höcker</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_893"/>
        <dcterms:isReferencedBy rdf:resource="#item_1336"/>
        <dc:subject>acute kidney failure</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>combination drug therapy</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>risk factor</dc:subject>
        <dc:subject>*Data Mining</dc:subject>
        <dc:subject>*Pharmacovigilance</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>rhabdomyolysis</dc:subject>
        <dc:subject>depression</dc:subject>
        <dc:subject>dizziness</dc:subject>
        <dc:subject>heart palpitation</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>tachycardia</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>United States Food and Drug Administration</dc:subject>
        <dc:subject>constipation</dc:subject>
        <dc:subject>headache</dc:subject>
        <dc:subject>insomnia</dc:subject>
        <dc:subject>nausea</dc:subject>
        <dc:subject>pain</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>vomiting</dc:subject>
        <dc:subject>epilepsy</dc:subject>
        <dc:subject>seizure</dc:subject>
        <dc:subject>somnolence</dc:subject>
        <dc:subject>suicide</dc:subject>
        <dc:subject>atrial fibrillation</dc:subject>
        <dc:subject>congestive heart failure</dc:subject>
        <dc:subject>deep vein thrombosis</dc:subject>
        <dc:subject>heart infarction</dc:subject>
        <dc:subject>*Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>*United States Food and Drug Administration</dc:subject>
        <dc:subject>clarithromycin</dc:subject>
        <dc:subject>anemia</dc:subject>
        <dc:subject>blurred vision</dc:subject>
        <dc:subject>creatinine</dc:subject>
        <dc:subject>data analysis software</dc:subject>
        <dc:subject>Data Mining</dc:subject>
        <dc:subject>diarrhea</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>computer language</dc:subject>
        <dc:subject>diabetes mellitus</dc:subject>
        <dc:subject>dyspnea</dc:subject>
        <dc:subject>heart disease</dc:subject>
        <dc:subject>creatinine blood level</dc:subject>
        <dc:subject>edema</dc:subject>
        <dc:subject>gastroesophageal reflux</dc:subject>
        <dc:subject>peripheral edema</dc:subject>
        <dc:subject>drug interaction</dc:subject>
        <dc:subject>Drug Interactions</dc:subject>
        <dc:subject>enalapril</dc:subject>
        <dc:subject>kidney failure</dc:subject>
        <dc:subject>febrile neutropenia</dc:subject>
        <dc:subject>fever</dc:subject>
        <dc:subject>decreased appetite</dc:subject>
        <dc:subject>pneumonia</dc:subject>
        <dc:subject>rash</dc:subject>
        <dc:subject>paresthesia</dc:subject>
        <dc:subject>bisoprolol</dc:subject>
        <dc:subject>computer program</dc:subject>
        <dc:subject>neutropenia</dc:subject>
        <dc:subject>thrombocytopenia</dc:subject>
        <dc:subject>Pharmacovigilance</dc:subject>
        <dc:subject>thorax pain</dc:subject>
        <dc:subject>statistical analysis</dc:subject>
        <dc:subject>pantoprazole</dc:subject>
        <dc:subject>gunshot injury</dc:subject>
        <dc:subject>urinary tract infection</dc:subject>
        <dc:subject>upper abdominal pain</dc:subject>
        <dc:subject>tremor</dc:subject>
        <dc:subject>xerostomia</dc:subject>
        <dc:subject>neuralgia</dc:subject>
        <dc:subject>anxiety disorder</dc:subject>
        <dc:subject>ondansetron</dc:subject>
        <dc:subject>unconsciousness</dc:subject>
        <dc:subject>pruritus</dc:subject>
        <dc:subject>falling</dc:subject>
        <dc:subject>drug classification</dc:subject>
        <dc:subject>suicidal ideation</dc:subject>
        <dc:subject>suicide attempt</dc:subject>
        <dc:subject>contingency table</dc:subject>
        <dc:subject>pregabalin</dc:subject>
        <dc:subject>Risk Factors</dc:subject>
        <dc:subject>access to information</dc:subject>
        <dc:subject>Access to Information</dc:subject>
        <dc:subject>affect</dc:subject>
        <dc:subject>Affect</dc:subject>
        <dc:subject>Affect/drug effects</dc:subject>
        <dc:subject>antiemetic agent</dc:subject>
        <dc:subject>Antiemetics</dc:subject>
        <dc:subject>Antiemetics/adverse effects</dc:subject>
        <dc:subject>chronic myeloid leukemia</dc:subject>
        <dc:subject>drowsiness</dc:subject>
        <dc:subject>drug antagonism</dc:subject>
        <dc:subject>drug effects</dc:subject>
        <dc:subject>drug potentiation</dc:subject>
        <dc:subject>Drug Therapy, Combination</dc:subject>
        <dc:subject>emotional disorder</dc:subject>
        <dc:subject>enzyme inhibition</dc:subject>
        <dc:subject>Epilepsy</dc:subject>
        <dc:subject>Epilepsy/drug therapy</dc:subject>
        <dc:subject>fibromyalgia</dc:subject>
        <dc:subject>fluid retention</dc:subject>
        <dc:subject>food and drug administration</dc:subject>
        <dc:subject>gabapentin</dc:subject>
        <dc:subject>hyperemesis gravidarum</dc:subject>
        <dc:subject>imatinib</dc:subject>
        <dc:subject>malignant neoplastic disease</dc:subject>
        <dc:subject>metoclopramide</dc:subject>
        <dc:subject>morphine</dc:subject>
        <dc:subject>Neuralgia</dc:subject>
        <dc:subject>Neuralgia/drug therapy</dc:subject>
        <dc:subject>neuropathic pain</dc:subject>
        <dc:subject>nilotinib</dc:subject>
        <dc:subject>postoperative nausea and vomiting</dc:subject>
        <dc:subject>prescription drug</dc:subject>
        <dc:subject>Prescription Drugs</dc:subject>
        <dc:subject>Prescription Drugs/adverse effects</dc:subject>
        <dc:subject>protein kinase inhibitor</dc:subject>
        <dc:subject>Protein Kinase Inhibitors</dc:subject>
        <dc:subject>Protein Kinase Inhibitors/pharmacology/therapeutic use</dc:subject>
        <dc:subject>weight gain</dc:subject>
        <dc:subject>withdrawal syndrome</dc:subject>
        <dc:title>OpenVigil FDA - Inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications</dc:title>
        <dcterms:abstract>Pharmacovigilance contributes to health care. However, direct access to the underlying data for academic institutions and individual physicians or pharmacists is intricate, and easily employable analysis modes for everyday clinical situations are missing. This underlines the need for a tool to bring pharmacovigilance to the clinics. To address these issues, we have developed OpenVigil FDA, a novel web-based pharmacovigilance analysis tool which uses the openFDA online interface of the Food and Drug Administration (FDA) to access U.S. American and international pharmacovigilance data from the Adverse Event Reporting System (AERS). OpenVigil FDA provides disproportionality analyses to (i) identify the drug most likely evoking a new adverse event, (ii) compare two drugs concerning their safety profile, (iii) check arbitrary combinations of two drugs for unknown drug-drug interactions and (iv) enhance the relevance of results by identifying confounding factors and eliminating them using background correction. We present examples for these applications and discuss the promises and limits of pharmacovigilance, openFDA and OpenVigil FDA. OpenVigil FDA is the first public available tool to apply pharmacovigilance findings directly to real-life clinical problems. OpenVigil FDA does not require special licenses or statistical programs. © 2016 Böhm et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</dcterms:abstract>
        <dc:date>2016</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281080030</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-84976583609&amp;doi=10.1371%2fjournal.pone.0157753&amp;partnerID=40&amp;md5=85daa0da2878facd5af08364b4240a12</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:19326203%20(ISSN)">
        <prism:volume>11</prism:volume>
        <dc:title>PLoS ONE</dc:title>
        <dc:identifier>DOI 10.1371/journal.pone.0157753</dc:identifier>
        <prism:number>6</prism:number>
        <dcterms:alternative>PLoS ONE</dcterms:alternative>
        <dc:identifier>ISSN 19326203 (ISSN)</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_893">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 196; Correspondence Address: R. Böhm; Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; email: ruwen.boehm@pharmakologie.uni-kiel.de; CODEN: POLNC&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Excluído - Não utiliza DM,Foco em ferramenta de software,Excluído - Não utiliza dados de farmacovigilância,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Memo rdf:about="#item_1336">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 196; Correspondence Address: R. Böhm; Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; email: ruwen.boehm@pharmakologie.uni-kiel.de; CODEN: POLNC&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Excluído - Não utiliza DM,Foco em ferramenta de software,Excluído - Não utiliza dados de farmacovigilância,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2002931645&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>41</prism:volume>
                <dc:title>Clinical Therapeutics</dc:title>
                <dc:identifier>DOI 10.1016/j.clinthera.2019.08.018</dc:identifier>
                <prism:number>11</prism:number>
                <dcterms:alternative>Clin. Ther.</dcterms:alternative>
                <dc:identifier>ISSN 1879-114X</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bhushan</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ray</foaf:surname>
                        <foaf:givenName>R.S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Prakash</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Singh</foaf:surname>
                        <foaf:givenName>G.N.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_912"/>
        <dcterms:isReferencedBy rdf:resource="#item_1191"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>prescription</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>cohort analysis</dc:subject>
        <dc:subject>connective tissue disease</dc:subject>
        <dc:subject>dizziness</dc:subject>
        <dc:subject>body weight gain</dc:subject>
        <dc:subject>nausea</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>vomiting</dc:subject>
        <dc:subject>gastrointestinal disease</dc:subject>
        <dc:subject>neurologic disease</dc:subject>
        <dc:subject>skin disease</dc:subject>
        <dc:subject>congestive heart failure</dc:subject>
        <dc:subject>eye disease</dc:subject>
        <dc:subject>diarrhea</dc:subject>
        <dc:subject>malignant neoplasm</dc:subject>
        <dc:subject>dyspnea</dc:subject>
        <dc:subject>heart disease</dc:subject>
        <dc:subject>mediastinum disease</dc:subject>
        <dc:subject>respiratory tract disease</dc:subject>
        <dc:subject>thorax disease</dc:subject>
        <dc:subject>comparative study</dc:subject>
        <dc:subject>kidney disease</dc:subject>
        <dc:subject>metabolic disorder</dc:subject>
        <dc:subject>musculoskeletal disease</dc:subject>
        <dc:subject>nutritional disorder</dc:subject>
        <dc:subject>urinary tract disease</dc:subject>
        <dc:subject>atorvastatin</dc:subject>
        <dc:subject>hyperglycemia</dc:subject>
        <dc:subject>fever</dc:subject>
        <dc:subject>neoplasm</dc:subject>
        <dc:subject>cyclosporine</dc:subject>
        <dc:subject>rash</dc:subject>
        <dc:subject>metformin</dc:subject>
        <dc:subject>acetylsalicylic acid</dc:subject>
        <dc:subject>bladder cancer</dc:subject>
        <dc:subject>geographic distribution</dc:subject>
        <dc:subject>pruritus</dc:subject>
        <dc:subject>Africa</dc:subject>
        <dc:subject>Asia</dc:subject>
        <dc:subject>bladder metastasis</dc:subject>
        <dc:subject>bladder tumor</dc:subject>
        <dc:subject>Europe</dc:subject>
        <dc:subject>glibenclamide</dc:subject>
        <dc:subject>glimepiride</dc:subject>
        <dc:subject>glipizide</dc:subject>
        <dc:subject>Indian</dc:subject>
        <dc:subject>insulin glargine</dc:subject>
        <dc:subject>Pacific islands</dc:subject>
        <dc:subject>pioglitazone</dc:subject>
        <dc:subject>prednisolone</dc:subject>
        <dc:subject>sitagliptin</dc:subject>
        <dc:subject>transitional cell carcinoma</dc:subject>
        <dc:subject>ureter cancer</dc:subject>
        <dc:subject>Western Hemisphere</dc:subject>
        <dc:title>Global Versus Indian Perspective of Pioglitazone-induced Adverse Drug Reactions Including Bladder Cancer: A Comparative Retrospective Pharmacovigilance Analysis</dc:title>
        <dcterms:abstract>Purpose: In 2011, France and Germany banned pioglitazone due to a concomitant risk for bladder cancer. There has been continued debate about this topic. Therefore, we present a detailed analysis of data from individual case safety reports of pioglitazone use (PG-ICSRs) associated with bladder cancer reported worldwide and in India. Methods: Data from PG-ICSRs reported by the National Coordination Centre's Pharmacovigilance Programme of India, as well as over 131 World Health Organization member countries in the Uppsala Monitoring Centre's VigiLyze pharmacovigilance database system, from January 1, 1967, to March 4, 2018, were collected. Comparisons between data from global and Indian PG-ICSRs were made by applying filters such as country, bladder cancer, age group, gender, time period, information component, and data mining. Findings: Among the adverse drug reactions (ADRs) reported with pioglitazone use worldwide, bladder cancer and related terms were the most highly reported (43%). The most frequently co-reported concurrently used drug was metformin, which was included in 25% and 40% of overall and bladder cancer–specific PG-ICSRs, respectively. Suspected bladder cancer–specific pioglitazone-related reactions were reported in 27 countries, with 8548 serious and 1858 fatal cases and an information components value of 9.15. The Americas had the highest relative percentage of suspected bladder cancer in PG-ICSRs (53%), while the prevalence was much lower in India (2%). In both cohorts, men over the age of 45 years constituted the most highly reported population. Implications: India has a very low prevalence of reported overall and bladder cancer–specific pioglitazone-related ADRs compared to Europe and the Americas. Possible explanations for the difference in reporting rates include variance in genetic makeup, low BC risk factor, pioglitazone prescription at a lower therapeutic dose, greater use of chemopreventive spices in the diet, higher frequency of metformin as a concurrent drug, and under-reporting of ADRs.</dcterms:abstract>
        <dc:date>2019</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079916</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2002931645&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>2252-2262</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_912">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Memo rdf:about="#item_1191">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2004877792&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:0975-2366"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bhatt</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Desai</foaf:surname>
                        <foaf:givenName>T.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_796"/>
        <dcterms:isReferencedBy rdf:resource="#item_1203"/>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>angiotensin receptor antagonist</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>hypertension</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>quantitative analysis</dc:subject>
        <dc:subject>statistical analysis</dc:subject>
        <dc:subject>proportional reporting ratio</dc:subject>
        <dc:subject>psoriasis</dc:subject>
        <dc:subject>candesartan hexetil</dc:subject>
        <dc:subject>irbesartan</dc:subject>
        <dc:subject>losartan</dc:subject>
        <dc:subject>reporting odd ratio</dc:subject>
        <dc:subject>skin biopsy</dc:subject>
        <dc:subject>telmisartan</dc:subject>
        <dc:subject>valsartan</dc:subject>
        <dc:title>New safety signal for psoriasis associated with angiotensin receptor blockers: Qualitative and quantitative analysis using pharmacovigilance tools</dc:title>
        <dcterms:abstract>Study objective: To qualitatively and quantitatively analyze the association between use of Angiotensin receptor blocker class of drugs and psoriasis from Canadian Adverse Reaction database and published literature. Research Design and method: Reports of psoriasis associated with use of Angiotensin receptor blocker class of drug were retrieved from public version of Canadian Adverse Reaction (CADRMP) database between January 2000 and December 2016 and analyzed for quantitative signal detection by data mining algorithms mainly reporting odds ratio (ROR), proportional reporting ratios (PRR) and 95% confidence interval (CI) of PRR. Also for qualitative analysis, reports for psoriasis associated with ARBs were obtained from literature regulatory agency reports for period from 2000 to 2016. Results: Based on CADRMP data from January 2000 and December 2016, total 9 reports were obtained for psoriasis associated with use of ARBs. Thus, as per our results obtained; value of PRR, ROR and 95% CI for PRR were found to be 17.5, 17.7 and 4.4, respectively indicating significant new signal for aggravated psoriasis associated with ARBs use, however these signals were stronger for Valsartan than other ARBs. Conclusions: Thus public version of CADRMP database as well as literatures and regulatory agency report represents an important source to detect signals of psoriasis. In particular, our present study generated significant new signals for psoriasis among ARBs for which further investigations and active surveillance are warranted. These signals should be considered in evaluating the benefit-risk profile of these drugs.</dcterms:abstract>
        <dc:date>2020</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079895</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2004877792&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>273-278</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:0975-2366">
        <prism:volume>12</prism:volume>
        <dc:title>International Journal of Pharmaceutical Research</dc:title>
        <dc:identifier>DOI 10.31838/ijpr/2020.12.04.068</dc:identifier>
        <prism:number>4</prism:number>
        <dcterms:alternative>Int. J. Pharm. Res.</dcterms:alternative>
        <dc:identifier>ISSN 0975-2366</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_796">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Memo rdf:about="#item_1203">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L623590838&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>17</prism:volume>
                <dc:title>Expert Opinion on Drug Safety</dc:title>
                <dc:identifier>DOI 10.1080/14740338.2018.1506763</dc:identifier>
                <prism:number>9</prism:number>
                <dcterms:alternative>Expert Opin. Drug Saf.</dcterms:alternative>
                <dc:identifier>ISSN 1744-764X</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Antonazzo</foaf:surname>
                        <foaf:givenName>I.C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Raschi</foaf:surname>
                        <foaf:givenName>E.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Forcesi</foaf:surname>
                        <foaf:givenName>E.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Riise</foaf:surname>
                        <foaf:givenName>T.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bjornevik</foaf:surname>
                        <foaf:givenName>K.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Baldin</foaf:surname>
                        <foaf:givenName>E.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>De Ponti</foaf:surname>
                        <foaf:givenName>F.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Poluzzi</foaf:surname>
                        <foaf:givenName>E.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_908"/>
        <dcterms:isReferencedBy rdf:resource="#item_1186"/>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>adalimumab</dc:subject>
        <dc:subject>antineoplastic agent</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>confidence interval</dc:subject>
        <dc:subject>drug</dc:subject>
        <dc:subject>etanercept</dc:subject>
        <dc:subject>infliximab</dc:subject>
        <dc:subject>drug exposure</dc:subject>
        <dc:subject>immunomodulating agent</dc:subject>
        <dc:subject>information retrieval</dc:subject>
        <dc:subject>multiple sclerosis</dc:subject>
        <dc:subject>systematic review</dc:subject>
        <dc:title>Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting System</dc:title>
        <dcterms:abstract>Background: Possible relationship between drug exposure and multiple sclerosis (MS) development is insufficiently investigated, and further challenged by the incomplete understanding of MS etiopathogenesis. The study aims to investigate whether drug exposure could contribute to MS, by analyzing worldwide spontaneous reporting archives of adverse drug reaction (ADRs). Research design and methods: We retrieved information from the US Food and Drug Administration Adverse Event Reporting System (FAERS) over a 13-year period. Reporting odds ratio (ROR) for MS was calculated for each single substance. Disproportionality signals were considered when at least 10 cases were retrieved with a lower limit of the 95% confidence interval (CI) &gt;1. Results: After a customized data-mining process, 3,226 reports of MS were retrieved. ‘Antineoplastic and immunomodulating drugs’ (33% of total reports) were the most frequently reported, with 10 disproportionality signals, including etanercept (445 cases; ROR: 2.48; 95% Cl: 2.24–2.74), adalimumab (329; 2.05; 1.83–2.30), and infliximab (119; 2.25; 1.87–2.70). We also observed signals for drugs acting on hormone balance, bone density, and central nervous system. Conclusion: Our findings suggest that immunomodulatory drugs increase the risk of MS and point out that some other drug classes should be further investigated for this risk.</dcterms:abstract>
        <dc:date>2018</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079933</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L623590838&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>869-874</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_908">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Memo rdf:about="#item_1186">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L609714961&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>15</prism:volume>
                <dc:title>Expert Opinion on Drug Safety</dc:title>
                <dc:identifier>DOI 10.1517/14740338.2016.1167184</dc:identifier>
                <prism:number>5</prism:number>
                <dcterms:alternative>Expert Opin. Drug Saf.</dcterms:alternative>
                <dc:identifier>ISSN 1744-764X</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ang</foaf:surname>
                        <foaf:givenName>P.S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chan</foaf:surname>
                        <foaf:givenName>C.L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tai</foaf:surname>
                        <foaf:givenName>B.C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_903"/>
        <dcterms:isReferencedBy rdf:resource="#item_1344"/>
        <dc:subject>article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>reporting odds ratio</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>quantitative analysis</dc:subject>
        <dc:subject>data processing</dc:subject>
        <dc:subject>reference database</dc:subject>
        <dc:subject>Bayesian confidence propagation neural network</dc:subject>
        <dc:subject>gamma poisson shrinker</dc:subject>
        <dc:subject>receiver operating characteristic</dc:subject>
        <dc:subject>sensitivity and specificity</dc:subject>
        <dc:subject>intermethod comparison</dc:subject>
        <dc:subject>predictive value</dc:subject>
        <dc:subject>Singapore</dc:subject>
        <dc:title>Data mining spontaneous adverse drug event reports for safety signals in Singapore - A comparison of three different disproportionality measures</dc:title>
        <dcterms:abstract>Objectives: Quantitative data mining methods can be used to identify potential signals of unexpected relationships between drug and adverse event (AE). This study aims to compare and explore the use of three data mining methods in our small spontaneous AE database.Methods: We consider reporting odds ratio (ROR), Bayesian Confidence Propagation Neural Network (BCPNN) and Gamma Poisson Shrinker (GPS) assuming two different sets of criteria: (1) ROR-1.96SE&gt;1, IC-1.96SD&gt;0, EB05&gt;1 (2) ROR-1.96SE&gt;2, IC-1.96SD&gt;1, EB05 &gt;2. Count of drug-AE pairs ≥3 was considered for ROR and GPS.Results: The Health Sciences Authority, Singapore received 151,180 AE reports between 1993 and 2013. ROR, BCPNN and GPS identified 2,835, 2,311 and 2,374 significant drug-AE pairs using Criterion 1, and 1,899, 1,101 and 1,358 respectively using Criterion 2. The performance of the three methods with respect to specificity, positive predictive value and negative predictive value were similar, although ROR yielded a higher sensitivity and larger area under the receiver operating characteristic curve. ROR and GPS picked up some potential signals which BCPNN missed.Conclusions: The defined threshold used for ROR (Criterion 1) is a useful screening tool for our small database. It may be used in conjunction with GPS to avoid missed signals.</dcterms:abstract>
        <dc:date>2016</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079954</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L609714961&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>583-590</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_903">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Base governamental,Desenvolvimento do método&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Memo rdf:about="#item_1344">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Base governamental,Desenvolvimento do método&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2005160329&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1432-0738"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Andronis</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Silva</foaf:surname>
                        <foaf:givenName>J.P.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lekka</foaf:surname>
                        <foaf:givenName>E.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Virvilis</foaf:surname>
                        <foaf:givenName>V.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Carmo</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bampali</foaf:surname>
                        <foaf:givenName>K.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ernst</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hu</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Loryan</foaf:surname>
                        <foaf:givenName>I.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Richard</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Carvalho</foaf:surname>
                        <foaf:givenName>F.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Savić</foaf:surname>
                        <foaf:givenName>M.M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_794"/>
        <dcterms:isReferencedBy rdf:resource="#item_1202"/>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>*Data Mining</dc:subject>
        <dc:subject>*Pharmacovigilance</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>cognitive defect</dc:subject>
        <dc:subject>mood disorder</dc:subject>
        <dc:subject>risk assessment</dc:subject>
        <dc:subject>*Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>alendronic acid</dc:subject>
        <dc:subject>Data Mining</dc:subject>
        <dc:subject>drospirenone plus ethinylestradiol</dc:subject>
        <dc:subject>finasteride</dc:subject>
        <dc:subject>isotretinoin</dc:subject>
        <dc:subject>levonorgestrel</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>drug effect</dc:subject>
        <dc:subject>protein analysis</dc:subject>
        <dc:subject>signal transduction</dc:subject>
        <dc:subject>Pharmacovigilance</dc:subject>
        <dc:subject>statistical analysis</dc:subject>
        <dc:subject>etoposide</dc:subject>
        <dc:subject>cytarabine</dc:subject>
        <dc:subject>apremilast</dc:subject>
        <dc:subject>DRUG-REACTIONS</dc:subject>
        <dc:subject>brain</dc:subject>
        <dc:subject>Brain</dc:subject>
        <dc:subject>affect</dc:subject>
        <dc:subject>Affect</dc:subject>
        <dc:subject>metoclopramide</dc:subject>
        <dc:subject>priority journal</dc:subject>
        <dc:subject>Adverse outcome pathways</dc:subject>
        <dc:subject>Affect/*drug effects</dc:subject>
        <dc:subject>ALPHA</dc:subject>
        <dc:subject>aprotinin</dc:subject>
        <dc:subject>BIPOLAR DISORDER</dc:subject>
        <dc:subject>BLOOD-BRAIN-BARRIER</dc:subject>
        <dc:subject>Brain/*drug effects/metabolism/physiopathology</dc:subject>
        <dc:subject>cognition</dc:subject>
        <dc:subject>Cognition</dc:subject>
        <dc:subject>Cognition/*drug effects</dc:subject>
        <dc:subject>Cognitive Dysfunction</dc:subject>
        <dc:subject>Cognitive Dysfunction/*chemically induced/genetics/metabolism/psychology</dc:subject>
        <dc:subject>Cross-talk analysis</dc:subject>
        <dc:subject>dimethyl fumarate</dc:subject>
        <dc:subject>DISPROPORTIONALITY ANALYSIS</dc:subject>
        <dc:subject>fumaric acid dimethyl ester</dc:subject>
        <dc:subject>gene expression regulation</dc:subject>
        <dc:subject>Gene Expression Regulation</dc:subject>
        <dc:subject>GENE GRIN2B</dc:subject>
        <dc:subject>gene regulatory network</dc:subject>
        <dc:subject>Gene Regulatory Networks</dc:subject>
        <dc:subject>genetic association</dc:subject>
        <dc:subject>genetics</dc:subject>
        <dc:subject>GLUTAMATE</dc:subject>
        <dc:subject>immunomodulation</dc:subject>
        <dc:subject>indapamide</dc:subject>
        <dc:subject>interferon</dc:subject>
        <dc:subject>memantine</dc:subject>
        <dc:subject>metabolism</dc:subject>
        <dc:subject>Mood Disorders</dc:subject>
        <dc:subject>Mood Disorders/*chemically induced/genetics/metabolism/psychology</dc:subject>
        <dc:subject>natalizumab</dc:subject>
        <dc:subject>Neurotoxicity</dc:subject>
        <dc:subject>NICOTINIC ACETYLCHOLINE-RECEPTORS</dc:subject>
        <dc:subject>pathophysiology</dc:subject>
        <dc:subject>peginterferon beta1a</dc:subject>
        <dc:subject>Pharmaceuticals' safety</dc:subject>
        <dc:subject>Pharmaceuticals’ safety</dc:subject>
        <dc:subject>population research</dc:subject>
        <dc:subject>Protein Interaction Maps</dc:subject>
        <dc:subject>Psychiatric</dc:subject>
        <dc:subject>Psychiatric/psychological adverse events</dc:subject>
        <dc:subject>psychological adverse events</dc:subject>
        <dc:subject>psychology</dc:subject>
        <dc:subject>ranolazine</dc:subject>
        <dc:subject>Risk Assessment</dc:subject>
        <dc:subject>rivastigmine</dc:subject>
        <dc:subject>rofecoxib</dc:subject>
        <dc:subject>Signal Transduction</dc:subject>
        <dc:subject>SIGNAL-DETECTION</dc:subject>
        <dc:subject>SUICIDE ATTEMPTS</dc:subject>
        <dc:subject>temozolomide</dc:subject>
        <dc:subject>varenicline</dc:subject>
        <dc:title>Molecular basis of mood and cognitive adverse events elucidated via a combination of pharmacovigilance data mining and functional enrichment analysis</dc:title>
        <dcterms:abstract>Drug-induced Mood- and Cognition-related adverse events (MCAEs) are often only detected during the clinical trial phases of drug development, or even after marketing, thus posing a major safety concern and a challenge for both pharmaceutical companies and clinicians. To fill some gaps in the understanding and elucidate potential biological mechanisms of action frequently associated with MCAEs, we present a unique workflow linking observational population data with the available knowledge at molecular, cellular, and psychopharmacology levels. It is based on statistical analysis of pharmacovigilance reports and subsequent signaling pathway analyses, followed by evidence-based expert manual curation of the outcomes. Our analysis: (a) ranked pharmaceuticals with high occurrence of such adverse events (AEs), based on disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database, and (b) identified 120 associated genes and common pathway nodes possibly underlying MCAEs. Nearly two-thirds of the identified genes were related to immune modulation, which supports the critical involvement of immune cells and their responses in the regulation of the central nervous system function. This finding also means that pharmaceuticals with a negligible central nervous system exposure may induce MCAEs through dysregulation of the peripheral immune system. Knowledge gained through this workflow unravels putative hallmark biological targets and mediators of drug-induced mood and cognitive disorders that need to be further assessed and validated in experimental models. Thereafter, they can be used to substantially improve in silico/in vitro/in vivo tools for predicting these adversities at a preclinical stage.</dcterms:abstract>
        <dc:date>2020</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079900</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2005160329&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>2829-2845</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1432-0738">
        <prism:volume>94</prism:volume>
        <dc:title>Archives of Toxicology</dc:title>
        <dc:identifier>DOI 10.1007/s00204-020-02788-1</dc:identifier>
        <prism:number>8</prism:number>
        <dcterms:alternative>Arch. Toxicol.</dcterms:alternative>
        <dc:identifier>ISSN 1432-0738</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_794">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 15; Correspondence Address: F. Carvalho; UCIBIO, REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Porto, 4050-313, Portugal; email: felixdc@ff.up.pt; M.M. Savić; Department of Pharmacology, Faculty of Pharmacy, University of Belgrade, Belgrade, Vojvode Stepe 450, 11000, Serbia; email: miroslav@pharmacy.bg.ac.rs; CODEN: ARTOD&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;14&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;16&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;77&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Memo rdf:about="#item_1202">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 15; Correspondence Address: F. Carvalho; UCIBIO, REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Porto, 4050-313, Portugal; email: felixdc@ff.up.pt; M.M. Savić; Department of Pharmacology, Faculty of Pharmacy, University of Belgrade, Belgrade, Vojvode Stepe 450, 11000, Serbia; email: miroslav@pharmacy.bg.ac.rs; CODEN: ARTOD&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;14&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;16&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;77&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2018957253&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:2284-0729"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Alroobaea</foaf:surname>
                        <foaf:givenName>R.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Rubaiee</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hanbazazah</foaf:surname>
                        <foaf:givenName>A.S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jahrami</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Garbarino</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Damiani</foaf:surname>
                        <foaf:givenName>G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bragazzi</foaf:surname>
                        <foaf:givenName>N.L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_801"/>
        <dcterms:isReferencedBy rdf:resource="#item_1208"/>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>insomnia</dc:subject>
        <dc:subject>sleep disorder</dc:subject>
        <dc:subject>restlessness</dc:subject>
        <dc:subject>somnolence</dc:subject>
        <dc:subject>dyspnea</dc:subject>
        <dc:subject>atopic dermatitis</dc:subject>
        <dc:subject>dupilumab</dc:subject>
        <dc:subject>bruxism</dc:subject>
        <dc:subject>lethargy</dc:subject>
        <dc:subject>restless legs syndrome</dc:subject>
        <dc:subject>big data</dc:subject>
        <dc:subject>coping</dc:subject>
        <dc:subject>pharmacoepidemiology</dc:subject>
        <dc:subject>World Health Organization</dc:subject>
        <dc:subject>personalized medicine</dc:subject>
        <dc:subject>clinical observation</dc:subject>
        <dc:subject>apnea hypopnea index</dc:subject>
        <dc:subject>Beck Anxiety Inventory</dc:subject>
        <dc:subject>dermatologist</dc:subject>
        <dc:subject>drug response</dc:subject>
        <dc:subject>effect size</dc:subject>
        <dc:subject>hypersomnia</dc:subject>
        <dc:subject>machine learning</dc:subject>
        <dc:subject>machine learning software</dc:subject>
        <dc:subject>narcolepsy</dc:subject>
        <dc:subject>night sweat</dc:subject>
        <dc:subject>nightmare</dc:subject>
        <dc:subject>polysomnography</dc:subject>
        <dc:subject>reporting bias</dc:subject>
        <dc:subject>sleep apnea syndromes</dc:subject>
        <dc:subject>sleep debt</dc:subject>
        <dc:subject>sleep quality</dc:subject>
        <dc:subject>statistical significance</dc:subject>
        <dc:subject>VigiBase</dc:subject>
        <dc:title>IL-4/13 Blockade and sleep-related adverse drug reactions in over 37,000 Dupilumab reports from the World Health Organization Individual Case Safety reporting pharmacovigilance database (VigiBase™): a big data and machine learning analysis</dc:title>
        <dcterms:abstract>OBJECTIVE: Atopic dermatitis displays a relevant sleep burden sustained by clinical (i.e., itch), psychological (i.e., inadequate coping strategies) and therapeutic (i.e., frequent loss of drug response) triggers. Dupilumab, the first biologic approved for atopic dermatitis, showed excellent effects on improving pruritus and sleep after only two weeks of treatment but, in some cases, may have paradoxical effects. The rate of sleep-related side-effects remains unknown. More specifically, adverse-drug reactions (ADRs) related to dupilumab have been investigated during the safety phase of randomized clinical trials or in small retrospective epidemiological surveys, but little is known about sleep-related ADRs in real-life settings. Therefore, we took advantage of a global largescale pharmacovigilance database, carrying out a comprehensive data mining analysis to look at different sleep-related ADRs reported among patients under anti IL-4/13 therapy. MATERIALS AND METHODS: We analyzed individual case study reports (ICSRs) in VigiBaseTM, the World Health Organization (WHO) global pharmacovigilance database of ADRs collected by national drug authorities in &gt; 140 countries (&gt; 90% of the world population). We looked for patterns of potentially sleep-related ADRs and we applied a disproportionality analysis based on Bayesian Confidence Propagation Neural Network (BCPNN). A meta-analytical approach was used to synthesize the overall effect size of sleep-related ADRs potentially associated to Dupilumab administration. RESULTS: From inception up to March 9, 2021, 94,065 ADRs from 37,848 unique reports were included and analyzed in the present paper: 1,294 of them (1.4%) concerned sleep disturbances (n=27). Most of sleep-related complaints were generic sleep disorders (n=630), followed by insomnia (n=312), somnolence (n=81), lethargy (n=60), night sweats (n=30), middle insomnia (n=39), hypersomnia (n=25), poor-quality sleep (n=21), initial insomnia (n=17), sleep apnea syndrome (n=13), nightmares (n=11) and sleep deficit (n=11). Interestingly, restlessness and restless leg syndrome, nocturnal dyspnea, narcolepsy and bruxism were reported in 7, 6, 5, 4 and 3 cases, respectively. Only sleep deficit [OR 15.67 (95% CrI 8.61-28.51); IC 3.24 (95% CrI 2.26-3.97)], generic sleep disorder [OR 6.22 (95% CrI 5.74-6.73); IC 2.60 (95% CrI 2.48-2.71)], nocturnal dyspnea [OR 3.68 (95% CrI 1.53-8.87); IC 1.56 (95% CrI 0.03-2.56)] and middle insomnia [OR 1.87 (95% CrI 1.36-2.56); IC 0.88 (95% CrI 0.39-1.30)] achieved the statistical significance threshold. CONCLUSIONS: In this work, we identified over 37,000 unique case-reports of Dupilumab side-effects reported on the WHO pharmacovigilance database. We specifically categorized those related to sleep issues, which were 1,294. Our findings from large numbers of cases provide data supporting the clinical observations that Dupilumab is usually effective in improving sleep quality and sleep disturbances/ impairments, given the lack of statistical significance of several sleep-related ADRs. Further work is needed to closely scrutinize the impact of Dupilumab on sleep, in terms of underlying mechanisms, and to better understand residual sleep disorders in patients with atopic dermatitis and other allergic diseases treated with Dupilumab. Thus, sleep monitoring may be helpful for dermatologists in managing atopic dermatitis patients treated with dupilumab. The limitations of spontaneous reporting systems including underreporting and reporting bias, heterogeneity of sources and impossibility to infer any causal relationship merit consideration and further research is needed.</dcterms:abstract>
        <dc:date>2022</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079875</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2018957253&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>4074-4081</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:2284-0729">
        <prism:volume>26</prism:volume>
        <dc:title>European Review for Medical and Pharmacological Sciences</dc:title>
        <dc:identifier>DOI 10.26355/eurrev_202206_28977</dc:identifier>
        <prism:number>11</prism:number>
        <dcterms:alternative>Eur. Rev. Med. Pharmacol. Sci.</dcterms:alternative>
        <dc:identifier>ISSN 2284-0729</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_801">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Memo rdf:about="#item_1208">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85204683859&amp;doi=10.1080%2f20523211.2024.2399716&amp;partnerID=40&amp;md5=589f4aeebbf043d9c7d91a480ffe3f1e">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:20523211%20(ISSN)"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ali</foaf:surname>
                        <foaf:givenName>Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ismail</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Rehman</foaf:surname>
                        <foaf:givenName>I.U.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Goh</foaf:surname>
                        <foaf:givenName>K.W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Razi</foaf:surname>
                        <foaf:givenName>P.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ming</foaf:surname>
                        <foaf:givenName>L.C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_887"/>
        <dcterms:isReferencedBy rdf:resource="#item_1323"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>age</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>prescription</dc:subject>
        <dc:subject>risk factor</dc:subject>
        <dc:subject>cardiovascular disease</dc:subject>
        <dc:subject>disproportionality analysis</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>sepsis</dc:subject>
        <dc:subject>bradycardia</dc:subject>
        <dc:subject>faintness</dc:subject>
        <dc:subject>heart arrest</dc:subject>
        <dc:subject>heart ventricle fibrillation</dc:subject>
        <dc:subject>heart ventricle tachycardia</dc:subject>
        <dc:subject>torsade de pointes</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>hyponatremia</dc:subject>
        <dc:subject>angina pectoris</dc:subject>
        <dc:subject>atrial fibrillation</dc:subject>
        <dc:subject>heart infarction</dc:subject>
        <dc:subject>amiodarone</dc:subject>
        <dc:subject>fluoxetine</dc:subject>
        <dc:subject>risperidone</dc:subject>
        <dc:subject>drug fatality</dc:subject>
        <dc:subject>hypocalcemia</dc:subject>
        <dc:subject>alprazolam</dc:subject>
        <dc:subject>anxiolytic agent</dc:subject>
        <dc:subject>bromazepam</dc:subject>
        <dc:subject>diazepam</dc:subject>
        <dc:subject>drug use</dc:subject>
        <dc:subject>atrioventricular block</dc:subject>
        <dc:subject>kidney disease</dc:subject>
        <dc:subject>hyperglycemia</dc:subject>
        <dc:subject>kidney failure</dc:subject>
        <dc:subject>gender</dc:subject>
        <dc:subject>hypokalemia</dc:subject>
        <dc:subject>haloperidol</dc:subject>
        <dc:subject>patient safety</dc:subject>
        <dc:subject>liver failure</dc:subject>
        <dc:subject>QT prolongation</dc:subject>
        <dc:subject>cocaine</dc:subject>
        <dc:subject>lorazepam</dc:subject>
        <dc:subject>methadone</dc:subject>
        <dc:subject>falling</dc:subject>
        <dc:subject>drug overdose</dc:subject>
        <dc:subject>liver dysfunction</dc:subject>
        <dc:subject>saquinavir</dc:subject>
        <dc:subject>midazolam</dc:subject>
        <dc:subject>oxazepam</dc:subject>
        <dc:subject>PREVENTION</dc:subject>
        <dc:subject>BROMAZEPAM</dc:subject>
        <dc:subject>cardiology</dc:subject>
        <dc:subject>drug competition</dc:subject>
        <dc:subject>famotidine</dc:subject>
        <dc:subject>flecainide</dc:subject>
        <dc:subject>GENDER</dc:subject>
        <dc:subject>human and disease</dc:subject>
        <dc:subject>hydroxyzine</dc:subject>
        <dc:subject>hypomagnesemia</dc:subject>
        <dc:subject>Medicine</dc:subject>
        <dc:subject>meprobamate</dc:subject>
        <dc:subject>Patient Safety</dc:subject>
        <dc:subject>preventable death</dc:subject>
        <dc:subject>QT INTERVAL PROLONGATION</dc:subject>
        <dc:subject>RISK-FACTORS</dc:subject>
        <dc:subject>trimethoprim</dc:subject>
        <dc:title>Association of anxiolytic drugs with Torsade de Pointes: a pharmacovigilance study of the Food and Drug Administration Adverse Event Reporting System</dc:title>
        <dcterms:abstract>Background: This study aimed to determine the association of Torsade de Pointes (TdP) with anxiolytic drugs and present a detailed overview of anxiolytic-induced cases of TdP reported to the Food and Drug Administration Adverse Event Reporting System (FAERS). Methods: All cases of anxiolytic-induced TdP (n = 260) between 1990 and 2020 were retrieved from the FAERS database using the Preferred Term ‘Torsade de Pointes, code: 10044066’ from the Medical Dictionary for Regulatory Activities (MedDRA version 22). Four data-mining algorithms were used for disproportionality analysis: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Empirical Bayes Geometric Mean (EBGM), and Information Content (IC). Anxiolytics with ≥3 TdP cases were included. Results: Of a total of eight drugs, this study identified seven signals of TdP, of which six signals were new, namely for alprazolam, bromazepam, lorazepam, meprobamate, midazolam, and oxazepam. Based on disproportionality analysis, among new signals, the highest risk of TdP was observed with bromazepam and midazolam. Alprazolam showed the lowest risk for TdP, while diazepam did not reach significant disproportionality. Conclusions: This study identified six new signals of TdP among anxiolytic drugs, so warranting stringent clinical studies to ascertain the actual risk of TdP and ensure patient safety. Clinical Trial Registration: This study is registered at ClinicalTrials.gov (NCT.gov ID: NCT04293432). © 2024 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281088754</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85204683859&amp;doi=10.1080%2f20523211.2024.2399716&amp;partnerID=40&amp;md5=589f4aeebbf043d9c7d91a480ffe3f1e</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:20523211%20(ISSN)">
        <prism:volume>17</prism:volume>
        <dc:title>Journal of Pharmaceutical Policy and Practice</dc:title>
        <dc:identifier>DOI 10.1080/20523211.2024.2399716</dc:identifier>
        <prism:number>1</prism:number>
        <dcterms:alternative>J. pharm. policy pract.</dcterms:alternative>
        <dc:identifier>ISSN 20523211 (ISSN)</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_887">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 1; Correspondence Address: M. Ismail; Department of Pharmacy, University of Peshawar, Peshawar, Pakistan; email: ismailrph@uop.edu.pk; P. Razi; Center of Disaster Monitoring and Earth Observation, Physics Department, Universitas Negeri Padang, Padang, West Sumatra, 25131, Indonesia; email: fhrrazi@fmipa.unp.ac.id&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;42&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Memo rdf:about="#item_1323">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 1; Correspondence Address: M. Ismail; Department of Pharmacy, University of Peshawar, Peshawar, Pakistan; email: ismailrph@uop.edu.pk; P. Razi; Center of Disaster Monitoring and Earth Observation, Physics Department, Universitas Negeri Padang, Padang, West Sumatra, 25131, Indonesia; email: fhrrazi@fmipa.unp.ac.id&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;42&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-86000142994&amp;doi=10.4103%2fpicr.picr_10_24&amp;partnerID=40&amp;md5=e395028cc7ba151a7905d90e7054849a">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:22293485%20(ISSN)"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Adusumilli</foaf:surname>
                        <foaf:givenName>P.K.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Begum</foaf:surname>
                        <foaf:givenName>F.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sangnure</foaf:surname>
                        <foaf:givenName>A.A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>George</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_902"/>
        <dcterms:isReferencedBy rdf:resource="#item_1339"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data analysis</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>chi square test</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>drug induced disease</dc:subject>
        <dc:subject>geriatric patient</dc:subject>
        <dc:subject>sex difference</dc:subject>
        <dc:subject>lung embolism</dc:subject>
        <dc:subject>azithromycin</dc:subject>
        <dc:subject>cefprozil</dc:subject>
        <dc:subject>antibiotic agent</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>groups by age</dc:subject>
        <dc:subject>drug use</dc:subject>
        <dc:subject>disease risk assessment</dc:subject>
        <dc:subject>moxifloxacin</dc:subject>
        <dc:subject>cefalexin</dc:subject>
        <dc:subject>cefazolin</dc:subject>
        <dc:subject>cefdinir</dc:subject>
        <dc:subject>cefotaxime</dc:subject>
        <dc:subject>pediatric patient</dc:subject>
        <dc:subject>medical information</dc:subject>
        <dc:subject>detection algorithm</dc:subject>
        <dc:subject>chloramphenicol</dc:subject>
        <dc:subject>Chloramphenicol</dc:subject>
        <dc:subject>Food and Drug Administration database of Adverse Event Reporting System</dc:subject>
        <dc:subject>levofloxacin</dc:subject>
        <dc:subject>minocycline</dc:subject>
        <dc:subject>pulmonary embolism</dc:subject>
        <dc:title>Antibiotics‑induced pulmonary embolism: A disproportionality analysis in Food and Drug Administration database of Adverse Event Reporting System using data mining algorithms</dc:title>
        <dcterms:abstract>Background: Antibiotics are among the most commonly prescribed drugs. Unnecessary use of antibiotics is particularly concerning because antibiotics may be associated with a number of adverse drug events. Aim: The study was designed to detect the association between pulmonary embolism and antibiotics by disproportionality analysis in the Food and Drug Administration database of Adverse Event Reporting System (FAERS) using data mining algorithms (DMAs). Materials and Methods: A retrospective case/noncase disproportionality analysis was performed in the FAERS database. This study was based on adverse events (AEs) reported to FAERS from 2004 Q1 to 2022 Q3. Reporting odds ratio (ROR), proportional reporting ratio (PRR), and information component (IC) were applied to measure the disproportionality in reporting. A positive signal of increased AE risk was defined as ROR &gt;1, Chi-square &gt;4, PRR R2 with the number of cases &gt;3, and IC &gt;0. Results: Total AEs in the FAERS database from 2004 Q1 to 2022 Q3 were found to be 26,555,430. Among which 80,809 reports of pulmonary embolism were considered. The same were selected for further analysis which showed that 11 antibiotics were reported for pulmonary embolism. The number of reports for minocycline, chloramphenicol, and moxifloxacin was found to be 113, 14, and 179. A significant potential signal was noted for minocycline (ROR – 2.87, Chi-square – 135.95, IC – 1.22), chloramphenicol (ROR – 3.35, Chi-square – 22.80, IC – 0.77), and moxifloxacin (ROR – 2.08, Chi-square – 99.37, IC – 0.83). Conclusion: This study found a statistically significant increased risk of reporting pulmonary embolism with minocycline, chloramphenicol, and moxifloxacin, although a causal relation cannot be definitively established. © 2024 Perspectives in Clinical Research.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079971</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-86000142994&amp;doi=10.4103%2fpicr.picr_10_24&amp;partnerID=40&amp;md5=e395028cc7ba151a7905d90e7054849a</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>44-49</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:22293485%20(ISSN)">
        <prism:volume>16</prism:volume>
        <dc:title>Perspectives in Clinical Research</dc:title>
        <dc:identifier>DOI 10.4103/picr.picr_10_24</dc:identifier>
        <prism:number>1</prism:number>
        <dcterms:alternative>Perspect. Clin. Res.</dcterms:alternative>
        <dc:identifier>ISSN 22293485 (ISSN)</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_902">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: J. George; Department of Pharmacy Practice, Faculty of Pharmacy, M. S. Ramaiah University of Applied Sciences, Bengaluru, Karnataka, India; email: jeesamanikombel@gmail.com&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Memo rdf:about="#item_1339">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: J. George; Department of Pharmacy Practice, Faculty of Pharmacy, M. S. Ramaiah University of Applied Sciences, Bengaluru, Karnataka, India; email: jeesamanikombel@gmail.com&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85044367073&amp;doi=10.1111%2fcts.12543&amp;partnerID=40&amp;md5=2c62737419c8133a835982a3ca1f75a0">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:17528054%20(ISSN)"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Racz</foaf:surname>
                        <foaf:givenName>R.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Soldatos</foaf:surname>
                        <foaf:givenName>T.G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jackson</foaf:surname>
                        <foaf:givenName>D.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Burkhart</foaf:surname>
                        <foaf:givenName>K.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1280"/>
        <dc:subject>Article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>risk factor</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>biology</dc:subject>
        <dc:subject>citalopram</dc:subject>
        <dc:subject>Computational Biology</dc:subject>
        <dc:subject>Antipsychotic Agents</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>neuroleptic agent</dc:subject>
        <dc:subject>quetiapine</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>United States Food and Drug Administration</dc:subject>
        <dc:subject>information processing</dc:subject>
        <dc:subject>mental disease</dc:subject>
        <dc:subject>risk assessment</dc:subject>
        <dc:subject>amfebutamone</dc:subject>
        <dc:subject>aripiprazole</dc:subject>
        <dc:subject>asenapine</dc:subject>
        <dc:subject>chemically induced</dc:subject>
        <dc:subject>clonazepam</dc:subject>
        <dc:subject>duloxetine</dc:subject>
        <dc:subject>escitalopram</dc:subject>
        <dc:subject>fluoxetine</dc:subject>
        <dc:subject>lurasidone</dc:subject>
        <dc:subject>paliperidone</dc:subject>
        <dc:subject>paroxetine</dc:subject>
        <dc:subject>risperidone</dc:subject>
        <dc:subject>sertraline</dc:subject>
        <dc:subject>venlafaxine</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>alprazolam</dc:subject>
        <dc:subject>diazepam</dc:subject>
        <dc:subject>disease association</dc:subject>
        <dc:subject>clozapine</dc:subject>
        <dc:subject>olanzapine</dc:subject>
        <dc:subject>ziprasidone</dc:subject>
        <dc:subject>drug efficacy</dc:subject>
        <dc:subject>drug interaction</dc:subject>
        <dc:subject>Drug Interactions</dc:subject>
        <dc:subject>hyperhidrosis</dc:subject>
        <dc:subject>lithium</dc:subject>
        <dc:subject>tremor</dc:subject>
        <dc:subject>bioinformatics</dc:subject>
        <dc:subject>lorazepam</dc:subject>
        <dc:subject>ondansetron</dc:subject>
        <dc:subject>lamotrigine</dc:subject>
        <dc:subject>drug potentiation</dc:subject>
        <dc:subject>priority journal</dc:subject>
        <dc:subject>mirtazapine</dc:subject>
        <dc:subject>trazodone</dc:subject>
        <dc:subject>serotonin syndrome</dc:subject>
        <dc:subject>information retrieval</dc:subject>
        <dc:subject>drug response</dc:subject>
        <dc:subject>Mental Disorders</dc:subject>
        <dc:subject>drug targeting</dc:subject>
        <dc:subject>paracetamol</dc:subject>
        <dc:subject>serotonin 1 agonist</dc:subject>
        <dc:subject>serotonin 2 antagonist</dc:subject>
        <dc:subject>Serotonin 5-HT1 Receptor Agonists</dc:subject>
        <dc:subject>Serotonin 5-HT2 Receptor Antagonists</dc:subject>
        <dc:subject>Serotonin Syndrome</dc:subject>
        <dc:subject>statistics and numerical data</dc:subject>
        <dc:subject>tramadol</dc:subject>
        <dc:subject>unindexed drug</dc:subject>
        <dc:title>Association Between Serotonin Syndrome and Second-Generation Antipsychotics via Pharmacological Target-Adverse Event Analysis</dc:title>
        <dcterms:abstract>Case reports suggest an association between second-generation antipsychotics (SGAs) and serotonin syndrome (SS). The US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) was analyzed to generate hypotheses about how SGAs may interact with pharmacological targets associated with SS. FAERS was integrated with additional sources to link information about adverse events with drugs and targets. Using Proportional Reporting Ratios, we identified signals that were further investigated with the literature to evaluate mechanistic hypotheses formed from the integrated FAERS data. Analysis revealed common pharmacological targets perturbed in both SGA and SS cases, indicating that SGAs may induce SS. The literature also supported 5-HT                             2A                              antagonism and 5-HT                             1A                              agonism as common mechanisms that may explain the SGA-SS association. Additionally, integrated FAERS data mining and case studies suggest that interactions between SGAs and other serotonergic agents may increase the risk for SS. Computational analysis can provide additional insights into the mechanisms underlying the relationship between SGAs and SS.                          © 2018 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics</dcterms:abstract>
        <dc:date>2018</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281102093</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85044367073&amp;doi=10.1111%2fcts.12543&amp;partnerID=40&amp;md5=2c62737419c8133a835982a3ca1f75a0</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>322-329</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:17528054%20(ISSN)">
        <prism:volume>11</prism:volume>
        <dc:title>Clinical and Translational Science</dc:title>
        <dc:identifier>DOI 10.1111/cts.12543</dc:identifier>
        <prism:number>3</prism:number>
        <dcterms:alternative>Clin. Transl. Sci.</dcterms:alternative>
        <dc:identifier>ISSN 17528054 (ISSN)</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1280">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 35; Correspondence Address: R. Racz; Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, United States; email: Rebecca.Racz@fda.hhs.gov&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Excluído - Não utiliza dados de farmacovigilância,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85057104209&amp;doi=10.1161%2fJAHA.118.008959&amp;partnerID=40&amp;md5=f4f60658ee63571e7aa163b2515c1928">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:20479980%20(ISSN)"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>S.-H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>W.J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hsu</foaf:surname>
                        <foaf:givenName>L.-Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chien</foaf:surname>
                        <foaf:givenName>K.-L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>C.-S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1277"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>risk factor</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>disease severity</dc:subject>
        <dc:subject>sex difference</dc:subject>
        <dc:subject>heart infarction</dc:subject>
        <dc:subject>antidiabetic agent</dc:subject>
        <dc:subject>2,4 thiazolidinedione derivative</dc:subject>
        <dc:subject>Administration, Oral</dc:subject>
        <dc:subject>alpha glucosidase inhibitor</dc:subject>
        <dc:subject>Data Mining</dc:subject>
        <dc:subject>dipeptidyl peptidase IV inhibitor</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>drug use</dc:subject>
        <dc:subject>drug effect</dc:subject>
        <dc:subject>Female</dc:subject>
        <dc:subject>insulin</dc:subject>
        <dc:subject>metformin</dc:subject>
        <dc:subject>case control study</dc:subject>
        <dc:subject>Case-Control Studies</dc:subject>
        <dc:subject>Male</dc:subject>
        <dc:subject>Middle Aged</dc:subject>
        <dc:subject>high risk population</dc:subject>
        <dc:subject>Risk Factors</dc:subject>
        <dc:subject>priority journal</dc:subject>
        <dc:subject>spontaneous reporting system</dc:subject>
        <dc:subject>Spontaneous reporting systems</dc:subject>
        <dc:subject>pioglitazone</dc:subject>
        <dc:subject>meglitinide</dc:subject>
        <dc:subject>sulfonylurea</dc:subject>
        <dc:subject>sex factor</dc:subject>
        <dc:subject>Sex Factors</dc:subject>
        <dc:subject>Case-only study</dc:subject>
        <dc:subject>chemical interaction</dc:subject>
        <dc:subject>Drug-associated adverse events</dc:subject>
        <dc:subject>host medication interaction</dc:subject>
        <dc:subject>Host-medication interactions</dc:subject>
        <dc:subject>Hypoglycemic Agents</dc:subject>
        <dc:subject>medical information system</dc:subject>
        <dc:subject>Metformin</dc:subject>
        <dc:subject>Myocardial Infarction</dc:subject>
        <dc:subject>oral antidiabetic agent</dc:subject>
        <dc:subject>oral drug administration</dc:subject>
        <dc:subject>rosiglitazone</dc:subject>
        <dc:subject>Sex differences</dc:subject>
        <dc:subject>Sulfonylurea Compounds</dc:subject>
        <dc:subject>sulfonylurea derivative</dc:subject>
        <dc:subject>Taiwan</dc:subject>
        <dc:subject>Thiazolidinediones</dc:subject>
        <dc:title>Use of spontaneous reporting systems to detect host-medication interactions: Sex differences in oral anti-diabetic drug-associated myocardial infarction</dc:title>
        <dcterms:abstract>Background Medical treatment should be tailored to an individual's characteristics to optimize treatment benefits. We examined whether case‐only analyses from spontaneous reporting systems can detect host‐medication interactions in oral antidiabetic drug‐associated myocardial infarction. Methods and Results Interaction between sex and use of oral antidiabetic drugs was mined among patients with myocardial infarction in the US Food and Drug Administration Adverse Event Reporting System from 2004 to 2014, including 55 718 males and 42 428 females. The odds ratio (OR) of multiplicative interactions was used to estimate sex‐drug interaction. Detected signs of these interactions were then validated by a nested case‐control study utilizing a healthcare record database, Taiwan's National Health Insurance Research Database, from 2001 to 2014, including 31 585 cases and 126 340 controls. In the US Food and Drug Administration Adverse Event Reporting System, a higher proportion of male than female patients used metformin (10.32% in males versus 7.82% in females) and sulfonylureas (4.75% in males versus 3.43% in females); after adjusting for patients’ pharmacy‐based chronic disease score, males had a higher risk of metformin‐associated (OR=1.07; 99% confidence interval, 1.00–1.14) and sulfonylureas‐associated (OR=1.21; 99% confidence interval, 1.10–1.33) myocardial infarction than females. Detected signs of sex‐drug interactions were validated in the National Health Insurance Research Database (OR for metformin=1.14; 99% confidence interval, 1.03–1.26; OR for sulfonylureas=1.13; 99% confidence interval, 1.02–1.25). Conclusions Males have a higher risk of metformin‐ and sulfonylureas‐associated myocardial infarction than females, which suggests that sex‐drug interactions are a key issue in diabetes mellitus treatment plan development. This case‐only approach using information from spontaneous reporting systems may be a potential tool for screening host‐medication interactions that cause adverse events. © 2018 The Authors.</dcterms:abstract>
        <dc:date>2018</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281102079</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85057104209&amp;doi=10.1161%2fJAHA.118.008959&amp;partnerID=40&amp;md5=f4f60658ee63571e7aa163b2515c1928</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:20479980%20(ISSN)">
        <prism:volume>7</prism:volume>
        <dc:title>Journal of the American Heart Association</dc:title>
        <dc:identifier>DOI 10.1161/JAHA.118.008959</dc:identifier>
        <prism:number>22</prism:number>
        <dcterms:alternative>J. Am. Heart Assoc.</dcterms:alternative>
        <dc:identifier>ISSN 20479980 (ISSN)</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1277">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 7; Correspondence Address: W.J. Chen; Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, 17 Xu-Zhou Rd, 10055, Taiwan; email: wjchen@ntu.edu.tw&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85041473126&amp;doi=10.1248%2fbpb.b17-00547&amp;partnerID=40&amp;md5=16058c0f6a2be4b8c73b8d803844ec7d">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:09186158%20(ISSN)"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yue</foaf:surname>
                        <foaf:givenName>Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shi</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1279"/>
        <dc:subject>acute kidney failure</dc:subject>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>Adult</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>Aged</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>United States Food and Drug Administration</dc:subject>
        <dc:subject>celecoxib</dc:subject>
        <dc:subject>chemically induced</dc:subject>
        <dc:subject>Data mining</dc:subject>
        <dc:subject>Data Mining</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>disease association</dc:subject>
        <dc:subject>comparative study</dc:subject>
        <dc:subject>drug effect</dc:subject>
        <dc:subject>Antiviral Agents</dc:subject>
        <dc:subject>antivirus agent</dc:subject>
        <dc:subject>diclofenac</dc:subject>
        <dc:subject>drug interaction</dc:subject>
        <dc:subject>Drug Interactions</dc:subject>
        <dc:subject>Female</dc:subject>
        <dc:subject>Acute Kidney Injury</dc:subject>
        <dc:subject>Male</dc:subject>
        <dc:subject>Middle Aged</dc:subject>
        <dc:subject>analogs and derivatives</dc:subject>
        <dc:subject>Anti-Inflammatory Agents, Non-Steroidal</dc:subject>
        <dc:subject>aciclovir</dc:subject>
        <dc:subject>Japan</dc:subject>
        <dc:subject>food and drug administration</dc:subject>
        <dc:subject>meloxicam</dc:subject>
        <dc:subject>pathophysiology</dc:subject>
        <dc:subject>rofecoxib</dc:subject>
        <dc:subject>high risk patient</dc:subject>
        <dc:subject>Acute kidney injury</dc:subject>
        <dc:subject>Acyclovir</dc:subject>
        <dc:subject>chi square distribution</dc:subject>
        <dc:subject>Chi-Square Distribution</dc:subject>
        <dc:subject>etodolac</dc:subject>
        <dc:subject>FDA Adverse Event Reporting System (FAERS)</dc:subject>
        <dc:subject>flurbiprofen</dc:subject>
        <dc:subject>frequency</dc:subject>
        <dc:subject>ibuprofen</dc:subject>
        <dc:subject>indometacin</dc:subject>
        <dc:subject>ketoprofen</dc:subject>
        <dc:subject>ketorolac</dc:subject>
        <dc:subject>kidney</dc:subject>
        <dc:subject>Kidney</dc:subject>
        <dc:subject>lornoxicam</dc:subject>
        <dc:subject>loxoprofen</dc:subject>
        <dc:subject>nabumetone</dc:subject>
        <dc:subject>naproxen</dc:subject>
        <dc:subject>nonsteroid antiinflammatory agent</dc:subject>
        <dc:subject>Nonsteroidal anti-inflammatory drug (NSAID)</dc:subject>
        <dc:subject>oxaprozin</dc:subject>
        <dc:subject>piroxicam</dc:subject>
        <dc:subject>prodrug</dc:subject>
        <dc:subject>Prodrugs</dc:subject>
        <dc:subject>risk</dc:subject>
        <dc:subject>Risk</dc:subject>
        <dc:subject>sulindac</dc:subject>
        <dc:subject>tenoxicam</dc:subject>
        <dc:subject>tolmetin</dc:subject>
        <dc:subject>valaciclovir</dc:subject>
        <dc:subject>Valacyclovir</dc:subject>
        <dc:subject>valine</dc:subject>
        <dc:subject>Valine</dc:subject>
        <dc:title>Association between concomitant use of acyclovir or valacyclovir with NSAIDs and an increased risk of acute kidney injury: Data mining of FDA adverse event reporting system</dc:title>
        <dcterms:abstract>Nonsteroidal anti-inflammatory drugs (NSAIDs) are likely to be used concomitantly with acyclovir or valacyclovir in clinical practice, but the study on the safety of such combinations was seldom reported. The objective of the study was to investigate reports of acute kidney injury (AKI) events associated with the concomitant use of oral acyclovir or valacyclovir with an NSAID by using the United States Food and Drug Administration (FDA) Adverse Event Reporting System (AERS) database between January 2004 and June 2012. The frequency of AKI events in patients while simultaneously taking either acyclovir or valacyclovir and an NSAID was compared using the Chi-square test. The effect of concomitant use of acyclovir or valacyclovir and individual NSAIDs on AKI was analyzed by the reporting odds ratio (ROR). The results showed that AKI was reported as the adverse event in 8.6% of the 10923 patients taking valacyclovir compared with 8.7% of the 2556 patients taking acyclovir (p=NS). However, AKI was significantly more frequently reported in patients simultaneously taking valacyclovir and an NSAID (19.4%) than in patients simultaneously taking acyclovir and an NSAID (10.5%) (p&lt;0.01). The results also suggested that increased risk of AKI was likely associated with the concomitant use of valacyclovir and some NSAIDs such as loxoprofen, diclofenac, etodolac, ketorolac, piroxicam or lornoxicam. The case series from the AERS indicated that compared with acyclovir, valacyclovir is more likely to be affected by NSAIDs, and the concomitant use of valacyclovir with some NSAIDs might be associated with increased risk of AKI. The drug interactions with this specific combination of medications are worth exploring further. © 2018 The Pharmaceutical Society of Japan.</dcterms:abstract>
        <dc:date>2018</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281102100</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85041473126&amp;doi=10.1248%2fbpb.b17-00547&amp;partnerID=40&amp;md5=16058c0f6a2be4b8c73b8d803844ec7d</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>158-162</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:09186158%20(ISSN)">
        <prism:volume>41</prism:volume>
        <dc:title>Biological and Pharmaceutical Bulletin</dc:title>
        <dc:identifier>DOI 10.1248/bpb.b17-00547</dc:identifier>
        <prism:number>2</prism:number>
        <dcterms:alternative>Biol. Pharm. Bull.</dcterms:alternative>
        <dc:identifier>ISSN 09186158 (ISSN)</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1279">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 16; Correspondence Address: Z. Yue; Chinese Pharmacopoeia Commission, Dongcheng District, Beijing, No. 11 Fahua Nanli, 100061, China; email: yuezhihua@chp.org.cn; CODEN: BPBLE&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85084170146&amp;doi=10.1155%2f2020%2f1747413&amp;partnerID=40&amp;md5=a7f4eb2447335daa6e0344b42d213173">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1748670X%20(ISSN)"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Pan</foaf:surname>
                        <foaf:givenName>W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>Q.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bai</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jiang</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1276"/>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>Algorithms</dc:subject>
        <dc:subject>cardiotoxicity</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>United States Food and Drug Administration</dc:subject>
        <dc:subject>liver toxicity</dc:subject>
        <dc:subject>transient ischemic attack</dc:subject>
        <dc:subject>arthritis</dc:subject>
        <dc:subject>anemia</dc:subject>
        <dc:subject>Data Mining</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>neurotoxicity</dc:subject>
        <dc:subject>drug database</dc:subject>
        <dc:subject>Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>drug interaction</dc:subject>
        <dc:subject>Drug interactions</dc:subject>
        <dc:subject>Drug Interactions</dc:subject>
        <dc:subject>Drug-drug interactions</dc:subject>
        <dc:subject>cyclophosphamide</dc:subject>
        <dc:subject>leukopenia</dc:subject>
        <dc:subject>peripheral neuropathy</dc:subject>
        <dc:subject>thrombocytopenia</dc:subject>
        <dc:subject>erythema</dc:subject>
        <dc:subject>hemolytic anemia</dc:subject>
        <dc:subject>cross validation</dc:subject>
        <dc:subject>Cross validation</dc:subject>
        <dc:subject>Logistic Models</dc:subject>
        <dc:subject>logistic regression analysis</dc:subject>
        <dc:subject>procedures</dc:subject>
        <dc:subject>receiver operating characteristic</dc:subject>
        <dc:subject>statistical model</dc:subject>
        <dc:subject>measurement accuracy</dc:subject>
        <dc:subject>epirubicin</dc:subject>
        <dc:subject>hyperthyroidism</dc:subject>
        <dc:subject>hypothyroidism</dc:subject>
        <dc:subject>adapalene</dc:subject>
        <dc:subject>autoimmune disease</dc:subject>
        <dc:subject>Co-occurrence-matrix</dc:subject>
        <dc:subject>Computational linguistics</dc:subject>
        <dc:subject>Databases, Pharmaceutical</dc:subject>
        <dc:subject>digoxin</dc:subject>
        <dc:subject>feature extraction</dc:subject>
        <dc:subject>Language model</dc:subject>
        <dc:subject>Large scale systems</dc:subject>
        <dc:subject>lepirudin</dc:subject>
        <dc:subject>Logistic regression</dc:subject>
        <dc:subject>Logistic regression classifier</dc:subject>
        <dc:subject>mitomycin</dc:subject>
        <dc:subject>modified skip gram algorithm</dc:subject>
        <dc:subject>Receiver operating characteristic curves</dc:subject>
        <dc:subject>recombinant alpha2a interferon</dc:subject>
        <dc:subject>Representation model</dc:subject>
        <dc:subject>vasculitis</dc:subject>
        <dc:title>A Modified Skip-Gram Algorithm for Extracting Drug-Drug Interactions from AERS Reports</dc:title>
        <dcterms:abstract>Drug-drug interactions (DDIs) are one of the indispensable factors leading to adverse event reactions. Considering the unique structure of AERS (Food and Drug Administration Adverse Event Reporting System (FDA AERS)) reports, we changed the scope of the window value in the original skip-gram algorithm, then propose a language concept representation model and extract features of drug name and reaction information from large-scale AERS reports. The validation of our scheme was tested and verified by comparing with vectors originated from the cooccurrence matrix in tenfold cross-validation. In the verification of description enrichment of the DrugBank DDI database, accuracy was calculated for measurement. The average area under the receiver operating characteristic curve of logistic regression classifiers based on the proposed language model is 6% higher than that of the cooccurrence matrix. At the same time, the average accuracy in five severe adverse event classes is 88%. These results indicate that our language model can be useful for extracting drug and reaction features from large-scale AERS reports. © 2020 Li Wang et al.</dcterms:abstract>
        <dc:date>2020</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281102085</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85084170146&amp;doi=10.1155%2f2020%2f1747413&amp;partnerID=40&amp;md5=a7f4eb2447335daa6e0344b42d213173</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1748670X%20(ISSN)">
        <prism:volume>2020</prism:volume>
        <dc:title>Computational and Mathematical Methods in Medicine</dc:title>
        <dc:identifier>DOI 10.1155/2020/1747413</dc:identifier>
        <dcterms:alternative>Comp. Math. Methods Med.</dcterms:alternative>
        <dc:identifier>ISSN 1748670X (ISSN)</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1276">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 5; Correspondence Address: Y. Zhang; Department of Medical Informatics, Medical School, Nantong University, Nantong, 226001, China; email: maxbirdzhang@ntu.edu.cn&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Desenvolvimento do método,Excluído - Não utiliza dados de farmacovigilância,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85094894274&amp;doi=10.1016%2fj.jbi.2020.103603&amp;partnerID=40&amp;md5=c6f23339af00002e5f0c5bb0cdb92566">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:15320464%20(ISSN)"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhan</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Roughead</foaf:surname>
                        <foaf:givenName>E.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Pratt</foaf:surname>
                        <foaf:givenName>N.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1284"/>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>adverse outcome</dc:subject>
        <dc:subject>Bayes Theorem</dc:subject>
        <dc:subject>rhabdomyolysis</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>United States Food and Drug Administration</dc:subject>
        <dc:subject>information processing</dc:subject>
        <dc:subject>reporting and data system</dc:subject>
        <dc:subject>Bayesian network</dc:subject>
        <dc:subject>Data Mining</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>apixaban</dc:subject>
        <dc:subject>drug</dc:subject>
        <dc:subject>drug industry</dc:subject>
        <dc:subject>Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>amitriptyline</dc:subject>
        <dc:subject>drug interaction</dc:subject>
        <dc:subject>Drug interactions</dc:subject>
        <dc:subject>Drug Interactions</dc:subject>
        <dc:subject>Drug-drug interactions</dc:subject>
        <dc:subject>dipyrone</dc:subject>
        <dc:subject>prochlorperazine</dc:subject>
        <dc:subject>Bayesian networks</dc:subject>
        <dc:subject>sotalol</dc:subject>
        <dc:subject>drug potentiation</dc:subject>
        <dc:subject>priority journal</dc:subject>
        <dc:subject>Signal detection</dc:subject>
        <dc:subject>verapamil</dc:subject>
        <dc:subject>machine learning</dc:subject>
        <dc:subject>ibuprofen</dc:subject>
        <dc:subject>Adverse Drug Events (ADEs)</dc:subject>
        <dc:subject>Adverse Event Reporting System (AERS)</dc:subject>
        <dc:subject>Bayesian network structure</dc:subject>
        <dc:subject>Domain knowledge</dc:subject>
        <dc:subject>Drug-Drug Interaction (DDI)</dc:subject>
        <dc:subject>Growing demand</dc:subject>
        <dc:subject>Large scale data</dc:subject>
        <dc:subject>Level-wise algorithms</dc:subject>
        <dc:subject>mathematical computing</dc:subject>
        <dc:subject>mathematical model</dc:subject>
        <dc:subject>online analysis</dc:subject>
        <dc:subject>Pharmaceutical Preparations</dc:subject>
        <dc:subject>phenprocoumon</dc:subject>
        <dc:subject>prazepam</dc:subject>
        <dc:subject>Pruning strategy</dc:subject>
        <dc:subject>United states food and drug administrations</dc:subject>
        <dc:title>Detecting high-quality signals of adverse drug-drug interactions from spontaneous reporting data</dc:title>
        <dcterms:abstract>As a medicine safety issue, Drug-Drug Interaction (DDI) may become an unexpected threat for causing Adverse Drug Events (ADEs). There is a growing demand for computational methods to efficiently and effectively analyse large-scale data to detect signals of Adverse Drug-drug Interactions (ADDIs). In this paper, we aim to detect high-quality signals of ADDIs which are non-spurious and non-redundant. We propose a new method which employs the framework of Bayesian network to infer the direct associations between the target ADE and medicines, and uses domain knowledge to facilitate the learning of Bayesian network structures. To improve efficiency and avoid redundancy, we design a level-wise algorithm with pruning strategy to search for high-quality ADDI signals. We have applied the proposed method to the United States Food and Drug Administration's (FDA) Adverse Event Reporting System (FAERS) data. The result shows that 54.45% of detected signals are verified as known DDIs and 10.89% were evaluated as high-quality ADDI signals, demonstrating that the proposed method could be a promising tool for ADDI signal detection. © 2020 Elsevier Inc.</dcterms:abstract>
        <dc:date>2020</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281102074</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85094894274&amp;doi=10.1016%2fj.jbi.2020.103603&amp;partnerID=40&amp;md5=c6f23339af00002e5f0c5bb0cdb92566</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:15320464%20(ISSN)">
        <prism:volume>112</prism:volume>
        <dc:title>Journal of Biomedical Informatics</dc:title>
        <dc:identifier>DOI 10.1016/j.jbi.2020.103603</dc:identifier>
        <dcterms:alternative>J. Biomed. Informatics</dcterms:alternative>
        <dc:identifier>ISSN 15320464 (ISSN)</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1284">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 11; Correspondence Address: C. Zhan; University of South Australia, Unisa STEM, 5000, Australia; email: chen.zhan@unisa.edu.au; CODEN: JBIOB&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Excluído - Não utiliza dados de farmacovigilância,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85055695309&amp;doi=10.1002%2fpsp4.12356&amp;partnerID=40&amp;md5=4897fa0bbd40fe740a622ca5ee1c0fd5">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:21638306%20(ISSN)"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Schotland</foaf:surname>
                        <foaf:givenName>P.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Racz</foaf:surname>
                        <foaf:givenName>R.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jackson</foaf:surname>
                        <foaf:givenName>D.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Levin</foaf:surname>
                        <foaf:givenName>R.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Strauss</foaf:surname>
                        <foaf:givenName>D.G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Burkhart</foaf:surname>
                        <foaf:givenName>K.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1282"/>
        <dc:subject>Article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>hypertension</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>thrombosis</dc:subject>
        <dc:subject>heart arrhythmia</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>delirium</dc:subject>
        <dc:subject>liver toxicity</dc:subject>
        <dc:subject>Medical Dictionary for Regulatory Activities</dc:subject>
        <dc:subject>accuracy</dc:subject>
        <dc:subject>adalimumab</dc:subject>
        <dc:subject>blood clotting disorder</dc:subject>
        <dc:subject>anemia</dc:subject>
        <dc:subject>duloxetine</dc:subject>
        <dc:subject>venlafaxine</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>artery thrombosis</dc:subject>
        <dc:subject>Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>edema</dc:subject>
        <dc:subject>infection</dc:subject>
        <dc:subject>infestation</dc:subject>
        <dc:subject>metabolic disorder</dc:subject>
        <dc:subject>certolizumab pegol</dc:subject>
        <dc:subject>drug approval</dc:subject>
        <dc:subject>pancreatitis</dc:subject>
        <dc:subject>neutropenia</dc:subject>
        <dc:subject>peripheral neuropathy</dc:subject>
        <dc:subject>Pharmacovigilance</dc:subject>
        <dc:subject>bioinformatics</dc:subject>
        <dc:subject>colitis</dc:subject>
        <dc:subject>hemolytic anemia</dc:subject>
        <dc:subject>toxic epidermal necrolysis</dc:subject>
        <dc:subject>comorbidity</dc:subject>
        <dc:subject>nephrotoxicity</dc:subject>
        <dc:subject>Stevens Johnson syndrome</dc:subject>
        <dc:subject>decision tree</dc:subject>
        <dc:subject>sorafenib</dc:subject>
        <dc:subject>heparin</dc:subject>
        <dc:subject>exendin 4</dc:subject>
        <dc:subject>food and drug administration</dc:subject>
        <dc:subject>imatinib</dc:subject>
        <dc:subject>prediction</dc:subject>
        <dc:subject>priority journal</dc:subject>
        <dc:subject>sensitivity and specificity</dc:subject>
        <dc:subject>predictive value</dc:subject>
        <dc:subject>drug recall</dc:subject>
        <dc:subject>rivaroxaban</dc:subject>
        <dc:subject>respiratory failure</dc:subject>
        <dc:subject>neuroleptic malignant syndrome</dc:subject>
        <dc:subject>unindexed drug</dc:subject>
        <dc:subject>ardeparin</dc:subject>
        <dc:subject>delavirdine</dc:subject>
        <dc:subject>desvenlafaxine</dc:subject>
        <dc:subject>didanosine</dc:subject>
        <dc:subject>etravirine</dc:subject>
        <dc:subject>fibroblast growth factor receptor</dc:subject>
        <dc:subject>fondaparinux</dc:subject>
        <dc:subject>genetic algorithm</dc:subject>
        <dc:subject>glucagon like peptide 1 receptor</dc:subject>
        <dc:subject>Human immunodeficiency virus</dc:subject>
        <dc:subject>IC50</dc:subject>
        <dc:subject>lamivudine</dc:subject>
        <dc:subject>liraglutide</dc:subject>
        <dc:subject>market</dc:subject>
        <dc:subject>measurement precision</dc:subject>
        <dc:subject>Medline</dc:subject>
        <dc:subject>molecular therapy agent</dc:subject>
        <dc:subject>noradrenalin transporter</dc:subject>
        <dc:subject>palifermin</dc:subject>
        <dc:subject>pazopanib</dc:subject>
        <dc:subject>Pilot Projects</dc:subject>
        <dc:subject>pilot study</dc:subject>
        <dc:subject>platelet derived growth factor receptor</dc:subject>
        <dc:subject>protein tyrosine kinase</dc:subject>
        <dc:subject>purine nucleoside</dc:subject>
        <dc:subject>sunitinib</dc:subject>
        <dc:subject>vasculotropin receptor 1</dc:subject>
        <dc:subject>wound healing impairment</dc:subject>
        <dc:subject>zidovudine</dc:subject>
        <dc:title>Target-Adverse Event Profiles to Augment Pharmacovigilance: A Pilot Study With Six New Molecular Entities</dc:title>
        <dcterms:abstract>Clinical trials can fail to detect rare adverse events (AEs). We assessed the ability of pharmacological target adverse-event (TAE) profiles to predict AEs on US Food and Drug Administration (FDA) drug labels at least 4 years after approval. TAE profiles were generated by aggregating AEs from the FDA adverse event reporting system (FAERS) reports and the FDA drug labels for drugs that hit a common target. A genetic algorithm (GA) was used to choose the adverse event (AE) case count (N), disproportionality score in FAERS (proportional reporting ratio (PRR)), and percent of comparator drug labels with an AE to maximize F-measure. With FAERS data alone, precision, recall, and specificity were 0.57, 0.78, and 0.61, respectively. After including FDA drug label data, precision, recall, and specificity improved to 0.67, 0.81, and 0.71, respectively. Eighteen of 23 (78%) postmarket label changes were identified correctly. TAE analysis shows promise as a method to predict AEs at the time of drug approval. © 2018 This article is a U.S. Government work and is in the public domain in the USA. CPT: Pharmacometrics &amp; Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics.</dcterms:abstract>
        <dc:date>2018</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281102066</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85055695309&amp;doi=10.1002%2fpsp4.12356&amp;partnerID=40&amp;md5=4897fa0bbd40fe740a622ca5ee1c0fd5</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>809-817</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:21638306%20(ISSN)">
        <prism:volume>7</prism:volume>
        <dc:title>CPT: Pharmacometrics and Systems Pharmacology</dc:title>
        <dc:identifier>DOI 10.1002/psp4.12356</dc:identifier>
        <prism:number>12</prism:number>
        <dcterms:alternative>CPT Pharmacometrics Syst. Pharmacol.</dcterms:alternative>
        <dc:identifier>ISSN 21638306 (ISSN)</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1282">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 17; Correspondence Address: P. Schotland; Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Science, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, United States; email: Peter.Schotland@fda.hhs.gov&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Desenvolvimento do método,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85066252641&amp;doi=10.3390%2fmedicina55050149&amp;partnerID=40&amp;md5=f6839659868343455c35d1c1f1b15bff">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1010660X%20(ISSN)"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Soldatos</foaf:surname>
                        <foaf:givenName>T.G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Iakovou</foaf:surname>
                        <foaf:givenName>I.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sachpekidis</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1283"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>Adult</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>antineoplastic agent</dc:subject>
        <dc:subject>Data mining</dc:subject>
        <dc:subject>treatment outcome</dc:subject>
        <dc:subject>Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>Antineoplastic Agents</dc:subject>
        <dc:subject>Male</dc:subject>
        <dc:subject>complication</dc:subject>
        <dc:subject>pathophysiology</dc:subject>
        <dc:subject>Retrospective Studies</dc:subject>
        <dc:subject>Bone metastases</dc:subject>
        <dc:subject>metastasis</dc:subject>
        <dc:subject>Neoplasm Metastasis</dc:subject>
        <dc:subject>Pharmacoepidemiology</dc:subject>
        <dc:subject>Proportional reporting ratio</dc:subject>
        <dc:subject>Prospective Studies</dc:subject>
        <dc:subject>prospective study</dc:subject>
        <dc:subject>Prostate cancer</dc:subject>
        <dc:subject>prostate tumor</dc:subject>
        <dc:subject>Prostatic Neoplasms</dc:subject>
        <dc:subject>radium</dc:subject>
        <dc:subject>Radium</dc:subject>
        <dc:subject>Radium-223</dc:subject>
        <dc:subject>Radium-223 dichloride (Xofigo®)</dc:subject>
        <dc:subject>Real world data</dc:subject>
        <dc:subject>Side effects</dc:subject>
        <dc:subject>survival analysis</dc:subject>
        <dc:subject>Survival Analysis</dc:subject>
        <dc:subject>Treatment Outcome</dc:subject>
        <dc:title>Retrospective toxicological profiling of radium-223 dichloride for the treatment of bone metastases in prostate cancer using adverse event data</dc:title>
        <dcterms:abstract>Background and Objective: Radium‐223 dichloride (Xofigo®) is a calcium mimetic agent approved for the treatment of castration‐resistant prostate cancer patients with symptomatic bone metastases and no known visceral metastatic disease. This targeted, α‐particle‐emitting therapy has demonstrated significant survival benefit accompanied by a favorable safety profile. Nevertheless, recent evidence suggests that its combined use with abiraterone and prednisone/prednisolone may be associated with increased risk of death and fractures. While the precise pathophysiologic mechanisms of these events are not yet clear, collecting evidence from more clinical trials and translational studies is necessary. The aim of our present study is to assess whether accessible sources of patient outcome data can help gain additional clinical insights to radium‐223 dichlorideʹs safety profile. Materials and Methods: We performed a retrospective analysis of cases extracted from the FDA Adverse Event Reporting System and characterized side effect occurrence by using reporting ratios. Results: A total of ~1500 prostate cancer patients treated with radium‐223 dichloride was identified, and side effects reported with the use of radium‐223 dichloride alone or in combination with other therapeutic agents were extracted. Our analysis demonstrates that radium‐ 223 dichloride may often come with hematological‐related reactions, and that, when administered together with other drugs, its safety profile may differ. Conclusions: While more prospective studies are needed to fully characterize the toxicological profile of radium‐223 dichloride, the present work constitutes perhaps the first effort to examine its safety when administered alone and in combination with other agents based on computational evidence from public real‐world post marketing data. © 2019 by the authors. Licensee MDPI, Basel, Switzerland.</dcterms:abstract>
        <dc:date>2019</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281102065</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85066252641&amp;doi=10.3390%2fmedicina55050149&amp;partnerID=40&amp;md5=f6839659868343455c35d1c1f1b15bff</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1010660X%20(ISSN)">
        <prism:volume>55</prism:volume>
        <dc:title>Medicina (Lithuania)</dc:title>
        <dc:identifier>DOI 10.3390/medicina55050149</dc:identifier>
        <prism:number>5</prism:number>
        <dcterms:alternative>Medicina</dcterms:alternative>
        <dc:identifier>ISSN 1010660X (ISSN)</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1283">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 22; Correspondence Address: T.G. Soldatos; Molecular Health GmbH, Heidelberg, Germany; email: soldatos@molecularhealth.com&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85099363481&amp;doi=10.1111%2fjdi.13481&amp;partnerID=40&amp;md5=80350249d43b062b9d7d73a8b26d26e0">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:20401116%20(ISSN)"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhao</foaf:surname>
                        <foaf:givenName>B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shen</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhao</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Pan</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1289"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>age</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>risk factor</dc:subject>
        <dc:subject>young adult</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>Adolescent</dc:subject>
        <dc:subject>Adult</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>Age Factors</dc:subject>
        <dc:subject>Aged</dc:subject>
        <dc:subject>Bayes Theorem</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>fracture</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>observational study</dc:subject>
        <dc:subject>sex difference</dc:subject>
        <dc:subject>very elderly</dc:subject>
        <dc:subject>antidiabetic agent</dc:subject>
        <dc:subject>alogliptin</dc:subject>
        <dc:subject>Data Mining</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>treatment outcome</dc:subject>
        <dc:subject>albiglutide</dc:subject>
        <dc:subject>bone density</dc:subject>
        <dc:subject>dulaglutide</dc:subject>
        <dc:subject>comparative study</dc:subject>
        <dc:subject>drug effect</dc:subject>
        <dc:subject>drug efficacy</dc:subject>
        <dc:subject>canagliflozin</dc:subject>
        <dc:subject>mortality rate</dc:subject>
        <dc:subject>aging</dc:subject>
        <dc:subject>Female</dc:subject>
        <dc:subject>Aged, 80 and over</dc:subject>
        <dc:subject>Pharmacovigilance</dc:subject>
        <dc:subject>dapagliflozin</dc:subject>
        <dc:subject>empagliflozin</dc:subject>
        <dc:subject>ertugliflozin</dc:subject>
        <dc:subject>metformin</dc:subject>
        <dc:subject>sodium glucose cotransporter 2 inhibitor</dc:subject>
        <dc:subject>Male</dc:subject>
        <dc:subject>Middle Aged</dc:subject>
        <dc:subject>clinical trial</dc:subject>
        <dc:subject>Young Adult</dc:subject>
        <dc:subject>exendin 4</dc:subject>
        <dc:subject>lixisenatide</dc:subject>
        <dc:subject>Risk Factors</dc:subject>
        <dc:subject>glibenclamide</dc:subject>
        <dc:subject>glimepiride</dc:subject>
        <dc:subject>glipizide</dc:subject>
        <dc:subject>pioglitazone</dc:subject>
        <dc:subject>sitagliptin</dc:subject>
        <dc:subject>saxagliptin</dc:subject>
        <dc:subject>sex factor</dc:subject>
        <dc:subject>Sex Factors</dc:subject>
        <dc:subject>Retrospective Studies</dc:subject>
        <dc:subject>Hypoglycemic Agents</dc:subject>
        <dc:subject>rosiglitazone</dc:subject>
        <dc:subject>liraglutide</dc:subject>
        <dc:subject>Treatment Outcome</dc:subject>
        <dc:subject>Hospitalization</dc:subject>
        <dc:subject>Benzhydryl Compounds</dc:subject>
        <dc:subject>benzhydryl derivative</dc:subject>
        <dc:subject>Bone Density</dc:subject>
        <dc:subject>Canagliflozin</dc:subject>
        <dc:subject>Fracture</dc:subject>
        <dc:subject>Fractures, Bone</dc:subject>
        <dc:subject>glucoside</dc:subject>
        <dc:subject>Glucosides</dc:subject>
        <dc:subject>multicenter study</dc:subject>
        <dc:subject>Sodium-Glucose Transporter 2 Inhibitors</dc:subject>
        <dc:subject>Sodium–glucose cotransporter 2 inhibitors</dc:subject>
        <dc:title>Do sodium–glucose cotransporter 2 inhibitors lead to fracture risk? A pharmacovigilance real-world study</dc:title>
        <dcterms:abstract>Aims/Introduction: Given the mechanism of action of sodium–glucose cotransporter 2 inhibitors (SGLT2is), these drugs can also reduce bone density and increase fracture risk. We aimed to identify and characterize fracture-related adverse events that are associated with SGLT2is. Materials and Methods: In this observational, retrospective, pharmacovigilance, real-world study, we used disproportionality and Bayesian analyses to compare fracture-related adverse event reporting in patients who received SGLT2is from the first quarter in 2004 to the fourth quarter in 2019 in the Food and Drug Administration Adverse Event Reporting System. We also compared the effect on combined therapy with SGLT2is and other glucose-lowering medications (GLMs), and compared their onset times and outcomes. Results: A total of 317 SGLT2is-associated fractures were identified. Affected patients tended to be aged &gt;45 years (68.76%) and were more often male than female (58.04% vs 34.07%). SGLT2is-associated fracture is most commonly reported with canagliflozin (51.10%), dapagliflozin (24.60%) and empagliflozin (23.66%). SGLT2is or SGLT2is combined with GLMs do not show an association with fracture risk under disproportionality and Bayesian analyses. SGLT2i-associated fractures result in hospitalization in 66.64% of patients and death in 9.38% of patients. GLMs show an increased hospitalization rate compared with SGLT2is (69.72% vs 55.14%, P &lt; 0.0001) and GLMs plus SGLT2is (69.72% vs 61.20%, P = 0.0197). Conclusions: Based on the Food and Drug Administration Adverse Event Reporting System database, no association is noted between fracture risk and SGLT2is, or SGLT2is combined with GLMs. Long-term follow up and high-quality studies need to further verify and explore the relationship between SGLT2is and fractures. © 2020 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley &amp; Sons Australia, Ltd</dcterms:abstract>
        <dc:date>2021</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281102038</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85099363481&amp;doi=10.1111%2fjdi.13481&amp;partnerID=40&amp;md5=80350249d43b062b9d7d73a8b26d26e0</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>1400-1407</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:20401116%20(ISSN)">
        <prism:volume>12</prism:volume>
        <dc:title>Journal of Diabetes Investigation</dc:title>
        <dc:identifier>DOI 10.1111/jdi.13481</dc:identifier>
        <prism:number>8</prism:number>
        <dcterms:alternative>J. Diabetes Invest.</dcterms:alternative>
        <dc:identifier>ISSN 20401116 (ISSN)</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1289">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 15; Correspondence Address: H. Pan; Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China; email: panhui20191111@163.com&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85163720665&amp;doi=10.54133%2fajms.v2i.58&amp;partnerID=40&amp;md5=9edcf97b37ba58f9eb57b9890037f123">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:27893219%20(ISSN)"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mohammed</foaf:surname>
                        <foaf:givenName>S.S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mustafa</foaf:surname>
                        <foaf:givenName>W.W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Younus</foaf:surname>
                        <foaf:givenName>M.M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1288"/>
        <dc:subject>VigiBase</dc:subject>
        <dc:subject>Iraqi pharmacovigilance system</dc:subject>
        <dc:subject>Tramadol</dc:subject>
        <dc:subject>VigiLyze</dc:subject>
        <dc:title>Consequences of Restricting Tramadol Dispensing in Iraqi Private Healthcare Facilities</dc:title>
        <dcterms:abstract>Background and aim: Tramadol is a codeine analogue with less analgesic power than morphine but with better abuse potential. However, chronic use is associated with different adverse effects like anxiety, euphoria, nervousness, insomnia, depression, and agitation. In this study, we assessed the outcome behind the restriction on dispensing Tramadol in private health sectors in Iraq. Methods: We look at tramadol data from VigiBase data searches and the Individual Case Safety Reports (ICSR) that are formally supported by the WHO worldwide database. All complaints were evaluated using Vigilyze data mining and computing IC25 to assess the strength of the link between Tramadol and the adverse reactions it causes, as well as to compare them to other records from around the world. Results: For patients who used tramadol in a variety of dose forms, 184 instances were gathered over the course of seven years by the Iraqi Pharmacovigilance Center. There were 32 cases of hyperhidrosis, which occurred when tramadol was used alone, 47 incidents of vomiting, and 67 cases of nausea. Many adverse effects, including chest pain, hyperhidrosis, headache, dyspnea, and constipation, are more common in Iraqi records than in internationally known instances. Other side effects, such as vomiting, hallucination, vertigo, respiratory depression, and chills, were found to be milder than previously reported. There were no deaths in any of the instances that were recorded during this time period. Conclusion: The number of reported tramadol-induced adverse events has fallen significantly, which can be attributed to the ministry of health restricting tramadol dispensing and enabling public hospitals to only dispense it under medical monitoring. © 2022 The Author(s).</dcterms:abstract>
        <dc:date>2022</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281102044</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85163720665&amp;doi=10.54133%2fajms.v2i.58&amp;partnerID=40&amp;md5=9edcf97b37ba58f9eb57b9890037f123</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>28-31</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:27893219%20(ISSN)">
        <prism:volume>2</prism:volume>
        <dc:title>Al-Rafidain Journal of Medical Sciences</dc:title>
        <dc:identifier>DOI 10.54133/ajms.v2i.58</dc:identifier>
        <dcterms:alternative>AlRafidain. J. Med. Sci.</dcterms:alternative>
        <dc:identifier>ISSN 27893219 (ISSN)</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1288">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: S.S. Mohammed; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Rafidain University College, Baghdad, 10052, Iraq; email: samer.shukur@ruc.edu.iq&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Excluído - Não utiliza dados de farmacovigilância,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85124008171&amp;doi=10.3389%2ffonc.2021.801199&amp;partnerID=40&amp;md5=28de650434e5197dcbc606f21333ae18">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:2234943X%20(ISSN)"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yang</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yu</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>An</foaf:surname>
                        <foaf:givenName>Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1286"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>disproportionality analysis</dc:subject>
        <dc:subject>very elderly</dc:subject>
        <dc:subject>enfortumab vedotin</dc:subject>
        <dc:subject>dermatitis</dc:subject>
        <dc:subject>rash</dc:subject>
        <dc:subject>blister</dc:subject>
        <dc:subject>cutaneous toxicity</dc:subject>
        <dc:subject>dry skin</dc:subject>
        <dc:subject>erythema</dc:subject>
        <dc:subject>toxic epidermal necrolysis</dc:subject>
        <dc:subject>pruritus</dc:subject>
        <dc:subject>Stevens Johnson syndrome</dc:subject>
        <dc:subject>epidermolysis</dc:subject>
        <dc:subject>skin toxicity</dc:subject>
        <dc:subject>EV</dc:subject>
        <dc:subject>Food and Drug Administration Adverse Event Reporting System</dc:subject>
        <dc:subject>real-word study</dc:subject>
        <dc:title>Cutaneous Toxicity Associated With Enfortumab Vedotin: A Real-Word Study Leveraging U.S. Food and Drug Administration Adverse Event Reporting System</dc:title>
        <dcterms:abstract>Introduction: Enfortumab vedotin (EV) has been demonstrated to have a significant response rate in early phase trials and is known for its tolerable side-effect profile. Emerging case reports have raised awareness of cutaneous toxicities, which may be a potentially fatal complication. Objective: To assess the potential relevance between EV and cutaneous toxicities reports through data mining of the U.S. Food and Drug Administration (FDA) adverse event reporting system (FAERS). Methods: Data from January 1, 2019, to November 4, 2021, in the FAERS database were retrieved. Information component (IC) and reporting odds ratio (ROR) were used to evaluate the association between EV and cutaneous toxicities events. Results: EV was significantly associated with cutaneous toxicities in the database compared with both all other drugs (ROR 12.90 [10.62–15.66], IC 2.76 [2.52–3.01], middle signal) and platinum-based therapy (ROR 15.11 [12.43–18.37], IC 2.91 [2.66–3.15], middle signal) in the FAERS database. A significant association was detected between EV and all the cutaneous adverse effects (AEs) except erythema, palmar–plantar erythrodysesthesia syndrome, and dermatitis allergic. Both Stevens–Johnson syndrome and toxic epidermal necrolysis occurred 15 times as frequently for EV compared with all other drugs (ROR = 15.20; ROR = 15.52), while Stevens–Johnson syndrome occurred 18 times and toxic epidermal necrolysis occurred 7 times as frequently for EV compared with platinum-based therapy in the database (ROR = 18.74; ROR = 7.80). All groups that limited the gender and age showed a significant association between EV and cutaneous toxicities. Conclusions: A significant signal was detected between EV use and cutaneous toxicities. It is worth noting that Stevens–Johnson syndrome and toxic epidermal necrolysis were significantly associated with EV use. Copyright © 2022 Yang, Yu and An.</dcterms:abstract>
        <dc:date>2022</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281102039</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85124008171&amp;doi=10.3389%2ffonc.2021.801199&amp;partnerID=40&amp;md5=28de650434e5197dcbc606f21333ae18</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:2234943X%20(ISSN)">
        <prism:volume>11</prism:volume>
        <dc:title>Frontiers in Oncology</dc:title>
        <dc:identifier>DOI 10.3389/fonc.2021.801199</dc:identifier>
        <dcterms:alternative>Front. Oncol.</dcterms:alternative>
        <dc:identifier>ISSN 2234943X (ISSN)</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1286">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 21; Correspondence Address: Z. An; Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China; email: anzhuoling@163.com&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85101085872&amp;doi=10.1038%2fs41598-021-83099-y&amp;partnerID=40&amp;md5=b60a53de13fe03a4f26b0aa0722df68d">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>11</prism:volume>
                <dc:title>Scientific Reports</dc:title>
                <dc:identifier>DOI 10.1038/s41598-021-83099-y</dc:identifier>
                <prism:number>1</prism:number>
                <dcterms:alternative>Sci. Rep.</dcterms:alternative>
                <dc:identifier>ISSN 20452322 (ISSN)</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>D.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xu</foaf:surname>
                        <foaf:givenName>T.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Luo</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>He</foaf:surname>
                        <foaf:givenName>Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1287"/>
        <dc:subject>acute kidney failure</dc:subject>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>young adult</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>Adolescent</dc:subject>
        <dc:subject>Adult</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>Aged</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>United States Food and Drug Administration</dc:subject>
        <dc:subject>Data Mining</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>chronic kidney failure</dc:subject>
        <dc:subject>Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>Female</dc:subject>
        <dc:subject>Acute Kidney Injury</dc:subject>
        <dc:subject>Male</dc:subject>
        <dc:subject>Middle Aged</dc:subject>
        <dc:subject>Young Adult</dc:subject>
        <dc:subject>proton pump inhibitor</dc:subject>
        <dc:subject>Proton Pump Inhibitors</dc:subject>
        <dc:subject>pathology</dc:subject>
        <dc:subject>Renal Insufficiency, Chronic</dc:subject>
        <dc:title>Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system</dc:title>
        <dcterms:abstract>Proton pump inhibitors (PPIs) were widely used. Observational studies suggested increasing risk of kidney injury in patients with PPIs treatment. We gathered six PPI regimens and adverse reports of acute kidney injury (AKI) and chronic kidney disease (CKD) based on US FDA Adverse Event Reporting System (FAERS) database from 2004 to 2019. We employed reporting odds ratio (ROR) to detect signals. Finally, we identified 3187 PPIs-associated AKI cases and 3457 PPIs-associated CKD cases. We detected significant signals between PPIs and AKI as well as CKD. The signal strength was stronger for CKD (ROR = 8.80, 95% CI 8.49–9.13) than AKI (ROR = 3.95, 95% CI 3.81–4.10), while dexlansoprazole performed stronger association for CKD (ROR = 34.94, 95% CI 30.89–39.53) and AKI (ROR = 8.18, 95% CI 7.04–9.51) than the other five PPIs. The median time from PPIs use to event occurrence was 23 days for AKI and 177 days for CKD. PPIs-associated AKI resulted larger proportion of death, life-threatening, hospitalization and disability events than PPIs-associated CKD. By mining the FAERS big data, we provided more information between PPIs use and the AKI and CKD events. PPIs rational use should be repeatedly stressed. © 2021, The Author(s).</dcterms:abstract>
        <dc:date>2021</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281102034</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85101085872&amp;doi=10.1038%2fs41598-021-83099-y&amp;partnerID=40&amp;md5=b60a53de13fe03a4f26b0aa0722df68d</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Memo rdf:about="#item_1287">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 35; Correspondence Address: T. Xu; Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, 37 Guoxue Alley, Wuhou, 610041, China; email: tingx2009@163.com&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85130167505&amp;doi=10.3389%2ffphar.2022.872854&amp;partnerID=40&amp;md5=cec88e97a6c43ffeb3297bcfb55cd44f">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>13</prism:volume>
                <dc:title>Frontiers in Pharmacology</dc:title>
                <dc:identifier>DOI 10.3389/fphar.2022.872854</dc:identifier>
                <dcterms:alternative>Front. Pharmacol.</dcterms:alternative>
                <dc:identifier>ISSN 16639812 (ISSN)</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ni</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yin</foaf:surname>
                        <foaf:givenName>X.-D.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hu</foaf:surname>
                        <foaf:givenName>W.-J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zeng</foaf:surname>
                        <foaf:givenName>N.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhao</foaf:surname>
                        <foaf:givenName>B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>Z.-L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1290"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>postmarketing surveillance</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>adverse event reporting system</dc:subject>
        <dc:subject>clinical feature</dc:subject>
        <dc:subject>epidemiology</dc:subject>
        <dc:subject>mortality rate</dc:subject>
        <dc:subject>Stevens Johnson syndrome</dc:subject>
        <dc:subject>linezolid</dc:subject>
        <dc:subject>SJS</dc:subject>
        <dc:subject>vancomycin</dc:subject>
        <dc:title>Stevens-Johnson Syndrome Following Vancomycin and Linezolid: A Real-World Analysis of Post-Marketing Surveillance Data</dc:title>
        <dcterms:abstract>Background: Stevens-Johnson syndrome (SJS) has been reported as a serious adverse effect in patients treated with vancomycin or linezolid, and there is currently a lack of real-world studies comparing specific differences in adverse effects of SJS. Methods: According to the FDA’s Adverse Event Reporting System (FAERS), from January 2004 to July 2021, the data of suspected SJS after the use of vancomycin and linezolid were analyzed by imbalance and Bayesian analysis. The onset time, fatality rate and hospitalization rate of vancomycin-associated SJS and linezolid-associated SJS were also investigated. Results: 276 cases of vancomycin-related SJS reports and 63 cases of linezolid-related SJS reports were identified. These two drugs are more common in middle-aged patients (45–64 years) than other age groups, and less common in underage children (&lt;18). Among them, linezolid-related SJS is more common in middle-aged and elderly patients (45–74 years old) than other groups. Except for unspecified data, in vancomycin-associated SJS cases, there are more men than women (49.28% vs 43.84%), while in linezolid-associated SJS cases, the proportion of men and women is almost equal (44.44%). From the point of view of the areas where adverse reactions were reported, about 1/2 of the reports on Vancomycin-related SJS came from North America, and 1/3 of the reports came from Europe. The median onset time of Linezolid-related SJS was 5 days (interquartile range [IQR] 2–7.75), which was significantly earlier than that of Vancomycin-related SJS (12 days, IQR 4–20) (Mann-Whitney test, p &lt; 0.0001). There were no significant differences in mortality and hospitalization rates after vancomycin and linezolid caused SJS. Conclusion: The analysis of faers data provides a comprehensive overview of the adverse reactions of SJS caused by the use of vancomycin and linezolid, and can warn clinical workers to timely intervene and continuously monitor the patients at risk of SJS when using such drugs. Copyright © 2022 Ni, Yin, Hu, Zeng, Zhao and Li.</dcterms:abstract>
        <dc:date>2022</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281102029</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85130167505&amp;doi=10.3389%2ffphar.2022.872854&amp;partnerID=40&amp;md5=cec88e97a6c43ffeb3297bcfb55cd44f</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Memo rdf:about="#item_1290">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 3; Correspondence Address: Z.-L. Li; Department of Pharmacy, Shanghai Children’s Hospital, Shanghai Jiao Tong University, Shanghai, China; email: lizhiling22@163.com; B. Zhao; Department of Pharmacy, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China; email: zhaobin@pumch.cn&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Excluído - Não utiliza DM,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85107945895&amp;doi=10.1038%2fs41598-021-91549-w&amp;partnerID=40&amp;md5=8651acc9bb9549ec4e340b5efbb79dbe">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>11</prism:volume>
                <dc:title>Scientific Reports</dc:title>
                <dc:identifier>DOI 10.1038/s41598-021-91549-w</dc:identifier>
                <prism:number>1</prism:number>
                <dcterms:alternative>Sci. Rep.</dcterms:alternative>
                <dc:identifier>ISSN 20452322 (ISSN)</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tian</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yao</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>He</foaf:surname>
                        <foaf:givenName>G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jia</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>K.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1291"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>young adult</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>Adolescent</dc:subject>
        <dc:subject>Adult</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>United States Food and Drug Administration</dc:subject>
        <dc:subject>Data Mining</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>darunavir</dc:subject>
        <dc:subject>Female</dc:subject>
        <dc:subject>Pharmacovigilance</dc:subject>
        <dc:subject>Male</dc:subject>
        <dc:subject>Middle Aged</dc:subject>
        <dc:subject>pregnancy</dc:subject>
        <dc:subject>Young Adult</dc:subject>
        <dc:subject>Darunavir</dc:subject>
        <dc:subject>HIV Infections</dc:subject>
        <dc:subject>HIV Protease Inhibitors</dc:subject>
        <dc:subject>Human immunodeficiency virus infection</dc:subject>
        <dc:subject>Human immunodeficiency virus proteinase inhibitor</dc:subject>
        <dc:subject>Pregnancy</dc:subject>
        <dc:subject>pregnancy complication</dc:subject>
        <dc:subject>Pregnancy Complications</dc:subject>
        <dc:title>Systematic analysis of safety profile for darunavir and its boosted agents using data mining in the FDA Adverse Event Reporting System database</dc:title>
        <dcterms:abstract>This current investigation was aimed to generate signals for adverse events (AEs) of darunavir-containing agents by data mining using the US Food and Drug Administration Adverse Event Reporting System (FAERS). All AE reports for darunavir, darunavir/ritonavir, or darunavir/cobicistat between July 2006 and December 2019 were identified. The reporting Odds Ratio (ROR), proportional reporting ratio (PRR), and Bayesian confidence propagation neural network (BCPNN) were used to detect the risk signals. A suspicious signal was generated only if the results of the three algorithms were all positive. A total of 10,756 reports were identified commonly observed in hepatobiliary, endocrine, cardiovascular, musculoskeletal, gastrointestinal, metabolic, and nutrition system. 40 suspicious signals were generated, and therein 20 signals were not included in the label. Severe high signals (i.e. progressive extraocular muscle paralysis, acute pancreatitis, exfoliative dermatitis, acquired lipodystrophy and mitochondrial toxicity) were identified. In pregnant women, umbilical cord abnormality, fetal growth restriction, low birth weight, stillbirth, premature rupture of membranes, premature birth and spontaneous abortion showed positive signals. Darunavir and its boosted agents induced AEs in various organs/tissues, and were shown to be possibly associated with multiple adverse pregnant conditions. This study highlighted some novel and severe AEs of darunavir which need to be monitored prospectively. © 2021, The Author(s).</dcterms:abstract>
        <dc:date>2021</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281102028</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85107945895&amp;doi=10.1038%2fs41598-021-91549-w&amp;partnerID=40&amp;md5=8651acc9bb9549ec4e340b5efbb79dbe</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Memo rdf:about="#item_1291">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 6; Correspondence Address: K. Wang; Department of Pharmacy, Chongqing Health Center for Women and Children, Chongqing, 400021, China; email: xiaojiang0912@sina.com; L. Chen; Department of Pharmacy, Chongqing Health Center for Women and Children, Chongqing, 400021, China; email: clfxmm@163.com&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85184676373&amp;doi=10.3389%2ffphar.2024.1290975&amp;partnerID=40&amp;md5=ce876cfc02f14060cb4eb3f531411fb5">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>15</prism:volume>
                <dc:title>Frontiers in Pharmacology</dc:title>
                <dc:identifier>DOI 10.3389/fphar.2024.1290975</dc:identifier>
                <dcterms:alternative>Front. Pharmacol.</dcterms:alternative>
                <dc:identifier>ISSN 16639812 (ISSN)</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gu</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhou</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xu</foaf:surname>
                        <foaf:givenName>Z.-X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1292"/>
        <dc:subject>acute kidney failure</dc:subject>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>hypertension</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>aminosalicylic acid</dc:subject>
        <dc:subject>arthralgia</dc:subject>
        <dc:subject>health care personnel</dc:subject>
        <dc:subject>injection site pain</dc:subject>
        <dc:subject>injection site swelling</dc:subject>
        <dc:subject>sepsis</dc:subject>
        <dc:subject>dizziness</dc:subject>
        <dc:subject>FAERS</dc:subject>
        <dc:subject>heart palpitation</dc:subject>
        <dc:subject>myocarditis</dc:subject>
        <dc:subject>tachycardia</dc:subject>
        <dc:subject>abdominal pain</dc:subject>
        <dc:subject>backache</dc:subject>
        <dc:subject>constipation</dc:subject>
        <dc:subject>fatigue</dc:subject>
        <dc:subject>headache</dc:subject>
        <dc:subject>insomnia</dc:subject>
        <dc:subject>nausea</dc:subject>
        <dc:subject>vomiting</dc:subject>
        <dc:subject>somnolence</dc:subject>
        <dc:subject>lung embolism</dc:subject>
        <dc:subject>arthritis</dc:subject>
        <dc:subject>abdominal distension</dc:subject>
        <dc:subject>anemia</dc:subject>
        <dc:subject>asthenia</dc:subject>
        <dc:subject>Crohn disease</dc:subject>
        <dc:subject>diarrhea</dc:subject>
        <dc:subject>congenital malformation</dc:subject>
        <dc:subject>hypotension</dc:subject>
        <dc:subject>drug hypersensitivity</dc:subject>
        <dc:subject>dysphagia</dc:subject>
        <dc:subject>dyspepsia</dc:subject>
        <dc:subject>gastroesophageal reflux</dc:subject>
        <dc:subject>malaise</dc:subject>
        <dc:subject>hematochezia</dc:subject>
        <dc:subject>leukopenia</dc:subject>
        <dc:subject>pancreatitis</dc:subject>
        <dc:subject>pneumonia</dc:subject>
        <dc:subject>rash</dc:subject>
        <dc:subject>paresthesia</dc:subject>
        <dc:subject>thrombocytopenia</dc:subject>
        <dc:subject>erythema</dc:subject>
        <dc:subject>migraine</dc:subject>
        <dc:subject>interstitial lung disease</dc:subject>
        <dc:subject>urticaria</dc:subject>
        <dc:subject>urinary tract infection</dc:subject>
        <dc:subject>pericardial effusion</dc:subject>
        <dc:subject>pericarditis</dc:subject>
        <dc:subject>colitis</dc:subject>
        <dc:subject>pruritus</dc:subject>
        <dc:subject>psoriasis</dc:subject>
        <dc:subject>pancytopenia</dc:subject>
        <dc:subject>loss of appetite</dc:subject>
        <dc:subject>CROHNS-DISEASE</dc:subject>
        <dc:subject>MAINTENANCE</dc:subject>
        <dc:subject>ULCERATIVE-COLITIS</dc:subject>
        <dc:subject>5-AMINOSALICYLATES</dc:subject>
        <dc:subject>COMPARATIVE EFFICACY</dc:subject>
        <dc:subject>fistula</dc:subject>
        <dc:subject>flatulence</dc:subject>
        <dc:subject>inflammatory bowel disease</dc:subject>
        <dc:subject>INFLAMMATORY-BOWEL-DISEASE</dc:subject>
        <dc:subject>macular degeneration</dc:subject>
        <dc:subject>MESALAMINE</dc:subject>
        <dc:subject>mesalazine</dc:subject>
        <dc:subject>NETWORK METAANALYSIS</dc:subject>
        <dc:subject>REMISSION</dc:subject>
        <dc:subject>THERAPIES</dc:subject>
        <dc:subject>ulcerative colitis</dc:subject>
        <dc:title>A real-world disproportionality analysis of mesalazine data mining of the public version of FDA adverse event reporting system</dc:title>
        <dcterms:abstract>Background: Mesalazine, a preparation of 5-aminosalicylic acid, is a medication widely used in clinical practice as a first-line therapy in the treatment of mild and moderate inflammatory bowel disease. However, the long-term safety of mesalazine in large sample population was unknown. The current study was to assess mesalazine -related adverse events of real-world through data mining of the US Food and Drug Administration Adverse Event Reporting System (FAERS). Methods: Disproportionality analyses, including the reporting odds ratio (ROR), the proportional reporting ratio the Bayesian confidence propagation neural network and the multi-item gamma Poisson shrinker (MGPS) algorithms were employed to quantify the signals of mesalazine -associated AEs. Results: Out of 14,149,980 reports collected from the FDA Adverse Event Reporting System database, 24,284 reports of mesalazine -associated AEs were identified. A total of 170 significant disproportionality preferred terms conforming to the four algorithms simultaneously were retained. The most common AEs included colitis ulcerative, diarrhoea, condition aggravated, crohn’s disease, fatigue, abdominal pain, nausea, haematochezia, which were corresponding to those reported in the specification and clinical trials. Unexpected significant AEs as dizziness, drug ineffective, drug hypersensitivity, infection, off label use, weight decreased, decreased appetite, arthralgia, rash might also occur. The median onset time of mesalazine -related AEs was 1,127 days (interquartile range [IQR] 1,127–1,674 days), and most of the cases occurred 2 years later (n = 610, 70.93%) and within the first 1 month (n = 89, 10.35%) after mesalazine initiation. Conclusion: Results of our study were consistent with clinical observations. We also found potential new and unexpected AEs signals for mesalazine, suggesting prospective clinical studies were needed to confirm these results and illustrate their relationship. Our results could provide valuable evidence for further safety studies of mesalazine. Copyright © 2024 Liu, Gu, Zhang, Zhou, Wang and Xu.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281102019</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85184676373&amp;doi=10.3389%2ffphar.2024.1290975&amp;partnerID=40&amp;md5=ce876cfc02f14060cb4eb3f531411fb5</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Memo rdf:about="#item_1292">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 11; Correspondence Address: Y. Wang; Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun,, Jilin, China; email: wangys@jlu.edu.en; Z.-X. Xu; Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun, Jilin, China; email: zhixiangxu@jlu.edu.cn; H. Zhou; Department of Urology, The First Hospital of Jilin University, Changchun, Jilin, China; email: hlzhou@jlu.edu.cn&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;11&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;11&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;33&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85199147441&amp;doi=10.3389%2ffphar.2024.1431579&amp;partnerID=40&amp;md5=13395b1062bf1edce3145234d75f2fef">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>15</prism:volume>
                <dc:title>Frontiers in Pharmacology</dc:title>
                <dc:identifier>DOI 10.3389/fphar.2024.1431579</dc:identifier>
                <dcterms:alternative>Front. Pharmacol.</dcterms:alternative>
                <dc:identifier>ISSN 16639812 (ISSN)</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Pan</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xiao</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ding</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shu</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Huang</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1294"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>postmarketing surveillance</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>health care personnel</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>dizziness</dc:subject>
        <dc:subject>headache</dc:subject>
        <dc:subject>dysarthria</dc:subject>
        <dc:subject>neurologic disease</dc:subject>
        <dc:subject>speech disorder</dc:subject>
        <dc:subject>CANCER</dc:subject>
        <dc:subject>CHEMOTHERAPY</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>neurotoxicity</dc:subject>
        <dc:subject>polyneuropathy</dc:subject>
        <dc:subject>drug use</dc:subject>
        <dc:subject>paresthesia</dc:subject>
        <dc:subject>dysphonia</dc:subject>
        <dc:subject>hypesthesia</dc:subject>
        <dc:subject>date mining</dc:subject>
        <dc:subject>hand foot syndrome</dc:subject>
        <dc:subject>NEUROTOXICITY</dc:subject>
        <dc:subject>ADJUVANT OXALIPLATIN</dc:subject>
        <dc:subject>adverse event signals</dc:subject>
        <dc:subject>food and drug adverse event reporting system</dc:subject>
        <dc:subject>INDUCED PERIPHERAL NEUROPATHY</dc:subject>
        <dc:subject>MODEL</dc:subject>
        <dc:subject>neurological adverse events</dc:subject>
        <dc:subject>oxaliplatin</dc:subject>
        <dc:subject>PREDICTORS</dc:subject>
        <dc:subject>the food and drug adverse event reporting system</dc:subject>
        <dc:title>Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system</dc:title>
        <dcterms:abstract>Objective: This study aimed to explore the neurological adverse events of oxaliplatin through the Food and Drug Administration Adverse Event Reporting System (FAERS) database and to provide reference for safe clinical drug use. Methods: The adverse events report data of oxaliplatin from the first quarter of 2019 (1 January 2019) to the third quarter of 2023 (30 September 2023) were extracted from FAERS database, and the adverse events signal intensity was determined using the reporting odds ratio, proportional reporting ratio, information component, and empirical Bayes geometric mean methods. Time-to-onset and univariate logistic regression analysis were performed to describe the characteristics and risk factors of oxaliplatin-associated neurological adverse events. Results: A total of 4,471 cases of oxaliplatin-associated neurological adverse events were identified, with 318 neurological adverse events being documented, among which 87 adverse events satisfied the thresholds of four methodologies. The median time-to-onset of oxaliplatin-associated neurological adverse events was 2 days (interquartile range 0–36 days). Among the factors significantly influencing oxaliplatin-related neurological adverse events, male sex and combination medication decreased the risk of neurological adverse events, while higher cumulative dose increased the risk. Conclusion: The real-world neurotoxicity spectrum of oxaliplatin and its characteristics and influencing factors were obtained through data mining of FAERS, providing valuable insights for healthcare professionals to effectively manage the risk of neurological adverse events associated with oxaliplatin in clinical practice. Copyright © 2024 Pan, Xiao, Ding, Shu, Zhang and Huang.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281102018</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85199147441&amp;doi=10.3389%2ffphar.2024.1431579&amp;partnerID=40&amp;md5=13395b1062bf1edce3145234d75f2fef</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Memo rdf:about="#item_1294">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 1; Correspondence Address: L. Huang; Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; email: huangliu@tjh.tjmu.edu.cn; W. Zhang; Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; email: wenting@hust.edu.cn&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;36&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85192204865&amp;doi=10.3389%2ffmed.2024.1366691&amp;partnerID=40&amp;md5=9c07f67b5ec23d34d1f10534275f9ed7">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:2296858X%20(ISSN)"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shi</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>He</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Dan</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yang</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1295"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>age</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>data analysis</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>death</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>adverse events</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>FAERS</dc:subject>
        <dc:subject>reporting and data system</dc:subject>
        <dc:subject>Medical Dictionary for Regulatory Activities</dc:subject>
        <dc:subject>inappropriate vasopressin secretion</dc:subject>
        <dc:subject>endocrine disease</dc:subject>
        <dc:subject>adrenal tumor</dc:subject>
        <dc:subject>sex</dc:subject>
        <dc:subject>atezolizumab</dc:subject>
        <dc:subject>nivolumab</dc:subject>
        <dc:subject>paraneoplastic hypercalcemia</dc:subject>
        <dc:subject>pembrolizumab</dc:subject>
        <dc:subject>adrenal insufficiency</dc:subject>
        <dc:subject>immune checkpoint inhibitor</dc:subject>
        <dc:subject>avelumab</dc:subject>
        <dc:subject>cemiplimab</dc:subject>
        <dc:subject>durvalumab</dc:subject>
        <dc:subject>adrenal cortex hyperfunction</dc:subject>
        <dc:subject>hyperthyroidism</dc:subject>
        <dc:subject>hypophysitis</dc:subject>
        <dc:subject>hypothyroidism</dc:subject>
        <dc:subject>thyroid disease</dc:subject>
        <dc:subject>thyroiditis</dc:subject>
        <dc:subject>Addison disease</dc:subject>
        <dc:subject>adrenal cortex insufficiency</dc:subject>
        <dc:subject>adrenal disease</dc:subject>
        <dc:subject>adrenal hemorrhage</dc:subject>
        <dc:subject>adrenomegaly</dc:subject>
        <dc:subject>autoimmune endocrine disease</dc:subject>
        <dc:subject>autoimmune hyperthyroidism</dc:subject>
        <dc:subject>autoimmune hypophysitis</dc:subject>
        <dc:subject>autoimmune hypothyroidism</dc:subject>
        <dc:subject>autoimmune thyroiditis</dc:subject>
        <dc:subject>central hypothyroidism</dc:subject>
        <dc:subject>corticotropin deficiency</dc:subject>
        <dc:subject>diabetes insipidus</dc:subject>
        <dc:subject>endocrine gland</dc:subject>
        <dc:subject>endocrine system</dc:subject>
        <dc:subject>endocrine toxicity</dc:subject>
        <dc:subject>fda adverse event reporting system</dc:subject>
        <dc:subject>glucocorticoid deficiency</dc:subject>
        <dc:subject>Graves disease</dc:subject>
        <dc:subject>hormone deficiency</dc:subject>
        <dc:subject>hyperpituitarism</dc:subject>
        <dc:subject>hypogonadism</dc:subject>
        <dc:subject>hypoparathyroidism</dc:subject>
        <dc:subject>hypophysis disease</dc:subject>
        <dc:subject>hypopituitarism</dc:subject>
        <dc:subject>hypothalamus disease</dc:subject>
        <dc:subject>immune mediated adrenal insufficiency</dc:subject>
        <dc:subject>length of stay</dc:subject>
        <dc:subject>lymphocytic hypophysitis</dc:subject>
        <dc:subject>nivolumab plus relatlimab</dc:subject>
        <dc:subject>PD-1/PD-L1 inhibitor</dc:subject>
        <dc:subject>pituitary enlargement</dc:subject>
        <dc:subject>primary adrenal insufficiency</dc:subject>
        <dc:subject>primary hyperparathyroidism</dc:subject>
        <dc:subject>programmed death 1 ligand 1</dc:subject>
        <dc:subject>programmed death 1 receptor</dc:subject>
        <dc:subject>secondary adrenocortical insufficiency</dc:subject>
        <dc:subject>silent thyroiditis</dc:subject>
        <dc:subject>subacute thyroiditis</dc:subject>
        <dc:subject>thyroid crisis</dc:subject>
        <dc:subject>toxicity</dc:subject>
        <dc:title>Endocrine system-related adverse events associated with PD-1/PD-L1 inhibitors: data mining from the FDA adverse event reporting system</dc:title>
        <dcterms:abstract>Background: Various immune checkpoint inhibitors, such as programmed cell death protein-1 (PD-1) and its ligand (PD-L1), have been approved for use, but they have side effects on the endocrine glands. Methods: Adverse event reports related to PD-1/PD-L1 inhibitors from the FDA Adverse Event Reporting System (FAERS) from the first quarter of 2019 to the first quarter of 2023 were extracted, and the reported Odds ratio methods (ROR method) and comprehensive standard methods (MHRA methods) were used for data mining and analysis. Results: A total of 5,322 reports (accounts for 6.68% of the total reports)of AEs in endocrine system were collected, including 1852 of pabolizumab (34.80%), 2,326 of navuliumab (43.71%), 54 of cimipriliumab (1.01%), 800 of atilizumab (15.03%), 222 of duvariumab (4.17%) and 68 of averumab (1.28%). Endocrine system-related AEs were mainly present in men (excluding those treated with pembrolizumab) aged ≥65 years. The ratio of AEs components in the endocrine system for the six drugs was approximately 3–8%. The main endocrine glands involved in AEs were the thyroid (pembrolizumab), pituitary and adrenal (nivolumab), adrenal (cemiplimab, atezolizumab, and avelumab), and thyroid (durvalumab). Most patients experienced AEs between 30 and 365 (mean, 117) days,the median time was 61d. AEs resulted in prolonged hospitalization in &gt;40% and death in &gt;10% of cases after administration of pembrolizumab, nivolumab, or durvalumab. Conclusion: Men aged ≥65 years should be concerned about endocrine-related AEs. There was a lengthy interval between the use of PD-1/PD-L1 inhibitors and endocrine system-related AEs, but the outcome was serious. Special attention should be given to endocrine system-related AEs when using pembrolizumab, nivolumab, or durvalumab. Copyright © 2024 Shi, He, Dan, Yang, Wang, Chen and Chen.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281102015</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85192204865&amp;doi=10.3389%2ffmed.2024.1366691&amp;partnerID=40&amp;md5=9c07f67b5ec23d34d1f10534275f9ed7</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:2296858X%20(ISSN)">
        <prism:volume>11</prism:volume>
        <dc:title>Frontiers in Medicine</dc:title>
        <dc:identifier>DOI 10.3389/fmed.2024.1366691</dc:identifier>
        <dcterms:alternative>Front. Med.</dcterms:alternative>
        <dc:identifier>ISSN 2296858X (ISSN)</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1295">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 2; Correspondence Address: J. Wang; Department of Pharmacy, Sichuan Mianyang 404 Hospital, Mianyang, China; email: 1040110291@qq.com; L. Chen; Department of Pharmacy/Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, China; email: chenl_hxey@scu.edu.cn&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85147199674&amp;doi=10.1016%2fj.ajg.2022.10.012&amp;partnerID=40&amp;md5=b1f91c0319c497f44e91375eb8989e27">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:16871979%20(ISSN)"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Nair</foaf:surname>
                        <foaf:givenName>H.P.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kulkarni</foaf:surname>
                        <foaf:givenName>A.R.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Eswaran</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Subeesh</foaf:surname>
                        <foaf:givenName>V.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1299"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>FAERS database</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>odds ratio</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>reporting odds ratio</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>hyponatremia</dc:subject>
        <dc:subject>very elderly</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>congenital malformation</dc:subject>
        <dc:subject>hypocalcemia</dc:subject>
        <dc:subject>data extraction</dc:subject>
        <dc:subject>disease association</dc:subject>
        <dc:subject>Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>dyspepsia</dc:subject>
        <dc:subject>infant</dc:subject>
        <dc:subject>pantoprazole</dc:subject>
        <dc:subject>long term care</dc:subject>
        <dc:subject>newborn</dc:subject>
        <dc:subject>proportional reporting ratio</dc:subject>
        <dc:subject>clinical assessment</dc:subject>
        <dc:subject>life threat</dc:subject>
        <dc:subject>Signal detection</dc:subject>
        <dc:subject>Retrospective Studies</dc:subject>
        <dc:subject>Dyspepsia</dc:subject>
        <dc:subject>Hypocalcemia</dc:subject>
        <dc:subject>Hyponatremia</dc:subject>
        <dc:subject>non prescription drug</dc:subject>
        <dc:subject>Pantoprazole</dc:subject>
        <dc:subject>short course therapy</dc:subject>
        <dc:title>Pantoprazole associated dyspepsia hypocalcemia and hyponatremia: A disproportionality analysis in FDA adverse event reporting system (FAERS) database</dc:title>
        <dcterms:abstract>Background and study aim: The study was designed to detect novel Adverse Events (AEs) of pantoprazole by disproportionality analysis in the FDA (Food and Drug Administration) database of Adverse Event Reporting System (FAERS) using Data Mining Algorithms (DMAs). Pantoprazole, the most commonly over-utilized Over The Counter (OTC) medication, was selected to assess any short-term or long-term AEs. The study aimed to analyze the novel adverse events of pantoprazole using the FAERS database. Materials and methods: A retrospective case/non-case disproportionality analysis was performed in the FAERS database. This study was based on AEs reported to FAERS from 2006Q1-2021Q3. Openvigil 2.1 was used for data extraction. Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), and Information Component (IC) were applied to measure the disproportionality in reporting. A value of ROR-1.96SE &gt; 1, PRR ≥ 2, and IC-2SD &gt; 0 were considered as the threshold for a positive signal. Results: A total of 1050 reports of dyspepsia, 7248 reports of hypocalcemia and 995 reports of hyponatremia were identified. A potential positive signal for dyspepsia (ROR-1.96SE = 2.231, PRR = 2.359, IC-2SD = 1.13), hypocalcemia (4.961, 5.45, 2.23) and hyponatremia (3.948, 4.179, 1.92) were identified for pantoprazole. Conclusion: Data mining in the FAERS database produced three potential signals associated with pantoprazole. As a result, further clinical surveillance is needed to quantify and validate potential hazards associated with pantoprazole-related adverse events. © 2022 Pan-Arab Association of Gastroenterology</dcterms:abstract>
        <dc:date>2023</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281102004</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85147199674&amp;doi=10.1016%2fj.ajg.2022.10.012&amp;partnerID=40&amp;md5=b1f91c0319c497f44e91375eb8989e27</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>1-4</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:16871979%20(ISSN)">
        <prism:volume>24</prism:volume>
        <dc:title>Arab Journal of Gastroenterology</dc:title>
        <dc:identifier>DOI 10.1016/j.ajg.2022.10.012</dc:identifier>
        <prism:number>1</prism:number>
        <dcterms:alternative>Arab J. Gastroenterol.</dcterms:alternative>
        <dc:identifier>ISSN 16871979 (ISSN)</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1299">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 5; Correspondence Address: V. Subeesh; Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Udupi, Karnataka, India; email: subeeshkviswam@gmail.com&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85205239350&amp;doi=10.3389%2ffendo.2024.1367607&amp;partnerID=40&amp;md5=dbcb0195168c43c5c5d2761bb2026fdc">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>15</prism:volume>
                <dc:title>Frontiers in Endocrinology</dc:title>
                <dc:identifier>DOI 10.3389/fendo.2024.1367607</dc:identifier>
                <dcterms:alternative>Front. Endocrinol.</dcterms:alternative>
                <dc:identifier>ISSN 16642392 (ISSN)</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhao</foaf:surname>
                        <foaf:givenName>C.-L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Fu</foaf:surname>
                        <foaf:givenName>Z.-H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1297"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>gingiva bleeding</dc:subject>
        <dc:subject>information component</dc:subject>
        <dc:subject>reporting odds ratio</dc:subject>
        <dc:subject>FAERS</dc:subject>
        <dc:subject>gingiva disease</dc:subject>
        <dc:subject>osteoporosis</dc:subject>
        <dc:subject>alendronic acid</dc:subject>
        <dc:subject>adverse drug reactions</dc:subject>
        <dc:subject>denosumab</dc:subject>
        <dc:subject>gingivitis</dc:subject>
        <dc:subject>periodontal disease</dc:subject>
        <dc:subject>periodontitis</dc:subject>
        <dc:subject>data extraction</dc:subject>
        <dc:subject>bisphosphonic acid derivative</dc:subject>
        <dc:subject>omeprazole</dc:subject>
        <dc:subject>Bayesian confidence propagation neural network</dc:subject>
        <dc:subject>proportional reporting ratio</dc:subject>
        <dc:subject>osteopenia</dc:subject>
        <dc:subject>levothyroxine</dc:subject>
        <dc:subject>hypothyroidism</dc:subject>
        <dc:subject>nonsteroid antiinflammatory agent</dc:subject>
        <dc:subject>antiresorptive drugs</dc:subject>
        <dc:subject>bisphosphonates</dc:subject>
        <dc:subject>calcium</dc:subject>
        <dc:subject>estrogen</dc:subject>
        <dc:subject>gingival disorders</dc:subject>
        <dc:subject>ibandronic acid</dc:subject>
        <dc:subject>risedronic acid</dc:subject>
        <dc:subject>wound healing</dc:subject>
        <dc:subject>zoledronic acid</dc:subject>
        <dc:title>Bisphosphonate- and disumab-related gingival disorders: case analysis from the U.S. Food and Drug Administration Adverse Event Reporting System</dc:title>
        <dcterms:abstract>Prior research has indicated that bisphosphonates (BPs) can improve periodontal disease because of their anti-osteoporosis properties. In vitro studies have shown that BPs induce cytotoxicity, inhibit wound healing, and thus affect periodontal disease. Denosumab and BPs have alternative indications. BP and denosumab are not known to correlate with gingival disorders. We assessed such a relationship by applying Bayesian and nonproportional analyses to data in the US FDA Adverse Event Reporting System (FAERS) database. The study analyzed BPs and denosumab-reported incidents with preferred terms found in the narrow Standardized MedDRA Queries for gingival disorders. A total of 5863 reported cases of gingival disorders were associated with five BPs (alendronate, pamidronate, ibandronate, risedronate, and zoledronate) and denosumab. More than 15% of patients with gingival disorders related to BPs and denosumab other than denosumab were hospitalized over short- or long-term periods. Our findings indicated BPs and denosumab had significant reporting odds ratios (ROR), proportional reporting ratios (PRR), and information components (IC) with respect to gingival disorders. Pamidronate had the highest association (ROR = 64.58, PRR = 57.99, IC = 5.71), while the weakest association was found with denosumab (ROR = 3.61, PRR = 3.60, IC = 1.77). Significant associations were found between the six drugs and gingival pain, gingival recession, gingivitis, periodontal disease, and periodontitis. In conclusion, our comprehensive overview of the correlations, clinical characteristics, and prognoses of BPs and denosumab-related gingival disorders suggests that these issues deserve continued surveillance and appropriate management. Copyright © 2024 Wang, Zhang, Zhao and Fu.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281102009</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85205239350&amp;doi=10.3389%2ffendo.2024.1367607&amp;partnerID=40&amp;md5=dbcb0195168c43c5c5d2761bb2026fdc</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Memo rdf:about="#item_1297">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 2; Correspondence Address: Z.-H. Fu; Department of Pharmacy, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, School of Clinical Medicine, Henan University, Zhengzhou, Henan, China; email: zhaocl725@zzu.edu.cn&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85201542029&amp;doi=10.3389%2ffpsyt.2024.1322939&amp;partnerID=40&amp;md5=9307bfdef6bc186358ec5acf287de35c">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:16640640%20(ISSN)"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mu</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1298"/>
        <dc:subject>Article</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>reporting odds ratio</dc:subject>
        <dc:subject>quetiapine</dc:subject>
        <dc:subject>diplopia</dc:subject>
        <dc:subject>blindness</dc:subject>
        <dc:subject>eye disease</dc:subject>
        <dc:subject>aripiprazole</dc:subject>
        <dc:subject>asenapine</dc:subject>
        <dc:subject>cataract</dc:subject>
        <dc:subject>blurred vision</dc:subject>
        <dc:subject>lurasidone</dc:subject>
        <dc:subject>paliperidone</dc:subject>
        <dc:subject>risperidone</dc:subject>
        <dc:subject>blepharospasm</dc:subject>
        <dc:subject>glaucoma</dc:subject>
        <dc:subject>night blindness</dc:subject>
        <dc:subject>demographics</dc:subject>
        <dc:subject>vascular disease</dc:subject>
        <dc:subject>atypical antipsychotic agent</dc:subject>
        <dc:subject>atypical antipsychotics</dc:subject>
        <dc:subject>brexpiprazole</dc:subject>
        <dc:subject>clozapine</dc:subject>
        <dc:subject>olanzapine</dc:subject>
        <dc:subject>ziprasidone</dc:subject>
        <dc:subject>eye infection</dc:subject>
        <dc:subject>eye irritation</dc:subject>
        <dc:subject>myopia</dc:subject>
        <dc:subject>eye inflammation</dc:subject>
        <dc:subject>intraocular hypertension</dc:subject>
        <dc:subject>metamorphopsia</dc:subject>
        <dc:subject>papilledema</dc:subject>
        <dc:subject>photopsia</dc:subject>
        <dc:subject>consumer</dc:subject>
        <dc:subject>accommodation disorder</dc:subject>
        <dc:subject>eye movement disorder</dc:subject>
        <dc:subject>cariprazine</dc:subject>
        <dc:subject>pharmacist</dc:subject>
        <dc:subject>physician</dc:subject>
        <dc:subject>color vision defect</dc:subject>
        <dc:subject>oculogyric crisis</dc:subject>
        <dc:subject>adverse food reaction</dc:subject>
        <dc:subject>vitreous hemorrhage</dc:subject>
        <dc:subject>real-world study</dc:subject>
        <dc:subject>blink rate</dc:subject>
        <dc:subject>chorioretinopathy</dc:subject>
        <dc:subject>dysmetropsia</dc:subject>
        <dc:subject>eye disorders</dc:subject>
        <dc:subject>Food and Drug Administration Adverse Event Reporting System (FAERS)</dc:subject>
        <dc:subject>gaze paralysis</dc:subject>
        <dc:subject>glare</dc:subject>
        <dc:subject>keratoconus</dc:subject>
        <dc:subject>Medicines and Healthcare products Regulatory Agency</dc:subject>
        <dc:subject>miosis</dc:subject>
        <dc:subject>myasthenia</dc:subject>
        <dc:subject>mydriasis</dc:subject>
        <dc:subject>neuromuscular disease</dc:subject>
        <dc:subject>nurse</dc:subject>
        <dc:subject>ocular adverse events</dc:subject>
        <dc:subject>ophthalmoplegia</dc:subject>
        <dc:subject>optic nerve disease</dc:subject>
        <dc:subject>presbyopia</dc:subject>
        <dc:subject>pupillary block</dc:subject>
        <dc:subject>retina degeneration</dc:subject>
        <dc:subject>saccadic eye movement</dc:subject>
        <dc:subject>strabismus</dc:subject>
        <dc:subject>xanthopsia</dc:subject>
        <dc:subject>xerophthalmia</dc:subject>
        <dc:title>Characteristics of eye disorders induced by atypical antipsychotics: a real-world study from 2016 to 2022 based on Food and Drug Administration Adverse Event Reporting System</dc:title>
        <dcterms:abstract>Background: Common atypical antipsychotics include risperidone, paliperidone, olanzapine, lurasidone, quetiapine, clozapine, aripiprazole, ziprasidone, asenapine, brexpiprazole, and cariprazine. Previous studies on ocular adverse reactions of antipsychotics were mainly focused on typical antipsychotics. Systematic research on atypical antipsychotics remains limited. Objective: This study aimed to evaluate the potential risks of different atypical antipsychotics causing ocular side effects by mining the Food and Drug Administration Adverse Event Reporting System (FAERS) database. Methods: Extract reports from the FAERS from the first quarter of 2016 to the fourth quarter of 2022 were obtained. Data mining of eye disorders associated with atypical antipsychotics was carried out using The Reporting Odds Ratio (ROR) method and The Medicines and Healthcare Products Regulatory Agency (MHRA) method to determine positive signals. Results: FAERS reports for 9913783 cases were included in these 28 quarters. 64 defined ocular adverse events were classified into 10 categories according to High-Level Group Terms (HLGT). Conclusions: There were differences in the types and severity of ocular-related adverse events associated with atypical antipsychotics. Ocular neuromuscular-related adverse events were found among all 11 atypical antipsychotics. Olanzapine had the highest signal intensity in oculogyric crisis. Aripiprazole had the highest signal strength in blepharospasm. Cariprazine was associated with cataract-related ocular adverse reactions. In terms of the types of adverse events, our study found that aripiprazole was associated with 28 types of ocular adverse events, followed by quetiapine. Clozapine was only associated with two types of ocular adverse events. Copyright © 2024 Mu and Chen.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281102005</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85201542029&amp;doi=10.3389%2ffpsyt.2024.1322939&amp;partnerID=40&amp;md5=9307bfdef6bc186358ec5acf287de35c</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:16640640%20(ISSN)">
        <prism:volume>15</prism:volume>
        <dc:title>Frontiers in Psychiatry</dc:title>
        <dc:identifier>DOI 10.3389/fpsyt.2024.1322939</dc:identifier>
        <dcterms:alternative>Front. Psychiatry</dcterms:alternative>
        <dc:identifier>ISSN 16640640 (ISSN)</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1298">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 3; Correspondence Address: L. Chen; Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China; email: chenl_hxey@scu.edu.cn&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85181191902&amp;doi=10.1177%2f15353702231211860&amp;partnerID=40&amp;md5=c9e71e4806edfddd671e57e066d300b0">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:15353702%20(ISSN)"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Le</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hong</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ge</foaf:surname>
                        <foaf:givenName>W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Francis</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lyn-Cook</foaf:surname>
                        <foaf:givenName>B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hwang</foaf:surname>
                        <foaf:givenName>Y.-T.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Rogers</foaf:surname>
                        <foaf:givenName>P.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tong</foaf:surname>
                        <foaf:givenName>W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zou</foaf:surname>
                        <foaf:givenName>W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1300"/>
        <dc:subject>acute kidney failure</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>Bayes Theorem</dc:subject>
        <dc:subject>bleeding</dc:subject>
        <dc:subject>burning sensation</dc:subject>
        <dc:subject>contusion</dc:subject>
        <dc:subject>joint swelling</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>depression</dc:subject>
        <dc:subject>epidemiology</dc:subject>
        <dc:subject>FAERS</dc:subject>
        <dc:subject>heart arrest</dc:subject>
        <dc:subject>heart palpitation</dc:subject>
        <dc:subject>tachycardia</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>abdominal pain</dc:subject>
        <dc:subject>constipation</dc:subject>
        <dc:subject>fatigue</dc:subject>
        <dc:subject>headache</dc:subject>
        <dc:subject>hypercalcemia</dc:subject>
        <dc:subject>muscle spasm</dc:subject>
        <dc:subject>nervousness</dc:subject>
        <dc:subject>tinnitus</dc:subject>
        <dc:subject>vomiting</dc:subject>
        <dc:subject>amnesia</dc:subject>
        <dc:subject>balance disorder</dc:subject>
        <dc:subject>cognitive defect</dc:subject>
        <dc:subject>coma</dc:subject>
        <dc:subject>confusion</dc:subject>
        <dc:subject>hallucination</dc:subject>
        <dc:subject>hyponatremia</dc:subject>
        <dc:subject>information processing</dc:subject>
        <dc:subject>mental disease</dc:subject>
        <dc:subject>respiration depression</dc:subject>
        <dc:subject>restlessness</dc:subject>
        <dc:subject>atrial fibrillation</dc:subject>
        <dc:subject>coronary artery disease</dc:subject>
        <dc:subject>heart infarction</dc:subject>
        <dc:subject>lung edema</dc:subject>
        <dc:subject>lung embolism</dc:subject>
        <dc:subject>aggression</dc:subject>
        <dc:subject>anaphylaxis</dc:subject>
        <dc:subject>anemia</dc:subject>
        <dc:subject>bone disease</dc:subject>
        <dc:subject>Data Mining</dc:subject>
        <dc:subject>dehydration</dc:subject>
        <dc:subject>dry eye</dc:subject>
        <dc:subject>pleura effusion</dc:subject>
        <dc:subject>dental caries</dc:subject>
        <dc:subject>coughing</dc:subject>
        <dc:subject>diabetes mellitus</dc:subject>
        <dc:subject>memory disorder</dc:subject>
        <dc:subject>peripheral swelling</dc:subject>
        <dc:subject>consciousness disorder</dc:subject>
        <dc:subject>cardiomegaly</dc:subject>
        <dc:subject>chronic kidney failure</dc:subject>
        <dc:subject>comparative study</dc:subject>
        <dc:subject>gastroesophageal reflux</dc:subject>
        <dc:subject>malaise</dc:subject>
        <dc:subject>hyperglycemia</dc:subject>
        <dc:subject>febrile neutropenia</dc:subject>
        <dc:subject>hypersensitivity</dc:subject>
        <dc:subject>pneumonia</dc:subject>
        <dc:subject>rash</dc:subject>
        <dc:subject>convulsion</dc:subject>
        <dc:subject>hypokalemia</dc:subject>
        <dc:subject>neutropenia</dc:subject>
        <dc:subject>peripheral neuropathy</dc:subject>
        <dc:subject>thrombocytopenia</dc:subject>
        <dc:subject>emotional stress</dc:subject>
        <dc:subject>erythema</dc:subject>
        <dc:subject>gait disorder</dc:subject>
        <dc:subject>muscle weakness</dc:subject>
        <dc:subject>migraine</dc:subject>
        <dc:subject>thorax pain</dc:subject>
        <dc:subject>drug abuse</dc:subject>
        <dc:subject>swelling</dc:subject>
        <dc:subject>lethargy</dc:subject>
        <dc:subject>alcoholism</dc:subject>
        <dc:subject>anxiety disorder</dc:subject>
        <dc:subject>irritability</dc:subject>
        <dc:subject>codeine</dc:subject>
        <dc:subject>methadone</dc:subject>
        <dc:subject>premature labor</dc:subject>
        <dc:subject>pruritus</dc:subject>
        <dc:subject>suicidal ideation</dc:subject>
        <dc:subject>morphine</dc:subject>
        <dc:subject>withdrawal syndrome</dc:subject>
        <dc:subject>drug dependence</dc:subject>
        <dc:subject>serotonin syndrome</dc:subject>
        <dc:subject>fentanyl</dc:subject>
        <dc:subject>sleep apnea syndromes</dc:subject>
        <dc:subject>tramadol</dc:subject>
        <dc:subject>abnormal substrate concentration in blood</dc:subject>
        <dc:subject>AEs</dc:subject>
        <dc:subject>alanine aminotransferase increased</dc:subject>
        <dc:subject>Analgesics, Opioid</dc:subject>
        <dc:subject>buprenorphine</dc:subject>
        <dc:subject>dihydrocodeine</dc:subject>
        <dc:subject>drug misuse</dc:subject>
        <dc:subject>drug toxicity</dc:subject>
        <dc:subject>Fentanyl</dc:subject>
        <dc:subject>food and drug administration adverse events reporting system</dc:subject>
        <dc:subject>hydrocodone</dc:subject>
        <dc:subject>Hydrocodone</dc:subject>
        <dc:subject>hydromorphone</dc:subject>
        <dc:subject>Hydromorphone</dc:subject>
        <dc:subject>hypoventilation</dc:subject>
        <dc:subject>intervertebral disk hernia</dc:subject>
        <dc:subject>maximum likelihood method</dc:subject>
        <dc:subject>Meperidine</dc:subject>
        <dc:subject>narcotic analgesic agent</dc:subject>
        <dc:subject>network analysis</dc:subject>
        <dc:subject>opiate</dc:subject>
        <dc:subject>oxycodone</dc:subject>
        <dc:subject>Oxycodone</dc:subject>
        <dc:subject>oxymorphone</dc:subject>
        <dc:subject>Oxymorphone</dc:subject>
        <dc:subject>pathologic nystagmus</dc:subject>
        <dc:subject>pethidine</dc:subject>
        <dc:subject>phylogenetic tree</dc:subject>
        <dc:subject>potential safety signals</dc:subject>
        <dc:subject>prematurity</dc:subject>
        <dc:subject>Prescription opioids</dc:subject>
        <dc:subject>spontaneous abortion</dc:subject>
        <dc:subject>swelling face</dc:subject>
        <dc:subject>synovitis</dc:subject>
        <dc:subject>tapentadol</dc:subject>
        <dc:subject>Tapentadol</dc:subject>
        <dc:title>A systematic analysis and data mining of opioid-related adverse events submitted to the FAERS database</dc:title>
        <dcterms:abstract>The opioid epidemic has become a serious national crisis in the United States. An indepth systematic analysis of opioid-related adverse events (AEs) can clarify the risks presented by opioid exposure, as well as the individual risk profiles of specific opioid drugs and the potential relationships among the opioids. In this study, 92 opioids were identified from the list of all Food and Drug Administration (FDA)-approved drugs, annotated by RxNorm and were classified into 13 opioid groups: buprenorphine, codeine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, meperidine, methadone, morphine, oxycodone, oxymorphone, tapentadol, and tramadol. A total of 14,970,399 AE reports were retrieved and downloaded from the FDA Adverse Events Reporting System (FAERS) from 2004, Quarter 1 to 2020, Quarter 3. After data processing, Empirical Bayes Geometric Mean (EBGM) was then applied which identified 3317 pairs of potential risk signals within the 13 opioid groups. Based on these potential safety signals, a comparative analysis was pursued to provide a global overview of opioid-related AEs for all 13 groups of FDA-approved prescription opioids. The top 10 most reported AEs for each opioid class were then presented. Both network analysis and hierarchical clustering analysis were conducted to further explore the relationship between opioids. Results from the network analysis revealed a close association among fentanyl, oxycodone, hydrocodone, and hydromorphone, which shared more than 22 AEs. In addition, much less commonly reported AEs were shared among dihydrocodeine, meperidine, oxymorphone, and tapentadol. On the contrary, the hierarchical clustering analysis further categorized the 13 opioid classes into two groups by comparing the full profiles of presence/absence of AEs. The results of network analysis and hierarchical clustering analysis were not only consistent and cross-validated each other but also provided a better and deeper understanding of the associations and relationships between the 13 opioid groups with respect to their adverse effect profiles. © 2023 by the Society for Experimental Biology and Medicine.</dcterms:abstract>
        <dc:date>2023</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281101997</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85181191902&amp;doi=10.1177%2f15353702231211860&amp;partnerID=40&amp;md5=c9e71e4806edfddd671e57e066d300b0</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>1944-1951</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:15353702%20(ISSN)">
        <prism:volume>248</prism:volume>
        <dc:title>Experimental Biology and Medicine</dc:title>
        <dc:identifier>DOI 10.1177/15353702231211860</dc:identifier>
        <prism:number>21</prism:number>
        <dcterms:alternative>Exp. Biol. Med.</dcterms:alternative>
        <dc:identifier>ISSN 15353702 (ISSN)</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1300">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 4; Correspondence Address: W. Zou; Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, 72079, United States; email: wen.zou@fda.hhs.gov; CODEN: EBMMB&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85217274115&amp;doi=10.1038%2fs41598-025-86959-z&amp;partnerID=40&amp;md5=3de40bd9f27478ca2fc67fead77dee8f">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>15</prism:volume>
                <dc:title>Scientific Reports</dc:title>
                <dc:identifier>DOI 10.1038/s41598-025-86959-z</dc:identifier>
                <prism:number>1</prism:number>
                <dcterms:alternative>Sci. Rep.</dcterms:alternative>
                <dc:identifier>ISSN 20452322 (ISSN)</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mao</foaf:surname>
                        <foaf:givenName>W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jiang</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xia</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1296"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>postmarketing surveillance</dc:subject>
        <dc:subject>young adult</dc:subject>
        <dc:subject>Adult</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>Aged</dc:subject>
        <dc:subject>FAERS</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>United States Food and Drug Administration</dc:subject>
        <dc:subject>very elderly</dc:subject>
        <dc:subject>Female</dc:subject>
        <dc:subject>Aged, 80 and over</dc:subject>
        <dc:subject>avapritinib</dc:subject>
        <dc:subject>Male</dc:subject>
        <dc:subject>Middle Aged</dc:subject>
        <dc:subject>Young Adult</dc:subject>
        <dc:subject>Product Surveillance, Postmarketing</dc:subject>
        <dc:subject>Avapritinib</dc:subject>
        <dc:subject>Neuropsychiatric disorders</dc:subject>
        <dc:subject>pyrazine derivative</dc:subject>
        <dc:subject>Pyrazines</dc:subject>
        <dc:subject>pyrazole derivative</dc:subject>
        <dc:subject>Pyrazoles</dc:subject>
        <dc:subject>pyrrole derivative</dc:subject>
        <dc:subject>Pyrroles</dc:subject>
        <dc:subject>Stratified analysis</dc:subject>
        <dc:subject>triazine derivative</dc:subject>
        <dc:subject>Triazines</dc:subject>
        <dc:title>Analysis of postmarketing neuropsychiatric adverse events of avapritinib based on the FDA adverse event reporting system</dc:title>
        <dcterms:abstract>Neuropsychiatric adverse events (AEs) significantly impact the quality of life of patients using avapritinib. However, the majority of current data comes from pre-marketing, with limited real-world studies. Our research aimed to explore post-marketing data of avapritinib. We evaluated the signals of avapritinib-related neuropsychiatric AEs by data mining using the FDA Adverse Event Reporting System (FAERS). Reporting odds ratio (ROR) and information component (IC) were employed to quantify the signals from the first quarter of 2020 through the fourth quarter of 2023. Subsequently, stratified analyses were conducted to further explore the effect of different stratification schemes on the association between avapritinib and neuropsychiatric AEs. Finally, a combination medication analysis was conducted to explore the impact of the co-administration of neuropsychiatric AEs. A total of 2029 neuropsychiatric AEs were reported, and 49 signals were detected, of which 5 were determined to be new signals. Avapritinib was significantly associated with the occurrence of neuropsychiatric AEs (ROR: 1.52, 95% CI: 1.44–1.61; IC: 0.43, IC025: 0.35). The stratified analysis found that gender, age and eight preferred terms (PTs), including cerebral haemorrhage, may affect the severity of AEs. Combination medication analysis showed that combining avapritinib with 19 other medications, including prochlorperazine, may increase the risk of neuropsychiatric AEs. The median time-to-onset (TTO) of avapritinib-related neuropsychiatric AEs was 32 (interquartile range [IQR] 2-200) days, with about 65% of cases occurring within the first three months of treatment. An increase in the signal for neuropsychiatric AEs was identified in post-marketing studies of avapritinib. Clinicians are advised to remain vigilant for such events, particularly during the initial stages of treatment with avapritinib. © The Author(s) 2025.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281101992</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85217274115&amp;doi=10.1038%2fs41598-025-86959-z&amp;partnerID=40&amp;md5=3de40bd9f27478ca2fc67fead77dee8f</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Memo rdf:about="#item_1296">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: L. Zhang; Department of Pharmacy, The First Affiliated Hospital of Army Medical University, Chongqing, China; email: zhanglin1@tmmu.edu.cn&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85200542008&amp;doi=10.1080%2f14740338.2024.2387323&amp;partnerID=40&amp;md5=db17090ae604504307e6453d2a4a7b87">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:14740338%20(ISSN)"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Peng</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhou</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhou</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jia</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhong</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1302"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>death</dc:subject>
        <dc:subject>disease course</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>Bayes Theorem</dc:subject>
        <dc:subject>cardiotoxicity</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>thrombosis</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>United States Food and Drug Administration</dc:subject>
        <dc:subject>backache</dc:subject>
        <dc:subject>constipation</dc:subject>
        <dc:subject>fatigue</dc:subject>
        <dc:subject>nausea</dc:subject>
        <dc:subject>pain</dc:subject>
        <dc:subject>vomiting</dc:subject>
        <dc:subject>cognitive defect</dc:subject>
        <dc:subject>liver toxicity</dc:subject>
        <dc:subject>neurologic disease</dc:subject>
        <dc:subject>lung embolism</dc:subject>
        <dc:subject>antineoplastic agent</dc:subject>
        <dc:subject>Adverse events</dc:subject>
        <dc:subject>alopecia</dc:subject>
        <dc:subject>anemia</dc:subject>
        <dc:subject>asthenia</dc:subject>
        <dc:subject>breast cancer</dc:subject>
        <dc:subject>Data Mining</dc:subject>
        <dc:subject>diarrhea</dc:subject>
        <dc:subject>drug fatality</dc:subject>
        <dc:subject>lymphatic system disease</dc:subject>
        <dc:subject>pleura effusion</dc:subject>
        <dc:subject>jaw osteonecrosis</dc:subject>
        <dc:subject>coughing</dc:subject>
        <dc:subject>dyspnea</dc:subject>
        <dc:subject>mediastinum disease</dc:subject>
        <dc:subject>peripheral swelling</dc:subject>
        <dc:subject>drug use</dc:subject>
        <dc:subject>hepatobiliary disease</dc:subject>
        <dc:subject>malaise</dc:subject>
        <dc:subject>musculoskeletal disease</dc:subject>
        <dc:subject>Antineoplastic Agents</dc:subject>
        <dc:subject>bone marrow suppression</dc:subject>
        <dc:subject>drug approval</dc:subject>
        <dc:subject>leukopenia</dc:subject>
        <dc:subject>abemaciclib</dc:subject>
        <dc:subject>cyclin dependent kinase 4</dc:subject>
        <dc:subject>cyclin dependent kinase 6</dc:subject>
        <dc:subject>palbociclib</dc:subject>
        <dc:subject>ribociclib</dc:subject>
        <dc:subject>fever</dc:subject>
        <dc:subject>pneumonia</dc:subject>
        <dc:subject>stomatitis</dc:subject>
        <dc:subject>hypokalemia</dc:subject>
        <dc:subject>neutropenia</dc:subject>
        <dc:subject>thrombocytopenia</dc:subject>
        <dc:subject>thorax pain</dc:subject>
        <dc:subject>interstitial lung disease</dc:subject>
        <dc:subject>lung toxicity</dc:subject>
        <dc:subject>erythema multiforme</dc:subject>
        <dc:subject>pruritus</dc:subject>
        <dc:subject>FDA Adverse Event Reporting System</dc:subject>
        <dc:subject>protein kinase inhibitor</dc:subject>
        <dc:subject>Protein Kinase Inhibitors</dc:subject>
        <dc:subject>skin toxicity</dc:subject>
        <dc:subject>pneumothorax</dc:subject>
        <dc:subject>risk</dc:subject>
        <dc:subject>aminopyridine derivative</dc:subject>
        <dc:subject>Aminopyridines</dc:subject>
        <dc:subject>Bayesian confidence propagation neural network method</dc:subject>
        <dc:subject>benzimidazole derivative</dc:subject>
        <dc:subject>Benzimidazoles</dc:subject>
        <dc:subject>CDK4 protein, human</dc:subject>
        <dc:subject>CDK6 protein, human</dc:subject>
        <dc:subject>cyclin dependent kinase</dc:subject>
        <dc:subject>cyclin dependent kinase inhibitor</dc:subject>
        <dc:subject>Cyclin-Dependent Kinase 4</dc:subject>
        <dc:subject>Cyclin-dependent kinase 4/6 inhibitors</dc:subject>
        <dc:subject>Cyclin-Dependent Kinase 6</dc:subject>
        <dc:subject>interstitial pneumonia</dc:subject>
        <dc:subject>mucosal disease</dc:subject>
        <dc:subject>osteosclerosis</dc:subject>
        <dc:subject>piperazine derivative</dc:subject>
        <dc:subject>Piperazines</dc:subject>
        <dc:subject>purine derivative</dc:subject>
        <dc:subject>Purines</dc:subject>
        <dc:subject>pyridine derivative</dc:subject>
        <dc:subject>Pyridines</dc:subject>
        <dc:subject>Reporting odds ratio method</dc:subject>
        <dc:title>A disproportionality analysis of CDK4/6 inhibitors in the FDA Adverse Event Reporting System (FAERS)</dc:title>
        <dcterms:abstract>Objective: The FDA Adverse Event Reporting System (FAERS) was used to mine and evaluate adverse events (AEs) associated with cyclin-dependent kinase (CDK) 4/6 inhibitors, thereby providing a reference for clinical rational drug use. Methods: AE data related to CDK4/6 inhibitors from the first quarter of 2015 to the first quarter of 2023 were acquired from FAERS, while the signal mining was processed using the reporting odds ratio (ROR) method and Bayesian confidence propagation neural network (BCPNN) method. Results: The number of AE reports for CDK4/6 inhibitors was, respectively, 132,494 for palbociclib, 56,151 for ribociclib, and 7,014 for abemaciclib. The corresponding numbers of AE signals were 322,522, and 59, with the number of involved System Organ Class (SOC) being 23, 23, and 15, mainly involving blood and lymphatic system disorders, respiratory, thoracic and mediastinal disorders, hepatobiliary disorders, skin and subcutaneous tissue disorders, etc. Conclusion: CDK4/6 inhibitors could lead to pulmonary toxicity, myelosuppression, skin reactions, etc. Special attention should be paid to abemaciclib for interstitial lung disease (ILD), erythema multiforme, and thrombosis risk; ribociclib for cardiac toxicity, hepatotoxicity, and musculoskeletal toxicity; palbociclib for neurocognitive impairment and osteonecrosis of the jaw. © 2024 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281101986</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85200542008&amp;doi=10.1080%2f14740338.2024.2387323&amp;partnerID=40&amp;md5=db17090ae604504307e6453d2a4a7b87</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>25-33</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:14740338%20(ISSN)">
        <prism:volume>24</prism:volume>
        <dc:title>Expert Opinion on Drug Safety</dc:title>
        <dc:identifier>DOI 10.1080/14740338.2024.2387323</dc:identifier>
        <prism:number>1</prism:number>
        <dcterms:alternative>Expert Opin. Drug Saf.</dcterms:alternative>
        <dc:identifier>ISSN 14740338 (ISSN)</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1302">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 3; Correspondence Address: Y. Zhong; Department of Pharmacy, Hospital of Chengdu Office of People’s Government of Tibetan Autonomous Region (Hospital. C. T), Chengdu, No. 20 Xi Mian Qiao Heng StreetSichuan Province, China; email: 1179349180@qq.com; CODEN: EODSA&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85201249867&amp;doi=10.1186%2fs40360-024-00772-4&amp;partnerID=40&amp;md5=607d1eb0eabf1aaf4c14af429e0c2b4a">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:20506511%20(ISSN)"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jin</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gu</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xia</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xie</foaf:surname>
                        <foaf:givenName>G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhu</foaf:surname>
                        <foaf:givenName>G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1303"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>age</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>data analysis</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>factual database</dc:subject>
        <dc:subject>FAERS database</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>young adult</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>Adolescent</dc:subject>
        <dc:subject>Adult</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>Aged</dc:subject>
        <dc:subject>connective tissue disease</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>Antipsychotic Agents</dc:subject>
        <dc:subject>bipolar disorder</dc:subject>
        <dc:subject>depression</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>neuroleptic agent</dc:subject>
        <dc:subject>schizophrenia</dc:subject>
        <dc:subject>clinical practice</dc:subject>
        <dc:subject>insomnia</dc:subject>
        <dc:subject>orthostatic hypotension</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>sleep disorder</dc:subject>
        <dc:subject>attention disturbance</dc:subject>
        <dc:subject>delirium</dc:subject>
        <dc:subject>delusion</dc:subject>
        <dc:subject>dysarthria</dc:subject>
        <dc:subject>gastrointestinal disease</dc:subject>
        <dc:subject>hallucination</dc:subject>
        <dc:subject>hypersalivation</dc:subject>
        <dc:subject>information processing</dc:subject>
        <dc:subject>mental disease</dc:subject>
        <dc:subject>mood disorder</dc:subject>
        <dc:subject>neurologic disease</dc:subject>
        <dc:subject>paranoia</dc:subject>
        <dc:subject>personality disorder</dc:subject>
        <dc:subject>psychosis</dc:subject>
        <dc:subject>restlessness</dc:subject>
        <dc:subject>sex difference</dc:subject>
        <dc:subject>skin disease</dc:subject>
        <dc:subject>eye disease</dc:subject>
        <dc:subject>risk assessment</dc:subject>
        <dc:subject>very elderly</dc:subject>
        <dc:subject>asenapine</dc:subject>
        <dc:subject>Databases, Factual</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>lymphatic system disease</dc:subject>
        <dc:subject>malignant neoplasm</dc:subject>
        <dc:subject>heart disease</dc:subject>
        <dc:subject>inner ear disease</dc:subject>
        <dc:subject>mediastinum disease</dc:subject>
        <dc:subject>respiratory tract disease</dc:subject>
        <dc:subject>thorax disease</dc:subject>
        <dc:subject>vascular disease</dc:subject>
        <dc:subject>disease association</dc:subject>
        <dc:subject>dysgeusia</dc:subject>
        <dc:subject>benign neoplasm</dc:subject>
        <dc:subject>breast disease</dc:subject>
        <dc:subject>drug therapy</dc:subject>
        <dc:subject>ear disease</dc:subject>
        <dc:subject>genital system disease</dc:subject>
        <dc:subject>hematologic disease</dc:subject>
        <dc:subject>hepatobiliary disease</dc:subject>
        <dc:subject>infection</dc:subject>
        <dc:subject>infestation</dc:subject>
        <dc:subject>injury</dc:subject>
        <dc:subject>kidney disease</dc:subject>
        <dc:subject>metabolic disorder</dc:subject>
        <dc:subject>musculoskeletal disease</dc:subject>
        <dc:subject>nutritional disorder</dc:subject>
        <dc:subject>urinary tract disease</dc:subject>
        <dc:subject>drug labeling</dc:subject>
        <dc:subject>endocrine disease</dc:subject>
        <dc:subject>Female</dc:subject>
        <dc:subject>auditory hallucination</dc:subject>
        <dc:subject>hypesthesia</dc:subject>
        <dc:subject>immunopathology</dc:subject>
        <dc:subject>sedation</dc:subject>
        <dc:subject>statistical analysis</dc:subject>
        <dc:subject>akathisia</dc:subject>
        <dc:subject>extrapyramidal syndrome</dc:subject>
        <dc:subject>hypomania</dc:subject>
        <dc:subject>mania</dc:subject>
        <dc:subject>oromandibular dystonia</dc:subject>
        <dc:subject>tardive dyskinesia</dc:subject>
        <dc:subject>tongue disease</dc:subject>
        <dc:subject>patient monitoring</dc:subject>
        <dc:subject>placebo</dc:subject>
        <dc:subject>bipolar II disorder</dc:subject>
        <dc:subject>dystonia</dc:subject>
        <dc:subject>parkinsonism</dc:subject>
        <dc:subject>restless legs syndrome</dc:subject>
        <dc:subject>Male</dc:subject>
        <dc:subject>Middle Aged</dc:subject>
        <dc:subject>Nervous System Diseases</dc:subject>
        <dc:subject>anxiety disorder</dc:subject>
        <dc:subject>Young Adult</dc:subject>
        <dc:subject>anosognosia</dc:subject>
        <dc:subject>antisocial personality disorder</dc:subject>
        <dc:subject>Asenapine</dc:subject>
        <dc:subject>binge eating disorder</dc:subject>
        <dc:subject>Bipolar disorder</dc:subject>
        <dc:subject>burning mouth syndrome</dc:subject>
        <dc:subject>cogwheel rigidity</dc:subject>
        <dc:subject>dibenzo[a,d]cycloheptene derivative</dc:subject>
        <dc:subject>Dibenzocycloheptenes</dc:subject>
        <dc:subject>disorders of acid base balance</dc:subject>
        <dc:subject>dyskinesia</dc:subject>
        <dc:subject>enuresis</dc:subject>
        <dc:subject>fused heterocyclic rings</dc:subject>
        <dc:subject>glossoptosis</dc:subject>
        <dc:subject>Heterocyclic Compounds, 4 or More Rings</dc:subject>
        <dc:subject>larynx disorder</dc:subject>
        <dc:subject>logorrhea</dc:subject>
        <dc:subject>major depression</dc:subject>
        <dc:subject>Mental Disorders</dc:subject>
        <dc:subject>neuroleptic malignant syndrome</dc:subject>
        <dc:subject>obsessive compulsive disorder</dc:subject>
        <dc:subject>paranoid schizophrenia</dc:subject>
        <dc:subject>posttraumatic stress disorder</dc:subject>
        <dc:subject>tooth discoloration</dc:subject>
        <dc:title>Safety assessment of asenapine in the FAERS database: real adverse event analysis and discussion on neurological and psychiatric side effects</dc:title>
        <dcterms:abstract>Purpose: This study aims to comprehensively assess the safety of Asenapine by conducting an comprehensive statistical analysis of adverse event reports in the FAERS database, with a particular focus on potential adverse reactions related to its use in the treatment of psychiatric disorders. Methods: Event reports from the first quarter of 2009 to the third quarter of 2023 were collected and analyzed. Detailed examinations of gender, age, reporter identity, and other aspects were conducted to reveal the fundamental characteristics of Asenapine-related adverse events. Signal mining techniques were employed to systematically evaluate various adverse reactions associated with Asenapine. Results: The study found that adverse event reports involving Asenapine were more common among female patients, with the age group mainly distributed between 18 and 45 years. Physicians were the primary reporters of adverse events, and psychiatric disorders, neurological disorders, and gastrointestinal disorders were the most common areas affected by adverse reactions. In addition to known adverse reactions, potential risks not mentioned in the drug label were identified, such as anosognosia, attentional drift, and psychogenic compensation disorder. Conclusion: Asenapine carries the risk of various adverse reactions alongside its therapeutic effects. In clinical practice, physicians should closely monitor the occurrence of neurological disorders, psychiatric disorders, and gastrointestinal system disorders. © The Author(s) 2024.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281101985</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85201249867&amp;doi=10.1186%2fs40360-024-00772-4&amp;partnerID=40&amp;md5=607d1eb0eabf1aaf4c14af429e0c2b4a</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:20506511%20(ISSN)">
        <prism:volume>25</prism:volume>
        <dc:title>BMC Pharmacology and Toxicology</dc:title>
        <dc:identifier>DOI 10.1186/s40360-024-00772-4</dc:identifier>
        <prism:number>1</prism:number>
        <dcterms:alternative>BMC Pharmacol. Toxicol.</dcterms:alternative>
        <dc:identifier>ISSN 20506511 (ISSN)</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1303">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: G. Zhu; Lishui Second People’s Hospital, Lishui, China; email: hzzcer@126.com; G. Xie; Department of Neurology, The Affiliated Lihuili Hospital of Ningbo University, Ningbo University, Ningbo, China; email: drxie01@qq.com&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Excluído - Não utiliza DM,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85197239227&amp;doi=10.1080%2f14740338.2023.2293200&amp;partnerID=40&amp;md5=55f74e17668ad09815037fb1c88b5c43">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>23</prism:volume>
                <dc:title>Expert Opinion on Drug Safety</dc:title>
                <dc:identifier>DOI 10.1080/14740338.2023.2293200</dc:identifier>
                <prism:number>9</prism:number>
                <dcterms:alternative>Expert Opin. Drug Saf.</dcterms:alternative>
                <dc:identifier>ISSN 14740338 (ISSN)</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lv</foaf:surname>
                        <foaf:givenName>B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shi</foaf:surname>
                        <foaf:givenName>A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Pan</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1304"/>
        <dc:subject>Article</dc:subject>
        <dc:subject>data analysis</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>factual database</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>odds ratio</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>postmarketing surveillance</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>epidemiology</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>United States Food and Drug Administration</dc:subject>
        <dc:subject>sex difference</dc:subject>
        <dc:subject>Data Mining</dc:subject>
        <dc:subject>Databases, Factual</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>drug utilization</dc:subject>
        <dc:subject>heart disease</dc:subject>
        <dc:subject>Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>computer simulation</dc:subject>
        <dc:subject>Computer Simulation</dc:subject>
        <dc:subject>drug interaction</dc:subject>
        <dc:subject>Drug Interactions</dc:subject>
        <dc:subject>Female</dc:subject>
        <dc:subject>Male</dc:subject>
        <dc:subject>Confounding Factors, Epidemiologic</dc:subject>
        <dc:subject>conceptual framework</dc:subject>
        <dc:subject>Bias</dc:subject>
        <dc:subject>simulation</dc:subject>
        <dc:subject>procedures</dc:subject>
        <dc:subject>statistical model</dc:subject>
        <dc:subject>midazolam</dc:subject>
        <dc:subject>confounding bias</dc:subject>
        <dc:subject>confounding effects</dc:subject>
        <dc:subject>FAERS (FDA Adverse Events Reporting System)</dc:subject>
        <dc:subject>false discovery rate</dc:subject>
        <dc:subject>individual effects</dc:subject>
        <dc:subject>model driven</dc:subject>
        <dc:subject>model driven reporting odds ratio</dc:subject>
        <dc:subject>Models, Statistical</dc:subject>
        <dc:subject>Odds Ratio</dc:subject>
        <dc:subject>poisson regression</dc:subject>
        <dc:subject>Poisson regression</dc:subject>
        <dc:subject>Product Surveillance, Postmarketing</dc:subject>
        <dc:subject>sex factor</dc:subject>
        <dc:subject>Sex Factors</dc:subject>
        <dc:subject>spontaneous adverse event reporting database</dc:subject>
        <dc:subject>statistical bias</dc:subject>
        <dc:title>Model driven method for exploring individual and confounding effects in spontaneous adverse event reporting databases</dc:title>
        <dcterms:abstract>Background: Spontaneous Adverse Event Reporting (SAER) databases play a crucial role in post-marketing drug surveillance. However, the traditional model-free disproportionality analysis has been challenged by the insufficiency in investigating subgroup and confounders. These issues result in significant low-precision and biases in data mining for SAER. Methods: The Model-Driven Reporting Odds Ratio (MD-ROR) was proposed to bridge the gap between SAER database and explainable models for exploring individual and confounding effects. MD-ROR is grounded in a well-designed model, rather than a 2 × 2 cross table, for estimating AE-drug signals. Consequently, individual and confounding effects can be parameterized based on these models. We employed simulation data and the FDA Adverse Event Reporting System (FAERS) database. Result: The simulated data indicated the subgroup effects estimated by MD-ROR were unbiased and efficient. Moreover, the adjusted-MD-ROR demonstrated greater robustness against confounding biases than the crude ROR. Applying our method to the FAERS database suggested higher occurrences of drug interactions and cardiac adverse events induced by Midazolam in females compared to males. Conclusion: The study underscored that MD-ROR holds promise as a method for investigating individual and confounding effects in SAER databases. © 2024 Informa UK Limited, trading as Taylor &amp; Francis Group.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281101981</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85197239227&amp;doi=10.1080%2f14740338.2023.2293200&amp;partnerID=40&amp;md5=55f74e17668ad09815037fb1c88b5c43</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>1173-1181</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1304">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: A. Shi; Department of Pharmacy, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, China; email: sam740411@163.com; CODEN: EODSA&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Desenvolvimento do método,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2017362404&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>14</prism:volume>
                <dc:title>Clinical Epidemiology</dc:title>
                <dc:identifier>DOI 10.2147/CLEP.S365513</dc:identifier>
                <dcterms:alternative>Clin. Epidemiol.</dcterms:alternative>
                <dc:identifier>ISSN 1179-1349</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shu</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>He</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>P.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>Q.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1305"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data analysis</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>odds ratio</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>injection site reaction</dc:subject>
        <dc:subject>FAERS</dc:subject>
        <dc:subject>RISK</dc:subject>
        <dc:subject>nausea</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>anemia</dc:subject>
        <dc:subject>creatinine</dc:subject>
        <dc:subject>ascites</dc:subject>
        <dc:subject>pleura effusion</dc:subject>
        <dc:subject>creatinine blood level</dc:subject>
        <dc:subject>dysgeusia</dc:subject>
        <dc:subject>glomerulus filtration rate</dc:subject>
        <dc:subject>hematologic disease</dc:subject>
        <dc:subject>musculoskeletal disease</dc:subject>
        <dc:subject>bone marrow suppression</dc:subject>
        <dc:subject>kidney failure</dc:subject>
        <dc:subject>blood toxicity</dc:subject>
        <dc:subject>bone marrow depression</dc:subject>
        <dc:subject>cytopenia</dc:subject>
        <dc:subject>ileus</dc:subject>
        <dc:subject>leukocyte count</dc:subject>
        <dc:subject>back propagation neural network</dc:subject>
        <dc:subject>decreased appetite</dc:subject>
        <dc:subject>pneumonia</dc:subject>
        <dc:subject>peripheral neuropathy</dc:subject>
        <dc:subject>platelet count</dc:subject>
        <dc:subject>thrombocytopenia</dc:subject>
        <dc:subject>interstitial lung disease</dc:subject>
        <dc:subject>statistical analysis</dc:subject>
        <dc:subject>hemoglobin</dc:subject>
        <dc:subject>taste disorder</dc:subject>
        <dc:subject>gene mutation</dc:subject>
        <dc:subject>hemolytic anemia</dc:subject>
        <dc:subject>blood cell count</dc:subject>
        <dc:subject>hydronephrosis</dc:subject>
        <dc:subject>pancytopenia</dc:subject>
        <dc:subject>erythrocyte count</dc:subject>
        <dc:subject>Pneumocystis pneumonia</dc:subject>
        <dc:subject>pure red cell anemia</dc:subject>
        <dc:subject>neutrophil count</dc:subject>
        <dc:subject>hypophagia</dc:subject>
        <dc:subject>abdominal mass</dc:subject>
        <dc:subject>bone marrow disease</dc:subject>
        <dc:subject>BRCA1/2 MUTATION</dc:subject>
        <dc:subject>CA 125 antigen</dc:subject>
        <dc:subject>CA 15-3 antigen</dc:subject>
        <dc:subject>CA 19-9 antigen</dc:subject>
        <dc:subject>creatine</dc:subject>
        <dc:subject>creatinine clearance</dc:subject>
        <dc:subject>dermatomyositis</dc:subject>
        <dc:subject>electrolyte</dc:subject>
        <dc:subject>electrolyte blood level</dc:subject>
        <dc:subject>erythema nodosum</dc:subject>
        <dc:subject>folic acid deficiency</dc:subject>
        <dc:subject>hematocrit</dc:subject>
        <dc:subject>intestine obstruction</dc:subject>
        <dc:subject>large intestine disease</dc:subject>
        <dc:subject>liver cyst</dc:subject>
        <dc:subject>lung tumor</dc:subject>
        <dc:subject>macrocytic anemia</dc:subject>
        <dc:subject>magnesium</dc:subject>
        <dc:subject>magnesium blood level</dc:subject>
        <dc:subject>mean corpuscular volume</dc:subject>
        <dc:subject>megalocytosis</dc:subject>
        <dc:subject>METAANALYSIS</dc:subject>
        <dc:subject>olaparib</dc:subject>
        <dc:subject>onset age</dc:subject>
        <dc:subject>PARP inhibitor</dc:subject>
        <dc:subject>PARP INHIBITORS</dc:subject>
        <dc:subject>pelvis tumor</dc:subject>
        <dc:subject>porokeratosis</dc:subject>
        <dc:subject>prostate specific antigen</dc:subject>
        <dc:subject>RELAPSED OVARIAN-CANCER</dc:subject>
        <dc:subject>small intestine obstruction</dc:subject>
        <dc:subject>study design</dc:subject>
        <dc:subject>TOXICITIES</dc:subject>
        <dc:subject>tumor marker</dc:subject>
        <dc:subject>tumor suppressor gene</dc:subject>
        <dc:title>A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System</dc:title>
        <dcterms:abstract>Background: Olaparib, the world’s first poly ADP-ribose polymerase (PARP) inhibitor (PARPi), has been approved for treatment of ovarian cancer, breast cancer, pancreatic cancer and prostate cancer by FDA. The current study was to assess olaparib-related adverse events (AEs) of real-world through data mining of the US Food and Drug Administration Adverse Event Reporting System (FAERS). Methods: Disproportionality analyses, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN) and the multi-item gamma Poisson shrinker (MGPS) algorithms were employed to quantify the signals of olaparib-associated AEs. Results: Out of 8,450,009 reports collected from the FAERS database, 6402 reports of olaparib-associated AEs were identified. A total of 118 significant disproportionality preferred terms (PTs) conforming to the four algorithms simultaneously were retained. The most common AEs included anemia, thrombocytopenia, nausea, decreased appetite, blood creatinine increased and dermatomyositis, which were corresponding to those reported in the specification and clinical trials. Unexpected significant AEs as interstitial lung disease, Pneumocystis jirovecii pneumonia, folate deficiency, renal impairment and intestinal obstruction might also occur. The median onset time of olaparib-related AEs was 61 days (interquartile range [IQR] 14–182 days), and most of the cases occurred within the first 1 month after olaparib initiation. Conclusion: Results of our study were consistent with clinical observations, and we also found potential new and unexpected AEs signals for olaparib, suggesting prospective clinical studies were needed to confirm these results and illustrate their relationship. Our results could provide valuable evidence for further safety studies of olaparib.</dcterms:abstract>
        <dc:date>2022</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281101959</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2017362404&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>789-802</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1305">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 96; Correspondence Address: Q. Zhang; Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, No. 1277 Jiefang Avenue, 430022, China; email: qilinzhang88@163.com&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;92&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;95&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;32&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L646797602&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>15</prism:volume>
                <dc:title>Scientific reports</dc:title>
                <dc:identifier>DOI 10.1038/s41598-025-92330-z</dc:identifier>
                <prism:number>1</prism:number>
                <dcterms:alternative>Sci Rep</dcterms:alternative>
                <dc:identifier>ISSN 2045-2322</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gao</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Cao</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1306"/>
        <dc:subject>acute kidney failure</dc:subject>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>factual database</dc:subject>
        <dc:subject>FAERS database</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>hypertension</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>young adult</dc:subject>
        <dc:subject>*Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>Adult</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>adverse events</dc:subject>
        <dc:subject>Aged</dc:subject>
        <dc:subject>Algorithms</dc:subject>
        <dc:subject>cardiovascular disease</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>Computational Biology</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>lung hemorrhage</dc:subject>
        <dc:subject>outcome assessment</dc:subject>
        <dc:subject>cardiopulmonary insufficiency</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>dizziness</dc:subject>
        <dc:subject>epidemiology</dc:subject>
        <dc:subject>FAERS</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>clinical practice</dc:subject>
        <dc:subject>insomnia</dc:subject>
        <dc:subject>nausea</dc:subject>
        <dc:subject>observational study</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>vomiting</dc:subject>
        <dc:subject>amnesia</dc:subject>
        <dc:subject>gastrointestinal disease</dc:subject>
        <dc:subject>information processing</dc:subject>
        <dc:subject>liver toxicity</dc:subject>
        <dc:subject>neurologic disease</dc:subject>
        <dc:subject>seizure</dc:subject>
        <dc:subject>atrial fibrillation</dc:subject>
        <dc:subject>lung edema</dc:subject>
        <dc:subject>unclassified drug</dc:subject>
        <dc:subject>risk assessment</dc:subject>
        <dc:subject>very elderly</dc:subject>
        <dc:subject>Alzheimer disease</dc:subject>
        <dc:subject>amoxicillin</dc:subject>
        <dc:subject>Animals</dc:subject>
        <dc:subject>antineoplastic agent</dc:subject>
        <dc:subject>Adverse event</dc:subject>
        <dc:subject>Adverse events</dc:subject>
        <dc:subject>anemia</dc:subject>
        <dc:subject>chill</dc:subject>
        <dc:subject>Data mining</dc:subject>
        <dc:subject>Data Mining</dc:subject>
        <dc:subject>Databases, Factual</dc:subject>
        <dc:subject>diarrhea</dc:subject>
        <dc:subject>malignant neoplasm</dc:subject>
        <dc:subject>cystitis</dc:subject>
        <dc:subject>heart disease</dc:subject>
        <dc:subject>case study</dc:subject>
        <dc:subject>confidence interval</dc:subject>
        <dc:subject>disease association</dc:subject>
        <dc:subject>electronic health record</dc:subject>
        <dc:subject>Electronic Health Records</dc:subject>
        <dc:subject>drug</dc:subject>
        <dc:subject>drug therapy</dc:subject>
        <dc:subject>Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>infection</dc:subject>
        <dc:subject>infestation</dc:subject>
        <dc:subject>injury</dc:subject>
        <dc:subject>intoxication</dc:subject>
        <dc:subject>overall survival</dc:subject>
        <dc:subject>fever</dc:subject>
        <dc:subject>neoplasm</dc:subject>
        <dc:subject>dupilumab</dc:subject>
        <dc:subject>Female</dc:subject>
        <dc:subject>rash</dc:subject>
        <dc:subject>deep learning</dc:subject>
        <dc:subject>Deep learning</dc:subject>
        <dc:subject>Pharmacovigilance</dc:subject>
        <dc:subject>statistical analysis</dc:subject>
        <dc:subject>Male</dc:subject>
        <dc:subject>Middle Aged</dc:subject>
        <dc:subject>monoclonal antibody</dc:subject>
        <dc:subject>nivolumab</dc:subject>
        <dc:subject>comorbidity</dc:subject>
        <dc:subject>*Electronic Health Records</dc:subject>
        <dc:subject>Area Under Curve</dc:subject>
        <dc:subject>Stevens Johnson syndrome</dc:subject>
        <dc:subject>central nervous system</dc:subject>
        <dc:subject>drug overdose</dc:subject>
        <dc:subject>vedolizumab</dc:subject>
        <dc:subject>Young Adult</dc:subject>
        <dc:subject>drug mechanism</dc:subject>
        <dc:subject>*Algorithms</dc:subject>
        <dc:subject>Data Mining/methods</dc:subject>
        <dc:subject>drug effects</dc:subject>
        <dc:subject>prediction</dc:subject>
        <dc:subject>procedures</dc:subject>
        <dc:subject>receiver operating characteristic</dc:subject>
        <dc:subject>ROC Curve</dc:subject>
        <dc:subject>natural language processing</dc:subject>
        <dc:subject>Natural Language Processing</dc:subject>
        <dc:subject>lisinopril</dc:subject>
        <dc:subject>study design</dc:subject>
        <dc:subject>*Deep Learning</dc:subject>
        <dc:subject>Breast cancer</dc:subject>
        <dc:subject>Deep Learning</dc:subject>
        <dc:subject>drug development</dc:subject>
        <dc:subject>drug repositioning</dc:subject>
        <dc:subject>electronic health record note</dc:subject>
        <dc:subject>generative pretrained transformer</dc:subject>
        <dc:subject>large language model</dc:subject>
        <dc:subject>molecular dynamics</dc:subject>
        <dc:subject>Natural language processing</dc:subject>
        <dc:subject>preschool child</dc:subject>
        <dc:subject>progression free survival</dc:subject>
        <dc:subject>public health</dc:subject>
        <dc:subject>relation extraction</dc:subject>
        <dc:subject>Relation extraction</dc:subject>
        <dc:subject>Retrospective Studies</dc:subject>
        <dc:subject>Semantics</dc:subject>
        <dc:subject>single and multidomain</dc:subject>
        <dc:subject>Software</dc:subject>
        <dc:title>Analysis and mining of Dupilumab adverse events based on FAERS database</dc:title>
        <dcterms:abstract>This study aims to explore potential adverse events (AEs) related to Dupilumab using data from the US FDA Adverse Event Reporting System (FAERS) database. The FAERS database from Q2 2017 to Q4 2023 was mined for AEs related to Dupilumab. The types of AEs reported, along with gender, age distribution, and severity, were evaluated. Signal detection methods including Reporting Odds Ratio, Proportional Reporting Ratio, Bayesian Confidence Propagation Neural Network, and Empirical Bayesian Geometric Mean were used. A total of 11,547,571 AE reports were collected, with 5335 reports suspected of being related to Dupilumab, identifying 307 Preferred Terms involving 27 System Organ Classes. Reports from female patients outnumbered males (56.08% vs. 34.65%). Patients aged 45-65 years reported the most events (21.34%). The number of reports increased significantly in 2023 (34.25%) compared to 2017 (0.42%), with the highest reporting rate from the US (98.07%). Common AEs included Pruritus, Product use in unapproved indication, and Rash, with Product dose omission issue indicating widespread misuse of Dupilumab. High signal strength AEs included Rebound atopic dermatitis, Rebound eczema, Dermatitis atopic, and Dry skin; injection site AEs like Injection site dryness and eczema; new potential AEs such as Dry eye, Eye pruritus, Ocular hyperaemia, Eye irritation, Conjunctivitis, Vision blurred, and Sleep disorder. This study reveals various potential AEs associated with Dupilumab, including newly identified risks. Future research needs to delve deeper into the safety of Dupilumab to better guide its clinical application.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281101915</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L646797602&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>8597</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1306">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: C. Liu; Jiangyin People’s Hospital Affiliated to Southeast University, Jiangyin, China; email: cy_liu111@139.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: D. Chen; Department of Anesthesiology, The Affiliated Lihuili Hospital, Ningbo University, Ningbo, Zhejiang Province, China; email: cdd202366@hotmail.com; CODEN: MEDIA&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: M. Russom; Eritrean Pharmacovigilance Centre, National Medicines and Food Administration, Asmara, Eritrea; email: satiswt@gmail.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: Z. Xiang; Department of Laboratory Medicine, The Second Xiangya Hospital, Central South University, Changsha, 139 Middle Renmin Road, 410011, China; email: xiangzhongyuan@csu.edu.cn&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 5; Correspondence Address: L. Ding; Department of Biotechnology and Biomedicine, Technical University of Denmark, Lyngby, Denmark; email: lidi@dtu.dk&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 8; Correspondence Address: V.A. Rudrapatna; Bakar Computational Health Sciences Institute, San Francisco, United States; email: vivek.rudrapatna@ucsf.edu; CODEN: CLPTA&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 19; Correspondence Address: H. Yu; Department of Computer Science, University of Massachusetts Lowell, Lowell, 1 University Ave, 01854, United States; email: hong_yu@uml.edu; CODEN: JAMAF&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 28; Correspondence Address: J. Zwaveling; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, Netherlands; email: J.zwaveling@lumc.nl; CODEN: CLPTA&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 33; CODEN: POLNC&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;15&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;28&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;6&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;6&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;27&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;25&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;26&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;27&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="#item_1119">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1482-1826"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yu</foaf:surname>
                        <foaf:givenName>ZC</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhu</foaf:surname>
                        <foaf:givenName>HB</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>HJ</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhu</foaf:surname>
                        <foaf:givenName>LF</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liao</foaf:surname>
                        <foaf:givenName>XL</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1308"/>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>CANCER</dc:subject>
        <dc:subject>CHEMOTHERAPY</dc:subject>
        <dc:subject>DISPROPORTIONALITY</dc:subject>
        <dc:subject>ALGORITHMS</dc:subject>
        <dc:subject>BEVACIZUMAB</dc:subject>
        <dc:subject>CARCINOMA</dc:subject>
        <dc:subject>SIGNAL-DETECTION</dc:subject>
        <dc:subject>gastrointestinal perforation</dc:subject>
        <dc:subject>GROWTH-FACTOR</dc:subject>
        <dc:subject>IMMUNE CHECKPOINT INHIBITORS</dc:subject>
        <dc:subject>MECHANISMS</dc:subject>
        <dc:subject>novel antineoplastic agents</dc:subject>
        <dc:subject>real-world study</dc:subject>
        <dc:title>Gastrointestinal perforation associated with novel antineoplastic agents: A real-world study based on the FDA Adverse Event Reporting System</dc:title>
        <dcterms:abstract>Purpose: Gastrointestinal perforation (GIP) is a fatal adverse event (AE). The AE of GIP induced by novel antineoplastic agents has attracted attention recently. We aimed to explore the AE signals of GIP related to novel antineoplastic agents comprehensively based on the FDA Adverse Event Reporting System (FAERS).Methods: The FAERS database containing 71 quarters of records was used for analysis. Reporting odds ratio (ROR), information component (IC), and empirical Bayesian geometric mean (EBGM) were utilized to evaluate the signals of GIP associated with novel antineoplastic drugs. Standardization of drug names was by employing MedEx-UIMA software and Python. Data analysis and visualization were performed using MySQL Workbench and R software.Results: After cleaning and handling the data, 5226 GIP cases were identified that were associated with new antineoplastic medications, where these agents were the main suspected contributors. A total of 37 novel antineoplastic drugs were detected with signals of GIP for ROR and IC. Only 22 drugs showed statistically significant signals for EBGM. We found the GIP signals of 22 novel antineoplastic drugs overlapped for the 3 indicators, including anti-vascular endothelial growth factor/vascular endothelial growth factor receptor, anti-endothelial growth factor receptor, immune checkpoint inhibitors, and so on.Conclusion: The potential risk of GIP associated with several novel antineoplastic agents was identified through data mining, which provided valuable information on the safety risks associated with GIP among these drugs. The potential threat of GIP should be recognized and managed properly when using these novel antineoplastic agents.</dcterms:abstract>
        <dc:date>2023</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281088805</dc:coverage>
        <dcterms:dateSubmitted>0002-01-01</dcterms:dateSubmitted>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1482-1826">
        <prism:volume>26</prism:volume>
        <dc:title>JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES</dc:title>
        <dc:identifier>DOI 10.3389/jpps.2023.11235</dc:identifier>
        <dc:identifier>ISSN 1482-1826</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1308">
        <rdf:value>&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;5&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;5&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;59&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="#item_1120">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1664-0640"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Koniuszewski</foaf:surname>
                        <foaf:givenName>F</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Vogel</foaf:surname>
                        <foaf:givenName>FD</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Dajic</foaf:surname>
                        <foaf:givenName>I</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Seidel</foaf:surname>
                        <foaf:givenName>T</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kunze</foaf:surname>
                        <foaf:givenName>M</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Willeit</foaf:surname>
                        <foaf:givenName>M</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ernst</foaf:surname>
                        <foaf:givenName>M</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1309"/>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>adverse events</dc:subject>
        <dc:subject>benzodiazepine</dc:subject>
        <dc:subject>FDA adverse event reporting system</dc:subject>
        <dc:subject>DISPROPORTIONALITY ANALYSIS</dc:subject>
        <dc:subject>SIGNAL-DETECTION</dc:subject>
        <dc:subject>A RECEPTOR</dc:subject>
        <dc:subject>benzodiazepine binding sites</dc:subject>
        <dc:subject>DATA MINING APPROACH</dc:subject>
        <dc:subject>DELTA-SUBUNIT</dc:subject>
        <dc:subject>GAMMA-AMINOBUTYRIC-ACID</dc:subject>
        <dc:subject>NONMEDICAL USE</dc:subject>
        <dc:subject>ORAL-CONTRACEPTIVES</dc:subject>
        <dc:subject>PRESYNAPTIC GABA(A) RECEPTORS</dc:subject>
        <dc:subject>sex differences</dc:subject>
        <dc:subject>side effects</dc:subject>
        <dc:subject>TRIPLICATE PRESCRIPTION</dc:subject>
        <dc:subject>Z-drugs</dc:subject>
        <dc:title>Navigating the complex landscape of benzodiazepine- and Z-drug diversity: insights from comprehensive FDA adverse event reporting system analysis and beyond</dc:title>
        <dcterms:abstract>IntroductionMedications which target benzodiazepine (BZD) binding sites of GABAA receptors (GABAARs) have been in widespread use since the nineteen-sixties. They carry labels as anxiolytics, hypnotics or antiepileptics. All benzodiazepines and several nonbenzodiazepine Z-drugs share high affinity binding sites on certain subtypes of GABAA receptors, from which they can be displaced by the clinically used antagonist flumazenil. Additional binding sites exist and overlap in part with sites used by some general anaesthetics and barbiturates. Despite substantial preclinical efforts, it remains unclear which receptor subtypes and ligand features mediate individual drug effects. There is a paucity of literature comparing clinically observed adverse effect liabilities across substances in methodologically coherent ways. MethodsIn order to examine heterogeneity in clinical outcome, we screened the publicly available U.S. FDA adverse event reporting system (FAERS) database for reports of individual compounds and analyzed them for each sex individually with the use of disproportionality analysis. The complementary use of physico-chemical descriptors provides a molecular basis for the analysis of clinical observations of wanted and unwanted drug effects. Results and DiscussionWe found a multifaceted FAERS picture, and suggest that more thorough clinical and pharmacoepidemiologic investigations of the heterogenous side effect profiles for benzodiazepines and Z-drugs are needed. This may lead to more differentiated safety profiles and prescription practice for particular compounds, which in turn could potentially ease side effect burden in everyday clinical practice considerably. From both preclinical literature and pharmacovigilance data, there is converging evidence that this very large class of psychoactive molecules displays a broad range of distinctive unwanted effect profiles - too broad to be explained by the four canonical, so-called &quot;diazepam-sensitive high-affinity interaction sites&quot;. The substance-specific signatures of compound effects may partly be mediated by phenomena such as occupancy of additional binding sites, and/or synergistic interactions with endogenous substances like steroids and endocannabinoids. These in turn drive the wanted and unwanted effects and sex differences of individual compounds.</dcterms:abstract>
        <dc:date>2023</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281088803</dc:coverage>
        <dcterms:dateSubmitted>0006-01-01</dcterms:dateSubmitted>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1664-0640">
        <prism:volume>14</prism:volume>
        <dc:title>FRONTIERS IN PSYCHIATRY</dc:title>
        <dc:identifier>DOI 10.3389/fpsyt.2023.1188101</dc:identifier>
        <dc:identifier>ISSN 1664-0640</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1309">
        <rdf:value>&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;3&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;154&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="#item_1121">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>13</prism:volume>
                <dc:title>FRONTIERS IN PHARMACOLOGY</dc:title>
                <dc:identifier>DOI 10.3389/fphar.2022.912256</dc:identifier>
                <dc:identifier>ISSN 1663-9812</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhao</foaf:surname>
                        <foaf:givenName>QF</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ma</foaf:surname>
                        <foaf:givenName>P</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Fu</foaf:surname>
                        <foaf:givenName>PS</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>JY</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>KJ</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>L</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yang</foaf:surname>
                        <foaf:givenName>Y</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1310"/>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>DISEASE</dc:subject>
        <dc:subject>DOUBLE-BLIND</dc:subject>
        <dc:subject>myelodysplastic syndrome</dc:subject>
        <dc:subject>acute myeloid leukemia</dc:subject>
        <dc:subject>METAANALYSIS</dc:subject>
        <dc:subject>MAINTENANCE THERAPY</dc:subject>
        <dc:subject>OLAPARIB</dc:subject>
        <dc:subject>OVARIAN-CANCER</dc:subject>
        <dc:subject>PARP inhibitors</dc:subject>
        <dc:subject>real-world</dc:subject>
        <dc:title>Myelodysplastic Syndrome/Acute Myeloid Leukemia Following the Use of Poly-ADP Ribose Polymerase (PARP) Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data</dc:title>
        <dcterms:abstract>Background and purpose: poly-ADP ribose polymerase (PARP) inhibitors show impressive efficacy in a range of tumors. However, concerns about rare and fatal adverse events, including myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML) have arisen. The aim of this study was to excavate and evaluate the risk of PARP inhibitors causing MDS and AML based on real-world data from two international pharmacovigilance databases.Methods: We analyzed adverse event (AE) reports of four PARP inhibitors (olaparib, niraparib, rucaparib and talazoparib) associated with MDS and AML from the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) and EudraVigilance (EV) databases between 1 October 2014, and 30 September 2021, including demographic characteristics, fatality and times to onset. Three different data mining algorithms were used to detect the signals of PARP inhibitors associated with MDS and AML.Results: In total, 16,710 and 11,937 PARP inhibitor AE reports were found in the FAERS and EV databases, of which 332 and 349 were associated with MDS and AML, respectively. The median latencies of MDS and AML associated with PARP inhibitors were 211 [interquartile range (IQR) 93.5-491.25] days and 355 (IQR 72.00-483.50) days, respectively. The average fatality rates of MDS and AML caused by the four PARP inhibitors were 37.96 and 60.41%, respectively, in the FAERS database, while those in the EV database were 5.83 and 12.16%, respectively. Based on the criteria used for the three algorithms, a significant disproportionate association was found between PARP inhibitors as a drug class and MDS/AML. Notably, the risk of MDS was much higher than that of AML. Olaparib appeared to have a stronger association with MDS and AML than did other PARP inhibitors.Conclusion: In the real world, PARP inhibitors increase the risk of MDS and AML, which can result in high mortality and tend to occur during long-term use. Our findings provide objective evidence for the postmarketing safety of PARP inhibitors.</dcterms:abstract>
        <dc:date>2022</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281088801</dc:coverage>
        <dcterms:dateSubmitted>0006-01-01</dcterms:dateSubmitted>
    </bib:Article>
    <bib:Memo rdf:about="#item_1310">
        <rdf:value>&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;21&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;21&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;37&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Excluído - Não utiliza DM,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="#item_1122">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>15</prism:volume>
                <dc:title>FRONTIERS IN PHARMACOLOGY</dc:title>
                <dc:identifier>DOI 10.3389/fphar.2024.1251961</dc:identifier>
                <dc:identifier>ISSN 1663-9812</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Pan</foaf:surname>
                        <foaf:givenName>YY</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>Y</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zheng</foaf:surname>
                        <foaf:givenName>YF</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>J</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>J</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1311"/>
        <dc:subject>data mining</dc:subject>
        <dc:subject>adverse events</dc:subject>
        <dc:subject>disproportionality analysis</dc:subject>
        <dc:subject>EFFICACY</dc:subject>
        <dc:subject>ASPIRIN</dc:subject>
        <dc:subject>ASSOCIATION</dc:subject>
        <dc:subject>CLOPIDOGREL</dc:subject>
        <dc:subject>FDA adverse event reporting system</dc:subject>
        <dc:subject>SAFETY</dc:subject>
        <dc:subject>ticagrelor</dc:subject>
        <dc:subject>OUTCOMES</dc:subject>
        <dc:subject>ACUTE CORONARY SYNDROME</dc:subject>
        <dc:subject>ANTAGONIST</dc:subject>
        <dc:subject>PLATELET INHIBITION</dc:subject>
        <dc:subject>PLATO</dc:subject>
        <dc:title>A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor</dc:title>
        <dcterms:abstract>Background: Ticagrelor is a commonly used antiplatelet agent, but due to the stringent criteria for trial population inclusion and the limited sample size, its safety profile has not been fully elucidated.Method: We utilized OpenVigil 2.1 to query the FDA Adverse Event Reporting System database and retrieved reports by the generic name &quot;ticagrelor&quot; published between 1 October 2010 and 31 March 2023. Adverse drug events (ADEs) were classified and described according to the preferred terms and system organ classes in the Medical Dictionary of Regulatory Activity. Proportional reporting ratio (PRR), reporting odds ratio (ROR) and Bayesian Confidence Propagation Neural Network (BCPNN) were used to detect signals.Results: The number of ADE reports with ticagrelor as the primary suspect drug was 12,909. The top three ADEs were dyspnea [1824 reports, ROR 7.34, PRR 6.45, information component (IC) 2.68], chest pain (458 reports, ROR 5.43, PRR 5.27, IC 2.39), and vascular stent thrombosis (406 reports, ROR 409.53, PRR 396.68, IC 8.02). The highest ROR, 630.24, was found for &quot;vascular stent occlusion&quot;. Cardiac arrest (137 reports, ROR 3.41, PRR 3.39, IC 1.75), atrial fibrillation (99 reports, ROR 2.05, PRR 2.04, IC 1.03), asphyxia (101 reports, ROR 23.60, PRR 23.43, IC 4.51), and rhabdomyolysis (57 reports, ROR 2.75, PRR 2.75, IC 1.45) were suspected new adverse events of ticagrelor.Conclusion: The FAERS database produced potential signals associated with ticagrelor that have not been recorded in the package inserts, such as cardiac arrest, atrial fibrillation, asphyxia, and rhabdomyolysis. Further clinical surveillance is needed to quantify and validate potential hazards associated with ticagrelor-related adverse events.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281088799</dc:coverage>
        <dcterms:dateSubmitted>0004-01-01</dcterms:dateSubmitted>
    </bib:Article>
    <bib:Memo rdf:about="#item_1311">
        <rdf:value>&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;3&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;3&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;47&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="#item_1123">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:2405-8440"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yu</foaf:surname>
                        <foaf:givenName>Z</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Luo</foaf:surname>
                        <foaf:givenName>J</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wei</foaf:surname>
                        <foaf:givenName>HS</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1314"/>
        <dc:subject>MANAGEMENT</dc:subject>
        <dc:subject>BCPNN</dc:subject>
        <dc:subject>CARCINOMA</dc:subject>
        <dc:subject>lenvatinib</dc:subject>
        <dc:subject>PATIENT</dc:subject>
        <dc:subject>EBGM</dc:subject>
        <dc:subject>PRR</dc:subject>
        <dc:subject>ROR</dc:subject>
        <dc:title>Novel insights into post-marketing adverse events associated with lenvatinib: A comprehensive analysis utilizing the FAERS database</dc:title>
        <dcterms:abstract>Purpose: The primary aim of this study was to closely monitor and identify adverse events (AEs) linked to lenvatinib, a pharmacotherapeutic agent employed for the management of renal cell carcinoma, thyroid cancer, and hepatocellular carcinoma. The ultimate goal was to optimize patient safety and provide evidence -based guidance for the appropriate utilization of this medication. Methods: A comprehensive collection and analysis of reports from the FDA Adverse Event Reporting System (FAERS) database was conducted, encompassing the period from the first quarter of 2015 to the first quarter of 2023. Disproportionality analysis, employing robust algorithms including ROR, PRR, BCPNN, and EBGM was employed for effective data mining to quantify signals associated with lenvatinib-related AEs. Results: Among the collected reports, a total of 15,193 cases were identified where lenvatinib was the &quot;primary suspected (PS)&quot; drug, resulting in 50,508 lenvatinib-induced AEs. An analysis was conducted to examine the occurrence of lenvatinib-induced adverse drug reactions (ADRs) across 26 organ systems. The findings revealed the presence of expected ADRs, including diarrhea, vomiting, stomatitis, hepatic encephalopathy, decreased appetite, dehydration, decreased weight, and electrolyte imbalances, which were consistent with the information provided in the drug labels. Furthermore, unexpected significant ADRs were observed at the preferred terms (PT) level, such as interstitial lung disease, pneumothorax, hypophysitis, failure to thrive, polycythemia, hypopituitarism, spontaneous pneumothorax, pulmonary cavitation, and limbic encephalitis. These findings indicated the potential occurrence of adverse effects that are currently not documented in the drug instructions. Conclusions: This study has successfully detected novel and unforeseen signals pertaining to ADRs associated with the administration of lenvatinib, thereby contributing significant insights into the intricate correlation between ADRs and the utilization of lenvatinib. The outcomes of this investigation underscore the utmost significance of continuous monitoring and vigilant surveillance in order to promptly identify and effectively manage AEs, consequently enhancing overall patient safety and well-being in the context of lenvatinib therapy.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281088797</dc:coverage>
        <dcterms:dateSubmitted>0003-01-01</dcterms:dateSubmitted>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:2405-8440">
        <prism:volume>10</prism:volume>
        <dc:title>HELIYON</dc:title>
        <dc:identifier>DOI 10.1016/j.heliyon.2024.e28132</dc:identifier>
        <prism:number>6</prism:number>
        <dc:identifier>ISSN 2405-8440</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1314">
        <rdf:value>&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;27&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="#item_1124">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>14</prism:volume>
                <dc:title>SCIENTIFIC REPORTS</dc:title>
                <dc:identifier>DOI 10.1038/s41598-024-62356-w</dc:identifier>
                <prism:number>1</prism:number>
                <dc:identifier>ISSN 2045-2322</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Qi</foaf:surname>
                        <foaf:givenName>YM</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>J</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lin</foaf:surname>
                        <foaf:givenName>SS</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>SS</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chai</foaf:surname>
                        <foaf:givenName>KQ</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jiang</foaf:surname>
                        <foaf:givenName>X</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Qian</foaf:surname>
                        <foaf:givenName>JC</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jiang</foaf:surname>
                        <foaf:givenName>C</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1315"/>
        <dc:subject>FAERS DATA</dc:subject>
        <dc:subject>LUNG-CANCER</dc:subject>
        <dc:subject>VOCAL CORD PARALYSIS</dc:subject>
        <dc:title>A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib</dc:title>
        <dcterms:abstract>Capmatinib is a potent selective mesenchymal-epithelial transition inhibitor approved in 2020 for the treatment of metastatic non-small cell lung cancer. As real-world evidence is very limited, this study evaluated capmatinib-induced adverse events through data mining of the FDA Adverse Event Reporting System database. Four disproportionality analysis methods were employed to quantify the signals of capmatinib-related adverse events. The difference in capmatinib-associated adverse event signals was further investigated with respect to sex, age, weight, dose, onset time, continent, and concomitant drug. A total of 1518 reports and 4278 adverse events induced by capmatinib were identified. New significant adverse event signals emerged, such as dysphagia, dehydration, deafness, vocal cord paralysis, muscle disorder, and oesophageal stenosis. Notably, higher risk of alanine aminotransferase and aspartate aminotransferase increases were observed in females, especially when capmatinib was combined with immune checkpoint inhibitors. Compared with Europeans and Asians, Americans were more likely to experience peripheral swelling, especially in people &gt; 65 years of age. Renal impairment and increased blood creatinine were more likely to occur with single doses above 400 mg and in Asians. This study improves the understanding of safety profile of capmatinib.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281088794</dc:coverage>
        <dcterms:dateSubmitted>0005-01-01</dcterms:dateSubmitted>
    </bib:Article>
    <bib:Memo rdf:about="#item_1315">
        <rdf:value>&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;7&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;7&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;36&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="#item_1125">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>15</prism:volume>
                <dc:title>SCIENTIFIC REPORTS</dc:title>
                <dc:identifier>DOI 10.1038/s41598-025-01583-1</dc:identifier>
                <prism:number>1</prism:number>
                <dc:identifier>ISSN 2045-2322</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tan</foaf:surname>
                        <foaf:givenName>AJ</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>WY</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lu</foaf:surname>
                        <foaf:givenName>JL</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tan</foaf:surname>
                        <foaf:givenName>QY</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yan</foaf:surname>
                        <foaf:givenName>Y</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mo</foaf:surname>
                        <foaf:givenName>DC</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1312"/>
        <dc:subject>FAERS</dc:subject>
        <dc:subject>Adverse events</dc:subject>
        <dc:subject>EVENTS</dc:subject>
        <dc:subject>INHIBITOR</dc:subject>
        <dc:subject>Pharmacovigilance</dc:subject>
        <dc:subject>PATIENT</dc:subject>
        <dc:subject>1ST-LINE</dc:subject>
        <dc:subject>Cytokine-release syndrome</dc:subject>
        <dc:subject>Durvalumab</dc:subject>
        <dc:subject>MEDI4736</dc:subject>
        <dc:subject>Pulmonary tuberculosis</dc:subject>
        <dc:subject>SYSTEMS</dc:subject>
        <dc:subject>TREMELIMUMAB</dc:subject>
        <dc:subject>TUBERCULOSIS</dc:subject>
        <dc:title>A pharmacovigilance analysis of post-marketing safety of durvalumab</dc:title>
        <dcterms:abstract>Durvalumab has demonstrated significant efficacy in several types of malignancies, while large-scale real-world safety studies remain limited. This study aimed to systematically evaluate the safety of durvalumab through data mining of the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). We extracted reports of durvalumab as the primary suspected drug from the FAERS database (January 2017 to June 2024). Four disproportionality analysis algorithms were used to detect signals between durvalumab and adverse events (AEs). Durvalumab was recorded in 10,120 reports as the primary suspected drug. Of these, 43.6% of AEs occurred during the first month of treatment, with a median onset time of 40 days (IQR: 14-99 ). Among 181 potential signals, 64 were unexpected preferred terms not listed in the prescribing information, including cytokine release syndrome (CRS), pulmonary tuberculosis, radiation esophagitis, oesophageal fistula, oesophageal perforation, pleural effusion, pneumothorax, cerebral infarction, biliary tract infection, cholecystitis, psoriasiform dermatitis, portal vein thrombosis, acute cholangitis and pericarditis malignant. Serious adverse events accounted for 93.3% of cases. Males exhibited a significantly higher risk of experiencing serious outcomes compared to females (OR = 1.83, 95% CI: 1.52-2.19, P &lt; 0.001). Older age groups demonstrated an elevated risk of severe outcomes relative to those under 65 years (65-74 years: OR = 1.52, 95% CI: 1.15-2.00, P = 0.003; &gt;= 75 years: OR = 1.40, 95% CI: 1.02-1.92, P = 0.038). This study comprehensively assessed the safety of durvalumab and discovered potential new adverse event signals, which may provide critical support for risk identification and monitoring of durvalumab.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281088790</dc:coverage>
        <dcterms:dateSubmitted>0005-01-01</dcterms:dateSubmitted>
    </bib:Article>
    <bib:Memo rdf:about="#item_1312">
        <rdf:value>&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;41&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="#item_1126">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>13</prism:volume>
                <dc:title>FRONTIERS IN PHARMACOLOGY</dc:title>
                <dc:identifier>DOI 10.3389/fphar.2022.967017</dc:identifier>
                <dc:identifier>ISSN 1663-9812</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xia</foaf:surname>
                        <foaf:givenName>S</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhao</foaf:surname>
                        <foaf:givenName>YC</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Guo</foaf:surname>
                        <foaf:givenName>L</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gong</foaf:surname>
                        <foaf:givenName>H</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>YK</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ma</foaf:surname>
                        <foaf:givenName>R</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>BK</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sheng</foaf:surname>
                        <foaf:givenName>Y</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sarangdhar</foaf:surname>
                        <foaf:givenName>M</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Noguchi</foaf:surname>
                        <foaf:givenName>Y</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yan</foaf:surname>
                        <foaf:givenName>M</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1313"/>
        <dc:subject>data mining</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>sepsis</dc:subject>
        <dc:subject>FAERS</dc:subject>
        <dc:subject>INHIBITORS</dc:subject>
        <dc:subject>antibody-drug conjugates</dc:subject>
        <dc:subject>OUTCOMES</dc:subject>
        <dc:subject>TIME</dc:subject>
        <dc:title>Do antibody-drug conjugates increase the risk of sepsis in cancer patients? A pharmacovigilance study</dc:title>
        <dcterms:abstract>Introduction: Antibody-drug conjugates (ADCs) produce unparalleled efficacy in refractory neoplasms but can also lead to serious toxicities. Although ADC-related sepsis has been reported, the clinical features are not well characterized in real-world studies.     Objective: The aim of this study was to identify the association between ADCs and sepsis using FAERS data and uncover the clinical characteristics of ADC-related sepsis.     Methods: We performed disproportionality analysis using FAERS data and compared rates of sepsis in cancer patients receiving ADCs vs. other regimens. Associations between ADCs and sepsis were assessed using reporting odds ratios (RORs) and information component (IC). For each treatment group, we detected drug interaction signals, and conducted subgroup analyses (age, gender, and regimens) and sensitivity analyses.     Results: A total of 24,618 cases were reported with ADCs between Q1, 2004 and Q3, 2021. Sepsis, septic shock, multiple organ dysfunction syndrome, and other sepsis-related toxicities were significantly associated with ADCs than other drugs in this database. Sepsis and multiple organ dysfunction syndrome have the highest safety concerns with ADCs compared with other anticancer monotherapies. Gemtuzumab ozogamicin and inotuzumab ozogamicin showed increased safety risks than other ADCs. For the top nine ADC-related sepsis, males showed higher sepsis safety concern than females (p &lt;0.001); however, age did not exert influence on the risk of sepsis. We identified that 973 of 2,441 (39.9%) cases had acute myeloid leukemia (AML), and 766 of 2613 (29.3%) cases on ADCs died during therapy. Time-to-onset analysis indicated ADC-related sepsis is prone to occur within a month after administration. Co-administration of ADCs with colony-stimulating factors, proton pump inhibitors, H2-receptor antagonists, or CYP3A4/5 inhibitors showed to synergistically increase the risk of sepsis-related toxicities.     Conclusion: Antibody-drug conjugates may increase the risk of sepsis in cancer patients, leading to high mortality. Further studies are warranted to characterize the underlying mechanisms and design preventive measures for ADC-related sepsis.</dcterms:abstract>
        <dc:date>2022</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281088800</dc:coverage>
        <dcterms:dateSubmitted>0011-01-01</dcterms:dateSubmitted>
    </bib:Article>
    <bib:Memo rdf:about="#item_1313">
        <rdf:value>&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;12&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;12&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;44&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="#item_1127">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1474-0338"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gao</foaf:surname>
                        <foaf:givenName>CX</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Dong</foaf:surname>
                        <foaf:givenName>XM</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>J</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mao</foaf:surname>
                        <foaf:givenName>LJ</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Guo</foaf:surname>
                        <foaf:givenName>CX</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Qin</foaf:surname>
                        <foaf:givenName>X</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zou</foaf:surname>
                        <foaf:givenName>Z</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1316"/>
        <dc:subject>FAERS</dc:subject>
        <dc:subject>adverse drug reactions</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>EFFICACY</dc:subject>
        <dc:subject>THERAPY</dc:subject>
        <dc:subject>SAFETY</dc:subject>
        <dc:subject>PATIENT</dc:subject>
        <dc:subject>ACYCLOVIR TREATMENT</dc:subject>
        <dc:subject>human herpesvirus</dc:subject>
        <dc:subject>NEUROTOXICITY</dc:subject>
        <dc:subject>Nucleoside analogues</dc:subject>
        <dc:subject>PREVENTION</dc:subject>
        <dc:subject>PROPHYLAXIS</dc:subject>
        <dc:subject>VALGANCICLOVIR</dc:subject>
        <dc:title>Recommendations for the selection of nucleoside analogues as antihuman herpesvirus drugs: a real-world analysis of reported cases from the FDA adverse event reporting system</dc:title>
        <dcterms:abstract>ObjectiveThe aim of this study is to provide guidance for refining medication protocols, developing alternative strategies, and enhancing protection against herpesvirus infections in personalized clinical settings.MethodsAdverse drug events (ADEs) data for anti-herpesvirus from the first quarter of 2004 to the fourth quarter of 2022 were collected from the FDA Adverse Event Reporting System (FAERS). Disproportionality analysis was performed using Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), and Bayesian Confidence Propagation Neural Network (BCPNN) methods for data mining.ResultsA total of 18,591, 24,206, 6,150, and 419 reports of ADEs associated with acyclovir (ACV), valacyclovir (VACV), ganciclovir (GCV), and famciclovir (FCV) were screened and extracted from the FAERS. In this study, the report summarized the high frequency and strong correlation of ADEs for the four drugs at the Preferred Term (PT) level. Additionally, the analysis also identified the relationship between ADEs and factors such as age, gender, and severity of outcome at the System Organ Class (SOC) level.ConclusionThe safety reports for the four-nucleoside analogue anti-herpesvirus drugs are diverse and interconnected. Dosing for patients with herpesvirus infections should be tailored to their specific conditions and the potential risk of disease.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281088786</dc:coverage>
        <dcterms:dateSubmitted>0006-01-01</dcterms:dateSubmitted>
        <bib:pages>695-709</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1474-0338">
        <prism:volume>24</prism:volume>
        <dc:title>EXPERT OPINION ON DRUG SAFETY</dc:title>
        <dc:identifier>DOI 10.1080/14740338.2024.2374919</dc:identifier>
        <prism:number>6</prism:number>
        <dc:identifier>ISSN 1474-0338</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1316">
        <rdf:value>&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;42&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="#item_1128">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>15</prism:volume>
                <dc:title>FRONTIERS IN PHARMACOLOGY</dc:title>
                <dc:identifier>DOI 10.3389/fphar.2024.1408135</dc:identifier>
                <dc:identifier>ISSN 1663-9812</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>KX</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>MM</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>WS</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>XH</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1317"/>
        <dc:subject>adverse events</dc:subject>
        <dc:subject>FAERS</dc:subject>
        <dc:subject>adverse drug reactions</dc:subject>
        <dc:subject>EFFICACY</dc:subject>
        <dc:subject>THERAPY</dc:subject>
        <dc:subject>OPEN-LABEL</dc:subject>
        <dc:subject>METAANALYSIS</dc:subject>
        <dc:subject>RENAL-CELL CARCINOMA</dc:subject>
        <dc:subject>ccRCC</dc:subject>
        <dc:subject>CROHNS-DISEASE</dc:subject>
        <dc:subject>MAINTENANCE</dc:subject>
        <dc:subject>MESALAZINE</dc:subject>
        <dc:subject>Tivozanib</dc:subject>
        <dc:subject>TREATMENT OPTIONS</dc:subject>
        <dc:subject>ULCERATIVE-COLITIS</dc:subject>
        <dc:title>A real-world disproportionality analysis of Tivozanib data mining of the public version of FDA adverse event reporting system</dc:title>
        <dcterms:abstract>Background Tivozanib, a vascular endothelial growth factor tyrosine kinase inhibitor, has demonstrated efficacy in a phase III clinical trials for the treatment of renal cell carcinoma. However, comprehensive evaluation of its long-term safety profile in a large sample population remains elusive. The current study assessed Tivozanib-related adverse events of real-world through data mining of the US Food and Drug Administration Adverse Event Reporting System FDA Adverse Event Reporting System.Methods Disproportionality analyses, utilizing reporting odds ratio proportional reporting ratio Bayesian confidence propagation neural network and multi-item gamma Poisson shrinker (MGPS) algorithms, were conducted to quantify signals of Tivozanib-related AEs. Weibull distribution was used to predict the varying risk incidence of AEs over time.Results Out of 5,361,420 reports collected from the FAERS database, 1,366 reports of Tivozanib-associated AEs were identified. A total of 94 significant disproportionality preferred terms (PTs) conforming to the four algorithms simultaneously were retained. The most common AEs included fatigue, diarrhea, nausea, blood pressure increased, decreased appetite, and dysphonia, consistent with prior specifications and clinical trials. Unexpected significant AEs such as dyspnea, constipation, pain in extremity, stomatitis, and palmar-plantar erythrodysaesthesia syndrome was observed. The median onset time of Tivozanib-related AEs was 37 days (interquartile range [IQR] 11.75-91 days), with a majority (n = 127, 46.35%) occurring within the initial month following Tivozanib initiation.Conclusion Our observations align with clinical assertions regarding Tivozanib's safety profile. Additionally, we unveil potential novel and unexpected AE signatures associated with Tivozanib administration, highlighting the imperative for prospective clinical studies to validate these findings and elucidate their causal relationships. These results furnish valuable evidence to steer future clinical inquiries aimed at elucidating the safety profile of Tivozanib.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281088785</dc:coverage>
        <dcterms:dateSubmitted>0006-01-01</dcterms:dateSubmitted>
    </bib:Article>
    <bib:Memo rdf:about="#item_1317">
        <rdf:value>&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;4&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;4&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;38&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="#item_1129">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:2296-858X"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Meng</foaf:surname>
                        <foaf:givenName>L</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yang</foaf:surname>
                        <foaf:givenName>B</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Qiu</foaf:surname>
                        <foaf:givenName>F</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jia</foaf:surname>
                        <foaf:givenName>YT</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sun</foaf:surname>
                        <foaf:givenName>SS</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yang</foaf:surname>
                        <foaf:givenName>JQ</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Huang</foaf:surname>
                        <foaf:givenName>J</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1319"/>
        <dc:subject>data mining</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>FAERS</dc:subject>
        <dc:subject>lung cancer</dc:subject>
        <dc:subject>angiotensin-converting enzyme inhibitors</dc:subject>
        <dc:title>Lung Cancer Adverse Events Reports for Angiotensin-Converting Enzyme Inhibitors: Data Mining of the FDA Adverse Event Reporting System Database</dc:title>
        <dcterms:abstract>Because of contradictory evidence from clinical trials, the association between angiotensin-converting enzyme inhibitors (ACEIs) and lung cancer needs further evaluation. As such, the current study is to assess disproportionate reporting of primary malignant lung cancer among reports for ACEIs submitted to the FDA adverse event reporting system utilizing a pharmacovigilance approach. We conducted a disproportionality analysis of primary malignant lung cancer adverse events associated with 10 ACEIs by calculating the reported odds ratios (ROR) and information component (IC) with 95% confidence intervals (CI). ROR was adjusted for sex, age, and reporting year by logistic regression analyses. From January 2004 to March 2020, a total of 622 cases of lung cancer adverse event reports were identified for ACEIs users. Significant disproportionate association was found for ACEIs as a drug class (ROR: 1.22, 95% CI: 1.13-1.32; IC: 0.28, 95% CI: 0.17-0.39. adjusted ROR: 1.23, 95% CI: 1.02-1.49). After stratification based on gender, a subset analysis suggested that female patients exhibited a significant disproportionate association, while male patients did not. Sensitivity analyses that limited the data by reporting region, comorbidity, and reporting year also showed similar trends. Statistical significant lung cancer signals were detected among patients who received ACEI, especially female patients. The disproportionality analysis of the FAERS database suggests mildly increased reporting of lung cancer among ACEI users. Further robust epidemiological studies are necessary to confirm this relationship.</dcterms:abstract>
        <dc:date>2021</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281088783</dc:coverage>
        <dcterms:dateSubmitted>0002-01-01</dcterms:dateSubmitted>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:2296-858X">
        <prism:volume>8</prism:volume>
        <dc:title>FRONTIERS IN MEDICINE</dc:title>
        <dc:identifier>DOI 10.3389/fmed.2021.594043</dc:identifier>
        <dc:identifier>ISSN 2296-858X</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1319">
        <rdf:value>&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;11&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;11&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;44&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="#item_1130">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:2050-084X"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xu</foaf:surname>
                        <foaf:givenName>X</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kawakami</foaf:surname>
                        <foaf:givenName>J</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gedara</foaf:surname>
                        <foaf:givenName>NIM</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Riviere</foaf:surname>
                        <foaf:givenName>JE</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Meyer</foaf:surname>
                        <foaf:givenName>E</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wyckoff</foaf:surname>
                        <foaf:givenName>GJ</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jaberi-Douraki</foaf:surname>
                        <foaf:givenName>M</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1320"/>
        <dc:subject>hypertension</dc:subject>
        <dc:subject>RISK</dc:subject>
        <dc:subject>DISPROPORTIONALITY</dc:subject>
        <dc:subject>artificial intelligence</dc:subject>
        <dc:subject>COVID-19-related pharmacovigilance</dc:subject>
        <dc:subject>SAFETY</dc:subject>
        <dc:subject>SIGNAL-DETECTION</dc:subject>
        <dc:subject>CONTROLLED-RELEASE NIFEDIPINE</dc:subject>
        <dc:subject>data-driven methodology</dc:subject>
        <dc:subject>DOSE COMBINATION THERAPY</dc:subject>
        <dc:subject>FDA ADE database</dc:subject>
        <dc:subject>None</dc:subject>
        <dc:subject>PROFILE</dc:subject>
        <dc:subject>pulmonary symptomology</dc:subject>
        <dc:title>Data mining methodology for response to hypertension symptomology-application to COVID-19-related pharmacovigilance</dc:title>
        <dcterms:abstract>Background: Potential therapy and confounding factors including typical co-administered medications, patient's disease states, disease prevalence, patient demographics, medical histories, and reasons for prescribing a drug often are incomplete, conflicting, missing, or uncharacterized in spontaneous adverse drug event (ADE) reporting systems. These missing or incomplete features can affect and limit the application of quantitative methods in pharmacovigilance for meta-analyses of data during randomized clinical trials. Methods: Data from patients with hypertension were retrieved and integrated from the FDA Adverse Event Reporting System; 134 antihypertensive drugs out of 1131 drugs were filtered and then evaluated using the empirical Bayes geometric mean (EBGM) of the posterior distribution to build ADE-drug profiles with an emphasis on the pulmonary ADEs. Afterward, the graphical least absolute shrinkage and selection operator (GLASSO) captured drug associations based on pulmonary ADEs by correcting hidden factors and confounder misclassification. Selected drugs were then compared using the Friedman test in drug classes and clusters obtained from GLASSO. Results: Following multiple filtering stages to exclude insignificant and noise-driven reports, we found that drugs from antihypertensives agents, urologicals, and antithrombotic agents (macitentan, bosentan, epoprostenol, selexipag, sildenafil, tadalafil, and beraprost) form a similar class with a significantly higher incidence of pulmonary ADEs. Macitentan and bosentan were associated with 64% and 56% of pulmonary ADEs, respectively. Because these two medications are prescribed in diseases affecting pulmonary function and may be likely to emerge among the highest reported pulmonary ADEs, in fact, they serve to validate the methods utilized here. Conversely, doxazosin and rilmenidine were found to have the least pulmonary ADEs in selected drugs from hypertension patients. Nifedipine and candesartan were also found by signal detection methods to form a drug cluster, shown by several studies an effective combination of these drugs on lowering blood pressure and appeared an improved side effect profile in comparison with single-agent monotherapy. Conclusions: We consider pulmonary ADE profiles in multiple long-standing groups of therapeutics including antihypertensive agents, antithrombotic agents, beta-blocking agents, calcium channel blockers, or agents acting on the renin-angiotensin system, in patients with hypertension associated with high risk for coronavirus disease 2019 (COVID-19). We found that several individual drugs have significant differences between their drug classes and compared to other drug classes. For instance, macitentan and bosentan from endothelin receptor antagonists show major concern while doxazosin and rilmenidine exhibited the least pulmonary ADEs compared to the outcomes of other drugs. Using techniques in this study, we assessed and confirmed the hypothesis that drugs from the same drug class could have very different pulmonary ADE profiles affecting outcomes in acute respiratory illness. Funding: GJW and MJD accepted funding from BioNexus KC for funding on this project, but BioNexus KC had no direct role in this article.</dcterms:abstract>
        <dc:date>2021</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281088780</dc:coverage>
        <dcterms:dateSubmitted>0011-01-01</dcterms:dateSubmitted>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:2050-084X">
        <prism:volume>10</prism:volume>
        <dc:title>ELIFE</dc:title>
        <dc:identifier>DOI 10.7554/eLife.70734.sa2</dc:identifier>
        <dc:identifier>ISSN 2050-084X</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1320">
        <rdf:value>&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;41&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="#item_1131">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:0114-5916"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shi</foaf:surname>
                        <foaf:givenName>Y</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yang</foaf:surname>
                        <foaf:givenName>YD</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>RQ</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sun</foaf:surname>
                        <foaf:givenName>AN</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Peng</foaf:surname>
                        <foaf:givenName>XQ</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>L</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>P</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>PY</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1318"/>
        <dc:subject>SIGNAL-DETECTION</dc:subject>
        <dc:subject>FALSE DISCOVERY</dc:subject>
        <dc:subject>PROBABILITY</dc:subject>
        <dc:subject>SEMANTIC SIMILARITY</dc:subject>
        <dc:title>A Drug Similarity-Based Bayesian Method for Early Adverse Drug Event Detection</dc:title>
        <dcterms:abstract>IntroductionBiochemical drug similarity-based methods demonstrate successes in predicting adverse drug events (ADEs) in preclinical settings and enhancing signals of ADEs in real-world data mining. Despite these successes, drug similarity-based ADE detection shall be expanded with false-positive control and evaluated under a time-to-detection setting.MethodsWe tested a drug similarity-based Bayesian method for early ADE detection with false-positive control. Under the tested method, prior distribution of ADE probability of a less frequent drug could be derived from frequent drugs with a high biochemical similarity, and posterior probability of null hypothesis could be used for signal detection and false-positive control. We evaluated the tested and reference methods by mining relatively newer drugs in real-world data (e.g., the US Food and Drug Administration (FDA)'s Adverse Event Reporting System (FAERS) data) and conducting a simulation study.ResultsIn FAERS analysis, the times to achieve a same probability of detection for drug-labeled ADEs following initial drug reporting were 5 years and &gt;= 7 years for the tested method and reference methods, respectively. Additionally, the tested method compared with reference methods had higher AUC values (0.57-0.79 vs. 0.32-0.71), especially within 3 years following initial drug reporting. In a simulation study, the tested method demonstrated proper false-positive control, and had higher probabilities of detection (0.31-0.60 vs. 0.11-0.41) and AUC values (0.88-0.95 vs. 0.69-0.86) compared with reference methods. Additionally, we identified different types of drug similarities had a comparable performance in high-throughput ADE mining.ConclusionThe drug similarity-based Bayesian ADE detection method might be able to accelerate ADE detection while controlling the false-positive rate.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281088777</dc:coverage>
        <dcterms:dateSubmitted>0004-01-01</dcterms:dateSubmitted>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:0114-5916">
        <dc:title>DRUG SAFETY</dc:title>
        <dc:identifier>DOI 10.1007/s40264-025-01545-6</dc:identifier>
        <dc:identifier>ISSN 0114-5916</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1318">
        <rdf:value>&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;44&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Base governamental,Desenvolvimento do método,Excluído - Não utiliza dados de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85055125243&amp;doi=10.5530%2fjyp.2018.10.97&amp;partnerID=40&amp;md5=e1d6090dcfce06df1a150ca73ba8d3ce">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:09751483%20(ISSN)"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Subeesh</foaf:surname>
                        <foaf:givenName>V.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Maheswari</foaf:surname>
                        <foaf:givenName>E.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Saraswathy</foaf:surname>
                        <foaf:givenName>G.R.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Swaroop</foaf:surname>
                        <foaf:givenName>A.M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Minnikanti</foaf:surname>
                        <foaf:givenName>S.S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1321"/>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>odds ratio</dc:subject>
        <dc:subject>ADVERSE DRUG-REACTIONS</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>DISPROPORTIONALITY</dc:subject>
        <dc:subject>comparative study</dc:subject>
        <dc:subject>drug labeling</dc:subject>
        <dc:subject>EVENTS</dc:subject>
        <dc:subject>Pharmacovigilance</dc:subject>
        <dc:subject>sensitivity analysis</dc:subject>
        <dc:subject>drug marketing</dc:subject>
        <dc:subject>food and drug administration</dc:subject>
        <dc:subject>priority journal</dc:subject>
        <dc:subject>drug recall</dc:subject>
        <dc:subject>SYSTEMS</dc:subject>
        <dc:subject>Data mining algorithms</dc:subject>
        <dc:subject>Disproportionality Analysis</dc:subject>
        <dc:subject>FDA AERS Database</dc:subject>
        <dc:subject>Information Component</dc:subject>
        <dc:subject>PHARMACOVIGILANCE</dc:subject>
        <dc:subject>Proportional Reporting Ratio</dc:subject>
        <dc:subject>Reporting Odds Ratio</dc:subject>
        <dc:subject>REPORTING ODDS RATIO</dc:subject>
        <dc:subject>Signal Detection</dc:subject>
        <dc:title>A comparative study of data mining algorithms used for signal detection in FDA AERS database</dc:title>
        <dcterms:abstract>Objective: Signal detection is a technique in pharmacovigilance for the early detection of new, rare reactions (desired or undesired) of a drug. This study aims to compare and appraise the performance of data mining algorithms used in signal detection. Method: Most commonly used three data mining algorithms (DMAs) (Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR) and Information Component (IC)) were selected and applied retrospectively in USFDA Adverse Event Reporting System database to detect five confirmed Drug Event Combinations. They were selected in such a way that the drug is withdrawn from the market or label change between 2006-2015. A value of ROR-1.96SE&gt;1, PRR≥2, χ2&gt;4 or IC- 2SD&gt;0 were considered as the positive signal. The data mining algorithms were compared for their sensitivity and early detection. Result: Among the three data mining algorithms, Information Component was found to have a maximum sensitivity (100%) followed by Reporting Odds Ratio (60%) and Proportional Reporting Ratio (40%). Sensitivity associated with the number of reports per drug event combination and early signal detection suggested that information component needs comparatively fewer reports to show positive signal than the other two data mining algorithms. ROR and PRR showed comparable results. Conclusion: Early detection of a reaction is possible using signal detection technique. Information component was found to be sensitive method compared with other two data mining algorithms in FDA Adverse Event Reporting System database. As the number of reports of drug event combination increased, the sensitivity and comparability of data mining algorithm also increased. © 2018 EManuscript Technologies. All rights reserved.</dcterms:abstract>
        <dc:date>2018</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281088765</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85055125243&amp;doi=10.5530%2fjyp.2018.10.97&amp;partnerID=40&amp;md5=e1d6090dcfce06df1a150ca73ba8d3ce</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>444-449</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:09751483%20(ISSN)">
        <prism:volume>10</prism:volume>
        <dc:title>Journal of Young Pharmacists</dc:title>
        <dc:identifier>DOI 10.5530/jyp.2018.10.97</dc:identifier>
        <prism:number>4</prism:number>
        <dcterms:alternative>J. Young Pharm.</dcterms:alternative>
        <dc:identifier>ISSN 09751483 (ISSN)</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1321">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 12; Correspondence Address: V. Subeesh; Department of Pharmacy Practice, Faculty of Pharmacy, M.S Ramaiah University of Applied Sciences, Bengaluru, Karnataka, India; email: subeeshkviswam@gmail.com&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;9&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;11&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;21&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Desenvolvimento do método,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85198755004&amp;doi=10.3389%2ffphar.2024.1392914&amp;partnerID=40&amp;md5=1b9e374137df37afeb7e2f3f47d607fc">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>15</prism:volume>
                <dc:title>Frontiers in Pharmacology</dc:title>
                <dc:identifier>DOI 10.3389/fphar.2024.1392914</dc:identifier>
                <dcterms:alternative>Front. Pharmacol.</dcterms:alternative>
                <dc:identifier>ISSN 16639812 (ISSN)</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zou</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ouyang</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhao</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Cheng</foaf:surname>
                        <foaf:givenName>Q.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shi</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sun</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1322"/>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>heart failure</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>adverse events</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>disability</dc:subject>
        <dc:subject>FAERS</dc:subject>
        <dc:subject>bone pain</dc:subject>
        <dc:subject>cognitive defect</dc:subject>
        <dc:subject>gastrointestinal disease</dc:subject>
        <dc:subject>sex difference</dc:subject>
        <dc:subject>brain infarction</dc:subject>
        <dc:subject>hypertensive crisis</dc:subject>
        <dc:subject>very elderly</dc:subject>
        <dc:subject>Bayesian network</dc:subject>
        <dc:subject>breast cancer</dc:subject>
        <dc:subject>goserelin</dc:subject>
        <dc:subject>leuprorelin</dc:subject>
        <dc:subject>libido disorder</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>pleura effusion</dc:subject>
        <dc:subject>anorexia</dc:subject>
        <dc:subject>dementia</dc:subject>
        <dc:subject>EFFICACY</dc:subject>
        <dc:subject>hepatobiliary disease</dc:subject>
        <dc:subject>urinary tract disease</dc:subject>
        <dc:subject>drug interaction</dc:subject>
        <dc:subject>pneumonia</dc:subject>
        <dc:subject>aortic aneurysm</dc:subject>
        <dc:subject>electrolyte disturbance</dc:subject>
        <dc:subject>infant</dc:subject>
        <dc:subject>muscle atrophy</dc:subject>
        <dc:subject>interstitial lung disease</dc:subject>
        <dc:subject>urinary tract infection</dc:subject>
        <dc:subject>liver necrosis</dc:subject>
        <dc:subject>newborn</dc:subject>
        <dc:subject>uterus myoma</dc:subject>
        <dc:subject>hydronephrosis</dc:subject>
        <dc:subject>lymphadenopathy</dc:subject>
        <dc:subject>liver disease</dc:subject>
        <dc:subject>suicidal ideation</dc:subject>
        <dc:subject>life threat</dc:subject>
        <dc:subject>JADER</dc:subject>
        <dc:subject>SAFETY</dc:subject>
        <dc:subject>respiratory failure</dc:subject>
        <dc:subject>ANALOGS</dc:subject>
        <dc:subject>bibliographic database</dc:subject>
        <dc:subject>disorders of lipid and lipoprotein metabolism</dc:subject>
        <dc:subject>endometriosis</dc:subject>
        <dc:subject>FDA adverse event reporting system database</dc:subject>
        <dc:subject>GnRHas</dc:subject>
        <dc:subject>gonadorelin derivative</dc:subject>
        <dc:subject>gonadotropin</dc:subject>
        <dc:subject>gonadotropin release</dc:subject>
        <dc:subject>HORMONE AGONISTS</dc:subject>
        <dc:subject>IC25</dc:subject>
        <dc:subject>japanese adverse drug event report database</dc:subject>
        <dc:subject>marasmus</dc:subject>
        <dc:subject>precocious puberty</dc:subject>
        <dc:subject>prostate cancer</dc:subject>
        <dc:subject>PROSTATE-CANCER</dc:subject>
        <dc:subject>triptorelin</dc:subject>
        <dc:subject>urinary tract hemorrhage</dc:subject>
        <dc:subject>urinary tract obstruction</dc:subject>
        <dc:title>A disproportionality analysis of adverse events caused by GnRHas from the FAERS and JADER databases</dc:title>
        <dcterms:abstract>Background: Gonadotrophin-releasing hormone analogs (GnRHas) play a significant role in addressing gynecological diseases, central precocious puberty, and cancer. However, ensuring the safety of GnRHas in real-world applications requires continuous vigilance. In light of this, we undertook a disproportionality analysis focused on adverse events (AEs) associated with GnRHas using data from both the FDA Adverse Event Reporting System (FAERS) and the Japanese Adverse Drug Event Report (JADER). We evaluated GnRHas-associated AEs and characterized the clinical priority of unlisted AEs caused by each GnRHa from the different databases. Methods: In the disproportionality analysis, we applied two adjusted algorithms to identify signals related to GnRHas in the FAERS and JADER databases from 2004 to 2023. Additionally, we utilized the Statistical Analysis System (SAS, 9.4) to examine potential and high-aROR (adjusted reporting odds ratio) signals associated with GnRHas. We performed clinical priority assessment for suspicious PTs and an analysis of serious/non-serious outcomes. We also gathered information on the onset times of AEs linked with GnRHas from both databases. Results: From January 2004 to September 2023, FAERS and JADER recorded a total of 50,360,413 and 1,440,200 AEs, respectively. Employing two algorithms, the suspicious preferred terms (PTs) related to leuprolide (Leu) were 562 potential PTs (44 unlisted in specifications), followed by goserelin (Gos) with 189 PTs (28 unlisted), triptorelin (Tri) with 172 PTs (28 unlisted), and Leu-JADER with 85 PTs (10 unlisted). At the same PT level, the differences in GnRHas between the two databases were observed, such as cardiac failure, diabetes mellitus, liver disorder, dementia, suicidal ideation, interstitial lung disease, urinary disorders, and hypertensive crisis. In an analysis of serious vs. non-serious outcomes, a total of 43 AEs of Leu were more likely to be reported as serious AEs with p &lt; 0.05 (such as asthenia, urinary retention, diabetes mellitus, interstitial lung disease, gait disturbance, and so on), following by Tri (6 AEs), and Gos (4 AEs). Based on the clinical priority score, 41 PTs of Leu, 26 PTs of Tri, 24 PTs of Gos, and 8 PTs of Leu-JADER were graded as weak. There were 3 PTs of Leu, 2 PTs of Tri, 4 PTs of Gos, and 2 PTs of Leu-JADER that were graded as moderate. Notably, in the assessment of the relevant evidence, 2 PTs (loss of libido and urinary tract toxicity caused by Leu), 1 PT (electrolyte imbalance caused by Tri), and 2 PTs (anorexia and suicidal ideation caused by Gos) showed a strong level of evidence with “++.” The differences in the signal strength of the same PTs from two databases were also worth noting. Moreover, the median onset time for GnRHas (Leu, Tri, and Gos) was 23 days (0, 298), 22 days (0, 181), and 217 days (29, 706), respectively, as median (Q1, Q3). Conclusion: An examination of two databases revealed suspicious AEs associated with GnRHas. Our study found potential new AE signals of GnRHas and supported continuous clinical monitoring, pharmacovigilance, regional differences, and further studies of GnRHas. Copyright © 2024 Zou, Ouyang, Zhao, Cheng, Shi and Sun.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281088755</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85198755004&amp;doi=10.3389%2ffphar.2024.1392914&amp;partnerID=40&amp;md5=1b9e374137df37afeb7e2f3f47d607fc</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Memo rdf:about="#item_1322">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 8; Correspondence Address: M. Sun; Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; email: smh007tj@163.com&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;8&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;8&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;52&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85106609752&amp;doi=10.1038%2fs41598-021-90108-7&amp;partnerID=40&amp;md5=00fce57f9a73d9bc74d0cdc3a8d33b05">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>11</prism:volume>
                <dc:title>Scientific Reports</dc:title>
                <dc:identifier>DOI 10.1038/s41598-021-90108-7</dc:identifier>
                <prism:number>1</prism:number>
                <dcterms:alternative>Sci. Rep.</dcterms:alternative>
                <dc:identifier>ISSN 20452322 (ISSN)</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hu</foaf:surname>
                        <foaf:givenName>Q.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tian</foaf:surname>
                        <foaf:givenName>F.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>F.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xu</foaf:surname>
                        <foaf:givenName>T.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1325"/>
        <dc:subject>data mining</dc:subject>
        <dc:subject>factual database</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>RISK</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>United States Food and Drug Administration</dc:subject>
        <dc:subject>Data Mining</dc:subject>
        <dc:subject>Databases, Factual</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>dementia</dc:subject>
        <dc:subject>Dementia</dc:subject>
        <dc:subject>Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>protein analysis</dc:subject>
        <dc:subject>Pharmacovigilance</dc:subject>
        <dc:subject>Male</dc:subject>
        <dc:subject>disease predisposition</dc:subject>
        <dc:subject>Disease Susceptibility</dc:subject>
        <dc:subject>health survey</dc:subject>
        <dc:subject>MEDEX</dc:subject>
        <dc:subject>Protein Interaction Mapping</dc:subject>
        <dc:subject>proton pump inhibitor</dc:subject>
        <dc:subject>Proton Pump Inhibitors</dc:subject>
        <dc:subject>Public Health Surveillance</dc:subject>
        <dc:title>A pharmacovigilance study of association between proton pump inhibitor and dementia event based on FDA adverse event reporting system data</dc:title>
        <dcterms:abstract>Proton pump inhibitor (PPI) was widely used around the world. Studies suggested conflicting results between PPI treatment and dementia event. This study examined the association between six PPI agents and dementia event by mining the US FDA Adverse Event Reporting System (FAERS) database from 2004 to 2020. We employed proportional reporting ratio (PRR) and information element (IC) methods to detect the signals of dementia relevant to PPI. We also analyzed characteristics of PPI and positive control reports, compared dementia event between long- and short-duration of PPI treatment. Finally, we identified 2396 dementia cases with PPI treatment. We did not detect significant signal between PPI and dementia event: PRR = 0.98, 95%CI 0.94 to 1.02, IC = −0.03, 95%CI − 0.17 to 0.10, even in gastroesophageal reflux disease cases: PRR = 0.65, 95%CI 0.59 to 0.72, IC = −0.62, 95%CI − 0.97 to − 0.27. No significant differences of dementia event were detected between long- and short- duration groups, the OR (95%CI) of the 3 years, 5 years and 10 years comparison were 0.70 (0.48 to 1.02), 0.72 (0.45 to 1.15) and 1.65 (0.75 to 3.63), respectively. Based on the current FAERS data mining, we discovered no association between PPI use and dementia event, even in long-term PPI therapy case. © 2021, The Author(s).</dcterms:abstract>
        <dc:date>2021</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281088761</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85106609752&amp;doi=10.1038%2fs41598-021-90108-7&amp;partnerID=40&amp;md5=00fce57f9a73d9bc74d0cdc3a8d33b05</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Memo rdf:about="#item_1325">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 33; Correspondence Address: T. Xu; Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, 37 Guoxue Alley, Wuhou, 610041, China; email: tingx2009@163.com&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;29&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;33&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;40&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85167740242&amp;doi=10.1186%2fs12885-023-11201-w&amp;partnerID=40&amp;md5=706ab7196fe3ed848ea01545d531d475">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:14712407%20(ISSN)"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>Q.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ding</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shu</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1328"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>factual database</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>postmarketing surveillance</dc:subject>
        <dc:subject>Adult</dc:subject>
        <dc:subject>adverse outcome</dc:subject>
        <dc:subject>alanine aminotransferase</dc:subject>
        <dc:subject>alanine aminotransferase blood level</dc:subject>
        <dc:subject>aspartate aminotransferase</dc:subject>
        <dc:subject>aspartate aminotransferase blood level</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>FAERS</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>United States Food and Drug Administration</dc:subject>
        <dc:subject>fatigue</dc:subject>
        <dc:subject>nausea</dc:subject>
        <dc:subject>observational study</dc:subject>
        <dc:subject>vomiting</dc:subject>
        <dc:subject>information processing</dc:subject>
        <dc:subject>CANCER</dc:subject>
        <dc:subject>Adverse event</dc:subject>
        <dc:subject>anemia</dc:subject>
        <dc:subject>CHEMOTHERAPY</dc:subject>
        <dc:subject>creatinine</dc:subject>
        <dc:subject>Data mining</dc:subject>
        <dc:subject>Databases, Factual</dc:subject>
        <dc:subject>dehydration</dc:subject>
        <dc:subject>creatinine blood level</dc:subject>
        <dc:subject>Disproportionality analysis</dc:subject>
        <dc:subject>gastroesophageal reflux</dc:subject>
        <dc:subject>Female</dc:subject>
        <dc:subject>thrombocytopenia</dc:subject>
        <dc:subject>Pharmacovigilance</dc:subject>
        <dc:subject>fallopian tube cancer</dc:subject>
        <dc:subject>peritoneum cancer</dc:subject>
        <dc:subject>SAFETY</dc:subject>
        <dc:subject>hypersomnia</dc:subject>
        <dc:subject>intestine obstruction</dc:subject>
        <dc:subject>ARIEL3</dc:subject>
        <dc:subject>BRCA1</dc:subject>
        <dc:subject>GERMLINE</dc:subject>
        <dc:subject>indole derivative</dc:subject>
        <dc:subject>Indoles</dc:subject>
        <dc:subject>iron</dc:subject>
        <dc:subject>iron blood level</dc:subject>
        <dc:subject>ovary carcinoma</dc:subject>
        <dc:subject>PARP INHIBITOR RUCAPARIB</dc:subject>
        <dc:subject>PLATINUM</dc:subject>
        <dc:subject>PROGRESSION</dc:subject>
        <dc:subject>RECURRENT OVARIAN-CARCINOMA</dc:subject>
        <dc:subject>rucaparib</dc:subject>
        <dc:subject>Rucaparib</dc:subject>
        <dc:title>A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data</dc:title>
        <dcterms:abstract>Background: Rucaparib has been approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. However, the long-term safety of rucaparib in large sample population was unknown. The presented study aimed to evaluate rucaparib-associated adverse events (AEs) according to the real-world pharmacovigilance database. Methods: Disproportionality analysis was conducted to assess the association between rucaparib and its AEs. Data were collected from the international pharmacovigilance database of US FDA Adverse Event Reporting System (FAERS) between January 2017 and June 2022. The characteristics of rucaparib-related AEs, and the onset time were further analyzed. Results: A total of 9,296,694 AE reports were recorded in the FAERS during the study period, among which 7,087 reports were associated with rucaparib. About 135 rucaparib-related AE signals in 15 system organ class (SOCs) were identified. The most common AEs included anaemia, thrombocytopenia, nausea, vomiting, fatigue, blood creatinine increase, alanine aminotransferase increase, and aspartate aminotransferase increase, which were listed in the label for rucaparib. Of note, 21 new and unexpected significant AEs that off-label were also found in our study, such as preferred term (PTs) of intestinal obstruction, gastrooesophageal reflux disease, blood iron decreased, dehydration, and hypersomnia. The median onset time of rucaparib-related AEs was 12 days (interquartile range [IQR] 1–62 days), and had early failure types. Conclusion: Our study demonstrated potential new AEs of rucaparib, and further studies were expected to confirm the results. © 2023, BioMed Central Ltd., part of Springer Nature.</dcterms:abstract>
        <dc:date>2023</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281088753</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85167740242&amp;doi=10.1186%2fs12885-023-11201-w&amp;partnerID=40&amp;md5=706ab7196fe3ed848ea01545d531d475</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:14712407%20(ISSN)">
        <prism:volume>23</prism:volume>
        <dc:title>BMC Cancer</dc:title>
        <dc:identifier>DOI 10.1186/s12885-023-11201-w</dc:identifier>
        <prism:number>1</prism:number>
        <dcterms:alternative>BMC Cancer</dcterms:alternative>
        <dc:identifier>ISSN 14712407 (ISSN)</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1328">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 16; Correspondence Address: Y. Shu; Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, No.1095 Jiefang Avenue, 430030, China; email: shuyamin1990hust@163.com; J. Chen; Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, No.1095 Jiefang Avenue, 430030, China; email: cj8004@163.com; CODEN: BCMAC&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;15&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;15&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;40&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85185462093&amp;doi=10.3389%2ffphar.2024.1362484&amp;partnerID=40&amp;md5=d395379af797325010ae606eacee2e7d">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>15</prism:volume>
                <dc:title>Frontiers in Pharmacology</dc:title>
                <dc:identifier>DOI 10.3389/fphar.2024.1362484</dc:identifier>
                <dcterms:alternative>Front. Pharmacol.</dcterms:alternative>
                <dc:identifier>ISSN 16639812 (ISSN)</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tang</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sun</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ding</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1326"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>brain hemorrhage</dc:subject>
        <dc:subject>disability</dc:subject>
        <dc:subject>lymphoma</dc:subject>
        <dc:subject>FAERS</dc:subject>
        <dc:subject>brain disease</dc:subject>
        <dc:subject>cerebellum hemorrhage</dc:subject>
        <dc:subject>capecitabine</dc:subject>
        <dc:subject>breast cancer</dc:subject>
        <dc:subject>antibody drug conjugate</dc:subject>
        <dc:subject>antibody-drug conjugates (ADCs)</dc:subject>
        <dc:subject>brentuximab vedotin</dc:subject>
        <dc:subject>enfortumab vedotin</dc:subject>
        <dc:subject>inotuzumab ozogamicin</dc:subject>
        <dc:subject>TOXICITY</dc:subject>
        <dc:subject>trastuzumab emtansine</dc:subject>
        <dc:subject>neurotoxicity</dc:subject>
        <dc:subject>polyneuropathy</dc:subject>
        <dc:subject>EFFICACY</dc:subject>
        <dc:subject>cyclophosphamide</dc:subject>
        <dc:subject>Guillain Barre syndrome</dc:subject>
        <dc:subject>leukemia</dc:subject>
        <dc:subject>leukoencephalopathy</dc:subject>
        <dc:subject>mortality rate</dc:subject>
        <dc:subject>THERAPY</dc:subject>
        <dc:subject>peripheral neuropathy</dc:subject>
        <dc:subject>taste disorder</dc:subject>
        <dc:subject>docetaxel</dc:subject>
        <dc:subject>bladder cancer</dc:subject>
        <dc:subject>central nervous system</dc:subject>
        <dc:subject>aciclovir</dc:subject>
        <dc:subject>polatuzumab vedotin</dc:subject>
        <dc:subject>progressive multifocal leukoencephalopathy</dc:subject>
        <dc:subject>OPEN-LABEL</dc:subject>
        <dc:subject>BRENTUXIMAB VEDOTIN</dc:subject>
        <dc:subject>gemtuzumab ozogamicin</dc:subject>
        <dc:subject>heparin</dc:subject>
        <dc:subject>idarubicin</dc:subject>
        <dc:subject>ODDS RATIO</dc:subject>
        <dc:subject>off-target effect</dc:subject>
        <dc:subject>paclitaxel</dc:subject>
        <dc:subject>PATIENT</dc:subject>
        <dc:subject>pregabalin</dc:subject>
        <dc:subject>PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY</dc:subject>
        <dc:subject>SINGLE-ARM</dc:subject>
        <dc:subject>solid tumor</dc:subject>
        <dc:subject>stomach cancer</dc:subject>
        <dc:subject>temazepam</dc:subject>
        <dc:subject>trastuzumab deruxtecan</dc:subject>
        <dc:subject>TRASTUZUMAB DERUXTECAN</dc:subject>
        <dc:subject>valganciclovir</dc:subject>
        <dc:title>A pharmacovigilance study on antibody-drug conjugate (ADC)-related neurotoxicity based on the FDA adverse event reporting system (FAERS)</dc:title>
        <dcterms:abstract>Background: Antibody-drug conjugates (ADCs) are a relatively new class of anticancer agents that use monoclonal antibodies to specifically recognize tumour cell surface antigens. However, off-target effects may lead to severe adverse events. This study evaluated the neurotoxicity of ADCs using the FDA Adverse Event Reporting System (FAERS) database. Research design and methods: Data were extracted from the FAERS database for 2004 Q1 to 2022 Q4. We analysed the clinical characteristics of ADC-related neurological adverse events (AEs). We used the reporting odds ratio (ROR) and proportional reporting ratio (PRR) for the disproportionality analysis to evaluate the potential association between AEs and ADCs. Results: A total of 562 cases of neurological AEs were attributed to ADCs. The median age was 65 years old [(Min; Max) = 3; 92]. Neurotoxic signals were detected in patients receiving brentuximab vedotin, enfortumab vedotin, polatuzumab vedotin, trastuzumab emtansine, gemtuzumab ozogamicin, inotuzumab ozogamicin, and trastuzumab deruxtecan. The payloads of brentuximab vedotin, enfortumab vedotin, polatuzumab vedotin, and trastuzumab emtansine were microtubule polymerization inhibitors, which are more likely to develop neurotoxicity. We also found that brentuximab vedotin- and gemtuzumab ozogamicin-related neurological AEs were more likely to result in serious outcomes. The eight most common ADC-related nervous system AE signals were peripheral neuropathy [ROR (95% CI) = 16.98 (14.94–19.30), PRR (95% CI) = 16.0 (14.21–18.09)], cerebral haemorrhage [ROR (95% CI) = 9.45 (7.01–12.73), PRR (95% CI) = 9.32 (6.95–12.50)], peripheral sensory neuropathy [ROR (95% CI) = 47.87 (33.13–69.19), PRR (95% CI) = 47.43 (32.93–68.30)], polyneuropathy [ROR (95% CI) = 26.01 (18.61–36.33), PRR (95% CI) = 25.75 (18.50–35.86)], encephalopathy [ROR (95% CI) = 5.16 (3.32–8.01), PRR (95% CI) = 5.14 (3.32–7.96)], progressive multifocal leukoencephalopathy [ROR (95% CI) = 22.67 (14.05–36.58), PRR (95% CI) = 22.52 (14.01–36.21)], taste disorder [ROR (95% CI) = 26.09 (15.92–42.76), PRR (95% CI) = 25.78 (15.83–42.00)], and guillain barrier syndrome [ROR (95% CI) = 17.844 (10.11–31.51), PRR (95% CI) = 17.79 (10.09–31.35)]. The mortality rate appeared to be relatively high concomitantly with AEs in the central nervous system. Conclusion: ADCs may increase the risk of neurotoxicity in cancer patients, leading to serious mortality. With the widespread application of newly launched ADC drugs, combining the FAERS data with other data sources is crucial for monitoring the neurotoxicity of ADCs. Further studies on the potential mechanisms and preventive measures for ADC-related neurotoxicity are necessary. Copyright © 2024 Tang, Sun, Liu, Wu and Ding.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281088752</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85185462093&amp;doi=10.3389%2ffphar.2024.1362484&amp;partnerID=40&amp;md5=d395379af797325010ae606eacee2e7d</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Memo rdf:about="#item_1326">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 9; Correspondence Address: L. Tang; Department of Pharmacy, Affiliated Hospital of Weifang Medical University, Weifang, China; email: tangkeke2021@163.com; C. Ding; Department of Pharmacy, Affiliated Hospital of Weifang Medical University, Weifang, China; email: dchh422@163.com; H. Wu; Department of Pharmacy, Central Hospital Affiliated to Shandong First Medical University, Ji’nan, China; email: wuhaiyanangel@163.com&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;6&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;6&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;54&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85161713748&amp;doi=10.1177%2f20420986231181334&amp;partnerID=40&amp;md5=845b9ecf0b5671626cffe9390f80cd5c">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:20420986%20(ISSN)"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Stottlemyer</foaf:surname>
                        <foaf:givenName>B.A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>McDermott</foaf:surname>
                        <foaf:givenName>M.C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Minogue</foaf:surname>
                        <foaf:givenName>M.R.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gray</foaf:surname>
                        <foaf:givenName>M.P.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Boyce</foaf:surname>
                        <foaf:givenName>R.D.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kane-Gill</foaf:surname>
                        <foaf:givenName>S.L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1330"/>
        <dc:subject>acute kidney failure</dc:subject>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>injection site reaction</dc:subject>
        <dc:subject>dizziness</dc:subject>
        <dc:subject>RISK</dc:subject>
        <dc:subject>constipation</dc:subject>
        <dc:subject>headache</dc:subject>
        <dc:subject>nausea</dc:subject>
        <dc:subject>vomiting</dc:subject>
        <dc:subject>diarrhea</dc:subject>
        <dc:subject>dipeptidyl peptidase IV inhibitor</dc:subject>
        <dc:subject>osteomyelitis</dc:subject>
        <dc:subject>diabetes mellitus</dc:subject>
        <dc:subject>albiglutide</dc:subject>
        <dc:subject>dulaglutide</dc:subject>
        <dc:subject>body weight loss</dc:subject>
        <dc:subject>canagliflozin</dc:subject>
        <dc:subject>hyperglycemia</dc:subject>
        <dc:subject>glucagon like peptide 1 receptor agonist</dc:subject>
        <dc:subject>decreased appetite</dc:subject>
        <dc:subject>mycosis</dc:subject>
        <dc:subject>dapagliflozin</dc:subject>
        <dc:subject>DIABETES-MELLITUS</dc:subject>
        <dc:subject>empagliflozin</dc:subject>
        <dc:subject>sodium glucose cotransporter 2 inhibitor</dc:subject>
        <dc:subject>SAFETY</dc:subject>
        <dc:subject>adverse drug reaction reporting systems</dc:subject>
        <dc:subject>antidiabetic activity</dc:subject>
        <dc:subject>body weight disorder</dc:subject>
        <dc:subject>diabetic ketoacidosis</dc:subject>
        <dc:subject>dipeptidyl-peptidase IV inhibitors</dc:subject>
        <dc:subject>drug surveillance</dc:subject>
        <dc:subject>drug-related side effects and adverse reactions</dc:subject>
        <dc:subject>exendin 4</dc:subject>
        <dc:subject>foot amputation</dc:subject>
        <dc:subject>GLP-1 RECEPTOR AGONISTS</dc:subject>
        <dc:subject>glucagon-like peptide-1 receptor agonists</dc:subject>
        <dc:subject>INFECTIONS</dc:subject>
        <dc:subject>non insulin dependent diabetes mellitus</dc:subject>
        <dc:subject>pancreas carcinoma</dc:subject>
        <dc:subject>postmarketing</dc:subject>
        <dc:subject>semaglutide</dc:subject>
        <dc:subject>SGLT2 INHIBITORS</dc:subject>
        <dc:subject>sodium-glucose transporter 2 inhibitors</dc:subject>
        <dc:subject>TRENDS</dc:subject>
        <dc:subject>type 2</dc:subject>
        <dc:subject>URINARY-TRACT</dc:subject>
        <dc:title>Assessing adverse drug reaction reports for antidiabetic medications approved by the food and drug administration between 2012 and 2017: a pharmacovigilance study</dc:title>
        <dcterms:abstract>Objective: Between 2012 and 2017, the U.S. Food and Drug Administration (FDA) approved 10 antidiabetic indicated therapies. Due to the limited literature on voluntarily reported safety outcomes for recently approved antidiabetic drugs, this study investigated adverse drug reactions (ADRs) reported in the FDA Adverse Event Reporting System (FAERS). Research Design and Methods: A disproportionality analysis of spontaneously reported ADRs was conducted. FAERS reports from January 1, 2012 to March 31, 2022 were compiled, allowing a 5-year buffer following drug approval in 2017. Reporting odds ratios were calculated for the top 10 ADRs, comparing new diabetic agents to the other approved drugs in their therapeutic class. Results: 127,525 reports were identified for newly approved antidiabetic medications listed as the primary suspect (PS). For sodium-glucose co-transporter-2 (SGLT-2) inhibitors, the odds of blood glucose increased, nausea, and dizziness being reported was greater for empagliflozin. Dapagliflozin was associated with greater reports of weight decreased. Canagliflozin was found to have a disproportionally higher number of reports for diabetic ketoacidosis, toe amputation, acute kidney injury, fungal infections, and osteomyelitis. Assessing glucagon-like peptide-1 (GLP-1) receptor agonists, dulaglutide and semaglutide were associated with greater reports of gastrointestinal adverse drug reactions. Exenatide was disproportionally associated with injection site reactions and pancreatic carcinoma reports. Conclusion: Pharmacovigilance studies utilizing a large publicly available dataset allow an essential opportunity to evaluate the safety profile of antidiabetic drugs utilized in clinical practice. Additional research is needed to evaluate these reported safety concerns for recently approved antidiabetic medications to determine causality. © The Author(s), 2023.</dcterms:abstract>
        <dc:date>2023</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281088750</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85161713748&amp;doi=10.1177%2f20420986231181334&amp;partnerID=40&amp;md5=845b9ecf0b5671626cffe9390f80cd5c</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:20420986%20(ISSN)">
        <prism:volume>14</prism:volume>
        <dc:title>Therapeutic Advances in Drug Safety</dc:title>
        <dc:identifier>DOI 10.1177/20420986231181334</dc:identifier>
        <dcterms:alternative>Ther. Adv. Drug Saf.</dcterms:alternative>
        <dc:identifier>ISSN 20420986 (ISSN)</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1330">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 15; Correspondence Address: S.L. Kane-Gill; email: kane-gill@pitt.edu&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;14&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;16&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;38&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85197783994&amp;doi=10.3389%2ffphar.2024.1363501&amp;partnerID=40&amp;md5=8137e6b0bde43e66ac1e4cfef7b61ba2">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>15</prism:volume>
                <dc:title>Frontiers in Pharmacology</dc:title>
                <dc:identifier>DOI 10.3389/fphar.2024.1363501</dc:identifier>
                <dcterms:alternative>Front. Pharmacol.</dcterms:alternative>
                <dc:identifier>ISSN 16639812 (ISSN)</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Guo</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wei</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yan</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shan</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>F.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1327"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>outcome assessment</dc:subject>
        <dc:subject>FAERS</dc:subject>
        <dc:subject>cerivastatin</dc:subject>
        <dc:subject>diabetes mellitus</dc:subject>
        <dc:subject>chronic kidney failure</dc:subject>
        <dc:subject>atorvastatin</dc:subject>
        <dc:subject>disproportionality analyses</dc:subject>
        <dc:subject>MANAGEMENT</dc:subject>
        <dc:subject>THERAPY</dc:subject>
        <dc:subject>ADULTS</dc:subject>
        <dc:subject>non insulin dependent diabetes mellitus</dc:subject>
        <dc:subject>ATORVASTATIN</dc:subject>
        <dc:subject>CARDIOVASCULAR RISK</dc:subject>
        <dc:subject>chronic kidney disease</dc:subject>
        <dc:subject>fluvastatin</dc:subject>
        <dc:subject>GUIDELINES</dc:subject>
        <dc:subject>hemodialysis</dc:subject>
        <dc:subject>INSULIN-RESISTANCE</dc:subject>
        <dc:subject>kidney function</dc:subject>
        <dc:subject>mevinolin</dc:subject>
        <dc:subject>pitavastatin</dc:subject>
        <dc:subject>pravastatin</dc:subject>
        <dc:subject>rosuvastatin</dc:subject>
        <dc:subject>simvastatin</dc:subject>
        <dc:subject>SIMVASTATIN</dc:subject>
        <dc:subject>statins</dc:subject>
        <dc:title>A pharmacovigilance study of chronic kidney disease in diabetes mellitus patients with statin treatment by using the US Food and Drug Administration adverse event reporting system</dc:title>
        <dcterms:abstract>Background: Statins were regarded as a main medication for managing hypercholesterolemia. Administration of statin therapy could reduce the incidence of cardiovascular disease in individuals diagnosed with type 2 diabetes mellitus (DM), which was recognized by multipal clinical guidelines. But previous studies had conflicting results on whether the long-term use of statins could benefit the renal function in diabetic patients. Aim: To evaluate the association between statin treatment and Chronic Kidney Disease in DM patients. Methods: This is a retrospective disproportionality analysis and cohort study based on real-world data. All DM cases reported in US Food and Drug Administration adverse event reporting system (FAERS) between the first quarter of 2004 and the fourth quarter of 2022 were included. Disproportionality analyses were conducted by estimating the reporting odds ratio (ROR) and the information component (IC). We further compared the CKD odds ratio (OR) between the statins group and the other primary suspected drug group among the included diabetes mellitus cases. Results: We finally included 593647 DM cases from FAERS, 5113 (5.31%) CKD cases in the statins group and 8810 (1.77%) CKD cases in the control group. Data analysis showed that the statins group showed a significant CKD signal (ROR: 3.11, 95% CI: 3.00–3.22; IC: 1.18, 95% CI: 1.07–1.29). In case group with two or more statins treatment history, the CKD signal was even stronger (ROR: 19.56, 95% CI: 18.10–21.13; IC: 3.70, 95% CI:3.44–3.93) compared with cases with one statin treatment history. Conclusion: The impact of statin therapy on the progression of renal disease in individuals diagnosed with type 2 diabetes mellitus (DM) remains inconclusive. After data mining on the current FAERS dataset, we discovered significant signals between statin treatment and CKD in diabetic patients. Furthermore, the incidence rate of CKD was higher among DM patients who used statins compared to those who did not. Copyright © 2024 Zhang, Guo, Wei, Yan, Shan, Wu and Wu.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281088749</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85197783994&amp;doi=10.3389%2ffphar.2024.1363501&amp;partnerID=40&amp;md5=8137e6b0bde43e66ac1e4cfef7b61ba2</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Memo rdf:about="#item_1327">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 2; Correspondence Address: B. Wu; Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, China; email: binw83@hotmail.com; F. Wu; Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, China; email: wfb_sc@163.com&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;53&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85216087996&amp;doi=10.3390%2fmicroorganisms13010136&amp;partnerID=40&amp;md5=ec9194e89740d40bae737a5245698232">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:20762607%20(ISSN)"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mo</foaf:surname>
                        <foaf:givenName>S.H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lee</foaf:surname>
                        <foaf:givenName>S.H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Choi</foaf:surname>
                        <foaf:givenName>C.-Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sunwoo</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shin</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Choi</foaf:surname>
                        <foaf:givenName>Y.J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1333"/>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>real-world data</dc:subject>
        <dc:subject>bacterial infection</dc:subject>
        <dc:subject>CRITICALLY-ILL PATIENTS</dc:subject>
        <dc:subject>antibacterial</dc:subject>
        <dc:title>A Comprehensive 10-Year Nationwide Pharmacovigilance Surveillance on Antibacterial Agents in Korea: Data Mining for Signal Detection of Trends and Seriousness of Adverse Events</dc:title>
        <dcterms:abstract>A comprehensive pharmacovigilance surveillance on antibacterials is lacking. This study aims to investigate safety signals of antibacterial-related adverse drug events (ADEs) with seriousness and to identify predictors of serious ADEs. This study investigated 52,503 antibacterial-induced ADEs reported to the Korea Adverse Event Reporting System Database from January 2013 to December 2022. Disproportionality analysis was conducted, and the effect sizes were estimated by reporting odds ratios (ROR), proportional reporting ratio (PRR), and information component (IC). Multivariate logistic regression was performed to investigate the predictors of serious ADEs by estimating the odds ratio (OR). Serious events were more likely to be cardiovascular disorders (ROR 6.77, PRR 6.6, IC 2.37), urinary system disorders (ROR 5.56, PRR 5.22, IC 2.12), and platelet, bleeding, and clotting disorders (ROR 5.41, PRR 5.17, IC 2.06). The predictors may include age (OR 1.05), the number of concomitant medications (OR 1.44), concomitant proton pump inhibitors (OR 1.46) and non-steroidal anti-inflammatory drugs (OR 1.38) use, and specific antibacterial classes, while multiple antibacterial therapy was associated with lower serious ADE risks. The sensitivity analysis also suggests the male sex (OR 1.18) as a potential predictor of serious ADEs. However, further studies are imperative to determine the causality of antibacterial-induced ADEs in critically ill patients. © 2025 by the authors.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281088747</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85216087996&amp;doi=10.3390%2fmicroorganisms13010136&amp;partnerID=40&amp;md5=ec9194e89740d40bae737a5245698232</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:20762607%20(ISSN)">
        <prism:volume>13</prism:volume>
        <dc:title>Microorganisms</dc:title>
        <dc:identifier>DOI 10.3390/microorganisms13010136</dc:identifier>
        <prism:number>1</prism:number>
        <dcterms:alternative>Microorg.</dcterms:alternative>
        <dc:identifier>ISSN 20762607 (ISSN)</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1333">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 1; Correspondence Address: Y.J. Choi; Department of Regulatory Science, Graduate School, Kyung Hee University, Seoul, 02447, South Korea; email: yeojin.choi@khu.ac.kr; S. Shin; Department of Pharmacy, College of Pharmacy, Ajou University, Suwon, 16499, South Korea; email: syshin@ajou.ac.kr&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;46&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85199396108&amp;doi=10.1016%2fj.heliyon.2024.e34969&amp;partnerID=40&amp;md5=7c8502ba28383f770027f1e5dacf1679">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:24058440%20(ISSN)"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Han</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bu</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tian</foaf:surname>
                        <foaf:givenName>N.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jin</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Feng</foaf:surname>
                        <foaf:givenName>Q.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ma</foaf:surname>
                        <foaf:givenName>B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Teng</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1334"/>
        <dc:subject>FAERS</dc:subject>
        <dc:subject>DRUG</dc:subject>
        <dc:subject>BCPNN</dc:subject>
        <dc:subject>OPEN-LABEL</dc:subject>
        <dc:subject>6-MONTH DEPOT</dc:subject>
        <dc:subject>EBGM</dc:subject>
        <dc:subject>GRANULOMAS</dc:subject>
        <dc:subject>INJECTION-SITE</dc:subject>
        <dc:subject>LEUPROLIDE ACETATE</dc:subject>
        <dc:subject>Leuprorelin</dc:subject>
        <dc:subject>PATHOGENESIS</dc:subject>
        <dc:subject>PRECOCIOUS PUBERTY</dc:subject>
        <dc:subject>PROSTATE-CANCER PATIENTS</dc:subject>
        <dc:subject>PRR</dc:subject>
        <dc:subject>ROR</dc:subject>
        <dc:subject>STERILE ABSCESS FORMATION</dc:subject>
        <dc:title>Novel insights into post-marketing AEs associated with leuprorelin: A comprehensive analysis utilizing the FAERS database</dc:title>
        <dcterms:abstract>Purpose: This research focused on meticulously tracking and identifying adverse reactions associated with leuprorelin, a drug prescribed for conditions such as prostate cancer, endometriosis, uterine fibroids, and early-onset puberty. The main objective was to enhance patient safety and offer informed guidance on the appropriate use of this treatment. Methods: From the first quarter of 2004 to the fourth quarter of 2023, a comprehensive analysis was conducted on a significant number of adverse event reports (AERs) from the FDA Adverse Event Reporting System (FAERS) database. Data mining with dismutation analysis was conducted to quantify signals associated with adverse events (AEs) related to leuprorelin, utilizing powerful algorithms such as ROR, PRR, BCPNN, and EBGM. Results: A total of 102 positive reaction terms (PT) spanning 24 System Organ Classes (SOCs) were identified from an analysis of 60,709 reports associated with leuprorelin use. Notably, several previously unrecognized adverse reactions were uncovered, including Artificial Menopause, Ovarian Adhesion, Follicular Cystitis, Intercepted product preparation error, among others. These findings underscore the importance of exercising additional vigilance regarding the potential adverse effects of leuprorelin, such as Abscess Sterile, Injection site granuloma, Intercepted medication error, and Bulbospinal muscular atrophy congenital. Conclusions: This research has successfully uncovered new and unforeseen signals associated with adverse drug reactions (ADRs) following leuprorelin administration. The study provides valuable insights into the intricate connection between ADRs and leuprorelin usage. The results underscore the crucial significance of continuous surveillance and meticulous monitoring to promptly identify and manage AEs, ultimately enhancing patient safety and well-being while undergoing leuprorelin therapy. © 2024</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281088746</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85199396108&amp;doi=10.1016%2fj.heliyon.2024.e34969&amp;partnerID=40&amp;md5=7c8502ba28383f770027f1e5dacf1679</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:24058440%20(ISSN)">
        <prism:volume>10</prism:volume>
        <dc:title>Heliyon</dc:title>
        <dc:identifier>DOI 10.1016/j.heliyon.2024.e34969</dc:identifier>
        <prism:number>15</prism:number>
        <dcterms:alternative>Heliyon</dcterms:alternative>
        <dc:identifier>ISSN 24058440 (ISSN)</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1334">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 1; Correspondence Address: Z. Li; Department of Orthopedics, The Second Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, No.23, Nanhu Road, Jianye District, Jiangsu Province, 210017, China; email: fsyy00797@njucm.edu.cn; J. Teng; Department of Orthopaedics, The Second Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, No.23, Nanhu Road, Jianye District, Jiangsu Province, 210017, China; email: dqtengjiasong@163.com&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;0&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;1&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;36&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85211041387&amp;doi=10.1371%2fjournal.pone.0314957&amp;partnerID=40&amp;md5=4c38f5df11d1dab550e58675e24382fb">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>19</prism:volume>
                <dc:title>PLoS ONE</dc:title>
                <dc:identifier>DOI 10.1371/journal.pone.0314957</dc:identifier>
                <prism:number>12</prism:number>
                <dcterms:alternative>PLoS ONE</dcterms:alternative>
                <dc:identifier>ISSN 19326203 (ISSN)</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Peng</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liang</foaf:surname>
                        <foaf:givenName>G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1331"/>
        <dc:subject>acute kidney failure</dc:subject>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>factual database</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>heart failure</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>young adult</dc:subject>
        <dc:subject>acute heart infarction</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>Adolescent</dc:subject>
        <dc:subject>Adult</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>Aged</dc:subject>
        <dc:subject>cardiovascular disease</dc:subject>
        <dc:subject>cerebrovascular accident</dc:subject>
        <dc:subject>Adverse Event Reporting System database</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>hematoma</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>epidemiology</dc:subject>
        <dc:subject>heart arrhythmia</dc:subject>
        <dc:subject>heart ventricle arrhythmia</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>tachycardia</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>United States Food and Drug Administration</dc:subject>
        <dc:subject>gastrointestinal disease</dc:subject>
        <dc:subject>brain infarction</dc:subject>
        <dc:subject>very elderly</dc:subject>
        <dc:subject>anemia</dc:subject>
        <dc:subject>Databases, Factual</dc:subject>
        <dc:subject>lymphatic system disease</dc:subject>
        <dc:subject>vascular disease</dc:subject>
        <dc:subject>DISEASE</dc:subject>
        <dc:subject>Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>hepatobiliary disease</dc:subject>
        <dc:subject>Female</dc:subject>
        <dc:subject>Aged, 80 and over</dc:subject>
        <dc:subject>Pharmacovigilance</dc:subject>
        <dc:subject>urogenital tract disease</dc:subject>
        <dc:subject>Male</dc:subject>
        <dc:subject>Middle Aged</dc:subject>
        <dc:subject>cilostazol</dc:subject>
        <dc:subject>Young Adult</dc:subject>
        <dc:subject>SAFETY</dc:subject>
        <dc:subject>central nervous system disease</dc:subject>
        <dc:subject>brain contusion</dc:subject>
        <dc:subject>Cilostazol</dc:subject>
        <dc:subject>CYCLIC-AMP</dc:subject>
        <dc:subject>IMPAIRMENT</dc:subject>
        <dc:subject>intermittent claudication</dc:subject>
        <dc:subject>peripheral arterial disease</dc:subject>
        <dc:subject>Peripheral Arterial Disease</dc:subject>
        <dc:subject>PHARMACOKINETICS</dc:subject>
        <dc:title>The drug risks of cilostazol: A pharmacovigilance study of FDA Adverse Event Reporting System database</dc:title>
        <dcterms:abstract>Objective Cilostazol is indicated for alleviating intermittent claudication (IC) in stable-phase peripheral arterial disease (PAD) patients. Conducting data mining on adverse events (AEs) of cilostazol in the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database to explore its potential medication risks and advance more rational and secure clinical medication practices. Methods This study utilized the Open Vigil 2.1-MedDRA tool to retrieve and extract AE reporting data related to cilostazol from the FAERS database spanning the first quarter of 2004 to the first quarter of 2024. The primary methodology employed was the application of the reporting odds ratio (ROR) method to detect risk signals associated with AEs of cilostazol. Results A total of 2,130 AE reports involving cilostazol were identified as the primary suspect drug, with a total of 7,134 AEs reported. These reports were predominantly concentrated among patients aged 60 and above, with a higher occurrence in males compared to females. Japan ranked first among the reporting countries, and the majority of reports were submitted by healthcare professionals. Through the screening of cilostazol, a total of 323 positive risk signals for AEs were identified, encompassing 23 system organ classes (SOCs). A comparison with the existing cilostazol product label revealed 8 AEs that were not included based on the number of AE reports, and 19 AEs that were not included based on the strength of the risk signals. Cilostazol exhibited positive risk signals for AEs primarily affecting 8 organ systems based on the SOC classification. Among these, cardiac disorders ranked highest, with a total of 53 positive risk signals for cardiovascular-related AEs identified. In terms of the number of reports, cardiac failure ranked first, aligning with the black box warning issued by the FDA regarding cilostazol. The occurrence of adverse reactions related to cilostazol is primarily concentrated within the first month of treatment. However, a certain proportion of adverse reactions have been reported to occur after long-term use (exceeding 360 days) of cilostazol therapy. Conclusion Our results have further enriched the observations from existing clinical and real-world studies, uncovering new AE signals for cilostazol, including fall, cerebral infarction, pneumonia, loss of consciousness, acute kidney injury, renal impairment, renal failure, cardiac vein perforation, basal ganglia haematoma, cerebral hyperperfusion syndrome, et al. This study also highlights the significant impact of cilostazol on the cardiovascular system, necessitating close attention to potential cardiovascular toxicities. In addition to focusing on the short-term adverse reactions following cilostazol administration, thorough research into its long-term safety profile is also imperative. This study provides recommendations and guidance for the rational and safe clinical use of cilostazol. In the future, prospective studies are needed to explore the occurrence of related AEs further. This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.</dcterms:abstract>
        <dc:date>2024</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281088743</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85211041387&amp;doi=10.1371%2fjournal.pone.0314957&amp;partnerID=40&amp;md5=4c38f5df11d1dab550e58675e24382fb</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Memo rdf:about="#item_1331">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 3; Correspondence Address: S. Liu; Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, China; email: liushibin202408@163.com; G. Liang; Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, China; email: lianggang202408@163.com; CODEN: POLNC&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;3&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;3&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;45&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="#item_1142">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>20</prism:volume>
                <dc:title>PloS one</dc:title>
                <dc:identifier>DOI 10.1371/journal.pone.0322378</dc:identifier>
                <prism:number>5</prism:number>
                <dcterms:alternative>PLoS One</dcterms:alternative>
                <dc:identifier>ISSN 1932-6203</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tan</foaf:surname>
                        <foaf:givenName>Feilong</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>Yanhua</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xia</foaf:surname>
                        <foaf:givenName>Hongying</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yin</foaf:surname>
                        <foaf:givenName>Wenjie</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1335"/>
        <dc:subject>*Data Mining</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>United States Food and Drug Administration</dc:subject>
        <dc:subject>Databases, Factual</dc:subject>
        <dc:subject>Female</dc:subject>
        <dc:subject>*Adverse Drug Reaction Reporting Systems/statistics &amp; numerical data</dc:subject>
        <dc:subject>*Drug-Related Side Effects and Adverse Reactions/epidemiology</dc:subject>
        <dc:subject>Male</dc:subject>
        <dc:subject>*Brentuximab Vedotin/adverse effects</dc:subject>
        <dc:subject>*Immunoconjugates/adverse effects</dc:subject>
        <dc:subject>Hodgkin Disease/drug therapy</dc:subject>
        <dc:subject>Japan/epidemiology</dc:subject>
        <dc:title>Signal mining and analysis of adverse events of Brentuximab Vedotin base on FAERS and JADER databases.</dc:title>
        <dcterms:abstract>OBJECTIVES: Brentuximab Vedotin (BV) is a novel antibody-drug conjugate (ADC) approved for the treatment of classical Hodgkin's lymphoma and systemic  anaplastic large cell lymphoma. However, as a relatively new therapeutic agent,  the long-term safety profile and adverse event (AE) profile of BV require further  investigation. This study aimed to identify significant and unexpected AEs  associated with BV using data from the FDA Adverse Event Reporting System (FAERS)  and the Japanese Adverse Drug Event Report (JADER) databases. METHODS: Data on  BV-related AEs were extracted from the FAERS and JADER databases. Signal  detection was performed using the reporting odds ratio (ROR) and 95% confidence  intervals (95% CI). Risk signals were categorized according to system organ  classes (SOCs) and preferred terms (PTs) as defined by the Medical Dictionary for  Regulatory Activities (MedDRA) version 26.0. In addition, the onset times of  BV-related AEs were analyzed. RESULTS: Between 2004 and 2023, a total of 19,279  and 2,561 AEs related to BV were recorded in the FAERS and JADER databases,  respectively. At the SOC level, prominent signals in the FAERS database included  blood and lymphatic system disorders, benign, malignant, and unspecified  neoplasms (including cysts and polyps), as well as congenital, familial, and  genetic disorders. In the JADER database, the most notable signals involved  benign, malignant, and unspecified neoplasms, blood and lymphatic system  disorders, and nervous system disorders. At the PT level, the top five signals in  the FAERS database were peripheral motor neuropathy, peripheral sensory  neuropathy, pneumocystis jirovecii pneumonia, febrile bone marrow aplasia, and  polyneuropathy. Unexpected AEs included febrile bone marrow aplasia and  Guillain-Barré syndrome. In the JADER database, the top five signals included  peripheral motor neuropathy, peripheral sensory neuropathy, bacterial  gastroenteritis, febrile neutropenia and pneumonia, with unexpected AEs such as  left ventricular dysfunction, cardiomegaly, retinal detachment, and marasmus. The  median onset time of AEs was 22 days (interquartile range [IQR] 7-81 days) in  FAERS and 27 days (IQR 7-73 days) in JADER. CONCLUSION: The signal detection  results from the FAERS and JADER databases highlight the importance of monitoring  significant and unexpected AEs associated with BV, particularly in the early  stages of treatment. These findings contribute to enhancing the post-marketing  safety profile of BV and offer valuable insights for clinical risk management  strategies.</dcterms:abstract>
        <dc:date>2025</dc:date>
        <z:language>eng</z:language>
        <dc:coverage>rayyan-281080038</dc:coverage>
        <bib:pages>e0322378</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1335">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85038876564&amp;doi=10.1002%2fpds.4364&amp;partnerID=40&amp;md5=568636aa59b7d1f824d14d6ddf75efd6">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:10538569%20(ISSN)"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Scholl</foaf:surname>
                        <foaf:givenName>J.H.G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>van Hunsel</foaf:surname>
                        <foaf:givenName>F.P.A.M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hak</foaf:surname>
                        <foaf:givenName>E.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>van Puijenbroek</foaf:surname>
                        <foaf:givenName>E.P.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1337"/>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>factual database</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>screening</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>Algorithms</dc:subject>
        <dc:subject>health care personnel</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>Data Mining</dc:subject>
        <dc:subject>Data Mining/*methods</dc:subject>
        <dc:subject>Databases, Factual</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>comparative study</dc:subject>
        <dc:subject>Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>Pharmacovigilance</dc:subject>
        <dc:subject>statistical analysis</dc:subject>
        <dc:subject>multivariate analysis</dc:subject>
        <dc:subject>Databases, Factual/*statistics &amp; numerical data</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems/*statistics &amp; numerical data</dc:subject>
        <dc:subject>drug marketing</dc:subject>
        <dc:subject>*Algorithms</dc:subject>
        <dc:subject>bootstrapping</dc:subject>
        <dc:subject>calibration</dc:subject>
        <dc:subject>Drug-Related Side Effects and Adverse Reactions/*epidemiology/prevention &amp; control</dc:subject>
        <dc:subject>evaluation study</dc:subject>
        <dc:subject>internal validity</dc:subject>
        <dc:subject>Logistic Models</dc:subject>
        <dc:subject>logistic regression analysis</dc:subject>
        <dc:subject>Multivariate Analysis</dc:subject>
        <dc:subject>Naranjo score</dc:subject>
        <dc:subject>Netherlands</dc:subject>
        <dc:subject>Netherlands/epidemiology</dc:subject>
        <dc:subject>pharmacoepidemiology</dc:subject>
        <dc:subject>prediction</dc:subject>
        <dc:subject>prediction model</dc:subject>
        <dc:subject>priority journal</dc:subject>
        <dc:subject>procedures</dc:subject>
        <dc:subject>receiver operating characteristic</dc:subject>
        <dc:subject>ROC Curve</dc:subject>
        <dc:subject>statistical model</dc:subject>
        <dc:subject>vaccine</dc:subject>
        <dc:title>A prediction model-based algorithm for computer-assisted database screening of adverse drug reactions in the Netherlands</dc:title>
        <dcterms:abstract>Purpose: The statistical screening of pharmacovigilance databases containing spontaneously reported adverse drug reactions (ADRs) is mainly based on disproportionality analysis. The aim of this study was to improve the efficiency of full database screening using a prediction model-based approach. Methods: A logistic regression-based prediction model containing 5 candidate predictors was developed and internally validated using the Summary of Product Characteristics as the gold standard for the outcome. All drug-ADR associations, with the exception of those related to vaccines, with a minimum of 3 reports formed the training data for the model. Performance was based on the area under the receiver operating characteristic curve (AUC). Results were compared with the current method of database screening based on the number of previously analyzed associations. Results: A total of 25 026 unique drug-ADR associations formed the training data for the model. The final model contained all 5 candidate predictors (number of reports, disproportionality, reports from healthcare professionals, reports from marketing authorization holders, Naranjo score). The AUC for the full model was 0.740 (95% CI; 0.734–0.747). The internal validity was good based on the calibration curve and bootstrapping analysis (AUC after bootstrapping = 0.739). Compared with the old method, the AUC increased from 0.649 to 0.740, and the proportion of potential signals increased by approximately 50% (from 12.3% to 19.4%). Conclusions: A prediction model-based approach can be a useful tool to create priority-based listings for signal detection in databases consisting of spontaneous ADRs. © 2017 The Authors. Pharmacoepidemiology &amp; Drug Safety Published by John Wiley &amp; Sons Ltd.</dcterms:abstract>
        <dc:date>2018</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281080028</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.scopus.com/inward/record.uri?eid=2-s2.0-85038876564&amp;doi=10.1002%2fpds.4364&amp;partnerID=40&amp;md5=568636aa59b7d1f824d14d6ddf75efd6</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>199-205</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:10538569%20(ISSN)">
        <prism:volume>27</prism:volume>
        <dc:title>Pharmacoepidemiology and Drug Safety</dc:title>
        <dc:identifier>DOI 10.1002/pds.4364</dc:identifier>
        <prism:number>2</prism:number>
        <dcterms:alternative>Pharmacoepidemiol. Drug Saf.</dcterms:alternative>
        <dc:identifier>ISSN 10538569 (ISSN)</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1337">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 18; Correspondence Address: J.H.G. Scholl; Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, Netherlands; email: j.scholl@lareb.nl; CODEN: PDSAE&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Desenvolvimento do método,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L621937009&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1477-0334"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tubert-Bitter</foaf:surname>
                        <foaf:givenName>P.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bégaud</foaf:surname>
                        <foaf:givenName>B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ahmed</foaf:surname>
                        <foaf:givenName>I.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1340"/>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>factual database</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>heart infarction</dc:subject>
        <dc:subject>chemically induced</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>comparative study</dc:subject>
        <dc:subject>France</dc:subject>
        <dc:subject>receiver operating characteristic</dc:subject>
        <dc:subject>anti human immunodeficiency virus agent</dc:subject>
        <dc:subject>nelfinavir</dc:subject>
        <dc:subject>saquinavir</dc:subject>
        <dc:subject>sensitivity and specificity</dc:subject>
        <dc:title>Comparison of two drug safety signals in a pharmacovigilance data mining framework</dc:title>
        <dcterms:abstract>Since adverse drug reactions are a major public health concern, early detection of drug safety signals has become a top priority for regulatory agencies and the pharmaceutical industry. Quantitative methods for analyzing spontaneous reporting material recorded in pharmacovigilance databases through data mining have been proposed in the last decades and are increasingly used to flag potential safety problems. While automated data mining is motivated by the usually huge size of pharmacovigilance databases, it does not systematically produce relevant alerts. Moreover, each detected signal requires appropriate assessment that may involve investigation of the whole therapeutic class. The goal of this article is to provide a methodology for comparing two detected signals. It is nested within the automated surveillance framework as (1) no extra information is required and (2) no simple inference on the actual risks can be extrapolated from spontaneous reporting data. We designed our methodology on the basis of two classical methods used for automated signal detection: the Bayesian Gamma Poisson Shrinker and the frequentist Proportional Reporting Ratio. A simulation study was conducted to assess the performances of both proposed methods. The latter were used to compare cardiovascular signals for two HIV treatments from the French pharmacovigilance database.</dcterms:abstract>
        <dc:date>2016</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079955</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L621937009&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>615-629</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1477-0334">
        <prism:volume>25</prism:volume>
        <dc:title>Statistical methods in medical research</dc:title>
        <dc:identifier>DOI 10.1177/0962280212462295</dc:identifier>
        <prism:number>2</prism:number>
        <dcterms:alternative>Stat Methods Med Res</dcterms:alternative>
        <dc:identifier>ISSN 1477-0334</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1340">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Base governamental,Desenvolvimento do método,Excluído - Artigo Teórico&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L607306793&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>56</prism:volume>
                <dc:title>Journal of Clinical Pharmacology</dc:title>
                <dc:identifier>DOI 10.1002/jcph.662</dc:identifier>
                <prism:number>6</prism:number>
                <dcterms:alternative>J. Clin. Pharmacol.</dcterms:alternative>
                <dc:identifier>ISSN 1552-4604</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gahr</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zeiss</foaf:surname>
                        <foaf:givenName>R.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lang</foaf:surname>
                        <foaf:givenName>D.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Connemann</foaf:surname>
                        <foaf:givenName>B.J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hiemke</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Schönfeldt-Lecuona</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1341"/>
        <dc:subject>article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>citalopram</dc:subject>
        <dc:subject>liver toxicity</dc:subject>
        <dc:subject>Medical Dictionary for Regulatory Activities</dc:subject>
        <dc:subject>amfebutamone</dc:subject>
        <dc:subject>clomipramine</dc:subject>
        <dc:subject>duloxetine</dc:subject>
        <dc:subject>escitalopram</dc:subject>
        <dc:subject>fluoxetine</dc:subject>
        <dc:subject>fluvoxamine</dc:subject>
        <dc:subject>milnacipran</dc:subject>
        <dc:subject>paroxetine</dc:subject>
        <dc:subject>sertraline</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>venlafaxine</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>quantitative analysis</dc:subject>
        <dc:subject>amitriptyline</dc:subject>
        <dc:subject>agomelatine</dc:subject>
        <dc:subject>amineptine</dc:subject>
        <dc:subject>Hypericum perforatum</dc:subject>
        <dc:subject>maprotiline</dc:subject>
        <dc:subject>mianserin</dc:subject>
        <dc:subject>mirtazapine</dc:subject>
        <dc:subject>moclobemide</dc:subject>
        <dc:subject>nefazodone</dc:subject>
        <dc:subject>nortriptyline</dc:subject>
        <dc:subject>psychopharmacotherapy</dc:subject>
        <dc:subject>reboxetine</dc:subject>
        <dc:subject>tianeptine</dc:subject>
        <dc:subject>toxic hepatitis</dc:subject>
        <dc:subject>tranylcypromine</dc:subject>
        <dc:subject>trazodone</dc:subject>
        <dc:subject>trimipramine</dc:subject>
        <dc:title>Drug-induced liver injury associated with antidepressive psychopharmacotherapy: An explorative assessment based on quantitative signal detection using different MedDRA terms</dc:title>
        <dcterms:abstract>Drug-induced liver injury is a major problem of pharmacotherapy and is also frequent with antidepressive psychopharmacotherapy. However, there are only few studies using a consistent methodologic approach to study hepatotoxicity of a larger group of antidepress ants. We performed a quantitative signal detection analysis using data from the Uppsala Monitoring Centre from the WHO that records adverse drug reaction (ADR) data from worldwide sources; we retrieved substance- and country-specific (Australia, France, Germany, Italy, Spain, the United Kingdom, and the United States) ADR data and calculated reporting odds ratios as measures for disproportionality within a case/noncase approach. To allow for identification of agents that cause severe forms of hepatotoxic ADRs, we used 2 terms of the MedDRA (&quot;drug-related hepatic disorders-comprehensive search&quot; [DRHD-CS] and &quot;... -severe events only&quot; [DRHD-SEO]). Distribution of signals was heterogeneous throughout the different data sets, and consistent findings were present for only a few substances: agomelatine (AGM) and tianeptine as well as both positive control agents (amineptine, nefazodone) generated signals related to DRHD-CS and DRHD-SEO in all analyzed data sets. Tri- and tetracyclic antidepressants (here amitriptyline, clomipramine, mianserin, mirtazapine, trimipramine) were associated with hepatotoxicity in several data sets. Using 2 MedDRA terms did not allow for detection of agents that cause severe hepatotoxic ADR. Our results support the findings of previous, primarily literature-based, systematic analyses of hepatotoxicity related to antidepressive psychopharmacotherapy. No new safety information could be generated. Application of 2 MedDRA terms did not increase the substance-specific safety information.</dcterms:abstract>
        <dc:date>2016</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079953</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L607306793&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>769-778</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1341">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Excluído - Não utiliza dados de farmacovigilância,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L617675848&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:2055-0294"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hatahira</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Abe</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hane</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Matsui</foaf:surname>
                        <foaf:givenName>T.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sasaoka</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Motooka</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hasegawa</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Fukuda</foaf:surname>
                        <foaf:givenName>A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Naganuma</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ohmori</foaf:surname>
                        <foaf:givenName>T.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kinosada</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Nakamura</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1342"/>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>incidence</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>risk factor</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>drug induced disease</dc:subject>
        <dc:subject>diazepam</dc:subject>
        <dc:subject>cyclosporine</dc:subject>
        <dc:subject>immunosuppressive agent</dc:subject>
        <dc:subject>mycophenolate mofetil</dc:subject>
        <dc:subject>everolimus</dc:subject>
        <dc:subject>sirolimus</dc:subject>
        <dc:subject>carbamazepine</dc:subject>
        <dc:subject>patient monitoring</dc:subject>
        <dc:subject>amlodipine</dc:subject>
        <dc:subject>clobazam</dc:subject>
        <dc:subject>benidipine</dc:subject>
        <dc:subject>calcium channel blocking agent</dc:subject>
        <dc:subject>anticonvulsive agent</dc:subject>
        <dc:subject>primidone</dc:subject>
        <dc:subject>levetiracetam</dc:subject>
        <dc:subject>valproic acid</dc:subject>
        <dc:subject>gabapentin</dc:subject>
        <dc:subject>priority journal</dc:subject>
        <dc:subject>aclonium</dc:subject>
        <dc:subject>adalat</dc:subject>
        <dc:subject>adalat 10</dc:subject>
        <dc:subject>adonal</dc:subject>
        <dc:subject>aephenal</dc:subject>
        <dc:subject>alboral</dc:subject>
        <dc:subject>aleviatin</dc:subject>
        <dc:subject>aliseum</dc:subject>
        <dc:subject>amlocard</dc:subject>
        <dc:subject>amlodis</dc:subject>
        <dc:subject>antisacer</dc:subject>
        <dc:subject>apo carbamazepine</dc:subject>
        <dc:subject>apo primidone</dc:subject>
        <dc:subject>atretol</dc:subject>
        <dc:subject>avugane</dc:subject>
        <dc:subject>cardene</dc:subject>
        <dc:subject>cardene iv</dc:subject>
        <dc:subject>cellcept</dc:subject>
        <dc:subject>certican</dc:subject>
        <dc:subject>chlorepin</dc:subject>
        <dc:subject>clorepin</dc:subject>
        <dc:subject>cyral</dc:subject>
        <dc:subject>drug induced gingiva hyperplasia</dc:subject>
        <dc:subject>excegran</dc:subject>
        <dc:subject>exegram</dc:subject>
        <dc:subject>gengraf</dc:subject>
        <dc:subject>gingiva hyperplasia</dc:subject>
        <dc:subject>intellectual impairment</dc:subject>
        <dc:subject>Japanese Adverse Drug Event Report database</dc:subject>
        <dc:subject>keppra</dc:subject>
        <dc:subject>lti valproic</dc:subject>
        <dc:subject>mucoloc</dc:subject>
        <dc:subject>neoral</dc:subject>
        <dc:subject>neurontin</dc:subject>
        <dc:subject>nicardipine</dc:subject>
        <dc:subject>nifedipine</dc:subject>
        <dc:subject>phenobarbital</dc:subject>
        <dc:subject>phenytoin</dc:subject>
        <dc:subject>rapamune</dc:subject>
        <dc:subject>spontaneous reporting system database</dc:subject>
        <dc:subject>sprinkle</dc:subject>
        <dc:subject>topamax</dc:subject>
        <dc:subject>topiramate</dc:subject>
        <dc:subject>US Food and Drug Administration Adverse Event Reporting System</dc:subject>
        <dc:subject>zonisamide</dc:subject>
        <dc:title>Drug-induced gingival hyperplasia: A retrospective study using spontaneous reporting system databases</dc:title>
        <dcterms:abstract>Background: Drug-induced gingival hyperplasia (DIGH) causes problems with chewing, aesthetics, and pronunciation, and leads to the deterioration of the patient's quality of life (QOL). Thus, the aim of this study was to evaluate the incidence of DIGH using spontaneous reporting system (SRS) databases. Methods: We analyzed reports of DIGH from SRS databases and calculated the reporting odds ratios (RORs) of suspected drugs (immunosuppressants, calcium channel blockers, and anticonvulsants). The SRS databases used were the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) and the Japanese Adverse Drug Event Report (JADER) database. With the data, we evaluated the time-to-onset profile and the hazard type using the Weibull shape parameter (WSP). Furthermore, we used the association rule mining technique to discover undetected relationships such as possible risk factors. Results: The FAERS contained 5,821,716 reports. The RORs (95% confidence interval: CI) for cyclosporine, everolimus, sirolimus, mycophenolate mofetil, amlodipine, nifedipine, carbamazepine, clobazam, levetiracetam, phenobarbital, phenytoin, primidone, topiramate, and valproic acid, were 39.4 (95% CI: 30.3-51.2), 4.2 (1.7-10.0), 6.6 (2.5-17.7), 13.1 (7.2-23.2), 94.8 (80.0-112.9), 57.9 (35.7-94.0), 15.1 (10.3-22.3), 65.4 (33.8-126.7), 6.5 (3.6-11.8), 19.7 (8.8-44.0), 65.4 (52.4-82.9), 56.5 (21.1-151.7), 2.9 (1.1-7.7), and 17.5 (12.6-24.4), respectively. The JADER database contained 430,587 reports. The median time-to-onset of gingival hyperplasia values for immunosuppressants, calcium channel blockers, and anticonvulsants use were 71, 262, and 37 days, respectively. Furthermore, the 95% CI of the WSP β for anticonvulsants was over and excluded 1, which meant that they were wear-out failure type. Conclusions: Our results suggest that DIGH monitoring of patients administered immunosuppressants, calcium channel blockers, or anticonvulsants is important. We demonstrated the potential risk of DIGH following the long-term use of calcium channel blocker over approximately 260 days. Based on the results of the association rule mining approach, patients with intellectual disability who are administered phenytoin should be monitored carefully. We recommend that patients who experience symptoms related to DIGH should be closely monitored.</dcterms:abstract>
        <dc:date>2017</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079941</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L617675848&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:2055-0294">
        <prism:volume>3</prism:volume>
        <dc:title>Journal of Pharmaceutical Health Care and Sciences</dc:title>
        <dc:identifier>DOI 10.1186/s40780-017-0088-5</dc:identifier>
        <prism:number>1</prism:number>
        <dcterms:alternative>J. Pharm. Health Care Sci.</dcterms:alternative>
        <dc:identifier>ISSN 2055-0294</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1342">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L616877012&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1872-7123"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kim</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Park</foaf:surname>
                        <foaf:givenName>K.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kim</foaf:surname>
                        <foaf:givenName>M.-S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yang</foaf:surname>
                        <foaf:givenName>B.R.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Choi</foaf:surname>
                        <foaf:givenName>H.J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Park</foaf:surname>
                        <foaf:givenName>B.-J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1345"/>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>adverse outcome</dc:subject>
        <dc:subject>brain hemorrhage</dc:subject>
        <dc:subject>depression</dc:subject>
        <dc:subject>dizziness</dc:subject>
        <dc:subject>heart palpitation</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>abdominal pain</dc:subject>
        <dc:subject>constipation</dc:subject>
        <dc:subject>headache</dc:subject>
        <dc:subject>insomnia</dc:subject>
        <dc:subject>muscle spasm</dc:subject>
        <dc:subject>nausea</dc:subject>
        <dc:subject>nervousness</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>vomiting</dc:subject>
        <dc:subject>hallucination</dc:subject>
        <dc:subject>psychosis</dc:subject>
        <dc:subject>somnolence</dc:subject>
        <dc:subject>speech disorder</dc:subject>
        <dc:subject>alopecia</dc:subject>
        <dc:subject>asthenia</dc:subject>
        <dc:subject>fluoxetine</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>vertebral canal stenosis</dc:subject>
        <dc:subject>anorexia</dc:subject>
        <dc:subject>sexual dysfunction</dc:subject>
        <dc:subject>body weight loss</dc:subject>
        <dc:subject>dysphagia</dc:subject>
        <dc:subject>dyspepsia</dc:subject>
        <dc:subject>malaise</dc:subject>
        <dc:subject>medication error</dc:subject>
        <dc:subject>stomatitis</dc:subject>
        <dc:subject>China</dc:subject>
        <dc:subject>abnormal dreaming</dc:subject>
        <dc:subject>urticaria</dc:subject>
        <dc:subject>extrapyramidal syndrome</dc:subject>
        <dc:subject>mania</dc:subject>
        <dc:subject>C reactive protein</dc:subject>
        <dc:subject>France</dc:subject>
        <dc:subject>disease exacerbation</dc:subject>
        <dc:subject>dystonia</dc:subject>
        <dc:subject>tremor</dc:subject>
        <dc:subject>xerostomia</dc:subject>
        <dc:subject>adrenal insufficiency</dc:subject>
        <dc:subject>anxiety disorder</dc:subject>
        <dc:subject>mental instability</dc:subject>
        <dc:subject>urine incontinence</dc:subject>
        <dc:subject>maculopapular rash</dc:subject>
        <dc:subject>suicide attempt</dc:subject>
        <dc:subject>priority journal</dc:subject>
        <dc:subject>drug dependence</dc:subject>
        <dc:subject>epidermolysis</dc:subject>
        <dc:subject>Germany</dc:subject>
        <dc:subject>hepatitis</dc:subject>
        <dc:subject>hyperkinesia</dc:subject>
        <dc:subject>impotence</dc:subject>
        <dc:subject>Korea</dc:subject>
        <dc:subject>lactation disorder</dc:subject>
        <dc:subject>mental function assessment</dc:subject>
        <dc:subject>muscle hypertonia</dc:subject>
        <dc:subject>myositis</dc:subject>
        <dc:subject>paradoxical drug reaction</dc:subject>
        <dc:subject>paroniria</dc:subject>
        <dc:subject>serotonin syndrome</dc:subject>
        <dc:subject>serotonin uptake inhibitor</dc:subject>
        <dc:subject>stupor</dc:subject>
        <dc:subject>United Kingdom</dc:subject>
        <dc:subject>vesicular rash</dc:subject>
        <dc:subject>yawning</dc:subject>
        <dc:title>Data-mining for detecting signals of adverse drug reactions of fluoxetine using the Korea Adverse Event Reporting System (KAERS) database</dc:title>
        <dcterms:abstract>Selective serotonin reuptake inhibitors (SSRIs) have become one of the most broadly used medications in psychiatry. Fluoxetine is the first representative antidepressant SSRI drug approved by the Food and Drug Administration (FDA) in 1987. Safety information on fluoxetine use alone was less reported than its combined use with other drugs. There were no published papers on adverse drug reactions (ADRs) of fluoxetine analyzing spontaneous adverse events reports. We detected signals of the adverse drug reactions of fluoxetine by data mining using the Korea Adverse Events Reporting System (KAERS) database. We defined signals in this study by the reporting odds ratios (ROR), proportional reporting ratios (PRR), and information components (IC) indices. The KAERS database included 860,224 AE reports, among which 866 reports contained fluoxetine. We compared the labels of fluoxetine among the United States, UK, Germany, France, China, and Korea. Some of the signals, including emotional lability, myositis, spinal stenosis, paradoxical drug reaction, drug dependence, extrapyramidal disorder, adrenal insufficiency, and intracranial hemorrhage, were not labeled in the six countries. In conclusion, we identified new signals that were not known at the time of market approval. However, certain factors should be required for signal evaluation, such as clinical significance, preventability, and causality of the detected signals.</dcterms:abstract>
        <dc:date>2017</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079940</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L616877012&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>237-242</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1872-7123">
        <prism:volume>256</prism:volume>
        <dc:title>Psychiatry Research</dc:title>
        <dc:identifier>DOI 10.1016/j.psychres.2017.06.038</dc:identifier>
        <dcterms:alternative>Psychiatry Res.</dcterms:alternative>
        <dc:identifier>ISSN 1872-7123</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1345">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L618350679&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1876-2026"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Subeesh</foaf:surname>
                        <foaf:givenName>V.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Singh</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Maheswari</foaf:surname>
                        <foaf:givenName>E.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Beulah</foaf:surname>
                        <foaf:givenName>E.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1343"/>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>insomnia</dc:subject>
        <dc:subject>agitation</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>vortioxetine</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>body weight loss</dc:subject>
        <dc:subject>abnormal dreaming</dc:subject>
        <dc:subject>anger</dc:subject>
        <dc:subject>priority journal</dc:subject>
        <dc:subject>brintellix</dc:subject>
        <dc:subject>information component algorithm</dc:subject>
        <dc:subject>ketoacidosis</dc:subject>
        <dc:subject>proportional reporting ratio algorithm</dc:subject>
        <dc:subject>reporting odds ratio algorithm</dc:subject>
        <dc:subject>trintellix</dc:subject>
        <dc:title>Novel adverse events of vortioxetine: A disproportionality analysis in USFDA adverse event reporting system database</dc:title>
        <dcterms:abstract>Background Signal detection is one of the most advanced and emerging field in pharmacovigilance. It is a modern method of detecting new reaction (which can be desired or undesired) of a drug. It facilitates early adverse drug reaction detection which enables health professionals to identify adverse events that may not have been identified in pre-marketing clinical trials. Vortioxetine, the first mixed serotonergic antidepressant was initially approved by the US Food and Drug Administration (USFDA) on September 30, 2013 for the treatment of adults with Major Depressive Disorder (MDD). This study was to identify the signal strength for vortioxetine associated ADRs using data mining technique in USFDA Adverse Event Reporting System (AERS) database. Methodology Most commonly used three data mining algorithms, Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR) and Information Component (IC) were selected for the study and they were applied retrospectively in USFDA AERS database from 2015Q1 to 2016Q3. A value of ROR-1.96SE &gt; 1, PRR ≥ 2, IC- 2SD &gt; 0 were considered as the positive signal. Result A study population of 61,22,000 were reported all over the world. Among which 3481 reactions were associated with vortioxetine which comprised of 632 unique events encompassed with 27 clinically relevant reactions. ROR, PRR and IC showed positive signal for weight loss, agitation, anger, ketoacidosis, insomnia and abnormal dreams. Conclusion The present study suggests that vortioxetine may result in these adverse events. Further pharmacoepidemiologic studies are necessary to confirm this conclusion and to improve the precision of the prevalence and/or the risk factors of this ADRs.</dcterms:abstract>
        <dc:date>2017</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079939</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L618350679&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>152-156</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1876-2026">
        <prism:volume>30</prism:volume>
        <dc:title>Asian Journal of Psychiatry</dc:title>
        <dc:identifier>DOI 10.1016/j.ajp.2017.09.005</dc:identifier>
        <dcterms:alternative>Asian J. Psychiatry</dcterms:alternative>
        <dc:identifier>ISSN 1876-2026</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1343">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L626838547&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:2385-409X"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Proy Vega</foaf:surname>
                        <foaf:givenName>B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Martínez Blázquez</foaf:surname>
                        <foaf:givenName>A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Solís-García Del Pozo</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jordán</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1184"/>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>incidence</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>mental disease</dc:subject>
        <dc:subject>neurologic disease</dc:subject>
        <dc:subject>clonazepam</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>mediastinum disease</dc:subject>
        <dc:subject>respiratory tract disease</dc:subject>
        <dc:subject>thorax disease</dc:subject>
        <dc:subject>alprazolam</dc:subject>
        <dc:subject>benzodiazepine derivative</dc:subject>
        <dc:subject>chlordiazepoxide</dc:subject>
        <dc:subject>clorazepate</dc:subject>
        <dc:subject>diazepam</dc:subject>
        <dc:subject>statistical analysis</dc:subject>
        <dc:subject>drug abuse</dc:subject>
        <dc:subject>clobazam</dc:subject>
        <dc:subject>lorazepam</dc:subject>
        <dc:subject>skin manifestation</dc:subject>
        <dc:subject>temazepam</dc:subject>
        <dc:subject>drug recall</dc:subject>
        <dc:subject>estazolam</dc:subject>
        <dc:subject>flurazepam</dc:subject>
        <dc:subject>midazolam</dc:subject>
        <dc:subject>oxazepam</dc:subject>
        <dc:subject>quazepam</dc:subject>
        <dc:subject>tetrazepam</dc:subject>
        <dc:subject>triazolam</dc:subject>
        <dc:title>Detecting pharmacovigilance signals: Data mining of benzodiazepines adverse reactions notified to FDA reporting system</dc:title>
        <dcterms:abstract>Since patients have easier access to information, thanks to the growing development of technology, their concern about everything related to drugs, especially adverse drug reactions, has increased. Resulting of this, authorities and health agencies are increasingly interested in drug safety and early detection of signals. Quantitative signals detection methods are useful for detecting pharmacovigilance signals, which can be analyzed to establish causality between an adverse event and a drug. Goal of this study was to deepen in signal detection of adverse drug reactions potentially associated to benzodiazepines, through the analysis of spontaneous notifications reported to the United States pharmacovigilance database (FAERS); after a previous work of signals detection of only cutaneous adverse reactions associated to this family of drugs, by applying data mining technique and different algorithms. All this, initially motivated by the market withdrawal of medicines containing tetrazepam in 2013, due to serious adverse skin reactions after the analysis of the suspected adverse reactions reported to the French pharmacovigilance database. The most frequently reported adverse reaction to FAERS associated to benzodiazepines marketed in the United States were analyzed. Our statistical analysis revealed the following signals generated by different algorithmic methods of disproportionality analysis: when Proportional Reporting Ratio applied, only a single signal for estazolam and &quot;Cardiac disorders» was detected. Reporting Odd Ratio algorithm detected 31, the largest number of signals. With Information Component, 24 signals were detected. Finally, using Empirical Bayesian Geometric Mean algorithm, two signals were detected: one for clobazam and &quot;Nervous system disorders», and another for quazepam and &quot;Lesions, intoxications and procedural complications». All these adverse events are described in the Summary of Product Characteristic of these drugs, in different frequencies. A signal is a suggestion that there is a statistical association between a medication and an event. Calculating signals does not provide an estimation of the incidence of adverse reaction or information about whether a statistical association between a drug and an adverse reaction is causal, but highlights potential drug problems that draw the attention of the pharmacovigilance community for investigating in more detail to maximize safety of the drug.</dcterms:abstract>
        <dc:date>2018</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079932</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L626838547&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>294-303</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:2385-409X">
        <prism:volume>20</prism:volume>
        <dc:title>European Journal of Clinical Pharmacy</dc:title>
        <prism:number>6</prism:number>
        <dcterms:alternative>European j.clin.pharm.</dcterms:alternative>
        <dc:identifier>ISSN 2385-409X</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1184">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L626424689&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>42</prism:volume>
                <dc:title>Drug Safety</dc:title>
                <dc:identifier>DOI 10.1007/s40264-018-00792-0</dc:identifier>
                <prism:number>6</prism:number>
                <dcterms:alternative>Drug Saf.</dcterms:alternative>
                <dc:identifier>ISSN 1179-1942</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Pham</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Cheng</foaf:surname>
                        <foaf:givenName>F.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ramachandran</foaf:surname>
                        <foaf:givenName>K.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1188"/>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>area under the curve</dc:subject>
        <dc:subject>drug</dc:subject>
        <dc:subject>priority journal</dc:subject>
        <dc:subject>receiver operating characteristic</dc:subject>
        <dc:subject>sensitivity and specificity</dc:subject>
        <dc:subject>Youden index</dc:subject>
        <dc:subject>genome-wide association study</dc:subject>
        <dc:subject>random forest</dc:subject>
        <dc:title>A Comparison Study of Algorithms to Detect Drug–Adverse Event Associations: Frequentist, Bayesian, and Machine-Learning Approaches</dc:title>
        <dcterms:abstract>Introduction: It is important to monitor the safety profile of drugs, and mining for strong associations between drugs and adverse events is an effective and inexpensive method of post-marketing safety surveillance. Objective: The objective of our work was to compare the accuracy of both common and innovative methods of data mining for pharmacovigilance purposes. Methods: We used the reference standard provided by the Observational Medical Outcomes Partnership, which contains 398 drug–adverse event pairs (165 positive controls, 233 negative controls). Ten methods and algorithms were applied to the US FDA Adverse Event Reporting System data to investigate the 398 pairs. The ten methods include popular methods in the pharmacovigilance literature, newly developed pharmacovigilance methods as at 2018, and popular methods in the genome-wide association study literature. We compared their performance using the receiver operating characteristic (ROC) plot, area under the curve (AUC), and Youden’s index. Results: The Bayesian confidence propagation neural network had the highest AUC overall. Monte Carlo expectation maximization, a method developed in 2018, had the second highest AUC and the highest Youden’s index, and performed very well in terms of high specificity. The regression-adjusted gamma Poisson shrinkage model performed best under high-sensitivity requirements. Conclusion: Our results will be useful to help choose a method for a given desired level of specificity. Methods popular in the genome-wide association study literature did not perform well because of the sparsity of data and will need modification before their properties can be used in the drug–adverse event association problem.</dcterms:abstract>
        <dc:date>2019</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079924</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L626424689&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>743-750</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1188">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Dados reais,Desenvolvimento do método&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L621106761&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>9</prism:volume>
                <dc:title>Frontiers in Pharmacology</dc:title>
                <dc:identifier>DOI 10.3389/fphar.2018.00197</dc:identifier>
                <dcterms:alternative>Front. Pharmacol.</dcterms:alternative>
                <dc:identifier>ISSN 1663-9812</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Noguchi</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ueno</foaf:surname>
                        <foaf:givenName>A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Otsubo</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Katsuno</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sugita</foaf:surname>
                        <foaf:givenName>I.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kanematsu</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yoshida</foaf:surname>
                        <foaf:givenName>A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Esaki</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tachi</foaf:surname>
                        <foaf:givenName>T.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Teramachi</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1185"/>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>clarithromycin</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>drug database</dc:subject>
        <dc:subject>drug drug interaction</dc:subject>
        <dc:subject>drug interaction</dc:subject>
        <dc:subject>Drug-drug interaction</dc:subject>
        <dc:subject>Apriori algorithm</dc:subject>
        <dc:subject>carbamazepine</dc:subject>
        <dc:subject>Stevens Johnson syndrome</dc:subject>
        <dc:subject>lamotrigine</dc:subject>
        <dc:subject>Association rule mining</dc:subject>
        <dc:subject>sensitivity and specificity</dc:subject>
        <dc:subject>phenytoin</dc:subject>
        <dc:subject>association rule mining</dc:subject>
        <dc:subject>measurement accuracy</dc:subject>
        <dc:subject>Signal detection</dc:subject>
        <dc:subject>spontaneous reporting system</dc:subject>
        <dc:subject>Spontaneous reporting systems</dc:subject>
        <dc:subject>Youden index</dc:subject>
        <dc:title>A new search method using association rule mining for drug-drug interaction based on spontaneous report system</dc:title>
        <dcterms:abstract>Background: Adverse events (AEs) can be caused not only by one drug but also by the interaction between two or more drugs. Therefore, clarifying whether an AE is due to a specific suspect drug or drug-drug interaction (DDI) is useful information for proper use of drugs. Whereas previous reports on the search for drug-induced AEs with signal detection using spontaneous reporting systems (SRSs) are numerous, reports on drug interactions are limited. This is because in methods that use &quot;a safety signal indicator&quot; (signal), which is frequently used in pharmacovigilance, a huge number of combinations must be prepared when signal detection is performed, and each risk index must be calculated, which makes interaction search appear unrealistic. Objective: In this paper, we propose association rule mining (AR) using large dataset analysis as an alternative to the conventional methods (additive interaction model (AI) and multiplicative interaction model (MI)). Methods: The data source used was the Japanese Adverse Drug Event Report database. The combination of drugs for which the risk index is detected by the &quot;combination risk ratio (CR)&quot; as the target was assumed to be true data, and the accuracy of signal detection using the AR methods was evaluated in terms of sensitivity, specificity, Youden's index, F-score. Results: Our experimental results targeting Stevens-Johnson syndrome indicate that AR has a sensitivity of 99.05%, specificity of 92.60%, Youden's index of 0.917, F-score of 0.876, AI has a sensitivity of 95.62%, specificity of 96.92%, Youden's index of 0.925, and F-score of 0.924, and MI has a sensitivity of 65.46%, specificity of 98.78%, Youden's index of 0.642, and F-score of 0.771. This result was about the same level as or higher than the conventional method. Conclusions: If you use similar calculation methods to create combinations from the database, not only for SJS, but for all AEs, the number of combinations would be so enormous that it would be difficult to perform the calculations. However, in the AR method, the &quot;Apriori algorithm&quot; is used to reduce the number of calculations. Thus, the proposed method has the same detection power as the conventional methods, with the significant advantage that its calculation process is simple.</dcterms:abstract>
        <dc:date>2018</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079936</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L621106761&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Memo rdf:about="#item_1185">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 40; Correspondence Address: Y. Noguchi; Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan; email: noguchiy@gifu-pu.ac.jp&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Desenvolvimento do método,Excluído - Não utiliza dados de farmacovigilância,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L623964659&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1099-1557"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhu</foaf:surname>
                        <foaf:givenName>T.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ye</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hou</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shi</foaf:surname>
                        <foaf:givenName>W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xu</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Guo</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>He</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1187"/>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>arsenic trioxide</dc:subject>
        <dc:subject>myalgia</dc:subject>
        <dc:subject>neuroleptic agent</dc:subject>
        <dc:subject>tachycardia</dc:subject>
        <dc:subject>gastrointestinal discomfort</dc:subject>
        <dc:subject>analgesic agent</dc:subject>
        <dc:subject>antineoplastic agent</dc:subject>
        <dc:subject>antibiotic agent</dc:subject>
        <dc:subject>gemfibrozil</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>amitriptyline</dc:subject>
        <dc:subject>bone marrow suppression</dc:subject>
        <dc:subject>leukopenia</dc:subject>
        <dc:subject>China</dc:subject>
        <dc:subject>thrombocytopenia</dc:subject>
        <dc:subject>face edema</dc:subject>
        <dc:subject>appetite disorder</dc:subject>
        <dc:subject>cephalosporin derivative</dc:subject>
        <dc:subject>daunorubicin</dc:subject>
        <dc:subject>liver dysfunction</dc:subject>
        <dc:subject>hydroxymethylglutaryl coenzyme A reductase inhibitor</dc:subject>
        <dc:subject>pharmacoepidemiology</dc:subject>
        <dc:subject>priority journal</dc:subject>
        <dc:subject>aminoglycoside</dc:subject>
        <dc:subject>antiinflammatory agent</dc:subject>
        <dc:subject>antipyretic agent</dc:subject>
        <dc:subject>epirubicin</dc:subject>
        <dc:subject>gold standard</dc:subject>
        <dc:subject>levothyroxine</dc:subject>
        <dc:subject>meloxicam</dc:subject>
        <dc:subject>quinolone derivative</dc:subject>
        <dc:subject>sartan derivative</dc:subject>
        <dc:subject>taxonomy</dc:subject>
        <dc:subject>tuberculostatic agent</dc:subject>
        <dc:title>Application of biclustering algorithm in adverse drug reaction monitoring system of China</dc:title>
        <dcterms:abstract>Purpose: Signal evaluation is considered to be a tedious process owing to the large number of disproportional signals detected. This study aimed to apply a biclustering algorithm in the spontaneous reporting system of China and to obtain the optimal parameters. The biclustering algorithm is expected to improve the efficiency of signal evaluation by identifying similar signal groups. Methods: Information component (IC) was the method used for disproportionality analysis. By using IC thresholds of various strengths (0.05–4.00), the original quantitative data matrix was transformed into 80 different binary data matrices, where each cell contained either a 1 or 0. The biclustering results were obtained using a total of 720 Bimax algorithm parameters (minimal number of columns and rows was 3, 4, or 5). Next, the optimal parameters were determined through the comprehensive evaluation of the rank sum ration. Finally, we examined the biclustering results under the optimal parameters and evaluated the effect of biclustering analysis on adverse drug reaction (ADR) data in China. Results: The optimal strength of the IC threshold was 0.80, and the minimum number of rows and columns was 3. After taxonomic evaluation, we also found that 1836 biclusters (42.8%) contained similar drugs or similar ADRs, which accounted for 72.3% of signals unevaluated. Conclusions: Applying biclustering analysis in spontaneous reporting system could provide support in confirming unrecognized ADRs, identifying rare ADRs, and screening drug-ADR pairs, which need more attention. Biclustering algorithm could improve the efficiency of signal detection and evaluation in China.</dcterms:abstract>
        <dc:date>2018</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079931</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L623964659&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>1257-1264</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1099-1557">
        <prism:volume>27</prism:volume>
        <dc:title>Pharmacoepidemiology and Drug Safety</dc:title>
        <dc:identifier>DOI 10.1002/pds.4661</dc:identifier>
        <prism:number>11</prism:number>
        <dcterms:alternative>Pharmacoepidemiol. Drug Saf.</dcterms:alternative>
        <dc:identifier>ISSN 1099-1557</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1187">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2003342063&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1432-0843"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shimada</foaf:surname>
                        <foaf:givenName>K.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hasegawa</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Nakao</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mukai</foaf:surname>
                        <foaf:givenName>R.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Matsumoto</foaf:surname>
                        <foaf:givenName>K.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tanaka</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Uranishi</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Masuta</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Nishida</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shimizu</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hayashi</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Suzuki</foaf:surname>
                        <foaf:givenName>A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Nakamura</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1190"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>risk factor</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>drug induced disease</dc:subject>
        <dc:subject>brain disease</dc:subject>
        <dc:subject>Medical Dictionary for Regulatory Activities</dc:subject>
        <dc:subject>priority journal</dc:subject>
        <dc:subject>aprepitant</dc:subject>
        <dc:subject>ifosfamide</dc:subject>
        <dc:title>Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases</dc:title>
        <dcterms:abstract>Purpose: Ifosfamide is extensively used to treat several malignant conditions. Administration of ifosfamide can cause encephalopathy and other neurotoxic effects. The aim of this study was to obtain novel information on the onset profiles of ifosfamide-induced encephalopathy (IIE) considering other associated clinical factors using the US Food and Drug Administration Adverse Event Reporting System (FAERS) and the Japanese Adverse Drug Event Report (JADER) databases. Methods: We analyzed the reports of encephalopathy between 2004 and 2018 from the FAERS and JADER databases. To define IIE, we used the Medical Dictionary for Regulatory Activities (MedDRA) preferred terms and standardized queries. The reporting odds ratios (ROR) at 95% confidence interval (CI) was used to detect the signal for IIE and adjusted for covariates using a multivariate logistic regression technique. We evaluated the time-to-onset profile of IIE and used the association rule mining technique to discover undetected associations, such as potential risk factors. Results: In the FAERS database, the ROR (CI) for encephalopathy (preferred term, PT) and encephalopathy (standardized MedDRA queries, SMQ) was 56.58 (51.69–61.93) and 1.57 (1.48–1.67), respectively. In the JADER database, the ROR (95% CI) for encephalopathy (PT) and encephalopathy (SMQ) was 13.54 (9.91–18.50) and 1.24 (1.01–1.53), respectively. The multivariate logistic regression analysis showed a significant contribution in IIE signal in the ≥ 60 year group (p = 0.00094; vs. &lt; 60 year group) and ≥ 2000 mg/m2 dosage group (p = 0.00045; vs. &lt; 2000 mg/m2 dosage group). The association rules of {ifosfamide, aprepitant} → {encephalopathy (SMQ)} demonstrated high lift values. The average dose of ifosfamide in patients with encephalopathy (PT) and without encephalopathy (PT) was 2022.8 ± 592.8 (mean ± standard deviation) and 1568.5 ± 703.2 mg/m2, respectively (p &lt; 0.05). Encephalopathy within the first 7 days of ifosfamide administration was 94.1% for encephalopathy (PT) and 87.7% for encephalopathy (SMQ), respectively. Conclusions: The present analysis demonstrated that the incidence of encephalopathy with ifosfamide should be closely monitored for a short onset (within 7 days). The patients who are administered a high dose of ifosfamide or co-administrated aprepitant should be carefully monitored for the development of encephalopathy.</dcterms:abstract>
        <dc:date>2019</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079917</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2003342063&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>1097-1105</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1432-0843">
        <prism:volume>84</prism:volume>
        <dc:title>Cancer Chemotherapy and Pharmacology</dc:title>
        <dc:identifier>DOI 10.1007/s00280-019-03949-5</dc:identifier>
        <prism:number>5</prism:number>
        <dcterms:alternative>Cancer Chemother. Pharmacol.</dcterms:alternative>
        <dc:identifier>ISSN 1432-0843</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1190">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2005649906&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>Expert Opinion on Drug Safety</dc:title>
                <dc:identifier>DOI 10.1080/14740338.2020.1799975</dc:identifier>
                <dcterms:alternative>Expert Opin. Drug Saf.</dcterms:alternative>
                <dc:identifier>ISSN 1744-764X</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Peng</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xiao</foaf:surname>
                        <foaf:givenName>K.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ottaviani</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Stebbing</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>Y.-J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1193"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>descriptive research</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>nephritis</dc:subject>
        <dc:subject>deep vein thrombosis</dc:subject>
        <dc:subject>retinal artery occlusion</dc:subject>
        <dc:subject>lung embolism</dc:subject>
        <dc:subject>coronavirus disease 2019</dc:subject>
        <dc:subject>hepatobiliary disease</dc:subject>
        <dc:subject>digestive system perforation</dc:subject>
        <dc:subject>neutropenia</dc:subject>
        <dc:subject>baricitinib</dc:subject>
        <dc:subject>opportunistic infection</dc:subject>
        <dc:subject>herpes virus infection</dc:subject>
        <dc:subject>herpes zoster</dc:subject>
        <dc:subject>pandemic</dc:subject>
        <dc:subject>Pneumocystis pneumonia</dc:subject>
        <dc:title>A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib</dc:title>
        <dcterms:abstract>Background: Baricitinib is approved for the treatment of rheumatoid arthritis (RA). The authors retrospectively investigated adverse events (AEs) by data-mining a self-reporting database to better understand toxicities, especially since it has been used during the coronavirus disease 2019 (COVID-19) pandemic. Methods: A reporting odds ratio (ROR) was used to detect the risk signals from the data in the US Food and Drug Administration (FDA) adverse event reporting system database (FAERS). The definition relied on system organ class (SOCs) and preferred terms (PTs) by the Medical Dictionary for Regulatory Activities (MedDRA). Results: The search retrieved 1,598 baricitinib-associated cases within the reporting period: 86 PTs with significant disproportionality were retained. Infections including “herpes zoster”, “oral herpes” and “herpes virus infection” were found at a similar rate to those reported in trials, and such events were rare. Reports emerged for several thrombotic adverse events, while these events were also rare. Unexpected safety signals as opportunistic infections were detected. Serious outcomes as death and life-threatening outcomes accounted for 9.76% of the reported cases. Conclusions: The incidence of these AEs does not appear above the background expected. These data are consistent with routine clinical observations and suggest the importance of pharmacovigilance.</dcterms:abstract>
        <dc:date>2020</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079910</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2005649906&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>1505-1511</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1193">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2003536453&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1434-9949"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ha</foaf:surname>
                        <foaf:givenName>D.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lee</foaf:surname>
                        <foaf:givenName>S.E.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Song</foaf:surname>
                        <foaf:givenName>I.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lim</foaf:surname>
                        <foaf:givenName>S.J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shin</foaf:surname>
                        <foaf:givenName>J.-Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1194"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>injection site pain</dc:subject>
        <dc:subject>injection site pruritus</dc:subject>
        <dc:subject>injection site rash</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>heart palpitation</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>injection site bleeding</dc:subject>
        <dc:subject>acne</dc:subject>
        <dc:subject>adalimumab</dc:subject>
        <dc:subject>alopecia</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>dyspnea</dc:subject>
        <dc:subject>hypotension</dc:subject>
        <dc:subject>drug use</dc:subject>
        <dc:subject>comparative study</dc:subject>
        <dc:subject>drug hypersensitivity</dc:subject>
        <dc:subject>methotrexate</dc:subject>
        <dc:subject>rash</dc:subject>
        <dc:subject>face edema</dc:subject>
        <dc:subject>hyperkeratosis</dc:subject>
        <dc:subject>thorax pain</dc:subject>
        <dc:subject>urticaria</dc:subject>
        <dc:subject>hypertransaminasemia</dc:subject>
        <dc:subject>pruritus</dc:subject>
        <dc:subject>etanercept</dc:subject>
        <dc:subject>infliximab</dc:subject>
        <dc:subject>liver dysfunction</dc:subject>
        <dc:subject>priority journal</dc:subject>
        <dc:subject>Korea</dc:subject>
        <dc:subject>herpes zoster</dc:subject>
        <dc:subject>body temperature sensation</dc:subject>
        <dc:subject>generalized edema</dc:subject>
        <dc:subject>rigor</dc:subject>
        <dc:subject>sarcoidosis</dc:subject>
        <dc:subject>thyroid cancer</dc:subject>
        <dc:subject>uveitis</dc:subject>
        <dc:title>Comparison of signal detection of tumour necrosis factor-α inhibitors using the Korea Adverse Events Reporting System Database, 2005–2016</dc:title>
        <dcterms:abstract>Objectives: There are no pharmacovigilance studies on adverse event (AE) data for tumour necrosis factor alpha (TNFα) inhibitors in South Korea. We analysed AEs induced by adalimumab, infliximab, and etanercept Methods: We used data from the Korea Institute of Drug Safety and Risk Management–Korea Adverse Events Reporting System Database (KIDS-KD) collected between 2005 and 2016. We used three different signal detection methods: proportional reporting ratio (PRR), reporting odds ratio (ROR), and information component (IC). The drug was compared with drug labels in the USA and Korea. Logistic regression analysis identified AEs that are more likely to occur with drug use. Results: Of the 5594 AEs identified, 350, 452, and 71 were related to adalimumab, infliximab, and etanercept, respectively. We identified seven new signals, which were not listed on drug labels in either Korea or the USA, for AEs associated with the study drugs: two for adalimumab (medication error and drug failure), two for infliximab (palpitation and temperature sensation change), and three for etanercept (hyperkeratosis, acne, and thyroid neoplasm malignant). Injection site pain (OR 6.14, 95% CI 1.15–32.74) and alopecia (OR 4.54, 95% CI 1.16–17.77) for adalimumab, chest pain (OR 6.01, 95% CI 1.35–26.77) for infliximab, and uveitis (OR 10.11, 95% CI 1.13–90.77) for etanercept were more likely to be reported in patients with each TNFα inhibitor than in those without, respectively. Conclusions: Seven new signals that were not included in the current label were identified for TNFα inhibitors and should be updated and monitored.Key Points• Large-scale spontaneous AE reporting data and data mining techniques are useful for detecting signals of rare AEs as well as common AEs induced by drugs.• Drug labels should be updated to reflect signals that are newly discovered by continuous monitoring.</dcterms:abstract>
        <dc:date>2020</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079908</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2003536453&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>347-355</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1434-9949">
        <prism:volume>39</prism:volume>
        <dc:title>Clinical Rheumatology</dc:title>
        <dc:identifier>DOI 10.1007/s10067-019-04802-z</dc:identifier>
        <prism:number>2</prism:number>
        <dcterms:alternative>Clin. Rheumatol.</dcterms:alternative>
        <dc:identifier>ISSN 1434-9949</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1194">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2004814708&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1573-904X"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Noguchi</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tachi</foaf:surname>
                        <foaf:givenName>T.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Teramachi</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1195"/>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>unclassified drug</dc:subject>
        <dc:subject>levothyroxine sodium</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>confidence interval</dc:subject>
        <dc:subject>comparative study</dc:subject>
        <dc:subject>diclofenac</dc:subject>
        <dc:subject>drug interaction</dc:subject>
        <dc:subject>allopurinol</dc:subject>
        <dc:subject>detection algorithm</dc:subject>
        <dc:subject>cimetidine</dc:subject>
        <dc:subject>frequency analysis</dc:subject>
        <dc:subject>contingency table</dc:subject>
        <dc:subject>priority journal</dc:subject>
        <dc:subject>statistical model</dc:subject>
        <dc:subject>spontaneous reporting system</dc:subject>
        <dc:subject>additive model</dc:subject>
        <dc:subject>auranofin</dc:subject>
        <dc:subject>azulene derivative</dc:subject>
        <dc:subject>chi square statistics model</dc:subject>
        <dc:subject>colestilan</dc:subject>
        <dc:subject>combination risk ratio model</dc:subject>
        <dc:subject>epinastine</dc:subject>
        <dc:subject>glutamine</dc:subject>
        <dc:subject>kappa statistics</dc:subject>
        <dc:subject>mecobalamin</dc:subject>
        <dc:subject>multiplicative model</dc:subject>
        <dc:subject>pentoxyverine</dc:subject>
        <dc:subject>pranoprofen</dc:subject>
        <dc:subject>shrinkage measure model</dc:subject>
        <dc:subject>sodium azulene sulfonate hydrate</dc:subject>
        <dc:title>Comparison of Signal Detection Algorithms Based on Frequency Statistical Model for Drug-Drug Interaction Using Spontaneous Reporting Systems</dc:title>
        <dcterms:abstract>Purpose: Adverse events (AEs) caused by polypharmacy have recently become a clinical problem, and it is important to monitor the safety profile of drug-drug interactions (DDIs). Mining signals using the spontaneous reporting systems is a very effective method for single drug-induced AE monitoring as well as early detection of DDIs. The objective of this study was to compare signal detection algorithms for DDIs based on frequency statistical models. Methods: Five frequency statistical models: the Ω shrinkage measure, additive (risk difference), multiplicative (risk ratio), combination risk ratio, and chi-square statistics models were compared using the Japanese Adverse Drug Event Report (JADER) database as the spontaneous reporting system in Japan. The drugs targeted for the survey are all registered and classified as “suspect drugs” in JADER, and the AEs targeted for this study were the same as those in a previous study on Stevens-Johnson syndrome (SJS). Results: Of 3924 pairs that reported SJS, the number of signals detected by the Ω shrinkage measure, additive, multiplicative, combination risk ratio, and chi-square statistics models was 712, 3298, 2252, 739, and 1289 pairs, respectively. Among the five models, the Ω shrinkage measure model showed the most conservative signal detection tendency. Conclusion: Specifically, caution should be exercised when the number of reports is low because results differ depending on the statistical models. This study will contribute to the selection of appropriate statistical models to detect signals of potential DDIs.</dcterms:abstract>
        <dc:date>2020</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079906</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2004814708&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1573-904X">
        <prism:volume>37</prism:volume>
        <dc:title>Pharmaceutical Research</dc:title>
        <dc:identifier>DOI 10.1007/s11095-020-02801-3</dc:identifier>
        <prism:number>5</prism:number>
        <dcterms:alternative>Pharm. Res.</dcterms:alternative>
        <dc:identifier>ISSN 1573-904X</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1195">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Desenvolvimento do método,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2005876655&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>84</prism:volume>
                <dc:title>International Immunopharmacology</dc:title>
                <dc:identifier>DOI 10.1016/j.intimp.2020.106601</dc:identifier>
                <dcterms:alternative>Int. Immunopharmacol.</dcterms:alternative>
                <dc:identifier>ISSN 1878-1705</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hu</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gong</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhao</foaf:surname>
                        <foaf:givenName>B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hai</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1197"/>
        <dc:subject>acute kidney failure</dc:subject>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>adverse outcome</dc:subject>
        <dc:subject>nephritis</dc:subject>
        <dc:subject>outcome assessment</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>liver toxicity</dc:subject>
        <dc:subject>unclassified drug</dc:subject>
        <dc:subject>arthritis</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>drug use</dc:subject>
        <dc:subject>pancreatitis</dc:subject>
        <dc:subject>pneumonia</dc:subject>
        <dc:subject>rash</dc:subject>
        <dc:subject>encephalitis</dc:subject>
        <dc:subject>neutropenia</dc:subject>
        <dc:subject>thrombocytopenia</dc:subject>
        <dc:subject>conjunctivitis</dc:subject>
        <dc:subject>colitis</dc:subject>
        <dc:subject>atezolizumab</dc:subject>
        <dc:subject>ipilimumab</dc:subject>
        <dc:subject>melanoma</dc:subject>
        <dc:subject>myasthenia gravis</dc:subject>
        <dc:subject>nivolumab</dc:subject>
        <dc:subject>pembrolizumab</dc:subject>
        <dc:subject>adrenal insufficiency</dc:subject>
        <dc:subject>immune checkpoint inhibitor</dc:subject>
        <dc:subject>monotherapy</dc:subject>
        <dc:subject>avelumab</dc:subject>
        <dc:subject>cemiplimab</dc:subject>
        <dc:subject>durvalumab</dc:subject>
        <dc:subject>lung cancer</dc:subject>
        <dc:subject>priority journal</dc:subject>
        <dc:subject>hepatitis</dc:subject>
        <dc:subject>uveitis</dc:subject>
        <dc:subject>hyperthyroidism</dc:subject>
        <dc:subject>hypophysitis</dc:subject>
        <dc:subject>hypothyroidism</dc:subject>
        <dc:subject>immunological antineoplastic agent</dc:subject>
        <dc:subject>oral mucositis</dc:subject>
        <dc:subject>pure red cell anemia</dc:subject>
        <dc:subject>Sjoegren syndrome</dc:subject>
        <dc:title>Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system</dc:title>
        <dcterms:abstract>Background: Although colitis has been reported in patients treated with immune checkpoint inhibitors (ICIs), associations between colitis and ICIs had not been thoroughly assessed in real-world studies. Here, we identified and characterized significant colitis-associated with ICIs. Methods: Based on the Food and Drug Administration Adverse Event Reporting System (FAERS) from January 2004 to December 2019, the disproportionality analysis and Bayesian analysis, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN) and the multi-item gamma Poisson shrinker (MGPS) algorithms were adopted to data mining of the suspected adverse events of colitis after ICIs administrating. Clinical characteristics of patients with ICIs-associated colitis and the time to onset of colitis following different ICI regimens were collected. Results: A total of 3786 reports of colitis adverse events were identified with ICIs. Seven ICI monotherapies were associated with the reporting of colitis. Statistically significant ROR, PRR, information component (IC), and empirical Bayesian geometric mean (EBGM) emerged for all ICI monotherapies and combination therapies. ICIs-associated colitis affected mostly male (53.51%), with a wide mean age range (60.65 to 72 years). Colitis adverse events were commonly reported in patients with melanoma and lung cancer. Adverse outcomes of colitis concerning ICI were mainly outcomes of hospitalization-initiated or prolonged and other serious. Among colitis cases, 17.43% cases of colitis concerning ICI lead to death. The adverse event of colitis occurred earliest in ipilimumab monotherapy with a median time to onset of 64.21 days (IQR: 27–69 days) among all monotherapies. Conclusions: ICI may lead to severe and disabling ICIs-associated colitis during therapy. Analysis of FAERS data identified signals for adverse events of colitis with ICI regimens. Practitioners should consider the factors that may increase the likelihood of colitis. The findings support a continued surveillance and risk factor identification studies.</dcterms:abstract>
        <dc:date>2020</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079902</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2005876655&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Memo rdf:about="#item_1197">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2005611214&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>43</prism:volume>
                <dc:title>Drug Safety</dc:title>
                <dc:identifier>DOI 10.1007/s40264-020-00939-y</dc:identifier>
                <prism:number>8</prism:number>
                <dcterms:alternative>Drug Saf.</dcterms:alternative>
                <dc:identifier>ISSN 1179-1942</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hult</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sartori</foaf:surname>
                        <foaf:givenName>D.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bergvall</foaf:surname>
                        <foaf:givenName>T.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hedfors Vidlin</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Grundmark</foaf:surname>
                        <foaf:givenName>B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ellenius</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Norén</foaf:surname>
                        <foaf:givenName>G.N.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1198"/>
        <dc:subject>acute kidney failure</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>factual database</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>*Pharmacovigilance</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>cytochrome P450</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>outcome assessment</dc:subject>
        <dc:subject>rhabdomyolysis</dc:subject>
        <dc:subject>bipolar disorder</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>quetiapine</dc:subject>
        <dc:subject>mental disease</dc:subject>
        <dc:subject>*Drug Interactions</dc:subject>
        <dc:subject>amiodarone</dc:subject>
        <dc:subject>ciprofloxacin</dc:subject>
        <dc:subject>Databases, Factual</dc:subject>
        <dc:subject>levonorgestrel</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>drug information</dc:subject>
        <dc:subject>clozapine</dc:subject>
        <dc:subject>Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>musculoskeletal disease</dc:subject>
        <dc:subject>atorvastatin</dc:subject>
        <dc:subject>drug interaction</dc:subject>
        <dc:subject>Drug Interactions</dc:subject>
        <dc:subject>enalapril</dc:subject>
        <dc:subject>Pharmacovigilance</dc:subject>
        <dc:subject>treatment response</dc:subject>
        <dc:subject>esomeprazole</dc:subject>
        <dc:subject>omeprazole</dc:subject>
        <dc:subject>pantoprazole</dc:subject>
        <dc:subject>signal processing</dc:subject>
        <dc:subject>metformin</dc:subject>
        <dc:subject>DATABASE</dc:subject>
        <dc:subject>acetylsalicylic acid</dc:subject>
        <dc:subject>furosemide</dc:subject>
        <dc:subject>clinical assessment</dc:subject>
        <dc:subject>lamotrigine</dc:subject>
        <dc:subject>valproic acid</dc:subject>
        <dc:subject>clinical evaluation</dc:subject>
        <dc:subject>pregabalin</dc:subject>
        <dc:subject>rosuvastatin</dc:subject>
        <dc:subject>priority journal</dc:subject>
        <dc:subject>natural language processing</dc:subject>
        <dc:subject>emergency health service</dc:subject>
        <dc:subject>World Health Organization</dc:subject>
        <dc:subject>ethinylestradiol</dc:subject>
        <dc:subject>Feasibility Studies</dc:subject>
        <dc:subject>feasibility study</dc:subject>
        <dc:subject>fentanyl</dc:subject>
        <dc:subject>pharmacodynamics</dc:subject>
        <dc:subject>pharmacokinetic parameters</dc:subject>
        <dc:subject>rivaroxaban</dc:subject>
        <dc:subject>Signal Processing, Computer-Assisted</dc:subject>
        <dc:subject>SYSTEM</dc:subject>
        <dc:subject>therapy effect</dc:subject>
        <dc:subject>ticagrelor</dc:subject>
        <dc:subject>Triage</dc:subject>
        <dc:title>A Feasibility Study of Drug–Drug Interaction Signal Detection in Regular Pharmacovigilance</dc:title>
        <dcterms:abstract>Introduction: Adverse drug reactions related to drug–drug interactions cause harm to patients. There is a body of research on signal detection for drug interactions in collections of individual case reports, but limited use in regular pharmacovigilance. Objective: The aim of this study was to evaluate the feasibility of signal detection of drug–drug interactions in collections of individual case reports of suspected adverse drug reactions. Methods: This study was conducted in VigiBase, the WHO global database of individual case safety reports. The data lock point was 31 August 2016, which provided 13.6 million reports for analysis after deduplication. Statistical signal detection was performed using a previously developed predictive model for possible drug interactions. The model accounts for an interaction disproportionality measure, expressed suspicion of an interaction by the reporter, potential for interaction through cytochrome P450 activity of drugs, and reported information indicative of unexpected therapeutic response or altered therapeutic effect. Triage filters focused the preliminary signal assessment on combinations relating to serious adverse events with case series of no more than 30 reports from at least two countries, with at least one report during the previous 2 years. Additional filters sought to eliminate already known drug interactions through text mining of standard literature sources. Preliminary signal assessment was performed by a multidisciplinary group of pharmacovigilance professionals from Uppsala Monitoring Centre and collaborating organizations, whereas in-depth signal assessment was performed by experienced pharmacovigilance assessors. Results: We performed preliminary signal assessment for 407 unique drug pairs. Of these, 157 drug pairs were considered already known to interact, whereas 232 were closed after preliminary assessment for other reasons. Ten drug pairs were subjected to in-depth signal assessment and an additional eight were decided to be kept under review awaiting additional reports. The triage filters had a major impact in focusing our preliminary signal assessment on just 14% of the statistical signals generated by the predictive model for drug interactions. In-depth assessment led to three signals communicated with the broader pharmacovigilance community, six closed signals and one to be kept under review. Conclusion: This study shows that signals of adverse drug interactions can be detected through broad statistical screening of individual case reports. It further shows that signal assessment related to possible drug interactions requires more detailed information on the temporal relationship between different drugs and the adverse event. Future research may consider whether interaction signal detection should be performed not for individual adverse event terms but for pairs of drugs across a spectrum of adverse events.</dcterms:abstract>
        <dc:date>2020</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079901</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2005611214&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>775-785</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1198">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 18; Correspondence Address: S. Hult; Uppsala Monitoring Centre, Uppsala, Sweden; email: sara.hult@who-umc.org; CODEN: DRSAE&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;17&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;17&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;34&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Desenvolvimento do método,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L631406770&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1867-1462"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                   <foaf:Person><foaf:surname>Yogita</foaf:surname></foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sangma</foaf:surname>
                        <foaf:givenName>J.W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Anal</foaf:surname>
                        <foaf:givenName>S.R.N.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Pal</foaf:surname>
                        <foaf:givenName>V.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1199"/>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>acetylsalicylic acid</dc:subject>
        <dc:subject>cluster analysis</dc:subject>
        <dc:title>Clustering-Based Hybrid Approach for Identifying Quantitative Multidimensional Associations Between Patient Attributes, Drugs and Adverse Drug Reactions</dc:title>
        <dcterms:abstract>The activity of post-marketing surveillance results in a collection of large amount of data. The analysis of data is very useful for raising early warnings on possible adverse reactions of drugs. Association rule mining techniques have been heavily explored by the research community for identifying binary association between drugs and their adverse effects. But these techniques perform poorly and miss out several interesting associations when it comes to analysis of multidimensional data which may include multiple patient attributes, drugs and adverse drug reactions. In the present work, a clustering-based hybrid approach has been presented for finding quantitative multidimensional association from the large amount of data. Firstly, it employs clustering technique for segmentation of data into semantically coherent clusters. Furthermore, disproportionality method called proportional reporting ratio is applied on clustered data for generating statistically strong associations. The performance of the proposed methodology has been examined on the data taken from the U.S. Food and Drug Administration Adverse Event Reporting System database corresponding to Aspirin and nine other drugs which are prescribed along with Aspirin. The experimental results show that the proposed approach discovered a number of association rules which are very comprehensive and informative regarding relationship of patient traits and drugs with adverse drug reactions. On comparing experimental results with LPMiner, it is observed that the quantitative association rules discovered by LPMiner are just 8.3% of what have been discovered by the proposed methodology.</dcterms:abstract>
        <dc:date>2020</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079899</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L631406770&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>237-251</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1867-1462">
        <prism:volume>12</prism:volume>
        <dc:title>Interdisciplinary sciences, computational life sciences</dc:title>
        <dc:identifier>DOI 10.1007/s12539-020-00365-9</dc:identifier>
        <prism:number>3</prism:number>
        <dcterms:alternative>Interdiscip Sci</dcterms:alternative>
        <dc:identifier>ISSN 1867-1462</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1199">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Base governamental,Desenvolvimento do método&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2014567976&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>25</prism:volume>
                <dc:title>European Review for Medical and Pharmacological Sciences</dc:title>
                <dc:identifier>DOI 10.26355/eurrev_202109_26652</dc:identifier>
                <prism:number>17</prism:number>
                <dcterms:alternative>Eur. Rev. Med. Pharmacol. Sci.</dcterms:alternative>
                <dc:identifier>ISSN 2284-0729</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Khamisy-Farah</foaf:surname>
                        <foaf:givenName>R.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Damiani</foaf:surname>
                        <foaf:givenName>G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kong</foaf:surname>
                        <foaf:givenName>J.D.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bragazzi</foaf:surname>
                        <foaf:givenName>N.L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1201"/>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>nerve cell network</dc:subject>
        <dc:subject>eczema</dc:subject>
        <dc:subject>atopic dermatitis</dc:subject>
        <dc:subject>dupilumab</dc:subject>
        <dc:subject>inflammation</dc:subject>
        <dc:subject>drug monitoring</dc:subject>
        <dc:subject>pregnancy</dc:subject>
        <dc:subject>pruritus</dc:subject>
        <dc:subject>distress syndrome</dc:subject>
        <dc:subject>ectopic pregnancy</dc:subject>
        <dc:subject>preeclampsia</dc:subject>
        <dc:subject>puerperium</dc:subject>
        <dc:title>Safety profile of Dupilumab during pregnancy: a data mining and disproportionality analysis of over 37,000 reports from the WHO individual case safety reporting database (VigiBase™)</dc:title>
        <dcterms:abstract>Atopic dermatitis, known also as atopic eczema, represents a commonly diagnosed, chronic or recurrent/relapsing inflammatory disorder. From a clinical point of view, it is characterized by acute flare-ups of intense itching, eczematous pruritic lesions involving dry skin. Dupilumab is the only biologic agent approved to treat moderate to severe course of atopic dermatitis, which can be particularly severe during pregnancy causing distress and impacting on maternal and fetal health. However, there is a dearth of data concerning the safety profile of Dupilumab during gestation. Therefore, we took advantage of a large global pharmacovigilance database. From inception up to March 9, 2021, 94,065 adverse drug reactions (ADRs) from 37,848 unique reports were retrieved. Of these, 36 reports related to pregnancy, puerperium and perinatal ADR could be extracted from the pharmacovigilance database. More than half of reports (n = 21; 58.3%) were spontaneous abortion, followed by other events, including exposure to the drug during the pregnancy (n = 8; 22.2%). Two cases of abortion were reported. No studied pregnancy, puerperium and perinatal ADR was found to be associated with the use of Dupilumab. The only OR significantly greater than 1 was the OR associated with the risk of developing heterotopic pregnancy (21.66 [95% CrI 2.95-159.02]) even if the IC was highly imprecise (1.45 [95% CrI from -2.34 to 3.09]), probably because of the single case of heterotopic pregnancy reported. In conclusion, Dupilumab use appears safe during gestation. Further studies are needed, especially to better understand the mechanisms underlying the pharmacological actions and ADR of Dupilumab.</dcterms:abstract>
        <dc:date>2021</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079891</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2014567976&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>5448-5451</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1201">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2005534046&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1179-1918"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Seo</foaf:surname>
                        <foaf:givenName>D.-E.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kim</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Park</foaf:surname>
                        <foaf:givenName>B.-J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1200"/>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>quetiapine</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>arthropathy</dc:subject>
        <dc:subject>insomnia</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>delusion</dc:subject>
        <dc:subject>hallucination</dc:subject>
        <dc:subject>paranoia</dc:subject>
        <dc:subject>personality disorder</dc:subject>
        <dc:subject>psychosis</dc:subject>
        <dc:subject>aggression</dc:subject>
        <dc:subject>aripiprazole</dc:subject>
        <dc:subject>breast tumor</dc:subject>
        <dc:subject>paliperidone</dc:subject>
        <dc:subject>risperidone</dc:subject>
        <dc:subject>gingivitis</dc:subject>
        <dc:subject>hyperlipidemia</dc:subject>
        <dc:subject>osteoarthritis</dc:subject>
        <dc:subject>atypical antipsychotic agent</dc:subject>
        <dc:subject>clozapine</dc:subject>
        <dc:subject>olanzapine</dc:subject>
        <dc:subject>ziprasidone</dc:subject>
        <dc:subject>body weight loss</dc:subject>
        <dc:subject>gastroesophageal reflux</dc:subject>
        <dc:subject>amisulpride</dc:subject>
        <dc:subject>migraine</dc:subject>
        <dc:subject>extrapyramidal syndrome</dc:subject>
        <dc:subject>tongue disease</dc:subject>
        <dc:subject>amenorrhea</dc:subject>
        <dc:subject>bradykinesia</dc:subject>
        <dc:subject>catatonia</dc:subject>
        <dc:subject>France</dc:subject>
        <dc:subject>dystonia</dc:subject>
        <dc:subject>uterus myoma</dc:subject>
        <dc:subject>risk management</dc:subject>
        <dc:subject>menstruation disorder</dc:subject>
        <dc:subject>Japan</dc:subject>
        <dc:subject>hyperprolactinemia</dc:subject>
        <dc:subject>suicide attempt</dc:subject>
        <dc:subject>hypertriglyceridemia</dc:subject>
        <dc:subject>priority journal</dc:subject>
        <dc:subject>Germany</dc:subject>
        <dc:subject>hyperkinesia</dc:subject>
        <dc:subject>muscle hypertonia</dc:subject>
        <dc:subject>paradoxical drug reaction</dc:subject>
        <dc:subject>United Kingdom</dc:subject>
        <dc:subject>anorgasmia</dc:subject>
        <dc:subject>intervertebral disk disease</dc:subject>
        <dc:subject>lactation</dc:subject>
        <dc:subject>liver cell damage</dc:subject>
        <dc:subject>obesity</dc:subject>
        <dc:subject>psychosomatic disorder</dc:subject>
        <dc:subject>schizophrenic reaction</dc:subject>
        <dc:subject>seborrhea</dc:subject>
        <dc:subject>South Korea</dc:subject>
        <dc:subject>vaginitis</dc:subject>
        <dc:subject>zotepine</dc:subject>
        <dc:title>Signals of Adverse Drug Reactions of Paliperidone Compared to Other Atypical Antipsychotics Using the Korean Adverse Event Reporting System Database</dc:title>
        <dcterms:abstract>Background and Objectives: Schizophrenia is a severe public health problem and one of the top ten causes of disability, affecting about 1.1% of the world’s population. Paliperidone is a new atypical antipsychotic used to treat schizophrenia. Several case reports about unexpected adverse drug reactions of paliperidone have been consistently reported around the world. The purpose of this study was to detect signals of adverse events (AEs) after paliperidone treatment using the Korea Institute of Drug Safety and Risk Management–Korea Adverse Event Reporting System database (KIDS-KD). Methods: We applied data-mining techniques based on a disproportionality analysis to KIDS-KD consisting of spontaneously reported AE reports related to atypical antipsychotics between January 2009 and December 2018. We calculated three data-mining indices of paliperidone compared to all other atypical antipsychotics. We defined signals that satisfied all three criteria of the indices. We checked if the signals identified were included in the drug labels for South Korea, the USA, the UK, Japan, Germany, and France. Results: The total number of suspected AE reports related to all atypical antipsychotics in the KIDS-KD from January 2009 to December 2018 was 43,970. Among those, the number of AE reports related to paliperidone was 9453. Overall, 13 signals such as seborrhea, hallucination, obesity, gingivitis, and intervertebral disorder were classified into newly detected meaningful signals. Conclusion: We detected new AE signals of paliperidone that were not listed on the drug labels of six countries, and many that were related to psychotic symptoms, metabolic problems, and endocrine disorders.</dcterms:abstract>
        <dc:date>2020</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079896</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2005534046&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>873-881</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1179-1918">
        <prism:volume>40</prism:volume>
        <dc:title>Clinical Drug Investigation</dc:title>
        <dc:identifier>DOI 10.1007/s40261-020-00945-z</dc:identifier>
        <prism:number>9</prism:number>
        <dcterms:alternative>Clin. Drug Invest.</dcterms:alternative>
        <dc:identifier>ISSN 1179-1918</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1200">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2011521287&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1742-1241"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xu</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Pan</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sun</foaf:surname>
                        <foaf:givenName>Q.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Fang</foaf:surname>
                        <foaf:givenName>W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1206"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>odds ratio</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>young adult</dc:subject>
        <dc:subject>epilepsy</dc:subject>
        <dc:subject>risk assessment</dc:subject>
        <dc:subject>very elderly</dc:subject>
        <dc:subject>Bayesian network</dc:subject>
        <dc:subject>disease association</dc:subject>
        <dc:subject>quantitative analysis</dc:subject>
        <dc:subject>carbamazepine</dc:subject>
        <dc:subject>toxic epidermal necrolysis</dc:subject>
        <dc:subject>Stevens Johnson syndrome</dc:subject>
        <dc:subject>clinical research</dc:subject>
        <dc:subject>clinical observation</dc:subject>
        <dc:subject>high risk patient</dc:subject>
        <dc:subject>oxcarbazepine</dc:subject>
        <dc:title>Assessing carbamazepine and oxcarbazepine-associated Stevens-Johnson syndrome/toxic epidermal necrolysis: Data mining the public version of the FDA adverse event reporting system</dc:title>
        <dcterms:abstract>Aims: Stevens-Johnson syndrome and toxic epidermal necrolysis are viewed as the most severe drug-induced types of cutaneous adverse reactions, with high rates of morbidity and mortality. We aimed to examine carbamazepine- and oxcarbazepine-associated Stevens-Johnson syndrome or toxic epidermal necrolysis, by data mining the US Food and Drug Administration Adverse Event Reporting System (FAERS). Methods: Reports in FAERs were analysed, from the first quarter of 2004 to the last quarter of 2019. Pharmacovigilance tools were employed for the quantitative detection of signals, where a signal represents a drug-associated adverse event, including the reporting odds ratio, proportional reporting ratio, an information component given by a Bayesian confidence propagation neural network, and the empirical Bayes geometric mean. Results: The total number of reports identified as Stevens-Johnson syndrome or toxic epidermal necrolysis associated with carbamazepine or oxcarbazepine included in this study was 1231. FAERS reports associated with carbamazepine were 1048, including Stevens-Johnson syndrome (n = 668) and toxic epidermal necrolysis(n = 380). FAERS reports associated with oxcarbazepine were 183, including 142 Stevens-Johnson syndrome and 41 toxic epidermal necrolysis reports. The risk for Stevens-Johnson syndrome is higher than for toxic epidermal necrolysis and carbamazepine is associated with a higher risk than oxcarbazepine. Conclusions: The results of our study are consistent with clinical observations, suggesting the necessity for further clinical research on Stevens-Johnson syndrome and toxic epidermal necrolysis associated with carbamazepine or oxcarbazepine.</dcterms:abstract>
        <dc:date>2021</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079880</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2011521287&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1742-1241">
        <prism:volume>75</prism:volume>
        <dc:title>International Journal of Clinical Practice</dc:title>
        <dc:identifier>DOI 10.1111/ijcp.14273</dc:identifier>
        <prism:number>8</prism:number>
        <dcterms:alternative>Int. J. Clin. Pract.</dcterms:alternative>
        <dc:identifier>ISSN 1742-1241</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1206">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2014679806&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:0946-1965"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ge</foaf:surname>
                        <foaf:givenName>W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hu</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xia</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1275"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>odds ratio</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>sepsis</dc:subject>
        <dc:subject>alkaline phosphatase</dc:subject>
        <dc:subject>alkaline phosphatase blood level</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>brain disease</dc:subject>
        <dc:subject>confusion</dc:subject>
        <dc:subject>delirium</dc:subject>
        <dc:subject>epilepsy</dc:subject>
        <dc:subject>hallucination</dc:subject>
        <dc:subject>neurologic disease</dc:subject>
        <dc:subject>seizure</dc:subject>
        <dc:subject>multiple organ failure</dc:subject>
        <dc:subject>neurotoxicity</dc:subject>
        <dc:subject>confidence interval</dc:subject>
        <dc:subject>drug eruption</dc:subject>
        <dc:subject>candidiasis</dc:subject>
        <dc:subject>esophagitis</dc:subject>
        <dc:subject>fever</dc:subject>
        <dc:subject>back propagation neural network</dc:subject>
        <dc:subject>consumer</dc:subject>
        <dc:subject>fungemia</dc:subject>
        <dc:subject>superinfection</dc:subject>
        <dc:subject>data processing</dc:subject>
        <dc:subject>health practitioner</dc:subject>
        <dc:subject>pharmacist</dc:subject>
        <dc:subject>physician</dc:subject>
        <dc:subject>liver failure</dc:subject>
        <dc:subject>Klebsiella infection</dc:subject>
        <dc:subject>QT prolongation</dc:subject>
        <dc:subject>toxic epidermal necrolysis</dc:subject>
        <dc:subject>liver disease</dc:subject>
        <dc:subject>meropenem</dc:subject>
        <dc:subject>Clostridium infection</dc:subject>
        <dc:subject>doripenem</dc:subject>
        <dc:subject>DRESS syndrome</dc:subject>
        <dc:subject>ertapenem</dc:subject>
        <dc:subject>herpes simplex</dc:subject>
        <dc:subject>histiocytosis</dc:subject>
        <dc:subject>imipenem</dc:subject>
        <dc:subject>infectious agent</dc:subject>
        <dc:subject>myoclonus</dc:subject>
        <dc:subject>neutrophil count</dc:subject>
        <dc:subject>skin toxicity</dc:subject>
        <dc:subject>visual hallucination</dc:subject>
        <dc:title>Safety profile of carbapenems: Data mining of the FDA adverse events reporting system</dc:title>
        <dcterms:abstract>Objective: To learn the safety profile of carbapenems and compare suspected adverse drug reactions (ADRs) among carbapenem classes by data mining the FDA adverse event reporting system (FAERS) database. Materials: This retrospective study described the general characteristics of adverse drug event (ADE) reports related to carbapenems in the FAERS during 2015 - 2018. Methods: The 95% confidence intervals (CIs) of proportional reporting ratio (PRR), the reporting odds ratio (ROR), and information component (IC) of Bayesian confidence propagation neural network (BCPNN) were calculated to identify potential safety signals. Results: A total number of 5,899 reports associated with carbapenems were submitted to the FAERS from January 1, 2015 to December 31, 2018. The most frequently reported ADE associated with carbapenems was drug ineffective (10.51%). Serious ADEs and death associated with carbapenems were reported in 41.24 and 25.12%, respectively. Infections and infestations was the strongest signal detected in both meropenem and imipenem. Nervous system disorders and psychiatric disorders were strongly detected in ertapenem. Hepatobiliary disorders were common in doripenem patients. Conclusion: Carbapenem resistance is alarming in the United States, and carbapenem is more likely to be associated with serious and fatal ADEs among β-lactam antibiotics. Both differences and similarities exist in the safety profile among carbapenems classes. Close attention should be paid to patients with special disease when administrated carbapenems.</dcterms:abstract>
        <dc:date>2021</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079878</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2014679806&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>594-602</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:0946-1965">
        <prism:volume>59</prism:volume>
        <dc:title>International Journal of Clinical Pharmacology and Therapeutics</dc:title>
        <dc:identifier>DOI 10.5414/CP203811</dc:identifier>
        <prism:number>9</prism:number>
        <dcterms:alternative>Int. J. Clin. Pharmacol. Ther.</dcterms:alternative>
        <dc:identifier>ISSN 0946-1965</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1275">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2015415397&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1574-8863"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shah</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kothari</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1207"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>postmarketing surveillance</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>cholestasis</dc:subject>
        <dc:subject>drospirenone</dc:subject>
        <dc:subject>Canada</dc:subject>
        <dc:subject>cholelithiasis</dc:subject>
        <dc:subject>comparative study</dc:subject>
        <dc:subject>drug industry</dc:subject>
        <dc:subject>cholecystitis</dc:subject>
        <dc:subject>acute cholecystitis</dc:subject>
        <dc:subject>Europe</dc:subject>
        <dc:subject>chronic cholecystitis</dc:subject>
        <dc:subject>gallbladder cancer</dc:subject>
        <dc:subject>gallbladder disease</dc:subject>
        <dc:subject>gallbladder polyp</dc:subject>
        <dc:title>Comparative Safety Assessment Study for Drospirenone Induced Gallbladder Diseases Using the Adverse Drug Reaction Database of USA, Europe, and Canada</dc:title>
        <dcterms:abstract>Background: Gallstone disease (GSD) is one of the most common gastroenterological disorders. It is known that drospirenone causes small increased risk of gallbladder diseases. However, the risk may vary between different adverse drug reaction databases. Objective: The purpose of this studty is to examine the safety and risk association between hormonal contraceptive drospirenone and gallbladder diseases using adverse drug reaction database of USFDA’s Federal Adverse Events Reporting System (FAERS), Europe’s Eudravigilance (EV) and Canada’s Canada Vigilance Adverse Reaction Online Database (CVARD). Methods: Individual Case Safety Reports of patients till October 2019 were downloaded from the Federal Adverse Event Reporting System, Eudravigilance, and Canadian database. These reports contained information on adverse events associated with all other drugs inclusive of drospirenone. The disproportionality method of data mining was used to calculate the risk association. Results: The lower limit of 95% CI of PRR was 3.27, 3.47 and 3.76, PRR was 33.08, 41.35 and 115.42, ROR was 37.20, 44.61 and 127.19, Chi-square value was 126572.89, 110392.95 and 362.46, and IC-2SD value was 0.16, 0.17, and 1.21 for FAERS, EU, and CVARD respectively indicating a week signal. Also, all the calculated parameters were above the threshold value. Conclusion: From our study, it was clear that the risk between drospirenone and gallbladder diseases was very low among three databases. There was no harm in prescribing this drug for a contraceptive action.</dcterms:abstract>
        <dc:date>2021</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079876</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2015415397&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>272-277</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1574-8863">
        <prism:volume>16</prism:volume>
        <dc:title>Current Drug Safety</dc:title>
        <dc:identifier>DOI 10.2174/1574886315999201027150243</dc:identifier>
        <prism:number>3</prism:number>
        <dcterms:alternative>Curr. Drug Saf.</dcterms:alternative>
        <dc:identifier>ISSN 1574-8863</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1207">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2017549497&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:2542-5641"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lao</foaf:surname>
                        <foaf:givenName>D.-H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Fan</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>J.-Z.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lyu.</foaf:surname>
                        <foaf:givenName>P.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1204"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>adverse outcome</dc:subject>
        <dc:subject>Bayes Theorem</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>health care personnel</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>United States Food and Drug Administration</dc:subject>
        <dc:subject>sex difference</dc:subject>
        <dc:subject>allergic reaction</dc:subject>
        <dc:subject>allergy</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>drug fatality</dc:subject>
        <dc:subject>peripheral neuropathy</dc:subject>
        <dc:subject>Pharmacovigilance</dc:subject>
        <dc:subject>docetaxel</dc:subject>
        <dc:subject>paclitaxel</dc:subject>
        <dc:subject>bone marrow toxicity</dc:subject>
        <dc:subject>Bone marrow toxicity</dc:subject>
        <dc:subject>bridged compound</dc:subject>
        <dc:subject>Bridged-Ring Compounds</dc:subject>
        <dc:subject>Peripheral neuropathy</dc:subject>
        <dc:subject>taxane</dc:subject>
        <dc:subject>Taxane</dc:subject>
        <dc:subject>taxoid</dc:subject>
        <dc:subject>Taxoids</dc:subject>
        <dc:title>Assessing taxane-associated adverse events using the FDA adverse event reporting system database</dc:title>
        <dcterms:abstract>Background:Taxanes are an essential class of antineoplastic agents used to treat various cancers and are a fundamental cause of hypersensitivity reactions. In addition, other adverse events, such as bone marrow toxicity and peripheral neuropathy, can lead to chemotherapy discontinuation. This study aimed to evaluate the safety of taxanes in the real world.Methods:Taxane-associated adverse events were identified by the Medical Dictionary for Regulatory Activities Preferred Terms and analyzed and compared by mining the US Food and Drug Administration Adverse Event Reporting System pharmacovigilance database from January 2004 to December 2019. Reported adverse events, such as hypersensitivity reaction, bone marrow toxicity, and peripheral neuropathy, were analyzed with the following signal detection algorithms: reporting odds ratio (ROR), proportional reporting ratio (PRR), multi-item gamma Poisson shrinker (MGPS), Bayesian confidence propagation neural network (BCPNN), and logistic regression methods. Adverse outcome events and death outcome rates were compared between different taxane groups using Pearson's χ2test, whereas significance was determined at P &lt; 0.05 with a 95% confidence interval (CI).Results:A total of 966 reports of hypersensitivity reactions, 1109 reports of bone marrow toxicity, and 1374 reports of peripheral neuropathy were analyzed. Compared with paclitaxel and docetaxel, bone marrow toxicity following the use of nab-paclitaxel had the highest ROR of 6.45 (95% two-sided CI, 6.05-6.88), PRR of 5.66, (χ2= 4342.98), information component of 2.50 (95% one-sided CI = 2.34), and empirical Bayes geometric mean of 5.64 (95% one-sided CI = 5.34). Peripheral neuropathy following the use of nab-paclitaxel showed a higher ROR of 12.78 (95% two-sided CI, 11.55-14.14), PRR of 12.16 (χ2= 4060.88), information component of 3.59 (95% one-sided CI = 3.25), and empirical Bayes geometric mean of 12.07 (95% one-sided CI = 11.09).Conclusions:The results showed that bone marrow toxicity and peripheral neuropathy were the major adverse events induced by taxanes. Nab-paclitaxel exhibited the highest potential for taxane-associated adverse events. Further research in the future is warranted to explain taxane-associated adverse effects in real-world circumstances.</dcterms:abstract>
        <dc:date>2021</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079887</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2017549497&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>1471-1476</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:2542-5641">
        <prism:volume>134</prism:volume>
        <dc:title>Chinese Medical Journal</dc:title>
        <dc:identifier>DOI 10.1097/CM9.0000000000001562</dc:identifier>
        <prism:number>12</prism:number>
        <dcterms:alternative>Chin. Med. J.</dcterms:alternative>
        <dc:identifier>ISSN 2542-5641</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1204">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 8; Correspondence Address: J.-Z. Zhang; Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, 180 Feng-Lin Road, 200032, China; email: zhang.jianzhong@zs-hospital.sh.cn; CODEN: CMDJA&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2012907419&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>77</prism:volume>
                <dc:title>European Journal of Clinical Pharmacology</dc:title>
                <dc:identifier>DOI 10.1007/s00228-021-03175-0</dc:identifier>
                <prism:number>8</prism:number>
                <dcterms:alternative>Eur. J. Clin. Pharmacol.</dcterms:alternative>
                <dc:identifier>ISSN 1432-1041</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shao</foaf:surname>
                        <foaf:givenName>Q.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xu</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chu</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1205"/>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>dipeptidyl carboxypeptidase inhibitor</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>research</dc:subject>
        <dc:subject>bradycardia</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>dizziness</dc:subject>
        <dc:subject>fatigue</dc:subject>
        <dc:subject>orthostatic hypotension</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>angiotensin 2 receptor antagonist</dc:subject>
        <dc:subject>blurred vision</dc:subject>
        <dc:subject>doxazosin</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>captopril</dc:subject>
        <dc:subject>enalapril</dc:subject>
        <dc:subject>aging</dc:subject>
        <dc:subject>diuretic agent</dc:subject>
        <dc:subject>atenolol</dc:subject>
        <dc:subject>bisoprolol</dc:subject>
        <dc:subject>pharmacist</dc:subject>
        <dc:subject>amlodipine</dc:subject>
        <dc:subject>furosemide</dc:subject>
        <dc:subject>metoprolol</dc:subject>
        <dc:subject>antihypertensive therapy</dc:subject>
        <dc:subject>calcium channel blocking agent</dc:subject>
        <dc:subject>candesartan</dc:subject>
        <dc:subject>falling</dc:subject>
        <dc:subject>nicardipine</dc:subject>
        <dc:subject>nifedipine</dc:subject>
        <dc:subject>indapamide</dc:subject>
        <dc:subject>candesartan hexetil</dc:subject>
        <dc:subject>irbesartan</dc:subject>
        <dc:subject>telmisartan</dc:subject>
        <dc:subject>valsartan</dc:subject>
        <dc:subject>acebutolol</dc:subject>
        <dc:subject>alpha 1 adrenergic receptor blocking agent</dc:subject>
        <dc:subject>benazepril</dc:subject>
        <dc:subject>beta adrenergic receptor blocking agent</dc:subject>
        <dc:subject>betaxolol</dc:subject>
        <dc:subject>chlorothiazide</dc:subject>
        <dc:subject>clevidipine</dc:subject>
        <dc:subject>diltiazem</dc:subject>
        <dc:subject>esmolol</dc:subject>
        <dc:subject>fall risk assessment</dc:subject>
        <dc:subject>felodipine</dc:subject>
        <dc:subject>fosinopril</dc:subject>
        <dc:subject>hydrochlorothiazide</dc:subject>
        <dc:subject>isradipine</dc:subject>
        <dc:subject>lisinopril</dc:subject>
        <dc:subject>nebivolol</dc:subject>
        <dc:subject>nisoldipine</dc:subject>
        <dc:subject>patient</dc:subject>
        <dc:subject>perindopril</dc:subject>
        <dc:subject>personalized medicine</dc:subject>
        <dc:subject>polypharmacy</dc:subject>
        <dc:subject>potentially inappropriate medication</dc:subject>
        <dc:subject>prazosin</dc:subject>
        <dc:subject>propranolol</dc:subject>
        <dc:subject>quinapril</dc:subject>
        <dc:subject>ramipril</dc:subject>
        <dc:subject>spironolactone</dc:subject>
        <dc:subject>terazosin</dc:subject>
        <dc:subject>timolol</dc:subject>
        <dc:subject>trandolapril</dc:subject>
        <dc:subject>verapamil</dc:subject>
        <dc:title>Research on Beers Criteria and STOPP/START Criteria based on the FDA FAERS database</dc:title>
        <dcterms:abstract>Purpose: Inappropriate medication criteria for the elderly have played an important role in ensuring the safety of medications for the elderly. Too few drugs included in the criteria cannot guarantee the safety of medication for the elderly. Too many drugs included in the criteria will result in less selective medication for the elderly. This paper uses real-world data to evaluate the relationship between antihypertensive drugs and falls, so as to provide references for experts and scholars to revise the criteria of potentially inappropriate medications for the elderly and clinical safe medication. Method: We use the US Food and Drug Administration Adverse Event Reporting System (FDA FAERS) to evaluate the association between specific antihypertensive drugs in six categories (alpha-1 receptor blockers (α-1 blockers), calcium channel blockers (CCBs), angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), beta-receptor blockers (β-blockers), and diuretics) and falls by data mining algorithms, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), Medicines and Healthcare Products Regulatory Agency (MHRA), and the empirical Bayes geometric mean (EBGM) and compared with the relevant drugs included in the Beers Criteria and STOPP/START Criteria. Result: There are a total of 5,157,172 co-occurrences found in 973,447 reports aged 65 years or older from 2016 to 2019 in the FDA FAERS database, and the number of co-occurrences of falls is 5917 for the six categories of 51 antihypertensive drugs. Four kinds of mining methods overlap detection of 12 kinds of positive signal drugs, none of which are not included in the Beers Criteria and 7 drugs are included in the STOPP/START Criteria; 1–3 kinds of mining methods overlap detection of positive signal drugs, a total of 12 kinds, and one drug is included in the Beers Criteria and 5 drugs are included in the STOPP/START Criteria; 22 drugs have fall adverse events, but no positive signal is detected, and 13 drugs are included in STOPP/START Criteria; and 5 drugs have no fall adverse events and 3 drugs are included in the STOPP/START Criteria. Conclusion: The FAERS database was used to confirm the potential connection between some antihypertensive drugs and fall adverse events through data mining algorithms. The Beers Criteria did not clearly indicate the antihypertensive drugs that caused falls, and the antihypertensive drugs included in the STOPP/START Criteria were too extensive and did not include β-blockers and diuretics. It is recommended that experts and scholars use real-world data (such as FAERS, EudraVigilance, WHO VigiBase, and so on) to further explore the relationship between specific antihypertensive drugs and falls in the elderly, so as to revise and improve the criteria for inappropriate medications for the elderly.</dcterms:abstract>
        <dc:date>2021</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079882</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2012907419&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>1147-1156</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1205">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Excluído - Não utiliza DM,Excluído - Não utiliza dados de farmacovigilância,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2014670700&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>21</prism:volume>
                <dc:title>Expert Opinion on Drug Safety</dc:title>
                <dc:identifier>DOI 10.1080/14740338.2022.2016696</dc:identifier>
                <prism:number>4</prism:number>
                <dcterms:alternative>Expert Opin. Drug Saf.</dcterms:alternative>
                <dc:identifier>ISSN 1744-764X</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shu</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ding</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Dai</foaf:surname>
                        <foaf:givenName>B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>Q.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1211"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>death</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>hypertension</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>kidney hemorrhage</dc:subject>
        <dc:subject>constipation</dc:subject>
        <dc:subject>fatigue</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>liver toxicity</dc:subject>
        <dc:subject>brain infarction</dc:subject>
        <dc:subject>malignant hypertension</dc:subject>
        <dc:subject>cancer staging</dc:subject>
        <dc:subject>creatinine</dc:subject>
        <dc:subject>dehydration</dc:subject>
        <dc:subject>diarrhea</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>malignant neoplasm</dc:subject>
        <dc:subject>posterior reversible encephalopathy syndrome</dc:subject>
        <dc:subject>mouth pain</dc:subject>
        <dc:subject>heart disease</dc:subject>
        <dc:subject>creatinine blood level</dc:subject>
        <dc:subject>body weight loss</dc:subject>
        <dc:subject>infection</dc:subject>
        <dc:subject>infestation</dc:subject>
        <dc:subject>kidney failure</dc:subject>
        <dc:subject>ileus</dc:subject>
        <dc:subject>leukoencephalopathy</dc:subject>
        <dc:subject>back propagation neural network</dc:subject>
        <dc:subject>decreased appetite</dc:subject>
        <dc:subject>metastatic renal cell carcinoma</dc:subject>
        <dc:subject>renal cell carcinoma</dc:subject>
        <dc:subject>stomatitis</dc:subject>
        <dc:subject>blister</dc:subject>
        <dc:subject>digestive system perforation</dc:subject>
        <dc:subject>dysphonia</dc:subject>
        <dc:subject>erythema</dc:subject>
        <dc:subject>hyperkeratosis</dc:subject>
        <dc:subject>mouth discomfort</dc:subject>
        <dc:subject>tongue disease</dc:subject>
        <dc:subject>elevated blood pressure</dc:subject>
        <dc:subject>liver function test</dc:subject>
        <dc:subject>second cancer</dc:subject>
        <dc:subject>ageusia</dc:subject>
        <dc:subject>disease exacerbation</dc:subject>
        <dc:subject>taste disorder</dc:subject>
        <dc:subject>adrenal insufficiency</dc:subject>
        <dc:subject>aphonia</dc:subject>
        <dc:subject>cholecystitis</dc:subject>
        <dc:subject>mucosa inflammation</dc:subject>
        <dc:subject>skin bleeding</dc:subject>
        <dc:subject>skin defect</dc:subject>
        <dc:subject>axitinib</dc:subject>
        <dc:subject>hypothyroidism</dc:subject>
        <dc:subject>abnormal blood pressure</dc:subject>
        <dc:subject>aortic disease</dc:subject>
        <dc:subject>appendix perforation</dc:subject>
        <dc:subject>atypical mycobacteriosis</dc:subject>
        <dc:subject>autoimmune liver disease</dc:subject>
        <dc:subject>bladder bleeding</dc:subject>
        <dc:subject>cancer pain</dc:subject>
        <dc:subject>clear cell renal cell carcinoma</dc:subject>
        <dc:subject>glossitis</dc:subject>
        <dc:subject>glossodynia</dc:subject>
        <dc:subject>hand foot and mouth disease</dc:subject>
        <dc:subject>hand foot syndrome</dc:subject>
        <dc:subject>healing impairment</dc:subject>
        <dc:subject>hypertension encephalopathy</dc:subject>
        <dc:subject>hypogeusia</dc:subject>
        <dc:subject>hypophagia</dc:subject>
        <dc:subject>immune complex nephritis</dc:subject>
        <dc:subject>kidney cancer</dc:subject>
        <dc:subject>kidney pelvis cancer</dc:subject>
        <dc:subject>lung cavitation</dc:subject>
        <dc:subject>metastatic renal cancer</dc:subject>
        <dc:subject>multiitem gamma Poisson shrinker</dc:subject>
        <dc:subject>nephrotic syndrome</dc:subject>
        <dc:subject>neutrophil percentage</dc:subject>
        <dc:subject>oral blister</dc:subject>
        <dc:subject>pneumatosis intestinalis</dc:subject>
        <dc:subject>pneumothorax</dc:subject>
        <dc:subject>polycythemia</dc:subject>
        <dc:subject>prostatitis</dc:subject>
        <dc:subject>protein urine level</dc:subject>
        <dc:subject>proteinuria</dc:subject>
        <dc:subject>retroperitoneal abscess</dc:subject>
        <dc:subject>scrotal swelling</dc:subject>
        <dc:subject>scrotal ulcer</dc:subject>
        <dc:subject>scrotum disorder</dc:subject>
        <dc:subject>senile dementia</dc:subject>
        <dc:subject>spinal cord tumor</dc:subject>
        <dc:subject>spontaneous pneumothorax</dc:subject>
        <dc:subject>throat disease</dc:subject>
        <dc:subject>thyroid disease</dc:subject>
        <dc:subject>thyroiditis</dc:subject>
        <dc:subject>thyrotropin</dc:subject>
        <dc:subject>thyrotropin blood level</dc:subject>
        <dc:subject>tongue blistering</dc:subject>
        <dc:subject>tumor bleeding</dc:subject>
        <dc:subject>urinary tract cancer</dc:subject>
        <dc:subject>urine</dc:subject>
        <dc:title>A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system</dc:title>
        <dcterms:abstract>Background: Axitinib was approved for treatment of advanced renal cell carcinoma (RCC). The current study was to assess axitinib-related adverse events (AEs) through data mining of the US Food and Drug Administration Adverse Event Reporting System (FAERS). Methods: Disproportionality analyses, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi-item gamma Poisson shrinker (MGPS) algorithms, were employed to quantify the signals of axitinib-associated AEs. Results: Out of 10,703,806 reports collected from the FAERS database, 9044 reports of axitinib as the ‘primary suspected (PS)’ AEs were identified. Axitinib induced AEs occurrence targeted 26 organ systems. A total of 95 significant disproportionality PTs conforming to the four algorithms were simultaneously retained. Rare reports and significant signals of aortic disease have emerged. Unexpected significant AEs such as scrotal swelling, scrotal ulcers, infections, and infestations might also occur. The median onset time of axitinib-associated AEs was 63.5 days (interquartile range [IQR] 20–182 days), and most of the cases occurred within the first one and 2 months after axitinib initiation. Conclusion: Our study found potential new AEs signals and might provide important support for clinical monitoring and risk identification of axitinib.</dcterms:abstract>
        <dc:date>2022</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079872</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2014670700&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>563-572</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1211">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2012746206&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1471-1753"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Heo</foaf:surname>
                        <foaf:givenName>J.Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Cho</foaf:surname>
                        <foaf:givenName>M.K.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kim</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1209"/>
        <dc:subject>acute kidney failure</dc:subject>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>United States</dc:subject>
        <dc:subject>abdominal pain</dc:subject>
        <dc:subject>confusion</dc:subject>
        <dc:subject>skin disease</dc:subject>
        <dc:subject>acne</dc:subject>
        <dc:subject>diarrhea</dc:subject>
        <dc:subject>malignant neoplasm</dc:subject>
        <dc:subject>bone necrosis</dc:subject>
        <dc:subject>Canada</dc:subject>
        <dc:subject>drug eruption</dc:subject>
        <dc:subject>dyspepsia</dc:subject>
        <dc:subject>malaise</dc:subject>
        <dc:subject>doxycycline</dc:subject>
        <dc:subject>ileus</dc:subject>
        <dc:subject>rash</dc:subject>
        <dc:subject>stomatitis</dc:subject>
        <dc:subject>blister</dc:subject>
        <dc:subject>dry skin</dc:subject>
        <dc:subject>erythema</dc:subject>
        <dc:subject>infant</dc:subject>
        <dc:subject>mouth edema</dc:subject>
        <dc:subject>angioneurotic edema</dc:subject>
        <dc:subject>folliculitis</dc:subject>
        <dc:subject>application site reaction</dc:subject>
        <dc:subject>mucosa inflammation</dc:subject>
        <dc:subject>Japan</dc:subject>
        <dc:subject>rosacea</dc:subject>
        <dc:subject>skin exfoliation</dc:subject>
        <dc:subject>Germany</dc:subject>
        <dc:subject>Korea</dc:subject>
        <dc:subject>United Kingdom</dc:subject>
        <dc:subject>ectopic pregnancy</dc:subject>
        <dc:subject>DRESS syndrome</dc:subject>
        <dc:subject>application site edema</dc:subject>
        <dc:subject>fixed drug eruption</dc:subject>
        <dc:subject>mottled skin</dc:subject>
        <dc:subject>ovary hyperstimulation</dc:subject>
        <dc:subject>paronychia</dc:subject>
        <dc:subject>seborrheic dermatitis</dc:subject>
        <dc:subject>skin crusting</dc:subject>
        <dc:subject>skin ulcer</dc:subject>
        <dc:subject>syphilis</dc:subject>
        <dc:subject>vagina bleeding</dc:subject>
        <dc:title>Data mining for detecting signals of adverse drug reaction of doxycycline using the Korea adverse event reporting system database</dc:title>
        <dcterms:abstract>Background: Doxycycline is one of the most prescribed antibiotics by dermatologists. However, the concern regarding adverse events of doxycyline has been rising. Objective: To detect the adverse events of doxycycline using the Korea Adverse Events Reporting System (KAERS) database from January 2014 to December 2018 through a data mining method. Methods: A signal was defined as one satisfying all three indices; a proportional reporting ratio, a reporting odds ratio, and an information component. We further checked whether the detected signals exist in drug labels in Korea and five developed countries, the United States, the United Kingdom, Germany, Canada, and Japan. Results: A total of 3,365,186 adverse event-drug pairs were reported and of which 3,075 were associated with doxycycline. Among the thirty-seven signals, nineteen (malaise, ileus, confusion, malignant neoplasm, ectopic pregnancy, ovarian hyperstimulation, vaginal hemorrhage, bone necrosis, acne, rosacea, seborrheic dermatitis, folliculitis, skin ulceration, crusting, dry skin, paronychia, mottled skin, application site reaction, and application site edema) were not included on any of the drug labels of the six countries. Conclusion: We identified nineteen new doxycycline signals that did not appear on drug labels in six countries. Further studies are warranted to evaluate the causality of the adverse events with doxycycline.</dcterms:abstract>
        <dc:date>2022</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079871</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2012746206&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>2192-2197</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1471-1753">
        <prism:volume>33</prism:volume>
        <dc:title>Journal of Dermatological Treatment</dc:title>
        <dc:identifier>DOI 10.1080/09546634.2021.1937480</dc:identifier>
        <prism:number>4</prism:number>
        <dcterms:alternative>J. Dermatol. Treat.</dcterms:alternative>
        <dc:identifier>ISSN 1471-1753</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1209">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2016661628&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>13</prism:volume>
                <dc:title>Frontiers in Pharmacology</dc:title>
                <dc:identifier>DOI 10.3389/fphar.2022.891336</dc:identifier>
                <dcterms:alternative>Front. Pharmacol.</dcterms:alternative>
                <dc:identifier>ISSN 1663-9812</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhou</foaf:surname>
                        <foaf:givenName>Z.-X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yin</foaf:surname>
                        <foaf:givenName>X.-D.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shao</foaf:surname>
                        <foaf:givenName>Q.-H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mao</foaf:surname>
                        <foaf:givenName>X.-Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hu</foaf:surname>
                        <foaf:givenName>W.-J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shen</foaf:surname>
                        <foaf:givenName>Y.-L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhao</foaf:surname>
                        <foaf:givenName>B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>Z.-L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1212"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>young adult</dc:subject>
        <dc:subject>risk assessment</dc:subject>
        <dc:subject>very elderly</dc:subject>
        <dc:subject>ketoconazole</dc:subject>
        <dc:subject>drug information</dc:subject>
        <dc:subject>drug interaction</dc:subject>
        <dc:subject>mortality rate</dc:subject>
        <dc:subject>medication error</dc:subject>
        <dc:subject>mortality</dc:subject>
        <dc:subject>liver injury</dc:subject>
        <dc:subject>fluconazole</dc:subject>
        <dc:subject>voriconazole</dc:subject>
        <dc:subject>posaconazole</dc:subject>
        <dc:subject>anidulafungin</dc:subject>
        <dc:subject>antifungal therapy</dc:subject>
        <dc:subject>caspofungin</dc:subject>
        <dc:subject>echinocandin</dc:subject>
        <dc:subject>itraconazole</dc:subject>
        <dc:subject>micafungin</dc:subject>
        <dc:title>Antifungal Drugs and Drug-Induced Liver Injury: A Real-World Study Leveraging the FDA Adverse Event Reporting System Database</dc:title>
        <dcterms:abstract>Aims: We aimed to estimate the risk of drug-induced liver injury (DILI) from various antifungal treatments with azoles and echinocandins causing in real-world practice. Methods: We performed disproportionality and Bayesian analyses based on data from the first quarter in 2004 to the third quarter in 2021 in the Food and Drug Administration Adverse Event Reporting System to characterize the signal differences of antifungal drugs-related DILI. We also compared the onset time and mortality differences of different antifungal agents. Results: A total of 2943 antifungal drugs-related DILI were identified. Affected patients tended to be aged &gt;45 years (51.38%), with more males than females (49.03% vs. 38.09%). Antifungal drug-induced liver injury is most commonly reported with voriconazole (32.45%), fluconazole (19.37%), and itraconazole (14.51%). Almost all antifungal drugs were shown to be associated with DILI under disproportionality and Bayesian analyses. The intraclass analysis of correlation between different antifungal agents and DILI showed the following ranking: caspofungin (ROR = 6.12; 95%CI: 5.36–6.98) &gt; anidulafungin (5.15; 3.69–7.18) &gt; itraconazole (5.06; 4.58–5.60) &gt; voriconazole (4.58; 4.29–4.90) &gt; micafungin (4.53; 3.89–5.27) &gt; posaconazole (3.99; 3.47–4.59) &gt; fluconazole (3.19; 2.93–3.47) &gt; ketoconazole (2.28; 1.96–2.64). The onset time of DILI was significantly different among different antifungal drugs (p &lt; 0.0001), and anidulafungin result in the highest mortality rate (50.00%), while ketoconazole has the lowest mortality rate (9.60%). Conclusion: Based on the Food and Drug Administration Adverse Event Reporting System database, antifungal drugs are significantly associated with DILI, and itraconazole and voriconazole had the greatest risk of liver injury. Due to indication bias, more clinical studies are needed to confirm the safety of echinocandins.</dcterms:abstract>
        <dc:date>2022</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079870</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2016661628&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Memo rdf:about="#item_1212">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2017572654&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>60</prism:volume>
                <dc:title>International Journal of Clinical Pharmacology and Therapeutics</dc:title>
                <dc:identifier>DOI 10.5414/CP204066</dc:identifier>
                <prism:number>1</prism:number>
                <dcterms:alternative>Int. J. Clin. Pharmacol. Ther.</dcterms:alternative>
                <dc:identifier>ISSN 0946-1965</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ohyama</foaf:surname>
                        <foaf:givenName>K.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tanaka</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shindo</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shibayama</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Iwata</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hori</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1210"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>hypertension</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>odds ratio</dc:subject>
        <dc:subject>androgen deficiency</dc:subject>
        <dc:subject>very elderly</dc:subject>
        <dc:subject>antidiabetic agent</dc:subject>
        <dc:subject>2,4 thiazolidinedione derivative</dc:subject>
        <dc:subject>alpha glucosidase inhibitor</dc:subject>
        <dc:subject>biguanide</dc:subject>
        <dc:subject>dipeptidyl peptidase IV inhibitor</dc:subject>
        <dc:subject>diabetes mellitus</dc:subject>
        <dc:subject>disease association</dc:subject>
        <dc:subject>glucagon like peptide 1 receptor agonist</dc:subject>
        <dc:subject>sodium glucose cotransporter 2 inhibitor</dc:subject>
        <dc:subject>dyslipidemia</dc:subject>
        <dc:subject>sitagliptin</dc:subject>
        <dc:subject>breast tissue</dc:subject>
        <dc:subject>estrogen blood level</dc:subject>
        <dc:subject>gland tissue</dc:subject>
        <dc:subject>gynecomastia</dc:subject>
        <dc:subject>meglitinide</dc:subject>
        <dc:subject>sulfonylurea</dc:subject>
        <dc:subject>vildagliptin</dc:subject>
        <dc:title>Association of gynecomastia with antidiabetic medications in older adults: Data mining from different national pharmacovigilance databases</dc:title>
        <dcterms:abstract>Objective: Gynecomastia is a benign proliferation of the glandular breast tissue in men and is generally caused by a decrease in androgen and an increase in estrogen. Diabetes has been reported to be a risk factor for lowering androgen levels. Moreover, lowered androgen levels are more common in older men. In the present study, we aimed to evaluate the signals for gynecomastia in older men on antidiabetic medications. Materials and methods: A disproportionality analysis was performed to detect the signals for antidiabetic drug-associated gynecomastia in the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) and the Japanese Adverse Drug Event Report database (JADER), using the reporting odds ratio (ROR) and information component (IC). Results: Among 8 classes of medications for diabetes, a signal was detected only for dipeptidyl peptidase- 4 (DPP-4) inhibitors (ROR: 1.90, 95% confidence interval (CI): 1.27 - 2.83; IC: 0.84, 95% CI: 0.26 - 1.42) in the FAERS. Regarding individual drugs, ROR and IC signals were detected for sitagliptin (ROR: 2.37, 95% CI: 1.48 - 3.79; IC: 1.12, 95% CI: 0.44 - 1.79) and vildagliptin (ROR: 3.34, 95% CI: 1.39 - 8.08; IC: 1.26, 95% CI: 0.07 - 2.44) in the FAERS and only for sitagliptin (ROR: 4.84, 95% CI: 1.92 - 12.2; IC: 1.48, 95% CI: 0.24 - 2.73) in the JADER. Conclusion: This study showed an association between DPP-4 inhibitor use and gynecomastia in older men with diabetes. Further pharmacoepidemiological studies are warranted to verify this finding.</dcterms:abstract>
        <dc:date>2022</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079874</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2017572654&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>24-31</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1210">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2015498598&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>44</prism:volume>
                <dc:title>International Journal of Clinical Pharmacy</dc:title>
                <dc:identifier>DOI 10.1007/s11096-022-01397-5</dc:identifier>
                <prism:number>3</prism:number>
                <dcterms:alternative>Int. J. Clin. Pharm.</dcterms:alternative>
                <dc:identifier>ISSN 2210-7711</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wei</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jiang</foaf:surname>
                        <foaf:givenName>A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1213"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>odds ratio</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>young adult</dc:subject>
        <dc:subject>outcome assessment</dc:subject>
        <dc:subject>liver toxicity</dc:subject>
        <dc:subject>cholestasis</dc:subject>
        <dc:subject>confidence interval</dc:subject>
        <dc:subject>doxycycline</dc:subject>
        <dc:subject>drug-induced liver injury</dc:subject>
        <dc:subject>minocycline</dc:subject>
        <dc:subject>liver failure</dc:subject>
        <dc:subject>liver cell damage</dc:subject>
        <dc:subject>drug dose</dc:subject>
        <dc:subject>tetracycline derivative</dc:subject>
        <dc:subject>tigecycline</dc:subject>
        <dc:title>A pharmacovigilance study of the association between tetracyclines and hepatotoxicity based on Food and Drug Administration adverse event reporting system data</dc:title>
        <dcterms:abstract>Background While tetracycline antibiotics are commonly prescribed in practice, the risk of drug-induced liver injury (DILI) remains controversial. Aim To evaluate the association of DILI with tetracycline antibiotics. Method All DILI cases of tetracycline antibiotics as primary suspected drugs were extracted from the US Food and Drug Administration adverse event reporting system (FAERS). The outcomes included severe DILI, hepatocellular injury, cholestatic injury, and liver failure. Disproportionality analyses were conducted by estimating the reporting odds ratio (ROR) and the information component (IC). Results A total of 1,435 liver injury cases associated with tetracycline antibiotics were identified. The DILI signal was detected in tigecycline, minocycline, and doxycycline. The RORs and the 95% confidence intervals (95% CI) of tigecycline, minocycline, and doxycycline were (ROR 5.85, 95% CI 4.96–6.91), (ROR 6.4, 95% CI 5.76–7.11), and (ROR 2.07, 95% CI 1.86–2.31), respectively. Compared to minocycline (ROR 5.5, 95% CI 4.94–6.12; IC 2.35, 95% CI 1.98–2.68) and doxycycline (ROR 1.91, 95% CI 1.71–2.12; IC 0.91, 95% CI 0.55–1.26), tigecycline showed a stronger association with hepatocellular injury (ROR 7.11, 95% CI 6.13–8.23; IC 2.68, 95% CI 2.16–3.13). Tigecycline also showed a stronger association with cholestatic injury (ROR 12.16, 95% CI 10.13–14.61; IC 3.51, 95% CI 2.79–4) than minocycline (ROR 3.23, 95% CI 2.59–4.04; IC 1.67, 95% CI 0.9–2.37) or doxycycline (ROR 2.86, 95% CI 2.47–3.31; IC 1.5, 95% CI 1–1.97). Tigecycline (ROR 6.56, 95% CI 4.57–9.41; IC 2.69, 95% CI 1.28–3.64) and minocycline (ROR 4.22, 95% CI 3.14–5.66; IC 2.06, 95% CI 1–2.93) showed a significant association with liver failure. Conclusion The data mining of FAERS suggested an association between DILI and tigecycline, minocycline, and doxycycline.</dcterms:abstract>
        <dc:date>2022</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079867</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2015498598&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>709-716</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1213">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2025695373&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:0031-7144"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tanaka</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Okuma</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ishii</foaf:surname>
                        <foaf:givenName>T.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1215"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>sex difference</dc:subject>
        <dc:subject>disease association</dc:subject>
        <dc:subject>drug use</dc:subject>
        <dc:subject>Bowen disease</dc:subject>
        <dc:subject>clinical article</dc:subject>
        <dc:subject>voriconazole</dc:subject>
        <dc:subject>Japan</dc:subject>
        <dc:subject>immunocompromised patient</dc:subject>
        <dc:subject>keratoacanthoma</dc:subject>
        <dc:subject>squamous cell skin carcinoma</dc:subject>
        <dc:title>Occurrence of voriconazole-induced cutaneous squamous cell carcinoma in Japan: data mining from different national pharmacovigilance databases</dc:title>
        <dcterms:abstract>Long-term voriconazole use may increase the risk of cutaneous squamous cell carcinoma (cSCC), especially in immunocompromised patients. However, relatively little is known regarding voriconazole-induced cSCC in Japan. Thus, the purpose of this study was to evaluate the association between voriconazole use and cSCC in Japan using different national pharmacovigilance databases. First, using the Japanese Adverse Drug Event Report (JADER) database, we evaluated the association between voriconazole use and cSCC in Japan. Second, using the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database, we examined regional differences in the occurrence of voriconazole-induced cSCC between Japan and other countries. We calculated reporting odds ratios (RORs) as disproportionality analysis to evaluate voriconazole-induced cSCC. In this study, cases in which one or more of &quot;Bowen's disease&quot;, &quot;Carcinoma in situ of skin&quot;, &quot;Keratoacanthoma&quot;, &quot;Squamous cell carcinoma in skin&quot;, or &quot;Squamous cell carcinoma&quot; were reported as adverse events were considered to be cSCC cases. The analysis based on the JADER database showed an association between voriconazole use and cSCC in Japan, with a ROR (95% confidence interval) of 35.37 (25.60-48.87). Further, the analysis based on the FAERS database revealed that signals were detected in Japan as well as in Western countries and Australia. This study is the first in which the association between voriconazole use and cSCC in Japan is assessed using national pharmacovigilance databases. Healthcare providers need to be fully aware of the potential for cSCC development owing to voriconazole use and in all countries, including Japan, ensure careful follow-up of patients' skin.</dcterms:abstract>
        <dc:date>2022</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079862</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2025695373&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>307-310</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:0031-7144">
        <prism:volume>77</prism:volume>
        <dc:title>Pharmazie</dc:title>
        <dc:identifier>DOI 10.1691/ph.2022.2453</dc:identifier>
        <prism:number>10</prism:number>
        <dcterms:alternative>Pharmazie</dcterms:alternative>
        <dc:identifier>ISSN 0031-7144</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1215">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2020405668&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>13</prism:volume>
                <dc:title>Frontiers in Pharmacology</dc:title>
                <dc:identifier>DOI 10.3389/fphar.2022.1017889</dc:identifier>
                <dcterms:alternative>Front. Pharmacol.</dcterms:alternative>
                <dc:identifier>ISSN 1663-9812</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ma</foaf:surname>
                        <foaf:givenName>P.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Pan</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenName>R.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Qu</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xie</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xie</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Cao</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1217"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>adverse events</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>aflibercept</dc:subject>
        <dc:subject>eye disease</dc:subject>
        <dc:subject>ranibizumab</dc:subject>
        <dc:subject>retinal artery occlusion</dc:subject>
        <dc:subject>cataract</dc:subject>
        <dc:subject>blepharitis</dc:subject>
        <dc:subject>dry eye</dc:subject>
        <dc:subject>glaucoma</dc:subject>
        <dc:subject>eye infection</dc:subject>
        <dc:subject>brolucizumab</dc:subject>
        <dc:subject>cornea edema</dc:subject>
        <dc:subject>cornea opacity</dc:subject>
        <dc:subject>intraocular hypertension</dc:subject>
        <dc:subject>photopsia</dc:subject>
        <dc:subject>retina disease</dc:subject>
        <dc:subject>retina hemorrhage</dc:subject>
        <dc:subject>retina ischemia</dc:subject>
        <dc:subject>retina macula hole</dc:subject>
        <dc:subject>retina vasculitis</dc:subject>
        <dc:subject>vitreous floaters</dc:subject>
        <dc:subject>cornea disease</dc:subject>
        <dc:subject>conjunctival hyperemia</dc:subject>
        <dc:subject>fibrosis</dc:subject>
        <dc:subject>retina detachment</dc:subject>
        <dc:subject>retina tear</dc:subject>
        <dc:subject>conjunctivitis</dc:subject>
        <dc:subject>conjunctival hemorrhage</dc:subject>
        <dc:subject>lacrimation</dc:subject>
        <dc:subject>beovu</dc:subject>
        <dc:subject>byooviz</dc:subject>
        <dc:subject>cornea erosion</dc:subject>
        <dc:subject>corneal abrasion</dc:subject>
        <dc:subject>endophthalmitis</dc:subject>
        <dc:subject>eylea</dc:subject>
        <dc:subject>hypopyon</dc:subject>
        <dc:subject>intraocular pressure</dc:subject>
        <dc:subject>lens capsule rupture</dc:subject>
        <dc:subject>lucentis</dc:subject>
        <dc:subject>retinal depigmentation</dc:subject>
        <dc:subject>retinal scar</dc:subject>
        <dc:subject>retinal vascular thrombosis</dc:subject>
        <dc:subject>safety signals</dc:subject>
        <dc:subject>subretinal fibrosis</dc:subject>
        <dc:subject>susvimo</dc:subject>
        <dc:subject>vitreous body detachment</dc:subject>
        <dc:subject>vitreous disease</dc:subject>
        <dc:subject>vitreous haze</dc:subject>
        <dc:subject>vitreous hemorrhage</dc:subject>
        <dc:subject>vitritis</dc:subject>
        <dc:subject>wet macular degeneration</dc:subject>
        <dc:subject>zaltrap</dc:subject>
        <dc:title>Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)</dc:title>
        <dcterms:abstract>Background: The purpose of this study is to identify and characterize ocular adverse events (AEs) that are significantly associated with anti-VEGF drugs for treatment of neovascular age-related macular degeneration and compare the differences between each drug, and provide clinical reference. Methods: Ocular AEs submitted to the US Food and Drug Administration were analyzed to map the safety profile of anti-VEGF drugs. The Pharmacovigilance tools used for the quantitative detection of signals were reporting odds ratio and bayesian confidence propagation neural network. Results: A total of 10,608,503 AE reports were retrieved from FAERS, with 20,836 for ranibizumab, 19,107 for aflibercept, and 2,442 for brolucizumab between the reporting period of Q1, 2004 and Q3, 2021. We found and analyzed the different AEs with the strongest signal in each drug—ranibizumab-macular ischaemia (ROR = 205.27, IC-2SD = 3.70), retinal pigment epithelial tear (ROR = 836.54, IC-2SD = 7.19); aflibercept-intraocular pressure increased (ROR = 31.09, IC-2SD = 4.61), endophthalmitis (ROR = 178.27, IC-2SD = 6.70); brolucizumab-retinal vasculitis (ROR = 2930.41, IC-2SD = 7.47) and/or retinal artery occlusion (ROR = 391.11, IC-2SD = 6.10), dry eye (ROR = 12.48, IC-2SD = 2.88). Conclusion: The presence of AEs should bring clinical attention. The use of anti-VEGF drugs should be based on the patient’s underlying or present medical condition to reduce any adverse event associated with the treatment.</dcterms:abstract>
        <dc:date>2022</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079860</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2020405668&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Memo rdf:about="#item_1217">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 24; Correspondence Address: Y. Chen; Department of Pharmacy, The First Affiliated Hospital of Army Medical University, Chongqing, China; email: zwmcyc@163.com&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2025222633&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>14</prism:volume>
                <dc:title>Frontiers in Pharmacology</dc:title>
                <dc:identifier>DOI 10.3389/fphar.2023.1200254</dc:identifier>
                <dcterms:alternative>Front. Pharmacol.</dcterms:alternative>
                <dc:identifier>ISSN 1663-9812</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wei</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1220"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>FAERS database</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>young adult</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>mental disease</dc:subject>
        <dc:subject>skin disease</dc:subject>
        <dc:subject>acne</dc:subject>
        <dc:subject>lymphatic system disease</dc:subject>
        <dc:subject>diverticulitis</dc:subject>
        <dc:subject>inner ear disease</dc:subject>
        <dc:subject>drug information</dc:subject>
        <dc:subject>EFFICACY</dc:subject>
        <dc:subject>breast disease</dc:subject>
        <dc:subject>drug effect</dc:subject>
        <dc:subject>ear disease</dc:subject>
        <dc:subject>bronchitis</dc:subject>
        <dc:subject>drug labeling</dc:subject>
        <dc:subject>endocrine disease</dc:subject>
        <dc:subject>pulmonary thrombosis</dc:subject>
        <dc:subject>urinary tract infection</dc:subject>
        <dc:subject>nephrolithiasis</dc:subject>
        <dc:subject>herpes zoster</dc:subject>
        <dc:subject>Pneumocystis pneumonia</dc:subject>
        <dc:subject>eczema herpeticum</dc:subject>
        <dc:subject>eosinopenia</dc:subject>
        <dc:subject>INHIBITORS</dc:subject>
        <dc:subject>lip tumor</dc:subject>
        <dc:subject>mediastinum tumor</dc:subject>
        <dc:subject>Moraxella infection</dc:subject>
        <dc:subject>subcutaneous tissue tumor</dc:subject>
        <dc:subject>therapeutic drug monitoring</dc:subject>
        <dc:subject>TRIAL</dc:subject>
        <dc:subject>upadacitinib</dc:subject>
        <dc:subject>ureter tumor</dc:subject>
        <dc:subject>urinary tract</dc:subject>
        <dc:subject>vulvar intraepithelial neoplasia</dc:subject>
        <dc:title>A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib</dc:title>
        <dcterms:abstract>Objective: To mine the adverse drug event (ADE) signals of upadacitinib based on the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database to provide a reference for the safe clinical use of the drug. Methods: The ADE data for upadacitinib from Q1 2004 to Q1 2023 in the FAERS database were retrieved, and data mining was performed using the reporting odds ratio and proportional reporting ratio. Results: A total of 21,213 ADE reports for the primary suspect drug upadacitinib were obtained, involving 444 ADEs. Patients aged ≥60 years (21.48%) and female (70.11%) patients were at a higher risk of ADEs with upadacitinib. After data cleaning, 182 ADE signals from 19 system organ classes (SOCs) were obtained. Six of these SOCs that occurred more frequently and were not mentioned in the drug labeling information included renal and urinary system (1.09%), reproductive and breast diseases (1.14%), ear and labyrinth disorders (0.57%), psychiatric disease (0.57%), blood and lymphatic system disorders (0.57%), and endocrine disorders (0.57%). The top ten most frequent ADE signals reported for upadacitinib were mainly related to: infections and infestations (7), investigations (2), and skin and subcutaneous tissue disorders (1). The top 10 ADEs in signal intensity ranking were lip neoplasm, ureteral neoplasm, eczema herpeticum, vulvar dysplasia, mediastinum neoplasm, eosinopenia, herpes zoster cutaneous disseminated, eye ulcer, acne cystic, and Moraxella infection. The top 10 high-frequency events leading to serious adverse events were urinary tract infection (2.74%), herpes zoster (1.63%), diverticulitis (1.19%), bronchitis (0.68%), nasopharyngitis (0.68%), localised infection (0.66%), nephrolithiasis (0.66%), pulmonary thrombosis (0.66%), blood cholesterol increased (0.55%), and Pneumocystis jirovecii pneumonia (0.53%). Conclusion: Clinicians should be vigilant to upadacitinib-induced events in systems not covered in the drug labeling information and to new and highly signaled ADEs to ensure the safe and effective use of upadacitinib.</dcterms:abstract>
        <dc:date>2023</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079856</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2025222633&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Memo rdf:about="#item_1220">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 16; Correspondence Address: J. Zhang; Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China; email: 3415340@zju.edu.cn&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;15&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;15&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;25&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2026604002&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>14</prism:volume>
                <dc:title>Frontiers in Pharmacology</dc:title>
                <dc:identifier>DOI 10.3389/fphar.2023.1225919</dc:identifier>
                <dcterms:alternative>Front. Pharmacol.</dcterms:alternative>
                <dc:identifier>ISSN 1663-9812</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Su</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhou</foaf:surname>
                        <foaf:givenName>G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Peng</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhao</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>K.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1219"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>death</dc:subject>
        <dc:subject>factual database</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>*Data Mining</dc:subject>
        <dc:subject>*Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>*Pharmacovigilance</dc:subject>
        <dc:subject>*Social Media</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>Adolescent</dc:subject>
        <dc:subject>Adult</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>Adverse drug reaction</dc:subject>
        <dc:subject>Adverse Drug Reaction Reporting Systems</dc:subject>
        <dc:subject>Adverse drug reactions</dc:subject>
        <dc:subject>adverse event</dc:subject>
        <dc:subject>adverse events</dc:subject>
        <dc:subject>Aged</dc:subject>
        <dc:subject>Bayes Theorem</dc:subject>
        <dc:subject>arthralgia</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>epidemiology</dc:subject>
        <dc:subject>backache</dc:subject>
        <dc:subject>bone pain</dc:subject>
        <dc:subject>*Neural Networks, Computer</dc:subject>
        <dc:subject>antineoplastic agent</dc:subject>
        <dc:subject>arthritis</dc:subject>
        <dc:subject>Bayesian network</dc:subject>
        <dc:subject>CANCER</dc:subject>
        <dc:subject>breast cancer</dc:subject>
        <dc:subject>CLASSIFICATION</dc:subject>
        <dc:subject>Data Mining</dc:subject>
        <dc:subject>Databases, Factual</dc:subject>
        <dc:subject>drug surveillance program</dc:subject>
        <dc:subject>drug fatality</dc:subject>
        <dc:subject>drug indication</dc:subject>
        <dc:subject>bone necrosis</dc:subject>
        <dc:subject>denosumab</dc:subject>
        <dc:subject>exostosis</dc:subject>
        <dc:subject>data extraction</dc:subject>
        <dc:subject>aplastic anemia</dc:subject>
        <dc:subject>DISPROPORTIONALITY</dc:subject>
        <dc:subject>adverse drug events</dc:subject>
        <dc:subject>Drug-Related Side Effects and Adverse Reactions</dc:subject>
        <dc:subject>computer model</dc:subject>
        <dc:subject>DRUG</dc:subject>
        <dc:subject>drug interaction</dc:subject>
        <dc:subject>Drug interactions</dc:subject>
        <dc:subject>Drug Interactions</dc:subject>
        <dc:subject>Drug-drug interactions</dc:subject>
        <dc:subject>ADVERSE DRUG EVENTS</dc:subject>
        <dc:subject>Biomedical literature</dc:subject>
        <dc:subject>Female</dc:subject>
        <dc:subject>back propagation neural network</dc:subject>
        <dc:subject>ADVERSE EVENTS</dc:subject>
        <dc:subject>Aged, 80 and over</dc:subject>
        <dc:subject>data processing</dc:subject>
        <dc:subject>acute myeloid leukemia</dc:subject>
        <dc:subject>clinical article</dc:subject>
        <dc:subject>disease exacerbation</dc:subject>
        <dc:subject>docetaxel</dc:subject>
        <dc:subject>*Drug-Related Side Effects and Adverse Reactions/epidemiology</dc:subject>
        <dc:subject>Blogging</dc:subject>
        <dc:subject>colitis</dc:subject>
        <dc:subject>atezolizumab</dc:subject>
        <dc:subject>Benchmarking</dc:subject>
        <dc:subject>animal experiment</dc:subject>
        <dc:subject>animal model</dc:subject>
        <dc:subject>chemical structure</dc:subject>
        <dc:subject>drug screening</dc:subject>
        <dc:subject>drug-drug interaction</dc:subject>
        <dc:subject>avelumab</dc:subject>
        <dc:subject>cemiplimab</dc:subject>
        <dc:subject>durvalumab</dc:subject>
        <dc:subject>ADULTS</dc:subject>
        <dc:subject>cytotoxic T lymphocyte antigen 4</dc:subject>
        <dc:subject>emotional disorder</dc:subject>
        <dc:subject>drug exposure</dc:subject>
        <dc:subject>association rule mining</dc:subject>
        <dc:subject>*Fabaceae</dc:subject>
        <dc:subject>*Lupus Erythematosus, Systemic/drug therapy/epidemiology</dc:subject>
        <dc:subject>*Medication Errors/prevention &amp; control</dc:subject>
        <dc:subject>*Plants, Medicinal</dc:subject>
        <dc:subject>*Triple Negative Breast Neoplasms</dc:subject>
        <dc:subject>3 hydroxystigmast 5 en 7 one</dc:subject>
        <dc:subject>ACELLULAR PERTUSSIS</dc:subject>
        <dc:subject>adjuvant therapy</dc:subject>
        <dc:subject>aloe emodin</dc:subject>
        <dc:subject>aplastic anaemia</dc:subject>
        <dc:subject>Apriori</dc:subject>
        <dc:subject>attention</dc:subject>
        <dc:subject>Attention</dc:subject>
        <dc:subject>awareness</dc:subject>
        <dc:subject>Background extraction</dc:subject>
        <dc:subject>burden</dc:subject>
        <dc:subject>Burden</dc:subject>
        <dc:subject>BURDEN</dc:subject>
        <dc:subject>campesterol</dc:subject>
        <dc:subject>carcinogenicity</dc:subject>
        <dc:subject>catechin</dc:subject>
        <dc:subject>chemical database</dc:subject>
        <dc:subject>chronic disease</dc:subject>
        <dc:subject>Chronic disease</dc:subject>
        <dc:subject>co-occurrence analysis</dc:subject>
        <dc:subject>combination index</dc:subject>
        <dc:subject>COMBINED DIPHTHERIA</dc:subject>
        <dc:subject>complex formation</dc:subject>
        <dc:subject>CONJUGATE VACCINE</dc:subject>
        <dc:subject>data</dc:subject>
        <dc:subject>Data</dc:subject>
        <dc:subject>DEREK</dc:subject>
        <dc:subject>Dig molecular structure</dc:subject>
        <dc:subject>disproportionality measures</dc:subject>
        <dc:subject>DOCETAXEL</dc:subject>
        <dc:subject>Drug–drug interactions</dc:subject>
        <dc:subject>Dug molecular structure</dc:subject>
        <dc:subject>ELECTRONIC HEALTH RECORDS</dc:subject>
        <dc:subject>Epidemiology</dc:subject>
        <dc:subject>EXPERT-SYSTEMS</dc:subject>
        <dc:subject>Extraction</dc:subject>
        <dc:title>Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)</dc:title>
        <dcterms:abstract>Objective: To investigate adverse events (AEs) associated with denosumab (Dmab) and zoledronic acid (ZA), compare their association strengths, and explore potential applications to provide clinical reference. Methods: We collected data from FAERS from January 2004 to November 2022 and mined AE signals for Dmab and ZA using ROR values. We compared signal intensity for same AEs and investigated off-label use. We also examined their AEs in adjuvant therapy for breast and prostate cancer. Results: 154,735 reports of primary suspect drugs were analyzed in the FAERS database (Dmab: 117,857; ZA: 36,878). Dmab and ZA had 333 and 1,379 AE signals, with 189 overlaps. The AEs of Dmab included death (ROR:3.478), osteonecrosis of jaw (ROR:53.025), back pain (ROR:2.432), tooth disorder (ROR:16.18), bone pain (ROR:6.523). For ZA, the AEs included osteonecrosis (ROR:104.866), death (ROR: 3.645), pain (ROR:3.963), osteonecrosis of jaw (ROR: 91.744), tooth extraction (ROR: 142.143). Among overlap signals, Dmab showed higher strength in exostosis of the jaw (ROR: 182.66 vs. 5.769), atypical fractures (ROR: 55.589 vs. 9.123), and atypical femur fractures (ROR:49.824 vs. 4.968). And ZA exhibited stronger associations in abscess jaw (ROR: 84.119 vs. 11.12), gingival ulceration (ROR: 74.125 vs. 4.827), increased bone formation (ROR: 69.344 vs. 3.218). Additionally, we identified 528 off-label uses for Dmab and 206 for ZA, with Dmab mainly used in prostate cancer (1.04%), breast cancer (1.03%), and arthritis (0.42%), while ZA in breast cancer (3.21%), prostate cancer (2.48%), and neoplasm malignant (0.52%). For Dmab in breast cancer treatment, AEs included death (11.6%), disease progression (3.3%), and neutropenia (2.7%), while for ZA included death (19.8%), emotional disorder (12.9%), osteomyelitis (11.7%). For prostate cancer treatment, Dmab`s AEs were death (8.9%), prostate cancer metastatic (1.6%), renal impairment (1.7%), while ZA`s included death (34.4%), general physical health deterioration (19.9%), and hemoglobin decreased (18.9%). Conclusion: Our analysis of FAERS database provided postmarketing surveillance data and revealed different strengths of reported AE signals between Dmab and ZA in some of their common AEs. It’s also worth noting that both drugs have potential off-label applications, which could introduce new AEs. This highlights the necessity for safety monitoring when using Dmab and ZA off-label.</dcterms:abstract>
        <dc:date>2023</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079857</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2026604002&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Memo rdf:about="#item_1219">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 2; Correspondence Address: J. Chen; School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 10 Sassoon Road, Pokfulam, Hong Kong; email: abchen@hku.hk&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 2; Correspondence Address: J. Sun; Department of Mathematics and Statistics, University of North Carolina at Greensboro, Greensboro, 27412, United States; email: j_sun4@uncg.edu&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 5; Correspondence Address: R. Eriksson; Disease Systems Biology Program, Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Copenhagen, Denmark; email: robert.eriksson@cpr.ku.dk&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 5; Correspondence Address: S. Matsuda; Real-World Data Science Department, Chugai Pharmaceutical Co Ltd, Tokyo, 2-1-1 Nihonbashi-Muromachi, Chuo-ku, 103-8324, Japan; email: matsudasni@chugai-pharm.co.jp&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 7; Correspondence Address: J.M. Cheng; School of Management, Shanxi Medical University, Taiyuan, Shanxi, China; email: chengjingmin@163.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 7; Correspondence Address: X. Wang; School of Pharmacy, Guangdong Medical University, Zhanjiang, China; email: wangxiao0719@163.com; K. Li; Department of Pharmacy, Shenzhen People’s Hospital, The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology, Shenzhen, Guangdong, China; email: li_kuan1989@126.com&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 8; Correspondence Address: O. Oyebode; Faculty of Computer Science, Dalhousie University, Halifax, Canada; email: oladapo.oyebode@dal.ca; CODEN: HIJEA&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 12; Correspondence Address: J. Peng; Wuhan University of Technology, Wuhan, GongDa Road, China; email: pengjing@whut.edu.cn; CODEN: BBMIC&lt;/p&gt;
&lt;p&gt;Export Date: 16 July 2025; Cited By: 24; Correspondence Address: K. Li; Department of Surgical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, 277 West Yanta Road, 710061, China; email: healthlee@xjtu.edu.cn; Y. Zhang; Department of Surgical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, 277 West Yanta Road, 710061, China; email: yongzhang761@mail.xjtu.edu.cn; CODEN: BCMAC&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;48&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;2&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;60&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;3&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;3&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;22&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;3&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;3&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;24&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;4&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;4&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;51&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;5&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;5&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;30&lt;/p&gt;
&lt;p&gt;Times Cited in Web of Science Core Collection:&amp;nbsp;&amp;nbsp;26&lt;br/&gt;Total Times Cited:&amp;nbsp;&amp;nbsp;26&lt;br/&gt;Cited Reference Count:&amp;nbsp;&amp;nbsp;28&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2025115437&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>22</prism:volume>
                <dc:title>Expert Opinion on Drug Safety</dc:title>
                <dc:identifier>DOI 10.1080/14740338.2023.2247971</dc:identifier>
                <prism:number>11</prism:number>
                <dcterms:alternative>Expert Opin. Drug Saf.</dcterms:alternative>
                <dc:identifier>ISSN 1744-764X</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wen</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lu</foaf:surname>
                        <foaf:givenName>C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Qi</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1221"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>odds ratio</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>prescription</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>clinical feature</dc:subject>
        <dc:subject>connective tissue disease</dc:subject>
        <dc:subject>arthralgia</dc:subject>
        <dc:subject>myalgia</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>dizziness</dc:subject>
        <dc:subject>abdominal pain</dc:subject>
        <dc:subject>body weight gain</dc:subject>
        <dc:subject>fatigue</dc:subject>
        <dc:subject>headache</dc:subject>
        <dc:subject>insomnia</dc:subject>
        <dc:subject>limb pain</dc:subject>
        <dc:subject>muscle spasm</dc:subject>
        <dc:subject>nausea</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>gastrointestinal disease</dc:subject>
        <dc:subject>information processing</dc:subject>
        <dc:subject>mental disease</dc:subject>
        <dc:subject>neurologic disease</dc:subject>
        <dc:subject>skin disease</dc:subject>
        <dc:subject>deep vein thrombosis</dc:subject>
        <dc:subject>eye disease</dc:subject>
        <dc:subject>lung embolism</dc:subject>
        <dc:subject>Bayesian network</dc:subject>
        <dc:subject>abdominal distension</dc:subject>
        <dc:subject>alopecia</dc:subject>
        <dc:subject>asthenia</dc:subject>
        <dc:subject>diarrhea</dc:subject>
        <dc:subject>drug indication</dc:subject>
        <dc:subject>lymphatic system disease</dc:subject>
        <dc:subject>malignant neoplasm</dc:subject>
        <dc:subject>dyspnea</dc:subject>
        <dc:subject>heart disease</dc:subject>
        <dc:subject>inner ear disease</dc:subject>
        <dc:subject>mediastinum disease</dc:subject>
        <dc:subject>peripheral swelling</dc:subject>
        <dc:subject>respiratory tract disease</dc:subject>
        <dc:subject>thorax disease</dc:subject>
        <dc:subject>vascular disease</dc:subject>
        <dc:subject>benign neoplasm</dc:subject>
        <dc:subject>breast disease</dc:subject>
        <dc:subject>drug hypersensitivity</dc:subject>
        <dc:subject>ear disease</dc:subject>
        <dc:subject>cyst</dc:subject>
        <dc:subject>genital system disease</dc:subject>
        <dc:subject>hematologic disease</dc:subject>
        <dc:subject>hepatobiliary disease</dc:subject>
        <dc:subject>infection</dc:subject>
        <dc:subject>infestation</dc:subject>
        <dc:subject>injury</dc:subject>
        <dc:subject>kidney disease</dc:subject>
        <dc:subject>malaise</dc:subject>
        <dc:subject>metabolic disorder</dc:subject>
        <dc:subject>musculoskeletal disease</dc:subject>
        <dc:subject>nutritional disorder</dc:subject>
        <dc:subject>polyp</dc:subject>
        <dc:subject>urinary tract disease</dc:subject>
        <dc:subject>endocrine disease</dc:subject>
        <dc:subject>hot flush</dc:subject>
        <dc:subject>rash</dc:subject>
        <dc:subject>paresthesia</dc:subject>
        <dc:subject>mycosis</dc:subject>
        <dc:subject>erythema</dc:subject>
        <dc:subject>hyperhidrosis</dc:subject>
        <dc:subject>immunopathology</dc:subject>
        <dc:subject>migraine</dc:subject>
        <dc:subject>thorax pain</dc:subject>
        <dc:subject>treatment response</dc:subject>
        <dc:subject>drug identification</dc:subject>
        <dc:subject>urticaria</dc:subject>
        <dc:subject>Bayesian confidence propagation neural network</dc:subject>
        <dc:subject>subcutaneous tissue</dc:subject>
        <dc:subject>abdominal discomfort</dc:subject>
        <dc:subject>elevated blood pressure</dc:subject>
        <dc:subject>urinary tract infection</dc:subject>
        <dc:subject>proportional reporting ratio</dc:subject>
        <dc:subject>vulvovaginitis</dc:subject>
        <dc:subject>drug intoxication</dc:subject>
        <dc:subject>anxiety disorder</dc:subject>
        <dc:subject>pruritus</dc:subject>
        <dc:subject>night sweat</dc:subject>
        <dc:subject>sleep quality</dc:subject>
        <dc:subject>vagina bleeding</dc:subject>
        <dc:subject>breast tenderness</dc:subject>
        <dc:subject>dyspareunia</dc:subject>
        <dc:subject>mood change</dc:subject>
        <dc:subject>multi item gamma Poisson shrinker algorithm</dc:subject>
        <dc:subject>ospemifene</dc:subject>
        <dc:subject>postmenopause bleeding</dc:subject>
        <dc:subject>prescribing error</dc:subject>
        <dc:subject>vagina atrophy</dc:subject>
        <dc:subject>vagina discharge (disease)</dc:subject>
        <dc:subject>vagina pain</dc:subject>
        <dc:subject>vaginal burning sensation</dc:subject>
        <dc:subject>vaginal dryness</dc:subject>
        <dc:subject>vaginal pruritus</dc:subject>
        <dc:subject>vulvovaginal discomfort</dc:subject>
        <dc:title>A real-world disproportionality analysis of ospemifene: data mining of the public version of FDA adverse event reporting system</dc:title>
        <dcterms:abstract>Background: Ospemifene has been authorized for the treatment of vulvovaginal atrophy (VVA). This study wasto evaluate adverse events (AEs) associated with ospemifene by data mining the US Food and Drug Administration Adverse Event Reporting System (FAERS). Methods: The signals of AEs linked to ospemifene were measured using disproportionality analyses, such as the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi-item gamma Poisson shrinker (MGPS) algorithms. Results: There were 2283 events of ospemifene being the ’primary suspected (PS)’ AE out of the 12,692,824 reports from the FAERS database. Ospemifene-induced AEs hit 25 organ systems. There were 726 severely disproportional preferred terms (PTs) that complied with the four algorithms. The investigation turned up a number of anticipated adverse drug reactions (ADRs), and significant unanticipated ADRs linked to eye and renal problems were found, indicating potential side effects not yet included in the prescription instructions. Conclusion: We detected novel AEs signals for ospemifene, and the results of our investigation were compatible with clinical observations. This suggests that further prospective clinical trials are required to confirm these findings and demonstrate their link. Our findings might be useful supporting data for ospemifene safety research in the future.</dcterms:abstract>
        <dc:date>2023</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079855</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2025115437&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>1133-1142</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1221">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2024296036&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>22</prism:volume>
                <dc:title>Expert Opinion on Drug Safety</dc:title>
                <dc:identifier>DOI 10.1080/14740338.2023.2234279</dc:identifier>
                <prism:number>11</prism:number>
                <dcterms:alternative>Expert Opin. Drug Saf.</dcterms:alternative>
                <dc:identifier>ISSN 1744-764X</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>F.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xu</foaf:surname>
                        <foaf:givenName>G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1222"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>prognosis</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>bradycardia</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>heart arrest</dc:subject>
        <dc:subject>heart arrhythmia</dc:subject>
        <dc:subject>heart ventricle fibrillation</dc:subject>
        <dc:subject>long QT syndrome</dc:subject>
        <dc:subject>sinus tachycardia</dc:subject>
        <dc:subject>tachycardia</dc:subject>
        <dc:subject>atrial fibrillation</dc:subject>
        <dc:subject>fatality</dc:subject>
        <dc:subject>cancer chemotherapy</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>heart atrium flutter</dc:subject>
        <dc:subject>alectinib</dc:subject>
        <dc:subject>anaplastic lymphoma kinase inhibitor</dc:subject>
        <dc:subject>brigatinib</dc:subject>
        <dc:subject>ceritinib</dc:subject>
        <dc:subject>crizotinib</dc:subject>
        <dc:subject>sinus node disease</dc:subject>
        <dc:subject>respiratory arrest</dc:subject>
        <dc:subject>non small cell lung cancer</dc:subject>
        <dc:subject>anaplastic lymphoma kinase</dc:subject>
        <dc:subject>complete heart block</dc:subject>
        <dc:subject>gene rearrangement</dc:subject>
        <dc:subject>lorlatinib</dc:subject>
        <dc:subject>sinus bradycardia</dc:subject>
        <dc:subject>sudden cardiac death</dc:subject>
        <dc:subject>time</dc:subject>
        <dc:title>Cardiac arrhythmias associated with anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS)</dc:title>
        <dcterms:abstract>Background: Anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) may provoke cardiac arrhythmias. We conducted this pharmacovigilance analysis to research cardiac arrhythmias associated with ALK-TKIs using the Food and Drug Administration Adverse Event Reporting System (FAERS). Research design and methods: The first ALK-TKI, named crizotinib, was approved by the Food and Drug Administration (FDA) on 26 August 2011 for the treatment of ALK-rearranged non-small cell lung cancer (NSCLC). We evaluated ALK-TKIs-induced cardiac arrhythmias, by using the reporting odds ratio (ROR) and information component (IC) for mining the adverse event report signals in the FAERS database between January 2016 and June 2022. Results: We identified a total of 362 ALK-TKIs-related cardiac arrhythmia reports which appeared to influence more men (64.44%) than women (30.76%), with a median age of 68 (interquartile range [IQR] 7–74) years. Compared with the full database, ALK-TKIs were detected with pharmacovigilance of cardiac arrhythmias (ROR025 = 1.26, IC025 = 0.26). Crizotinib and alectinib were found to be related to higher reporting of arrhythmias. The median time to onset (TTO) among five ALK-TKI therapies was significantly different (p = 0.044). Conclusion: ALK-TKIs present different frequencies of cardiac arrhythmias reporting, with only crizotinib and alectinib producing positive signals in high-level group term (HLGT) level arrhythmia. The time interval between the initial of drug treatment to the onset of arrhythmia varies greatly and cannot be predicted.</dcterms:abstract>
        <dc:date>2023</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079854</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2024296036&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>1127-1132</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1222">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2023817046&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>22</prism:volume>
                <dc:title>Expert Opinion on Drug Safety</dc:title>
                <dc:identifier>DOI 10.1080/14740338.2023.2223956</dc:identifier>
                <prism:number>10</prism:number>
                <dcterms:alternative>Expert Opin. Drug Saf.</dcterms:alternative>
                <dc:identifier>ISSN 1744-764X</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xiang</foaf:surname>
                        <foaf:givenName>D.-C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Fu</foaf:surname>
                        <foaf:givenName>Z.-W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>X.-H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gao</foaf:surname>
                        <foaf:givenName>P.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1225"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>arthralgia</dc:subject>
        <dc:subject>injection site erythema</dc:subject>
        <dc:subject>injection site pain</dc:subject>
        <dc:subject>injection site pruritus</dc:subject>
        <dc:subject>injection site rash</dc:subject>
        <dc:subject>injection site reaction</dc:subject>
        <dc:subject>injection site swelling</dc:subject>
        <dc:subject>liver cirrhosis</dc:subject>
        <dc:subject>headache</dc:subject>
        <dc:subject>injection site bleeding</dc:subject>
        <dc:subject>injection site contusion</dc:subject>
        <dc:subject>injection site irritation</dc:subject>
        <dc:subject>nail disease</dc:subject>
        <dc:subject>erectile dysfunction</dc:subject>
        <dc:subject>Medical Dictionary for Regulatory Activities</dc:subject>
        <dc:subject>arthritis</dc:subject>
        <dc:subject>allergy</dc:subject>
        <dc:subject>cellulitis</dc:subject>
        <dc:subject>diarrhea</dc:subject>
        <dc:subject>abscess</dc:subject>
        <dc:subject>diverticulitis</dc:subject>
        <dc:subject>mouth infection</dc:subject>
        <dc:subject>coronavirus disease 2019</dc:subject>
        <dc:subject>drug eruption</dc:subject>
        <dc:subject>genital system disease</dc:subject>
        <dc:subject>infection</dc:subject>
        <dc:subject>injury</dc:subject>
        <dc:subject>intoxication</dc:subject>
        <dc:subject>bronchitis</dc:subject>
        <dc:subject>Coronavirus infection</dc:subject>
        <dc:subject>anaphylactoid reaction</dc:subject>
        <dc:subject>erysipelas</dc:subject>
        <dc:subject>hepatitis B</dc:subject>
        <dc:subject>injection site extravasation</dc:subject>
        <dc:subject>pneumonia</dc:subject>
        <dc:subject>rash</dc:subject>
        <dc:subject>gastroenteritis</dc:subject>
        <dc:subject>lower respiratory tract infection</dc:subject>
        <dc:subject>mycosis</dc:subject>
        <dc:subject>neutropenia</dc:subject>
        <dc:subject>joint stiffness</dc:subject>
        <dc:subject>immunopathology</dc:subject>
        <dc:subject>migraine</dc:subject>
        <dc:subject>Bayesian confidence propagation neural network</dc:subject>
        <dc:subject>Hodgkin disease</dc:subject>
        <dc:subject>complication</dc:subject>
        <dc:subject>pruritus</dc:subject>
        <dc:subject>ear infection</dc:subject>
        <dc:subject>psoriasis</dc:subject>
        <dc:subject>herpes virus infection</dc:subject>
        <dc:subject>herpes zoster</dc:subject>
        <dc:subject>herpes simplex</dc:subject>
        <dc:subject>multiitem gamma Poisson shrinker</dc:subject>
        <dc:subject>prostatitis</dc:subject>
        <dc:subject>keratoacanthoma</dc:subject>
        <dc:subject>Human immunodeficiency virus infection</dc:subject>
        <dc:subject>Graves disease</dc:subject>
        <dc:subject>acute leukemia</dc:subject>
        <dc:subject>alcohol liver cirrhosis</dc:subject>
        <dc:subject>angioimmunoblastic T cell lymphoma</dc:subject>
        <dc:subject>appendicitis</dc:subject>
        <dc:subject>bacterial pneumonia</dc:subject>
        <dc:subject>cornea ulcer</dc:subject>
        <dc:subject>cutaneous T cell lymphoma</dc:subject>
        <dc:subject>dermatomycosis</dc:subject>
        <dc:subject>duodenum perforation</dc:subject>
        <dc:subject>endometrium cancer</dc:subject>
        <dc:subject>eosinophilic esophagitis</dc:subject>
        <dc:subject>erythroderma</dc:subject>
        <dc:subject>erythrodermic psoriasis</dc:subject>
        <dc:subject>flu like syndrome</dc:subject>
        <dc:subject>genital rash</dc:subject>
        <dc:subject>guselkumab</dc:subject>
        <dc:subject>guttate psoriasis</dc:subject>
        <dc:subject>herpes zoster ophthalmicus</dc:subject>
        <dc:subject>herpetic stomatitis</dc:subject>
        <dc:subject>hordeolum</dc:subject>
        <dc:subject>injection site edema</dc:subject>
        <dc:subject>injection site nodule</dc:subject>
        <dc:subject>injection site plaque</dc:subject>
        <dc:subject>injection site vesicle</dc:subject>
        <dc:subject>injection site warmth</dc:subject>
        <dc:subject>invasive ductal breast carcinoma</dc:subject>
        <dc:subject>kidney infection</dc:subject>
        <dc:subject>kidney tumor</dc:subject>
        <dc:subject>latent tuberculosis</dc:subject>
        <dc:subject>learning algorithm</dc:subject>
        <dc:subject>lichen planus</dc:subject>
        <dc:subject>limb tumor</dc:subject>
        <dc:subject>lung tuberculosis</dc:subject>
        <dc:subject>melanoma in situ</dc:subject>
        <dc:subject>Mycobacterium avium complex infection</dc:subject>
        <dc:subject>nail psoriasis</dc:subject>
        <dc:subject>nonalcoholic steatohepatitis</dc:subject>
        <dc:subject>nummular dermatitis</dc:subject>
        <dc:subject>onychomadesis</dc:subject>
        <dc:subject>pemphigoid</dc:subject>
        <dc:subject>peptic ulcer bleeding</dc:subject>
        <dc:subject>psoriatic arthritis</dc:subject>
        <dc:subject>pustular psoriasis</dc:subject>
        <dc:subject>pyoderma gangrenosum</dc:subject>
        <dc:subject>rectal adenocarcinoma</dc:subject>
        <dc:subject>rectum cancer</dc:subject>
        <dc:subject>respiratory tract infection</dc:subject>
        <dc:subject>rhinopharyngitis</dc:subject>
        <dc:title>Adverse events of guselkumab in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system</dc:title>
        <dcterms:abstract>Background: Guselkumab is an IL−23 inhibitor widely used for the treatment of moderate-to-severe plaque psoriasis. Our study aimed to characterize the profile of adverse events (AEs) associated with guselkumab from the FDA adverse event reporting system (FAERS). Methods: Disproportionality analysis including the proportional reporting ratio (PRR), the reporting odds ratio (ROR), the Bayesian confidence propagation neural network (BCPNN), and the multiitem gamma Poisson shrinker (MGPS) algorithms were used to assess the signals of guselkumab related AE. Results: A total of 22,950,014 reports were collected from the FAERS database, of which 24,312 reports regarding guselkumab as the ‘primary suspected (PS)’ AEs were identified. AEs induced by guselkumab were distributed in 27 organ systems. In this study, 205 significant disproportionality preferred terms (PTs) that matched four algorithms simultaneously were obtained for analysis. Unexpected significant AEs such as onychomadesis, malignant melanoma in situ, endometrial cancer, and erectile dysfunction were observed. Conclusion: The clinical observed AEs, along with potential new AE signals associated with guselkumab were identified based on the analysis of FAERS data, which could provide valuable evidence for clinical monitoring, risk identification, and further safety studies of identification.</dcterms:abstract>
        <dc:date>2023</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079851</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2023817046&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>943-955</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1225">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2022428408&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>22</prism:volume>
                <dc:title>Expert Opinion on Drug Safety</dc:title>
                <dc:identifier>DOI 10.1080/14740338.2023.2193392</dc:identifier>
                <prism:number>9</prism:number>
                <dcterms:alternative>Expert Opin. Drug Saf.</dcterms:alternative>
                <dc:identifier>ISSN 1744-764X</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Qiu</foaf:surname>
                        <foaf:givenName>T.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhou</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>E.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1227"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>mortality rate</dc:subject>
        <dc:subject>interstitial lung disease</dc:subject>
        <dc:subject>osimertinib</dc:subject>
        <dc:subject>non small cell lung cancer</dc:subject>
        <dc:subject>cabozantinib</dc:subject>
        <dc:subject>cancer prognosis</dc:subject>
        <dc:subject>gefitinib</dc:subject>
        <dc:subject>protein tyrosine kinase inhibitor</dc:subject>
        <dc:subject>selpercatinib</dc:subject>
        <dc:subject>trametinib</dc:subject>
        <dc:subject>vemurafenib</dc:subject>
        <dc:title>Tyrosine kinase inhibitors-associated interstitial lung disease used in non-small cell lung cancer: a pharmacovigilance analysis based on the FDA adverse event reporting system database</dc:title>
        <dcterms:abstract>Background: Interstitial lung disease (ILD) was a relatively common cause of drug-induced mortality. However, the safety profile of the whole TKIs induced ILD was largely unknown. Research design and methods: The reported cases of ILD associated with TKIs were downloaded from the FDA adverse event reporting system (FAERS) database between 1 January 2004 and 30 April 2022 to detect ILD signals by disproportionality analysis. Furthermore, the fatality rate and time to onset (TTO) of various TKIs were also calculated. Results: The median age of total 2999 reported cases was 67. The largest reported cases came from osimertinib (n = 736, 24.5%). However, gefitinib had the highest ROR of 12.47 (11.4, 13.64) and IC of 3.53 (3.23, 3.86), means the strongest association with ILD. Trametinib, vemurafenib, larotectinib, selpercatinib, and cabozantinib did not show ILD signal. The median age of dead cases was 72 (Q1:62, Q3:83), and 53.02% (n = 579) were female and 41.11% (n = 449) were male. MET group showed the highest fatality rate of 55.17% with the shortest median TTO of 21 days (Q1: 8.5, Q3: 35.5). Conclusions: TKIs were significantly associated with ILD. More attention should be paid to female, older, MET group with shorter TTO, as their prognosis might be worse.</dcterms:abstract>
        <dc:date>2023</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079849</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2022428408&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>849-856</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1227">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2022366910&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>22</prism:volume>
                <dc:title>Expert Opinion on Drug Safety</dc:title>
                <dc:identifier>DOI 10.1080/14740338.2023.2193391</dc:identifier>
                <prism:number>8</prism:number>
                <dcterms:alternative>Expert Opin. Drug Saf.</dcterms:alternative>
                <dc:identifier>ISSN 1744-764X</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Luo</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Long</foaf:surname>
                        <foaf:givenName>E.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1223"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>age</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>brain hemorrhage</dc:subject>
        <dc:subject>data base</dc:subject>
        <dc:subject>sensory dysfunction</dc:subject>
        <dc:subject>brain disease</dc:subject>
        <dc:subject>hyponatremia</dc:subject>
        <dc:subject>motor dysfunction</dc:subject>
        <dc:subject>seizure</dc:subject>
        <dc:subject>sex difference</dc:subject>
        <dc:subject>speech disorder</dc:subject>
        <dc:subject>brain embolism</dc:subject>
        <dc:subject>brain hematoma</dc:subject>
        <dc:subject>brain ischemia</dc:subject>
        <dc:subject>cerebrovascular disease</dc:subject>
        <dc:subject>fatality</dc:subject>
        <dc:subject>neurotoxicity</dc:subject>
        <dc:subject>polyneuropathy</dc:subject>
        <dc:subject>posterior reversible encephalopathy syndrome</dc:subject>
        <dc:subject>prevalence</dc:subject>
        <dc:subject>dysgeusia</dc:subject>
        <dc:subject>brain edema</dc:subject>
        <dc:subject>presyncope</dc:subject>
        <dc:subject>acute motor axonal neuropathy</dc:subject>
        <dc:subject>Guillain Barre syndrome</dc:subject>
        <dc:subject>paresthesia</dc:subject>
        <dc:subject>demyelinating disease</dc:subject>
        <dc:subject>peripheral neuropathy</dc:subject>
        <dc:subject>aphasia</dc:subject>
        <dc:subject>taste disorder</dc:subject>
        <dc:subject>docetaxel</dc:subject>
        <dc:subject>autonomic neuropathy</dc:subject>
        <dc:subject>unconsciousness</dc:subject>
        <dc:subject>clonic seizure</dc:subject>
        <dc:subject>areflexia</dc:subject>
        <dc:subject>brain toxicity</dc:subject>
        <dc:subject>liquorrhea</dc:subject>
        <dc:subject>metabolic encephalopathy</dc:subject>
        <dc:subject>sensory neuropathy</dc:subject>
        <dc:subject>paclitaxel</dc:subject>
        <dc:subject>stupor</dc:subject>
        <dc:subject>neuromuscular disease</dc:subject>
        <dc:subject>time</dc:subject>
        <dc:subject>abducens nerve paralysis</dc:subject>
        <dc:subject>artery embolism</dc:subject>
        <dc:subject>carotid artery aneurysm</dc:subject>
        <dc:subject>cerebellum disease</dc:subject>
        <dc:subject>cranial neuropathy</dc:subject>
        <dc:subject>demyelinating neuropathy</dc:subject>
        <dc:subject>dysesthesia</dc:subject>
        <dc:subject>dysmetria</dc:subject>
        <dc:subject>hydrocephalus</dc:subject>
        <dc:subject>intracranial hypertension</dc:subject>
        <dc:subject>meningism</dc:subject>
        <dc:subject>motor neuropathy</dc:subject>
        <dc:subject>myelooptic neuropathy</dc:subject>
        <dc:subject>neuritis</dc:subject>
        <dc:subject>paraplegia</dc:subject>
        <dc:subject>paresis</dc:subject>
        <dc:subject>parosmia</dc:subject>
        <dc:subject>small fiber neuropathy</dc:subject>
        <dc:subject>taxane derivative</dc:subject>
        <dc:subject>vagus nerve disease</dc:subject>
        <dc:subject>vocal cord paralysis</dc:subject>
        <dc:title>Neurotoxicity induced by taxane-derived drugs: analysis of the FAERS database 2017–2021</dc:title>
        <dcterms:abstract>Objectives: Taxane‐related neurotoxicity is a frequent clinical problem but lacks postmarketing data regarding neurological disorders. This study aimed to evaluate the potential association between neurological adverse events and several taxanederived drugs via the Food and Drug Administration Adverse Event Reporting System (FAERS). Methods: Disproportionality analysis was applied to data mining of the suspected cases of neurological disorders after using different taxanes based on the FAERS data from January 2017 and December 2021. We also investigated the times to onset, fatality, and hospitalization proportions of taxanerelated neurotoxicity. Results: In total, 3,940 cases were screened out, which were more prevalent in elderly patients and females. Peripheral neuropathy was a common adverse event among all taxanes with relatively strong association. Generally, the median time to neurological adverse effect onset was 27 days (interquartile range, 11.0 ~ 78.0 days) following taxane regimens, and the majority of cases were detected within the first 30 days. Among cases of neurological adverse events treated with taxane, the fatality and hospitalization proportions were 6.13% and 28.63%, respectively. Conclusion: By analyzing the FAERS data, we provided a detailed profile of neurotoxicity and different taxanes in detail in terms of clinical characteristics, time to onset, and patient outcomes.</dcterms:abstract>
        <dc:date>2023</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079848</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2022366910&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>715-724</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1223">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2023923514&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>22</prism:volume>
                <dc:title>Expert Opinion on Drug Safety</dc:title>
                <dc:identifier>DOI 10.1080/14740338.2023.2223952</dc:identifier>
                <prism:number>10</prism:number>
                <dcterms:alternative>Expert Opin. Drug Saf.</dcterms:alternative>
                <dc:identifier>ISSN 1744-764X</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>X.-P.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lu</foaf:surname>
                        <foaf:givenName>X.-K.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>Z.-T.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Huang</foaf:surname>
                        <foaf:givenName>L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Cai</foaf:surname>
                        <foaf:givenName>R.-W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yu</foaf:surname>
                        <foaf:givenName>H.-M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>J.-Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xiao</foaf:surname>
                        <foaf:givenName>J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1224"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>postmarketing surveillance</dc:subject>
        <dc:subject>arthralgia</dc:subject>
        <dc:subject>drug safety</dc:subject>
        <dc:subject>joint effusion</dc:subject>
        <dc:subject>range of motion</dc:subject>
        <dc:subject>thrombosis</dc:subject>
        <dc:subject>myocarditis</dc:subject>
        <dc:subject>arthropathy</dc:subject>
        <dc:subject>headache</dc:subject>
        <dc:subject>nausea</dc:subject>
        <dc:subject>rheumatoid arthritis</dc:subject>
        <dc:subject>side effect</dc:subject>
        <dc:subject>Medical Dictionary for Regulatory Activities</dc:subject>
        <dc:subject>arthritis</dc:subject>
        <dc:subject>cataract</dc:subject>
        <dc:subject>cholesterol blood level</dc:subject>
        <dc:subject>anaphylaxis</dc:subject>
        <dc:subject>breast cancer</dc:subject>
        <dc:subject>bursitis</dc:subject>
        <dc:subject>cholesterol</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>diverticulitis</dc:subject>
        <dc:subject>exostosis</dc:subject>
        <dc:subject>nerve compression</dc:subject>
        <dc:subject>osteoarthritis</dc:subject>
        <dc:subject>sciatica</dc:subject>
        <dc:subject>scoliosis</dc:subject>
        <dc:subject>vertebral canal stenosis</dc:subject>
        <dc:subject>coughing</dc:subject>
        <dc:subject>peripheral swelling</dc:subject>
        <dc:subject>Canada</dc:subject>
        <dc:subject>coronavirus disease 2019</dc:subject>
        <dc:subject>cyst</dc:subject>
        <dc:subject>infection</dc:subject>
        <dc:subject>musculoskeletal disease</dc:subject>
        <dc:subject>chickenpox</dc:subject>
        <dc:subject>fever</dc:subject>
        <dc:subject>atopic dermatitis</dc:subject>
        <dc:subject>pneumonia</dc:subject>
        <dc:subject>Escherichia coli infection</dc:subject>
        <dc:subject>immune deficiency</dc:subject>
        <dc:subject>inflammation</dc:subject>
        <dc:subject>bacterial arthritis</dc:subject>
        <dc:subject>gait disorder</dc:subject>
        <dc:subject>joint mobility</dc:subject>
        <dc:subject>musculoskeletal stiffness</dc:subject>
        <dc:subject>pulmonary thrombosis</dc:subject>
        <dc:subject>oxygen saturation</dc:subject>
        <dc:subject>urinary tract infection</dc:subject>
        <dc:subject>hemoglobin</dc:subject>
        <dc:subject>colitis</dc:subject>
        <dc:subject>foot malformation</dc:subject>
        <dc:subject>stomach disease</dc:subject>
        <dc:subject>skin cancer</dc:subject>
        <dc:subject>Japan</dc:subject>
        <dc:subject>fibromyalgia</dc:subject>
        <dc:subject>Germany</dc:subject>
        <dc:subject>Western Hemisphere</dc:subject>
        <dc:subject>herpes zoster</dc:subject>
        <dc:subject>herpes simplex</dc:subject>
        <dc:subject>healing impairment</dc:subject>
        <dc:subject>squamous cell skin carcinoma</dc:subject>
        <dc:subject>upadacitinib</dc:subject>
        <dc:subject>ulcerative colitis</dc:subject>
        <dc:subject>intervertebral disk hernia</dc:subject>
        <dc:subject>flu like syndrome</dc:subject>
        <dc:subject>psoriatic arthritis</dc:subject>
        <dc:subject>ankylosing spondylitis</dc:subject>
        <dc:subject>Brazil</dc:subject>
        <dc:subject>carpal tunnel syndrome</dc:subject>
        <dc:subject>COVID-19 testing</dc:subject>
        <dc:subject>enzyme</dc:subject>
        <dc:subject>erythrocyte sedimentation rate</dc:subject>
        <dc:subject>finger malformation</dc:subject>
        <dc:subject>grip strength</dc:subject>
        <dc:subject>hemoglobin blood level</dc:subject>
        <dc:subject>high density lipoprotein</dc:subject>
        <dc:subject>intervertebral disk degeneration</dc:subject>
        <dc:subject>lipid</dc:subject>
        <dc:subject>peritonsillar abscess</dc:subject>
        <dc:subject>pyelonephritis</dc:subject>
        <dc:subject>rheumatic disease</dc:subject>
        <dc:subject>shoulder impingement syndrome</dc:subject>
        <dc:subject>spinal cord compression</dc:subject>
        <dc:subject>stomach hemorrhage</dc:subject>
        <dc:subject>surgical infection</dc:subject>
        <dc:subject>systemic lupus erythematosus</dc:subject>
        <dc:subject>trigger finger</dc:subject>
        <dc:subject>vulva cancer</dc:subject>
        <dc:title>Post-Marketing Safety Concerns with Upadacitinib: A Disproportionality Analysis of the FDA Adverse Event Reporting system</dc:title>
        <dcterms:abstract>Background: Upadacitinib was approved to treat rheumatoid arthritis, psoriasis, ulcerative colitis, ankylosing spondylitis, and atopic dermatitis. This study assessed the adverse events (AEs) associated with upadacitinib by mining data from the US Food and Drug Administration Adverse Event Reporting System (FAERS). Methods: Disproportionality analyses, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi-item gamma Poisson shrinker (MGPS) algorithms, were employed to quantify the signals of upadacitinib-associated AEs. Results: A total of 3,837,420 reports of AEs were collected from the FAERS database, of which 4494 reports were identified with upadacitinib as the “primary suspect (PS)”. Upadacitinib-induced AEs occurrence targeted 27 system organ clases (SOCs). A total of 200 significant disproportionality PTs conforming to the four algorithms were simultaneously retained. Unexpected significant AEs, such as arthralgia, musculoskeletal stiffness, diverticulitis, and cataract might also occur. The median onset time of upadacitinib-associated AEs was 65 days (interquartile range [IQR] 21–182 days), and most of the onsets occurred within the first 1, 2, 3, and 4 months after initiation of upadacitinib. Conclusion: This study found potential new AEs signals and might provide important support for clinical monitoring and risk identification of upadacitinib.</dcterms:abstract>
        <dc:date>2023</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079852</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2023923514&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>975-984</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1224">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2022682179&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>22</prism:volume>
                <dc:title>Expert Opinion on Drug Safety</dc:title>
                <dc:identifier>DOI 10.1080/14740338.2023.2203487</dc:identifier>
                <prism:number>9</prism:number>
                <dcterms:alternative>Expert Opin. Drug Saf.</dcterms:alternative>
                <dc:identifier>ISSN 1744-764X</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>L.-Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liao</foaf:surname>
                        <foaf:givenName>L.-F.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lei</foaf:surname>
                        <foaf:givenName>C.-L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wu</foaf:surname>
                        <foaf:givenName>Q.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Guo</foaf:surname>
                        <foaf:givenName>Y.-J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1226"/>
        <dc:subject>adult</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>adolescent</dc:subject>
        <dc:subject>adverse drug reaction</dc:subject>
        <dc:subject>child</dc:subject>
        <dc:subject>connective tissue disease</dc:subject>
        <dc:subject>liver cirrhosis</dc:subject>
        <dc:subject>thrombosis</dc:subject>
        <dc:subject>depression</dc:subject>
        <dc:subject>gastrointestinal disease</dc:subject>
        <dc:subject>mental disease</dc:subject>
        <dc:subject>neurologic disease</dc:subject>
        <dc:subject>skin disease</dc:subject>
        <dc:subject>embolism</dc:subject>
        <dc:subject>eye disease</dc:subject>
        <dc:subject>Medical Dictionary for Regulatory Activities</dc:subject>
        <dc:subject>dehydration</dc:subject>
        <dc:subject>signal detection</dc:subject>
        <dc:subject>lymphatic system disease</dc:subject>
        <dc:subject>prevalence</dc:subject>
        <dc:subject>heart disease</dc:subject>
        <dc:subject>inner ear disease</dc:subject>
        <dc:subject>mediastinum disease</dc:subject>
        <dc:subject>respiratory tract disease</dc:subject>
        <dc:subject>thorax disease</dc:subject>
        <dc:subject>vascular disease</dc:subject>
        <dc:subject>drug information</dc:subject>
        <dc:subject>breast disease</dc:subject>
        <dc:subject>ear disease</dc:subject>
        <dc:subject>genital system disease</dc:subject>
        <dc:subject>hematologic disease</dc:subject>
        <dc:subject>hepatobiliary disease</dc:subject>
        <dc:subject>infection</dc:subject>
        <dc:subject>infestation</dc:subject>
        <dc:subject>injury</dc:subject>
        <dc:subject>intoxication</dc:subject>
        <dc:subject>kidney disease</dc:subject>
        <dc:subject>metabolic disorder</dc:subject>
        <dc:subject>musculoskeletal disease</dc:subject>
        <dc:subject>nutritional disorder</dc:subject>
        <dc:subject>leukopenia</dc:subject>
        <dc:subject>congenital disorder</dc:subject>
        <dc:subject>cytopenia</dc:subject>
        <dc:subject>endocrine disease</dc:subject>
        <dc:subject>familial disease</dc:subject>
        <dc:subject>genetic disorder</dc:subject>
        <dc:subject>digestive system perforation</dc:subject>
        <dc:subject>peripheral neuropathy</dc:subject>
        <dc:subject>thrombocytopenia</dc:subject>
        <dc:subject>infant</dc:subject>
        <dc:subject>immunopathology</dc:subject>
        <dc:subject>interstitial lung disease</dc:subject>
        <dc:subject>subcutaneous tissue</dc:subject>
        <dc:subject>liver failure</dc:subject>
        <dc:subject>liver injury</dc:subject>
        <dc:subject>newborn</dc:subject>
        <dc:subject>docetaxel</dc:subject>
        <dc:subject>hemolytic anemia</dc:subject>
        <dc:subject>liver fibrosis</dc:subject>
        <dc:subject>agranulocytosis</dc:subject>
        <dc:subject>contingency table</dc:subject>
        <dc:subject>paclitaxel</dc:subject>
        <dc:subject>biliary tract disease</dc:subject>
        <dc:subject>drug packaging</dc:subject>
        <dc:subject>eyelid disease</dc:subject>
        <dc:subject>sociology</dc:subject>
        <dc:subject>urinary dysfunction</dc:subject>
        <dc:title>Data mining for signal detection of adverse events for taxanes based on the food and drug administration adverse drug events reporting system database</dc:title>
        <dcterms:abstract>Background: This study aimed to mine and compare the positive signals of adverse drug events (ADE) in paclitaxel, docetaxel, and nab-paclitaxel to evaluate the accuracy of current drug package information inserts and enable clinicians to select the appropriate treatment. Research design and methods: ADE data reported from January 2006 to December 2020 were extracted from the Food and Drug Adverse Drug Events Reporting System (FAERS) database, and the reporting odds ratio (ROR) was used to detect the risk signals of the 3 taxanes. The definition relied on system organ class (SOCs) and preferred terms (PTs) by the Medical Dictionary for Regulatory Activities (MedDRA). Results: A total of 39,163 case reports on paclitaxel, docetaxel and nab-paclitaxel involving 25 different system organ classes (SOCs) were retrieved from the database. The ADE paclitaxel and nab-paclitaxel reports mainly focused on ‘general disorders and administration site conditions’ and the docetaxel ADE reports focused on ‘skin and subcutaneous tissue diseases.’ Among the three taxanes, nab-paclitaxel had the highest positive signal for serious adverse events. Conclusions: Overall, the most common ADE signals and ADE mapping systems obtained in this study were consistent with the package inserts. However, some inconsistencies were noted. Further research is recommended to confirm some of the strong risk signals for ADEs for taxanes before updating the drug package information inserts.</dcterms:abstract>
        <dc:date>2023</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079850</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2022682179&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <bib:pages>833-839</bib:pages>
    </bib:Article>
    <bib:Memo rdf:about="#item_1226">
        <rdf:value>&lt;p&gt;RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância&lt;/p&gt;</rdf:value>
    </bib:Memo>
    <bib:Article rdf:about="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2024226833&amp;from=export">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:2153-8174"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenName>Y.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ren</foaf:surname>
                        <foaf:givenName>Q.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Luo</foaf:surname>
                        <foaf:givenName>H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenName>G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhao</foaf:surname>
                        <foaf:givenName>B.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenName>X.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <dcterms:isReferencedBy rdf:resource="#item_1231"/>
        <dc:subject>ACEI</dc:subject>
        <dc:subject>acute kidney failure</dc:subject>
        <dc:subject>acute kidney injury</dc:subject>
        <dc:subject>adult</dc:subject>
        <dc:subject>age</dc:subject>
        <dc:subject>aged</dc:subject>
        <dc:subject>algorithm</dc:subject>
        <dc:subject>angiotensin receptor antagonist</dc:subject>
        <dc:subject>ARB</dc:subject>
        <dc:subject>article</dc:subject>
        <dc:subject>Article</dc:subject>
        <dc:subject>Bayes theorem</dc:subject>
        <dc:subject>combination drug therapy</dc:subject>
        <dc:subject>controlled study</dc:subject>
        <dc:subject>data analysis</dc:subject>
        <dc:subject>data mining</dc:subject>
        <dc:subject>death</dc:subject>
        <dc:subject>dipeptidyl carboxypeptidase inhibitor</dc:subject>
        <dc:subject>disease course</dc:subject>
        <dc:subject>factual database</dc:subject>
        <dc:subject>FAERS database</dc:subject>
        <dc:subject>female</dc:subject>
        <dc:subject>Food and Drug Administration</dc:subject>
        <dc:subject>heart failure</dc:subject>
        <dc:subject>hospitalization</dc:subject>
        <dc:subject>human</dc:subject>
        <dc:subject>hyperkalemia</dc:subject>
        <dc:subject>hypertension</dc:subject>
        <dc:subject>hypertensive patient</dc:subject>
        <dc:subject>incidence</dc:subject>
        <dc:subject>major clinical study</dc:subject>
        <dc:subject>male</dc:subject>
        <dc:subject>middle aged</dc:subject>
        <dc:subject>mortality risk</dc:subject>
        <dc:subject>odds ratio</dc:subject>
        <dc:subject>pharmacovigilance</dc:subject>
        <dc:subject>postmarketing surveillance</dc:subject>
        <dc:subject>prescription</dc:subject>
        <dc:subject>prognosis</dc:subject>
        <dc:subject>retrospective study</dc:subject>
        <dc:subject>risk factor</dc:subject>
        <dc:subject>screening</dc:subject>
        <dc:subject>treatment response time</dc:subject>
        <dc:subject>young adult</dc:subject>
        <dc:title>A Real-World Analysis of Post-Marketing Surveillance Data Assessing the Incidence of Hyperkalemia or Acute Kidney Injury in Patients on Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin-Receptor Blockers</dc:title>
        <dcterms:abstract>Background: The widely used Renin-angiotensin-aldosterone system inhibitor (RASI) may increase the risk of hyperkalemia and acute kidney injury (AKI). We aimed to analyze the RASI-related AKI or hyperkalemia reported in the Food and Drug Administration's Adverse Event Reporting System (FAERS) database to optimize patients' treatment and provide a reference for a clinically safe and rational prescription. Methods: We obtained data in FAERS recorded from January 2004 to December 2020. Disproportionality analysis and Bayesian analysis were used in data mining to screen the suspected AKI or hyperkalemia after RASI. The time to onset, hospitalization, and prognosis of RASI-associated AKI or hyperkalemia were also investigated. Results: We identified 11,301 RASI-related adverse events (AEs) of hyperkalemia and AKI in the FAERS database; 4997 were due to Angiotensin-converting enzyme inhibitors (ACEIs), 5658 were due to angiotensin receptor blockers (ARBs), and 646 were due to the combination of ACEI and ARB. AKI was more commonly reported in patients with ARB (78.42%) than ACEI users (57.27%). Hyperkalemia cases were reported more in ACEI users (28.70%) than ARB users (14.14%). The median time to onset of RAS-associated AKI was 135.0 (17.0-620.0) days. RASI-associated hyperkalemia occurred relatively later in ACEI users, with a median onset time of 261.0 (43.0-1097.7) days, compared with that of 200.5 (52.0-636.0) days in ARB users (p &lt; 0.001). Among all AEs, 72.39% of cases received hospitalization. Death occurred in 6.3% of the renal AE cases. The elderly and heart failure were potential risk factors for death in patients who developed RASI-associated renal AEs, with an increased Odds Ratio (OR) compared with younger age (OR = 1.32) and hypertension patients (OR = 2.55). Based on the criteria of the four algorithms, the ACEI and ARB combination further increased the incidence of AKI and hyperkalemia, demonstrating the highest Reporting Odds Ratios (RORs), Proportional Reporting Ratios (PRRs) and Empirical Bayesian Geometric Average (EBGMs). Conclusions: Patients who indicated RASI for heart failure demonstrated a higher death risk when AEs occurred. ACEI combined with ARB can increase the incidence of hyperkalemia and AKI. Careful and individualized management is necessary.</dcterms:abstract>
        <dc:date>2023</dc:date>
        <z:language>English</z:language>
        <dc:coverage>rayyan-281079843</dc:coverage>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.embase.com/search/results?subaction=viewrecord&amp;id=L2024226833&amp;from=export</rdf:value>
            </dcterms:URI>
        </dc:identifier>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:2153-8174">
        <prism:volume>24</prism:volume>
        <dc:title>Reviews in Cardiovascular Medicine</dc:title>
        <dc:identifier>DOI 10.31083/j.rcm2404107</dc:identifier>
        <prism:number>4</prism:number>
        <dcterms:alternative>Rev. Cardiovasc. Med.</dcterms:alternative>
        <dc:identifier>ISSN 2153-8174</dc:identifier>
    </bib:Journal>
    <bib:Memo rdf:about="#item_1231">
        <rdf:value>&lt;p&gt;Export Date: 16 July 2025; Cited By: 0; Correspondence Address: G. Chen; Nephrology Department, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100730, China; email: chengang@pumch.cn; CODEN: RCMEC&lt;/p&gt; | RAYYAN-INCLUSION: {&quot;Mell&quot;=&gt;&quot;Included&quot;, &quot;Carolina&quot;=&gt;&quot;Included&quot;} | RAYYAN-LABELS: Incluído,Mineração de dados em base governamental de farmacovigilância</rdf:value>
    </bib:Memo>
</rdf:RDF>
